<SEC-DOCUMENT>0000896262-23-000045.txt : 20230504
<SEC-HEADER>0000896262-23-000045.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504080636
ACCESSION NUMBER:		0000896262-23-000045
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		23886620

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c,d:6e7754e074c6458bb4bc162efb884713--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:amed="http://www.amedisys.com/20230331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV80LTEtMS0xLTY3MTI0_2de4cf07-620a-4013-8a80-a481d8e9b271">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV82LTEtMS0xLTY3MTI0_97220ac9-872a-497b-a7b8-8a36bcda53d4">2023</ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV83LTEtMS0xLTY3MTI0_a38646e0-dcf5-4ad0-affc-0e576739d6de">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV85LTEtMS0xLTY3MTI0_0f40e9d6-aa4b-4f2f-b0f0-6d1eecd71ece">AMEDISYS INC</ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV8xMC0xLTEtMS02NzEyNA_30f4b8fb-a550-45ec-8cb9-9e912ee7fddf">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV8xMS0xLTEtMS02NzEyNA_02852408-c6f7-4e0d-9e15-d57c75d2c027">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331" name="amed:AcutePhaseForHighAcuityCareServices" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321">P5D</ix:nonNumeric><ix:nonNumeric contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331" name="amed:AcutePhaseForHighAcuityCareServices" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830">P7D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ief1c33a09cd14865bd58df0e8caa349b_D20220101-20220331" decimals="INF" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180Ni9mcmFnOjI1MDVmNmU4MDU4MjQ4NDU4ODU5MjcyYzg2NmRmY2NmL3RhYmxlOjFhODMxNjUxNTZhMTQwMmM5MzU5YzNiNGViZWI3YjNjL3RhYmxlcmFuZ2U6MWE4MzE2NTE1NmExNDAyYzkzNTljM2I0ZWJlYjdiM2NfNC0xLTEtMS02NzEyNA_e9a79bb8-3aa0-4325-8911-8a8b0205ed7c">0.5</ix:nonFraction><ix:nonNumeric contextRef="iaf465ab991ea4ad1a42917b2b2e56157_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTg4_24315a26-40ac-43a0-9b7d-1ad27911f76d">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i8e7a39871825490a8097d1f9e1694885_D20230310-20230310" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182MS9mcmFnOjJmZmIxNDhmYWM5NDQ3MjJiMWEzOTNmZmMzZmU2OWU5L3RleHRyZWdpb246MmZmYjE0OGZhYzk0NDcyMmIxYTM5M2ZmYzNmZTY5ZTlfODA5_468cada5-febe-4cab-a001-4ca7537f348b">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Term SOFR Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="ic0910412b19c4213a4ffb7e02eb82775_D20230310-20230310" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182MS9mcmFnOjJmZmIxNDhmYWM5NDQ3MjJiMWEzOTNmZmMzZmU2OWU5L3RleHRyZWdpb246MmZmYjE0OGZhYzk0NDcyMmIxYTM5M2ZmYzNmZTY5ZTlfODEw_f35a034c-b590-4898-900a-15ca84cb3bb5">Quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb8bbe31c8d4d68ae6e3368641dacfc_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i585e48375f81452ca5c935a0f065bef9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibae6bf17ed294532b75bf96bee0338d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5843cd49ba0a4334b1931cf4711be4c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657094f859994e9fbdfefe4e999a8f7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03af0315b2e4303b57c3cb1aba7e7ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a54c309d06045c6a14dd53174c211ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee19286cb774518ad12dae14f165205_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6600d688c04ae3a1a2ff7f2efeb29c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadff83126f1146d38e7ed86ddbf9557e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b484011fea4455cbccfb47a9d0aa132_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1606c535e6b347d68dcc0de266b16147_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacba65ec8491499e9686e3381410fabe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ad24f8b9a043c19e668c1f83237ee0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eff4d47f36149c99910fdb01ba03dcb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961ed8ba937246e8bc366e595df4bda5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa99208e33a5497b97b9ff4d09865d65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10644ac975cd41d899b6ab34ac1c632b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eadcd74787f4d9f97ed1b8cb8b481f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32337689aea04d268b36f9d550c54a4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e116f3558448349842abb6755ed247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea60378b78054b2fac50a824142a5da9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895883f4f0404807a2543d994b1d240e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451c109a997045aba66d6e6f5f7a5b9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0efa54710f40b2adb0bf8a574fa295_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4a52b5e404494a99fb252c273edde2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb59d0a96fa84c18aa8e014c4d01bf7b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib188ac253c154843ad5c1a8d5049ca12_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06fb355109d402d9d8eb2a57521c878_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd566e0c30743bf921e7b51a845e441_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d65acc48b54ea4920cbeb26d75cd99_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i3e66fad7247f4614bb05acb8bacd747f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib066174649554b6aa169bff0a92b837c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofjointventures"><xbrli:measure>amed:numberOfJointVentures</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="ie0e0b0dcad1b459fbea67c1673d384bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e00191bd0ce47ae90a1b68b4dba7fbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392b34a2cbe44843ba2061fbdd365ff8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0c93dea83646f48e87329ba7bd8c58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2828517b0d45a29ac576ac753e94b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12394786d4c4d53b3346da0a457c35f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91c656ae45745a298a5b5024aef1f6d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49bceefe212449c7998aae8bb17d3e36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c3d28d3fe1472b8e434cb3e3faf3ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7decd3ddff141e79829e8d0ac8e68e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i457334445c94411eb7f7acd978196cee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0228a33ce76d4c2a9d5a57c7a7ee513c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f354bf9afa4fe39ba362e4a560be60_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12658449a4884e519551b1d2d371a76a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="visit"><xbrli:measure>amed:visit</xbrli:measure></xbrli:unit><xbrli:context id="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c6c1787206460dac3d072a59137173_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb50bbe21d045c2a7ea675b3d961273_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ec104e809d413fb7d22fa2c4dd41d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17ad04ba345428b8e033676549332db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e38279713af4551b387f31072d970c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae72a9173c944f7a4f1774565c96ca2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844b80bb13084f3b83010b9b474a966d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60919be84a16478885dd33d5c2ce0245_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1c33a09cd14865bd58df0e8caa349b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e5cae45c3e4926b672d2954605b617_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2ada7611794e0da3ad8606cb9d5fcc_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d005834749b442bb9d70d938394e533_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d541af44184deb951b6a071ab45e26_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59444987df584e7690a09dcbaa54b67d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288ea770324347e580e9797adb70ccbe_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b723d973d441aaa74151c4d5f39cbc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf465ab991ea4ad1a42917b2b2e56157_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22b0a888f0d4dbbb0def16d61c7e330_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67866a4322944973b5d992071251c8d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4e25adb7824b9094d7319f338e24c2_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67042e4013b4e38b79944277c4dd150_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb46cbc81ad49b3b6d2fb087cadcb23_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963c4518f769492dbf4ac0527afcbf9d_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e851f9c134745c698fdeeff9b69831f_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4834125dbb44494abec45d7f5e2ac7b_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58bb9667d6ae49158d64d74c1293836f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie474c65087de4fcd9f03f6114faa2034_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96882539f8d4eed92cde59a1e4c6c16_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ad22f782c84a46af3f9772a7af2667_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3159160953145aebe0e174490333355_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d2e1865d544d56bc61bafc92378512_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cebef82b22470c9b04463e506d3f78_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40995d245e1849f6a663395f8252db2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b451bfc136446abd99c9651bda4093_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7e815971ae49ee868e7a75f749208f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55b972867c94e8bb889ae04e28fdb15_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia492b736de1e47179438373b2738ee0a_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d5def30a27419ab88f280a1a8227a2_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e2df2ee5cb4b85b62420ced1fb93c9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c32b0de3217439f96df3b34a22fb3cf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60579582fb34f4ca10b3cc4b36399dd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f6956ee4104b5cac9dcd8b0e43e85c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870058a53843477c9351bc8199925557_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33e2d83e5d1461081b910b52e23d2bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa0ee06acc245068f9ee47a8f9534fd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf2a36d31e3405891903d3fee681e78_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25ced89f8d94908bec90fa9845fe731_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278de941823643d5a9ebedb448bfe966_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd1d1bf51b1148e0aca183be9b4f10c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed24a55c79b48a9a4f962dcbc7f923c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fc1915a4e5409f9acf5b031d0f164e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae944944b29040f5a2b123f79d05d2cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida89fe95351140f6b7664868c8647802_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec5894fd66b4d3f82b50f315effcf79_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1960f86c82bb4f3b9b446612846b3561_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6924c05d92fe48d08e15de81fa474e53_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74251b39fdf4162865cb8772044613f_D20210730-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62968d493c546e9be2fb5e44a2238d0_D20210730-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1414dda84f1a4039b0c9c62176b05341_D20231001-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3cbf205560418db36bba9e6b1a9d42_D20230310-20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2bd5dd04d541069c60eda0585eb542_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2beea370526f4c58885810023a334383_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d894bb39c82450382991fab6b6370d0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99635620a5d140d8a4a7b0b502e0957d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7a39871825490a8097d1f9e1694885_D20230310-20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0910412b19c4213a4ffb7e02eb82775_D20230310-20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbca5f3a4ed84661b6142d602c23319c_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb0213b931749a29f65d87002bd3697_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i4656df3498d04d67889bc6a6d94519c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73cbf69d99243349bd20c6351ede631_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8de4359d28d41ae8006eb4ac5462691_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4649b57d4264b6487be77b0ddca78b6_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b13a5963884c508a47edd37af0affe_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3eba185d82244d6b36d702c87bd4b49_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0503aff1b6d474d8e740e5f1f22aa0f_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54da14b3e36b46ce878e835cb8028e7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie009f517271a4d76847c8f3d3582e49e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ec2786358a4520ab9eae39cdb96053_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5ad00097724ab594a7deaf5d111fef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bca8c668b9c4f898b4b708846df0658_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942ca593c3da41b39bd5dd41b049950e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>amed:Segments</xbrli:measure></xbrli:unit><xbrli:context id="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecea7797edce4d7f827be77680105619_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375e7e760e9d4aa1a92757ae86a0d210_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830c428bb89b41599cc12c2881b394b5_D20210802-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5be9befb4f734cae91c1a764171dddf2_I20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23b318b43a44f01bf8a8c58852671ce_D20230202-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebd4093f9e54759abfee45439a836a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-03</xbrli:startDate><xbrli:endDate>2023-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6e7754e074c6458bb4bc162efb884713_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQy_d6878cd0-d4a4-4a57-aa35-abc9121fb355">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6MTNlYWE1NmI0ZTVhNGI0ODhmZjM3MzEyZDBjMmViODMvdGFibGVyYW5nZToxM2VhYTU2YjRlNWE0YjQ4OGZmMzczMTJkMGMyZWI4M18wLTAtMS0xLTY3MTI0_0cbb76dd-bdc0-4c30-a9a8-c0d59d6b5e48">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8xMzg_5c6fb71f-04ce-468b-b5e8-4248a617bd18">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OTE3ZjE0MmVhYmYzNDY4ZWIyNTk1NzNjMzZlODNhNDEvdGFibGVyYW5nZTo5MTdmMTQyZWFiZjM0NjhlYjI1OTU3M2MzNmU4M2E0MV8wLTAtMS0xLTY3MTI0_2a8ff22d-1419-4404-a8d9-639130886d14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM1_041e67df-9288-4396-b40b-b458521d048f">0-24260</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><img src="amed-20230331_g1.jpg" alt="image0.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">AMEDISYS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6M2RjYWIyYWFhYWUwNDEyYThkMGMzNmYxMmM2ZTNlNGEvdGFibGVyYW5nZTozZGNhYjJhYWFhZTA0MTJhOGQwYzM2ZjEyYzZlM2U0YV8xLTAtMS0xLTY3MTI0_1a0849c3-2f77-4862-9af5-d9509a2c8914">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6M2RjYWIyYWFhYWUwNDEyYThkMGMzNmYxMmM2ZTNlNGEvdGFibGVyYW5nZTozZGNhYjJhYWFhZTA0MTJhOGQwYzM2ZjEyYzZlM2U0YV8xLTItMS0xLTY3MTI0_5848c6c7-19a6-4482-95c3-5c3f48b5e255">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQz_ceb70962-27b9-4c42-84a0-010a4e8e7075">3854 American Way</ix:nonNumeric>, <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM3_951213c4-912d-4326-8f4f-26bbfbb93c8f">Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM4_022ff803-7415-4c13-b0d1-8d1aa4a37c76">Baton Rouge</ix:nonNumeric>, <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM5_53756b60-6568-4835-af42-3e6c2255c282">LA</ix:nonNumeric> <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM2_78b7c380-2437-4f82-9201-004c760706d0">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjMy_69bd6913-cd15-4984-b355-ba061bb396c4">225</ix:nonNumeric>) <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQw_829a3dd7-b695-47e6-a6bb-e48018bce24e">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTAtMS0xLTY3MTI0_aeacc973-965c-4b3e-9d39-a6531a943ec0">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTItMS0xLTY3MTI0_2625f8b0-76de-4879-a53b-c1fd97a5edd0">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTQtMS0xLTY3MTI0_c7cc709b-e468-4ba9-b951-5017f61ed1ef">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjMz_e700b4bd-95fc-4aa3-836e-af559b3251c3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM0_aa1790d1-e549-40a5-b465-924ed3f7c62b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl8xLTAtMS0xLTY3MTI0_62382cb4-ea43-4c70-be60-a31ca7151748">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl8zLTYtMS0xLTY3MTI0_e27b110e-b256-4067-8b55-756c64607824">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl81LTItMS0xLTY3MTI0_3d40d50d-25a7-4eb3-bbe1-ccc1bb3ddbaa">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQx_505f0b6d-804f-4cc7-901c-33fd69e44ce9">&#9744;</ix:nonNumeric>&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, <ix:nonFraction unitRef="shares" contextRef="i6fb8bbe31c8d4d68ae6e3368641dacfc_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMTk5_ddd90900-a7e0-424d-99ec-49cf43386e56">32,559,388</ix:nonFraction> shares outstanding as of April&#160;28, 2023.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.854%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">;;;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_16">FINANCIAL STATEMENTS:</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2023 (UNAUDITED) AND DECEMBER&#160;31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_25">CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_34">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_91">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_91">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_94">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_94">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_97">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_97">39</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_100">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_103">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_103">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_106">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_106">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_109">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_109">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_112">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_112">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_115">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_115">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_118">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_118">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_121">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_121">43</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6e7754e074c6458bb4bc162efb884713_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6e7754e074c6458bb4bc162efb884713_124">44</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: the risk that the cost savings and any revenue synergies or other synergies from the proposed merger with Option Care Health may not be realized or may take longer than anticipated to be realized; disruption from the proposed merger with patient, payer, provider, referral sources, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with Option Care Health or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that  necessary regulatory approvals for the proposed merger with Option Care Health are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders at Option Care Health or Amedisys or to satisfy any other condition in a timely manner or at all; the risks related to the integration of the combined businesses, including the risk that the integration will be materially delayed or will be more costly or difficult than expected; the ability of the combined company to execute carefully its strategic plans; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the ability of Option Care Health to effectively manage the larger and more complex operations of the combined company following the proposed merger with the Company; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19") on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February 16, 2023, particularly, Part I, Item&#160;1A - Risk Factors therein, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i6e7754e074c6458bb4bc162efb884713_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i6e7754e074c6458bb4bc162efb884713_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:73.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMy0xLTEtMS02NzEyNA_7cdef2d1-1248-46ac-948f-48fc0d968040">49,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMy0zLTEtMS02NzEyNA_877c663f-d90c-4b1a-a9c1-c5ed38e5391d">40,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNC0xLTEtMS02NzEyNA_845821d2-3375-4dc5-9388-de084411ca91">19,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNC0zLTEtMS02NzEyNA_c9fb73d3-38d6-41c3-add8-e2abda7826f9">13,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNS0xLTEtMS02NzEyNA_163ec406-1981-403b-953c-6f522fe4928d">294,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNS0zLTEtMS02NzEyNA_989cde00-d615-479b-9756-18c3c13df856">296,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNi0xLTEtMS02NzEyNA_543962bb-f375-4618-ae69-03ff17adec52">18,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNi0zLTEtMS02NzEyNA_5680fc88-34ac-4ba8-badf-0be38842cedd">11,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNy0xLTEtMS02NzEyNA_32101992-e99d-457e-8640-f79ee299678f">23,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNy0zLTEtMS02NzEyNA_0c319b5e-841d-4cfb-a44d-f3e98aaabeed">26,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOC0xLTEtMS02NzEyNA_c8259b60-1226-4099-a2d4-340b01764ea1">405,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOC0zLTEtMS02NzEyNA_b72822ea-b8b9-4947-8fd6-3d693097b32e">388,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJlOWVmOTA0NGQ3ZjRjNTBiMjUwNDQxYmE4MmMwMjUxXzYz_e89989f6-8a03-4020-8939-e2b19434c2ce">105,183</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJlOWVmOTA0NGQ3ZjRjNTBiMjUwNDQxYmE4MmMwMjUxXzcw_a4bf0871-a19d-47aa-801e-b86108462b16">101,364</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0xLTEtMS02NzEyNA_a5baaa62-4f66-47b2-9ea0-7e0c41e9da42">33,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0zLTEtMS02NzEyNA_1a27ad8a-52c0-4a49-a2fa-5e7366a219df">16,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTAtMS0xLTEtNjcxMjQ_d00ea250-619a-48bd-a00b-06801c912d39">85,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTAtMy0xLTEtNjcxMjQ_28df709a-b47c-4f12-acaa-1a5653b4d2d2">102,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTEtMS0xLTEtNjcxMjQ_5c9b5a6f-9485-456b-9c4a-51dc1a80b507">1,244,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTEtMy0xLTEtNjcxMjQ_a494e507-6a3a-4449-8918-55287a6a5046">1,287,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmZDVjNDgwY2QwMmE0NDVkYTRmNWI1YTcwZWZjNDI5MV81OA_3c4c11ae-7e34-4695-9bda-79124fc1e6f8">16,071</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmZDVjNDgwY2QwMmE0NDVkYTRmNWI1YTcwZWZjNDI5MV82NQ_b833d5b0-4c56-495d-a53d-abd2e9127ded">14,604</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMS0xLTEtNjcxMjQ_5c1d266a-fe98-40e7-a6da-2f984a43718f">99,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMy0xLTEtNjcxMjQ_ac61f867-1d07-4844-b9bc-8b17df25f7c0">101,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTQtMS0xLTEtNjcxMjQ_ea373dbc-dc5c-4fcf-8798-aab96650737d">78,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTQtMy0xLTEtNjcxMjQ_8b076ed8-8c82-494c-abd8-5e44a632d3d2">79,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTUtMS0xLTEtNjcxMjQ_7ffb60ed-499d-46e3-8ef1-fbc0c717e5c7">1,946,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTUtMy0xLTEtNjcxMjQ_38c26e93-041f-469e-a663-938d11c2b698">1,976,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTgtMS0xLTEtNjcxMjQ_617dcef5-104a-4025-b2f6-a1cb99b98ece">40,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTgtMy0xLTEtNjcxMjQ_c8886a89-6c49-4d2d-93da-4032ed739fcb">43,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTktMS0xLTEtNjcxMjQ_737b6682-e1da-470c-b97b-f062a019951d">122,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTktMy0xLTEtNjcxMjQ_60a90bfe-1ea5-42eb-9432-eab0490fcdfd">125,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjAtMS0xLTEtNjcxMjQ_23282a72-af02-4628-8479-e1b4e228f3bb">137,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjAtMy0xLTEtNjcxMjQ_f91aac2e-e0bc-4c96-9788-b75f6e26f484">137,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjEtMS0xLTEtNjcxMjQ_7e1e6114-0d25-4110-84f1-bddef0ca52e9">26,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjEtMy0xLTEtNjcxMjQ_812cb676-f334-4713-9db7-a74325fded02">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjItMS0xLTEtNjcxMjQ_52f3b85d-ecdd-40cf-a4a3-5160c76bde07">25,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjItMy0xLTEtNjcxMjQ_4f245621-5507-4116-a79f-1920fa65604e">33,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjMtMS0xLTEtNjcxMjQ_daec6061-9acf-4001-abc0-1d2c65330310">353,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjMtMy0xLTEtNjcxMjQ_4057e1ed-ad92-4d73-bd01-fde87c2679b6">355,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjQtMS0xLTEtNjcxMjQ_d74bc8b1-bd99-4493-b5ad-fb57956ca82f">373,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjQtMy0xLTEtNjcxMjQ_b5649d9a-2ee7-435e-ab53-28e4bb1496a0">419,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjUtMS0xLTEtNjcxMjQ_3be768f0-13ee-4821-aa8d-894e64bf3749">59,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjUtMy0xLTEtNjcxMjQ_beb62766-4b06-487b-9d92-14eb6da8e3d2">69,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjYtMS0xLTEtNjcxMjQ_755c4659-cfaa-4d5d-858c-41fd04623671">22,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjYtMy0xLTEtNjcxMjQ_4c746d7f-181a-4781-8a7c-e40c87635ad0">20,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjctMS0xLTEtNjcxMjQ_11a49d37-fded-4092-8477-1f569b454999">4,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjctMy0xLTEtNjcxMjQ_2ef257f8-4070-4f49-be2b-a3e87c6e19af">4,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjgtMS0xLTEtNjcxMjQ_a36029f9-20e8-4a3a-88bd-f3a74e083e0b">813,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjgtMy0xLTEtNjcxMjQ_93ae99de-08d0-4cc2-8dcb-ccad25c16c5c">869,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies&#8212;Note 7</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjktMS0xLTEtNjcxMjQ_cb5d49b8-2d37-45d4-88a2-fd0806a917ce"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18yMQ_7e638054-fd45-419e-9b26-44683f8f9be2"><ix:nonFraction unitRef="usdPerShare" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18yMQ_ff192d10-2b4d-495c-8687-905f0058a4d7">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18zNQ_7426c61a-dae0-4091-a5b8-d377b377c8de"><ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18zNQ_8a22ee97-dd34-4176-acfe-c4b895bbffe2">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_6c30d627-27aa-49ff-a66c-93d2820206a2"><ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_8de9bbe4-fd63-4c12-bd80-c737a9e634c5"><ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_988fb724-c7db-49fc-bd93-589a1f0cca23"><ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_efd009a7-ed79-44d1-85d7-aaa2710fe15d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne issued or outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMS0xLTEtNjcxMjQ_ac18568a-8a49-4cca-9343-429d16b12a0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMy0xLTEtNjcxMjQ_11187aaa-1028-4f8d-be47-f704ab49df26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8xOA_15167204-cfdf-4903-bfe7-68587f6c5ab7"><ix:nonFraction unitRef="usdPerShare" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8xOA_c82ae63f-7cf9-4f60-9d3d-221a33b15c87">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8zMg_180b46ba-59ae-46df-9bb2-2e6b85f02e46"><ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8zMg_a6a4b7fa-18ec-4ed9-8692-200d652f1a8d">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl81NA_6c58b570-35da-4760-9ce4-183f5fa5707b">37,938,354</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl82MQ_2f2a0006-766c-4253-8409-6275af4ab729">37,891,186</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl84Mw_d8bf58d1-db6a-4f4d-a6df-12ba94f5af97">32,544,145</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl85MA_d475b8bf-972b-411a-9f9c-8f372cecc6e9">32,511,465</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMS0xLTEtNjcxMjQ_ef7fcb70-84b9-4afe-807d-f1c9b7170019">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMy0xLTEtNjcxMjQ_d8a3f101-ec26-4ccd-8d2a-eff29c6ca9ed">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzMtMS0xLTEtNjcxMjQ_8f77368c-6397-4bf4-bce3-fa2a19b10da0">758,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzMtMy0xLTEtNjcxMjQ_0c3e93aa-fb9e-4780-a362-5035501722d0">755,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjowMzE2MTE3NWZiMzQ0NWIwYWM0ZWFhOTYyZTIyZDUyZV8yOA_a615113a-58f1-46a4-8700-f435340a2424">5,394,209</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjowMzE2MTE3NWZiMzQ0NWIwYWM0ZWFhOTYyZTIyZDUyZV8zNQ_4e58a949-9216-4087-8d90-ac37cb9fd54b">5,379,721</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMS0xLTEtNjcxMjQ_900c49d4-690e-4178-8d48-a88fc19c557b">462,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMy0xLTEtNjcxMjQ_93fb48d0-eaab-44db-9a4d-e24074ed26e0">461,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzYtMS0xLTEtNjcxMjQ_4ff5d9e6-4f5c-459d-af63-af3c27904e94">782,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzYtMy0xLTEtNjcxMjQ_92a26257-9fcf-4102-861c-9bb4c81cb2fd">757,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzctMS0xLTEtNjcxMjQ_3b57f677-d61e-4552-bb4d-0606079688c3">1,079,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzctMy0xLTEtNjcxMjQ_1360aebe-8fd2-46bd-8f91-7c14199f8c36">1,051,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzgtMS0xLTEtNjcxMjQ_9dcf5087-17b1-4f59-8015-00fd5bff6d4e">54,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzgtMy0xLTEtNjcxMjQ_79c73a7b-4887-451e-a0e8-e205c2503d35">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzktMS0xLTEtNjcxMjQ_9953090b-454b-4523-9fed-b4f83a38689d">1,133,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzktMy0xLTEtNjcxMjQ_bff4ac6b-ccc9-44df-a0d2-c611e3f888ae">1,106,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNDAtMS0xLTEtNjcxMjQ_f9b1ddd2-5c08-433a-b8d6-c745adbcbcbb">1,946,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNDAtMy0xLTEtNjcxMjQ_a747ac6b-59e1-43f3-9a0e-a7020aac615f">1,976,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED INCOME STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMi0xLTEtMS02NzEyNA_6f76652b-94b7-4ebd-bdb0-3074fd8efeb7">556,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMi0zLTEtMS02NzEyNA_1247d595-5889-498a-bdf4-d17d5ce6a854">545,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNC0xLTEtMS02NzEyNA_86f15fa1-c3f3-499d-bb73-cf31b1eb5cda">315,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNC0zLTEtMS02NzEyNA_4d6e64b6-ca43-4fb8-a7c9-9453a9d78192">304,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNi0xLTEtMS02NzEyNA_795281be-cc3f-41b7-9a24-377db4a6bcba">126,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNi0zLTEtMS02NzEyNA_269c8553-7a0e-4be2-9d72-3427ad8485b9">123,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNy0xLTEtMS02NzEyNA_ba93d79e-826b-4b80-9558-78b4c5398d0e">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNy0zLTEtMS02NzEyNA_edd7d22c-66bd-453c-b92d-ccec1e151a16">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0xLTEtMS03NDg2Ng_8c9e4d0b-1eba-4b19-96c6-333f4317c241">4,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0zLTEtMS03NDg2Ng_67e9c163-d903-4311-ba50-8b904e42b4ed">8,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0xLTEtMS02NzEyNA_0e177dec-236b-4ca5-b973-cbdb4f323f28">64,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0zLTEtMS02NzEyNA_901c947f-4aaa-4d6b-b2ed-287f13230240">53,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTAtMS0xLTEtNjcxMjQ_f79c83d6-6fb9-4984-bec6-cc814d2561f0">514,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTAtMy0xLTEtNjcxMjQ_96ab3ebc-ea11-4a16-a1a1-f1d9358199dd">497,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTEtMS0xLTEtNjcxMjQ_6bc86bb9-4909-48ed-82b5-cb772825c452">42,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTEtMy0xLTEtNjcxMjQ_9b191c29-e530-4c2c-81e2-ad2dcae3bf12">47,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTMtMS0xLTEtNjcxMjQ_8c6696e9-8d17-4777-a640-19a9571631e6">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTMtMy0xLTEtNjcxMjQ_030c0c79-6a0c-4397-ae32-43736faed919">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTQtMS0xLTEtNjcxMjQ_9a0a6a84-650f-41fe-9439-5c77b74e72fa">7,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTQtMy0xLTEtNjcxMjQ_187b3184-aff3-4a4a-b47f-430ed2cb448d">3,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTUtMS0xLTEtNjcxMjQ_24be7743-be68-4359-ac60-bfbbc287b169">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTUtMy0xLTEtNjcxMjQ_b6eb7fcd-f953-4024-ae85-4abab53a7bd0">1,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTYtMS0xLTEtNjcxMjQ_ef57566e-66bc-4f7c-871a-d94540a26c83">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTYtMy0xLTEtNjcxMjQ_e563d5a7-a02a-4fe7-b885-fcc73024221b">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTctMS0xLTEtNjcxMjQ_4d964097-1551-404a-9a7a-b113b125761a">7,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTctMy0xLTEtNjcxMjQ_799ff0d0-b503-4fdd-a708-2e82f0895628">4,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTgtMS0xLTEtNjcxMjQ_e2572c23-68cf-4ef5-ae87-515034ec4ea5">34,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTgtMy0xLTEtNjcxMjQ_a99af12c-39ec-44e9-814b-90240b76cd6a">43,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTktMS0xLTEtNjcxMjQ_c1e1b148-ad71-480f-bd72-342b81fc12c5">9,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTktMy0xLTEtNjcxMjQ_cc2832c0-ab46-4a4d-99d0-6f7be971d34b">12,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjAtMS0xLTEtNjcxMjQ_d392ec1b-4e97-4636-a41b-f511b129dc5a">24,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjAtMy0xLTEtNjcxMjQ_c2c26047-07c1-4d50-87c6-151153f29fce">31,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjEtMS0xLTEtNjcxMjQ_d1477a73-3823-40b2-acec-81d8cc2743ed">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjEtMy0xLTEtNjcxMjQ_bb98933e-38e1-4614-9fdc-ad0b6e4ae3c5">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjItMS0xLTEtNjcxMjQ_3ac35e6b-610c-4681-b3e8-a2502c611e19">25,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjItMy0xLTEtNjcxMjQ_ea323238-47c5-4ff8-a4db-0225c227771e">31,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjQtMS0xLTEtNjcxMjQ_194d936f-8699-494f-832a-f3e2fa5d2e1c">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjQtMy0xLTEtNjcxMjQ_6f03339a-3af6-42ab-b8f5-fcd5690b37ae">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjUtMS0xLTEtNjcxMjQ_35f629c5-8d27-451c-9e4a-9a942a95993d">32,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjUtMy0xLTEtNjcxMjQ_c6245bd3-2d77-46e4-8202-e75e7afef630">32,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjctMS0xLTEtNjcxMjQ_1e72df11-7f00-4b04-a48d-936daa4e4b12">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjctMy0xLTEtNjcxMjQ_23bca33f-e0c4-4f8e-ab15-94cef8b040be">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjgtMS0xLTEtNjcxMjQ_bb2eba00-0c6d-41f1-8f95-3b824cfe7328">32,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjgtMy0xLTEtNjcxMjQ_62fad8b9-7d89-4b68-9bcc-fdc9ef6fe166">32,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_28"></div><hr style="page-break-after:always"/><div style="min-height:4.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.694%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended March 31, 2023</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xLTEtMS02NzEyNA_1d1012df-052c-40d1-a9d8-e00b421a0120">1,106,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibae6bf17ed294532b75bf96bee0338d2_I20221231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0zLTEtMS02NzEyNA_9b443b88-9d3e-4f0d-85c0-7b46cc6af540">37,891,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae6bf17ed294532b75bf96bee0338d2_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy01LTEtMS02NzEyNA_be82e71f-3339-4132-899b-23486de0e25d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5843cd49ba0a4334b1931cf4711be4c1_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy03LTEtMS02NzEyNA_c6ca677c-be43-4f36-aa80-864ec3867503">755,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657094f859994e9fbdfefe4e999a8f7d_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy05LTEtMS02NzEyNA_cd17feeb-76c4-4489-9b1e-63f1ff6fb079">461,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03af0315b2e4303b57c3cb1aba7e7ff_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xMS0xLTEtNjcxMjQ_f8bf61d2-8b11-44ee-ac0e-e79f747dc3bc">757,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a54c309d06045c6a14dd53174c211ba_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xMy0xLTEtNjcxMjQ_466f3951-e744-4431-87af-6541fbd134e6">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC0xLTEtMS02NzEyNA_0645deea-768f-49aa-8cc4-28b7e081602b">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC0zLTEtMS02NzEyNA_d5f51944-ebcf-419e-8ae4-f8669ea53091">11,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC03LTEtMS02NzEyNA_d621d3b0-5b44-416f-8ecf-013d718bf1fa">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS0xLTEtMS02NzEyNA_61314bd3-f0ab-4093-ad27-ec8b4df3619d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS0zLTEtMS02NzEyNA_3a7c1e4b-094e-4bf9-8cd1-de4b7e474f5d">35,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS03LTEtMS02NzEyNA_4bc51cc8-cc90-462d-86cb-21ceac675a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNy0xLTEtMS02NzEyNA_01f5f849-896d-42c7-9700-2835446de214">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNy03LTEtMS02NzEyNA_84b76ffd-a48b-408f-ab89-52fa75380c02">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOC0xLTEtMS02NzEyNA_7001b132-9a27-4043-899c-a2e1cb112e05">1,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f6600d688c04ae3a1a2ff7f2efeb29c_D20230101-20230331" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOC05LTEtMS02NzEyNA_2dc1963d-76d4-4816-998b-d186b56a2049">1,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS0xLTEtMS02NzEyNA_6a17076f-567a-4016-bef0-6d6a2e2a894e">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS03LTEtMS02NzEyNA_35b69ad7-f9a3-45cf-b44e-befdb1854608">483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS0xMy0xLTEtNjcxMjQ_db86521d-587a-46c5-bf12-132260922569">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTAtMS0xLTEtNjcxMjQ_9380b313-fc33-4a92-a95f-25fa3c19df20">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTAtMTMtMS0xLTY3MTI0_19085811-d443-46bd-9d90-c2ee438c09a2">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMS0xLTEtNjcxMjQ_4a6dfd47-5aa1-42b5-9341-067edfdef6ab">24,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadff83126f1146d38e7ed86ddbf9557e_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMTEtMS0xLTY3MTI0_3fb786a1-7e53-48b6-a6b8-dc2d461c8f25">25,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMTMtMS0xLTY3MTI0_db47246e-558b-4898-98ce-f24c621081d3">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMS0xLTEtNjcxMjQ_495be912-3506-459b-b2c2-fd719c65fd10">1,133,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b484011fea4455cbccfb47a9d0aa132_I20230331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMy0xLTEtNjcxMjQ_e4f270bc-860e-420f-b0bf-e3082be3f55d">37,938,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b484011fea4455cbccfb47a9d0aa132_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItNS0xLTEtNjcxMjQ_9d965ce6-75a8-4fe9-9cfc-c4b7d94fbc17">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1606c535e6b347d68dcc0de266b16147_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItNy0xLTEtNjcxMjQ_0a50f494-8aec-4f06-ae40-ad01162f210f">758,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacba65ec8491499e9686e3381410fabe_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItOS0xLTEtNjcxMjQ_811ceef9-43d7-4710-82a2-e28f2ae8618a">462,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ad24f8b9a043c19e668c1f83237ee0_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMTEtMS0xLTY3MTI0_0b58040e-2d2e-49ba-be66-e07c188e0e7b">782,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eff4d47f36149c99910fdb01ba03dcb_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMTMtMS0xLTY3MTI0_835ea900-74ca-42b6-b9aa-3071fdd47f9e">54,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended March 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961ed8ba937246e8bc366e595df4bda5_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMS0xLTEtNjcxMjQ_0a6225b2-0d01-4623-8e5b-83827313a027">976,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa99208e33a5497b97b9ff4d09865d65_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMy0xLTEtNjcxMjQ_e4310780-3ee3-4f53-8520-a2af02ae9e1c">37,674,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99208e33a5497b97b9ff4d09865d65_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctNS0xLTEtNjcxMjQ_6a97be9f-5254-4560-b674-ea1628d9e319">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10644ac975cd41d899b6ab34ac1c632b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctNy0xLTEtNjcxMjQ_bf343ab5-0acd-41f9-bc7d-00dc7801df18">728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eadcd74787f4d9f97ed1b8cb8b481f0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctOS0xLTEtNjcxMjQ_9c9e971b-947d-4717-9bf8-d3305ce1a08a">435,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32337689aea04d268b36f9d550c54a4c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMTEtMS0xLTY3MTI0_effc533b-4eed-42d1-b0d7-8e1afb93c46f">639,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e116f3558448349842abb6755ed247_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMTMtMS0xLTY3MTI0_46f0ffb9-560c-4450-a370-ca2667f0ec22">44,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtMS0xLTEtNjcxMjQ_49afa916-6c94-4503-92fd-5c293750847d">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtMy0xLTEtNjcxMjQ_1feddd22-4054-4aca-8728-096880d424d4">7,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtNy0xLTEtNjcxMjQ_b4ee7803-52b5-46a0-80b1-7ea52f8c740e">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktMS0xLTEtNjcxMjQ_cc322fec-b8ea-4841-8363-6ba6418c9ba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktMy0xLTEtNjcxMjQ_c7b251ce-e566-4f47-88a4-1f6e6501cfde">80,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktNS0xLTEtNjcxMjQ_8d052e3f-9d14-4d1c-bd01-d5d99a433d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktNy0xLTEtNjcxMjQ_f8768ead-2a2a-4b79-a029-8012225cb9cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtMS0xLTEtNjcxMjQ_0abb1ef5-3814-48d2-928f-1e5cd585707a">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtMy0xLTEtNjcxMjQ_4f6d5ffd-6321-478b-99cd-9a7d2ec27226">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtNy0xLTEtNjcxMjQ_1641ebd7-8eef-4752-9cf1-f6bff04cedc4">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjEtMS0xLTEtNjcxMjQ_0d48a6f5-d415-42dd-8487-ff6c0e528d6d">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjEtNy0xLTEtNjcxMjQ_5723322d-839d-475e-bd84-a83fc9dac4cf">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjItMS0xLTEtNjcxMjQ_f1439ac4-72e1-48ce-86b2-981b0f072efa">4,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i895883f4f0404807a2543d994b1d240e_D20220101-20220331" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjItOS0xLTEtNjcxMjQ_40929ed1-d96d-4a86-b2ad-758f37c12b4b">4,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjMtMS0xLTEtNjcxMjQ_976f97e1-e672-4491-a4b7-efc1aa5126a9">9,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjMtMTMtMS0xLTY3MTI0_8f0f376d-8cb8-4dad-8cb7-98a6cbf48bb2">9,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjQtMS0xLTEtNjcxMjQ_159c0a26-5f99-400e-8eef-2256b0e1c273">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjQtMTMtMS0xLTY3MTI0_96af0c3d-7988-44c5-9d8c-01e6bc477031">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMS0xLTEtNjcxMjQ_67de6076-7638-4fef-9238-214cb0c31600">31,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451c109a997045aba66d6e6f5f7a5b9d_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMTEtMS0xLTY3MTI0_362052f6-57e8-4f11-b2f9-60a643758f19">31,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMTMtMS0xLTY3MTI0_0b632f73-1a72-4b63-9f4f-53f72dd704f2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0efa54710f40b2adb0bf8a574fa295_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMS0xLTEtNjcxMjQ_b13525fa-c292-4f6f-b579-d4bbd5bbaa5b">1,020,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd4a52b5e404494a99fb252c273edde2_I20220331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMy0xLTEtNjcxMjQ_665b1da6-535f-4f4f-8043-33a65dcecf8e">37,763,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4a52b5e404494a99fb252c273edde2_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtNS0xLTEtNjcxMjQ_315af71c-4d05-4a69-9fdd-01cdaea1ef39">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb59d0a96fa84c18aa8e014c4d01bf7b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtNy0xLTEtNjcxMjQ_5c128922-48c2-468a-8e84-f172888c0b9f">736,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib188ac253c154843ad5c1a8d5049ca12_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtOS0xLTEtNjcxMjQ_52f1842d-d524-4387-b449-85ed30792309">440,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06fb355109d402d9d8eb2a57521c878_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMTEtMS0xLTY3MTI0_90c9dd69-b080-426a-8025-ac67430c7a79">670,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd566e0c30743bf921e7b51a845e441_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMTMtMS0xLTY3MTI0_786875b7-d0d8-456d-95b1-957bbddefce2">53,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:4.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended March 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMy0xLTEtMS02NzEyNA_58a0484b-cb42-47ea-93ca-d340b7b7496b">24,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMy0zLTEtMS02NzEyNA_051047aa-ad74-4982-8876-46d2eec1a506">31,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization (inclusive of depreciation included in cost of service)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNS0xLTEtMS02NzEyNA_ef8c8f51-d3dd-4096-8cb7-b314da2b27b6">5,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNS0zLTEtMS02NzEyNA_eb28b9de-ab27-4340-a7de-0789045d9b44">8,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNi0xLTEtMS02NzEyNA_3330a162-7a1c-43e9-8da5-ded7033d67e1">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNi0zLTEtMS02NzEyNA_33628ede-87f0-4ab2-8a28-cec20a5fe163">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNy0xLTEtMS02NzEyNA_450c7cc6-7868-4720-bfa3-3dac6f42ae0b">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNy0zLTEtMS02NzEyNA_d7b99b61-c35c-4889-ab0e-85c83607a1d1">10,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOC0xLTEtMS02NzEyNA_4adc4dfe-2bfa-4512-b9ef-3ee1052e7fef">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOC0zLTEtMS02NzEyNA_6c5d4efd-fd38-41b6-9f4d-0f18d8cdaf27">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on personal care divestiture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0xLTEtMS03MzU0MQ_e77fc917-d86c-411e-b89b-bd1243d7b8e0">2,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0zLTEtMS03MzU0MQ_2bb8cf41-59b6-4517-a58f-be73b041cd8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0xLTEtMS02NzEyNA_babd5840-af57-4152-a3e4-9e0373cd6fde">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0zLTEtMS02NzEyNA_d0c08809-0062-439b-96e2-a0957b632e17">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in (earnings) loss from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTAtMS0xLTEtNjcxMjQ_5fda6826-5125-4b04-85db-a5eaa19b4809">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTAtMy0xLTEtNjcxMjQ_6270fd15-b1c1-4655-b4ad-d35d408b0b93">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTEtMS0xLTEtNjcxMjQ_574bf53a-d9eb-44f7-bda9-52efab005eed">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTEtMy0xLTEtNjcxMjQ_483a21b1-e2cd-4790-8f20-6cf85729808b">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTItMS0xLTEtNjcxMjQ_7861151c-3f17-4e22-bb7f-a24060ac5fe8">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTItMy0xLTEtNjcxMjQ_6d359291-1641-44e3-98ee-ac593762de6d">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTQtMS0xLTEtNjcxMjQ_379b962e-ee26-4f95-a7ff-5e7fa0a8f328">7,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTQtMy0xLTEtNjcxMjQ_afd86372-6a8c-4f2a-9519-e19602eaa4e0">18,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTUtMS0xLTEtNjcxMjQ_2b01094f-883c-44e6-840d-e3911cc571fa">4,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTUtMy0xLTEtNjcxMjQ_a57938bf-fad6-446c-a024-baa0958a3afc">7,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMS0xLTEtNzIwNTI_17e9d0c1-58e0-42ee-bb0e-62cdfc0aec6b">918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMy0xLTEtNzIwNTI_ac4ee5fa-57ec-444e-9ff7-18df64a9b9eb">749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTYtMS0xLTEtNjcxMjQ_16b8bd9e-1202-40ec-ab1b-f02d24ffa75b">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTYtMy0xLTEtNjcxMjQ_f4e875ef-6069-49d8-9e79-7c34ff178c7f">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTctMS0xLTEtNjcxMjQ_1a48c012-f725-42ab-ac3a-5a0f5e7966ca">3,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTctMy0xLTEtNjcxMjQ_45e1c1eb-57b1-45dd-a96a-888a938830fa">2,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMS0xLTEtNjcxMjQ_03ce37f9-711d-4162-b40b-f99458dec708">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMy0xLTEtNjcxMjQ_c196cc79-538d-4ca1-9ec4-905da211ca45">7,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTktMS0xLTEtNjcxMjQ_fbec93f0-9d2e-4a66-bfe0-226930777911">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTktMy0xLTEtNjcxMjQ_b1ccb4f6-f573-4217-a3ec-efc609e9edb9">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjAtMS0xLTEtNjcxMjQ_b3d51a3a-fe4f-42d0-9c0a-7e383465b1ee">7,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjAtMy0xLTEtNjcxMjQ_59a014f7-5c4f-43a2-a5d6-2d39381f5477">9,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjItMS0xLTEtNjcxMjQ_03288072-9a14-4f8d-a787-4e0604032a86">25,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjItMy0xLTEtNjcxMjQ_8b1e9317-891d-4391-987b-308885c87edf">48,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjQtMS0xLTEtNjcxMjQ_554a14b2-7841-43bb-9d2e-b0aeb636f2ef">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjQtMy0xLTEtNjcxMjQ_4130c96c-d4c8-4a22-9c08-6412103e08b9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjUtMS0xLTEtNjcxMjQ_48b47638-0fb0-4bf8-9057-a53de72e1184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjUtMy0xLTEtNjcxMjQ_169f98fb-a481-450f-9acc-1dc72198618a">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjYtMS0xLTEtNjcxMjQ_e0b5df63-1543-4ae4-b7ba-24f3d2a86047">1,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjYtMy0xLTEtNjcxMjQ_3a48f9f3-7ba9-4f8a-a566-46425a553568">902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in technology assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjctMS0xLTEtNjcxMjQ_838a0808-674d-4142-a4d4-0ff8b7bd6ae7">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjctMy0xLTEtNjcxMjQ_1636b1c5-e9fe-44ff-848d-fc5bb33e2de0">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of cost method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjgtMS0xLTEtNjcxMjQ_849de6b1-4499-40c6-9c28-9f36fe1efafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjgtMy0xLTEtNjcxMjQ_783c8d64-ca4e-4cda-b96e-155de4a0917f">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from personal care divestiture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMS0xLTEtNzM2MDE_2dda0ed9-5b8f-4c03-b2ec-478a1bf704ed">47,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMy0xLTEtNzM2MDE_d686df59-342c-4933-9e93-e3da99e2eb8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjktMS0xLTEtNjcxMjQ_ec3577f8-d73f-4163-974f-ade0f6680bd6">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjktMy0xLTEtNjcxMjQ_fd3c764e-d067-4b2c-b9cb-7dc7cfdfa5cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzAtMS0xLTEtNjcxMjQ_262fa48d-bc4b-4883-ad84-9eae8dd4cea4">45,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzAtMy0xLTEtNjcxMjQ_5b98cd29-166e-45e6-8c73-a92551e7b425">16,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzItMS0xLTEtNjcxMjQ_b56d7ee6-a6b3-427a-8bd9-2ce3ecdba449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzItMy0xLTEtNjcxMjQ_be85c204-7f56-496f-a42c-a4335d274d30">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMS0xLTEtNjcxMjQ_178c9201-900e-4efd-887a-1388802b8fa2">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMy0xLTEtNjcxMjQ_539fdae7-87dc-4115-8c32-203c637d674a">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzQtMS0xLTEtNjcxMjQ_2f82ba52-56b8-4983-860e-3c36cdb79c3c">1,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzQtMy0xLTEtNjcxMjQ_7f39ea6d-1b25-4070-868a-33130862b3bc">4,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzUtMS0xLTEtNjcxMjQ_53c4e0c7-9c05-496b-bf5a-38e417433ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzUtMy0xLTEtNjcxMjQ_e3ae9937-63f9-4924-b90b-e12559d1ba92">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzYtMS0xLTEtNjcxMjQ_b09d4f60-535b-4dd0-aa51-b0fd3562cb56">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzYtMy0xLTEtNjcxMjQ_3eec4a24-d555-4e90-8d38-1ff158105f8e">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzctMS0xLTEtNjcxMjQ_a2a0d9a4-a0e8-4ffa-af88-470f9f7dd186">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzctMy0xLTEtNjcxMjQ_021e020d-3d54-40bb-92aa-fccc4ec8b1c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzgtMS0xLTEtNjcxMjQ_e04f0ee2-c2e4-41d1-ad61-b206ae2ebffa">8,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzgtMy0xLTEtNjcxMjQ_70542acf-887e-444e-aab8-c41d7776d212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzktMS0xLTEtNjcxMjQ_0123e04f-b82a-41fd-8a0e-637a10569c50">55,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzktMy0xLTEtNjcxMjQ_8f8f1553-9d33-4216-a2bd-d3081a81190f">3,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMS0xLTEtNzM2NDk_f731e010-429a-43ab-9dfc-2632e810f2e1">800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMy0xLTEtNzM2NDk_0f8e1286-113f-421b-8734-e1bc02196f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDItMS0xLTEtNjcxMjQ_a6dcea89-2654-4e8d-89a8-e1e73366c0d4">56,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDItMy0xLTEtNjcxMjQ_597a9f01-9109-459b-a016-6b6f200f8579">7,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDMtMS0xLTEtNjcxMjQ_962d746d-6f7a-45f8-b8c8-c0370b0725ef">14,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDMtMy0xLTEtNjcxMjQ_787830b8-974c-4668-a10f-748e49ccfef7">25,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDQtMS0xLTEtNjcxMjQ_b68b202f-e780-4fcf-8640-1901763769bd">54,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961ed8ba937246e8bc366e595df4bda5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDQtMy0xLTEtNjcxMjQ_167a5235-a7c2-461b-ab03-c9c64b8d5fb7">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMS0xLTEtNjcxMjQ_1a311ece-1483-45d4-a3e4-8e472cdcd64d">69,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0efa54710f40b2adb0bf8a574fa295_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMy0xLTEtNjcxMjQ_3fabf5cf-f15b-473c-a628-dd3509ee8946">70,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTMtMS0xLTEtNjcxMjQ_5bad44cb-44f2-4fc8-8ee8-0c473aeb353d">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTMtMy0xLTEtNjcxMjQ_217f9811-8ae4-400e-8a0f-821e21f0d7c1">1,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTQtMS0xLTEtNjcxMjQ_f19c5f3e-48dc-44ce-80e6-f231c9ec042a">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTQtMy0xLTEtNjcxMjQ_2d8e9a44-d9f9-4e9f-a4bd-3d1713d45180">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:CashPaidForOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTUtMS0xLTEtNjcxMjQ_214145c6-fce5-47ce-86b0-98f9695fc297">8,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:CashPaidForOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTUtMy0xLTEtNjcxMjQ_b8276f52-290f-4e7f-a88e-dc36b9aa1213">9,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTYtMS0xLTEtNjcxMjQ_740270d5-3a81-47da-a88b-8c56659ca69e">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTYtMy0xLTEtNjcxMjQ_b69422b7-bde4-4eb7-9dbb-e66e9a50d82b">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTgtMS0xLTEtNjcxMjQ_3e9bd92d-021d-4376-9aa3-9846d0f3d1f8">7,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTgtMy0xLTEtNjcxMjQ_307d9795-b060-4137-b9da-d8cccd19b20a">11,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMS0xLTEtNjcxMjQ_c65733b7-9cb2-4331-b692-288986e3ba37">20,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMy0xLTEtNjcxMjQ_054d986a-9e68-4530-839d-a94e07c0c246">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to right of use assets resulting from reductions to operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjAtMS0xLTEtNjcxMjQ_8897a8d2-9d2f-490c-86ce-86fa7019767c">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjAtMy0xLTEtNjcxMjQ_3b304436-e55c-44f1-b47d-b48ae119418b">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to right of use assets resulting from reductions to finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMS0xLTEtNzIzOTI_5cb867ad-2bb9-4301-b0c0-7ea5e9405b03">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMy0xLTEtNzIzOTI_30e41102-6190-40f4-8a19-4a67b943302a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest contribution</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjEtMS0xLTEtNjcxMjQ_2421b46b-ef33-462c-bc5f-3cae142451b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjEtMy0xLTEtNjcxMjQ_8715f3dc-d041-47a4-b198-0e08a0b0b802">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i6e7754e074c6458bb4bc162efb884713_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM3MA_abb0d9a7-a36b-454e-a17a-16adda1539ee" continuedAt="i43e8d239e49347f0904cb0b64f1e90fc" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i43e8d239e49347f0904cb0b64f1e90fc"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately <ix:nonFraction unitRef="number" contextRef="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTQ5NzU1ODI1MzY4_02ff7236-9bf0-4498-b972-c08e42085ec5">72</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfMzQx_e94f58f5-1d7e-4e8a-a73a-6cbac5110aee">75</ix:nonFraction>% of our consolidated net service revenue derived from Medicare for the three-month periods ended March 31, 2023 and 2022, respectively. As of March&#160;31, 2023, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i45d65acc48b54ea4920cbeb26d75cd99_I20230331" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNDg0_3f65908e-093c-4fc8-b9e6-a5ae7dd8d7d3">348</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="i3e66fad7247f4614bb05acb8bacd747f_I20230331" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTMy_b446ab44-04bf-45a8-bf83-2f0b38f247b3">165</ix:nonFraction> Medicare-certified hospice care centers and <ix:nonFraction unitRef="numberofjointventures" contextRef="ib066174649554b6aa169bff0a92b837c_I20230331" decimals="INF" name="amed:NumberOfJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjEw_e7d22a93-1f6c-44dd-a40b-f6661309b429">9</ix:nonFraction> admitting high acuity care joint ventures in <ix:nonFraction unitRef="state" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjQ4_c1bb6eb7-9a78-433f-8b2f-c0dbe46fe2ac">37</ix:nonFraction> states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023.</span></div><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM2NQ_047e80fa-4c2a-477a-86c7-1ae83ba56ead" continuedAt="i9c9c5117573f4f3ebbb35947daa6f478" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c9c5117573f4f3ebbb35947daa6f478">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 16, 2023 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM1NA_489ee842-3fae-4a1d-9b54-f97e76a5971b" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ComparabilityOfPriorYearFinancialData" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTQ5NzU1ODI1Njkx_fc67be19-b3ea-4e43-9193-96761ff5f248" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM2Nw_6fe8615c-679c-460a-85cb-e002c9049414" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_43"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTA_efb261d3-5d4b-4748-82f0-eb773bd1ac6b" continuedAt="i79b2338b34544e6aa7de4805d1fc3fa2" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i79b2338b34544e6aa7de4805d1fc3fa2" continuedAt="i6ae97dbb612d4288a117ae5efe2f304a"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTM_71435544-2367-4f09-9e40-32607f4b1e12" continuedAt="iea354f69c4134b0a836ab580a3183a55" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately <ix:nonFraction unitRef="number" contextRef="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NDQ2_02ff7236-9bf0-4498-b972-c08e42085ec5">72</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0MjA3_e94f58f5-1d7e-4e8a-a73a-6cbac5110aee">75</ix:nonFraction>% of our consolidated net service revenue for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMzg2Mw_0c391a4c-34f9-488c-a319-6453396f8a81">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6ae97dbb612d4288a117ae5efe2f304a" continuedAt="i5a2d6ac79ec24f73b87a525fafacba3b"><ix:continuation id="iea354f69c4134b0a836ab580a3183a55" continuedAt="if62ce23bce55414aa89eda27647979a9"><div><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDU_640d48b0-afe6-4c31-91cb-46a6ecd74e76" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0e0b0dcad1b459fbea67c1673d384bb_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMy0xLTEtMS02NzEyNA_10c36aa5-1768-40dc-bc74-e279948d1309">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e00191bd0ce47ae90a1b68b4dba7fbd_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMy0zLTEtMS02NzEyNA_6260e0e8-54d0-446f-8ddd-4ca932dc647b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i392b34a2cbe44843ba2061fbdd365ff8_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNC0xLTEtMS02NzEyNA_60684c30-b865-445c-9970-d1221218825b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b0c93dea83646f48e87329ba7bd8c58_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNC0zLTEtMS02NzEyNA_662e29df-de23-4a5c-99d2-059792bc6c7b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a2828517b0d45a29ac576ac753e94b0_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNS0xLTEtMS02NzEyNA_712ba55c-7edf-46a6-a3b1-38c83650d878">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if12394786d4c4d53b3346da0a457c35f_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNS0zLTEtMS02NzEyNA_1085d34b-5d0a-43af-9c65-ef5722ac0c2e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic91c656ae45745a298a5b5024aef1f6d_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNy0xLTEtMS02NzEyNA_efd893a0-9625-4eb6-af89-762afc1d3609">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49bceefe212449c7998aae8bb17d3e36_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNy0zLTEtMS02NzEyNA_70cc9b2c-69b6-46b3-a845-3c5d1f4c6837">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44c3d28d3fe1472b8e434cb3e3faf3ed_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOC0xLTEtMS02NzEyNA_f13b9dcf-d928-4128-91a0-d39bc132d6ae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7decd3ddff141e79829e8d0ac8e68e4_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOC0zLTEtMS02NzEyNA_ed9e1e6a-6740-4c12-9bfe-d26058484699">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i457334445c94411eb7f7acd978196cee_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOS0xLTEtMS02NzEyNA_8096eb18-378a-44fa-8799-aa35e535b414">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0228a33ce76d4c2a9d5a57c7a7ee513c_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOS0zLTEtMS02NzEyNA_9df1c5ab-a31d-4b49-ba7d-7bd6446e9b14">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36f354bf9afa4fe39ba362e4a560be60_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTAtMS0xLTEtNzMyOTk_31b676df-0b90-43ce-9341-42464c438575">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTEtMS0xLTEtNjcxMjQ_96944923-9623-43ac-abc6-41aa42147f3c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTEtMy0xLTEtNjcxMjQ_5fc3c495-cf39-4882-aed5-bc7f76684be9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NzE0_faad6dfe-34cf-4474-9a36-284cf4b04c84">60</ix:nonNumeric>-day episode includes two <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQxNQ_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day payment periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTU0NA_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjAwMQ_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day payment period. We utilize our historical average length of stay for each <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjA4Mg_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjM1Mw_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjU0Nw_3f714d69-693b-4c0a-9ef3-769f91df7b4b">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="visit" contextRef="i12658449a4884e519551b1d2d371a76a_D20230101-20230331" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjczNw_e99fe821-01cc-45a8-b1f2-8470d1e18c3d">two</ix:nonFraction> to <ix:nonFraction unitRef="visit" contextRef="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjc0Mw_67dbebbe-8df7-40e7-8aeb-a75e753e2d46">six</ix:nonFraction> visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjkwNw_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNzA0Mg_324f14d9-1109-49e9-b081-b65ea73d8720">30</ix:nonNumeric>-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNzM2MA_d39311a4-81c8-4c9a-a2fa-d1926a30ed42">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5a2d6ac79ec24f73b87a525fafacba3b" continuedAt="i7a879518d71b4441ae685352982c7257"><ix:continuation id="if62ce23bce55414aa89eda27647979a9" continuedAt="i833902881ccf44e4b56a501f87def417"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, CMS implemented a new Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately <ix:nonFraction unitRef="number" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="3" name="amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQyNDIy_ee36713c-8346-4552-a2e4-4029a12194fb">30</ix:nonFraction>% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from <ix:nonFraction unitRef="number" contextRef="i12658449a4884e519551b1d2d371a76a_D20230101-20230331" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfOTE3Mw_002b3337-e2db-4743-897d-9b169b2a0872">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfOTE3OQ_b9dd15d2-551b-4142-9b1b-9dee6d54b32e">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTAzNTc_2d70d148-8405-4c0b-b5e6-52480d1b305f"><ix:nonFraction unitRef="number" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTAzNTc_f5fd6941-bb51-477c-b523-20dac9bb0ecf">97</ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for the three-month periods ended March&#160;31, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTEzNjY_2847f001-10a1-4d9f-83b2-bb82ff957c69">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of March&#160;31, 2023, we have recorded $<ix:nonFraction unitRef="usd" contextRef="iffb50bbe21d045c2a7ea675b3d961273_I20230331" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTIxMTM_c799c361-4e12-4534-9c98-29b484ba224d">4.1</ix:nonFraction> million for estimated amounts due back to Medicare </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7a879518d71b4441ae685352982c7257" continuedAt="i42e90ae3b1d14a55861b1b121355eebe"><ix:continuation id="i833902881ccf44e4b56a501f87def417"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2022, we had recorded $<ix:nonFraction unitRef="usd" contextRef="i81ec104e809d413fb7d22fa2c4dd41d5_I20221231" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTIyODI_80839cd1-8c28-4760-8faa-78ad1963c61e">4.3</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a <ix:nonNumeric contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTQ4ODc_630520d4-38ec-4416-adf9-82e2a385ad27">30</ix:nonNumeric>-day (H@H) or <ix:nonNumeric contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTQ5MDM_4ccb15f0-da47-436f-ba74-f788a108dca7">60</ix:nonNumeric>-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the <ix:nonNumeric contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUwODE_630520d4-38ec-4416-adf9-82e2a385ad27">30</ix:nonNumeric>-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the <ix:nonNumeric contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUxNjk_4ccb15f0-da47-436f-ba74-f788a108dca7">60</ix:nonNumeric>-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a <ix:nonNumeric contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUzMzU_630520d4-38ec-4416-adf9-82e2a385ad27">30</ix:nonNumeric>-day or <ix:nonNumeric contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUzNDU_4ccb15f0-da47-436f-ba74-f788a108dca7">60</ix:nonNumeric>-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i42e90ae3b1d14a55861b1b121355eebe" continuedAt="ia2b0936eea1a4d3f9266374cf54150de"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDE_f79c6b32-5a11-4455-85e5-48f7a3ece54c" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2023 and December 31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="id17ad04ba345428b8e033676549332db_I20230331" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NjU0_a8c07e16-3831-4d66-b1c7-853f467f411d">19.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3e38279713af4551b387f31072d970c1_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTgzNjI_a3b2e5ab-d38c-4ef2-8c73-b9787f7dbfca">13.6</ix:nonFraction>&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDc_c4b231c9-e9f2-445c-a49c-d6d11ff1104b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMS0xLTEtMS02NzEyNA_95bef3cc-c2b2-4d24-afaa-b136439d95d9">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMS0zLTEtMS02NzEyNA_a16893db-375c-4f75-ad6e-0063e2c414dd">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMi0xLTEtMS02NzEyNA_63065369-c5f2-4f05-a36f-8b44cb73f54c">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMi0zLTEtMS02NzEyNA_b2538fd1-4301-498f-8d1f-ae64b1b932f6">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMy0xLTEtMS02NzEyNA_5ef87dc0-d948-4217-a821-b2b97296ad8e">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMy0zLTEtMS02NzEyNA_d99af4f6-26f9-4165-8ed3-72149d2cc636">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTQ_9e2f62c9-52bf-4a8c-8d4f-3bccf98359d1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of March&#160;31, 2023, there is no single payor, other than Medicare, that accounts for more than <ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTkyNzY_d96bd6ba-ff1e-4189-8654-8d1cb761b4e1">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk3MzU_cbfffdc2-628d-4c28-930a-a7711fb45921"><ix:nonFraction unitRef="number" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk3MzU_de2cddec-f19f-4d2a-b537-97e6a5eaa26b">67</ix:nonFraction></ix:nonFraction>% of our patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk4NTg_0e5c5650-a112-46c8-9d8b-d4745c725a0b">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia2b0936eea1a4d3f9266374cf54150de"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDI_6bbc8ecb-94e0-4e40-a461-193bb4a70b2b" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTc_65990e8c-a3cd-4b9e-b4b6-ebb27da76a7e" continuedAt="i5f5cb95f17ed4a4ab0eaf4e47c052c7b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQzOTc_b83e2305-6b51-4e14-9da3-9b5b291ec15f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi0xLTEtMS02NzEyNA_7e3c6544-48a2-4130-bdc8-18fd7a9bfbcd">383.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae72a9173c944f7a4f1774565c96ca2_I20230331" decimals="1" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi0zLTEtMS02NzEyNA_3d36c7f3-a374-462c-9569-e8131a8fbe13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844b80bb13084f3b83010b9b474a966d_I20230331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi01LTEtMS02NzEyNA_5b9561af-14dc-4aa2-9003-e7dc300926f4">374.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60919be84a16478885dd33d5c2ce0245_I20230331" decimals="1" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi03LTEtMS02NzEyNA_6337b68b-a633-4c73-bb1a-5c52b0778e3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f5cb95f17ed4a4ab0eaf4e47c052c7b">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTU_14c2e001-f2e3-4da4-8f13-2d27c700cd0c" continuedAt="ied094a1eab714b69807204b10fcca1b2" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied094a1eab714b69807204b10fcca1b2">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDQ_ef0822cf-b46f-4d74-892e-8bd238309653" continuedAt="ib700befcca8a47ab9d3a65c70483388b" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ib700befcca8a47ab9d3a65c70483388b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfMi0xLTEtMS02NzEyNA_d288203e-347d-4dbc-b76a-934724c4fd50">32,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfMi0zLTEtMS02NzEyNA_c3f01ecb-dd2c-4ecf-97e7-f01140bf3a98">32,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNC0xLTEtMS02NzEyNA_2de4686c-b690-4d8e-a227-24a9d5d96d71">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNC0zLTEtMS02NzEyNA_d35fe982-ea3e-487f-88ee-2403928863b0">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNS0xLTEtMS02NzEyNA_65d36a12-9f26-4d1c-893f-74109dfeccc9">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNS0zLTEtMS02NzEyNA_133af7c2-4f0a-4249-8b14-02212e5c8ebf">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNi0xLTEtMS02NzEyNA_cee4c67e-6218-48f2-b876-73a0afea419e">32,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNi0zLTEtMS02NzEyNA_8c39dc09-093b-43cf-8b92-d7fe333f2ca3">32,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNy0xLTEtMS02NzEyNA_4907ee38-91bd-4335-8646-d89906615ffb">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNy0zLTEtMS02NzEyNA_852f0ce3-7b78-411c-af3b-bd31fda63406">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_1218"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTg4Njc_983eaa6d-c95a-4e25-a3e8-ba21695722d2" continuedAt="i10904b821840486c835e3f5325d2e890" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i10904b821840486c835e3f5325d2e890" continuedAt="i78db77071cf2436d88b27a0f82e9f4e9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQxMTQ_46c4b3b1-01ea-45df-a3ce-0db199ee3afa">50</ix:nonFraction>%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ0MTU_1f3d0523-a28d-4892-b12e-b9a5cee62724">50</ix:nonFraction>% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ2MDg_c3e46375-788e-42b1-8704-3125fe6f5340">38.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ2MTY_dd8f80ed-413b-49be-9399-09cb7e7c51d1">40.5</ix:nonFraction> million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="3" name="amed:MaximumPercentOwnershipForCostMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ4Mjk_b16e39bd-08b9-4a69-9019-4bebd42b25e6">20</ix:nonFraction>% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $<ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUwMzM_792c5663-756d-41ef-9fb6-95ca50129821">15.0</ix:nonFraction>&#160;million investment in a home health benefit manager, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUxODg_1714bc42-09fa-4a22-b711-2896cb3f3832"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUxODg_25ae3f55-bb17-4d84-971a-ed24e50c49fd">20.0</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of March 31, 2023, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. Our high acuity care segment also includes one admitting joint venture with a health system partner that is accounted for under the equity method of accounting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTg4ODE_00e91b9c-b79b-465c-928d-407ad04e0b76" continuedAt="i151f2d93b9bd417387a21913b82f2d7e" escape="true">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i78db77071cf2436d88b27a0f82e9f4e9"><ix:continuation id="i151f2d93b9bd417387a21913b82f2d7e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:61.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8zLTEtMS0xLTcwOTg3_667f64d7-687b-4b79-97e3-a449a911d4f4">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8zLTMtMS0xLTcwOTg5_aca28e1b-79a0-4a7d-a526-afc9058e67ae">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF80LTEtMS0xLTcwOTkx_4abd18e1-7f1e-4061-8e5e-b3d9c68044a3">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF80LTMtMS0xLTcxMDIx_c7fca60b-a761-40a1-80e4-fac1a15f53cf">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF81LTEtMS0xLTc2NjA1_2b783b43-1ca8-439b-85b4-119d2409bedd">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF81LTMtMS0xLTc2NjA3_d908069b-0bd3-4a3d-877a-e7c039275857">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF82LTEtMS0xLTcxMDEx_92f21546-f28b-4d85-94dc-523f4e3fd6af">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF82LTMtMS0xLTcxMDAz_23b2eabb-b54b-4803-84cd-684584b07775">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF83LTEtMS0xLTcxMDE5_c147c2f7-3558-4fc1-9b55-5a5b74db39d7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF83LTMtMS0xLTcxMDA1_3dc36772-d7c8-40f8-a7ae-4b5c356327fd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF84LTEtMS0xLTcxNDc5_5466a456-44df-47d6-bd00-8246c6eae5bc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF84LTMtMS0xLTcxNDgz_0efaa7a9-58d6-4be8-b4c9-eb8abe434075">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF85LTEtMS0xLTc2NjEw_5db9550c-8e5f-42fc-8387-3c4d5885ce87">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF85LTMtMS0xLTc2NjI3_0cbab964-1b01-4229-a5eb-16afcc4d435a">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMC0xLTEtMS03NjYzMA_5dec613f-8cc9-4d43-bba7-e2fdcd6ef70f">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMC0zLTEtMS03NjYzMw_693212c1-add9-4260-aff5-9f47966d93f4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMS0xLTEtMS03MTAyOQ_f9c68d26-dfbd-40fc-aa7d-e4830107ac5f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMS0zLTEtMS03MTAzMQ_fc1798be-de56-4c83-9fe1-ace2952d0f6e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMi0xLTEtMS03MTAxMw_acd1bbb3-756e-42fe-958b-ce726134848c">24.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMi0zLTEtMS03MTAwMQ_22ce2b1a-248e-409e-8461-69ed411e614c">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNS0xLTEtMS03MTQ4MQ_f127784d-bedc-485d-b974-19f4af35ead4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNS0zLTEtMS03MTQ4NQ_89024bb1-9efe-411f-9726-ba4221c66dd6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNi0xLTEtMS03MDk5NQ_01cfc798-bb47-4e7e-8cd3-f2f0b4c01fb3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNi0zLTEtMS03MTAxNQ_b9338ddc-68e2-404e-bc75-dcb3bdd2659f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNy0xLTEtMS03MTAyNQ_eb1dc3c9-9cbc-43ab-a9a9-819326869166">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNy0zLTEtMS03MTAyNw_f10d0d1f-37a6-490c-b70d-733ab482d8df">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOC0xLTEtMS03MTQ4MQ_ee984db2-943c-425f-a684-78fa81596342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOC0zLTEtMS03MTQ4NQ_93852ae7-92d5-4096-b363-a9106afd2f60">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOS0xLTEtMS03MTAyMw_d448c10e-e2c0-47f0-bd05-1845fb1a3217">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOS0zLTEtMS03MTAwNw_62c86b8d-978e-49b1-9691-27d679f2aaab">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8yMC0xLTEtMS03MDk5OQ_1db9d0ce-b306-4ac1-babb-3eb57b40f4b5">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8yMC0zLTEtMS03MDk5Nw_023133ac-5722-4886-a43b-9eeee6e8ca70">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div id="i6e7754e074c6458bb4bc162efb884713_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfMzc0Ng_f2324910-3796-4ea9-92b8-386a81043b08" continuedAt="ife8df87aaaec42c69254768d4d40ee14" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="ife8df87aaaec42c69254768d4d40ee14" continuedAt="ib15eb39f91c34e0283f5c5cbd130e8a0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Acquisitions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, we acquired the regulatory assets of a home health provider in West Virginia for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i2c2ada7611794e0da3ad8606cb9d5fcc_D20230120-20230120" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjIx_07a17976-9b33-433e-b329-e74da00bdb45">0.4</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i7d005834749b442bb9d70d938394e533_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjM1_b0686d36-4e17-45f4-86fd-d5a2fda21c68">0.3</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i83d541af44184deb951b6a071ab45e26_I20230120" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjQ5_ce96b7e8-26e4-4966-9499-82eac93c3501">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib15eb39f91c34e0283f5c5cbd130e8a0" continuedAt="ie3142ab828cc4e659768b6b944138c7b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjYz_7e8694fb-f330-4208-8d90-ce0d685eab37">15</ix:nonFraction> home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjY3_d8848800-91cf-43be-8c3b-f45d63120890">67.8</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mjgy_3e9e0f3c-feeb-43fa-87cd-8efbc9dbfed2">51.1</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mjk3_b07eb59a-507a-48c9-8e6f-561cd5009f3c">16.7</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $<ix:nonFraction unitRef="usd" contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzEy_739dfb20-0d66-42bf-af01-d55af0be58bb">16.7</ix:nonFraction>&#160;million placed into escrow, $<ix:nonFraction unitRef="usd" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="-6" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzI3_5657039b-1a6c-4707-b533-30c5b0418529">1.0</ix:nonFraction>&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, reduced the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i288ea770324347e580e9797adb70ccbe_D20220701-20220930" decimals="-5" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzQx_2105a857-6aef-414f-9f95-683c04d798ba">1.3</ix:nonFraction>&#160;million from $<ix:nonFraction unitRef="usd" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzU1_80fc5bc2-6b42-459c-ad47-1986cd7ca38e">67.8</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="if5b723d973d441aaa74151c4d5f39cbc_I20220930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mzcw_b9765004-e5ce-47ed-9136-3254126c5969">66.5</ix:nonFraction>&#160;million. The remaining $<ix:nonFraction unitRef="usd" contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mzg1_aeb6872f-eaa3-4e24-a22d-dbd179d52ef6">15.7</ix:nonFraction>&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of March 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:AmountReleasedFromEscrow" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDAw_73aa7ec6-bec4-41bb-be65-4a5157e9b840">5.7</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDE0_98d21ca1-10d3-4b55-ba69-08a5fc156f29">16.7</ix:nonFraction>&#160;million has been released from escrow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NDgw_97d5cd43-19c1-4969-9948-a996e0904d30">15</ix:nonFraction>&#160;million of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTg4_24315a26-40ac-43a0-9b7d-1ad27911f76d">two</span> to <ix:nonNumeric contextRef="ie22b0a888f0d4dbbb0def16d61c7e330_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTk1_52428589-c3e6-4642-a4d4-6cc667d8739b">five years</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. During the three-month period ended March 31, 2023, total assets acquired decreased $<ix:nonFraction unitRef="usd" contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331" decimals="-5" sign="-" name="amed:IncreaseDecreaseInAssetsAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI3ODU1_6b5fe187-549a-4255-be67-14906857335d">0.2</ix:nonFraction>&#160;million (primarily patient accounts receivable) and total liabilities assumed remained flat as a result of our review. These adjustments resulted in a $<ix:nonFraction unitRef="usd" contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI3ODY5_111bc294-419d-467a-bcf0-22d29af7e00f">0.2</ix:nonFraction>&#160;million increase in goodwill. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njk0_075373f7-e097-46bb-8662-d1c04e78f585" continuedAt="i79855773757b4679ad38ba360e848216" escape="true">The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDc4_1b35a10b-766e-40f9-948e-16670c12eb92">66.5</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie3142ab828cc4e659768b6b944138c7b"><div style="margin-top:6pt;text-align:center"><ix:continuation id="i79855773757b4679ad38ba360e848216"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMi0xLTEtMS03MTQ2Mg_1e7f3849-93b2-4119-bf74-ccbdd9c5905c">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMy0xLTEtMS03MTQ2Mg_ead66a08-cbe7-42b7-bef0-03ba70d4f625">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNC0xLTEtMS03MTQ2Mg_3bcb59be-9528-4b11-ac81-dbd64aabe8ab">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNS0xLTEtMS03MTQ2Mg_f28e4c1e-1f12-4b2d-8ecf-2326852b80af">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNi0xLTEtMS03MTQ2Mg_d307ff51-ef62-4a48-99ef-2a4c8f6a9324">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67866a4322944973b5d992071251c8d1_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNy0xLTEtMS03MTQ2Mg_43f69630-031e-4ced-8e62-da59cb880432">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOC0xLTEtMS03NjU4NQ_690add1f-37a1-47fe-8033-4bdd1630e54f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOC0xLTEtMS03MTQ2Mg_87bf5941-73d6-4f53-89d4-0784293ea33a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOS0xLTEtMS03MTQ2Mg_1108d9f5-b945-4218-b6cc-1353173ff701">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTEtMS0xLTEtNzE0NjU_41715d9e-4d92-4059-abff-1acfa08646ce">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTItMS0xLTEtNzE0NjU_4e768112-4bcb-424c-bf7b-ad4d7d84b10b">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTMtMS0xLTEtNzE0NjU_bff46a34-2b41-4b23-9c28-893d7a682a86">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTQtMS0xLTEtNzE0NjU_b29ea3de-67fb-4179-8cc7-c88e324ac03b">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTYtMS0xLTEtNzE0NjU_fb6097f2-8504-49ba-a2d0-b107bd3d74f5">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTctMS0xLTEtNzE0NjU_40907ef6-70e2-46da-8a9f-74073b95d4c8">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTgtMS0xLTEtNzE0NjU_2e91ef67-ae93-4250-81ea-ec1f1e0b4133">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTktMS0xLTEtNzE0NjU_50d2cf2c-afe5-4e0c-9f5c-99a07f1d8d54">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMjAtMS0xLTEtNzE0NjU_93afaeba-5eec-44c4-b229-75ad4a2e1ded">66.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njc0_72884334-a66d-4de9-81f6-2e3682ca880a">two</ix:nonFraction> home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDkz_458e8e63-ed47-483c-bff2-1acdea47b0bd">24.7</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTA4_005d8191-5713-40f6-96c3-08dee58c9e93">22.2</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTIz_778f8989-f5b1-41fe-8733-83ee87f9dde1">2.5</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $<ix:nonFraction unitRef="usd" contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTM3_168c1ba4-ffaf-418b-b455-00bae728f7e6">2.5</ix:nonFraction>&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTUx_538d21ad-ca31-4438-a837-ed718d456518"><ix:nonFraction unitRef="usd" contextRef="ic67042e4013b4e38b79944277c4dd150_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTUx_7fd24982-35c0-48e0-a559-1dfbe4b591c9">24.0</ix:nonFraction></ix:nonFraction>&#160;million and other intangibles of $<ix:nonFraction unitRef="usd" contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTY2_4517e2ba-a9b0-421b-91e8-f981e11bf3d2">0.7</ix:nonFraction>&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="i4fb46cbc81ad49b3b6d2fb087cadcb23_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTgw_5c4e14f3-42d0-4c84-a091-fe6a9ddd8f63">0.5</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="i963c4518f769492dbf4ac0527afcbf9d_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTk0_e6abbffa-2d79-419c-b68d-9a4c20bf8893">0.2</ix:nonFraction>&#160;million) and acquired names (less than $<ix:nonFraction unitRef="usd" contextRef="i1e851f9c134745c698fdeeff9b69831f_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njgx_f09691c4-612e-4eb6-b70c-b100e2ad6c35">0.1</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted average period of <ix:nonNumeric contextRef="ie4834125dbb44494abec45d7f5e2ac7b_D20220401-20220401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NjEx_e3c59526-1faa-484b-a277-6dd51a1a9e0c">one year</ix:nonNumeric>. The entire amount of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NjMw_bf96ff90-857a-4c81-9e85-be9efe6df932">15</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_1199"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTUxMTM_48c5ffca-c690-4fda-839a-53a9281e9b34" continuedAt="i8d2b057ba7de4364bdd0d33983ccb212" escape="true">DISPOSITIONS</ix:nonNumeric></span></div><ix:continuation id="i8d2b057ba7de4364bdd0d33983ccb212"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestiture closed on March 31, 2023. We received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTgxNzI_55a6dec6-0bcd-4a04-a761-b2f6e92e7da0">47.8</ix:nonFraction>&#160;million and recognized a $<ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTc4NTg_f496f599-814e-465f-b283-23487d782fc2">2.2</ix:nonFraction>&#160;million loss during the three-month period ended March 31, 2023 which is reflected in miscellaneous, net within our condensed consolidated income statement. The net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTgzNzE_55a6dec6-0bcd-4a04-a761-b2f6e92e7da0">47.8</ix:nonFraction>&#160;million is inclusive of $<ix:nonFraction unitRef="usd" contextRef="i58bb9667d6ae49158d64d74c1293836f_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTc4ODc_9368b2e0-8493-4b39-9386-0229f951b52b">6.0</ix:nonFraction>&#160;million that was placed into an escrow account in accordance with the closing payment and indemnity provisions within the purchase agreement; this amount is recorded as restricted cash within our condensed consolidated balance sheet as of March 31, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposition of our personal care business did not qualify as a discontinued operation because it did not represent a strategic shift that has or will have a major effect on the Company's operations or financial results.</span></div><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTUxMTQ_55427fdd-f460-48b3-ba5c-f71d5d70f706" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8zLTMtMS0xLTcxMTgw_281422c0-558f-40ff-9add-bb5f90a4802e">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF80LTMtMS0xLTcxMTgz_b75aedf4-1bc5-4f93-ad72-f75ef4276434">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF81LTMtMS0xLTcxMTgz_863ad7e9-217f-43ec-8086-22a9c111fe57">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF82LTMtMS0xLTcxMTgz_bf31d856-c9c1-484c-a4fe-e1a42e5afc23">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF83LTMtMS0xLTcxMTgz_19640fd2-cf99-4baa-80e4-3db5ea764e0d">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF84LTMtMS0xLTcxMTgz_d5aefcf1-5cf0-4450-b759-62dfa5f57973">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xMC0zLTEtMS03MTE4Mw_8e9ab4a8-f127-4282-845e-d77aca43c9aa">55.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xMy0zLTEtMS03MTE4Mw_b14fee25-6f9a-4141-b177-788bb3aaabed">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNC0zLTEtMS03MTE4Mw_eb268ec4-40db-4a2d-87ca-894958f89726">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNS0zLTEtMS03MTE4Mw_129edca7-2a67-451f-94a7-f815460b07d8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNi0zLTEtMS03MTE4Mw_8b3b8a72-f9dd-4d4e-96b3-9641a609f6ab">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNy0zLTEtMS03MTE4Mw_45fc8a40-5b20-45a0-a522-f0c4046e4022">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xOC0zLTEtMS03MTE4Mw_a2025b1c-2892-49fc-901d-0cabe86122cc">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xOS0zLTEtMS03MTE4Mw_746052cb-ebc1-48ed-88d6-613ab7661e3e">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_58"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2NA_95ef58c8-18ed-4a8e-a78c-ea461c4497b9" continuedAt="i461aecaa05dc401bb5e2a40ee418477c" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="i461aecaa05dc401bb5e2a40ee418477c" continuedAt="ib37c955b2666439c807cffbcfe6ef364"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2MA_94a113ae-005d-4b5f-8f71-568a5ecf9e2a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:66.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie474c65087de4fcd9f03f6114faa2034_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzQ_7f8c3c28-78ee-4c17-b221-ae8d47563390">450.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="id96882539f8d4eed92cde59a1e4c6c16_I20230331" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzEwNw_b41899f7-76a3-4c01-bffe-05c10242a1a9">6.1</ix:nonFraction>% at March 31, 2023); due <ix:nonNumeric contextRef="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzEzNA_59b55cf5-9f22-4901-ab3a-28563c397d93">July&#160;30, 2026</ix:nonNumeric></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie474c65087de4fcd9f03f6114faa2034_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0xLTEtMS02NzEyNA_259a519e-0a01-49c2-b835-91a8ed406a50">383.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad22f782c84a46af3f9772a7af2667_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0zLTEtMS02NzEyNA_54c6e45f-5fc8-4795-b9a2-b521a1e1c552">435.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOmRmM2EwZWU2YTRjMjQ4NmJhNzM3MTBlYWJkNmVjN2RhXzQ_090c8ce4-e55c-4608-ab69-747fb86681c7">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate; due <ix:nonNumeric contextRef="ic3159160953145aebe0e174490333355_D20230101-20230331" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOmRmM2EwZWU2YTRjMjQ4NmJhNzM3MTBlYWJkNmVjN2RhXzE1MQ_299eaaec-6a18-4bb0-a218-fbd4f7cf995a">July&#160;30, 2026</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0xLTEtMS02NzEyNA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"><ix:nonFraction unitRef="usd" contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0xLTEtMS02NzEyNA_cd24514f-9698-46c2-a531-38d14f54e65e">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cebef82b22470c9b04463e506d3f78_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0zLTEtMS02NzEyNA_6e769c77-818b-4474-9df8-95535aa198ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMy0xLTEtMS02NzEyNA_1fdbaea0-f1fb-4fbe-8bf7-18b6d35154bf">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40995d245e1849f6a663395f8252db2e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMy0zLTEtMS02NzEyNA_b68431ac-3ba7-42a1-b463-f10467c6e5bd">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b451bfc136446abd99c9651bda4093_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNC0xLTEtMS02NzEyNA_4ae2c2a8-fe5b-47a1-abbf-d248ec5a6b74">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7e815971ae49ee868e7a75f749208f_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNC0zLTEtMS02NzEyNA_3b7df7b4-f3c1-449a-bd9f-08fd67b0a4e5">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNS0xLTEtMS02NzEyNA_ccea9b53-c46f-4288-ae4d-711313094816">403.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNS0zLTEtMS02NzEyNA_5d640868-9f83-4849-ad86-903eb8ae078d">438.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNi0xLTEtMS02NzEyNA_de21fe4a-aba2-471b-9b66-71505aad92dc">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNi0zLTEtMS02NzEyNA_16cf296c-49e8-4f72-9186-4392f65238f1">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNy0xLTEtMS02NzEyNA_d2e5661d-16a3-465f-8524-7f00bf1352c9">400.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNy0zLTEtMS02NzEyNA_6a7e6c98-11cb-4c35-8170-53444c54ddd3">434.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOC0xLTEtMS02NzEyNA_0fb9e1ee-0869-410d-af61-ba300f985a0c">26.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOC0zLTEtMS02NzEyNA_da90259f-c57b-4821-9068-ef996928edb2">15.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOS0xLTEtMS02NzEyNA_6b72b756-a6fd-4aec-8104-87e6b6b4736f">373.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOS0zLTEtMS02NzEyNA_441a14f7-fae1-46cc-92c3-61eb9e853ba8">419.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia55b972867c94e8bb889ae04e28fdb15_I20210730" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDUx_4bed4a33-bb63-49ca-8527-053d17a77a43">1.0</ix:nonFraction>&#160;billion, which includes a $<ix:nonFraction unitRef="usd" contextRef="ia492b736de1e47179438373b2738ee0a_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDcy_c5a3d8c2-9ae7-4328-9c5c-3ac1143b0326">550.0</ix:nonFraction>&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i96d5def30a27419ab88f280a1a8227a2_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTU5_14ae1298-f3e8-4ae5-abb5-96295ecc3680">450.0</ix:nonFraction>&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 10, 2023, we entered into the Third Amendment to our Credit Agreement (as amended by the Third Amendment, the "Third Amended Credit Agreement"). The Third Amendment (i) formally replaced the use of the London Interbank Offered Rate ("LIBOR") with the Secured Overnight Financing Rate ("SOFR") for interest rate pricing and (ii) allowed for the disposition of our personal care business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Term SOFR Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTA5Nw_28dd0405-c19d-4a22-946b-051e7033c346">0.50</ix:nonFraction>% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTIxNg_763627ad-e9c6-498b-bac5-32ed429b0679">1</ix:nonFraction>% per annum. The &#8220;Term SOFR Rate&#8221; means the quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of <ix:nonFraction unitRef="number" contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310" decimals="INF" name="amed:SOFRAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI2NzE5_144cd41c-948f-4864-b59b-88bdfe8339a8">0.10</ix:nonFraction>%. The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2023, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="if0e2df2ee5cb4b85b62420ced1fb93c9_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTYxMw_20ee2767-d7ad-4aae-8c1f-c8cfdbde246e">0.50</ix:nonFraction>% per annum for Base Rate loans and <ix:nonFraction unitRef="number" contextRef="i6c32b0de3217439f96df3b34a22fb3cf_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTY1MA_b74fcf0a-44e9-458e-a876-5f607d6b3af0">1.50</ix:nonFraction>% per annum for Term SOFR Rate loans. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2MQ_24a15ee9-eeeb-4d1a-942e-259648721257" continuedAt="i5480108704954fbbb56f59e32b7b878b" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i5480108704954fbbb56f59e32b7b878b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:9.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term SOFR Loans and SOFR Daily Floating Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; <ix:nonFraction unitRef="number" contextRef="id60579582fb34f4ca10b3cc4b36399dd_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjlkYTAxNTY3YWVkMDQxMDQ4Y2RjMmZjM2VjZTcyYzMyXzY_1d8f1148-c4e6-494f-9dc3-73696fddc33e">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46f6956ee4104b5cac9dcd8b0e43e85c_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0yLTEtMS02NzEyNA_dfbf82c1-80b2-4aae-954a-326af043bc0e">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i870058a53843477c9351bc8199925557_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0zLTEtMS02NzEyNA_397430a4-e569-41ec-8b76-020672222c26">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS00LTEtMS02NzEyNA_28943e4c-7419-44db-b910-0f04647aada6">0.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS01LTEtMS02NzEyNA_44166588-f63c-422a-bc36-18e1927ae9cf">1.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonFraction unitRef="number" contextRef="ia33e2d83e5d1461081b910b52e23d2bf_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJhZWI3MWQxMzZiODQ3ODE4MDYxMDU1MzM0MjVkNTc3Xzc_f8956068-7d8e-4512-93fd-9865ff7221b2">3.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i2aa0ee06acc245068f9ee47a8f9534fd_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJhZWI3MWQxMzZiODQ3ODE4MDYxMDU1MzM0MjVkNTc3XzIz_d872eab3-0a59-4791-9278-0adf9fe51207">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbf2a36d31e3405891903d3fee681e78_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0yLTEtMS02NzEyNA_98dba5db-77dc-4025-87ad-9ea7ce39bfce">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia25ced89f8d94908bec90fa9845fe731_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0zLTEtMS02NzEyNA_071ee9f7-812e-4d44-9ef7-c60241295783">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i278de941823643d5a9ebedb448bfe966_D20230101-20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi00LTEtMS02NzEyNA_0eaf824b-0425-4ad4-8c46-971f8b8a7dda">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i278de941823643d5a9ebedb448bfe966_D20230101-20230331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi01LTEtMS02NzEyNA_4415f890-6ae6-4fcb-8e6f-f5a66206d817">1.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="ifd1d1bf51b1148e0aca183be9b4f10c1_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOmUwMTk0NmQ0MGRmMTRhZjE4MDBhOTdiY2U0ZWMxNmVlXzY_9e1ac79e-1bfe-4c9c-a3e9-a570b470fbf9">2.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i5ed24a55c79b48a9a4f962dcbc7f923c_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOmUwMTk0NmQ0MGRmMTRhZjE4MDBhOTdiY2U0ZWMxNmVlXzIy_dcbd3747-0e5e-432a-a871-2b23817f4a5c">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81fc1915a4e5409f9acf5b031d0f164e_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0yLTEtMS02NzEyNA_b06b8b3c-d4c1-47ce-8cf6-4b955adc6991">0.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae944944b29040f5a2b123f79d05d2cb_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0zLTEtMS02NzEyNA_982cf95f-78fb-4e3c-b0a5-c5e6ec8eb5f6">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida89fe95351140f6b7664868c8647802_D20230101-20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy00LTEtMS02NzEyNA_d0d047fd-1125-49b2-a7a0-d8dfaa72382a">0.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida89fe95351140f6b7664868c8647802_D20230101-20230331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy01LTEtMS02NzEyNA_6f441abb-dc80-44c1-bb34-62d6cc795209">1.25</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i6ec5894fd66b4d3f82b50f315effcf79_D20230101-20230331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjg1MTVlMjQ4MDhhZTQ3ZDk4ODU0Y2E3MDgxOGVhM2MzXzY_674ce663-95ed-437f-9b38-7bc714749b74">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1960f86c82bb4f3b9b446612846b3561_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0yLTEtMS02NzEyNA_ff4d176c-2e33-4945-a3cf-bbc5defa36ba">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6924c05d92fe48d08e15de81fa474e53_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0zLTEtMS02NzEyNA_ea838e36-8a06-4ad6-9356-81cc2443c977">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC00LTEtMS02NzEyNA_4c6e3f45-9e20-4583-8736-e4e31634db72">0.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC01LTEtMS02NzEyNA_4ddbbfaf-1369-4686-a7aa-3daa68b02262">1.00</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is <ix:nonNumeric contextRef="ic74251b39fdf4162865cb8772044613f_D20210730-20260730" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTkwNQ_4a2ebe52-ba17-49c9-a2c7-eef56140235d">July 30, 2026</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="ie62968d493c546e9be2fb5e44a2238d0_D20210730-20230930" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjEyMA_0f99c84c-b970-4159-8450-55baf19d0e72">0.625</ix:nonFraction>% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) <ix:nonFraction unitRef="number" contextRef="i1414dda84f1a4039b0c9c62176b05341_D20231001-20260730" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjIwOQ_412fd664-f956-40fe-b6d8-694a2dd74add">1.250</ix:nonFraction>% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib37c955b2666439c807cffbcfe6ef364" continuedAt="if390e800d671473b9cb2355b9fb2d992"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i7d3cbf205560418db36bba9e6b1a9d42_D20230310-20230310" decimals="-5" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjgzMA_d827e0ee-46e0-4345-aa3e-11622fdce31d">5</ix:nonFraction>&#160;million or (b) any debt issuance that is not permitted under the Third Amended Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net proceeds received from the divestiture of our personal care line of business were used to pay a portion of our Term Loan during the three-month period ended March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Third Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Third Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Third Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Third Amended Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Third Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310" decimals="INF" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDEyNA_05735839-d38a-44aa-9cc4-fa8328401a40">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310" decimals="INF" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDMwNw_b245beab-3760-420e-af70-d7f787d0b486">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, we had <ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDQzNA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"><ix:nonFraction unitRef="usd" contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDQzNA_cd24514f-9698-46c2-a531-38d14f54e65e">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under our $550.0 million Revolving Credit Facility. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDc0OA_ce9226e8-8466-473d-a889-de8de874b10b">6.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icc2bd5dd04d541069c60eda0585eb542_D20220101-20220331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDc1NQ_5d91543a-00c1-4ac6-bce3-f846678ce361">1.7</ix:nonFraction>% for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDg3Nw_f44f2724-8706-4d65-9a6a-7329ad4ae8f4">1.6</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331" decimals="INF" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDkyNg_b81c1b72-d152-449f-94bf-b1049c501939">10.3</ix:nonFraction> and we are in compliance with our covenants under the Third Amended Credit Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our availability under our $<ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTMxMQ_f73d6297-d63e-4aa8-b38d-98870d1cf8ea">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM0NA_5ef72104-1f09-42eb-9b69-c23d6830599b">519.2</ix:nonFraction> million as we have <ix:nonFraction unitRef="usd" contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM1OA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"><ix:nonFraction unitRef="usd" contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM1OA_cd24514f-9698-46c2-a531-38d14f54e65e">no</ix:nonFraction></ix:nonFraction> outstanding borrowings and $<ix:nonFraction unitRef="usd" contextRef="i2beea370526f4c58885810023a334383_I20230331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM4OA_7bb130df-008e-43c3-9995-28c3a95d03d5">30.8</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if390e800d671473b9cb2355b9fb2d992" continuedAt="i9feb10a94d6a4561b92a79cb94c1a973"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing or arising after the respective effective dates of the Joinders, under the Third Amended Credit Agreement pursuant to the terms of the Joinders and the Third Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Notes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding promissory note totaling $<ix:nonFraction unitRef="usd" contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTI2_738bf91f-69b6-4832-bde0-f4397a6bef74">0.2</ix:nonFraction>&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of <ix:nonFraction unitRef="number" contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTQw_a8548e79-cb1f-435b-88e9-0a639288a469">6.5</ix:nonFraction>%.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding finance leases totaling $<ix:nonFraction unitRef="usd" contextRef="i93b451bfc136446abd99c9651bda4093_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTQ2_83feb233-9883-42c6-86fb-707b6b74c114">20.1</ix:nonFraction>&#160;million relate to leased equipment and fleet vehicles and bear interest rates ranging from <ix:nonFraction unitRef="number" contextRef="i3d894bb39c82450382991fab6b6370d0_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTYw_5ea31edf-3ae3-4860-9d8e-e3c5136e00fd">2.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i99635620a5d140d8a4a7b0b502e0957d_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTY2_4f7a1204-840c-431c-871e-3fd379956b34">7.7</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9feb10a94d6a4561b92a79cb94c1a973">Effective January 1, 2023, the master lease agreement for our fleet leases was modified to remove the residual value guarantee provided by the lessor on each of our fleet leases. The modification resulted in a change in the classification of our fleet leases from operating leases to finance leases. In connection with the modification, we reclassified approximately $<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="amed:ReclassificationOfOperatingLeaseToFinanceLease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTcy_9ea13c22-4ff9-490e-b8e6-a40739d9e95a">15</ix:nonFraction>&#160;million from the operating lease asset and liability accounts to the property and equipment and current/long-term obligations accounts within our condensed consolidated balance sheet. Additionally, following the modification, expenses associated with our fleet leases will now be recorded in depreciation expense and interest expense within our condensed consolidated income statement as opposed to cost of service and general and administrative expenses which is where the expenses were reflected in prior periods.</ix:continuation> </span></div><div><span><br/></span></div><div id="i6e7754e074c6458bb4bc162efb884713_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAyNDQ_7b6ea667-dc88-4016-8bd6-4344f2c87df6" continuedAt="iba92b7b03e0b4500adcb176a76a6a4dd" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iba92b7b03e0b4500adcb176a76a6a4dd" continuedAt="i6dac954553ef40f697f658cdd589a7c4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="ibbca5f3a4ed84661b6142d602c23319c_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMzY2OA_e2863147-2689-4374-ba2a-85dd3f67afad">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDExMg_01921a21-70d7-4d37-8728-2b62a2d76d0b">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="ideb0213b931749a29f65d87002bd3697_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDkxNQ_3257c30c-6bcc-4e86-9955-3307ad3a508b">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="ideb0213b931749a29f65d87002bd3697_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDk0MQ_5538678b-b717-46d8-8499-88bfd7bed15a">5.6</ix:nonFraction> million, including interest, based on <ix:nonFraction unitRef="claim" contextRef="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDk3NA_f007d240-1600-4746-b133-257831c8b6dc">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTAwNQ_7cf600df-1125-471a-8b80-77063f5ea4fc">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTA3OA_d3978267-a04d-44df-8f63-c611d739eb3e">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2023, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="i4656df3498d04d67889bc6a6d94519c5_I20230331" decimals="-5" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTMyMw_c764338b-0712-4155-863d-fb2a77da4556">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6dac954553ef40f697f658cdd589a7c4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="id73cbf69d99243349bd20c6351ede631_I20190110" decimals="-5" name="amed:IndemnificationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTgyOA_3082b3a4-761f-4fe7-977e-f81008b635c8"><ix:nonFraction unitRef="usd" contextRef="id8de4359d28d41ae8006eb4ac5462691_I20230331" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTgyOA_f1de5489-0e8a-4582-baa9-1bf1fb76f73c">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjY3Mw_3b086ee1-f216-4e48-9cc8-541019c49d59">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="i32b13a5963884c508a47edd37af0affe_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjcyMw_a4368477-dd29-4ca3-8b70-8e41f61e5599">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjc1MQ_60ee6093-5477-4124-8d6a-8b10eafaa997">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjc4OA_13537f3d-17bb-4008-9ac8-e77cdc4600be">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjgyNA_251a036f-af90-4ae5-bf3e-eacb27068508">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="if0503aff1b6d474d8e740e5f1f22aa0f_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjg3NQ_0f0f9e86-1a42-4ce9-8003-26aeb819bedf">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjkwMw_ee272856-790c-4251-b00e-7dd30cb53dda">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjk0MA_f05fcb88-0a5c-46fd-be09-5ef921a8de73">100</ix:nonFraction>% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $<ix:nonFraction unitRef="usd" contextRef="i54da14b3e36b46ce878e835cb8028e7d_I20221231" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNzMwNA_6919803f-51b8-4429-b61b-a6f2151b88b5">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center was reduced to $<ix:nonFraction unitRef="usd" contextRef="ie009f517271a4d76847c8f3d3582e49e_I20221231" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNzM4Ng_60cbcb10-2e4b-467f-b7d8-8d1dbcd64634">3.3</ix:nonFraction> million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. </span></div><div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $<ix:nonFraction unitRef="usd" contextRef="ie4ec2786358a4520ab9eae39cdb96053_I20220331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NjE5_18fec538-a5e7-4c64-b6aa-2ddcefd993de">17.4</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i6e5ad00097724ab594a7deaf5d111fef_I20220630" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NjM0_9a836208-d134-44ec-90e0-5c85a5468910">25.2</ix:nonFraction>&#160;million, excluding interest. The repayment for the Lakeland Care Centers totaling $<ix:nonFraction unitRef="usd" contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930" decimals="-5" name="amed:TotalLegalSettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Njkz_f80b9c90-3bc9-4da5-a30d-94e5a22304a6">34.3</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930" decimals="-5" name="amed:LegalSettlementPaymentLessInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzA4_1a90de83-ae2b-4b16-a42b-36b9b6f31897">22.8</ix:nonFraction>&#160;million extrapolated repayment plus $<ix:nonFraction unitRef="usd" contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930" decimals="-5" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzIz_efdfb088-e47c-436e-b1c0-8e1eca4149cb">11.5</ix:nonFraction>&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $<ix:nonFraction unitRef="usd" contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231" decimals="-5" name="amed:TotalLegalSettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzM4_52fa45f1-d220-49a8-81df-5d0c9574d098">3.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231" decimals="-5" name="amed:LegalSettlementPaymentLessInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzUy_9719209c-cbe3-4b01-9eb7-d318d2308b9b">2.4</ix:nonFraction>&#160;million extrapolated repayment plus $<ix:nonFraction unitRef="usd" contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231" decimals="-5" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzY2_6cb7f492-5d8d-4163-aac6-677480577387">1.2</ix:nonFraction>&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i2bca8c668b9c4f898b4b708846df0658_D20220701-20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Nzgw_d79ab183-64b4-4361-997e-bb482735a62d">1.5</ix:nonFraction>&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $<ix:nonFraction unitRef="usd" contextRef="i942ca593c3da41b39bd5dd41b049950e_I20230331" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Nzk0_469d7ae2-64f6-40d8-b15e-5ab7102dc133">10.9</ix:nonFraction>&#160;million and have recorded this amount within other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation, professional liability and fleet. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="amed:HealthInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAwNDc_74c4214b-6a37-41ff-b3b5-c78cdd05a37f">1.3</ix:nonFraction> million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="amed:WorkersCompensationInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAxNDQ_789af391-c965-41c5-b794-9abe237edaaa">2.0</ix:nonFraction> million per incident. Our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAyMjY_cd0d35c4-a6ec-4128-a218-c2c1789e0c56">0.3</ix:nonFraction> million per incident. Our fleet insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="amed:FleetInsuranceExposureLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM1Njgz_06a184de-c2ba-4c72-b33f-e1a5d5afa7e8">0.4</ix:nonFraction>&#160;million per accident.</span></div></ix:continuation><div id="i6e7754e074c6458bb4bc162efb884713_70"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfMTU5MQ_0db4af87-7c8b-4375-8ff1-11f3ba8b9578" continuedAt="i0bd50a4b4f1f45739b851846ee3f99df" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bd50a4b4f1f45739b851846ee3f99df" continuedAt="i90561200c56a4b14b9aac3d3b1ca9159">Our operations involve servicing patients through our <ix:nonFraction unitRef="segments" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfODI_39a565dd-0f20-4caf-8cf4-2627d1c67488">four</ix:nonFraction> reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i90561200c56a4b14b9aac3d3b1ca9159"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our reorganization initiatives, management has revised its measurement of our reportable segments' operating income (loss). Effective January 1, 2023, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function in order to realize operational efficiencies. Additionally, effective January 1, 2023, we transitioned from the high acuity care segment to the home health segment the operations of a home health care center that was contributed to the high acuity care segment by one of our health system partners during 2022. Prior periods have been recast to conform to the current year presentation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfMTU5NA_d0145448-5af0-4391-9131-ea03e8e4546c" continuedAt="i1b05c8e49074430ab7ff4194e9a5ecff" escape="true">Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><ix:continuation id="i1b05c8e49074430ab7ff4194e9a5ecff"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:45.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0xLTEtMS02NzEyNA_8bd4740b-9234-48e1-8269-a30d5e257fac">343.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0zLTEtMS02NzEyNA_1a6c2250-5fc1-41c2-9d36-3da574cc4ada">193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi01LTEtMS02NzEyNA_24230851-d088-4b67-a05d-42169e8a5025">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi03LTEtMS02NzEyNA_1fabe4d4-b13b-4726-a984-187efe49f6f2">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi05LTEtMS02NzEyNA_6ef23a09-5a4e-4ce8-b106-184f285d9fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0xMS0xLTEtNjcxMjQ_6f545113-7fe6-4fd6-aadc-88578531173b">556.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0xLTEtMS02NzEyNA_b02f9dc0-5354-4902-9593-99615884f501">197.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0zLTEtMS02NzEyNA_892b78e6-1c6a-4c1a-ae0d-96d020c1ed22">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy01LTEtMS02NzEyNA_fe62e19d-040d-46a2-ba28-0aa432708008">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy03LTEtMS02NzEyNA_7a66e0d2-8f28-4157-aaff-309dbc358626">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy05LTEtMS02NzEyNA_3372a8a0-8631-4693-8e37-5b7650cc6fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0xMS0xLTEtNjcxMjQ_3f55abe9-b6ef-48f3-845e-79ea0291f62e">315.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0xLTEtMS02NzEyNA_6a57dfbd-374a-4f92-8441-6cca8dd266dc">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0zLTEtMS02NzEyNA_39d23323-d3e8-408f-a84f-9c01fbee845c">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC01LTEtMS02NzEyNA_ac34e3af-7b27-4167-917f-6b2f65458de6">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC03LTEtMS02NzEyNA_907f0e93-780f-48c7-8104-5103c6a6b9f9">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC05LTEtMS02NzEyNA_f7392758-1125-44ae-817b-d4657048ae3c">50.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0xMS0xLTEtNjcxMjQ_67a83ea9-1351-45c8-bbf5-276b6f150e67">194.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0xLTEtMS02NzEyNA_d321224e-dc7b-4e2d-9eda-cb55b00d3605">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0zLTEtMS02NzEyNA_085f5c8d-46c7-418a-9189-48bd1672ef2e">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS01LTEtMS02NzEyNA_b3e7e45e-bc63-449e-83bc-1e0b92ae18ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS03LTEtMS02NzEyNA_cca87762-deb5-4aa7-bb92-82011b8036b0">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS05LTEtMS02NzEyNA_7ce1656c-23a4-48d8-b26f-564bf9f74716">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0xMS0xLTEtNjcxMjQ_1a7e8cf8-b9b5-44cb-8bfc-76b8f72ef403">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0xLTEtMS02NzEyNA_c24433d8-a636-482c-b213-a1cacfce2daf">287.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0zLTEtMS02NzEyNA_dd3804df-5459-4294-95a9-1f7d82faf363">149.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi01LTEtMS02NzEyNA_2efd1868-0f3a-4950-820c-0a53f20e2c5b">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi03LTEtMS02NzEyNA_29730a41-b43a-4043-b7b7-a37654284a30">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi05LTEtMS02NzEyNA_d0491ba2-d0be-4faa-aa48-9e4334bc5ba8">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0xMS0xLTEtNjcxMjQ_a430ed15-409e-4303-832c-e88469c13607">514.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0xLTEtMS02NzEyNA_38a3775d-6eb6-4b46-8441-28546fd4793e">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0zLTEtMS02NzEyNA_8c42d027-881c-438d-82c0-abe738d01ffb">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy01LTEtMS02NzEyNA_47ac3941-f6e1-47c6-a3fa-0ba78e2e6702">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy03LTEtMS02NzEyNA_c824dff9-d32b-4db6-831c-e884b01b0ac0">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy05LTEtMS02NzEyNA_b12299ed-28bc-4f56-9617-338e7ed2c001">52.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0xMS0xLTEtNjcxMjQ_caa79fa1-7963-490f-8e1f-1d49a2eecbe3">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMS0xLTEtNjcxMjQ_9a8cfe65-2ee4-41c8-a6ed-3b37b23670ff">335.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMy0xLTEtNjcxMjQ_2bbcd07e-a97e-43ba-8bd5-c799eb6278e2">193.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtNS0xLTEtNjcxMjQ_3c44da34-41d2-45d1-8c0b-8460b17febdf">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtNy0xLTEtNjcxMjQ_90034899-4761-4beb-8d98-c38070a43bd3">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtOS0xLTEtNjcxMjQ_1ba23e3f-cc39-481b-abd3-a6c0f97b4361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMTEtMS0xLTY3MTI0_018bc5bd-0889-4c54-9e26-11e90d47bb97">545.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMS0xLTEtNjcxMjQ_e6a3389c-9bd0-48bc-8e49-cd15de16315e">185.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMy0xLTEtNjcxMjQ_f69846e6-2dad-4cbd-8435-c63f17ae67c2">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtNS0xLTEtNjcxMjQ_f4113744-c147-40d6-96f1-c34e39a7439c">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtNy0xLTEtNjcxMjQ_f664df6a-9841-44b3-bdc6-8160766f60fb">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtOS0xLTEtNjcxMjQ_74f9e29d-dd57-4b30-a546-f5998f5f58c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMTEtMS0xLTY3MTI0_a647859a-12e1-4dff-8c0a-ffc7ae25ba1e">304.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMS0xLTEtNjcxMjQ_2a512ae4-51e4-4033-88d9-2fa192f0c4cf">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMy0xLTEtNjcxMjQ_4257fd79-81c1-486a-ac5f-2c5fb8175507">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtNS0xLTEtNjcxMjQ_304369d6-5edb-4a7c-85db-30eb0177d9bc">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtNy0xLTEtNjcxMjQ_da88e9d5-4f31-4ae5-918e-615751d21c09">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtOS0xLTEtNjcxMjQ_a8143f42-bb53-4a66-b94f-c20a933b7109">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMTEtMS0xLTY3MTI0_0df6125c-f537-48a9-b04d-4ebc92135b1a">184.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMS0xLTEtNjcxMjQ_4c4aada5-60fb-4ee8-ae6c-7b8c54e130b3">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMy0xLTEtNjcxMjQ_975b669e-b841-40f9-a809-beda9b1c1265">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtNS0xLTEtNjcxMjQ_4eb107ef-df3b-4ff5-a6e1-336650d04ea0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtNy0xLTEtNjcxMjQ_9a856e90-63e9-440f-8840-97f9cce5e0fd">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtOS0xLTEtNjcxMjQ_144eeb1f-cda6-46ee-be9e-ba497c2b60fb">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMTEtMS0xLTY3MTI0_75e6a6aa-ed4d-4517-a49e-af8c2aa6ff33">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMS0xLTEtNjcxMjQ_21dcea2d-7013-49b3-9501-174844416af8">269.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMy0xLTEtNjcxMjQ_b746ba65-3bd1-4ac8-9d75-e164136ab5a5">158.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtNS0xLTEtNjcxMjQ_93f20e7d-8e5a-41d3-9ce6-82b7e8af2f04">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtNy0xLTEtNjcxMjQ_0b53950f-fd8d-4675-ba0d-25226c96c924">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtOS0xLTEtNjcxMjQ_6d73c7e4-6e29-4d73-972a-01519f933f11">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMTEtMS0xLTY3MTI0_83b7acdc-0cd5-404e-b65f-efeed9d8b3f3">497.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMS0xLTEtNjcxMjQ_9f7b2f2e-f3b0-40af-b4ea-edf030049fc7">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMy0xLTEtNjcxMjQ_1a7da9a8-c4c0-42e5-8ad2-0e335e458685">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctNS0xLTEtNjcxMjQ_95fdca3a-a608-4a76-aa35-cf0fbc350545">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctNy0xLTEtNjcxMjQ_c23c8220-b11e-4bf9-8bfc-a6f60cdde4fd">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctOS0xLTEtNjcxMjQ_f3cbcd3c-1699-4acf-963c-91bfebf8864d">49.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMTEtMS0xLTY3MTI0_62792af8-d465-4e47-9c63-ddacc9b897fb">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div id="i6e7754e074c6458bb4bc162efb884713_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMjE0Mg_5b9032b1-d946-4ebe-977e-f5fa70d0c475" continuedAt="i12843a037011491080645592a16adf6f" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><ix:continuation id="i12843a037011491080645592a16adf6f" continuedAt="i4e6e48c509ef46269f991b1ad4a3da6d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i375e7e760e9d4aa1a92757ae86a0d210_I20210802" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMTI4OQ_c0b2d9fc-b94b-4cf8-a2e9-2bab93999da0">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i830c428bb89b41599cc12c2881b394b5_D20210802-20221231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMTMzMg_72f2ec09-1451-445c-b064-fb943afbd6f6">December 31, 2022</ix:nonNumeric> (the "2022 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. We did not repurchase any shares under the 2022 Share Repurchase Program during the three-month period ended March 31, 2022. The 2022 Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i5be9befb4f734cae91c1a764171dddf2_I20230202" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfNTQ5NzU1ODIwNzQ1_ea67c1e0-cf8a-4167-b6bd-137bb11efb1c">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="ic23b318b43a44f01bf8a8c58852671ce_D20230202-20231231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfNTQ5NzU1ODIwNzU5_96958522-3e49-424d-ad17-ac0bbb899c66">December 31, 2023</ix:nonNumeric> (the "2023 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e6e48c509ef46269f991b1ad4a3da6d">repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of March 31, 2023.</ix:continuation></span></div><div id="i6e7754e074c6458bb4bc162efb884713_82"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfNDQ2_1d614c04-63ff-4b5b-9707-ffee4cc8c58e" continuedAt="icf1c1ea189e84e8c89748d8f91ad6e45" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf1c1ea189e84e8c89748d8f91ad6e45">We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i0ebd4093f9e54759abfee45439a836a5_D20220101-20220331" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfMjYz_1f4af896-3e36-4ce2-a002-39352371e7c1"><ix:nonFraction unitRef="usd" contextRef="ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfMjYz_243708b9-4e2e-4c25-b8af-b26a0a313842">2.4</ix:nonFraction></ix:nonFraction>&#160;million during each of the three-month periods ended March&#160;31, 2023 and 2022 in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</ix:continuation></span></div><div id="i6e7754e074c6458bb4bc162efb884713_88"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTY4_fc0c6c21-458d-4549-894e-6bcf11f0be48" continuedAt="i697c96320bf3444d8537ce96d077effb" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i697c96320bf3444d8537ce96d077effb" continuedAt="ia4dc18cd3ece4896ace01c30deac5b18"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2023, Amedisys, Option Care Health, Inc., a Delaware corporation ("Option Care Health"), and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Option Care Health ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides for, among other things and subject to the satisfaction or waiver of the conditions set forth therein, the merger of Merger Sub with and into Amedisys (the "Merger"), with Amedisys surviving the Merger as a wholly-owned subsidiary of Option Care Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Amedisys&#8217; common stock issued and outstanding (excluding shares held by Amedisys as treasury stock or owned by Option Care Health or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time) will be converted into the right to receive <ix:nonFraction unitRef="shares" contextRef="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503" decimals="4" name="amed:BusinessAcquisitionShareExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTQ5NzU1ODIxMzg3_ff4ee86e-5ae3-4573-baca-d910e45a191f">3.0213</ix:nonFraction> (the "Exchange Ratio") fully paid and nonassessable shares of Option Care Health common stock (and, if applicable, cash in lieu of fractional shares) (the "Merger Consideration"), less any applicable withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Merger Agreement, as of the Effective Time, each outstanding time-based vesting Amedisys restricted stock unit award (each, an "Amedisys RSU") and Amedisys option to purchase shares of Amedisys common stock (each, an "Amedisys Option") will be converted into an equivalent restricted stock unit award or option, as applicable, of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted RSU" or a "Converted Option", as applicable) equal to (1) the number of shares of Amedisys common stock subject to such Amedisys RSU or Amedisys Option immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, rounded to the nearest whole number of shares of Option Care Health common stock. A Converted Option will have an exercise price per share equal to (1) the exercise price per share of the equivalent Amedisys Option immediately prior to the Effective Time divided by (2) the Exchange Ratio, rounded to the nearest whole cent. In addition, each Amedisys performance-based vesting restricted stock unit award (each, an "Amedisys PSU") will be converted into an equivalent restricted stock unit award of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted PSU") equal to (1) the number of shares of Amedisys common stock subject to such Amedisys PSU immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, assuming achievement at target performance with respect to any Amedisys PSU for which the level of performance-vesting has not yet been determined, rounded to the nearest whole number of shares of Option Care Health common stock. Each Converted RSU, Converted Option and Converted PSU shall have the same terms and conditions (including any double-trigger protections but excluding any performance-based vesting conditions) that applied to the corresponding Amedisys RSU, Amedisys Option or Amedisys PSU immediately prior to the Effective Time (other than any other terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement or other immaterial or administrative or ministerial changes).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The completion of the Merger is subject to certain conditions, including: (1) the adoption of the Merger Agreement by Amedisys&#8217; stockholders, (2) the adoption of the Charter Amendment (as defined in the Merger Agreement) and the approval of the issuance of shares of Option Care Health common stock in the Merger by Option Care Health stockholders, (3) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the receipt of other required regulatory approvals, (5) the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger, (6) the approval for listing of the shares of Option Care Health common stock to be issued in connection with the Merger on the Nasdaq Global Select Market and the effectiveness of a registration statement with respect to such common stock, (7) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (8) performance by each party of its respective obligations under the Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amedisys expects to incur certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, as well as other customary payments. If the Merger Agreement is terminated due to a recommendation change by Amedisys&#8217; board of directors or under certain circumstances where a proposal for an alternative transaction has been made to Amedisys and, within 12 months following termination, Amedisys enters into a definitive </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia4dc18cd3ece4896ace01c30deac5b18">agreement providing for an alternative transaction or consummates an alternative transaction, Amedisys will be required to pay to Option Care Health a termination fee of $<ix:nonFraction unitRef="usd" contextRef="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503" decimals="-5" name="amed:BusinessAcquisitionTerminationFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTQ5NzU1ODIxMzk1_6e04d26d-ae07-4835-838e-cb8318d71583">106,000,000</ix:nonFraction>.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three-month period ended March&#160;31, 2023. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 16, 2023 (the &#8220;Form 10-K&#8221;). Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;the Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 72% and 75% of our consolidated net service revenue derived from Medicare for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients assistance with the essential activities of daily living. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility ("SNF") care to patients in their homes. As of March&#160;31, 2023, we owned and operated 348 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 9 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Startups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures/Closures/Consolidations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) We have 9 admitting high acuity care joint ventures, which operate in 10 markets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed Merger</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2023, Amedisys, Option Care Health, Inc., a Delaware corporation ("Option Care Health"), and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Option Care Health ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides for, among other things and subject to the satisfaction or waiver of the conditions set forth therein, the merger of Merger Sub with and into Amedisys (the "Merger"), with Amedisys surviving the Merger as a wholly-owned subsidiary of Option Care Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Amedisys&#8217; common stock issued and outstanding (excluding shares held by Amedisys as treasury stock or owned by Option Care Health or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time) will be converted into the right to receive 3.0213 (the "Exchange Ratio") fully paid and nonassessable shares of Option Care Health common stock (and, if applicable, cash in lieu of fractional shares) (the "Merger Consideration"), less any applicable withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Merger Agreement, as of the Effective Time, each outstanding time-based vesting Amedisys restricted stock unit award (each, an "Amedisys RSU") and Amedisys option to purchase shares of Amedisys common stock (each, an "Amedisys Option") will be converted into an equivalent restricted stock unit award or option, as applicable, of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted RSU" or a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">"Converted Option", as applicable) equal to (1) the number of shares of Amedisys common stock subject to such Amedisys RSU or Amedisys Option immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, rounded to the nearest whole number of shares of Option Care Health common stock. A Converted Option will have an exercise price per share equal to (1) the exercise price per share of the equivalent Amedisys Option immediately prior to the Effective Time divided by (2) the Exchange Ratio, rounded to the nearest whole cent. In addition, each Amedisys performance-based vesting restricted stock unit award (each, an "Amedisys PSU") will be converted into an equivalent restricted stock unit award of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted PSU") equal to (1) the number of shares of Amedisys common stock subject to such Amedisys PSU immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, assuming achievement at target performance with respect to any Amedisys PSU for which the level of performance-vesting has not yet been determined, rounded to the nearest whole number of shares of Option Care Health common stock. Each Converted RSU, Converted Option and Converted PSU shall have the same terms and conditions (including any double-trigger protections but excluding any performance-based vesting conditions) that applied to the corresponding Amedisys RSU, Amedisys Option or Amedisys PSU immediately prior to the Effective Time (other than any other terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement or other immaterial or administrative or ministerial changes).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The completion of the Merger is subject to certain conditions, including: (1) the adoption of the Merger Agreement by Amedisys&#8217; stockholders, (2) the adoption of the Charter Amendment (as defined in the Merger Agreement) and the approval of the issuance of shares of Option Care Health common stock in the Merger by Option Care Health stockholders, (3) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the receipt of other required regulatory approvals, (5) the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger, (6) the approval for listing of the shares of Option Care Health common stock to be issued in connection with the Merger on the Nasdaq Global Select Market and the effectiveness of a registration statement with respect to such common stock, (7) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (8) performance by each party of its respective obligations under the Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The board of directors of each of Option Care Health and Amedisys has approved the Merger Agreement and the transactions contemplated thereby.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, which has been filed with the SEC as an exhibit to Amedisys&#8217; Current Report on Form 8-K filed on May 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Leadership</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2023, our Board of Directors named Richard Ashworth as the Company&#8217;s President and Chief Executive Officer and elected Mr. Ashworth as a director, all effective April 10, 2023. Mr. Ashworth will not serve on any committees of the Board of Directors. Paul B. Kusserow ceased serving as Chief Executive Officer effective April 10, 2023 but will continue serving as Chairman of the Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Personal Care Divestiture</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestiture closed on March 31, 2023. We received net proceeds of $47.8 million and recognized a loss of $2.2 million in connection with the divestiture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Centers for Medicare and Medicaid Services ("CMS") Payment Updates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2022, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2023, effective for services provided beginning October 1, 2022. CMS estimated hospices serving Medicare beneficiaries would see a 3.8% increase in payments. This increase is the result of a 4.1% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act ("PPACA") less a 0.3% productivity adjustment. Additionally, CMS increased the aggregate cap amount by 3.8% to $32,487. Based on our analysis of the final rule, we expect our impact to be in line with the 3.8% increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 31, 2023, CMS issued a proposed rule to update hospice payment rates and the wage index for fiscal year 2024, effective for services provided beginning October 1, 2023. CMS estimates hospices serving Medicare beneficiaries will see a 2.8% increase in payments. This increase is the result of a 3.0% market basket adjustment as required under PPACA less a 0.2% productivity adjustment. Additionally, CMS proposed to increase the aggregate cap amount by 2.8% to $33,397. Based on our analysis of the proposed rule, we expect our impact to be in line with the 2.8% increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2022, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2023. CMS estimated that the final rule would result in a 0.7% increase in payments to home health providers. This increase is the result of a 4.0% payment update (4.1% market basket adjustment less a 0.1% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -3.5% based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% permanent adjustment was derived from a -3.925% behavioral assumption adjustment which was only applied to the 30-day payment rate and not the low utilization payment adjustment. The -3.925% behavioral assumption adjustment is only half of the total proposed adjustment of -7.85%. The remaining -3.925% adjustment will be considered in future rulemaking. The final rule also finalized a permanent 5% cap on negative wage index changes for home health agencies. Based on our analysis of the final rule, we expect our impact to be flat, which is less than the estimated 0.7% rate increase.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the permanent adjustments, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS has elected not to apply the temporary adjustment to calendar year 2023; however, CMS is still considering how to best apply the adjustment in future rulemaking. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sequestration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Congress passed the bipartisan Coronavirus Aid, Relief and Economic Security Act ("CARES Act") which provided for the suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements for the period April 1, 2022 through June 30, 2022 and was fully reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The reinstatement of sequestration has resulted in a reduction of our net service revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance have been impacted by COVID-19. While we currently believe that we have a reasonable view of operations, the ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations, is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three-Month Period Ended March&#160;31, 2023 Compared to the Three-Month Period Ended March&#160;31, 2022 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On a consolidated basis, our operating income decreased $6 million on an $11 million increase in net service revenue. Our year-over-year results were impacted by the return of sequestration (prior year included a benefit of $9 million associated with the suspension of sequestration) and the acquisitions of Evolution and AssistedCare on April 1, 2022 (which combined contributed $10 million in net service revenue and an operating loss of less than $1 million for the three-month period ended March 31, 2023). Excluding these items, our operating income increased $4 million on a $10 million increase in net service revenue due to the hospice rate increase, lower COVID-related costs and lower depreciation and amortization partially offset by planned wage increases, an increase in our general and administrative expenses and higher revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a $10 million increase in our general and administrative expenses compared to prior year. Excluding our acquisitions, our general and administrative expenses increased $7 million (4%) primarily due to costs associated with our clinical optimization and reorganization initiatives, planned wage increases, increased information technology fees, higher recruiting fees, higher insurance-related costs and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated income statement as of January 1, 2023 due to the modification of our fleet leases. Partially offsetting these items, our general and administrative expenses were favorably impacted by lower staffing levels and lower executive compensation costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense includes the following items (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings (loss) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $4 million year over year as a result of higher interest rates on our outstanding term loan borrowings under our Third Amended Credit Agreement (see Note 6 - Long-Term Obligations to our condensed consolidated financial statements for additional information regarding our Third Amended Credit Agreement). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Miscellaneous, net includes a $2 million loss on the sale our personal care business recorded during the three-month period ended March 31, 2023 (see Note 5 - Dispositions to our condensed consolidated financial statements for additional information) which was partially offset by gains on the sale of our fleet vehicles totaling $1 million during the three-month period ended March 31, 2023. Our fleet leases were modified effective January 1, 2023 resulting in a change in the presentation of gains which were previously reflected as a reduction to our general and administrative expenses (see Note 6 - Long-Term Obligations to our condensed consolidated financial statements for additional information). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,620&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting clinician cost per visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manager cost per visit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost per visit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the three-month period ended March 31, 2022 and the reinstatement of sequestration at 2% for the three-month period ended March 31, 2023. </span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Prior year has been recast to conform to the current year presentation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. The home health operations were reflected in our high acuity care segment during 2022. Effective January 1, 2023, the operating results of this home health care center are included within our home health segment. Prior periods have been recast to conform to the current year presentation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $10 million on an $8 million increase in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare (which contributed net service revenue of $10 million and an operating loss of less than $1 million for the three-month period ended March 31, 2023) and a prior year benefit of $5 million in connection with the suspension of sequestration. Excluding these items, our operating income decreased $4 million on a $3 million increase in net service revenue. The decline in our operating income is primarily due to a shift in our payor mix, higher revenue adjustments and planned wage increases. These items were partially offset by improvement in our operating performance driven by improvements in clinician utilization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $8 million. Excluding our acquisitions and the sequestration benefit recognized in prior year, our net service revenue increased $3 million due to 5% total volume growth and an increase in our non-Medicare revenue per visit. Our volumes continue to be impacted by staffing shortages driven by the competitive labor market. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Inclusive of Depreciation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 6% due to a 3% increase in our total cost per visit and a 3% increase in total visits. The 3% increase in our total cost per visit is primarily due to planned wage increases, an increase in salaried employees and visit mix partially offset by lower COVID-related costs. The 3% increase in total visits was driven by growth in volumes and our acquisitions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses increased $6 million. Excluding our acquisitions, our general and administrative expenses increased $3 million primarily due to planned wage increases, higher information technology fees and higher insurance-related costs partially offset by lower staffing levels and savings associated with clinical optimization and reorganization activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total includes acquisitions and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $9 million on flat net service revenue. Our year over year results were positively impacted by the increase in reimbursement effective October 1, 2022, savings associated with clinical optimization and reorganization initiatives, reductions in staffing levels and a decrease in our general and administrative expenses. These items were partially offset by a benefit recognized in the prior year totaling $4 million associated with the suspension of sequestration, a decline in our hospice average daily census and planned wage increases.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue remained flat as the increase in reimbursement effective October 1, 2022 was offset by the reinstatement of sequestration at 2% and a decline in our average daily census. Our decline in average daily census year over year is primarily due to a decline in our hospice admissions as well as care center closures. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Inclusive of Depreciation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service decreased 5% primarily due to a 4% decrease in our cost of service per day. The 4% decrease in our cost of service per day is due to reductions in staffing levels, savings associated with clinical optimization and reorganization initiatives, lower utilization of contractors to supplement our staffing levels and lower COVID-19 costs. These items were partially offset by planned wage increases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses decreased $3&#160;million primarily due to reductions in staffing levels and travel and training spend partially offset by planned wage increases.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr></table></div><div style="margin-top:9pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:9pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the sale of our personal care business on March 31, 2023.</span></div><div style="margin-top:9pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment increased $1 million on a $1 million increase in net service revenue driven by an increase in rates. Our cost of service and general and administrative expenses remained flat. </span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk revenue per episode</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk revenue per episode</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of admitting joint venture markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Prior year has been recast to conform to the current year presentation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our reorganization initiatives, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function effective January 1, 2023. Additionally, during the three-month period ended March 31, 2022, we entered into a transaction with one of our high acuity care health system partners in which our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. The home health operations were reflected in our high acuity care segment during 2022. Effective January 1, 2023, the operating results of this home health care center are included within our home health segment. Prior periods have been recast to conform to the current year presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our year over year results reflect net service revenue growth resulting from our home recovery care services. Our gross margin for the three-month period ended March 31, 2023 reflects a forecasted loss on the first performance year of our new risk-based palliative care contract resulting from investments in resources to support this contract as well as future palliative care arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect our high acuity care segment to continue to generate operating losses, we also expect improvement as we leverage our operating structure through growth in current and future joint ventures and expansion of palliative care at home arrangements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Inclusive of Depreciation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, costs associated with our virtual care unit (&#8220;VCU&#8221;), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth and costs associated with resources to support our palliative care at home programs. The increase in cost of service over prior year is primarily related to a forecasted loss on the first performance year of our new risk-based palliative care contract resulting from investments in resources to support this contract as well as future palliative care arrangements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses which primarily consist of salaries and benefits were flat year over year. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Prior year has been recast to conform to the current year presentation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our reorganization initiatives, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function effective January 1, 2023. Prior periods have been recast to conform to the current year presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate general and administrative expenses increased $7 million during the three-month period ended March 31, 2023 primarily due to planned wage increases, costs associated with our clinical optimization and reorganization initiatives, higher recruiting fees and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated income statement as of January 1, 2023 due to the modification of our fleet leases partially offset by lower executive compensation costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate depreciation and amortization decreased $4 million during the three-month period ended March 31, 2023 due to a reduction in amortization expense related to acquired names and non-compete agreements that were fully amortized as of December 31, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased $22.6&#160;million during the three-month period ended March&#160;31, 2023 compared to the three-month period ended March&#160;31, 2022 primarily due to lower operating income and higher interest payments combined with the timing of the payment of accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities primarily consist of the purchase of property and equipment, investments and acquisitions. Cash provided by investing activities totaled $45.9 million during the three-month period ended March&#160;31, 2023 primarily due to the divestiture of our personal care line of business. Cash used in investing activities totaled $16.1 million during the three-month period ended March&#160;31, 2022 primarily due to our purchase of a cost method investment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options, proceeds related to the purchase of stock under our employee stock purchase plan and our purchase of company stock under our stock repurchase program. Cash used in financing activities totaled $56.9 million and $7.4 million during the three-month periods ended March&#160;31, 2023 and 2022, respectively, and was primarily related to the repayment of borrowings and the remittance of taxes associated with shares withheld on non-cash compensation. Net proceeds from the divestiture of our personal care line of business were used to pay a portion of our Term Loan during the three-month period ended March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended March&#160;31, 2023, we spent $1.6 million in capital expenditures and investments in technology assets as compared to $1.1 million during the three-month period ended March&#160;31, 2022. Our capital expenditures and investments in technology assets for 2023 are expected to be approximately $17.0 million to $18.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $49.4 million in cash and cash equivalents and $519.2 million in availability under our $550.0&#160;million Revolving Credit Facility. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements for the next twelve months and beyond.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable decreased $2.7&#160;million from December 31, 2022. Our cash collection as a percentage of revenue was 99% and 97% for the three-month periods ended March&#160;31, 2023 and 2022, respectively. Our days revenue outstanding at March&#160;31, 2023 was 46.3 days, which is an increase of 0.2 days from December&#160;31, 2022 and flat when compared to March 31, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by pre-claim reviews required by the Medicare Administrative Contractors in the five Review Choice Demonstration states, voluntary pre-bill edits and review, efforts to secure needed documentation to bill (orders, consents, etc.), integrations of recent acquisitions, changes of ownership and any regulatory and procedural updates impacting claim submission. The timely filing deadline for Medicare is one year from the date of the last billable service in the 30-day billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:42.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At March 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.1&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over 365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022 by our average daily net service revenue for the three-month periods ended March&#160;31, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 10, 2023, we entered into the Third Amendment to our Credit Agreement (as amended by the Third Amendment, the "Third Amended Credit Agreement"). The Third Amendment (i) formally replaced the use of the London Interbank Offered Rate ("LIBOR") with the Secured Overnight Financing Rate ("SOFR") for interest rate pricing and (ii) allowed for the disposition of our personal care business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Term SOFR Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Administrative Agent, and (c) the Term SOFR Rate plus 1% per annum. The &#8220;Term SOFR Rate&#8221; means the quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023 and 2022, we had no outstanding borrowings under our $550.0 million Revolving Credit Facility. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 6.1% and 1.7% for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, our consolidated leverage ratio was 1.6, our consolidated interest coverage ratio was 10.3 and we are in compliance with our covenants under the Third Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, our availability under our $550.0&#160;million Revolving Credit Facility was $519.2 million as we have no outstanding borrowings and $30.8 million outstanding in letters of credit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 6 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2022 (the "2022 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. We did not repurchase any shares under the 2022 Share Repurchase Program during the three-month period ended March 31, 2022. The 2022 Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of March 31, 2023.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations have been materially impacted by the current inflationary environment as we have experienced higher labor costs and increases in supply costs, fuel costs and mileage reimbursements. We expect inflation to continue to impact our operations in 2023. As of March 31, 2023, the impacts of inflation on our results of operations have been partially mitigated by rate increases, improvements in clinician utilization, reductions in hospice staffing levels and clinical optimization and reorganization initiatives. No assurance can be given as to our ability to offset the impacts of inflation in the future.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2022 Annual Report on Form 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. These critical accounting estimates include revenue recognition, business combinations and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2022 Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Secured Overnight Financing Rate ("SOFR") and the Prime Rate, and therefore, our condensed consolidated income statement and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of March&#160;31, 2023, the total amount of outstanding debt subject to interest rate fluctuations was $383.1 million. A 1.0% interest rate change would cause interest expense to change by approximately $3.8 million annually, assuming the Company makes no principal repayments.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Quarterly Report on Form 10-Q, as of March&#160;31, 2023, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March&#160;31, 2023, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended March&#160;31, 2023, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of March&#160;31, 2023, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i6e7754e074c6458bb4bc162efb884713_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022. These risks, which could materially affect our business, financial condition or future results, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition and/or operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, the following risks are related to the proposed Merger:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The proposed Merger is subject to approval of our stockholders as well as the satisfaction of other closing conditions, including government consents and approvals, some or all of which may not be satisfied or completed within the expected timeframe, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of the Merger is subject to a number of closing conditions, including obtaining the approval of our stockholders and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. We can provide no assurance that all required consents and approvals will be obtained or that all closing conditions will otherwise be satisfied (or waived, if applicable), and, even if all required consents and approvals can be obtained and all closing conditions are satisfied (or waived, if applicable), we can provide no assurance as to the terms, conditions and timing of such consents and approvals or the timing of the completion of the Merger. Many of the conditions to completion of the Merger are not within our control, and we cannot predict when or if these conditions will be satisfied (or waived, if applicable). Any adverse consequence of the pending Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party&#8217;s obligation to consummate the Merger is also subject to the accuracy of the representations and warranties of the other party (subject to certain exceptions)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and performance by each party of its respective obligations under the Merger Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including, agreements by us and Option Care Health to use our reasonable best efforts to carry on our respective businesses in all material respects in the ordinary course, consistent with past practice, and to preserve our business organization and relationships with customers, suppliers, licensors, licensees and other third parties, and to comply with certain operating covenants. In addition, the Merger Agreement may be terminated under certain specified circumstances, including, but not limited to, if our board of directors make an Amedisys Recommendation Change (as defined in the Merger Agreement) or if the board of directors of Option Care Health makes an Option Care Health Recommendation Change (as defined in the Merger Agreement). As a result, we cannot assure you that the Merger will be completed, even if our stockholders approve the Merger, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not complete the proposed Merger within the time frame we anticipate or at all, which could have an adverse effect on our business, financial results and/or operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed Merger may not be completed within the expected timeframe, or at all, as a result of various factors and conditions, some of which may be beyond our control. If the Merger is not completed for any reason, including as a result of our stockholders failing to adopt the Merger Agreement, our stockholders will not receive any payment for their shares of our common stock in connection with the Merger. Instead, we will remain a public company, our common stock will continue to be listed and traded on The Nasdaq Global Select Market and registered under the Exchange Act, and we will be required to continue to file periodic reports with the SEC. Moreover, our ongoing business may be materially adversely affected, and we would be subject to a number of risks, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience negative reactions from the financial markets, including negative impacts on our stock price, and it is uncertain when, if ever, the price of the shares would return to the prices at which the shares currently trade;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience negative publicity, which could have an adverse effect on our ongoing operations including, but not limited to, retaining and attracting employees, customers, partners, suppliers and others with whom we do business;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will still be required to pay certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, which may relate to activities that we would not have undertaken other than in connection with the Merger;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to pay a termination fee to Option Care Health of $106,000,000, as required under the Merger Agreement under certain circumstances;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">while the Merger Agreement is in effect, we are subject to restrictions on our business activities, including, among other things, restrictions on our ability to engage in certain kinds of material transactions, which could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may as a result materially adversely affect our business, results of operations and financial condition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">matters relating to the Merger require substantial commitments of time and resources by our management, which could result in the distraction of management from ongoing business operations and pursuing other opportunities that could have been beneficial to us; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may commit significant time and resources to defending against litigation related to the Merger.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Merger is not consummated, the risks described above may materialize, and they may have a material adverse effect on our business operations, financial results and stock price, particularly to the extent that the current market price of our common stock reflects an assumption that the Merger will be completed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to various uncertainties while the Merger is pending that may cause disruption and may make it more difficult to maintain relationships with employees, customers and other third-party business partners.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our results of operation and our business. Uncertainty as to whether the Merger will be completed may affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the Merger is pending because employees may experience uncertainty about their roles following the Merger. As mentioned above, a substantial amount of our management&#8217;s and employees&#8217; attention is being directed toward the completion of the Merger and thus is being diverted from our day-to-day operations. Uncertainty as to our future could adversely affect our business and our relationship with customers and potential customers. For example, customers, suppliers and other third parties may defer decisions concerning working with us, or seek to change existing business relationships with us. Changes to or termination of existing business relationships could adversely affect our revenue, earnings and financial condition, as well as the market price of our common stock. The adverse effects of the pendency of the Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In certain instances, the Merger Agreement requires us to pay a termination fee to Option Care Health, which could affect the decisions of a third party considering making an alternative acquisition proposal.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, we may be required to pay Option Care Health a termination fee of $106,000,000 under specified conditions, including in the event the Merger Agreement is terminated due to a recommendation change by our board of directors or under certain circumstances where a proposal for an alternative transaction has been made to us and, within 12 months following termination, we enter into a definitive agreement providing for an alternative transaction or consummate an alternative transaction. This payment could affect the structure, pricing and terms proposed by a third party seeking to acquire or merge with us and could discourage a third party from making a competing acquisition proposal, including a proposal that would be more favorable to our stockholders than the Merger.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred, and will continue to incur, significant costs and expenses, including regulatory costs, fees for professional services and other transaction costs in connection with the Merger, for which we will have received little or no benefit if the Merger is not completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses. Many of these fees and costs will be payable by us even if the Merger is not completed and may relate to activities that we would not have undertaken other than to complete the Merger.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation challenging the Merger Agreement may prevent the Merger from being consummated within the expected timeframe or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits may be filed against us, our board of directors or other parties to the Merger Agreement, challenging the Merger or making other claims in connection therewith. Such lawsuits may be brought by our purported stockholders and may seek, among other things, to enjoin consummation of the Merger. One of the conditions to the consummation of the Merger is the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger. As such, if the plaintiffs in such potential lawsuits are successful in obtaining an injunction prohibiting the defendants from completing the Merger on the agreed upon terms, then such injunction may prevent the Merger from becoming effective, or from becoming effective within the expected timeframe.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended March&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:33.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(a)&#160;Total&#160;Number<br/>of&#160;Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(b)&#160;Average&#160;Price<br/>Paid&#160;per&#160;Share&#160;(or<br/>Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number&#160;of<br/>Shares (or Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(d)&#160;Maximum&#160;Number&#160;(or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units) That May Yet Be<br/>Purchased Under the<br/>Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023&#160;to&#160;January 31,&#160;2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1,&#160;2023&#160;to February 28,&#160;2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023 to March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2018 Omnibus Incentive Compensation Plan.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i6e7754e074c6458bb4bc162efb884713_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report or Registration Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21_equitypurchaseag.htm">Equity Purchase Agreement, by and among Associated Home Care, L.L.C., Amedisys Personal Care, LLC, Amedisys, Inc. and HouseWorks Holdings, LLC, dated February 10, 2023 (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626221000110/amed-20213009xex32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 20, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_separationagree.htm">Separation Agreement and General Release, by and between Amedisys, Inc. and Christopher T. Gerard</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102thirdamendmentto.htm">Third Amendment to Amended and Restated Credit Agreement, dated as of March 10, 2023, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, the Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and the other L/C Issuers party thereto (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx311.htm">Certification of Richard Ashworth, President and Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx312.htm">Certification of Scott G. Ginn, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx312.htm">Acting Chief Operating Officer, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx312.htm">Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx321.htm">Certification of Richard Ashworth, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20233103xexx322.htm">Certification of Scott G. Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i6e7754e074c6458bb4bc162efb884713_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.912%"><tr><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.062%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT G. GINN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Financial Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Duly Authorized Officer</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit21_equitypurchaseag.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id90c41438ec044d2ab4dc073fdf3e6fa_1"></div><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 2.1</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">______________________________________________________________________</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EQUITY PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by and among</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASSOCIATED HOME CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS PERSONAL CARE, LLC,</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOUSEWORKS HOLDINGS, LLC</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated as of February 10, 2023</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">______________________________________________________________________</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Table of Contents</font></div><div style="text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 1 PURCHASE AND SALE OF INTERESTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Purchase and Sale of Interests</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Payments at the Closing</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Calculation of Closing and Final Consideration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">The Closing</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 2 CONDITIONS TO CLOSING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conditions to All Parties&#8217; Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conditions to Buyer&#8217;s Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conditions to Seller&#8217;s Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Waiver of Conditions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">2.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Withholding</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 3 REPRESENTATIONS AND WARRANTIES&#160;OF SELLER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Power and Organization</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Authorization&#59; Execution and Delivery&#59; Valid and Binding </a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">A</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">greement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Breach</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Ownership</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Brokerage</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">3.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Litigation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 4 REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Organization and Corporate Power</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Subsidiaries</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement&#59; No Breach.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Capital Stock</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Financial Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Absence of Certain Developments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.07</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Title to Properties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.08</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Real Property</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.09</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Tax Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.10</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Contracts and Commitments.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.11</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Intellectual Property.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.12</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Litigation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.13</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Employee Benefit Plans.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.14</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Insurance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.15</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Compliance with Laws&#59; Permits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.16</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Environmental Compliance and Conditions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.17</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Affiliated Transactions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.18</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Employment and Labor Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.19</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Accounts Receivable and Accounts Payable</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.20</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Brokerage</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.21</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Bank Accounts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.22</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Power of Attorney</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.23</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Healthcare Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.24</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Relationships with Customers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.25</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Investment Company Status</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.26</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Home Health Services Business.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.27</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Miscellaneous.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">4.28</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Other Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BUYER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Organization and Power</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Breach</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Litigation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Brokerage</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Investment Representation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.07</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Sufficient Funds</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.08</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Solvency</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">5.09</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Other Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 6 CERTAIN PRE-CLOSING COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conduct of the Business</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Access to Books and Records</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Third-Party Consents</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conditions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Notifications</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Exclusivity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.07</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Regulatory Filings.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.08</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Employment Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.09</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Miscellaneous.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.10</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Cash Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">6.11</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Transition Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 7 POST-CLOSING COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Access to Books and Records</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Employment Matters.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">7.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Confidentiality</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 8 TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Effect of Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 9 ADDITIONAL COVENANTS AND AGREEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">37</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Survival</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Indemnification of Buyer.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Indemnification of Seller</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Expiration of Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Inter-Party Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Third Party Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.07</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Determination of Loss Amount.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.08</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Acknowledgments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.09</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Tax Matters.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.10</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Reserved.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.11</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Director and Officer Liability and Indemnification</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.12</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Release</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.13</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Non-Competition and Non-Solicitation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9.14</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Further Assurances</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 10 DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">51</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Definitions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">51</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Other Definitional Provisions.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">ARTICLE 11 MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.01</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Press Releases and Communications</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.02</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Expenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.03</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Prevailing Party</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.04</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Knowledge Defined</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.05</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Notices</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.06</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.07</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.08</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Strict Construction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.09</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Amendment and Waiver</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.10</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Complete Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.11</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Counterparts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.12</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Governing Law</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.13</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Consent to Jurisdiction and Service of Process</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.14</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Waiver of Jury Trial</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.15</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">No Third Party Beneficiaries</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.16</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Representation of the Seller and their Affiliates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.17</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Deliveries to Buyer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.18</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Conflict Between Transaction Documents</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.19</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Specific Performance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11.20</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">Dispute Resolution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id90c41438ec044d2ab4dc073fdf3e6fa_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibits</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit A&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Escrow Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Release Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedules and Annexes</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disclosure Schedule</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 1.03(a)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Sample Aggregate Closing Consideration Calculation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.01&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Conduct of Business Prior to Closing</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.03&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Third Party Consents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.08&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Employee Contacts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.09(e)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Terminated Contracts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.11(b) &#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Transferring Employees</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 6.11(c) &#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Designated Contracts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 9.02(a)(v)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Specifically Indemnified Matters</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 9.09(g)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Allocation Methodology</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 10.01(i)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Net Working Capital Accounting Principles </font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_158"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Index of Defined Terms</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounting Firm&#160;&#160;&#160;&#160;1.03(c)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acquired Business&#160;&#160;&#160;&#160;9.13(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Consents&#160;&#160;&#160;&#160;6.03</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Action&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Affiliate&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Closing Consideration&#160;&#160;&#160;&#160;1.03(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement&#160;&#160;&#160;&#160;Preamble</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allocation&#160;&#160;&#160;&#160;9.09(g)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alternative Arrangements&#160;&#160;&#160;&#160;9.07(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AAA&#160;&#160;&#160;&#160;11.20(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance Sheet Date&#160;&#160;&#160;&#160;4.05(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit Plan&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Billing Arrangements&#160;&#160;&#160;&#160;4.26(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Business Day&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Butler Snow&#160;&#160;&#160;&#160;11.16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer&#160;&#160;&#160;&#160;Preamble</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer Employee Benefit Plans&#160;&#160;&#160;&#160;7.02(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer Indemnitees&#160;&#160;&#160;&#160;9.02(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer&#8217;s Representatives&#160;&#160;&#160;&#160;6.02</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash on Hand&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CERCLA&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change of Control Payments&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Claiming Party&#160;&#160;&#160;&#160;9.05</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Closing&#160;&#160;&#160;&#160;1.04</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Closing Date&#160;&#160;&#160;&#160;1.04</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Closing Statement&#160;&#160;&#160;&#160;1.03(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Code&#160;&#160;&#160;&#160;4.13(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company&#160;&#160;&#160;&#160;Preamble</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company Intellectual Property&#160;&#160;&#160;&#160;4.11(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company Lease&#160;&#160;&#160;&#160;4.08</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidential Information&#160;&#160;&#160;&#160;7.03(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality Agreement&#160;&#160;&#160;&#160;6.02</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covered Employees&#160;&#160;&#160;&#160;7.02(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deductible&#160;&#160;&#160;&#160;9.02(b)(ii)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Defending Party&#160;&#160;&#160;&#160;9.05</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disclosure Schedule&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disputed Items&#160;&#160;&#160;&#160;1.03(c)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Distribution Schedule&#160;&#160;&#160;&#160;1.03(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Employees&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Environmental Laws&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow Agent&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow Agreement&#160;&#160;&#160;&#160;1.02(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Aggregate Closing Consideration&#160;&#160;&#160;&#160;1.03(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Closing Statement&#160;&#160;&#160;&#160;1.03(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Final Aggregate Closing Consideration&#160;&#160;&#160;&#160;1.03(d)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial Statements&#160;&#160;&#160;&#160;4.05(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fundamental Representations&#160;&#160;&#160;&#160;9.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Government Programs&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Governmental Authority&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Governmental Order&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hazardous Substance&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Healthcare Laws&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Health Care Representations&#160;&#160;&#160;&#160;4.23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indebtedness&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indemnified Persons&#160;&#160;&#160;&#160;9.11(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indemnity Escrow Amount&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indemnity Escrow Fund&#160;&#160;&#160;&#160;10.01</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intellectual Property&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interests&#160;&#160;&#160;&#160;Preamble</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Latest Company Balance Sheet&#160;&#160;&#160;&#160;4.05(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Law&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Leased Real Property&#160;&#160;&#160;&#160;4.08</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal Requirement&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liens&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss&#59; Losses&#160;&#160;&#160;&#160;9.02(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Material Adverse Effect&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Material Contract&#59; Material Contracts&#160;&#160;&#160;&#160;4.10(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Minor Claim&#160;&#160;&#160;&#160;9.02(b)(i)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net Working Capital&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Objections Statement&#160;&#160;&#160;&#160;1.03(c)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Permit&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Permitted Liens&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Permitted Acquisition&#160;&#160;&#160;&#160;9.13(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Person&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Post-Closing Tax Period&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-Closing Company Service&#160;&#160;&#160;&#160;7.02(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-Closing Tax Period&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Private Programs&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeding&#160;&#160;&#160;&#160;9.11(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prohibited Activities&#160;&#160;&#160;&#160;9.13(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Release Agreement&#160;&#160;&#160;&#160;2.02(o)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted Period&#160;&#160;&#160;&#160;9.13(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Securities Act&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller&#160;&#160;&#160;&#160;Preamble</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller Confidential Information&#160;&#160;&#160;&#160;7.03(b)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller Indemnitees&#160;&#160;&#160;&#160;9.03</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller Transaction Expenses&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Straddle Period&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Straddle Tax Return&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subsidiary&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax Claim&#160;&#160;&#160;&#160;9.09(d)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax Returns&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax&#59; Taxes&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s knowledge&#59; To the knowledge of the Company&#160;&#160;&#160;&#160;11.04</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Claim&#160;&#160;&#160;&#160;9.06(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Payor&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Payor Requirements&#160;&#160;&#160;&#160;4.23(c)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Transaction Documents&#160;&#160;&#160;&#160;9.12(a)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Transaction Tax Deductions&#160;&#160;&#160;&#160;9.09(i)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Transfer Taxes&#160;&#160;&#160;&#160;9.09(e)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Transition Services Agreement&#160;&#160;&#160;&#160;2.02(k)</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upstream Transaction&#160;&#160;&#160;&#160;6.06</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Working Capital Adjustment Escrow Amount&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Working Capital Escrow Fund&#160;&#160;&#160;&#160;10.01</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EQUITY PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This EQUITY PURCHASE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made as of February 10, 2023, by and among AMEDISYS PERSONAL CARE, LLC, a Delaware limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), ASSOCIATED HOME CARE, L.L.C., a Massachusetts limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), HouseWorks Holdings, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and AMEDISYS, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Seller Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms used and not otherwise defined herein have the meanings set forth in ARTICLE 10 below.  </font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Seller owns all of the issued and outstanding Equity Interests of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, subject to the terms and conditions set forth herein, at the Closing, the Seller desires to sell to Buyer, and Buyer desires to purchase from the Seller, all of the Interests in exchange for an aggregate purchase price of $50,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as adjusted in accordance with the terms and conditions herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises, representations and warranties and mutual covenants contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and intending to be legally bound, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PURCHASE AND SALE OF INTERESTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Purchase and Sale of Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, the Seller shall sell, assign, transfer and convey to Buyer, and Buyer shall purchase and acquire from the Seller, free and clear of all Liens, all of the Interests, in exchange for the consideration payable in accordance with the terms and conditions in this ARTICLE 1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Payments at the Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At the Closing, Buyer shall make the following payments by wire transfer of immediately available funds in accordance with the instructions set forth in the Funds Flow&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">first, on behalf of the Company to the respective holders of Indebtedness, if any, outstanding as of the Closing, the amounts specified in the Payoff Letters delivered by the Company to Buyer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">second, to the Escrow Agent, an amount equal to the sum of the Indemnity Escrow Amount plus the Working Capital Adjustment Escrow Amount, to be held and disbursed pursuant to the terms of this Agreement and the Escrow Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">third, on behalf of the Company, to such payees of the Seller Transaction Expenses as directed in writing by the Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, it being understood and agreed that any Change of Control Payments will be paid to Amedisys Holding, L.L.C. for the account and benefit of the payment recipients, with Amedisys Holding, L.L.C. to disburse such Change of Control Payments, less the applicable withholdings, to such recipients on the next regularly scheduled payroll date following the Closing&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">fourth, to the Seller, an aggregate amount in cash equal to the Estimated Aggregate Closing Consideration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Calculation of Closing and Final Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">At least three (3) Business Days prior to the Closing Date, the Company shall deliver to Buyer a statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting forth its good faith estimate of the Aggregate Closing Consideration and each component thereof as of the opening of business on the Closing Date (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated Aggregate Closing Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) presented in a manner consistent with the sample calculation of the Aggregate Closing Consideration attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 1.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and prepared in a manner consistent with the definitions of the terms Cash on Hand, Indebtedness, Seller Transaction Expenses and Net Working Capital, which Estimated Closing Statement is to be prepared in consultation with Buyer (with the Company agreeing to consider Buyer&#8217;s comments in good faith), together with (i) a spreadsheet (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Distribution Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting forth a list of the payees of the Seller Transaction Expenses that will receive payment at the Closing, the amounts payable thereto, and their wire instructions for payment, including the recipients of the Change of Control Payments and the amount each is entitled to be paid, if any, and (ii) at least three (3) Business Days prior to the Closing Date, a signed payoff letter from each holder of outstanding Indebtedness, in form and substance reasonably acceptable to Buyer, which sets forth (x) the amounts required to repay in full all Indebtedness of such holder to be paid off at the Closing, including the outstanding principal, accrued and unpaid interest and prepayment and other penalties, (y)  the wire transfer instructions for if the repayment of such Indebtedness to such holder and (z) a release and termination of all guarantees and Liens granted by the Company to such holder or otherwise arising with respect to such Indebtedness, automatically and without further action permanently effective upon repayment of such Indebtedness, together with all instruments and other documentation necessary to release all guarantees by the Company and any Liens on the assets of the Company, including appropriate UCC financing statement terminations in form and substance reasonably acceptable to the Buyer (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payoff Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">As promptly as possible, but in any event within ninety (90) days after the Closing Date, Buyer shall deliver to the Seller a statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting forth Buyer&#8217;s calculation of the Aggregate Closing Consideration and each component thereof presented in a manner consistent with the sample calculation of the Aggregate Closing Consideration attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 1.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer shall prepare the Closing Statement in a manner consistent with the definitions of the terms Cash on Hand, Indebtedness, Seller Transaction Expenses and Net Working Capital, with the related amounts being computed as of the opening of business on the Closing Date.  The Closing Statement will disregard (i)&#160;any and all effects on the assets or liabilities of the Company as a result of the transactions contemplated hereby or of any financing or refinancing arrangements entered into at any time by Buyer or any other transaction entered into by Buyer in connection with the consummation of the transactions contemplated hereby, and (ii)&#160;any of the plans, transactions or changes that Buyer intends to initiate or make or cause to be initiated or made after the Closing with respect to the Companies or their business or assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer will, and will cause the Company to, (i) provide the Seller with reasonable access during normal business hours to the relevant books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Company involved in the preparation of the Closing Statement for purposes of their review of the Closing Statement, subject to the Seller&#8217;s obligation to maintain all such information in confidence and use it solely for purposes of its review of the Closing Statement and resolution of any disputes relating thereto, and (ii) reasonably cooperate with the Seller and its representatives in connection with such review, including providing on a timely basis all other information necessary or useful in connection with the review of the Closing Statement as is reasonably requested by the Seller.  If the Seller has any objections to the Closing Statement, the Seller will deliver to Buyer a written statement setting forth its objections thereto (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Objections Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which statement will identify in reasonable detail (to include relevant supporting calculations, schedules, and documentation) each item to which the Seller objects, each amount in dispute, and the basis for each such dispute (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disputed Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If an Objections Statement is not delivered to Buyer within sixty (60) days after delivery of the Closing Statement to the Seller, the Closing Statement as prepared by Buyer (including the calculations set forth therein) will be final, binding and non-appealable by the parties, provided that, in the event (x) the Seller delivers a written request for papers, documents or other cooperation reasonably available to Buyer and reasonably necessary to assist the Seller in its review of the Closing Statement, such request to be made by the Seller within forty-five (45) days following its receipt of the Closing Statement, and (y) Buyer does not provide such papers, documents or other cooperation within five (5) Business Days of request therefor, then such sixty (60)-day period will be extended by one (1) day for each additional day required for Buyer to fully </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respond to such request.  The Seller and Buyer will negotiate in good faith to resolve the Disputed Items but if they do not reach a final resolution within thirty (30) days after the delivery of the Objections Statement to Buyer, the Seller and Buyer will submit any unresolved Disputed Items to Grant Thornton LLP or such other independent national accounting firm mutually selected by Buyer and the Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In the event the parties submit any unresolved Disputed Items to the Accounting Firm, each party will submit a statement prepared in a manner consistent with the Closing Statement (which in the case of each party may be a statement that, with respect to the unresolved Disputed Items (but not, for the avoidance of doubt, with respect to any other items), is different than the Closing Statement initially submitted to the Seller, or the Objections Statement delivered to Buyer, as applicable) together with such supporting documentation as it deems appropriate, to the Accounting Firm within thirty (30) days after the date on which such unresolved Disputed Items were submitted to the Accounting Firm for resolution. The Seller and Buyer will use their respective commercially reasonable efforts to cause the Accounting Firm to resolve such dispute as soon as practicable, but in any event within thirty (30) days after the date on which the Accounting Firm receives the statements prepared by the Seller and Buyer.  The Accounting Firm will promptly review only the unresolved Disputed Items and resolve the dispute with respect to each such specific item and amount in accordance with the definitions of Cash on Hand, Indebtedness, Seller Transaction Expenses and Net Working Capital, provided that, the Accounting Firm shall not assign a value to any item greater than the greatest value for such item, or lower than the lowest value of such item, claimed in closing statements provided to such Accounting Firm pursuant hereto.  The Seller and Buyer will use their respective commercially reasonable efforts to cause the Accounting Firm to notify them in writing of its resolution of such dispute as soon as practicable.  The determination of the Accounting Firm will be final, binding and non-appealable by the parties.  Each party will bear its own costs and expenses in connection with the resolution of such dispute by the Accounting Firm.  The costs and expenses of the Accounting Firm will be paid by the non-prevailing party, as determined by the Accounting Firm, in proportion with the extent to which the prevailing party prevails, and the remainder of such costs and expenses will be paid by the prevailing party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If the Aggregate Closing Consideration as finally determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Final Aggregate Closing Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is greater than the Estimated Aggregate Closing Consideration (the amount of such excess, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Positive Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then, within five (5) Business Days after the determination of the Final Aggregate Closing Consideration (x) Buyer will pay to the Seller or such other Person as the Seller shall otherwise direct in writing to Buyer, by wire transfer of immediately available funds, an amount equal to such Positive Adjustment Amount and (y) Buyer and the Seller shall jointly instruct the Escrow Agent in writing to distribute the full amount of the Working Capital Adjustment Escrow Fund to the Seller. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If the Final Aggregate Closing Consideration is less than the Estimated Aggregate Closing Consideration (the absolute value of such shortfall, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negative Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then, within five (5) Business Days after the determination of the Final Aggregate Closing Consideration, the Seller will pay to Buyer, by wire transfer of immediately available funds, an amount equal to such Negative Adjustment Amount.  Any payment required by the Seller pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall come first, from the Working Capital Escrow Fund, for an amount up to the Working Capital Adjustment Escrow Amount (such amount to be paid pursuant to joint written instructions provided by Buyer and the Seller to the Escrow Agent), and second, from the Indemnity Escrow Amount, and Buyer and the Seller shall jointly instruct the Escrow Agent in writing to make such distributions of the Negative Adjustment Amount to Buyer within five (5) Business Days after the determination of the Final Aggregate Closing Consideration.  To the extent any amount distributed by the Escrow Agent to Buyer pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is less than the Working Capital Adjustment Escrow Amount, Buyer and the Seller promptly shall jointly instruct the Escrow Agent in writing to distribute an amount equal to the remaining balance of the Working Capital Escrow Fund to the Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">If the Final Aggregate Closing Consideration is equal to the Estimated Aggregate Closing Consideration, then, no (x) payment will be due from any party as a result of the determination of the Final Aggregate Closing Consideration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (y) Buyer and the Seller shall jointly instruct the Escrow Agent in writing to distribute the full amount of the Working Capital Adjustment Escrow Fund to the Seller.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All payments required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections&#160;1.03(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">1.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be deemed to be adjustments for Tax purposes to the aggregate purchase price paid by Buyer for the Interests purchased by it pursuant to this Agreement to the extent permitted by applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">The Closing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions hereof, including those set forth in ARTICLE 2 hereof, the closing of the transactions contemplated by this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall take place on the date which is five (5) Business Days following the date on which all conditions to Closing set forth in ARTICLE 2 have been satisfied or waived in accordance with their terms or such other time and place as agreed upon by the parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Unless another time and&#47;or date is agreed to in writing by the Company and Buyer, the Closing shall be effective as of (a) 11&#58;59 p.m. (ET) on the Closing Date if the Closing Date is the final calendar day of any month or (b) 12&#58;01 a.m. (ET) on the Closing Date if the Closing Date is any day other than the final calendar day of any month.  The Closing shall take place via the electronic exchange of documents and funds.  No transaction contemplated hereby will be deemed to have been completed and no document, instrument or certificate contemplated hereby shall be deemed to have been delivered until all transactions contemplated hereby are completed and all documents contemplated hereby delivered.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CONDITIONS TO CLOSING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conditions to All Parties&#8217; Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The obligations of the Seller and Buyer to consummate the transactions contemplated by this Agreement are subject to the satisfaction of the following conditions as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All required notifications and filings with Governmental Authorities in connection with the transactions contemplated by this Agreement shall have been made and each applicable Governmental Authority, to the extent required before Closing, shall either have (i) given the approvals, consents or clearances required under relevant applicable Law for the completion of the transactions contemplated by this Agreement, (ii) rendered a decision that no approval, consent or clearance is required under relevant applicable Law for completion of the transactions contemplated by this Agreement, (iii) failed to render a decision within the applicable waiting period under relevant applicable Law and such failure is considered under such Law to be a grant of all requisite consents or clearances under such Law, or (iv) referred the transactions contemplated by this Agreement or any part thereof to another Governmental Authority in accordance with relevant applicable Law and one of the requirements listed in items (i) through (iii) above has been fulfilled in respect of such other Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except for any pending or threatened suit, action or other proceeding directly or indirectly initiated by the party asserting its right not to consummate the transactions contemplated by this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, no action or proceeding before any Governmental Authority will be pending or threatened in writing wherein an unfavorable judgment, decree or order would prevent the performance of this Agreement or the consummation of any of the transactions contemplated hereby, declare unlawful the transactions contemplated by this Agreement or cause such transactions to be rescinded.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This Agreement will not have been terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conditions to Buyer&#8217;s Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The obligation of Buyer to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the following conditions as of the Closing Date&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each of (i) the representations and warranties of the Seller and the Company contained in ARTICLE 3 and ARTICLE 4 herein (other than the Fundamental Representations) shall be true and correct (determined for this purpose without giving effect to any materiality, Material Adverse Effect or similar qualifications) in all respects as of the date hereof and as of the Closing Date (except to the extent that any such representation and warranty expressly addresses matters as of a specific date, in which case such representation and warranty shall be true and correct as of such date), except where the failure to be so true and correct has not had a Material Adverse Effect, (ii) the Fundamental Representations of the Seller and the Company contained in ARTICLE 3 and ARTICLE 4 herein (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.03(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) shall be true and correct (determined for this purpose without giving effect to any materiality, Material Adverse Effect or similar qualifications) in all material respects as of the date hereof and as of the Closing Date (except to the extent that any such Fundamental Representation expressly address matters as of a specific date, in which case such Fundamental Representation shall be true and correct in all material respects as of such date), and (iii) the Fundamental Representations of the Seller and the Company that are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.03(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be true and correct in all respects as of the date hereof and as of the Closing Date (except to the extent that any such representation and warranty expressly address matters as of a specific date, in which case such representation and warranty shall be true and correct in all respects as of such date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company and the Seller will each have performed, in all material respects, all of the covenants and agreements under this Agreement and any Transaction Documents that are required to be performed by them at or prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Seller will have delivered to Buyer a duly executed assignment of the Interests, in form reasonably acceptable to Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company and the Seller will have delivered to Buyer a certificate, dated as of the Closing Date, certifying that the conditions specified in subsections (a) and (b) above as they relate to the Company or Seller, as applicable, have been satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Since the date of this Agreement, no event has occurred and, as of the Closing Date, no fact, circumstance or condition exists that has had a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">The Company will have delivered to Buyer certificates of good standing for the Company issued not earlier than ten (10) Business Days before the Closing Date by the secretary of state or equivalent Governmental Authority of the Company&#8217;s jurisdiction of formation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company will have obtained the Third Party Consents.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Seller will have delivered to Buyer a properly completed and valid IRS Form W-9 executed by the Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Company will have delivered to Buyer the written resignations of all managers and officers of the Company in office immediately prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Escrow Agreement shall have been executed by the Seller and the Escrow Agent. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Seller shall have delivered to Buyer a transition services agreement, consistent with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and otherwise in form and substance reasonably acceptable to Buyer and the Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), duly executed and delivered by Amedisys Holding, L.L.C. and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Seller shall have delivered to Buyer the Payoff Letters. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The Company shall have delivered to Buyer documentation, in form and content reasonably acceptable to Buyer, evidencing that all loans referenced on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, if any, have been or will be repaid in full at or prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Buyer shall have received certificates of insurance or other evidence that the Insurance Tail Policies have been obtained and are in effect as of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Seller shall have delivered to Buyer the release agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), duly executed and delivered by the Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conditions to Seller&#8217;s Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The obligations of the Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction of the following conditions as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each of the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof will be true and correct as of the Closing Date as if made anew as of such date (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except where any failure of any such representation and warranty to be true and correct would not have a Material Adverse Effect on Buyer&#8217;s ability to perform the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Buyer will have performed in all material respects all of the covenants and agreements under this Agreement and any Transaction Documents that are required to be performed by Buyer at or prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer will have made the payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> due on the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Buyer will have delivered to the Seller a certificate in the form, dated as of the Closing Date, stating that the conditions specified in subsections (a) and (b) hereof have been satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Escrow Agreement shall have been executed by the Buyer and the Escrow Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Waiver of Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event the parties actually consummate the transactions contemplated by this Agreement, then all conditions to the Closing set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be deemed to have been satisfied or waived from and after the Closing solely for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.04.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Withholding</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer and the Company shall be entitled to deduct and withhold from any amounts payable under this Agreement such amounts as Buyer or the Company is required to deduct and withhold with respect to the making of such payment under the Code or any provision of applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Buyer shall provide Seller with a written notice of Buyer&#8217;s intention to withhold at least three (3) Business Days prior to any such withholding (other than withholding on compensatory payments and withholding attributable to a failure to deliver an IRS Form W-9 in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Buyer and Seller shall use commercially reasonable efforts to minimize any such Taxes to the extent allowed under applicable Law.  To the extent that amounts payable to a recipient are so withheld by Buyer or the Company and remitted to the applicable Governmental Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the recipient.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES&#160;OF SELLER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Seller represents and warrants to Buyer as follows as of the date hereof (unless otherwise indicated) and as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Power and Organization</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Such Seller has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder. Such Seller is duly organized, formed or incorporated, as applicable, validly existing and in good standing under the Laws of the jurisdictions of its organization and of the jurisdictions in which it does business.  Such Seller is not in default under or in violation of any provision of its organizational documents, as amended and currently in effect, in each case in any material respect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The execution, delivery and performance of this Agreement and each Transaction Document to which such Seller is party by such Seller and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite action on the part of such Seller, and no other proceedings on such Seller&#8217;s part are necessary to authorize the execution, delivery or performance of this Agreement by such Seller.  This Agreement and each Transaction Document to which such Seller is party has been duly executed and delivered by such Seller, and assuming that this Agreement is the valid and binding agreement of Buyer, this Agreement and each applicable Transaction Document constitutes the valid and binding obligation of such Seller, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar laws affecting creditors&#8217; rights and general principles of equity affecting the availability of specific performance and other equitable remedies.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Breach</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the execution, delivery and performance of this Agreement and all Transaction Documents to which such Seller is a party and the performance of the transactions contemplated hereby and thereby do not and will not in any material respect&#58; (a)&#160;contravene, require any consent or notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, accelerate any obligation under, or give rise to a right of acceleration, cancellation or termination of, or result in the creation of a Lien on any of the properties or assets of such Seller pursuant to, any material contract, agreement, obligation, permit, license or authorization to which such Seller is a party or by which any of its assets are bound&#59; (b) contravene, require any consent or notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, or accelerate any obligation under, any provision of such Seller&#8217;s organizational documents&#59; (c) contravene or violate or result in a violation of, or constitute a breach or default (whether after the giving of notice, lapse of time or both) under, any provision of any Law, or any judgment or order of, or any restriction imposed by, any court or Governmental Authority applicable to such Seller&#59; or (d) require from such Seller any notice to, declaration or filing with, or consent or approval of, any Governmental Authority or other third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Ownership</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Such Seller is the sole record and beneficial owner of the Interests, free and clear of all Liens, options, warrants, proxies, voting trusts or agreements and other restrictions and limitations of any kind, other than applicable federal and state securities law restrictions.  The Interests are not certificated. Such Seller is not a party to any option, warrant, purchase right or other contract or commitment other than this Agreement that could require such Seller to sell, transfer or otherwise dispose of any Interests, or that gives any other Person any rights with respect to the Interests owned by such Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Brokerage</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, there are no claims for brokerage commissions, finders&#8217; fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made by or on behalf of such Seller or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Litigation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There are no (i) outstanding judgments against Seller, (ii) Actions pending or, to the knowledge of Seller, threatened against Seller, or (iii) investigations by any Governmental Authority that are pending or, to the knowledge of Seller, threatened against Seller, in any case, which would adversely affect Seller&#8217;s performance under this Agreement or the consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company represents and warrants to Buyer as follows as of the date hereof (unless otherwise indicated) and as of the Closing Date&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Organization and Corporate Power</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company is a limited liability company duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts, and the Company has all requisite limited liability company power and authority necessary to own and operate its properties. The Company is qualified to do business in every jurisdiction in which its ownership of property or the conduct of business as now conducted requires it to qualify, except where the failure to be so qualified would not have a Material Adverse Effect.  The Company has delivered to Buyer true and complete copies of the Company&#8217;s Articles of Organization and Operating Agreement, each as amended and as in effect as of the date hereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Subsidiaries</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company does not own or hold the right to acquire any Equity Interests in any other Person.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement&#59; No Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The execution, delivery and performance of this Agreement and each Transaction Document to which the Company is party by the Company and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite limited liability company action on the part of the Company, and no other proceedings on the Company&#8217;s part are necessary to authorize the execution, delivery or performance of this Agreement or any applicable Transaction Document by the Company.  This Agreement and each Transaction Document to which the Company is party has been duly executed and delivered by the Company and assuming that this Agreement is a valid and binding obligation of Buyer, this Agreement and each applicable Transaction Document constitutes a valid and binding obligation of the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, or moratorium laws, other similar Laws affecting creditors&#8217; rights and general principles of equity affecting the availability of specific performance and other equitable remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the execution, delivery and performance of this Agreement and all Transaction Documents to which the Company is a party and the performance of the transactions contemplated hereby and thereby do not and will not in any material respect&#58;  (i)&#160;contravene, require any consent or notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, accelerate any obligation under, or give rise to a right of acceleration, cancellation or termination of, or result in the creation of a Lien on any of the properties or assets of the Company pursuant to, any material contract, agreement, obligation, permit, license or authorization to which the Company is a party or by which the Company&#8217;s assets are bound&#59; (ii) contravene, require any consent or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, or accelerate any obligation under, any provision of the Company&#8217;s organizational documents&#59; (iii) contravene or violate or result in a violation of, or constitute a breach or default (whether after the giving of notice, lapse of time or both) under, any provision of any Law, or any judgment or order of, or any restriction imposed by, any court or Governmental Authority applicable to the Company&#59; or (iv) require from the Company any notice to, declaration or filing with, or consent or approval of, any Governmental Authority or other third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Capital Stock</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company does not have any other Equity Interests, convertible securities or other securities containing any equity features authorized, issued or outstanding, and there are no agreements, options, warrants or other rights or arrangements existing or outstanding which provide for the sale or issuance of any of the foregoing by the Company.  The Interests represent one hundred percent (100%) of the issued and outstanding Equity Interests of the Company.  Except for the Interests, there are no outstanding (a)&#160;membership interests or other Equity Interests or voting securities of the Company, (b)&#160;securities convertible or exchangeable into Equity Interests of any of the Company, (c)&#160;options, warrants, purchase rights, subscription rights, preemptive rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other contracts that require the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem Equity Interests of any of the Company or (d)&#160;equity appreciation, phantom equity, profit participation or similar rights with respect to the Company.  The Interests are duly authorized and validly issued.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Financial Statements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Section 4.05(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule attaches true and correct copies of (i) the unaudited balance sheet of the Company as of December 31, 2022 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Latest Company Balance Sheet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the related statement of income for the calendar year then ended&#59; and (ii) unaudited combined balance sheets of the Company as of December 31, 2021 and December 31, 2020 (all such financial statements referred to in clauses (i) through (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#160; Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.05(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Financial Statements present fairly, in all material respects, the financial condition of the Company as of the times and for the periods referred to therein.  The Financial Statements were prepared in all material respects in accordance with GAAP, and to the extent consistent with GAAP, using consistently applied accounting methods, assumptions, policies, principles, practices, and procedures, with consistent classification, judgments, and estimation methodology, except in the case of the financial statements referred to in clauses (i), (iii) and (iv) above, for the absence of footnote disclosures and in the case of the financial statements referred to in clauses (i) and (iii) above, normal recurring changes resulting from year-end adjustments.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company does not have any liabilities or obligations of any nature (whether known or unknown and whether absolute, accrued, contingent or otherwise) relating to the operation of its business that are required under GAAP to be accrued on the face of a balance sheet, except for (i) current liabilities incurred in the ordinary course of business, consistent with past practice, since December 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Balance Sheet Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that are not individually or in the aggregate material, (ii) Seller Transaction Expenses incurred in connection with the transactions contemplated by this Agreement, (iii) obligations arising in the ordinary course under (A) Material Contracts and (B) other agreements that are not Material Contracts and were entered into by the Company in the ordinary course of business, consistent with its past practice (in each case, to the extent not constituting Indebtedness and excluding any liabilities resulting from any breach of such contracts or agreements or resulting from any violation of Law), (iv) liabilities set forth on the Latest Company Balance Sheet, and (v) those liabilities set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.05(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company is not insolvent, has not proposed a compromise or arrangement to its creditors generally, has not had any petition for a receiving order in bankruptcy filed against it, has not made a voluntary assignment in bankruptcy, has not taken any proceeding with respect to a compromise or arrangement, has not taken any proceeding to have itself declared bankrupt or wound-up, has not taken </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any proceeding to have a receiver appointed to any part of its assets, and has not had any debtor take possession of any of its property.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Absence of Certain Developments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Since the Balance Sheet Date, there has not occurred any Material Adverse Effect.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule and except as expressly contemplated by this Agreement, since the Balance Sheet Date, the Company has conducted its business in the ordinary course, consistent with past practice, and the Company has not&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">mortgaged, pledged or subjected to any Lien any of its material assets, except Permitted Liens&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">sold, assigned or transferred any material portion of its tangible assets, except in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">issued, sold, redeemed or transferred any of its Equity Interests, securities convertible into its Equity Interests or other equity securities or warrants, options or other rights to acquire its Equity Interests or other equity securities, or any bonds or debt securities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">amended its certificate of formation or operating agreement or other applicable organizational documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">acquired by merger, equity purchase or consolidation with, or by purchase of a substantial portion of the assets or stock of, or by any other manner, any business or any division thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">made any material capital investment in, or any material loan to, any other Person&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">made any material capital expenditures or commitments therefor, except in the ordinary course of business consistent with past practice or pursuant to its existing capital expenditure budget&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">deferred an capital expenditures, except in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">made any changes in wages, salary or other compensation with respect to its officers, directors or employees, in each case other than changes made in the ordinary course of business consistent with past practice or pursuant to existing agreements or arrangements listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">paid, loaned or advanced (other than the payment of salary and benefits, the payment, advancement or reimbursement of expenses in the ordinary course of business consistent with past practice) any amounts to, or sold, transferred or leased any of its assets to, or entered into any other transactions with, any of its Affiliates other than in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">commenced or settled any litigation involving an amount in excess of $75,000 for any one case&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">cancelled or waived any claims with a potential value in excess of $75,000, other than in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">terminated, assigned, amended, canceled or waived any material right under any Material Contract, other than in the ordinary course of business consistent with past practice&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">changed its accounting methods or principles theretofore adopted, except as required by GAAP and reflected in the Financial Statements&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">experienced any damage, destruction or casualty loss (other than those covered by insurance) with respect to any of the assets or properties of the Company that, individually or in the aggregate with respect to the Company, exceeds $75,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">made any material change to its Benefit Plans or the benefits payable thereunder&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">experienced any labor grievances or similar claims filed&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">accelerated the collection of or discounted any accounts receivable, or made any material change in the terms of payment by its patients&#47;payors for any services it performs the effect of which is to enable it to receive payment or recognize revenues in its statement of operations for any period ending on or before the Closing Date which, but for that change, it would not so receive or recognize before a period beginning after the Closing Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.4pt">terminated (other than for cause) the employment of any officer, executive, or employee of the Company with annual compensation in excess of $175,000, or otherwise implemented any reductions in force, layoffs, early retirement programs, or other voluntary or involuntary employment termination programs (other than individual employee terminations in the ordinary course of business consistent with past practice)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">delayed the payment of or made any material change in its practices with respect to timely payment of accounts payable or other obligations payable to vendors, suppliers or other third parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">made or changed any material Tax election, changed an annual accounting period, adopted or changed any accounting method, filed any amended Tax Return, entered into any closing agreement, settled any Tax claim or assessment, surrendered any right to claim a refund of Taxes, consented to any extension or waiver of the limitation period applicable to any Tax claim or assessment, or taken any other similar action relating to the filing of any Tax Return or the payment of any tax&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">committed to do any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Title to Properties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth a true, correct and complete listing of all tangible personal property owned by the Company as of the Balance Sheet Date with a depreciated book value in excess of $10,000.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has good title to, or holds pursuant to valid and enforceable leases, all of the personal property owned or leased (or purported to be owned or leased) by it as of the Balance Sheet Date or acquired by it since the Balance Sheet Date, free and clear of all Liens, except for Permitted Liens, and except for assets disposed of by the Company in the ordinary course of business consistent with past practice since the Balance Sheet Date.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, all of the assets of the Company constitute all of the assets reasonably necessary for the conduct of the business of the Company as currently conducted on the date hereof.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, all of the tangible personal property of the Company is in good working order and condition in accordance with industry practice, ordinary wear and tear excepted, and adequate in all material respects for the purposes for which they presently are being used or held for use. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth a list of all leases of tangible personal property to which the Company is party.  Each such lease remains in full force and effect and the Company is not in breach or default in any material respect thereunder and, to the Company&#8217;s knowledge, no lessor thereunder is in breach or default in any material respect.  True and complete copies of all such leases, together with all modifications, extensions, amendments and assignments thereof, if any, have been made available to Buyer.&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Real Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The real property described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.08(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Leased Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) constitutes all of the real property leased by the Company. The Company does not own any real property.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.08(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth a list of all leases pursuant to which the Company leases real property (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the address of the real property to which it relates.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.08(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, each Company Lease is in full force and effect, and the Company holds a valid and existing leasehold interest under each such lease, subject to proper authorization and execution of such lease by the other party and the application of any bankruptcy or creditor&#8217;s rights Laws and Permitted Liens.  The Company has delivered or made available to Buyer copies of each of the Company Leases, together with all modifications, extensions, amendments and assignments thereof.  The Company is not in material default under any Company Lease and, to the Company&#8217;s knowledge, no counterparty to any such lease is in material default thereunder.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.08(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has not subleased or granted any other right to the use or occupancy of any real property that is the subject of any Company Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company is not party to and are not otherwise bound by, nor is any of the Leased Real Property subject to, any contract requiring the Company to pay any commissions or other compensation to any brokers or agents in connection with the Leased Real Property, and have had no dealing with any broker or agent with respect to the Leased Real Property upon which any such broker or agent would be entitled to a commission or other compensation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Tax Matters</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company or an Affiliate thereof has timely filed (taking into account any extensions) with the appropriate Tax authorities all Tax Returns that were required to be filed for or on behalf of the Company, and has paid all material Taxes due and owing (whether or not shown on any Tax Return) by the Company.  All such Tax Returns were true, correct and complete in all material respects and were prepared in all material respects in accordance with all applicable Tax Laws. The Company has withheld and paid to the appropriate Tax authorities all material Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party, and all Forms W-2 and 1099 required with respect thereto have been properly completed in all material respects and timely filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The unpaid Taxes of the Company for all Tax periods through the Balance Sheet Date did not as of such date exceed the reserve for Taxes (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth in the Latest Company Balance Sheet and such unpaid Taxes will not exceed as of the Closing Date such reserve as adjusted for the passage of time in accordance with the GAAP-compliant past custom and practice of the Company through the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company has not received from any Tax authority in the preceding three (3) years any written notice of any proposed adjustment, deficiency or underpayment of any Taxes, and there is no material dispute, audit, action, suit, investigation (to the Company&#8217;s knowledge), proceeding or claim now pending or, to the Company&#8217;s knowledge, that has been threatened in writing concerning any Tax liability of the Company.  The Company has not waived any statute of limitations in respect of Taxes of the Company beyond the Closing Date or agreed to any extension of time beyond the Closing Date with respect to a Tax assessment or deficiency.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company is not party to any Tax allocation or Tax-sharing agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company is not a U.S. real property holding corporation within the meaning of Section 897(c)(2) of the Code.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">The Company is not nor has been a party to any &#8220;listed transaction&#8221; as defined in Code Section 6707A(c)(2) and Treasury Regulations Section 1.6011-4(b)(2) in the preceding three (3) years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">There are no Liens for Taxes against the Company&#8217;s assets, other than Liens that constitute a Permitted Lien.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All Tax Returns filed by the Company, examination reports, and statements of deficiencies assessed against or agreed to by the Company, for all taxable periods ending prior to the Closing Date that are still open to examination under all applicable statutes of limitations have been made available to Buyer.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule identifies those Tax Returns that have been audited and those currently subject to audit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Company is not a party to any agreement, contract, arrangement, or plan that has resulted or could result, separately or in the aggregate, in the payment of (i) any &#8220;excess parachute payment&#8221; within the meaning of Code &#167;280G (or any corresponding provision of state, local, or non-U.S. Tax law) or (ii) any amount that will not be fully deductible as a result of Code &#167;162(m) (or any corresponding provision of state, local, or non-U.S. Tax law). The Company has disclosed on its federal income Tax Returns all positions taken therein that could give rise to a substantial understatement of federal income Tax within the meaning of Code &#167;6662. The Company (A) has not been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was the Company) and (B) does not have any liability for the Taxes of any Person under Treasury Regulations &#167;1.1502-6 (or any similar provision of state, local, or non-U.S. law), as a transferee or successor, or by contract. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Within the past three (3) years, the Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Code &#167;355 or Code &#167;361.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company has not, in the past three (3) years, (A) acquired assets from another corporation in a transaction in which such Company&#8217;s federal income Tax basis for the acquired assets was determined, in whole or in part, by reference to the federal income Tax basis of the acquired assets (or any other property) in the hands of the transferor or (B) acquired the stock of any corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(A) change in method of accounting for a taxable period ending on or prior to the Closing Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;use of an improper method of accounting for a taxable period ending on or prior to the Closing Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(C) &#8220;closing agreement&#8221; as described in Code &#167;7121 (or any corresponding or similar provision of state, local, or non-U.S. income Tax law) executed on or prior to the Closing Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(D) intercompany transactions or any excess loss account described in Treasury Regulations under Code &#167;1502 (or any corresponding or similar provision of state, local, or non-U.S. income Tax law)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(E) installment sale or open transaction disposition made on or prior to the Closing Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(F) prepaid amount received on or prior to the Closing Date.&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">No written claim has been asserted in the preceding three (3) years by a Governmental Authority of a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by such jurisdiction.  The Company has not had or engaged in a &#8220;reportable transaction&#8221; within the meaning of Section 6707A(c)(1) of the Code in the preceding three (3) years.  The Company is not currently the beneficiary of any extension of time within which to file any Tax Return.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company is and at all times since its formation has been disregarded as separate from the Seller for U.S. federal and applicable state and local income Tax purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company is not currently a party to any joint venture, partnership or other arrangement or contract properly treated as a partnership for U.S. federal and applicable state and local income tax purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except for the deferral of Social Security Taxes pursuant to the Cares Act (which Taxes have been repaid in full), the Company has not made an election to defer any Taxes under Section 2302 of the Cares Act for 2020, IRS notice 2020-65 or any similar election under state or local tax law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The representations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, are the only representations in this Agreement with respect to Taxes and any claim for breach of representation with respect to Taxes will be based on the representations made in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and will not be based on the representations set forth in any other provision of this Agreement. The representations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (except for the representations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) refer only to past activities of the Company and are not intended to serve as representations and warranties regarding, nor can they be relied upon with respect to, Taxes attributable to a Post-Closing Tax Period or a position taken after the Closing Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Contracts and Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company is not party to any written or oral&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">joint venture agreement, operating agreement, management agreement, cost sharing agreement, or partnership agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">collective bargaining agreement or contract with any labor union&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">bonus, pension, profit sharing, severance, retention, change of control, retirement or other form of deferred compensation plan, in each case, other than as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">stock purchase, stock option or similar plan with respect to Equity Interests of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">contract for the employment of any officer, individual employee or other person on a full-time or consulting basis providing for fixed compensation in excess of $100,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per annum, other than offer letters, non-disclosure, non-solicitation, non-competition or similar agreements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">agreement or indenture relating to Indebtedness or to mortgaging, pledging or otherwise placing a Lien on any assets of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">guaranty of any obligation for borrowed money&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">lease or agreement under which it is lessee of, or holds or operates any personal property owned by any other party, for which the annual rental payment exceeds $100,000&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">lease or agreement under which it is lessor of or permits any third party to hold or operate any property, real or personal, for which the annual rental payment exceeds $100,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">contract or group of related contracts with the same party for the purchase of products or services, involving payments by the Company for goods, services or materials of $100,000 or more in any calendar year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">contract or group of related contracts with the same party for the sale of products or services involving payments to the Company for goods, services or materials of $100,000 or more in any calendar year&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">Aging Services Access Point, Medicaid managed care organization contracts, or other contracts for participation with any Governmental Program&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">contract that by its terms contains non-competition restrictions that restrict the ability of the Company to compete in any geographical area or business (other than confidentiality agreements entered into in the ordinary course of business)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.63pt">distributorship or sales agency agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.68pt">contract related to an acquisition or divestiture of any corporation, partnership or other business organization or division thereof or collection of assets constituting all or substantially all of a business or business unit by the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.63pt">contract between the Company and any officer, director or equity holder, or, to the knowledge of the Company, any Affiliate thereof&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xvii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.58pt">contract providing for an exclusive relationship or the purchase from a supplier of all or substantially all of the requirements of the Company of a particular product or service, including cell phone contracts, utilities, healthcare insurance, leases and the like&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xviii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.53pt">settlement, conciliation or similar agreements (A) with any Governmental Authority or (B) pursuant to which the Company is obligated after the date of this Agreement to pay consideration in excess of $100,000 or satisfy any material non-monetary requirements&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.63pt">Billing Arrangement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.68pt">any contract between the Company and any physician, physician group or other referral source to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Buyer has been given true and correct copies of all written contracts which are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, together with all amendments, waivers or other changes thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Material Contracts are in full force and effect and are valid binding obligations of the Company. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, (i) the Company is not in default in any material respect under any Material Contract and (ii) to the Company&#8217;s knowledge, the counterparty or counterparties to each such agreement or contract are not in material default thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the consummation of the transactions contemplated by this Agreement will not result in any material default by the Company under any such Material Contract or afford any other party the right to terminate any such Material Contract.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has not received written notice of any intention of any other party to any Material Contract to exercise any right to cancel or terminate that Material Contract.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All of the internet domain names, registered trademarks, registered trade names, registered service marks, registered copyrights or applications for any of the foregoing and software (other than off-the-shelf software) owned or licensed by the Company and used in the conduct of the business of the Company are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> separately identifies the Company Intellectual Property owned by the Company. The Company does not hold any patents nor have any pending patent applications. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company owns or has the right to use all Company Intellectual Property and, to the Company&#8217;s knowledge, the Company Intellectual Property owned by the Company does not infringe upon, violate, misappropriate or make unlawful use of the Intellectual Property or other rights of any other Person, in each case in any material respect.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, no Company Intellectual Property owned by the Company is the subject of any pending or, to the Company&#8217;s knowledge, threatened actions, suits or proceedings.  To the Company&#8217;s knowledge,&#160;no Person is currently infringing or, within the past three (3) years has infringed, on any Company Intellectual Property owned by the Company.  The Company has not granted to any Person exclusive rights to any of the Company Intellectual Property.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Section 4.11(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth all licenses, sublicenses and other agreements whereby the Company is or has granted rights, interests and authority, whether on an exclusive or non-exclusive basis, to use Company Intellectual Property in the conduct of its business (other than &#8220;off the shelf&#8221; or standard software licenses).  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has not within the past three (3) years received in writing any charge, complaint, claim, demand or notice alleging any infringement, misappropriation, or violation (including any claim that the Company must license or refrain from using any Intellectual Property of any third party in order to avoid infringement) of the Intellectual Property of any third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The representations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are the only representations in this Agreement with respect to Intellectual Property and any claim for breach of representation with respect to Intellectual Property will be based on the representations made in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and will not be based on the representations set forth in any other provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Litigation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, there are no material Actions pending or, to the Company&#8217;s knowledge, threatened against the Company, at law or in equity, or before or by any Governmental Authority, and the Company is not subject to any outstanding Governmental Order entered against the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Section 4.13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth a list of each Benefit Plan. The Company has made available to Buyer true and complete copies of, in each case, to the extent applicable&#58;  (i) any current plan documents, amendments thereto, and related trust agreements&#59; (ii) the current summary plan description and any material modifications thereto&#59; (iii) the most recent Form 5500 annual report&#59; (iv) the most recent IRS determination or opinion letter&#59; (v) the last three (3) years of non-discrimination testing results&#59; and (vi) all non-routine correspondence to and from any governmental agency, with respect to such Benefit Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Benefit Plan has been established and administered in all material respects in accordance with its terms and applicable Law and Legal Requirements, including, as to each Benefit Plan that is subject to United States Law, ERISA and the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Each of the Benefit Plans that is intended to be qualified under Section 401(a) of the Code, has received a favorable determination letter or can rely on an opinion letter from the Internal Revenue Service, and, to the knowledge of the Company, nothing has occurred that could be reasonably expected </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to cause the revocation of such determination letter or the unavailability of reliance on such opinion letter which would reasonably be expected to cause such Benefit Plan to lose its qualified status. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Benefit Plans comply in form and in operation in all material respects with the terms of such Benefit Plan and the requirements of the Code and ERISA, to the extent applicable. No Benefit Plan is, or within the past five (5) years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program. No litigation or governmental administrative proceeding, audit or other proceeding (other than those relating to routine claims for benefits) is pending or, to the knowledge of the Company, threatened with respect to any Benefit Plan, and, to the knowledge of the Company, there is no reasonable basis for any such litigation or proceeding.  The Benefit Plans satisfy in all material respects the minimum coverage, affordability and non-discrimination requirements under the Code, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">With respect to the Benefit Plans, all required contributions of the Company due on or before the Closing Date have been made or properly accrued on the Company&#8217;s books and records on or before the Closing Date, in each case in all material respects.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby could (either alone or in conjunction with any other event) (i) accelerate the time of payment or vesting under any Benefit Plan, (ii) increase the amount of compensation due to any current or former officer, employee, director or independent contractor of the Company, (iii) entitle any current or former employee, officer, director or independent contractor of the Company to severance pay, unemployment compensation or any other payment, (iv) directly or indirectly cause the Company to transfer or set aside any assets to fund or otherwise provide for the benefits under any Benefit Plan for any current or former employee, officer, director or independent contractor, or (v) result in any non-exempt prohibited transaction described in ERISA Section 406 or Code Section 4975. Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will result in &#8220;excess parachute payments&#8221; within the meaning of Section 280G of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">None of the Benefit Plans is subject to Title IV of ERISA nor provides for medical or life insurance benefits to retired or former employees of the Company (other than as required under Code Section 4980B, or similar state law).  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">neither the Company, nor any of its ERISA Affiliates, either currently or at any time during the six (6) year period ended on the date hereof, sponsored, maintained, or were otherwise obligated to contribute to a &#8220;multiemployer plan&#8221; as defined in Section 4001(a)(3) of ERISA, any pension plan subject to Section 412 of the Code or Section 302 of ERISA, any funded welfare benefit plan within the meaning of Section 419 of the Code, any &#8220;multiple employer plan&#8221; (within the meaning of Section 210 of ERISA or Section 413(c) of the Code), or any &#8220;multiple employer welfare arrangement&#8221; as defined in Section 3(40) of ERISA.  Any trust funding a Benefit Plan, which is intended to be exempt from U.S. federal income Tax under Section 501(c)(9) of the Code, satisfies the requirements of that Section and has received a favorable determination letter from the IRS regarding that exempt status and has not, since receipt of the most recent favorable determination letter, been amended or operated in a way that would adversely affect that exempt status. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.13(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, no Benefit Plan provides health or long-term disability benefits that are not fully insured through an insurance contract. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Benefit Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section 409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section 409A of the Code (or an available exemption therefrom) and applicable guidance thereunder.  No payment to be made under any Benefit Plan, with respect to any employees of the Company, is, or to the knowledge of the Company, will be, subject to the penalties of Section 409A(a)(1) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No Benefit Plan is subject to the laws of any jurisdiction outside the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">No Benefit Plan provides for any tax &#8220;gross-up&#8221; or similar &#8220;make-whole&#8221; payments with respect to any employees of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Insurance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth each insurance policy maintained by the Company, true and correct copies of which have been made available by the Company to Buyer.  All such insurance policies are in full force and effect, the Company is not in material default with respect to its obligations under any such insurance policies, and no written notice of cancellation has been received by the Company with respect to any such insurance policy.  The Company have made available to Buyer true and correct copies of all insurance loss runs and worker&#8217;s compensation claims for the Company for the most recently ended three (3) policy years.  Further, no material insurance carried by the Company has been canceled during the past three (3) years, and the Company has not been denied any material coverage during such period.  Except as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, there are no pending material claims under any such insurance policy as to which the respective insurers have denied coverage.  The Company has not received any written notice of any material increase (or proposed material increase) after the date hereof in any deductibles, retained amounts or premiums payable under the insurance policies listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule that, to the Company&#8217;s knowledge, is disproportionate to other increases occurring in the industry in which the Company operates.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compliance with Laws&#59; Permits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company is, and during the past three (3)-years has been, in compliance in all material respects with all Laws and Legal Requirements applicable to the conduct of its business as currently conducted, including Laws and Legal Requirements respecting employment and employment practices, immigration, terms and conditions of employment, wages and hours, and workplace health and safety, applicable security and privacy standards regarding protected health information under HIPAA, all applicable state privacy and security Laws, and with all applicable regulations promulgated under any such legislation.  The Company has not, during the three (3)-year period preceding the date hereof, received written notice of any Action by any Person alleging material liability under, or material noncompliance with, any such Law or Legal Requirement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Section 4.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule contains a true and complete list of all material Permits held by the Company and currently in effect.  All such Permits are valid and in full force and effect and none of such Permits shall terminate as a result of the consummation of the transactions contemplated hereby.  The Company is (and during the three (3)-year period preceding the date hereof has been) in material compliance with the terms and conditions of such Permits.  The Company has not received any written notice from a Governmental Authority of its intention to cancel, terminate, restrict, limit or otherwise qualify or not renew any of such Permits.  The Company has all material Permits that are necessary in order to enable the Company to own and operate its business as currently conducted.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> does not relate to (i) Environmental Laws or environmental Permits, which are the subject of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or (ii) Permits required under Healthcare Laws, which are the subject of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Environmental Compliance and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the Company is, and for the last three (3) years has been, in compliance in all material respects with all Environmental Laws applicable to the conduct of its business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Company is, and for the last three (3) years has been, in compliance with all material Permits required under Environmental Law to conduct its business at the Leased Real Property&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the Company has not received during the last three (3) years any written notice, information request, demand, claim or notice of violation from any Governmental Authority regarding any actual or alleged material violation of Environmental Laws, or any material liabilities or potential material liabilities for investigation costs, cleanup costs, response costs, corrective action costs, personal injury, property damage, natural resources damages or attorney fees under Environmental Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">there are no material Actions pending or, to the Company&#8217;s knowledge, threatened before or by any Governmental Authority against the Company which assert any claim under any Environmental Law&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the Company has not disposed of or released any Hazardous Substance so as to give rise to any material liability for investigation costs, cleanup costs, response costs, corrective action costs, personal injury, property damage, natural resources damages or attorney fees under CERCLA or any other Environmental Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">The representations and warranties in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are the sole and exclusive representations and warranties in this Agreement concerning environmental matters, including matters arising under Environmental Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Affiliated Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, no officer, director, stockholder, member or manager of the Company or, to the Company&#8217;s knowledge, any individual in such officer&#8217;s or director&#8217;s immediate family or any Affiliate thereof is a party to any material agreement, contract, commitment or transaction with the Company or has any material interest in any material property used by the Company.  The Company has not made any material loans to any officer, director, stockholder, member, manager or employee of the Company that remain outstanding except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, all of which outstanding loans shall be repaid in full at or prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Employment and Labor Matters</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule lists all employees of the Company as of February 7, 2023, and their state of residence, job title, length of service, hourly rates of compensation or base salaries (as applicable), classification as exempt or nonexempt for purposes of wage and hour laws, and bonus payments (fixed and discretionary), if any, and any other form of compensation (other than salary, bonuses or customary benefits) paid or payable to such person for the most recent fiscal year.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule sets forth, for each person listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the amount of accrued vacation, sick and paid time off for such person as of the last payroll date immediately preceding the date of this Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule also identifies each employee who is not fully available to perform his or her duties as a result of disability or other leave and sets forth the basis of such leave and the anticipated date of return to full service.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, (a)&#160;the Company is not a party to or bound by any collective bargaining agreement, nor has it experienced any strike or material grievance, claim of unfair labor practices, or other collective bargaining dispute within the past three (3) years, and (b)&#160;(i) the Company is not subject to any labor dispute, labor-related arbitration, labor-related lawsuit or labor-related administrative proceeding, no such labor dispute, labor-related arbitration, labor-related lawsuit or labor-related administrative proceeding is pending, and, to the knowledge of the Company, none is threatened, and (ii) none of the Company&#8217;s employees are or, to the Company&#8217;s knowledge, have been represented by any labor union and no union organizing activities involving such employees have occurred within the past three (3) years, are pending or, to the Company&#8217;s knowledge, threatened.  The Company is currently, and for the prior three (3) years has been, in compliance in all material respects with all applicable Laws relating to employment and labor, including those related to employment practices (including unfair employment practices), terms and conditions of employment, wage and hours, overtime pay, hiring practices, parental and family leave and pay, immigration, non-discrimination in employment, workers compensation, health and safety, and the collection and payment of withholding and&#47;or payroll Taxes.  The Company is not, and as of the Closing Date, will not be delinquent in payments to any employees or independent contractors for any wages, salaries, bonuses, benefits or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">compensation for any services performed by them to date or through the Closing Date, as the case may be, or any amounts required to be paid to any employee or independent contractor for any post-employment or post-engagement obligations of any type due on or prior to the date hereof or the Closing Date, as the case may be.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the employment or engagement, as applicable, of each employee of the Company is &#8220;at will&#8221; and may be terminated without material liability of the Company, other than those obligations arising under applicable Laws and Legal Requirement, including with respect to payment of accrued wages and benefits.  The Company has made available to Buyer all written employment contracts and severance plans of the Company in effect (or under which the Company has continuing obligations) as of February 7, 2023, and has disclosed to Buyer any such contracts and plans that are not written.  The Company has not, in the preceding three (3) years, classified any worker as an independent contractor who should reasonably be classified as an employee of the Company pursuant to the United States Department of Labor&#8217;s and Internal Revenue Service&#8217;s regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Accounts Receivable and Accounts Payable</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All of the accounts receivable of the Company (i) have arisen from bona fide transactions in the ordinary course of business consistent with past practice, and (ii) are valid and enforceable claims in all material respects.  No material discount or allowance from any such receivable has been made or agreed to and none represents billings prior to actual sale of goods or provision of services.  No obligor of any such receivable has refused or threatened in writing to pay its obligations for any reason and, to the knowledge of the Company, no such obligor has been declared bankrupt or is subject to any bankruptcy proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All accounts payable and accrued expenses of the Company have arisen only from bona fide transactions in the ordinary course of business consistent with past practice. Since the Balance Sheet Date, the Company has paid its accounts payable in the ordinary course of business and in a manner which is materially consistent with its past practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Brokerage</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There are no claims for brokerage commissions, finders&#8217; fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made by or on behalf of the Company or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Bank Accounts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule lists the names and locations of all banks or other financial institutions in which the Company has bank accounts, instrument of deposit or safe deposit box.  The schedule identifies the nature of the account, the account number, and the names of all persons authorized to draw thereon or who have access thereto.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Power of Attorney</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has not given to any Person (other than an employee of the Company or any Affiliate thereof) for any purpose any power of attorney which is currently in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Healthcare Matters</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#58; (A)&#160;the Company is, and during the past three (3) years has been, conducted in material compliance with all applicable Healthcare Laws&#59; (B) the Company has not received during the past three (3) years any written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice from any Governmental Authority regarding any material violation of any Healthcare Laws&#59; and (C) there are no, and within the past three (3) years there have not been any Proceedings pending or, to the knowledge of the Company, threatened alleging any material non-compliance by the Company with respect to any Healthcare Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#58; (A) the Company and its employees and independent contractors possess all Permits required by applicable Healthcare Laws necessary for the operation of the Company as currently conducted, which Permits are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#59; (B) none of such Permits will terminate as a result of the consummation of the transactions contemplated by this Agreement&#59; (C) the Company is, and has been during the past three (3) years, in compliance with such Permits in all material respects, and all of such Permits are valid, in good standing and in full force and effect&#59; (D) there is no Action by or before any Governmental Authority pending, or, to the Company&#8217;s knowledge, threatened against the Company to revoke, withdraw, suspend, cancel, terminate or otherwise limit any such Permit&#59; (E)&#160;the Company has not, during the past three (3) years, received any written notice from any Governmental Authority regarding any material violation of any such Permit or any revocation, withdrawal, suspension, cancellation or termination of any such Permit&#59; and (F) the Company has, in the past three (3) years, filed all required reports and maintained and retained all records required by applicable Healthcare Laws, in each case in all material respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule&#58; (A) all billing practices (including billing, coding, filing, and claims practices, and the related reports and filings) of the Company is, and during the past three (3) years have been, in compliance with applicable Healthcare Laws and all applicable requirements of Third Party Payors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Payor Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in all material respects&#59; (B) in the past three (3) years, the Company has paid or caused to be paid all known and undisputed material refunds, overpayments, discounts or adjustments, which have become due to any Governmental Authority or Third Party Payor&#59; (C) the Company does not have any material reimbursement, payment or payment rate appeals, disputes or contested positions pending before any Governmental Authority or Third Party Payor and, to the knowledge of the Company, none are threatened&#59; (D) in the past three (3) years, the Company has not claimed or received any material reimbursements from Government Programs or Private Programs, directly or indirectly through Third Party Payors, in excess of amounts permitted by applicable Healthcare Laws or Third Party Payor Requirements, with the exception of payor overpayments received and adjusted, recouped, or refunded in the ordinary course of business&#59; (E) in the past three (3) years, the right of the Company to receive reimbursements pursuant to any Government Program or Private Program has not been terminated, rescinded, suspended or otherwise adversely affected as a result of any Action by a Governmental Authority or Third Party Payor&#59; and (F) to the knowledge of the Company, there are no additional document requests made by Third Party Payors to which the Company has not responded. Within the past three (3) years, neither the Company nor, to the Company&#8217;s knowledge, any of its directors, managers, officers, employees, or independent contractors has submitted to any Third Party Payor any false or fraudulent claim for payment (as defined under the federal False Claims Act or counterpart state false claim laws), nor has the Company or, to the Company&#8217;s knowledge, any of their directors, managers, officers, employees, or independent contractors at any time knowingly violated any condition for participation of any Third Party Payor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither the Company nor any of its directors, officers, managers, employees or, to the Company&#8217;s knowledge, independent contractors has been in the past three (3) years or is currently&#58; (A) suspended, excluded or debarred from contracting with the United States federal or any state government or from participating in any Federal Health Care Program (as defined in 42 U.S.C. &#167; 1320a-7b(f))&#59; (B) subject to a civil monetary penalty assessed under Section 1128A of the Social Security Act, sanctioned, indicted, or convicted of a crime, or pled nolo contendere or to sufficient facts, in connection with any allegation of violation of any Federal Health Care Program requirement or Law&#59; (C) to the Company&#8217;s knowledge, charged with or investigated for a Federal Health Care Program related offense or a violation of applicable Laws related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, or obstruction of an investigation, or the unlawful manufacture, distribution, prescription, or dispensing of controlled substances&#59; or (D) to the Company&#8217;s knowledge, subject to an investigation or proceeding by any Governmental Authority that has resulted in or would </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonably be expected to result in any of the actions described in the foregoing subsections (A), (B) or (C). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Neither the Company nor, to the Company&#8217;s knowledge, any of its directors, officers, employees, agents or contractors (while acting on behalf of the Company), have, during the past three (3) years, solicited, received, paid or offered to pay any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, for any referral or generation of business in violation of any applicable Healthcare Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company is not nor has been in the past three (3) years&#58; (A) a party to a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services or any other consent decree, judgment, order, settlement or similar agreement with a Governmental Authority&#59; (B) to the Company&#8217;s knowledge, the subject of any investigation, program integrity review or audit conducted by any federal, state or local Governmental Authority&#59; (C) to the Company&#8217;s knowledge, a defendant or named party in any qui tam&#47;False Claims Act litigation&#59; (D) subject to any mandatory or discretionary exclusion or suspension from Federal Health Care Program participation&#59; (E) the subject of any investigation, program integrity review, audit or survey conducted by any federal, state or local Governmental Authority that resulted in a finding of any material improper activity or the Company&#8217;s receipt of either a written notice of deficiency or other written notice of any type of material violation of any Healthcare Law or Third Party Payor Requirement&#59; or (F) the recipient of any search warrant, subpoena, civil investigative demand or similar inquiry from a Governmental Authority with jurisdiction in respect of any Healthcare Law.  The Company has made available to Buyer true, correct and complete copies of each survey of the Company conducted by or on behalf of any Governmental Authority or Third Party Payor in the preceding three (3) years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, for the past three (3) years, the Company has materially complied, and is currently in material compliance with, HIPAA and the applicable health care data privacy and security Laws of the states in which the Company operates.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company has not, during the preceding three (3) years&#58; (A) had any security or data breaches compromising or otherwise involving Protected Health Information, as that term is defined in HIPAA, that required notification under 45 C.F.R. &#167; 164.406 or 45 C.F.R. &#167; 164.408(b)&#59; (B)&#160;received any written notice from any Person alleging or referencing the investigation of any material breach or any materially improper use, disclosure or access to any Protected Health Information in its possession, custody or control&#59; or (C) received any written communication from any Governmental Authority alleging that the Company is not in material compliance with HIPAA that has not been resolved&#59; or (D) to the Company&#8217;s knowledge, otherwise violated HIPAA, or any applicable health care data privacy and security Laws.  The Company has established and implemented such policies, programs, procedures, contracts (including business associate agreements), and systems as are necessary to comply with HIPAA in all material respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedules, in the past three (3) years and to the Company&#8217;s knowledge&#59; (i)&#160;the Company has not entered into any material joint venture, partnership, co-ownership or other financial arrangement involving any ownership, lease or investment interest in or by the Company with an individual known by it to be a physician or an immediate family member of a physician&#59; (ii) no institutional referral source of the Company maintains an ownership interest in, or compensation arrangement with, the Company&#59; and (iii)&#160;no physician who has, or whose immediate family member has, a financial relationship (as such terms are defined in the Stark Law), with the Company directly or indirectly makes (or has made) referrals, as that term is defined in the Stark Law, to the Company or any predecessor business without complying with an applicable exception to the Stark Law&#8217;s referral prohibition as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">All employees and independent contractors of the Company possess, in all material respects, the necessary licenses, registrations, permits, certificates and qualifications, as required by applicable Healthcare Laws, Third Party Payor Requirements, state professional licensing agencies, and professional organizations to carry out their respective material duties to the Company.  All of such licenses and certificates in effect are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule.  In the past three </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3) years, to the Company&#8217;s knowledge, no such employee or independent contractor has (i) had any professional license, certification, Drug Enforcement Administration number (if applicable), Medicare, Medicaid or TRICARE provider number suspended or revoked, (ii) been reprimanded, sanctioned or disciplined by any state licensing board or any Governmental Authority, professional society, hospital, Third Party Payor or specialty board, or (iii) had a final judgment or settlement without judgment entered against him or her in connection with a malpractice or similar action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The Company is not required, and has not been required during the past three (3) years, to file any cost reports in order to comply with applicable Government Program or Private Program requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company is not relying on any exemption from or deferral of any Healthcare Laws (other than applicable exceptions to the Stark Law&#8217;s referral prohibition as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">For the avoidance of doubt, and without limitation, &#8220;material&#8221; matters for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall include the following&#58; (i) a substantial amount of money received by the Company or any predecessors of the Company in excess of the amount due and payable under any Government Program or Private Program requirements or Third Party Payor Requirements&#59; (ii) a matter that a reasonable person would consider a probable violation of Law applicable to any Federal Health Care Program (as defined in 42 U.S.C. &#167; 1320a-7b(f)) for which penalties or exclusion may be authorized&#59; or (iii) the employment of or contracting with a Person who has been or is currently suspended, excluded or debarred from contracting with the United States federal or any state government or from participating in any Federal Health Care Program (as defined in 42 U.S.C. &#167; 1320a-7b(f)).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The representations and warranties in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Health Care Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are the sole and exclusive representations and warranties in this Agreement concerning health care matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Relationships with Customers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule includes a list of the Company&#8217;s top twenty (20) Customers in order of gross revenue for each of the years ended December 31, 2022, December 31, 2021, and December 31, 2020.  There are not, and have not been during the three (3)-year period preceding the date hereof, any material disputes with any such Customer that have not been resolved.  No such Customer has in the past three (3) years (i) cancelled or otherwise terminated any contract with the Company prior to the expiration of such contract&#8217;s term, (ii) cancelled or has threatened in writing to cancel or otherwise terminate its relationship with the Company, (iii)&#160;reduced or has threatened in writing to materially reduce its volume of business with the Company, or (iv) has delivered written notice seeking to materially change the amount payable to the Company in connection with the Company&#8217;s services.  To the knowledge of the Company, no such Customer has been declared bankrupt or is subject to any bankruptcy proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Investment Company Status</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company is not required to be registered as an &#8220;investment company&#8221; as defined in, or subject to regulation under, the Investment Company Act of 1940, as amended. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Home Health Services Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The material billing arrangements pursuant to which the Company receives payment for services in connection with their business operations are identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Billing Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Other than the Billing Arrangements, the Company does not participate in or receive reimbursement under, and does not maintain current provider agreements or numbers with, any Government Program or Private Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All material reports, invoices and documentation required to be filed with respect to the Billing Arrangements in the past three (3) years have been timely filed or filed within the grace </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">periods permitted under the applicable Billing Arrangements, and all such reports, invoices and documentation are complete and accurate in all material respects and have been prepared in all material respects in accordance with all contract requirements and applicable Laws and Legal Requirements.  The Company&#58; (i) has not in the past three (3) years claimed or received any material reimbursements from Billing Arrangements in excess of amounts permitted by Law or Legal Requirements&#59; (ii) has not in the past three (3) years received any written notice of any liability under any Billing Arrangement for any material refund, overpayment, discount or adjustment, other than ordinary course adjustments and refunds resolved in accordance with Third Party Payor policies&#59; (iii) has not, during the past three (3) years, received written notice of any Action pending or recommended by any Governmental Authority (or contractor acting on behalf of a Governmental Authority) to terminate the participation of the Company in any Billing Arrangements&#59; and (iv)&#160;is not a party to any material audit being conducted by any Governmental Authority, contractor acting on behalf of a Government Authority, or other Person, nor has the Company received any written notice that any such audits are planned.  The Company&#8217;s systems and software used in connection with all requests for reimbursement and related underlying information comply in all material respects with all rules, regulations, policies and procedures applicable to such Billing Arrangements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All of the Company&#8217;s professional staff are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.26(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule.  All such staff are qualified and, to the extent required by any applicable Governmental Authority, certifying body, licensing agency, professional organization or Billing Arrangement, are licensed, registered, or certified, as applicable, to practice without restriction or limitation in such capacity in the states in which the Company operates and, to the Company&#8217;s knowledge, none are employed by a third-party home health service agency.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Health Care Representations are the sole and exclusive representations and warranties in this Agreement concerning health care matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Distribution Schedule is true and correct in all material respects and accurately sets forth the amount of Aggregate Closing Consideration to be paid to the payees of the Seller Transaction Expenses, including the amounts owing to the recipients of the Change of Control Payments.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Section 4.27(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule contains a list of the current members of the governing board and officers of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company has made available to Buyer true and correct copies of all cybersecurity policies and procedures currently maintained by them.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.27(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the Company is in compliance with such policies and procedures in all material respects and no material violations or breaches thereof have occurred during the two (2)-year period preceding the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">There is no contract, lease, agreement of the Company that contains a covenant not to compete, nor is there any Order binding on the Company that prohibits the Company from competing with another Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Other Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> OR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> OF THIS AGREEMENT OR IN ANY TRANSACTION DOCUMENT, NEITHER THE COMPANY NOR THE SELLER MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, AND THE COMPANY AND SELLER HEREBY DISCLAIM ANY SUCH REPRESENTATION OR WARRANTY, WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.  BUYER WILL ACQUIRE THE COMPANY WITHOUT ANY REPRESENTATION OR WARRANTY AS TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, IN AN &#8220;AS IS&#8221; CONDITION AND ON A &#8220;WHERE IS&#8221; BASIS, EXCEPT AS OTHERWISE </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXPRESSLY REPRESENTED OR WARRANTED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> OR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> OF THIS AGREEMENT OR IN ANY TRANSACTION DOCUMENT.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF BUYER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer represents and warrants to the Seller and the Company as follows as of the date hereof and as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Organization and Power</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware, with full limited liability company power and authority to enter into this Agreement and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The execution, delivery and performance of this Agreement and any Transaction Document to which Buyer is party by Buyer and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite action on the part of Buyer, and no other proceedings on Buyer&#8217;s part are necessary to authorize the execution, delivery or performance of this Agreement by Buyer.  This Agreement and each Transaction Document to which Buyer is party has been duly executed and delivered by Buyer and assuming that this Agreement is a valid and binding obligation of the Seller and the Company, this Agreement and each applicable Transaction Document constitutes a valid and binding obligation of Buyer, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, or moratorium Laws, other similar Laws affecting creditors&#8217; rights and general principles of equity affecting the availability of specific performance and other equitable remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Breach</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule, the execution, delivery and performance of this Agreement and all Transaction Documents to which Buyer is a party and the performance of the transactions contemplated hereby and thereby do not and will not&#58;  (a)&#160;contravene, require any consent or notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, accelerate any obligation under, or give rise to a right of acceleration, cancellation or termination of, or result in the creation of a Lien on any of the properties or assets of Buyer pursuant to, any contract, agreement, obligation, permit, license or authorization to which Buyer is a party or by which any of its assets are bound&#59; (b) contravene, require any consent or notice under or violate or result in a violation of, conflict with or constitute or result in a breach or default (whether after the giving of notice, lapse of time or both) under, or accelerate any obligation under, any provision of Buyer&#8217;s organizational documents&#59; (c) contravene or violate or result in a violation of, or constitute a breach or default (whether after the giving of notice, lapse of time or both) under, any provision of any Law, or any judgment or order of, or any restriction imposed by, any court or Governmental Authority applicable to Buyer&#59; or (d) require from Buyer any notice to, declaration or filing with, or consent or approval of, any Governmental Authority or other third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Litigation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There are no actions, suits or proceedings pending or, to Buyer&#8217;s knowledge, threatened against or affecting Buyer at law or in equity, or before or by any Governmental Authority, which would adversely affect Buyer&#8217;s performance under this Agreement or the consummation of the transactions contemplated hereby.  Buyer is not subject to any outstanding Governmental Order, which would adversely affect Buyer&#8217;s performance under this Agreement or the consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Brokerage</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There are no claims for brokerage commissions, finders&#8217; fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made by or on behalf of Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Investment Representation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer is acquiring the Interests for its own account with the present intention of holding such securities for investment purposes and not with a view to, or for sale in connection with, any distribution of such securities in violation of any federal or state securities Laws.  Buyer is an &#8220;accredited investor&#8221; as defined in Regulation&#160;D promulgated by the U.S. Securities and Exchange Commission under the Securities Act.  Buyer acknowledges that the Interests have not been registered under the Securities Act of 1933, as amended, or any state or foreign securities Laws and that the Interests may not be sold, transferred, offered for sale, assigned, pledged, hypothecated or otherwise disposed of unless such transfer, sale, assignment, pledge, hypothecation or other disposition is pursuant to the terms of an effective registration statement under the Securities Act and the Interests are registered under any applicable state or foreign securities Laws or sold pursuant to an exemption from registration under the Securities Act as amended, and any applicable state or foreign securities Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Sufficient Funds</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer shall have as of the Closing Date the financial capability and sufficient cash on hand or other sources of immediately available funds necessary to consummate the transactions contemplated by this Agreement on the terms and subject to the conditions set forth herein.  Buyer understands and acknowledges that the obligations of Buyer to consummate the contemplated transactions are not in any way contingent upon or otherwise subject to any consummation of any financing arrangement, any obtaining of any financing or the availability, grant, provision or extension of any financing to Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Solvency</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon consummation of the transaction contemplated hereby, and subject to the accuracy of the representations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Buyer and its Subsidiaries, including the Company, will not (a) be insolvent or left with unreasonably small capital, (b) have incurred debts beyond their ability to pay such debts as they mature or (c) have liabilities in excess of the reasonable market value of their assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Other Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> OF THIS AGREEMENT, BUYER DOES NOT MAKE ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, AND BUYER HEREBY DISCLAIMS ANY SUCH REPRESENTATION OR WARRANTY, WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CERTAIN PRE-CLOSING COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conduct of the Business</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, contemplated by this Agreement or consented to in writing by Buyer, (a) the Company will use its commercially reasonable efforts to carry on its business in the ordinary course of business and substantially in the same manner as heretofore conducted and (b) the Company will not take any action which, if taken after December 31, 2022, would be required to be disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule.  Additionally, during the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Company will not&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">make any non-cash dividend or distribution on the Interests&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">make or change any material Tax election, change an annual accounting period, adopt or change any accounting method, file any amended Tax Return, enter into any closing agreement, settle any Tax claim or assessment, surrender any right to claim a refund of Taxes, consent to any extension or waiver of the limitation period applicable to any Tax claim or assessment, or take any other similar action relating to the filing of any Tax Return or the payment of any Tax (in each case without Buyer&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">adopt a complete or partial plan of liquidation or resolutions authorizing or providing for such a liquidation or dissolution, consolidation, recapitalization, reorganization or bankruptcy, or make a general assignment for the benefit of creditors&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">cause or permit any material modification to be made to any of the Company Intellectual Property owned by the Company, other than maintenance and security-related modifications made in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">increase the compensation or agree to any bonus, severance, or Change of Control Payments to any employee, director, or officer of the Company, other than in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">make any material changes to any Benefit Plan, other than any change required by applicable Law&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">agree or otherwise commit to take any of the actions prohibited by the foregoing clauses (i) through (vi).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Access to Books and Records</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the period from the date of this Agreement until the Closing Date or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each of the Seller and the Company will provide Buyer and its and their respective authorized representatives (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer&#8217;s Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with access to (a) the offices, properties, contracts, books, records and, to the extent permitted by the Seller, the systems of the Company as reasonably requested by Buyer in order for Buyer to have the opportunity to make such investigation as it reasonably desires to make of the affairs of the Company (except that Buyer will conduct no physically invasive sampling or testing, including soil or groundwater sampling, without the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed)) and (y) all officers and management-level employees of the Company for discussion of the business operations and personnel of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in each case, such access shall be provided only during normal business hours upon reasonable advance notice to the Company, under the supervision of the Company&#8217;s personnel and in such a manner as not to interfere with the normal operations of such the Company.  All requests by Buyer or Buyer&#8217;s Representatives for access pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be submitted or directed exclusively to the Seller or such other individuals as the Company may designate in writing from time to time. Notwithstanding anything to the contrary in this Agreement, (a) the Company will not be required to disclose any information to Buyer or Buyer&#8217;s Representatives if such disclosure would (i) jeopardize any attorney-client or other legal privilege or (ii) contravene any applicable Laws, fiduciary duty or agreement entered into prior to the date hereof and (b) prior to the Closing Date, without the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed), neither Buyer nor any of Buyer&#8217;s Representatives shall contact or cause to be contacted any customers of the Company concerning the transactions contemplated hereby.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer acknowledges that it is and remains bound by the Confidentiality and Non-Disclosure Agreement, dated September 15, 2021, between Amedisys, Inc. and HouseWorks, LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and that Buyer shall cause Buyer&#8217;s Representatives to abide by the terms of the Confidentiality Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that in the event the Closing is consummated, the Confidentiality Agreement shall be terminated and become null and void.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Third-Party Consents</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall give all notices to, and use commercially reasonable efforts to obtain all consents from, all third parties that are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Company and the Seller shall use commercially reasonable efforts to cause the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof to be satisfied and to consummate the transactions contemplated hereby as soon as reasonably practicable after the satisfaction of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (other than those to be satisfied at the Closing).  Buyer shall use commercially reasonable efforts to cause the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to be satisfied and to consummate the transactions contemplated hereby as soon as reasonably practicable after the satisfaction of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (other than those to be satisfied at the Closing). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Company or the Seller shall disclose to Buyer in writing any development, fact or circumstance arising after the date hereof that would result in any of the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof to no longer be true and correct in all material respects and of any material breach of the covenants in this Agreement made by the Company or Seller&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, except as expressly provided below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any such notification shall be solely for informational purposes and shall (x) not be deemed to amend the Disclosure Schedule or qualify or cure the related representations and warranties of the Company or Seller herein and (y) be disregarded for purposes of the indemnification provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the conditions to Closing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to any such notification that relates solely to any action, occurrence, fact, development or event that (i) both arises and becomes known to the Company after the date hereof and would have been required or permitted to be set forth or described in the Disclosure Schedule had such matter existed as of the date hereof and (ii) would prevent the satisfaction or cause a failure to be satisfied of any of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such notification shall be deemed an update and amendment to the Disclosure Schedule solely for purposes of the conditions set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (and not for purposes of indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) if such notification is delivered to Buyer at least five (5) Business Days prior to the Closing Date (such written update to the Disclosure Schedule, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule Update</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that in the event that the matter set forth in a Schedule Update cannot be cured to Buyer&#8217;s reasonable satisfaction within three (3) Business Days after delivery of such Schedule Update, then Buyer will be entitled to terminate this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by delivery of a written termination notice that is delivered to the Seller within five (5) Business Days following Buyer&#8217;s receipt of the related Schedule Update.  The Parties agree that Buyer shall be entitled to review and comment on any Schedule Update (such review not to be unreasonably delayed), and that the Parties shall mutually agree on the substance of any Schedule Update prior to the Closing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such right to comment on any Schedule Update shall not modify the foregoing five (5) Business Day period with respect to delivery of a termination notice pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any Schedule Update and any other updates with respect to the Disclosure Schedule shall have no effect on the right of the Buyer Indemnitees to indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Exclusivity</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In consideration of the substantial expenditure of time, effort and expense undertaken by Buyer in connection with its due diligence review of the Company and its business and the preparation and negotiation of this Agreement, from and after the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, none of the Company or the Seller, nor will they permit any of their respective Affiliates, directors, officers, employees, members, managers, shareholders, advisors, representatives or other agents, to, directly or indirectly, initiate, solicit, negotiate, discuss, knowingly encourage or enter into any negotiations, discussions or agreement with respect to, or provide any information to any third party with respect to, the potential sale of the Company or any portion thereof or a substantial interest therein, or any other transaction that would be inconsistent with the transactions contemplated hereby, in any case whether by sale of assets or equity, merger, recapitalization, reorganization or other transaction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, nothing herein shall prohibit or otherwise restrict Amedisys, Inc. or any of its Affiliates from initiating, soliciting, negotiating, discussing, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">knowingly encouraging or entering into any negotiations, discussions or agreement with respect to, or providing any information to any third party with respect to, the potential sale of all or substantially all of the Equity Interests or assets of Seller Parent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, for the avoidance of doubt, any such Upstream Transaction shall not include any terms or conditions that prohibit the consummation of the transactions contemplated by this Agreement.  If, from the date of this Agreement until the Closing or the earlier termination of this Agreement, the Company, the Seller or any of the other Persons referenced above receives an offer or proposal relating to any acquisition of the business of the Company (excluding an Upstream Transaction), such Person shall notify Buyer of the receipt of such offer and, unless otherwise prohibited by the terms of a confidentiality agreement in existence as of the date hereof, the terms of the offer and the identity of the offeror.  Unless otherwise prohibited by the terms of any definitive agreement with respect to an Upstream Transaction, Seller shall, as soon as is permissible under applicable Law (including applicable stock exchange rules) and the internal policies and procedures of Amedisys, Inc., notify Buyer of the execution of any such definitive agreement with respect to an Upstream Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer shall, as promptly as possible and at Buyer&#8217;s sole cost and expense (including filing fees), use its reasonable best efforts to obtain or cause to be obtained all consents, authorizations, orders, approvals or clearances from, and make or cause to be made all declarations, filings or notices with, all Governmental Authorities that are required by Law for the consummation of the transactions contemplated hereby (including such filings as are necessary or advisable in any jurisdiction in order to comply with all applicable Laws relating to competition, merger control or antitrust), provided that each party shall provide such reasonable cooperation as may be requested by the other party in seeking to obtain any such consents, authorizations, orders, approvals and clearances or in making any such declarations, filings or notices.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The parties agree to comply with any additional requests for information, including requests for production of documents and production of witnesses for interviews or depositions by any Governmental Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer will keep the Company apprised of the status of all filings and submissions referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, including promptly furnishing the Company with copies of notices or other communications received by Buyer in connection therewith.  Buyer will not permit any of its officers, employees or other representatives or agents to participate in any meeting with any Governmental Authority in respect of such filings and submissions unless it consults with the Company in advance and, to the extent permitted by such Governmental Authority, gives the Company the opportunity to attend and participate thereat. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If any administrative or judicial action or proceeding is instituted (or threatened to be instituted) to prohibit the transactions contemplated by this Agreement, the parties will use their respective best efforts to avoid the institution of any such action or proceeding and to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any temporary, preliminary or permanent decree, judgment, injunction or other order that is in effect and that prohibits, prevents, delays or restricts consummation of the transactions contemplated hereby (it being understood that the foregoing obligation of the parties will cease in the event a permanent decree, judgment, injunction or other order is issued or is in effect that is non-appealable and prohibits, prevents, delays or restricts consummation of the transactions contemplated hereby).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Employment Matters</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">From the date hereof to the Closing Date or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Company shall provide Buyer the opportunity reasonably requested by it to contact and have access to the Employees set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for pre-Closing introductions and training sessions. Neither Buyer nor any of its Affiliates shall contact any other Employee without prior notice to and consent of the Company (which consent may be provided by any of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller, Geoffrey Abraskin and Kristopher Novak, orally or by any written means, including e-mail) and to the extent any such contact involves a meeting between Buyer (or any Affiliate) and such Employee, the Company shall be entitled to have a representative present at any such meeting and pre-approve, in its sole discretion, the contents of any discussions with Employees. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">From the date hereof to the Closing Date or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Company shall use commercially reasonable efforts to seek to obtain a transaction bonus and release agreement, in form and content reasonably acceptable to both Buyer and Seller, duly executed by each recipient of a Change of Control Payment&#59; provided, however, (i) the Company shall not be obligated to incur any out-of-pocket costs in connection with such efforts, and (ii) it shall not be a condition to Closing that the Company shall have obtained such transaction bonus and release agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From the date hereof until the Closing Date, the Company shall provide monthly income statements for the Company and year-to-date income statements for the Company, prepared in accordance with GAAP consistent with the Company&#8217;s past practices, as such financial statements are prepared by the Company in the ordinary course consistent with past practice, as may be reasonably requested by Buyer.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Maintenance of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  From the date hereof until the Closing Date, the Company shall maintain insurance coverage for its operations no less favorable than the insurance coverages for them in effect as of the date hereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company shall, at least three (3) Business Days prior to the Closing, provide Buyer with a schedule setting forth the information required to be set forth on the schedule delivered pursuant to the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with respect to each officer, employee and independent contractor of the Company employed or engaged by the Company as of such date.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Bank Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As soon a reasonably practicable, and in any event no later than fourteen (14) Business Days following the Closing, the Company shall deliver to Buyer all documentation required to change authorizations for the accounts identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Disclosure Schedule to the individuals designated by Buyer, with any such documentation delivered prior to Closing to be held in escrow by Buyer until expressly released by the Company at the Closing.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Terminated Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At or prior to the Closing, the Company shall cause the contracts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.09(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if any, to be terminated and of no further force or effect effective as of the Closing.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Cash Distribution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Prior to the Closing Date, the Company shall, and the Seller shall cause the Company to, distribute to the Seller any unrestricted Cash on Hand of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that beginning as of 12&#58;01 a.m. (ET) on the Closing Date the Company shall not distribute or transfer any Cash on Hand (other than payments to third parties in respect of bona fide accounts payable in the ordinary course of business consistent with past practices) without Buyer&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Transition Matters</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer and Seller shall, and Seller shall cause Amedisys Holding, L.L.C. to, negotiate in good faith to seek to agree upon the terms of the Transition Services Agreement as soon as reasonably practicable following the parties&#8217; execution and delivery of this Agreement.  Buyer and Seller hereby acknowledge that it is anticipated that (a) the term of the Transition Services Agreement shall extend for approximately one hundred twenty (120) days following the Closing, (b) the Company shall be obligated under the Transition Services Agreement to reimburse Amedisys Holding, L.L.C. for all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonable documented out-of-pocket costs and expenses incurred by it and its Affiliates in providing the mutually agreed upon transition services thereunder, and (c) the Transition Services Agreement shall provide for the Company to provide Amedisys Holding, L.L.C. and its Affiliates with such access to the Company&#8217;s scheduling system and such other support as is reasonably necessary for Amedisys Holding, L.L.C. and its Affiliates to wind-down the operations of Angel Watch Home Care, L.L.C., in each case on terms reasonably acceptable to Buyer and Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">During the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties shall reasonably cooperate to determine whether any Person who is employed by the Seller or any of its Affiliates (excluding the Company) needs to be employed by the Company following the Closing (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transferring Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and shall set forth the name of each Transferring Employee on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the Closing.  The Parties agree that, except as otherwise provided in the Transition Services Agreement, the Parties shall reasonably cooperate to effect an orderly transition of any Transferring Employees to the Company effective as of the Closing Date (or such later date as set forth in the Transition Services Agreement), including that (i) each Transferring Employee shall be offered &#8220;at-will&#8221; employment with the Company, and the Seller and its Affiliates shall use commercially reasonable efforts to assist the Company with hiring each such Transferring Employee, and (ii) the Seller (or its applicable Affiliate (excluding the Company) who is the employer of such Transferring Employee) shall be responsible for the payment of, and shall pay, all wages, salaries and other compensation and employee benefits (including any vacation pay, severance pay, notice pay, insurance, supplemental pension, deferred compensation, &#8220;stay&#8221; or other similar incentive bonuses, Change of Control Payments, retirement and any other benefits, premiums, claims and related costs) to any Transferring Employee that are accrued as of the date of such Transferring Employee&#8217;s termination with the Seller (or its applicable Affiliate (excluding the Company) who is the employer of such Transferring Employee) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accrued Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except to the extent any such Accrued Payments are assumed by the Company and accrued for in Net Working Capital, it being the intent of the Parties that to the extent practicable any accrued paid time off balance for each Transferring Employee shall be transferred to the Company (and not paid out to such Transferring Employee) and included in the calculation of Net Working Capital.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties shall reasonably cooperate to determine whether any contract to which the Seller or any of its Affiliates (excluding the Company) is party that is used in the operation of the Company&#8217;s business and is necessary for the Company to conduct its business following the Closing in the same manner as currently conducted (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Designated Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and shall set forth each Designated Contract on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 6.11(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the Closing. The Parties agree to reasonably cooperate in good faith to determine a mutually acceptable transition plan with respect to each Designated Contract, which may include (i) an assignment of the Designated Contracts to the Company and&#47;or (ii) a mutually agreed upon transition arrangement under the Transition Services Agreement.  For the avoidance of doubt, Buyer acknowledges and agrees that no enterprise contracts to which the Seller or any of its Affiliates are parties shall be assigned to the Company unless such contract is used exclusively in the operation of the Company&#8217;s business.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">POST-CLOSING COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Access to Books and Records</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of six (6) years after the Closing Date, Buyer shall, and shall cause the Company to, provide the Seller and its authorized representatives with reasonable access, during normal business hours, to the personnel, books and records (for the purpose of examining and copying at Seller&#8217;s expense) of the Company with respect to periods or occurrences prior to the Closing Date as may be reasonably required by the Seller in connection with any legitimate matter relating to the Seller&#8217;s pre-Closing ownership of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that (x) such access will be subject to the confidentiality obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof and will not unreasonably interfere with the operation of the Company, and (y) nothing herein will require Buyer, the Company or any of their respective Affiliates or representatives to furnish to the Seller or its Representatives, or provide the Seller or its representatives </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with access to, information that legal counsel for Buyer, the Company or any of their respective Affiliates reasonably concludes may violate applicable Law or that is subject to attorney-client privilege.  For a period of six (6) years after the Closing Date, Buyer shall maintain the books and records of the Company relating to periods prior to the Closing Date in accordance with the record retention policy of Buyer, as such record retention policy may be amended from time to time by Buyer.  In the event of any litigation or threatened litigation between the parties relating to this Agreement or the transactions contemplated hereby, the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not be considered a waiver by any party of any right to assert the attorney-client privilege.  For a period of six (6) years after the Closing Date, Buyer will cause the Company to maintain a records retention policy substantially consistent with the record retention policy of Buyer as previously provided to the Seller, as such record retention policy may be amended from time to time by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Employment Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">For a period of one (1) year following the Closing (or, if earlier, until the date of the applicable Employee&#8217;s termination of his or her employment with Buyer other than a termination without cause by Buyer (except as permitted herein below)), Buyer shall provide for each Employee who is employed as of immediately prior to the Closing and who remains employed as of immediately following the Closing (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covered Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (i) salary and target cash bonus opportunity (or base pay for non-salaried employees) that is substantially comparable to the salary and target cash bonus opportunity (or base pay for non-salaried employees) paid to similarly situated employees of Buyer, and (ii) retirement and welfare benefits that are substantially comparable in the aggregate to those offered to similarly situated employees of Buyer&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, notwithstanding the foregoing but subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the aforementioned one (1) year period may be shortened by Buyer if, in its good faith discretion, Buyer needs to implement operational changes (e.g., changes in staffing ratios, reductions in staffing, etc.) in order to improve the profitability of the related Company location, but only to the extent such shortened period does not cause any WARN Act liabilities for the Seller. With respect to any employee benefit plan maintained by Buyer or any of its Affiliates (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer Employee Benefits Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that the Covered Employees participate in after the Closing, if any, (i) Buyer shall undertake commercially reasonable efforts to, or shall cause its Affiliates to undertake commercially reasonable efforts to, recognize all service of the Covered Employees prior to the Closing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Closing Company Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as if such service were with Buyer or its Affiliates, for vesting and eligibility purposes in such Buyer Employee Benefit Plans, provided that no such service shall be credited to the extent that it would result in a duplication of benefits or for the purpose of any defined benefit pension plan.  With respect to any Buyer Employee Benefit Plans providing for, medical, dental and vision benefits in which the Covered Employees participate after the Closing, if any, Buyer shall, to the extent permitted by the related Buyer Employee Benefit Plans, undertake commercially reasonable efforts to (i) waive or cause to be waived any exclusionary provisions, waiting period, proof of insurability requirements and pre-existing condition limitations to the extent the same are not applicable under the related Buyer Employee Benefit Plans prior to the Closing&#59; and (ii) credit or cause to be credited the Covered Employees for all deductible expenses incurred by the Covered Employees under the comparable Buyer Employee Benefit Plan in the year in which the Closing occurs, provided such expenses would have been covered expenses under Buyer Employee Benefit Plan and that such credit does not result in the duplication of benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Buyer shall assure that a sufficient number of Covered Employees shall remain employed by Buyer for at least a ninety (90)-day period following the Closing so as not to create liability for the Seller under the Worker Adjustment and Retraining Notification Act, 29 U.S. Stat. &#167; 2101 et. seq. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Effective at least one (1) day prior to the Closing, the Covered Employees shall cease to be covered as active participants in the Amedisys Holding, L.L.C. 401(k) Plan sponsored by Amedisys Holding, L.L.C and adopted by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amedisys 401(k) Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Company shall take all action necessary to terminate their participation in the Amedisys 401(k) Plan at least one (1) day prior to the Closing. In connection with the Company&#8217;s termination of participation in the Amedisys 401(k) Plan, and in accordance with applicable Law, the parties agree to effectuate a spin-off of the Amedisys 401(k) Plan assets relating to the Covered Employees who are participants in the Amedisys 401(k) Plan as a result of their employment with the Company (including an in-kind transfer of any Covered Employee loan notes) into a new plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Spin Off Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and terminate such Spin Off Plan at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">least one (1) day prior to the Closing, and Buyer agrees to undertake commercially reasonable efforts or cause its Affiliates to undertake commercially reasonable efforts to cause Buyer&#8217;s or its Affiliates&#8217; 401(k) plan to accept rollovers from the Spin Off Plan (including an in-kind transfer of any Covered Employee loan notes to the extent permitted under Buyer&#8217;s or its Affiliates&#8217; 401(k) plan).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Following the Closing, Buyer will be responsible for providing, or causing the Company to provide, continuation coverage and all related notices to any Covered Employee or a qualified beneficiary who incurs or incurred a qualifying event as a result of the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, under the continuation health care coverage requirements of Section 4980B of the Code and Sections 601 through 608 of ERISA and any similar state Law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be binding upon and inure solely to the benefit of each of the parties, and nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, express or implied, shall confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing contained herein, express or implied, shall be construed to establish, amend or modify any Plans, including any benefit plan, program, agreement or arrangement. The parties acknowledge and agree that the terms set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not create any right in any Employee or any other Person to any continued employment with the Company, Buyer or any of their respective Affiliates or compensation or benefits of any nature or kind whatsoever, any right of any Employee or any other Person to participate in any Buyer Employee Benefit Plan or any obligation of Buyer or Buyer Parent to allow any Employee or any other Person to participate in any Buyer Employee Benefit Plan. Nothing in this Agreement shall be deemed to confer upon any Person (nor any beneficiary thereof) any rights under or with respect to any Plans, including any plan, program or arrangement described in or contemplated by this Agreement, and each Person (and any beneficiary thereof) shall be entitled to look only to the express terms of any such plan, program or arrangement for his or her rights thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Confidentiality</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">From and after the Closing, the Seller agrees to, and shall instruct its agents, representatives, Affiliates, employees, officers and directors (in each case, as applicable) to, treat and hold as confidential all of Buyer&#8217;s and the Company&#8217;s proprietary, nonpublic and&#47;or confidential information relating to their respective businesses, which specifically includes without limitation &#8220;know how,&#8221; financial information, trade secrets, formulas, inventions, lease or construction terms, consultant and employment contracts, customer and patient lists and information, prospective customer and patient lists and information, vendor and supplier information, pricing policies, corporate records and organizational documents, operational methods, marketing or franchising plans or strategies, sales strategies, other corporate strategies, product development techniques or plans, business acquisition plans, new personnel acquisition plans, training materials, data, inventions, processes, unpublished patent applications, works of authorship, designs and design projects and other business affairs relating to Buyer, the Company or their respective businesses (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and refrain from using any Confidential Information except in connection with this Agreement, and deliver promptly to Buyer, at Buyer&#8217;s request, all Confidential Information (and all copies thereof in whatever form or medium) in its possession or under its control.  Notwithstanding the foregoing, Confidential Information shall not include information that, at the time of disclosure, is available publicly and was not disclosed in breach of this Agreement.  Further, in the event any portion of the Confidential Information includes any proprietary, nonpublic and&#47;or confidential information of the Seller or its Affiliates (excluding the Company) that is used by any of them in the operation of their respective businesses apart from the business of the Company, then the Seller and its Affiliates (excluding the Company) shall not be prohibited from using or disclosing any such portion of the Confidential Information that contains Seller Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Seller or any of its agents, representatives, Affiliates, employees, officers or directors (as applicable) becomes legally compelled to disclose any Confidential Information, such Person shall, to the extent legally permissible, provide Buyer with prompt written notice of such requirement so that Buyer may seek, at its sole cost and expense, a protective order or other remedy or waive compliance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that a protective order or other remedy is not obtained or if Buyer waives compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such Person shall furnish only that portion of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidential Information that is legally required to be provided and exercise commercially reasonable efforts (at the sole cost and expense of Buyer) to obtain assurances that confidential treatment will be accorded such information.  The Seller shall be responsible for any breaches of the confidentiality obligations hereunder by their respective agents, representatives, Affiliates, employees, officers and directors as if such their respective agents, representatives, Affiliates, employees, officers and directors, as applicable, were party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">From and after the Closing, Buyer agrees to, and shall instruct its agents, representatives, Affiliates, employees, officers and directors (in each case, as applicable) to, treat and hold as confidential any and all proprietary, nonpublic and&#47;or confidential information of Seller and its Affiliates (excluding the Company) relating to their respective businesses (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Seller Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and refrain from using any Seller Confidential Information, and deliver promptly to Seller, at Seller&#8217;s request, all Seller Confidential Information (and all copies thereof in whatever form or medium) in its possession or under its control.  Notwithstanding the foregoing, Seller Confidential Information shall not include information that, at the time of disclosure, is available publicly and was not disclosed in breach of this Agreement.  Further, in the event any portion of the Seller Confidential Information includes any Confidential Information of the Company that is necessary to be used by the Company in the operation of its businesses following the Closing, then the Company shall not be prohibited from using or disclosing any such portion of the Seller Confidential Information containing Confidential Information of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that Buyer or any of its agents, representatives, Affiliates, employees, officers or directors (as applicable) becomes legally compelled to disclose any Seller Confidential Information, such Person shall, to the extent legally permissible, provide Seller with prompt written notice of such requirement so that Seller may seek, at its sole cost and expense, a protective order or other remedy or waive compliance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that a protective order or other remedy is not obtained or if Seller waives compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such Person shall furnish only that portion of such Seller Confidential Information that is legally required to be provided and exercise commercially reasonable efforts (at the sole cost and expense of Seller) to obtain assurances that confidential treatment will be accorded such information.  Buyer shall be responsible for any breaches of the confidentiality obligations hereunder by its agents, representatives, Affiliates, employees, officers and directors as if such their respective agents, representatives, Affiliates, employees, officers and directors, as applicable, were party hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated at any time prior to the Closing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">by the mutual written consent of Buyer and Seller&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">by Buyer, if (x) there has been a material violation or breach by the Company or Seller of any covenant, representation or warranty contained in this Agreement which has prevented the satisfaction of any condition to the obligations of Buyer at the Closing and such violation or breach has not been waived by Buyer or, in the case of a covenant breach, cured by the Company or Seller within ten (10) days after written notice thereof from Buyer or (y) the Seller delivers a Schedule Update pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the underlying matter set forth in such Schedule Update cannot be cured to Buyer&#8217;s reasonable satisfaction within three (3) Business Days after delivery of such Schedule Update, provided Buyer delivers such termination notice within five (5) Business Days after its receipt of the related Schedule Update&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">by the Seller, if there has been a material violation or breach by Buyer of any covenant, representation or warranty contained in this Agreement which has prevented the satisfaction of any condition to the obligations of the Seller at the Closing and such violation or breach has not been waived by the Seller or, in the case of a covenant breach, cured by Buyer within ten (10) days after written notice thereof by the Seller (provided that neither a breach by Buyer of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> nor the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">failure to deliver the full consideration payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> at the Closing as required hereunder will be subject to cure hereunder unless otherwise agreed to in writing by Seller)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">by either Party if any Governmental Authority having competent jurisdiction has issued a final and non-appealable order, decree or ruling permanently restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated by this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the right to terminate this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not be available to any party whose breach of any provision of this Agreement results in such order, decree or ruling&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">by either Buyer or the Seller if the transactions contemplated hereby have not been consummated by 5&#58;00 p.m., Eastern time on June 10, 2023, provided that, neither Buyer nor the Seller will be entitled to terminate this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> if such Person&#8217;s knowing or willful breach of this Agreement has prevented the consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Effect of Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of the termination of this Agreement by either Buyer or the Seller as provided above, the provisions of this Agreement will immediately become void and of no further force or effect (other than this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which will survive the termination of this Agreement in accordance with their terms&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and the Confidentiality Agreement referred to therein, will survive the termination of this Agreement for a period of three (3) years following the date of such termination (and, notwithstanding anything contained in this Agreement or the Confidentiality Agreement to the contrary, the Confidentiality Agreement term will be automatically amended to be extended for such additional three (3) year period)), and there will be no liability on the part of any of Buyer, the Company or the Seller to one another, except for knowing and willful breaches of the covenants contained in this Agreement prior to the time of such termination (as such breaches are determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.36pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ADDITIONAL COVENANTS AND AGREEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Survival</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Articles 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will survive the Closing and will terminate on the date that is eighteen (18) months after the Closing Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the representations and warranties set forth in (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Corporate Power), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Authorization&#59; Execution and Delivery), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Ownership), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Brokerage), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Organization and Corporate Power), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Capital Stock), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Tax Matters), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Brokerage) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fundamental Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Corporate Power), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Authorization&#59; Execution and Delivery&#59; Valid and Binding Agreement) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Brokerage), and (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Affiliated Transactions), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Employment and Labor Matters), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Healthcare Matters) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Home Health Services) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Special Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), shall in each case survive until 11&#58;59 PM on the date that is three (3) years after the Closing Date.  The covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall terminate on the date that is sixty (60) days after the Closing Date.  The covenants and agreements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Articles 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will survive the Closing in accordance with the terms thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the covenants and agreements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive until 11&#58;59 PM on the date that is three (3) years after the Closing Date and the covenants and agreements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive until the date that is ninety (90) days after the final resolution of all matters listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 9.02(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Indemnification of Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">From and after the Closing (but subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Seller and Seller Parent, jointly and severally, will indemnify Buyer and its Affiliates (which, following the Closing, shall include the Company), and their respective officers, directors, employees and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">agents (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), against and hold them harmless from any actual losses, obligations, assessments, fines, penalties, Taxes, costs, expenses, liabilities and damages, including interest, penalties, reasonable attorneys&#8217;, consultant, expert and other professional fees, court costs, investigation and remediation costs, compliance costs, and amounts paid in settlements (hereinafter individually a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) suffered or incurred by any Buyer Indemnitee to the extent such Loss results or arises from&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">any breach or inaccuracy of any representation or warranty of Seller contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the Company contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">any breach of any covenant of Seller contained in this Agreement or any breach of any covenant by the Company requiring performance prior to the Closing&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">any Indemnified Taxes&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">the failure of any portion of the Seller Transaction Expenses or the Indebtedness of the Company outstanding as of the Closing to be paid at Closing other than as a result of Buyer&#8217;s breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any of the matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 9.02(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, including any litigation against, or investigations of, the Company by any Person or Governmental Authority that is pending or outstanding as of the Closing as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 9.02(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Specifically Indemnified Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">any Fraud committed by the Company or Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Limitations on Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary set forth in this Agreement, but subject to the other provisions of this ARTICLE 9, even if a Buyer Indemnitee would otherwise be entitled to recover a Loss pursuant to this Agreement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">no Buyer Indemnitee will be entitled to any indemnification for a Loss under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> if, with respect to any such individual item of Loss, such item is less than Ten Thousand Dollars ($10,000)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Minor Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that in the event that the aggregate amount of such Minor Claims equals or exceeds Fifty Thousand Dollars ($50,000), the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall no longer be applicable and any and all such Losses incurred by the Buyer Indemnitees shall be recoverable from the first dollar subject to the other provisions of this ARTICLE 9&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the limitation in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not be applicable to any breach or breaches of any Fundamental Representations or any claims with respect to Fraud&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">no Buyer Indemnitee will be entitled to any indemnification for a Loss under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> unless the aggregate amount of all such Losses (excluding Minor Claims to the extent the aggregate amount of Minor Claims is less than $50,000) arising therefrom exceeds on a cumulative basis Three Hundred Seventy-Five Thousand Dollars ($375,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deductible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and then only to the extent such Losses exceed the Deductible&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Deductible shall not be applicable to any breach or breaches of any Fundamental Representations or any claims with respect to Fraud&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">other than Losses arising from Fraud or any breach or breaches of any Fundamental Representations or Special Representations, the aggregate liability of the Seller and Seller Parent for all Losses claimed under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed the Indemnity Escrow Amount&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">other than Losses arising from Fraud, the aggregate liability of the Seller and Seller Parent for Losses arising from any breach or breaches of any Fundamental Representations shall not exceed the Purchase Price&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">other than Losses arising from Fraud, the aggregate liability of the Seller and Seller Parent for Losses arising from any breach or breaches of any Special Representations shall not exceed twenty percent (20%) of the Purchase Price&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">in no event whatsoever shall the aggregate liability of the Seller and Seller Parent for Losses under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> exceed the Purchase Price except in the case of a claim for Fraud.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Manner of Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Notwithstanding anything to the contrary in this Agreement, but subject to the other provisions of this ARTICLE 9, the Buyer Indemnitees shall recover any and all indemnifiable Losses first from the Indemnity Escrow Fund until the earlier of (A) such time as the Indemnity Escrow Fund has been fully depleted and (B) the date that is twelve (12) months after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Escrow Release Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), following which the Buyer Indemnitees shall have the right to recover, in their sole discretion, any remaining indemnifiable Losses directly from the Seller and Seller Parent in accordance with this ARTICLE 9. Within five (5) Business Days following the Escrow Release Date, Buyer and the Seller shall execute and deliver joint instructions to the Escrow Agent instructing the Escrow Agent to release the balance of the then remaining funds in the Indemnity Escrow Fund (subject to any offsets as contemplated herein), if any, less any amounts then subject to a pending claim for indemnification hereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Any indemnification obligations of the Seller and Seller Parent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be paid to Buyer within thirty (30) days after the final determination thereof or agreement of the parties with respect thereto.  Payment of any such amounts shall be effected by wire transfer of immediately available funds from the Seller to an account designated in writing by Buyer (on behalf of such Buyer Indemnitee).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">All payments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be treated by the parties as an adjustment to the proceeds received by the Seller pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">For purposes of determining both (i) whether Seller or the Company has breached any of their respective representations and warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Articles 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (ii) the amount of Losses suffered or incurred by any Buyer Indemnitee by reason of any such breach, qualifications therein referring to &#8220;material&#8221;, &#8220;Material Adverse Effect&#8221; and other qualifications of similar import or effect shall be disregarded (but, for the avoidance of doubt, qualifications referring to &#8220;Knowledge&#8221; or specified dollar amounts or dates or periods shall not be disregarded)&#59; provided, however, that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(c)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not modify the definitions of &#8220;Material Contracts&#8221; or &#8220;Material Adverse Effect.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Indemnification of Seller</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  From and after the Closing (but subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article&#160;9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), Buyer shall indemnify the Seller and its Affiliates, and their respective officers, directors, employees and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Seller Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), against and hold them harmless from any Losses suffered or incurred by any such indemnified party to the extent arising from or related to (a) any breach of any representation or warranty of Buyer contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or (b) any breach of any covenant of Buyer contained in this Agreement or any breach of any covenant of the Company contained in this Agreement requiring performance by the Company after the Closing.  All payments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be treated by the parties as an adjustment to the proceeds received by the Seller pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any indemnification obligations of Buyer pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be paid to the Seller within thirty (30) days after the final determination thereof or agreement of the parties with respect thereto.  Payment of any such amounts shall be effected by wire transfer of immediately available funds from Buyer to an account designated in writing by the Seller (on behalf of such Seller Indemnitee).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Expiration of Claims</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ability of any Person to receive indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will terminate on the applicable survival termination date (as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), unless such Person will have incurred a Loss prior to the termination date and made a proper claim for indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to such termination date, as applicable.  If an indemnified party has made a proper claim for indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to such termination date, then such claim for such Loss incurred (and only such claim for such Loss incurred), if then unresolved, will not be extinguished by the passage of the deadlines set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  It is the express intent of the parties that, if the applicable survival period of an item as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is shorter than the statute of limitations that would otherwise have been applicable to such item, then, by contract, the applicable statute of limitations with respect to such item shall be reduced to the shortened survival period contemplated hereby.  The parties further acknowledge that the time periods set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for the assertion of claims under this Agreement are the result of arms&#8217;-length negotiation between the parties and that they intend for the time periods to be enforced as agreed by the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Inter-Party Claims</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In order for a party to be entitled to seek any indemnification provided for under this Agreement (such party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claiming Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Claiming Party must notify the other party or parties from whom such indemnification is sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Defending Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in writing promptly after the occurrence of the event giving rise to such Claiming Party&#8217;s claim for indemnification, specifying in reasonable detail the basis of such claim, provided that, failure to give such notification will not affect the indemnification provided hereunder except to the extent the Defending Party will have been actually materially prejudiced as a result of such failure.  The Claiming Party will thereupon give the Defending Party reasonable access during normal business hours to the books, records and assets of the Claiming Party which evidence or support such claim or the act, omission or occurrence giving rise to such claim.  If the Defending Party disputes its liability with respect to any such claim, the Defending Party and the Claiming Party will proceed to negotiate a resolution of such dispute and, if not resolved through negotiations, such dispute will, subject to the terms of this Agreement, be resolved by litigation in an appropriate court of competent jurisdiction.  The Claiming Party will have the burden of proof in establishing the amount of Losses suffered by it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Third Party Claims</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In order for a Claiming Party to seek any indemnification provided for under this Agreement in respect of a claim or demand made by any Person against the Claiming Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Claiming Party must notify the Defending Party in writing, and in reasonable detail, of the Third Party Claim as promptly as reasonably possible after receipt by such Claiming Party of notice of the Third Party Claim, provided that, failure to give such notification on a timely basis will not affect the indemnification provided hereunder except to the extent the Defending Party will have been materially prejudiced as a result of such failure.  Thereafter, the Claiming Party will deliver to the Defending Party, within five (5) Business Days after the Claiming Party&#8217;s receipt thereof, copies of all notices and documents (including court papers) received by the Claiming Party relating to the Third Party Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If a Third Party Claim is made against a Claiming Party, the Defending Party will be entitled to participate in the defense thereof and, if it so chooses, to assume the defense thereof with counsel selected by the Defending Party and reasonably satisfactory to the Claiming Party, provided the Defending Party (i) timely notifies the Claiming Party in writing that it has assumed such defense and that it will indemnify the Claiming Party against all Losses arising out of such Third Party Claim (subject to any applicable limitations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), (ii)&#160;provides evidence of its financial wherewithal to do so, and (iii) diligently uses its commercially reasonable efforts to defend and protect the interests of the Claiming Party with respect to such Third Party Claim.  Should a Defending Party so elect to assume the defense of a Third Party Claim, the Defending Party will not be liable to the Claiming Party for legal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">expenses subsequently incurred by the Claiming Party in connection with the defense thereof.  If the Defending Party assumes such defense, the Claiming Party will have the right to participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the Defending Party, it being understood, however, that the Defending Party will control such defense.  In any event, all the parties will use commercially reasonable efforts to cooperate in the defense or prosecution of any Third Party Claim, including by retaining and providing all records and information which are reasonably relevant to such Third Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.  In the event that either (X) the Defending Party has agreed to indemnify the Claiming Party with respect to any Third Party Claim (subject to any applicable limitations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) or (Y) the Defending Party is not entitled to assume or maintain control of the defense of a Third Party Claim under the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> but the Defending Party has agreed in writing that it will indemnify the Claiming Party against all Losses arising out of such Third Party Claim (subject to any applicable limitations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), then the Claiming Party shall not consent to the entry of any judgment or enter into any settlement with respect to any Third Party Claim without the prior written consent of the Defending Party (which consent shall not be unreasonably withheld, conditioned or delayed) if such settlement would result in indemnifiable Losses payable by the Defending Party or any other relief against the Defending Party.  If the Defending Party has assumed the defense of a Third Party Claim, then the Defending Party shall not consent to the entry of any judgment or enter into any settlement with respect to any Third Party Claim without the prior written consent of the Claiming Party (which consent shall not be unreasonably withheld, conditioned or delayed), unless such settlement (x) requires only the payment of money that the Defending Party is obligated to pay, (y) provides for a full and unconditional release of the Claiming Party without any admission of wrongdoing or liability, and (z) will not materially adversely affect the continued operations of the Claiming Party and its Affiliates.  Notwithstanding the foregoing, the Defending Party shall not be entitled to assume or maintain control of the defense of any Third Party Claim if (I) the Third Party Claim is a criminal proceeding, action, indictment, allegation or investigation, (II) the Defending Party has failed to defend or is failing to defend in good faith the Third Party Claim that is not cured within a reasonable time after receiving written notice from the Claiming Party specifying in reasonable detail the manner in which the Defending Party has so failed or is failing, (III) the primary relief sought in respect of the Third Party Claim is non-monetary relief (other than a general boilerplate request for such other and further relief as the court deems just and proper), (IV) it is reasonably apparent from the face of such Third Party Claim (as of the date the Claiming Party notifies the Defending Party in writing of such Third Party Claim pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) that the Defending Party would be required to indemnify the Claiming Party for less than half of the of Losses that would be reasonably expected to result from any such Third Party Claim, or (V) such Third Party Claim is covered by insurance and the applicable insurance carrier has assumed the defense of such Third Party Claim.  In the case of clause (IV) above, in the event the Defending Party and the Claiming Party, each acting reasonably and in good faith, do not agree it is reasonably apparent from the face of such Third Party Claim that the Defending Party would be required to indemnify the Claiming Party for less than half of the Losses that would be reasonably expected to result from such Third Party Claim, and if such disagreement cannot be resolved within ten (10) days of the Defending Party&#8217;s delivery of written notice to the Claiming Party of such disagreement, then the Defending Party shall be entitled to assume and maintain control of the defense of such Third Party subject to any applicable limitations on liability and satisfaction of the other terms and conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable.  For the avoidance of doubt, the procedures for any Third Party Claims that relate to Taxes shall be governed by the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and not this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">  Notwithstanding anything herein to the contrary, the Parties hereby agree that defense of the Specifically Indemnified Matters shall be deemed to have been assumed by the Seller in accordance with and subject to the terms, conditions and limitations of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> without the need for any further action by any Party.  The Parties further agree that (i) the applicable law firm(s) that is presently representing the Company in each Specifically Indemnified Matter shall continue to act as legal counsel with respect to such matters unless the Parties mutually agree to replace such legal counsel (in which case the Parties shall cooperate in good faith to find a mutually acceptable replacement counsel, each Party agreeing that consent to replacement legal counsel shall not be unreasonably withheld, conditioned or delayed), (ii) any and all fees and costs arising from or related to the defense of the Specifically Indemnified Matters</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(excluding, for the avoidance of doubt, any settlement or judgment costs against the Company, which shall be subject to indemnification pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) shall be paid by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Seller or its Affiliates (excluding the Company), (iii) the Parties shall direct the applicable legal counsel representing the Company in each Specifically Indemnified Matter to direct any invoices for such representation to the Seller to be paid by the Seller or its Affiliates (excluding the Company), (iv) until the settlement or final resolution of the Specifically Indemnified Matters, the Seller shall provide Buyer with reasonable periodic updates (no less frequently than once per month) regarding the status of such Specifically Indemnified Matters, and (v) any Losses suffered by any Buyer Indemnitee arising from or related to any of the Specifically Indemnified Matters shall be subject to the Buyer Indemnitees&#8217; right to obtain indemnification in accordance with the terms, conditions and limitations of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, including, without limitation, the limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.02(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Determination of Loss Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The amount of any and all Losses under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be determined net of&#160;any amounts actually recovered by any Claiming Party or any of such Claiming Party&#8217;s Affiliates under or pursuant to any insurance policy, title insurance policy, indemnity, reimbursement arrangement or contract pursuant to which or under which such Claiming Party or such Claiming Party&#8217;s Affiliates is a party or has rights (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alternative Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), after giving effect to any applicable deductible or retention, premium increases, and any out of pocket costs (including costs of collection) incurred by the Claiming Party in connection therewith.  In the event any recovery from an Alternative Arrangement is received after the Defending Party has paid in full any indemnification obligation under this Agreement that did not take into account such recovery, then such Claiming Party shall pay to such Defending Party, as promptly as reasonably practicable after receipt, a sum equal to the amount of such insurance proceeds or other amounts received (net of deductibles, premium increases, costs of collection or similar costs in respect of such claim), up to the aggregate amount of any indemnification payments received from such Defending Party pursuant to this Agreement in respect of such Losses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;Intentionally Omitted&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding anything to the contrary contained herein, no party shall be liable or otherwise responsible to any other party hereto or any Affiliate of any other party hereto for exemplary or punitive damages, other than exemplary or punitive damages payable to a third party pursuant to a Third Party Claim.  No information obtained by Buyer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof or otherwise shall be deemed to amend or supplement the Disclosure Schedule, to prevent or cure any breach of any representation nor warranty, or breach of covenant, or to otherwise limit or affect any rights of the Buyer Indemnitees under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No Buyer Indemnitee will be entitled to any indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for any Losses to the extent such Losses were fully taken into account in determining the Final Aggregate Closing Consideration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each Party shall take all commercially reasonable steps to mitigate any of its Losses upon becoming aware of any event which would reasonably be expected to, or does, give rise thereto.  Each of the Parties hereto shall cooperate with the others with respect to resolving any claim or liability with respect to which one Party is obligated to indemnify another Party hereunder, including by using commercially reasonable efforts to mitigate or resolve any such claim or liability.  Except pursuant to a settlement agreement permitted in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Claiming Party will not waive or release any contractual right to recover from a third party any Loss subject to indemnification hereunder without the prior written consent of the Defending Party (such consent not to be unreasonably withheld).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Acknowledgments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each party understands, acknowledges and agrees that except for (i) instances of Fraud, (ii) the parties&#8217; right to seek specific performance or injunctive relief pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and (iii) the parties&#8217; rights and obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, from and after the Closing, the indemnification provided to the parties pursuant to, and subject to the terms and conditions of, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will be the sole and exclusive remedy of the parties with respect to the subject matter of this Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or the transactions contemplated hereby.  Buyer acknowledges and agrees that the Buyer Indemnitees may not avoid such limitation on liability by (x) seeking damages for breach of contract, tort or pursuant to any other theory of liability, all of which are hereby waived or (y) asserting or threatening any claim against any Person that is not a party (or a successor to a party) for breaches of the representations, warranties and covenants contained in this Agreement. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall limit or restrain (whether a temporal limitation, a dollar limitation or otherwise) the ability of any Person to seek remedies against any other Person for Fraud.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">THE REPRESENTATIONS AND WARRANTIES BY THE COMPANY AND SELLER IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLES 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> HEREOF AND IN THE TRANSACTION DOCUMENTS CONSTITUTE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND SELLER TO BUYER IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY, AND BUYER UNDERSTANDS, ACKNOWLEDGES AND AGREES THAT ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE EXPRESS OR IMPLIED (INCLUDING ANY RELATING TO THE FUTURE OR HISTORICAL FINANCIAL CONDITION, RESULTS OF OPERATIONS, ASSETS OR LIABILITIES OR AS TO THE ACCURACY OR COMPLETENESS OF ANY INFORMATION PROMOTED TO BUYER OF THE COMPANY OR TO ANY ENVIRONMENTAL, HEALTH OR SAFETY MATTERS) ARE SPECIFICALLY DISCLAIMED BY THE COMPANY AND SELLER AND ARE NOT BEING RELIED UPON BY BUYER OR ANY OF ITS REPRESENTATIVES OR AFFILIATES.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer hereby acknowledges and agrees that it has not relied upon any statements, information, material, representations, warranties or financial projections delivered or made available to Buyer or its representatives (including representations as to the accuracy or completeness of any such information) other than the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Agreement and in the Transaction Documents.  Buyer acknowledges and agrees that, except as expressly provided in this Agreement or any Transaction Document, neither the Seller nor any of their direct or indirect Affiliates, directors, officers, members, employees or representatives will have or be subject to any liability to Buyer or any of its Affiliates resulting from the distribution to Buyer, or Buyer&#8217;s use of, or reliance on (including with respect to accuracy or completeness), any information, statements, material or financial projections prepared by the Company, the Seller or their respective Affiliates delivered or made available to Buyer or its representatives or any information, document or material made available to Buyer or its Affiliates or representatives in certain &#8220;data rooms&#8221; and online &#8220;data sites,&#8221; management presentations or any other form in expectation of the transactions contemplated by this Agreement.  In connection with Buyer&#8217;s investigation of the Company, Buyer has received from or on behalf of the Company certain projections, including projected statements of operating revenues and income from operations of the Company and certain business plan information of the Company.  Buyer acknowledges that there are uncertainties inherent in attempting to make such estimates, projections and other forecasts and plans, that Buyer is familiar with such uncertainties, that Buyer is taking full responsibility for making its own evaluation of the adequacy and accuracy of all estimates, projections and other forecasts and plans so furnished to it (including the reasonableness of the assumptions underlying such estimates, projections and forecasts), and that Buyer will have no claim against Seller or any other Person with respect thereto.  Accordingly, the Seller and the Company make no representations or warranties whatsoever with respect to such estimates, projections and other forecasts and plans (including the reasonableness of the assumptions underlying such estimates, projections and forecasts), and Buyer agrees that it has not relied thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Responsibility for Filing Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Seller (which for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall include any representative of the Seller) shall prepare or cause to be prepared and file or cause to be filed all Tax Returns of the Company for all Taxable periods ending on or before the Closing Date.  Buyer shall be responsible for the due preparation and timely filing of all Tax Returns of the Company for all Taxable periods beginning after the Closing Date, and (without limiting Buyer&#8217;s right to be indemnified for any such Taxes under this Agreement or any other agreement) Buyer shall be responsible for the timely and complete payment of any related Taxes due with respect to such Tax Returns. With respect to any Tax Returns of the Company that are due for any Straddle Periods (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Straddle Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Buyer shall be responsible for the due preparation and timely filing of all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such Straddle Tax Returns on a basis consistent with the past practices of the Company (to the extent permitted by applicable Law), and shall provide a draft of any such Straddle Tax Return to Seller for review and comment reasonably in advance of the due date for such Straddle Tax Return (together with schedules, statements and, to the extent required by Seller, supporting documentation).  Buyer shall consider in good faith all comments provided by Seller with respect to such Straddle Tax Returns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Amended Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as required by applicable Law, without the prior written consent of the Seller, which consent shall not be unreasonably conditioned, withheld or delayed, Buyer shall not amend any Tax Returns of the Company for a Pre-Closing Tax Period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties will reasonably cooperate with each other to provide each other with such assistance as may be reasonably requested by them in connection with the preparation and filing of any Tax Returns, making of any election related to Taxes, and any Tax audit or other examination in connection with an administrative or judicial proceeding involving a taxing authority relating to Taxes.  Without limiting the foregoing, Buyer shall cooperate reasonably with the Seller, to the extent reasonably necessary, in the preparation and filing of all Tax Returns of the Company for all Taxable periods ending on or before the Closing Date, including by making the Company&#8217;s book and records available for inspection by the Seller, the Seller&#8217;s accountants, auditors and attorneys upon reasonable advance notice and including, if required by applicable Law, causing such Tax Returns to be signed by appropriate pre-Closing officers of the Company, as the case may be.  Buyer shall cause the Company to retain all books and records with respect to Tax matters pertinent to the Company relating to any Pre-Closing Tax Period until the expiration of the applicable statute of limitations (and, to the extent notified by the Seller, any extensions thereof) of the respective taxable periods, and to abide by all record retention agreements entered into with any taxing authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Tax Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any written notice of any pending or threatened audit or assessment, suit, proposed adjustment, deficiency, dispute, administrative or judicial proceeding or other similar claim is made by any taxing authority, which, if successful, might result in an indemnity payment to an indemnified party pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then such indemnified party shall give notice to the indemnifying party in writing of such claim and of any counterclaim the indemnified party proposes to assert (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, however, the failure to give such notice shall not affect the indemnification provided hereunder except to the extent the indemnifying party has been materially prejudiced as a result of such failure. With respect to any Tax Claim relating solely to a Pre-Closing Tax Period (other than a portion of any Straddle Period), Seller shall, solely at its own cost and expense, control all proceedings and may make all decisions in connection with such Tax Claim (including selection of counsel).  Notwithstanding the foregoing, Seller shall not settle or otherwise resolve such Tax Claim without the prior written consent of Buyer, which consent shall not be unreasonably conditioned, withheld, or delayed. Buyer shall control all proceedings taken in connection with any Tax Claim relating to Taxes of the Company for a Straddle Period and Seller may participate in such proceedings at its own expense. Buyer shall not settle any such Tax Claim without the prior written consent of the Seller, which consent shall not be unreasonably conditioned, withheld, or delayed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer shall pay any real property transfer Tax, stamp duty, stock transfer Tax, sales Tax, use Tax, value added Tax, or other similar Tax imposed on Buyer, the Company or Seller as a result of the transactions contemplated by this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and any penalties or interest with respect to the Transfer Taxes.  Buyer shall file all necessary Tax Returns and other documentation with respect to Transfer Taxes (except to the extent such Tax Returns are required by Law to be filed by the Seller), and the Seller agrees to reasonably cooperate with Buyer in the filing of any such Tax Returns, including promptly supplying any information in its possession that is reasonably necessary to complete such Tax Returns or secure exemptions from such Transfer Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Straddle Period Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, in the case of any Straddle Period, the amount of Taxes allocable to the Pre-Closing Tax Period portion of such Straddle Period shall be deemed to be&#58; (i) in the case of Taxes that are imposed on a periodic basis (such as real or personal property Taxes), the amount of such Tax for the entire Straddle Period (or, in the case of such Taxes determined on an arrears basis, the amount of such Taxes for the immediately preceding period), multiplied by a fraction, the numerator of which is the number of days in the Straddle Period ending on and including the Closing Date and the denominator of which is the number of days in the entire Straddle </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Period, and (ii) in the case of any Tax not described in clause (i) (such as franchise Taxes, Taxes that are based upon or related to income or receipts or imposed in connection with any sale or transfer or assignment of property) the amount of any such Taxes shall be determined as if the Straddle Period ended on and included the Closing Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that exemptions, allowances or deductions that are calculated on an annual basis (including depreciation and amortization deductions) shall be allocated between the period ending on the Closing Date and the period after the Closing Date in proportion to the number of days in each period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Allocation of Aggregate Closing Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Purchase Price (and any other consideration paid hereunder for the Interests) and the liabilities (to the extent included in amount realized for federal income Tax purposes) of the Company, plus other relevant items, shall be allocated among the assets of the Company in accordance with Code Section 1060 and the Treasury Regulations promulgated thereunder and the methodology set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 9.09(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within sixty (60) days after the determination of the adjustments, if any, to the Purchase Price hereunder, or, if sooner, ninety (90) days before IRS Form 8594 must be filed, Buyer will provide to the Seller copies of IRS Form 8594 and any required exhibits thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with Buyer&#8217;s proposed allocation of the Purchase Price consistent with Code Section 1060 and the Treasury Regulations promulgated thereunder and the methodology set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 9.09(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within thirty (30) days after the receipt of such Allocation, the Seller will submit to Buyer in writing any proposed changes to such Allocation or shall indicate its concurrence therewith, which concurrence shall not be unreasonably withheld, conditioned or delayed (and in the event no such changes are proposed in writing to Buyer within such period of time, the Seller will be deemed to have agreed to, and accepted, the Allocation).  Buyer and the Seller will endeavor in good faith to resolve any differences with respect to the Allocation within fifteen (15) days after Buyer&#8217;s receipt of written notice of objection from Seller. Any unresolved disputes will be resolved by the Accounting Firm, the costs of which shall be borne by each party in the percentage inversely proportionate to the percentage of the total dollar amount of the total items submitted for dispute that are resolved in such party&#8217;s favor.  The determination of the Accounting Firm shall be binding on the parties.  The Seller and Buyer shall each timely file IRS Form 8594 by attaching such form to their respective timely filed U.S. federal income Tax Returns in a manner reflecting the Allocation, and the Seller and Buyer shall reasonably cooperate with each other in connection with such preparation and filing.  The Allocation, as determined in the manner described above, shall be binding upon the parties, and all Tax Returns and reports filed by Buyer, the Company and the Seller will be prepared consistently with the Allocation.  None of Buyer, the Company or the Seller shall take any position (whether in audits, Tax Returns or otherwise) that is inconsistent with the Allocation unless required to do so by Law.  The parties shall cooperate in updating the Allocation and any IRS Form 8594 with respect to any post-Closing adjustments to the purchase price hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The amount or economic benefit of any refunds, credits or offsets of Taxes of the Company, for any Pre-Closing Tax Period shall be for the account of Seller.  Such amounts shall not include any Taxes already taken into account as part of Net Working Capital or Indebtedness or that otherwise resulted in an adjustment to purchase price hereunder.&#160; Notwithstanding the foregoing, any such refunds, credits or offsets of Taxes shall be for the account of Buyer to the extent such refunds, credits or offsets of Taxes (i) are attributable (determined on a marginal basis) to the carryback from a Post-Closing Tax Period of items of loss, deduction or credit, or other Tax items, of the Company (or any of its Affiliates, including Buyer), or (ii) results from the payment of Taxes by Buyer, the Company, or their Affiliates with respect to a Pre-Closing Tax Period made on or after the Closing Date to the extent (X) the Buyer Indemnitees were not indemnified or otherwise reimbursed for such Taxes or (Y) such Taxes were not taken into account in the calculation of Indebtedness or Net Working Capital.  The amount or economic benefit of any refunds, credits or offsets of Taxes of the Company for any Post-Closing Tax Period shall be for the account of Buyer.  The amount or economic benefit of any refunds, credits or offsets of Taxes of the Company for any Straddle Period shall be equitably apportioned between the Seller and Buyer in accordance with the principles of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party shall forward, and shall cause its Affiliates to forward, to the party entitled to receive the amount or economic benefit of a refund, credit or offset to Tax the amount of such refund, or the economic benefit of such credit or offset to Tax, within ten (10) days after such refund is received or after such credit or offset is allowed or applied against another Tax liability, as the case may be. The Seller shall reimburse Buyer, the Company, and their Affiliates for any third-party expenses incurred in obtaining, attempting to obtain, retaining or attempting to retain, any Pre-Closing Tax Refunds for the benefit of the Seller. To the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">extent any Tax refund is subsequently determined by any Governmental Authority to be less than the amount paid to the Seller pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Seller shall promptly repay such amount to Buyer. Notwithstanding the foregoing, Buyer shall not be required to file, or cause to be filed, an amended return or otherwise seek a Tax refund for a Pre-Closing Tax Period of the Company if Buyer reasonably determines that any such action could give rise to a material adverse tax effect to Buyer, the Company, or their Affiliates in a Post-Closing Tax Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Transaction Tax Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent permitted by Law, any and all deductions related to all Seller Transaction Expenses and payments that are paid by or on behalf of the Company prior to or in connection with the Closing and deductible by the Company for Tax purposes at a &#8220;more likely than not&#8221; or higher level of comfort, including other fees and expenses of legal counsel, accountants, and investment bankers and any Change of Control Payments (such deductions, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction Tax Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be treated for income Tax purposes as having been incurred by the Company in, and reflected as a deduction on the income Tax Returns of the Company (or the Seller, as applicable) for, the taxable period or portion thereof ending on the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Director and Officer Liability and Indemnification</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">For a period of six (6) years after the Closing, Buyer will not, and will not permit the Company to amend, repeal or modify any provision in the Company&#8217;s organizational documents relating to the exculpation, indemnification or advancement of expenses of any officers, managers and directors of the Company (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (unless required by Law), it being the intent of the parties that the officers and directors of the Company will continue to be entitled to such exculpation, indemnification and advancement of expenses to the full extent of the Law.  Further, from and after the Closing, Buyer agrees to cause the Company to comply with and honor any such rights to exculpation, indemnification, and advancement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if any claims are asserted or made within such period, all rights to indemnification and exculpation (and to advancement of expenses) in respect of any such claims shall continue, without diminution, until disposition of any and all such claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">An Indemnified Person shall notify the Company of the existence of any threatened or actual claim, action, suit, proceeding or investigation, whether civil, criminal or administrative (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for which such Indemnified Person is entitled to indemnification under the Company&#8217;s organizational documents as promptly as reasonably practicable after such Indemnified Person learns of such Proceeding&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the failure to so notify shall not affect the obligations of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> except to the extent such failure to notify actually and materially prejudices the Company.  The Company, at its expense, shall have the right to control the defense of the Proceeding with counsel selected by the Company and reasonably acceptable to the Indemnified Person.  The Company shall cooperate with all reasonable requests made by the Indemnified Person, and the Indemnified Person shall cooperate with all reasonable requests made by the Company, in connection with the defense of any Proceeding.  No settlement of a Proceeding may be made by the Company without the Indemnified Person&#8217;s consent, except for a settlement which (i) requires no more than a monetary payment by the Company for which the Indemnified Person is fully indemnified, (ii) provides for a full and unconditional release of the Indemnified Person and (iii) which does not require the admission of liability or wrongdoing.  No settlement of a Proceeding may be made by an Indemnified Person without the consent of the Company (such consent not to be unreasonably withheld, delayed or conditioned).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">At or prior to the Closing, Buyer shall, on behalf of the Company, obtain an extended reporting period endorsement for the directors&#8217; and officers&#8217; liability and employment practices liability insurance policies of the Company in the form and on terms reasonably acceptable to the Seller so that the Indemnified Persons shall be covered for a period of six (6) years after the Closing under the terms of such policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance Tail Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; the cost of such Insurance Tail Policy shall be borne by Buyer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Buyer shall not, and shall not permit Buyer Parent to, cancel such policy within six (6) years after the Closing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event that all or substantially all of the assets of the Company are sold, whether in one transaction or a series of transactions, then the Company will, in each such case, make proper provisions so that the successors and assigns of the Company assume the obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Release</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Effective upon the Closing, the Seller hereby releases the Company, its successors and assigns (excluding Buyer and its Affiliates), and their respective members, managers, directors, and officers, from any and all claims, liabilities, obligations, causes of action, known or unknown, which such Seller (i) now has, or claims to have, (ii) at any time previously had, or claimed to have had, or (iii) at any time hereafter may have, or claim to have, against any of such Persons and that, in each case, accrued or otherwise arose prior to the Closing, provided that, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will release or be deemed to constitute a release by Seller of any of its rights to enforce its rights under this Agreement, or any other agreement, document or instrument contemplated by this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), any claim arising from or relating to this Agreement or the Transaction Documents, arising from the transactions contemplated by this Agreement or Transaction Documents, or any other right or claim that may arise from Fraud.  SELLER EXPRESSLY WAIVES ALL RIGHTS AFFORDED BY ANY STATUTE WHICH LIMITS THE EFFECT OF A RELEASE WITH RESPECT TO UNKNOWN CLAIMS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Effective upon the Closing, the Company hereby releases Seller from any and all claims, liabilities, obligations, causes of action, known or unknown, which the Company (i) now has, or claims to have, (ii) at any time previously had, or claimed to have had, or (iii) at any time hereafter may have, or claim to have, against Seller and that, in each case, accrued or otherwise arose prior to the Closing, provided that, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will release or be deemed to constitute a release by the Company of any of its rights to enforce its rights under this Agreement or any other Transaction Document, any claim arising from or relating to this Agreement or the Transaction Documents, or any other right or claim that may arise from Fraud.&#160; THE COMPANY EXPRESSLY WAIVES ALL RIGHTS AFFORDED BY ANY STATUTE WHICH LIMITS THE EFFECT OF A RELEASE WITH RESPECT TO UNKNOWN CLAIMS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The release provided by the Seller pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are expressly made subject to a reservation of any rights in favor of such parties pursuant to any insurance policies held by or for the benefit of them&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for the avoidance of doubt, none of the related insurers shall have any right of subrogation against Seller with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Non-Competition and Non-Solicitation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9.13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> below, Seller and Seller Parent each covenants and agrees that, commencing on the Closing Date and ending on the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) anniversary thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Seller and Seller Parent shall not, and shall not permit any of their respective Affiliates to, directly or indirectly&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">engage or participate in, own, acquire, operate, be employed by, consult for, lend money to, invest in or otherwise have a financial interest in any Competitive Business within the Commonwealth of Massachusetts or (y) the geographic territory included within a twenty-five mile radius of the Company&#8217;s present office location in Knoxville, Tennessee (such activities within the specified territory, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the foregoing shall not preclude the Seller or any of its Affiliates from owning less than one percent (1%) of the issued and outstanding equity securities of any company engaged in Prohibited Activities&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">solicit, entice, encourage, intentionally influence, hire, employ, or attempt to solicit, entice, encourage, intentionally influence, hire or employ any natural person who is at that time employed by Buyer, the Company or any of their respective Affiliates to leave Buyer&#8217;s, the Company&#8217;s or any of their respective Affiliates&#8217; employment or to otherwise reduce, disrupt or alter their employment relationship with Buyer, the Company or any of their respective Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the foregoing shall not prohibit Seller, Seller Parent or any of their respective Affiliates from (x) conducting general solicitations of employment not targeted at the employees of Buyer, the Company or any of their respective Affiliates, or (y) hiring or offering to hire any such person (a) who has been involuntarily terminated by Buyer, the Company or any of their respective Affiliates, or (b) whose employment with Buyer, the Company or any of their respective Affiliates ceased at least six (6) months prior to such solicitation or hiring&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">(A) solicit, entice, encourage or influence, or attempt to solicit, entice, encourage or influence, any current or prospective patient, referral source, partner, affiliate, governmental health care program, health plan, health insurer, health care provider, payor, service provider, contractor, customer, supplier, vendor, licensee, licensor, or other business relation of Buyer or any of the Company or any of their respective Affiliates (individually a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Relation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Relations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), whether such person is a Business Relation as of the Closing Date or at any other time during the Restricted Period, to conduct or engage in a Prohibited Activity or (B) solicit, entice, encourage or influence, or attempt to solicit, entice, encourage or influence, any Business Relation with the intention of causing such Business Relation to (x) cease or materially reduce doing business with Buyer, the Company or any of their respective Affiliates or (y) materially alter the terms and conditions of their business with Buyer, the Company or any of their respective Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for the avoidance of doubt, the foregoing shall not prohibit or limit the ability of Seller, Seller Parent or any of their respective Affiliates to solicit, entice, encourage or influence, or attempt to solicit, entice, encourage or influence any Business Relation in connection with their respective home health, hospice, and&#47;or palliative care operations, their high acuity programs provided through Amedisys&#8217; Contessa division, their &#8220;Hospital-in-the-home and SNF&#64;Home&#8221; programs, or any other operations that do not constitute Prohibited Activities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding anything herein to the contrary, the Seller and its Affiliates may acquire, merge or consolidate with or into any other Person engaged in Prohibited Activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquired Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) if the Prohibited Activities represent an insubstantial portion of the Acquired Business (any such acquisition, merger or consolidation, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, during the Restricted Period, the Seller shall not permit the expansion of such Prohibited Activities except for organic growth and expansion occurring in the ordinary course of business that does not exceed twenty percent (20%) of the total revenues of such Acquired Business unless otherwise consented to in writing by Buyer.  For purposes of this subsection, the Prohibited Activities shall constitute an &#8220;insubstantial portion&#8221; of the Acquired Business if the revenues of the Acquired Business from the Prohibited Activities in the twelve-month period preceding the Permitted Acquisition constitute less than twenty percent (20%) of the total revenues of the Acquired Business during such period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">For the avoidance of doubt, nothing herein shall prohibit or limit the Seller and its Affiliates from providing health care services rendered by home health aide, certified nursing assistant or other paraprofessional care givers through home health, hospice, skilled nursing facility at home, hospital at home, palliative care or other bundled reimbursement programs (which services are hereby expressly excluded from Prohibited Activities).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each party covenants and agrees that, during the Restricted Period, no party shall make publicly any negative or disparaging statements or communications regarding any other party or any Affiliate of any other party that is intended to adversely affect such other party&#59; provided, however, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is intended to or shall be interpreted to&#58; (x) restrict or otherwise interfere with a party&#8217;s obligation to testify truthfully in any forum&#59; (y) restrict or otherwise interfere with a party&#8217;s obligation to provide information to any Governmental Authority&#59; or (z) restrict or otherwise interfere with a party&#8217;s enforcement of any right or remedy under this Agreement or the Transaction Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each party acknowledges that a breach or threatened breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> may give rise to irreparable harm to the other parties, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by a party of any such obligations, each other party shall, in addition to any and all other rights and remedies that may be available to he or it in respect of such breach, be entitled to seek equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">The time period during which the prohibitions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall apply shall be tolled and suspended for a period equal to the aggregate time during which the related party violates such prohibitions in any respect (not to exceed the number of days between the date of initial violation and the end of the Restricted Period).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The parties agree that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> imposes a reasonable restraint on the parties in light of the activities and business of Seller on the date hereof and the current business plans of Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The covenants in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are severable and separate, and the unenforceability of any specific covenant in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is not intended by any party hereto to, and will not, affect the provisions of any other covenant in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or elsewhere in this Agreement.  If any court of competent jurisdiction determines that the scope, time or territorial restrictions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are unreasonable as applied to any party, the parties hereto, respectively acknowledge their mutual intention and agreement that those restrictions be enforced to the fullest extent the court deems reasonable, and thereby will be reformed to that extent as applied to such party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">All the covenants in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are intended by each party hereto to, and will, be construed as an agreement independent of any other provision in this Agreement, and the existence of any claim or cause of action of a party against another party, whether predicated on this Agreement or otherwise, will not constitute a defense to the enforcement by such other party of any covenant in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The covenants in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will not be affected by any other party&#8217;s breach of any other provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The parties acknowledge that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is a material and substantial part of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For purposes of this Section 9.13, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the business of the Company as currently conducted as of the date hereof, including the business of providing any personal care or private pay services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Further Assurances</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  From time to time, as and when requested by any party and at such requesting party&#8217;s expense, any other party will execute and deliver, or cause to be executed and delivered, all such documents and instruments and will take, or cause to be taken, all such further or other actions as the requesting party may reasonably deem necessary or desirable to evidence and effectuate the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.86pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes hereof, the following terms, when used herein with initial capital letters, will have the respective meanings set forth herein&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any action, claim, complaint, investigation, petition, suit, arbitration or similar proceeding, whether civil or criminal, at law or in equity by or before any Governmental Authority.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of any particular Person means any other Person controlling, controlled by or under common control with such particular Person.  For the purposes of this definition, &#8220;controlling,&#8221; &#8220;controlled&#8221; and &#8220;control&#8221; means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Aggregate Closing Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an aggregate amount equal to (i) the Purchase Price, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (ii) the total amount of Cash on Hand, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (iii) the outstanding amount of Indebtedness as of the Closing Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (iv) the Seller Transaction Expenses, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (v) the Working Capital Adjustment Amount (which may be positive or negative), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (vi) the Working Capital Adjustment Escrow Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (vii) the Indemnity Escrow Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each &#8220;employee benefit plan&#8221; within the meaning of Section 3(3) of ERISA (whether or not subject to ERISA) and each other pension, retirement, savings, disability, medical, dental, health, life, death benefit, group insurance, profit sharing, deferred compensation, stock option, bonus, compensation, incentive, or performance awards, vacation pay, actual or phantom ownership of any equity interest, tuition reimbursement, severance or termination pay, or other employee benefit plan, trust, agreement, contract, arrangement, practice, program, policy or commitment, in each case that is established, maintained, sponsored or contributed to by the Company, or to which the Company has any obligation to contribute to or provide benefits under or through such plan, or if such plan provides benefits to or otherwise currently covers any current or former employees, contractors, directors or officers thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any day except Saturday, Sunday or any other day on which commercial banks located in the Commonwealth of Massachusetts are authorized or required by Law to be closed for business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Coronavirus Aid, Relief, and Economic Security Act, as amended from time to time by any subsequent laws, including the Paycheck Protection Flexibility Act of 2020 (Public Law 116-142), the Consolidated Appropriations Act, 2021, Economic Aid Act (Public Law 116-260), and the American Rescue Plan Act (Public Law 117-2), and all rules, regulations and guidance issued by any governmental entity with respect thereto (including, without limitation, the U.S. Small Business Administration), in each case as in effect from time to time, and further including, without limitation, IRS Notice 2020-65, and the Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing COVID-19 Disaster, dated August 8, 2020).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash on Hand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, as of the opening of business on the Closing Date all cash, cash equivalents, marketable securities and cash deposits held by third parties, in each case determined in accordance with GAAP, excluding the amount of any cash in reserve or escrow accounts (or otherwise subject to escrow or similar holdback arrangements), custodial cash, cash supporting insurance obligations and any other restricted cash.  For the avoidance of doubt, Cash on Hand will be calculated net of issued but uncleared checks and drafts and will include checks, other wire transfers and drafts deposited or available for deposit for the account of the Company, but only to the extent that the amounts payable in respect of such outstanding checks or amounts receivable in respect of such received checks are not included as current liabilities or current assets, respectively, in the calculation of Net Working Capital.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CERCLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any severance, change in control, termination, retention, sale bonuses, incentive or similar amounts or benefits payable by the Company to any current or former employee, independent consultant or any other person as a result of the consummation of the transactions contemplated hereby.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company Knowledge Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Geoffrey Abraskin, Michael Katz, Kristopher Novak, Aimee Nethercutt, Denise Bohnert, and Indy Edwards. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that is an Aging Services Access Point (ASAP) or other non-profit entity providing services of a type ordinarily provided by an ASAP.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the disclosure schedule delivered by the Company concurrently with the execution and delivery of this Agreement and attached hereto as may be amended or supplemented pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those Persons employed by the Company as of any relevant time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Laws that are binding upon the Company concerning pollution or protection of the environment, including all those relating to the generation, handling, transportation, treatment, storage, disposal, distribution, labeling, discharge, release, threatened release, control, remediation or cleanup of any Hazardous Substances, as such of the foregoing are promulgated and in effect on or prior to the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any entity, trade or business that is, or at any applicable time was, a member of a group described in Section 414(b), (c), (m) or (o) of the Code or Section 4001(b)(1) of ERISA that includes the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Regions Bank, N.A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">  </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equity Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, (a)&#160;any capital stock, partnership or membership interest, joint venture interest, unit of participation or other similar interest (however designated) in such Person and (b)&#160;any option, warrant, call, right (including purchase rights, conversion rights, exchange rights, preemptive rights, co-sale rights, rights of first refusal and similar rights) or other contract which would entitle any other Person to acquire any such interest in such Person.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fraud</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, an actual and intentional fraud under Delaware common law with respect to the making of the representations and warranties pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Funds Flow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain funds flow statement, dated as of the Closing Date, by and among Buyer, the Company and the Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means generally accepted accounting principles in the United States, as consistently applied by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Government Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Medicare, Medicaid, CHAMPUS, TRICARE and all other health care reimbursement programs funded and&#47;or regulated by the Federal, state or local government.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any national, federal, state, local or foreign government or political subdivision thereof, or any regulatory authority, agency, bureau, board, commission, department or instrumentality of such government or political subdivision, or any arbitrator, court or tribunal of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hazardous Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means petroleum or any hazardous substance as defined in CERCLA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Law or Legal Requirement relating to the regulation, provision or administration of, or payment for, health care goods and services, including but not limited to&#58; (i) 42 U.S.C. &#167;&#167; 1320a-7 (the Exclusion Statute), 1320a-7a (the Civil Monetary Penalties Law), and 1320a-7b(b) (the Anti-Kickback Statute), and their state law counterparts, including, without limitation, MGL c. 175H, &#167; 3&#59; (ii) 42 U.S.C. &#167; 1395nn, (the Stark Law) and its state law counterparts&#59; (iii) 31 U.S.C. &#167;&#167; 3729-3733(the federal False Claims Act) and its state law counterparts&#59; (iv) the False Statements Act, 18 U.S.C. &#167; 1001&#59; (v) the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812&#59; (vi) the Criminal False Claims Act, 18 U.S.C. &#167; 287&#59; (vii) the Anti-Kickback Act of 1986, 41 U.S.C. &#167;&#167; 51-58&#59; (viii) the federal TRICARE statute, 10 U.S.C. &#167; 1071 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (ix) HIPAA and any other applicable Laws or Legal Requirements concerning the privacy and security of health information&#59; (x) the anti-fraud and related provisions of HIPAA, 18 U.S.C. &#167;&#167; 1035 and 1347&#59; (xi) Laws and Legal Requirements relating to participation in or submission of claims to Government Programs and Private Programs, including, but not limited to, the Medicare and Medicaid programs&#59; (xii) applicable provisions of the Patient Protection and Affordable Care Act, 42 U.S.C. &#167; 18001 et seq., together with its implementing regulations and any other rules or regulations promulgated thereunder&#59; (xiii) any federal, state or local statute or regulation relevant to mail fraud, wire fraud, false statements or claims&#59; (xiv) any other Laws governing arrangements among health care providers, patients, and health care professionals or rules of professional conduct&#59; (xv) Laws relating to the licensure, certification, and registration of health care providers, suppliers, and health care professionals&#59; (xvi) Laws relating to the regulation, provision, administration, prescribing, or dispensing of drug products, including, but not limited to, the federal Food, Drug and Cosmetic Act, the federal Controlled Substances Act (21 U.S.C. &#167; 801 et seq.), and any counterpart state or local Laws&#59; (xvii) the Travel Act (18 U.S.C. &#167; 1952)&#59; and (xviii) the Deficit Reduction Act of 2005.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the following, as the same may be amended, modified or supplemented from time to time, any successor statute thereto, and together with any and all rules or regulations promulgated from time to time thereunder&#58; (a) the Health Insurance Portability and Accountability Act of 1996&#59; and (b) the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all obligations of the Company (including any unpaid principal, accrued and unpaid interest, consent or other fees, premiums or penalties, related expenses, breakage costs, &#8220;make-whole&#8221; amounts, reimbursements, indemnities and all other amounts or similar contractual charges payable in connection therewith, computed as though payment is being made in respect thereof on the Closing Date) with respect to the following&#58; (a) indebtedness for borrowed money, (b) evidenced by any note, bond, debenture or other similar instrument or debt security, (c) upon which interest charges are customarily paid, but not to the extent that such obligations are reflected as accounts payable or other accrued liabilities in the current liabilities of the Company in the Financial Statements, (d) created or arising under any conditional sale or other title retention agreement with respect to property acquired by the Company, (e) secured by a Lien on the equity interests of the Company, (f) due and owing by the Company under any future contracts, swaps, collars, caps, foreign exchange contracts, or other similar hedging obligations or drawn letters of credit as if such arrangements were terminated on the Closing Date, (g) owed by the Company for all or any portion of the deferred purchase price of property or services (x) with respect to which the Company is liable, contingently or otherwise as obligor, including earn-outs, holdbacks, contingency payments, seller notes, installment payments, deferred taxes and similar deferred payment obligations (other than trade payables in the ordinary course of business) or (y) which is otherwise not accounted for in the computation of Net Working Capital, (h) under or in respect of any lease that (x) has been or should be accounted for as a capital lease in accordance with GAAP and (y) under which the Company is liable as a lessee, (i) owed by the Company under any letters of credit, performance bonds, bankers acceptances or similar obligations, contingent or otherwise, (j) of the types described in the foregoing clauses (a) through (i) of another Person the payment of which is guaranteed by the Company or is secured by a Lien on any property or asset of the Company (whether or not such obligations are assumed by the Company), (k) any accrued and unpaid Taxes for Pre-Closing Tax Periods (l) any client deposits, (m) all defined benefit pension, multiemployer pension, post-retirement health and welfare benefit, accrued annual or other bonus obligations, any unpaid severance liabilities currently being paid or payable in respect of employees and service providers of the Company who terminated employment or whose services to the Company have ceased (as applicable) prior to the Closing and deferred compensation liabilities of the Company, together, in each case, with any associated employer payroll taxes (but without duplication of any amounts referenced in clause (g) above), and (n) of the types described in the foregoing clauses (a) through (m) of another Person the payment of which is guaranteed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by the Company or is secured by a Lien on any property or asset of the Company (whether or not such obligations are assumed by the Company).  Notwithstanding the foregoing, Indebtedness does not include any operating lease obligations that should not be accounted for as a capital lease in accordance with GAAP.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, without duplication, (a) Taxes of the Company (including Taxes for which the Company is liable) with respect to any Pre-Closing Tax Period (determined, with respect to any Straddle Period, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#59; (b) Taxes of any member of an affiliated, consolidated, combined or unitary group of which the Company (or any predecessor thereof) is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar state, local or non-U.S. Law&#59; (c) Taxes of any Person (other than the Company) imposed on the Company as a transferee or successor, by contract, pursuant to any Law or otherwise, which Taxes relate to an event or transaction occurring before the Closing&#59; (d) employment Taxes (including withholding Taxes) required to be paid or collected with respect to any payments contemplated by this Agreement or arising in connection with the transactions contemplated by this Agreement&#59; and (e) Taxes that the Company has elected to defer pursuant to Section 2302 of the CARES Act or IRS Notice 2020-65 (or any similar provision of federal, state, local or non-U.S. Law)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Pre-Closing Taxes shall not include any Taxes that result from transactions or actions taken by Buyer or any of its Affiliates (including, following the Closing, for the avoidance of doubt, the Company) after the Closing on the Closing Date that are not in the ordinary course of business or that are not contemplated by this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnity Escrow Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an amount equal to ten percent (10%) of the Purchase Price.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnity Escrow Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement (including all interest and earnings thereunder) for purposes of satisfying indemnification claims hereunder, with the initial amount of such funds being the Indemnity Escrow Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all intellectual property rights arising from or in respect of the following&#58; (i) all patents and applications therefor, including continuations, divisionals, continuations-in-part, or reissues of patent applications and patents issuing thereon, and inventions and discoveries that may be patentable, (ii) all trademarks, service marks, trade names, service names, brand names and trade dress rights, and all applications, registrations and renewals thereof, (iii) copyrights and registrations and applications therefor, works of authorship and mask work rights, and (iv)&#160;all trade secrets, know-how, customer lists, software, technical information, data, process technology, plans, drawings and blue prints.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any statute, law, ordinance, regulation, rule, order, judgment, decree or code of any Governmental Authority, including any Governmental Order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Legal Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means at any time (i) any Law, injunction, writ, edict, award, authorization or other legally binding requirement of any Governmental Authority in effect at that time or (ii) any legally binding obligation included in any certificate, certification, franchise, Permit or license issued by any Governmental Authority at that time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any charge, lien, mortgage, deed of trust, security interest, option, pledge, deposit, encumbrance, claim, negative pledge, license, lease, right of first refusal or first offer, easement conditional sale or other title retention agreement, defect in title, claim, community or other marital property interest, equitable interest, covenant, or other restriction of a similar kind, including with respect to voting (in the case of any security or equity interest), transfer, receipt of income or exercise of any other attribute of ownership.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any event, series of events, change or effect that, individually or in the aggregate with other events, series of events, changes, or effects, has had an adverse effect on the financial condition or results of operations of the Company taken as a whole, except any adverse effect related to or resulting from (i)&#160;general business or economic conditions affecting any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">industry in which the Company operates that do not disproportionately affect the Company as compared to comparable businesses operating in the same or similar industry, (ii)&#160;national or international political or social conditions, including the engagement by the United States in hostilities or the escalation thereof, whether or not pursuant to the declaration of a national emergency or war, or the occurrence or the escalation of any military or terrorist attack upon the United States, or any of its territories, possessions or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States, (iii)&#160;financial, banking or securities markets conditions (including any disruption thereof and any decline in the price of any security or any market index), except to the extent such conditions disproportionately affect the Company as compared to comparable businesses operating in the same or similar industry, (iv)&#160;changes in Law, except to the extent such changes disproportionately affect the Company as compared to comparable businesses operating in the same or similar industry, (v) changes in accounting standards, including GAAP, except to the extent such changes disproportionately affect the Company as compared to comparable businesses operating in the same or similar industry, (vi) any existing event, condition or other matter described on the Disclosure Schedule, or (vii)&#160;any adverse change in or effect on the business of the Company that is cured by or on behalf of the Company to Buyer&#8217;s reasonable satisfaction before the earlier of the Closing Date and the date on which this Agreement is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a calculation of the total current assets of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the total current liabilities of the Company, in each case calculated in accordance with the Net Working Capital Accounting Principles.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (a) In the event that the Closing Date is the final calendar day of any month, then Net Working Capital shall be calculated as of 11&#58;59 p.m. (ET) on the Closing Date, and (b) if the Closing Date is any day other than the final calendar day of any month, then Net Working Capital shall be calculated as of 11&#58;59 p.m. (ET) on the day prior to the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Working Capital Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means GAAP, as modified by the principles set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex 10.01(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Working Capital Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means $8,800,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any permit, license, franchise, approval, accreditation, qualification, certification, authorization, registration, filing, waiver, exemption, clearance or consent obtained from or filed with any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) statutory Liens for current Taxes or other governmental charges not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings by the Company, in each case provided that adequate reserves with respect thereto are maintained in accordance with GAAP, (ii) mechanic&#8217;s, materialmen&#8217;s, supplier&#8217;s, vendor&#8217;s, carriers&#8217;, workers&#8217;, repairers&#8217; and similar statutory Liens arising or incurred in the ordinary course of business securing amounts that are not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings by the Company and for which appropriate reserves have been established in accordance with GAAP (iii) zoning, entitlement, building and other land use regulations imposed by Governmental Authorities having jurisdiction over the Leased Real Property which are not violated by the current use and operation of the Leased Real Property and do not materially interfere with the Company&#8217;s present use or occupancy of the Leased Real Property, (iv) covenants, conditions, restrictions, easements and other similar matters of record affecting title to the Leased Real Property which do not and will not adversely impair the occupancy or use of the Leased Real Property for the purposes for which it is currently used or proposed to be used in connection with the Company&#8217;s business, (v) public roads and highways and (vi) pledges or deposits to secure obligations arising in the ordinary course of business under worker&#8217;s compensation, unemployment insurance, social security, retirement and similar legislation that do not limit in any material respect the ordinary conduct of the business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Post-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Taxable period of the Company beginning after the Closing Date and the portion of any Straddle Period beginning after the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Taxable period of the Company ending on or before the Closing Date and the portion of any Straddle Period up to and including the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Private Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means such private non-governmental programs, including any private insurance program, under which the Company, directly or indirectly, is presently receiving payments or is eligible to receive payments in connection with its business operations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Seller Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all fees and expenses incurred by the Company or the Seller, or for which the Company is liable, at or prior to the Closing in connection with the preparation, negotiation and execution of this Agreement and the Transaction Documents, and the performance and consummation of the transactions contemplated by this Agreement, in each case that are unpaid as of immediately prior to the Closing and not accrued for in the calculation of Net Working Capital, and all taxes payable by the Company relating thereto, (b) any change-of-control or similar payment or increased cost for which the Company is liable that is triggered in whole or in part by the transactions contemplated by this Agreement including all Change of Control Payments, including the employer portion of any payroll Taxes associated with the foregoing for which the Company is liable and (c) all costs, fees and expenses of the Escrow Agent under the Escrow Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Taxable period of the Company beginning on or prior to and ending after the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Straddle Tax Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any corporation, partnership, association, limited liability company, or other business entity of which (i)&#160;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii)&#160;if a partnership, association, limited liability company, or other business entity, a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any return, report, declaration, claim for refund, information return or other document (including schedules or any related or supporting information) filed or required to be filed with any governmental entity or other authority in connection with the determination, assessment or collection of any Tax or the administration of any laws, regulations or administrative requirements relating to any Tax.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (and, with correlative meaning &#8220;Taxing&#8221; and &#8220;Taxable&#8221;) means all taxes, charges, fees, duties (including customs duties), levies or other assessments, including income, gross receipts, net proceeds, ad valorem, turnover, real and personal property (tangible and intangible), sales, use, franchise, excise, goods and services, value added, stamp, leasing, lease, user, transfer, fuel, excess profits, occupational, interest equalization, windfall profits, escheat and unclaimed property, severance, license, payroll, employment, premium, environmental (including Taxes under Section 59A of the Code), registration, alternative or add-on minimum, estimated, capital stock, disability, employee&#8217;s income withholding, other withholding, unemployment and Social Security taxes, which are imposed by any Governmental Authority, and such term shall include any interest, penalties or additions to tax attributable thereto and obligations to indemnify or otherwise approve or succeed to the Tax liability of any other Person. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; includes any Person charged with paying claims or reimbursing the Company for health care services, as appropriate, provided to Government Program or Private Program </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">patients, including but not limited to Private Program health insurance administrators or third party administrators.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Working Capital Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an amount, which can be positive or negative, equal to the Net Working Capital </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Net Working Capital Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Working Capital Adjustment Escrow Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an amount equal to $1,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Working Capital Escrow Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement (including all interest and earnings thereunder) for purposes of satisfying working capital adjustments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, with the initial amount of such funds being the Working Capital Adjustment Escrow Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Other Definitional Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All references in this Agreement to Exhibits, disclosure schedules, Articles, Sections, subsections and other subdivisions refer to the corresponding Exhibits, disclosure schedules, Articles, Sections, subsections and other subdivisions of or to this Agreement unless expressly provided otherwise.  Titles appearing at the beginning of any Articles, Sections, subsections or other subdivisions of this Agreement are for convenience only, do not constitute any part of this Agreement, and will be disregarded in construing the language hereof.  All references in this Agreement to &#8220;days&#8221; refers to &#8220;calendar days&#8221; unless otherwise specified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Exhibits and schedules to this Agreement are attached hereto and by this reference incorporated herein for all purposes.  The Recitals set forth herein above are incorporated into this Agreement in their entirety.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The words &#8220;this Agreement,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereunder&#8221; and &#8220;hereof,&#8221; and words of similar import, refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited.  The words &#8220;this Article,&#8221; &#8220;this Section&#8221; and &#8220;this subsection,&#8221; and words of similar import, refer only to the Article, Section or subsection hereof in which such words occur.  The word &#8220;or&#8221; is exclusive, and the word &#8220;including&#8221; (in its various forms) means including without limitation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All references to &#8220;$&#8221; and dollars will be deemed to refer to United States currency unless otherwise specifically provided.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Pronouns in masculine, feminine or neuter genders will be construed to state and include any other gender, and words, terms and titles (including terms defined herein) in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.86pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Press Releases and Communications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Prior to the Closing, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, no press release or public announcement related to this Agreement or the transactions contemplated hereby will be issued or made by or on behalf of any party, and no party shall disclose the terms of this Agreement or any agreement entered into in connection herewith other than to such party&#8217;s legal or accounting advisors who are subject to a duty of confidentiality, without the joint approval of Buyer and Seller (not to be unreasonably withheld, conditioned or delayed), in each case unless such disclosure is required by Law (including applicable stock exchange rules) or Governmental Order, in which case Buyer and Seller will have the right to review and comment upon such press release, announcement, communication or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">disclosure prior to its issuance, distribution or publication.  After the Closing, no press releases or public announcements related to this Agreement and the transactions contemplated herein, or other announcements to the employees, customers, patients&#47;payors or suppliers of the Company, will be issued without the approval of Buyer (which approval, in each case, shall not be unreasonably withheld, conditioned or delayed)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Buyer shall first permit Seller a reasonable opportunity to review and comment on the press release proposed to be issued by Buyer upon consummation of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Upon execution of this Agreement, the Parties have agreed that a mutually agreeable public announcement will be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided herein, Buyer and the Seller will each pay their own expenses (including attorneys&#8217; and accountants&#8217; fees and expenses) in connection with the negotiation of this Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated by this Agreement (whether consummated or not).  All Seller Transaction Expenses will be borne by the Seller.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Prevailing Party</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of a dispute between any of the parties with respect to obligations under this Agreement, the prevailing party in any action or proceeding in any court or arbitration in connection therewith will be entitled to recover from such other party its costs and expenses, including reasonable legal fees and associated court costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Knowledge Defined</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">the Company&#8217;s knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">to the knowledge of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the actual knowledge of the members of the Company Knowledge Group, as of the related date, and such additional knowledge as such individuals would reasonably be expected to obtain in the normal performance of their duties in their respective capacities with respect to the Company and upon due inquiry of those employees reporting thereto&#59; provided, however, for the avoidance of doubt, in no event shall such persons be required to undertake any review, search or investigation of any public files, records or dockets, engage any third parties in connection with such due inquiry or obtain any freedom-to-operate or other legal opinion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Notices</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement will be in writing and will be deemed to have been given (a) when personally delivered, (b) when transmitted via electronic mail (c) when transmitted via telecopy (or other facsimile device) to the number set out below if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid), (c) the day following the day (except if not a Business Day then the next Business Day) on which the same has been delivered prepaid to a reputable national overnight air courier service or (d) the third Business Day following the day on which the same is sent by certified or registered mail, postage prepaid.  Notices, demands and communications, in each case to the respective parties, will be sent to the applicable address set forth below, unless another address has been previously specified in writing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notices to Seller (and, before the Closing, the Company)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amedisys Personal Care, LLC</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o Amedisys, Inc.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3854 American Way, Suite A</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Baton Rouge, LA 70816-4013</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fax Number&#58; (225) 299-3796</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58;&#160;&#160;&#160;&#160;Paul B. Kusserow </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; paul.kusserow&#64;amedisys.com</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amedisys Personal Care, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o Amedisys, Inc.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3854 American Way, Suite A</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Baton Rouge, LA 70816-4013</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58;&#160;&#160;&#160;&#160;Legal Department</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">with a copy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to (which shall not constitute notice)&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Butler Snow LLP</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">445 North Boulevard, Suite 300</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Baton Rouge, LA 70802</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Facsimile&#58; (225) 343-0637</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58;&#160;&#160;&#160;&#160;Lee C. Kantrow, Esq. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Jacob M. Kantrow, Esq.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;George P. Holmes, Esq.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; &#160;&#160;&#160;&#160;lee.kantrow&#64;butlersnow.com</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">jacob.kantrow&#64;butlersnow.com</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">george.holmes&#64;butlersnow.com</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notices to Buyer and Buyer Parent (and, after the Closing, the Company)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HouseWorks Holdings, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 Unicorn Park Drive</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Woburn, MA 01801</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Mike Trigilio </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; mtrigilio&#64;house-works.com</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With copy to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o InTandem Capital Partners<br>One Vanderbilt Avenue, Suite 2400<br>New York, NY 10017<br>Attention&#58;  Brad Coppens and Steve Cohen<br>Email&#58; bcoppens&#64;intandemcapital.com&#59;<br>scohen&#64;intandemcapital.com</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (which shall not constitute notice)&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwin Procter LLP<br>100 Northern Avenue </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Boston, MA 02110<br>Attention&#58;  Chris Wilson <br>Email&#58;  cwilson&#64;goodwinlaw.com </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Assignment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and the rights hereunder are not assignable unless such assignment is consented to in writing by Buyer, the Company, and Seller, and, subject to the preceding clause, this Agreement and all the provisions hereof shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors or permitted assigns&#59; provided, that, Buyer and its Affiliates shall have the right to assign, without such consent, Buyer&#8217;s rights and obligations hereunder in whole or in part for collateral security purposes to any existing or future lender or group thereof (including without any limitation any agent, trustee or other representative acting on their behalf) providing financing to Buyer and&#47;or any of its Affiliates and to any purchaser or other transferee in any foreclosure sale or other exercise of remedies thereby, and any such lenders (or agent, trustee or other representative) or such purchaser (or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">transferee) may exercise all of the rights and remedies Buyer hereunder, all without any further consent of the Company or Seller.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Severability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement, and the parties will amend or otherwise modify this Agreement to replace any prohibited or invalid provision with an effective and valid provision that gives effect to the intent of the parties to the maximum extent permitted by applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Strict Construction</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction will be applied against any Person.  Information set forth on any Section of the Disclosure Schedule shall be deemed to qualify each Section of this Agreement to which such Section of the Disclosure Schedule relates (or makes cross-reference), as well as representations and warranties in other Sections of this Agreement but only to the extent that the specific item on any such Section of the Disclosure Schedule is reasonably apparent on its face as being applicable to such other Section and only as related to such specific item. Capitalized terms used in the Disclosure Schedule and not otherwise defined therein have the meanings given to them in this Agreement.  The specification of any dollar amount or the inclusion of any item in the representations and warranties contained in this Agreement or the Disclosure Schedule or Exhibits is not intended to imply that the amounts, or higher or lower amounts, or the items so included, or other items, are or are not required to be disclosed (including whether such amounts or items are required to be disclosed as material or threatened) or are within or outside of the ordinary course of business, and no party will use the fact of the setting of the amounts or the fact of the inclusion of any item in this Agreement or the Disclosure Schedule or Exhibits in any dispute or controversy between the parties as to whether any obligation, item or matter not described or included in this Agreement or in any Disclosure Schedule or Exhibit is or is not required to be disclosed (including whether the amount or items are required to be disclosed as material or threatened) or is within or outside of the ordinary course of business for purposes of this Agreement.  The information contained in this Agreement and in the Disclosure Schedule and Exhibits is disclosed solely for purposes of this Agreement, and no information contained herein or therein will be deemed to be an admission by any party to any third party of any matter whatsoever (including any violation of law or breach of contract). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendment and Waiver</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of this Agreement may be amended or waived only in a writing signed by Buyer, the Company and Seller.  No waiver of any provision hereunder or any breach or default thereof will extend to or affect in any way any other provision or prior or subsequent breach or default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Complete Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement (including the exhibits, schedules and annexes hereto) and the documents referred to herein (including the Confidentiality Agreement) contain the complete agreement between the parties and supersede any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Counterparts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in multiple counterparts (including by means of telecopied or PDF signature pages), any one of which need not contain the signatures of more than one party, but all such counterparts taken together will constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Governing Law</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All matters relating to the interpretation, construction, validity, and enforcement of this Agreement, and all claims or causes of action that may be based upon, arise out of or relate to this Agreement or the transactions contemplated hereby, whether based on contract, tort, statutory or other Law, will be governed by and construed in accordance with the domestic Laws of the State of Delaware without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Consent to Jurisdiction and Service of Process</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties to this Agreement submit to the exclusive jurisdiction of any state or federal court of competent jurisdiction located in the State of Delaware in respect of the interpretation and enforcement of the provisions of this Agreement and any related agreement, certificate or other document delivered in connection herewith and by this Agreement waive, and agree not to assert, any defense in any action for the interpretation or enforcement of this Agreement and any related agreement, certificate or other document delivered in connection herewith, that they are not subject thereto or that such action may not be brought or is not maintainable in such courts or that this Agreement may not be enforced in or by such courts or that their property is exempt or immune from execution, that the action is brought in an inconvenient forum, or that the venue of the action is improper.  Service of process with respect thereto may be made upon any party hereto by mailing a copy thereof by registered or certified mail, postage prepaid, to such party at its or his address as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Waiver of Jury Trial</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party hereby acknowledges and agrees that any controversy which may arise under this Agreement is likely to involve complicated and difficult issues, and therefore each such party hereby irrevocably and unconditionally waives any right such party may have to a trial by jury in respect of any litigation directly or indirectly arising out of or relating to this Agreement or the transactions contemplated by this Agreement.  Each party certifies and acknowledges that (i) no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii) each such party understands and has considered the implications of this waiver, (iii) each such party makes this waiver voluntarily, and (iv) each such party has been induced to enter into this agreement by, among other things, the mutual waivers and certifications in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Third Party Beneficiaries</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No Person other than the parties will have any rights, remedies, obligations or benefits under any provision of this Agreement, other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections&#160;9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (to the extent provided therein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Representation of the Seller and their Affiliates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer agrees, on its own behalf and on behalf of the Buyer Indemnitees, that, following the Closing, Butler Snow LLP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Butler Snow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may serve as counsel to the Seller and its Affiliates in connection with any matters related to this Agreement and the transactions contemplated hereby, including any litigation, claim or obligation arising out of or relating to this Agreement or the transactions contemplated by this Agreement notwithstanding any representation by Butler Snow prior to the Closing Date of the Company.  Buyer and the Company hereby (i) waive any claim they have or may have that Butler Snow has a conflict of interest or is otherwise prohibited from engaging in such representation and (ii) agree that, in the event that a dispute arises after the Closing between Buyer, the Company and Seller or any of their Affiliates, Butler Snow may represent the Seller or any of its Affiliates in such dispute even though the interests of such Person(s) may be directly adverse to Buyer, the Company and even though Butler Snow may have represented the Company in a matter substantially related to such dispute.  Buyer and the Company also further agree that, as to all communications among Butler Snow and the Company, Seller, Seller&#8217;s Affiliates or any of their respective representatives that relate in any way to the transactions contemplated by this Agreement, the attorney-client privilege with respect to such matters (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction Privilege</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the expectation of client confidence with respect to such matters belongs to Seller and may be controlled by Seller and will not pass to or be claimed by Buyer or the Company.  None of Buyer or its Affiliates or the Company shall intentionally access, or attempt to access, any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">privileged communications.  Furthermore, if such communications remain accessible on the computer network of the Company following the Closing, the continued existence of such communications on that network following the Closing shall not be, and shall not be claimed to be by the Buyer, the Company, a waiver of the attorney-client privilege held and enjoyed by Seller.  Notwithstanding the foregoing, in the event that a dispute arises between Buyer, the Company and a third party other than a party to this Agreement after the Closing, the Company may assert the attorney-client privilege to prevent disclosure of confidential communications by Butler Snow to such third party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company may not waive the Transaction Privilege.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Deliveries to Buyer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer agrees and acknowledges that all documents or other items delivered to Buyer&#8217;s Representatives will be deemed to be delivered to Buyer for all purposes hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conflict Between Transaction Documents</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties agree and acknowledge that to the extent any terms and provisions of this Agreement are in any way inconsistent with or in conflict with any term, condition or provision of any Transaction Document, this Agreement will govern and control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Specific Performance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed by a party hereto in accordance with their specific terms or were otherwise breached by a party hereto.  It is accordingly agreed that the non-breaching party(ies) will be entitled to an injunction or injunctions to prevent breaches of this Agreement by the other party(ies) and to enforce specifically the terms and provisions hereof against such other party(ies) in any court having jurisdiction under this Agreement, this being in addition to any other remedy to which the aggrieved parties are entitled at law or in equity.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Dispute Resolution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except for the resolution of Disputed Items pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and Actions brought pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Any disagreement or dispute between the parties arising out of or related to this Agreement or any of the agreements delivered in connection herewith or any of the transactions contemplated hereby or thereby (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be resolved by Buyer and the Seller in the manner provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer and the Seller shall attempt to resolve any Dispute hereunder in good faith by meeting to discuss the Dispute within ten (10) Business Days following the original written notice of any Dispute by the party making such a claim and shall seek to resolve the Dispute in writing within thirty (30) days following the original written notice of any Dispute by the party making such a claim.  No settlement reached under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be binding on the parties until reduced to a writing signed on behalf of the parties by Buyer and Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Should Buyer and the Seller fail to meet within ten (10) Business Days or fail to resolve the related outstanding Dispute within thirty (30) days following the giving of the notice as outlined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then, the Dispute shall be settled by binding arbitration administered by the American Arbitration Association (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in accordance with its Commercial Arbitration Rules.  The parties shall conduct an arbitration hearing, commencing within ninety (90) days following the preliminary hearing with the arbitrator(s), in order to resolve the Dispute, or such portion of that Dispute that the parties are unable to resolve in the period set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   A panel of three arbitrators based in the Boston, Massachusetts area shall be selected from the AAA&#8217;s National Roster as follows&#58; (i) one arbitrator shall be selected by Buyer, (ii) one arbitrator shall be selected by Seller, and (iii)&#160;one arbitrator shall be mutually agreed to by Buyer and Seller&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, if the parties cannot mutually agree to the third arbitrator, the third arbitrator shall be appointed pursuant to the process set forth in R-12 of the AAA&#8217;s Commercial Arbitration Rules. Each arbitrator must have reasonable experience in transactions involving the purchase and sale of all or substantially all of a company&#8217;s assets </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or equity. Each party agrees to execute an engagement letter in the customary form required by the arbitrator(s). The arbitration shall be conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association in effect from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except as modified by the agreement of the parties and the other provisions contained herein, including, but not limited to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">On any conflict between the Commercial Rules in effect from time to time and the provisions of this Agreement, the provisions of this Agreement shall be controlling.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">The forum for arbitration shall be in Boston, Massachusetts. Any party may commence arbitration of a Dispute by a demand for arbitration served on the other parties to the extent that any Dispute is not fully resolved through the process and timeframe as set forth above in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 11.20(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">11.20(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">The arbitrator(s) will be empowered to hear all Disputes, including the determination of the scope of arbitration. The parties shall meet and confer in advance of the preliminary hearing before the arbitrator(s) in order to develop a plan for discovery in advance of the hearing.  Any disagreements among the parties with respect to the scope or timing of discovery shall be submitted to the arbitrator(s) during the preliminary hearing.  Any such disagreement (or any other dispute regarding discovery), or the relevance or scope thereof, shall be conclusively determined by the arbitrator(s).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The arbitrators may enter a default decision against any party who fails to participate in the arbitration proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The arbitrators shall be bound by and shall enforce the terms of this Agreement. The arbitrators&#8217; decision shall be made by majority vote of the arbitrators. The arbitrators&#8217; decision shall be in writing and in the form of a reasoned opinion, and a court reporter shall record all hearings. Any award rendered by the arbitrators regarding the Dispute shall be final, non-appealable, conclusive and binding upon the parties, and judgment thereon may be entered and enforced in any court of competent jurisdiction, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the arbitrators shall have no power or authority to grant punitive damages, injunctive relief, specific performance or other equitable relief.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The Expedited Procedures of the American Arbitration Association shall apply in any case in which no disclosed claim or counterclaim exceeds $75,000, exclusive of interest, attorneys&#8217; fees, and arbitration fees and costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">Notwithstanding the foregoing, in the event a Dispute involves less than $250,000, such Dispute shall be determined by a single arbitrator to be mutually agreed upon by the parties.  If the parties cannot agree upon such single arbitrator, such arbitrator shall be appointed pursuant to the process set forth in R-12 of the AAA&#8217;s Commercial Arbitration Rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">Notwithstanding the foregoing, nothing herein shall prohibit a party from instituting judicial proceedings to (A) compel arbitration in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (B)&#160;obtain orders to require witnesses to obey subpoenas issued by the arbitrators or as may otherwise be necessary to facilitate the arbitration proceedings&#59; or (C)&#160;secure confirmation or enforcement of any arbitration award rendered pursuant to this Agreement. The prevailing party shall be entitled to receive from the other party or parties&#8217; reimbursement of the prevailing party&#8217;s reasonable legal fees and disbursements incurred in connection with such arbitration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Buyer and the Seller shall maintain, and cause their respective Affiliates and their respective employees, agents and other representatives to maintain, the confidential nature of the existence, nature, underlying facts and circumstances, and status of the Dispute and the dispute resolution process contemplated under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, except as may be necessary (i)&#160;to prepare for or conduct the dispute resolution proceedings contemplated hereby, including the presentation of claims and defenses, (ii) to pursue or oppose legal remedies in court pertaining to this dispute resolution process, (iii) to comply in good faith with applicable Laws and Legal Requirements, or (iv) comply with or enforce any award pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The parties reserve the right to enter into, or request from the arbitrator, a more detailed confidentiality agreement or protective order.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Equity Purchase Agreement on the day and year first above written.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SELLER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS PERSONAL CARE, LLC</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Paul B. Kusserow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Paul B. Kusserow</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58; Chief Executive Officer</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SELLER PARENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Paul B. Kusserow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Paul B. Kusserow</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BUYER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOUSEWORKS HOLDINGS, LLC</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Michael Trigilio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Michael Trigilio</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58; Chief Executive Officer</font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASSOCIATED HOME CARE, L.L.C.</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Paul B. Kusserow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Paul B. Kusserow</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58; Chief Executive Officer</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="id90c41438ec044d2ab4dc073fdf3e6fa_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form of Escrow Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(See attached.)</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form of Release Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(See attached.)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exhibit101_separationagree.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i48d5a7d7eb404b6094b69654d7b20afa_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Unless and until this Agreement is &#8220;Effective,&#8221; it, and the discussions about entering into such an agreement, are Confidential </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Under F.R.E. 408 and its state counterparts and not admissible.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SEPARATION AGREEMENT AND GENERAL RELEASE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">This Separation Agreement and General Release (&#8220;Agreement&#8221;) is entered into by and effective between Amedisys, Inc. (the &#8220;Company&#8221;) and Christopher T. Gerard (the &#8220;Employee&#8221;) as of the eighth (8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) day after the Employee has signed the Agreement if he has not timely revoked his acceptance of the Agreement during the seven (7) days following his signing of the Agreement (the &#8220;Effective Date&#8221;). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">WHEREAS, the Employee and the Company desire to enter into an agreement regarding the Employee&#8217;s separation of employment from the Company and a release of claims&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">WHEREAS, the Employee&#8217;s termination constitutes a termination by the Company without &#8220;Cause,&#8221; as defined in the Amedisys Holding, L.L.C. Severance Plan for Chief Executive Officer, dated January 6, 2022 (the &#8220;CEO Severance Plan&#8221;)&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">WHEREAS, the Employee and the Company currently are parties to (i) that certain Amedisys, Inc. Dispute Resolution Agreement (&#8220;DRA&#8221;), a true and correct copy of the DRA is attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> and (ii) that certain Executive Protective Covenants Agreement (the &#8220;EPCA&#8221;), a true and correct copy of the EPCA is attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">NOW, THEREFORE, in consideration of the mutual promises and agreements contained herein and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Company and the Employee agree as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Separation from Employment&#59; Resignation as Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee&#8217;s employment with the Company was terminated without cause at the close of business on November 17, 2022 (such date referred to herein as the &#8220;Separation Date&#8221;). The Employee was removed from any and all officer positions that the Employee holds with Company and, as applicable, its affiliates as of the Separation Date. In accordance with the Company&#8217;s Corporate Governance Guidelines, the Employee hereby resigns as a director of the Company and any of its subsidiaries and affiliates. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Pursuant to the terms of the CEO Severance Plan, subject to the remainder of this Agreement, and provided that the Employee signs and returns this Agreement to the Company within twenty-one (21) days after his receipt thereof,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">does not revoke this Agreement within seven (7) days after signing it in accordance with Section 20 below, and complies with its terms&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:57pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:7.57pt">The Employee shall be entitled to a severance payment (the &#8220;Severance Payment&#8221;) in the gross amount of FOUR MILLION FIFTY THOUSAND DOLLARS AND ZERO CENTS ($4,050,000.00) (constituting two (2) times the sum of (A) the Employee&#8217;s base salary, as in effect on the Separation Date and (B) an amount equal to the Employee&#8217;s short-term incentive bonus target percentage for 2022 times the Employee&#8217;s base salary, as in effect on the Separation Date). Subject to the foregoing, this Severance Payment will be paid in substantially equal installments over the twelve (12)-month period immediately following the Separation Date&#59; provided, however, (i) any monthly payments otherwise due during the six (6)-month period immediately following the Separation Date shall be accumulated and paid in a single lump sum (without interest) on the first regularly-scheduled payroll date on or following the date that is one day after the day that is six (6) months following the Separation Date and (ii) the balance of any such payments due to be paid to the Employee under this Section 2(a) shall continue to be paid monthly over the remainder of the twelve (12)-month period following the Separation Date. All applicable withholdings from these payments will be made on the basis of a miscellaneous payroll period of 365 days.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:57pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:7.57pt">The Employee&#8217;s equity awards will be governed by the individual equity award agreements. Per the terms of the agreements, all vested stock options must be exercised within ninety (90) days of Employee&#8217;s termination.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Employee acknowledges and agrees that the foregoing payments and benefits each provide the Employee with valuable consideration to which the Employee would not otherwise be entitled if the Employee had not signed this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Final Paycheck and Business Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Regardless of whether the Employee signs this Agreement, the Company will pay the Employee his final paycheck for his employment services. The Company also will reimburse the Employee for reasonable business expenses appropriately incurred by the Employee prior to the Separation Date in furtherance of his employment with the Company, subject to the Company&#8217;s applicable business expense reimbursement policy and the remainder of this Section 3. The Employee shall submit all requests to the Company for expense reimbursements within twenty-one (21) days after the Separation Date. Any requests submitted thereafter shall not be eligible for reimbursement, except as required by applicable law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Except as set forth in this Agreement or as otherwise required by applicable law (including without limitation the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended), the Employee&#8217;s participation in and rights under any Company employee benefit plans and programs will be governed by the terms and conditions of those plans and programs, which plans, programs, terms and conditions may be amended, modified, suspended or terminated by the Company at any time for any or no reason to the extent permitted by law. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Released Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The term &#8220;Released Parties&#8221; as used in this Agreement includes&#58; (a) the Company, Amedisys Holdings, L.L.C., and each of their past, present, and future parents, divisions, subsidiaries, partnerships, affiliates, and other related entities (whether or not they are wholly owned)&#59; and (b) the past, present, and future owners, trustees, fiduciaries, administrators, shareholders, directors, officers, partners, agents, representatives, members, associates, insurance carriers, employees, and attorneys of each entity listed in subpart (a) above&#59; and (c) the predecessors, successors, and assigns of each entity listed in subparts (a) and (b) above.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Release of All Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee, and anyone claiming through the Employee or on the Employee&#8217;s behalf, hereby waive and release the Company and the other Released Parties with respect to any and all claims, whether currently known or unknown, that the Employee now has or has ever had against the Company or any of the other Released Parties arising from or related to any act, omission, or thing occurring or existing at any time prior to or on the date on which the Employee signs this Agreement. Without limiting the generality of the foregoing, the claims waived and released by the Employee hereunder include, but are not limited to&#58;</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:4.57pt">all claims arising out of or related in any way to the Employee&#8217;s employment, compensation, other terms and conditions of employment, or termination from employment with the Company, including without limitation all claims for any compensation payments, bonus, severance pay, equity, or any other compensation or benefit&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:4.57pt">all claims that were or could have been asserted by the Employee or on his behalf&#58; (i) in any federal, state, or local court, commission, or agency&#59; or (ii) under any common law theory (including without limitation all claims for breach of contract (oral, written or implied), wrongful termination, defamation, invasion of privacy, infliction of emotional distress, tortious interference, fraud, estoppel, unjust enrichment, and any other contract, tort or other common law claim of any kind)&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:5.18pt">all claims that were or could have been asserted by the Employee or on his behalf under&#58; (i) the Age Discrimination in Employment Act, as amended&#59; and (ii) any other</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">federal, state, local, employment, services or other law, regulation, ordinance, constitutional provision, executive order or other source of law, including without limitation under any of the following laws, as amended from time to time&#58; Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167;&#167; 1981 &#38; 1981a, the Americans with Disabilities Act, the Equal Pay Act, the Employee Retirement Income Security Act, the Lilly Ledbetter Fair Pay Act of 2009, the Family and Medical Leave Act, the Genetic Information Nondiscrimination Act, and the Fair Credit Reporting Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Notwithstanding Section 6 above, nothing in this Agreement shall waive or release&#58; (a) any claim that cannot be waived or released by law&#59; (b) any claim to enforce this Agreement&#59; (c) any claim for any vested benefits to which the Employee is otherwise entitled pursuant to the terms and conditions of any applicable benefit plans&#59; (d) any claim for workers&#8217; compensation or unemployment insurance benefits&#59; or (e) any claim, if any, to indemnification under any applicable law, any Company by-laws, or any director and officer insurance, it being understood and agreed that this Agreement does not create or expand upon any such rights (if any) to indemnification. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Covenant Not to Sue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee promises not to file, or become a plaintiff or claimant of any kind, in any arbitration, proceeding or lawsuit in court, against the Company or any of the Released Parties for, or based on, any claim or charge of employment discrimination or for any claim or action that is released under this Agreement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Nothing in this Agreement limits or terminates the Employee&#8217;s right to file a charge or complaint with or participate in an investigation conducted by the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;), the National Labor Relations Board (&#8220;NLRB&#8221;), or any other federal, state, or local governmental agency (collectively, the &#8220;Governmental Agencies&#8221;). However, by signing this Agreement, the Employee is waiving the right to any monetary recovery or other relief (other than monetary awards from the Securities and Exchange Commission&#8217;s whistleblower program) should the Governmental Agencies pursue any claims on the Employee&#8217;s behalf and assigns any such recovery to the Company. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">No Other Actions or Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee represents and warrants that&#58; (a) there has not been filed by the Employee or on the Employee&#8217;s behalf any legal or other proceedings against any of the Released Parties (provided, however, that the Employee need not disclose to the Company, and the foregoing representation and warranty in this subpart (a) does not apply to, conduct or matters that cannot be waived or released)&#59; (b) no such proceedings have been initiated against any of the Released Parties on the Employee&#8217;s behalf&#59; (c) the Employee is the sole owner of the claims that are released in Section 6 above&#59; (d) none of these claims has been transferred or assigned or caused to be transferred or assigned to any other person, firm or other legal entity&#59; and (e) the Employee has the full right and power to grant, execute, and deliver the releases, undertakings, and agreements contained in this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">No Other Payments or Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Except as expressly provided in this Agreement, the Employee acknowledges and agrees that he is not entitled to and will not receive any other compensation, payments, benefits, or recovery of any kind from the Company or the other Released Parties, including without limitation any bonus, severance, equity or other payments. In the event of any further proceedings whatsoever based upon any matter released herein, the Employee hereby waives, and agrees that the Employee shall not have and the Released Parties shall not be liable for, any further monetary or other recovery of any kind arising out of or related to any such matter, including without limitation any costs, expenses and attorneys' fees incurred by or on behalf of the Employee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee represents and warrants that he has fully disclosed to the Company any matter of which he was aware of during his employment with the Company that might give rise to, constitute evidence of, or support any claim of any unlawful conduct or regulatory violation against the Company. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Other Agreements&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee hereby reaffirms his commitment to comply in full with all obligations under the DRA. Without limiting the foregoing in any way, and except as permitted under this Agreement, the Employee represents and warrants that he has returned to the Company all information (electronic and hardcopy) and other property of the Company and its affiliates in his possession or control, including without limitation all confidential and proprietary information of the Company and its affiliates and all laptops and other computer equipment, electronic storage devices, smart- or cell-phones, blackberries and similar devices, Company-provided credit cards, keys and other access cards, and electronic and hardcopy files. The Employee further represents and warrants that&#58; (a) he has not retained possession or control of any copies of any Company information (electronic and hardcopy) or other property&#59; and (b) except as permitted under Section 18 below, he has not provided and will not provide copies of any Company information (electronic or hardcopy) and&#47;or other property or written or oral descriptions of such Company information (electronic or hardcopy) and&#47;or other property to any entity or person other than in the performance of the Employee&#8217;s duties as a Company employee and in the ordinary course of the Company&#8217;s business.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee acknowledges and agrees that a breach by him of any provision of this Agreement will result in immediate and irreparable harm to the Company and its affiliates for which full damages cannot readily be calculated and for which damages are an inadequate remedy. Accordingly, the Employee agrees that the Company and its affiliates shall be entitled to injunctive relief to prevent any such actual or threatened breach or any continuing breach by the Employee (without posting a bond or other security), without limiting any other remedies that may be available to them. The Employee further agrees to reimburse the Company and its affiliates for all costs and expenditures, including but not limited to reasonable attorneys' fees and court costs, incurred by any of them in connection with the successful enforcement of any of their rights under this Agreement. Additionally, the Employee agrees that, notwithstanding any other provision herein, and without limiting the foregoing provisions of this Section 12 or any other available remedy, upon any breach by him of this Agreement, he shall promptly repay to the Company (but in no event later than seven (7) calendar days following the date on which such breach is discovered) any and all Severance Payment paid to the Employee by the Company prior to the discovery of such breach. Nothing herein shall, or is intended to, in any way limit or restrict the damages or other relief that the Company and its affiliates may seek and recover in the event of a breach by the Employee of any provision of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Following the Separation Date, and except as otherwise provided in this Agreement, the Employee shall cooperate fully with the Company and the other Released Parties (defined above) in any administrative, investigative, litigation or other legal matter(s) that may arise or have arisen involving the Company or any of the other Released Parties and which in any way relate to or involve the Employee&#8217;s employment with the Company. The Employee's obligation to cooperate hereunder shall include, without limitation, meeting and conferring with such persons at such times and in such places as the Company and the other Released Parties may reasonably require, and giving truthful evidence and truthful testimony and executing and delivering to the Company and any of the other Released Parties any truthful papers reasonably requested by any of them. The Employee shall be reimbursed for reasonable out-of-pocket expenses that the Employee incurs in rendering cooperation after the Separation Date pursuant to this Section 13, and the Company will pay the Employee a fee equal to $750 per hour for any such cooperation under this Section 13 that the Company requests after the twelve (12)-month anniversary of the Separation Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee agrees that any and all discussions leading up to this Agreement are strictly confidential. The Employee agrees to take all reasonable efforts to preserve the confidentiality of all discussions leading to the parties&#8217; entry into this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">No Right to Employment or Services Relationship</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee acknowledges and agrees that the Employee has no present or future right to employment with the Company or any of the other Released Parties, and will not apply or seek consideration for any employment, engagement, or contract with any of them. Nothing in this Agreement shall prohibit the Employee from providing services to the Company or becoming re-employed by the Company if an entity utilizing the Employee as an employee, director or contractor, acquires or merges with the Company or if the Company acquires an entity utilizing the Employee as an employee, director or contractor. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Non-disparagement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Except as otherwise provided in this Agreement, the Employee shall refrain from all conduct, verbal or otherwise, that disparages or damages the reputation, goodwill, or standing in the community of the Company or any of the other Released Parties, provided that nothing herein shall prohibit the Employee from giving truthful testimony or evidence to a governmental entity, or if properly subpoenaed or otherwise required to do so under applicable law. Furthermore, all of the Company&#8217;s executive officers and directors shall refrain from all conduct, verbal or otherwise, that disparages or damages the reputation, goodwill, or standing in the community of the Employee, provided that nothing herein shall prohibit such executive officers or directors from giving truthful testimony </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">or making statements to Company directors, officers or employees about the Employee in the ordinary course of business where such statement is reasonably necessary to protect the legitimate business interests of the Company or to perform their respective duties for the Company. The Company&#8217;s executive officers and directors will respond to any direct inquiries about Employee by stating that Employee &#8220;was separated from employment without any cause.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">References</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Employee shall direct all third parties inquiring or reasonably likely to inquire about the Employee&#8217;s employment with the Company to The Work Number at 800-367-2884 or www.theworknumber.com (Employer Code&#58; 15071). In response to such inquiries received by such person, the Company will communicate only the Employee&#8217;s dates of employment and last position held with the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Non-Interference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement prohibits the Employee from confidentially or otherwise communicating or filing a charge or complaint with a governmental or regulatory entity, participating in a governmental or regulatory entity investigation, or giving truthful testimony or statements to a governmental or regulatory entity, or from responding if properly subpoenaed or otherwise required to do so under applicable law.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">No Admission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Nothing in this Agreement is intended to or shall be construed as an admission by the Company or any of the other Released Parties that any of them violated any law, interfered with any right, breached any obligation or otherwise engaged in any improper or illegal conduct with respect to the Employee or otherwise. The Company and the other Released Parties expressly deny any such illegal or wrongful conduct.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">ACKNOWLEDGMENTS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. THE EMPLOYEE ACKNOWLEDGES, UNDERSTANDS, AND AGREES THAT&#58; (a) THE EMPLOYEE HAS READ AND UNDERSTANDS THE TERMS AND EFFECT OF THIS AGREEMENT&#59; (b) THE EMPLOYEE RELEASES AND WAIVES CLAIMS UNDER THIS AGREEMENT KNOWINGLY AND VOLUNTARILY, IN EXCHANGE FOR CONSIDERATION IN ADDITION TO ANYTHING OF VALUE TO WHICH THE EMPLOYEE ALREADY IS ENTITLED&#59; (c) THE EMPLOYEE HEREBY IS AND HAS BEEN ADVISED TO HAVE THE EMPLOYEE&#8217;S ATTORNEY REVIEW THIS AGREEMENT (AT THE EMPLOYEE&#8217;S COST) BEFORE SIGNING IT&#59; (d) THE EMPLOYEE HAS TWENTY-ONE (21) DAYS IN WHICH TO CONSIDER WHETHER TO EXECUTE THIS AGREEMENT&#59; AND (e) WITHIN SEVEN (7) DAYS AFTER THE DATE ON WHICH THE EMPLOYEE SIGNS THIS AGREEMENT, THE EMPLOYEE MAY, AT THE EMPLOYEE&#8217;S SOLE OPTION, REVOKE THE AGREEMENT UPON WRITTEN NOTICE TO AMEDISYS, INC. ATTN&#58; ADAM Y. HOLTON, CHIEF PEOPLE OFFICER, 49 MUSIC SQUARE WEST, SUITE 410, NASHVILLE, TENNESSEE 37203, AND THE AGREEMENT WILL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THIS SEVEN-DAY REVOCATION PERIOD HAS EXPIRED WITHOUT ANY REVOCATION BY THE EMPLOYEE. IF THE EMPLOYEE REVOKES THIS AGREEMENT, IT SHALL BE NULL AND VOID.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Entire Agreement, Amendment, Waiver and Headings&#59; Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. This Agreement, which incorporates herein the DRA and the EPCA, embodies the entire agreement and understanding of the parties hereto with regard to the matters described herein and supersedes any and all prior and&#47;or contemporaneous agreements and understandings, oral or written, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">between said parties regarding such matters, provided that nothing in this Agreement shall limit or release the Employee from any other obligation regarding arbitration, confidentiality, intellectual or other property, or post-employment competitive activities that the Employee has or may have to the Company or any of its affiliates including without limitation the DRA and the EPCA. Notwithstanding the foregoing, the Company agrees that it will consider requests for waivers of the Employee&#8217;s covenants under the EPCA on a case by case basis, provided that nothing in this Agreement shall require the Company to grant any such waivers of any of the terms of the ECPA.  The Employee shall direct any such requests for waivers of specific provisions of the EPCA to the Company&#8217;s Chief Legal Officer, who will present them to the chair of the Compensation Committee of the Company&#8217;s Board of Directors for consideration.  This Agreement may be modified only in a written agreement signed by both parties, and any party's failure to enforce this Agreement in the event of one or more events which violate this Agreement shall not constitute a waiver of any right to enforce this Agreement against subsequent violations. The Section headings used herein are for convenience of reference only and are not to be considered in construction of the provisions of this Agreement. This Agreement may be assigned or transferred to, and shall be binding upon and shall inure to the benefit of&#58; (a) the Company, (b) Amedisys Holdings, L.L.C., (c) any of the other Released Parties, and (d) any person or entity that at any time (whether by merger, purchase or otherwise) acquires all or substantially all of the assets, ownership interests or business of the Company, Amedisys Holdings, L.L.C., or any of the other Released Parties. The Employee may not assign any of his rights or obligations under this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. This Agreement shall be construed and interpreted in accordance with the internal laws of the State of Tennessee, without regard to its choice of law rules.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">23.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">.  The compensation and benefits payable pursuant this Agreement are intended to be exempt from, or comply with, as applicable, the requirements of Internal Revenue Code Section&#160;409A and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other such guidance that may be issued after the Effective Date (collectively, &#8220;Section 409A&#8221;). To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A. Each monthly payment described in this Agreement is designated as a &#8220;separate payment&#8221; for purposes of Section&#160;409A. For purposes of this Agreement, a termination of employment means a separation from service as defined in Section&#160;409A. No reimbursement payable to the Employee pursuant to any provisions of this Agreement or pursuant to any plan or arrangement of the Company shall be paid later than the last day of the calendar year following the calendar year in which the related expense was incurred, and no such reimbursement during any calendar year shall affect the amounts eligible for reimbursement in any other calendar year, except, in each case, to the extent that the right to reimbursement does not provide for a &#8220;deferral of compensation&#8221; within the meaning of Section&#160;409A. Notwithstanding anything herein to the contrary, the Company shall not have any liability to the Employee or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">compliant with, Section&#160;409A are not so exempt or compliant or for any taxes, interest or penalties imposed under Section 409A or any corresponding provision of state or local law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. This Agreement may be executed in two counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Executive Protective Covenants Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. As a material inducement to the Company entering into this Agreement, the Employee agrees to continue to be bound by the terms of the EPCA, and any breach thereof constitutes a breach of this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">THE PARTIES STATE THAT THEY HAVE READ AND UNDERSTAND THE FOREGOING AND KNOWINGLY AND VOLUNTARILY INTEND TO BE BOUND THERETO&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EMPLOYEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">AMEDISYS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">By&#58; _&#47;s&#47; Christopher T. Gerard______ &#160;&#160;&#160;&#160;By&#58;__&#47;s&#47; Jennifer Guckert Griffin__________</font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Name&#58; Christopher T. Gerard&#160;&#160;&#160;&#160;Title&#58; Interim Chief Legal Officer &#38; Corporate Secretary</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Date&#58; 1&#47;9&#47;2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Date&#58; 1&#47;10&#47;2023</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">AMEDISYS, INC. DISPUTE RESOLUTION AGREEMENT</font></div><div style="padding-left:6pt;padding-right:6pt;text-align:center;text-indent:27pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">EXECUTIVE PROTECTIVE COVENANTS AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>exhibit102thirdamendmentto.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5691bec2d7554cedbaaa8b01a446339b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION VERSION</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), dated as of March 10, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered into among AMEDISYS, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; Amedisys Holding, together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Guarantors party hereto, the Lenders party hereto, BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer, and the other L&#47;C Issuers party hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrowers, the Guarantors party thereto, the Lenders from time to time party thereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer, and the other L&#47;C Issuers party thereto, have entered into that certain Amended and Restated Credit Agreement dated as of June 29, 2018 (as amended, modified, extended, restated, replaced, or supplemented from time to time prior to the Third Amendment Effective Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrowers have informed the Administrative Agent that the Company, Associated Home Care, L.L.C., a Massachusetts limited liability company, and Amedisys Personal Care, LLC, a Delaware limited liability company, entered into an Equity Purchase Agreement, dated as of February 10, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PCL Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with HouseWorks Holdings, LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to which the Company and its Subsidiaries will Dispose of the personal care line of business, excluding the Florida operations, to the Buyer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PCL Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrowers have requested that the Existing Credit Agreement be amended as set forth below and that the Lenders consent to the PCL Disposition, subject to the terms and conditions specified in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Existing Credit Agreement or the Amended Credit Agreement (as defined below), as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments to Existing Credit Agreement&#59; Effect of this Agreement&#59; No Impairment&#59; Treatment of Existing Eurodollar Rate Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Existing Credit Agreement is amended in its entirety to read in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the credit agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> being referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amended Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Exhibits C, F, G and K to the Existing Credit Agreement are amended to read in the forms attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annex B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The parties hereto agree that, on and as of the Third Amendment Effective Date, the following transactions shall be deemed to occur automatically, without further action by any party hereto&#58; (i) the Existing Credit Agreement shall automatically be amended in its entirety to read in the form of the Amended Credit Agreement, (ii) all Obligations under the Existing Credit Agreement outstanding on and as of the Third Amendment Effective Date shall in all respects be continuing and shall be deemed to be Obligations outstanding under the Amended Credit Agreement, (iii) the Guaranty provided pursuant to the Existing Credit Agreement shall remain in full force and effect with respect to the Secured Obligations and is hereby reaffirmed, and (iv) all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Letters of Credit outstanding under the Existing Credit Agreement on and as of the Third Amendment Effective Date shall be deemed to be Letters of Credit outstanding on and as of the Third Amendment Effective Date under the Amended Credit Agreement.  Except as expressly modified and amended in this Agreement, all of the terms, provisions and conditions of the Loan Documents shall remain unchanged and in full force and effect.  The Loan Documents and any and all other documents heretofore, now or hereafter executed and delivered pursuant to the terms of the Existing Credit Agreement are hereby amended so that any reference to the Existing Credit Agreement shall mean a reference to the Amended Credit Agreement.  The Amended Credit Agreement is not a novation of the Existing Credit Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Except as expressly set forth herein, this Agreement shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of the Secured Parties under the Existing Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Existing Credit Agreement or any other Loan Document, all of which, as amended, supplemented or otherwise modified hereby, are ratified and affirmed in all respects and shall continue in full force and effect.  Nothing herein shall be deemed to entitle any Loan Party to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Existing Credit Agreement or any other Loan Document in similar or different circumstances.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;It is understood and agreed that, with respect to any Eurodollar Rate Loan outstanding on the Third Amendment Effective Date, (i) such Eurodollar Rate Loan shall continue to bear interest at the Eurodollar Rate until the end of the current Interest Period applicable to such Eurodollar Rate Loan, and (ii) any Eurodollar Rate-related provisions of the Existing Credit Agreement applicable to such Eurodollar Rate Loan are incorporated into the Amended Credit Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and the parties hereto hereby agree that such provisions shall continue to apply to such Eurodollar Rate Loan until the end of the current Interest Period applicable thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding the terms of Section 7.05 of the Amended Credit Agreement, the Administrative Agent and the Required Lenders hereby consent to the PCL Disposition substantially in accordance with the PCL Purchase Agreement as in effect on February 10, 2023&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for the avoidance of doubt, the PCL Disposition shall not be considered usage of the baskets set forth in Section 7.05(d) of the Amended Credit Agreement.  The foregoing consent shall not modify or affect any Loan Party&#8217;s obligation to otherwise comply fully with the terms of Section 7.05 of the Amended Credit Agreement or the Company&#8217;s or any Subsidiary&#8217;s obligations to otherwise comply fully with any other duty, term, condition or covenant contained in the Amended Credit Agreement or any other Loan Document in a transaction other than the PCL Disposition.  The consent set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is limited solely to the specific consent identified above and nothing contained in this Agreement shall be deemed to constitute a waiver of any other rights or remedies the Administrative Agent or any Lender may have under the Amended Credit Agreement or any other Loan Document or under applicable Law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Condition Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall become effective upon receipt by the Administrative Agent of counterparts of this Agreement, properly executed by a Responsible Officer of each Loan Party, each Lender, the Swingline Lender, each L&#47;C Issuer and the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Loan Parties agree to reimburse the Administrative Agent for all reasonable fees, charges, and disbursements of the Administrative Agent in connection with the preparation, execution, and delivery of this Agreement, including all reasonable fees, charges, and disbursements of counsel to the Administrative Agent (paid directly to such counsel if requested by the Administrative Agent).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Loan Documents (as expressly amended and modified by this Agreement) and the obligations of the Loan Parties thereunder are hereby ratified and confirmed and shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">remain in full force and effect according to their terms.  This Agreement shall constitute a Loan Document.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Each Loan Party (i) agrees that the Collateral Documents continue to be in full force and effect and are not impaired or adversely affected in any manner whatsoever, (ii) confirms its grant of security interests pursuant to the Collateral Documents to which it is a party as Collateral for the Secured Obligations, and (iii) acknowledges that all Liens granted (or purported to be granted) pursuant to the Collateral Documents remain and continue in full force and effect in respect of, and to secure, the Secured Obligations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Each Guarantor (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its obligations under the Loan Documents, and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its obligations under the Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Each Loan Party hereby represents and warrants as follows&#58; (i) such Loan Party has taken all necessary corporate, limited liability or other organizational action to authorize the execution, delivery and performance of this Agreement&#59; (ii) this Agreement has been duly executed and delivered by such Loan Party and constitutes the legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#8217; rights generally and by general equitable principles and&#47;or principles of good faith and fair dealing (whether enforcement is sought by proceedings in equity or at law)&#59; (iii) no approval, consent, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, such Loan Party of this Agreement&#59; and (iv) after giving effect to the transactions contemplated by this Agreement to occur on the Third Amendment Effective Date, (A) the representations and warranties of the Company and each other Loan Party contained in Article II and Article V of the Amended Credit Agreement or in any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the Third Amendment Effective Date, except to the extent such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(d)(iv)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the representations and warranties contained in subsections (a) and (b) of Section 5.05 of the Amended Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Existing Credit Agreement, and (B) no Default or Event of Default has occurred and is continuing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Subject to Section 11.18 of the Amended Credit Agreement, this Agreement may be in the form of an Electronic Record and may be executed using Electronic Signatures (including facsimile and .pdf) and shall be considered an original, and shall have the same legal effect, validity and enforceability as a paper record.  This Agreement may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Agreement.  The authorization under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> may include use or acceptance by the Administrative Agent, any L&#47;C Issuer and each Lender of a manually signed paper copy of this Agreement which has been converted into electronic form (such as scanned into .pdf format), or an electronically signed copy of this Agreement converted into another format, for transmission, delivery and&#47;or retention.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;If any provision of this Agreement is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;The terms of Sections 11.14 and 11.15 of the Amended Credit Agreement with respect to submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and the parties hereto agree to such terms.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="margin-bottom:24pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BORROWERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;AMEDISYS, INC.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Executive Vice President and Chief Financial Officer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GUARANTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;ACCUMED HEALTH SERVICES, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ACCUMED HOME HEALTH OF GEORGIA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ADVENTA HOSPICE, L.L.C., </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ALBERT GALLATIN HOME CARE AND HOSPICE SERVICES, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS ALABAMA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Alabama limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS ARIZONA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Arizona limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS ARKANSAS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Arkansas limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS BA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS DELAWARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS FLORIDA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS GEORGIA, L.L.C., </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HEALTH CARE WEST, L.L.C., </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOME HEALTH OF ALABAMA, L.L.C., </font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Alabama limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOME HEALTH OF SOUTH CAROLINA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a South Carolina limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOME HEALTH OF VIRGINIA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Virginia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOSPICE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS IDAHO, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Idaho limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS ILLINOIS, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Illinois limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS INDIANA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Indiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS KANSAS, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Kansas limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS LA ACQUISITIONS, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:360pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS LOUISIANA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS MAINE, P.L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Maine professional limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS MARYLAND, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Maryland limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS MISSISSIPPI, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Mississippi limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS MISSOURI, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Missouri limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS NEW HAMPSHIRE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Hampshire limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS NEW JERSEY, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Jersey limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS NORTH CAROLINA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a North Carolina limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS NORTHWEST, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS OHIO, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Ohio limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS OKLAHOMA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Oklahoma limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS OREGON, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Oregon limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS PENNSYLVANIA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS PERSONAL CARE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS RHODE ISLAND, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Rhode Island limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS SC, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a South Carolina limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMEDISYS SPECIALIZED MEDICAL SERVICES, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS SP-IN, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Indiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS SP-KY, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Kentucky limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS SP-OH, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Ohio limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS SP-TN, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Tennessee limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS TENNESSEE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Tennessee limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS TEXAS, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS TLC ACQUISITION, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS WASHINGTON, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Washington limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS WEST VIRGINIA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a West Virginia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AMEDISYS WISCONSIN, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Wisconsin limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ANGEL WATCH HOME CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ASSOCIATED HOME CARE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Massachusetts limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;AVENIR VENTURES, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;BEACON HOSPICE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;CH HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPREHENSIVE HOME HEALTHCARE SERVICES, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Tennessee limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;EMERALD CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a North Carolina limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;FAMILY HOME HEALTH CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Kentucky limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HI-TECH CARE, INC.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HHC, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Tennessee limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HOME HEALTH OF ALEXANDRIA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HOME HOSPITALISTS OF AMERICA, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HORIZONS HOSPICE CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Alabama limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;HOUSECALL HOME HEALTH, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Tennessee limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE ACQUISITION CORP.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF BROWARD, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF JACKSONVILLE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF LAKELAND, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF OCALA, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF PINELLAS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOME CARE OF PORT CHARLOTTE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;INFINITY HOMECARE OF DISTRICT 9, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NINE PALMS 2, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Mississippi limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NINE PALMS 1, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Virginia limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES INTERNATIONAL, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF BROWARD, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF ERIE NIAGARA, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New York limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF GEORGIA, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF NASSAU SUFFOLK, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New York limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF NEW ENGLAND, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES OF WEST VIRGINIA, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES SOUTHEAST, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TENDER LOVING CARE HEALTH CARE SERVICES WESTERN, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TLC HEALTH CARE SERVICES, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TLC HOLDINGS I, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOSPICE PREFERRED CHOICE, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOSPICE OF EASTERN CAROLINA, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a North Carolina corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOMECARE PREFERRED CHOICE, INC.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; TENNESSEE, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; SENATOBIA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; RUSSELLVILLE, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; NEW HORIZONS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; MONROEVILLE, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; JACKSON, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; HAMILTON, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASERACARE HOSPICE &#8211; DEMOPOLIS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF SAN DIEGO, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PEACEFUL DAYS HOSPICE, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PATHWAYS TO COMPASSION OF CALIFORNIA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE WEST, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF DELAWARE, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF THE DELMAR</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PENINSULA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE GROUP, INC.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE FLORIDA KEYS, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Florida corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF CENTRAL GEORGIA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF NORTHERN GEORGIA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF SAVANNAH, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Georgia limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF ILLINOIS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Illinois limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF KANSAS CITY, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Kansas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF CENTRAL LOUISIANA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF MAINE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Maine limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_61"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF MASSACHUSETTS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Massachusetts limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MASSACHUSETTS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Massachusetts limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF MICHIGAN, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Michigan limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF MINNESOTA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Minnesota limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF SOUTHERN</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MISSISSIPPI, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Mississippi limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PATHWAYS TO COMPASSION, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Nebraska limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF NEW HAMPSHIRE, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Hampshire limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF CLIFTON, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Jersey limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF MARLTON, L.L.C., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Jersey limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF NORTHERN NEW</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JERSEY, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Jersey limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PATHWAYS TO COMPASSION, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a New Jersey limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF OHIO, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Ohio limited liability company </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania corporation </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF GWYNEDD, INC., </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF NORTHWESTERN PENNSYLVANIA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF PITTSBURGH, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF SOUTH CAROLINA, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a South Carolina limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF THE MIDWEST, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a South Dakota limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_70"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF BRYAN TEXAS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF CENTRAL TEXAS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF HOUSTON, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF NORTH TEXAS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN TEXAS, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COMPASSIONATE CARE HOSPICE OF THE CHESAPEAKE BAY, LLC, </font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Virginia limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_73"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COMPASSIONATE CARE HOSPICE OF WISCONSIN, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Wisconsin limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASANA HOSPICE CLEVELAND, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ASANA PALLIATIVE CLEVELAND, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BEAUFORT HOME HEALTH PARTNERS, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOME HEALTH OF NEBRASKA, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Nebraska limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOSPICE HOLDINGS DFW, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Texas limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_76"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOSPICE HOLDINGS HARRISBURG, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MISSOURI HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Missouri limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OHIO HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PENNSYLVANIA HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TAYLOR HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TEXAS HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WT HOSPICE HOLDINGS, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Pennsylvania limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TUCSON HOME HEALTH, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTESSA HEALTH, INC.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTESSA HEALTH HOLDING COMPANY, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTESSA HEALTH MANAGEMENT, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTRADO CLAIM, LLC,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;S&#47; Scott G. Ginn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Scott G. Ginn</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice-President and Treasurer</font></div><div style="text-align:justify"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_82"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ADMINISTRATIVE AGENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;BANK OF AMERICA, N.A.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Administrative Agent</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Liliana Claar&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Liliana Claar</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Vice President</font></div><div style="padding-left:180pt;text-indent:-180pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">LENDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;BANK OF AMERICA, N.A.,</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Lender, L&#47;C Issuer and Swingline Lender</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; H. Hope Walker&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; H. Hope Walker</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JPMORGAN CHASE BANK, N.A.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender and L&#47;C Issuer</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Helen D. Davis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Helen D. Davis</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Executive Director</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_88"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CITIZENS BANK, N.A.,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Doug Cornett&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Doug Cornett</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Managing Director</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_91"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FIFTH THIRD BANK, NATIONAL ASSOCIATION,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Thomas Avery&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Thomas Avery</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Managing Director</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Santiago Caraballo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Santiago Caraballo</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">REGIONS BANK,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Mark Hardison&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Mark Hardison</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Managing Director</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_100"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CAPITAL ONE BANK, NATIONAL ASSOCIATION,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Anthony B. Sendik&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Anthony B. Sendik</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Duly Authorized Signatory</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_103"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Lender</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Eugene Stunson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Eugene Stunson</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Director</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_106"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HANCOCK WHITNEY BANK,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Michael Woodnorth&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Michael Woodnorth</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Vice President</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_109"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BOKF, NA DBA BANK OF TEXAS,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as a Lender</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;S&#47; Gary Whitt&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Gary Whitt</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Annex A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended Credit Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">See attached.</font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:180pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">**ANNEX A TO THIRD AMENDMENT**</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Published CUSIP Numbers</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deal&#58; 02343LAK1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Revolver&#58; 02343LAL9</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Loan&#58; 02343LAM7</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of June 29, 2018</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">among</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMEDISYS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Borrowers,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CERTAIN SUBSIDIARIES OF THE COMPANY PARTY HERETO,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Guarantors,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BANK OF AMERICA, N.A.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Administrative Agent, Swingline Lender and L&#47;C Issuer,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIZENS BANK, N.A.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIFTH THIRD BANK, NATIONAL ASSOCIATION,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JPMORGAN CHASE BANK, N.A.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Co-Syndication Agents,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPITAL ONE BANK, NATIONAL ASSOCIATION,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REGIONS BANK,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Co-Documentation Agents,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE LENDERS PARTY HERETO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BofA SECURITIES, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIZENS BANK, N.A.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIFTH THIRD BANK, NATIONAL ASSOCIATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JPMORGAN CHASE BANK, N.A.,</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Joint Lead Arrangers and Joint Bookrunners</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_112"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TABLE OF CONTENTS</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article I DEFINITIONS AND ACCOUNTING TERMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Defined Terms</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Other Interpretive Provisions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Accounting Terms</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Rounding</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Times of Day</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Letter of Credit Amounts</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UCC Terms</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Interest Rates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II COMMITMENTS AND CREDIT EXTENSIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Loans</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Borrowings, Conversions and Continuations of Loans</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Letters of Credit</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Swingline Loans</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Prepayments</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination or Reduction of Commitments</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">66</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Repayment of Loans</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">67</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Interest and Default Rate</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">68</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fees</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">69</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Computation of Interest and Fees&#59; Retroactive Adjustments of Applicable Rate</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">69</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Evidence of Debt</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">70</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Payments Generally&#59; Administrative Agent&#8217;s Clawback</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">70</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sharing of Payments by Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Collateral</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Defaulting Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">74</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article III TAXES, YIELD PROTECTION AND ILLEGALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">77</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxes</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">77</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Illegality and Designated Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">81</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Inability to Determine Rates</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">82</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Increased Costs</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">84</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation for Losses</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Mitigation Obligations&#59; Replacement of Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">3.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Survival</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV CONDITIONS PRECEDENT TO CREDIT EXTENSIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">4.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#91;Reserved&#93;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">4.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conditions to all Credit Extensions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article V REPRESENTATIONS AND WARRANTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Existence, Qualification and Power</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#59; No Contravention</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governmental Authorization&#59; Other Consents</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Binding Effect</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Statements&#59; No Material Adverse Effect</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">89</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Litigation</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">89</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Default</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">89</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership of Property</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Environmental Compliance</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Insurance</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxes</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">91</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ERISA Compliance</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">91</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Margin Regulations&#59; Investment Company Act</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">92</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Disclosure</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">92</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Laws</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Solvency</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sanctions Concerns&#59; Anti-Corruption Laws&#59; PATRIOT Act</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.18</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Responsible Officers</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.19</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Subsidiaries&#59; Equity Interests&#59; Loan Parties</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.20</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Collateral Representations</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.21</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Regulation H</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.22</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Health Care Laws</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.23</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Labor Matters</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">97</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.24</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Affected Financial Institution</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">98</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">5.25</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Covered Entities</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">98</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VI AFFIRMATIVE COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">98</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Statements</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">98</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certificates&#59; Other Information</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">99</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">101</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Payment of Obligations</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">103</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Preservation of Existence, Etc</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">103</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Maintenance of Properties</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">103</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Maintenance of Insurance</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">103</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Laws</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">104</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Books and Records</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">104</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Inspection Rights</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">104</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Use of Proceeds</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">104</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Material Contracts</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">105</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Covenant to Guarantee Obligations</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">105</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Covenant to Give Security</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">105</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Further Assurances</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">106</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Anti-Corruption Laws&#59; Sanctions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance Programs</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.18</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Condition of Participation in Third Party Payor Programs</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII NEGATIVE COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Liens</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">108</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indebtedness</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">109</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Investments</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">111</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Fundamental Changes</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dispositions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Restricted Payments</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Change in Nature of Business</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">114</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transactions with Affiliates</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">114</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Burdensome Agreements</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">114</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Use of Proceeds</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">115</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Covenants</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">115</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendments of Organization Documents&#59; Fiscal Year&#59; Legal Name, State of Organization&#59; Form of Entity and Accounting Changes</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">115</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sale and Leaseback Transactions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">116</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Prepayments, Etc. of Junior Debt</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">116</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment, Etc. of Indebtedness</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">116</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership of Subsidiaries</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">116</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sanctions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">117</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.18</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Anti-Corruption Laws</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">117</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">7.19</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Specified Entities</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">117</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII EVENTS OF DEFAULT AND REMEDIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">117</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">8.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Events of Default</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">117</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">8.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Remedies upon Event of Default</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">119</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">8.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Application of Funds</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX ADMINISTRATIVE AGENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">121</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Appointment and Authority</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">121</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Rights as a Lender</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">122</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exculpatory Provisions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">122</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reliance by Administrative Agent</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">123</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Delegation of Duties</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">124</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation of Administrative Agent</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">124</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Reliance on Administrative Agent, Arrangers and Other Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">125</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Other Duties, Etc</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">126</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Administrative Agent May File Proofs of Claim&#59; Credit Bidding</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">126</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Collateral and Guaranty Matters</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">127</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Secured Cash Management Agreements and Secured Hedge Agreements</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">128</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ERISA Matters</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">129</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">9.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Recovery of Erroneous Payments</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">130</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article X CONTINUING GUARANTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">130</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Guaranty</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">130</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Rights of Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">130</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Certain Waivers</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">131</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Obligations Independent</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">131</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Subrogation</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">131</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination&#59; Reinstatement</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Stay of Acceleration</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Condition of Borrower</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Appointment of Company</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Right of Contribution</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Keepwell</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">132</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">10.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Guarantor Waivers and Agreements</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">133</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article XI MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">134</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.01</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendments, Etc</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">134</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.02</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices&#59; Effectiveness&#59; Electronic Communications</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">137</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.03</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Waiver&#59; Cumulative Remedies&#59; Enforcement</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">139</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.04</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Expenses&#59; Indemnity&#59; Damage Waiver</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">139</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.05</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Payments Set Aside</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">141</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.06</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Successors and Assigns</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">141</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.07</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Treatment of Certain Information&#59; Confidentiality</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">146</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.08</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Right of Setoff</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">148</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.09</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Interest Rate Limitation</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">148</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.10</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Integration&#59; Effectiveness</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">149</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Survival of Representations and Warranties</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">149</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">149</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Replacement of Lenders</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">149</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law&#59; Jurisdiction&#59; Etc</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">150</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Waiver of Jury Trial</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">151</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Subordination</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">152</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Advisory or Fiduciary Responsibility</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">152</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.18</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Electronic Execution&#59; Electronic Records&#59; Counterparts</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">153</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.19</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">USA PATRIOT Act Notice</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">154</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.20</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Concerning Joint and Several Liability</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">154</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.21</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ENTIRE AGREEMENT</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">155</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.22</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> Acknowledgement and Consent to Bail-In of Affected Financial Institutions</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">156</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.23</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment and Restatement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">156</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">11.24</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Acknowledgement Regarding Any Supported QFCs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#i5691bec2d7554cedbaaa8b01a446339b_115" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">157</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SCHEDULES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.01(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Addresses for Notices</font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.01(b)&#160;&#160;&#160;&#160;Commitments and Applicable Percentages as of the Second Amendment Effective Date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.01(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Existing Letters of Credit</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.01(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Responsible Officers</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Insurance</font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.19(a)&#160;&#160;&#160;&#160;Subsidiaries, Joint Ventures, Partnerships and Other Equity Investments</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.19(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Loan Parties</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.20(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intellectual Property</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.20(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deposit Accounts and Securities Accounts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.20(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Real Properties</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.22&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Health Care Laws</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 7.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens Existing as of the Second Amendment Effective Date</font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 7.02&#160;&#160;&#160;&#160;Indebtedness Existing as of the Second Amendment Effective Date</font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 7.03&#160;&#160;&#160;&#160;Investments Existing as of the Second Amendment Effective Date</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 7.08&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Transactions with Affiliates</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBITS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Assignment and Assumption</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit B&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Compliance Certificate</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Incremental Term Loan Lender Joinder Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit D&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Incremental Term Note</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit E&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Joinder Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit F&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Loan Notice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit G&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Notice of Loan Prepayment</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit H&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Revolving Note</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit I&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Secured Party Designation Notice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit J&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Solvency Certificate</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit K&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Swingline Loan Notice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit L&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Forms of U.S. Tax Compliance Certificates</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit M&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Term Note</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v</font></div><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_115"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This AMENDED AND RESTATED CREDIT AGREEMENT is entered into as of June 29, 2018, among AMEDISYS, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Guarantors (defined herein), the Lenders (defined herein), and BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PRELIMINARY STATEMENTS&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Borrowers, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as administrative agent, swingline lender and letter of credit issuer, have entered into that certain Credit Agreement, dated as of August 28, 2015 (as amended or modified from time to time prior to the Closing Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the parties hereto wish to amend the Existing Credit Agreement to make certain amendments and modifications to the Existing Credit Agreement, subject to the conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.63pt"><br><br>DEFINITIONS AND ACCOUNTING TERMS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this Agreement, the following terms shall have the meanings set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the acquisition, whether through a single transaction or a series of related transactions, of (a) a majority of the Voting Stock or other controlling ownership interest in another Person (including the purchase of an option, warrant or convertible or similar type security to acquire such a controlling interest at the time it becomes exercisable by the holder thereof), whether by purchase of such equity or other ownership interest or upon the exercise of an option or warrant for, or conversion of securities into, such equity or other ownership interest, or (b) assets of another Person which constitute all or substantially all of the assets of such Person or of a division, line of business or other business unit of such Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the purchase consideration for any Permitted Acquisition and all other payments by any Loan Party or any Wholly Owned Subsidiary in exchange for, or as part of, or in connection with, any Permitted Acquisition, whether paid in cash or by exchange of Equity Interests (other than Qualified Capital Stock of the Company (to the extent not constituting a Change of Control)) or of properties or otherwise and whether payable at or prior to the consummation of such Permitted Acquisition or deferred for payment at any future time, whether or not any such future payment is subject to the occurrence of any contingency, and includes any and all payments representing the purchase price and any assumptions of Indebtedness, deferred purchase price, Earn Out Obligations and other agreements to make any payment the amount of which is, or the terms of payment of which are, in any respect subject to or contingent upon the revenues, income, cash flow or profits (or the like) of any Person.  For purposes of determining the aggregate consideration paid for an Acquisition at the time of such Acquisition, the amount of any Earn Out Obligations shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed to be the maximum amount of the earn-out payments in respect thereof as specified in the documents relating to such Acquisition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Secured Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements, and (b) all costs and expenses incurred in connection with enforcement and collection of the foregoing, including the fees, charges and disbursements of counsel, in each case whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Additional Secured Obligations of a Loan Party shall exclude any Excluded Swap Obligations with respect to such Loan Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Bank of America in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent&#8217;s Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Administrative Agent&#8217;s address and, as appropriate, account as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or such other address or account as the Administrative Agent may from time to time notify the Company and the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Questionnaire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Administrative Questionnaire in a form supplied by the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Adverse Proceeding&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any action, suit, proceeding (whether administrative, judicial or otherwise), claim, dispute, prosecution, governmental investigation, audit or arbitration (whether or not purportedly on behalf of the Company or any of its Subsidiaries) at law or in equity, or before or by any Governmental Authority, domestic or foreign (including any claims relating to any Environmental Liability) that is pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries or any property of the Company or any of its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affected Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any EEA Financial Institution, or (b) any UK Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Aggregate Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Commitments of all the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means this Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in the introductory paragraph hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) in respect of the Revolving Facility, with respect to any Revolving Lender at any time, the percentage (carried out to the ninth decimal place) of the Revolving Facility represented by such Revolving Lender&#8217;s Revolving Commitment at such time, subject to adjustment as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (b) in respect of the Term Facility, with respect to any Term Lender at any time, the percentage (carried out to the ninth decimal place) of the Term Facility represented by the outstanding principal amount of such Term Lender&#8217;s Term Loan at such time, and (c) in respect of an Incremental Term Facility, with respect to any Incremental Term Lender at any time, the percentage (carried out to the ninth decimal place) of such Incremental Term Facility represented by the outstanding principal amount of such Incremental Term Lender&#8217;s Incremental Term Loans with respect to such Incremental Term Facility at such time.  If the Commitments of all of the Lenders to make Loans and the obligation of the L&#47;C Issuer to make L&#47;C Credit Extensions have been terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or if the Commitments have expired, then the Applicable Percentage of each Lender in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respect of the applicable Facility shall be determined based on the Applicable Percentage of such Lender in respect of such Facility most recently in effect, giving effect to any subsequent assignments.  The initial Applicable Percentage of each Lender in respect of each Facility is set forth opposite the name of such Lender on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in the Assignment and Assumption pursuant to which such Lender becomes a party hereto or in any documentation executed by such Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to the Incremental Term Loans made pursuant to any Incremental Term Loan Lender Joinder Agreement, the percentage(s) per annum set forth in such Incremental Term Loan Lender Joinder Agreement, and (b) with respect to Revolving Loans, Term Loans, Swingline Loans, Letter of Credit Fees and the Commitment Fee, the following percentages per annum, based upon the Consolidated Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:14.28pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:10.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Pricing Tier</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Consolidated Leverage Ratio</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Commitment Fee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Letter of Credit Fee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Term SOFR Loans and SOFR Daily Floating Rate Loans</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Base Rate Loans</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">I</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#62; 3.00 to 1.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.30%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.75%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.00%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.00%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">II</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 3.00 to 1.0 but &#62; 2.00 to 1.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.25%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.50%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.75%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.75%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">III</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#60; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.00 to 1.0 but &#62; 0.75 to 1.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.20%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.25%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.50%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.50%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">IV</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 0.75 to 1.0</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.15%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.00%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.25%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.25%</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any increase or decrease in the Applicable Rate resulting from a change in the Consolidated Leverage Ratio shall become effective as of the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if a Compliance Certificate is not delivered when due in accordance with such Section, then, upon the request of the Required Lenders, Pricing Tier I shall apply as of the first Business Day after the date on which such Compliance Certificate was required to have been delivered and shall remain in effect until the first Business Day immediately following the date on which such Compliance Certificate is delivered in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, whereupon the Applicable Rate shall be adjusted based upon the calculation of the Consolidated Leverage Ratio contained in such Compliance Certificate.  The Applicable Rate in effect from the Second Amendment Effective Date to the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the fiscal quarter ending September 30, 2021 shall be determined based upon Pricing Tier III.  Notwithstanding anything to the contrary contained in this definition, the determination of the Applicable Rate for any period shall be subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Revolving Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any Revolving Lender at any time, such Revolving Lender&#8217;s Applicable Percentage in respect of the Revolving Facility at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Appropriate Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, (a) with respect to any Facility, a Lender that has a Commitment with respect to such Facility or holds a Loan under such Facility at such time, (b) with respect to the Letter of Credit Sublimit, (i) the L&#47;C Issuer and (ii) if any Letters of Credit have been issued pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Revolving Lenders and (c) with respect to the Swingline Sublimit, (i) the Swingline Lender and (ii) if any Swingline Loans are outstanding pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Revolving Lenders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Arranger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of BofA Securities, Citizens Bank, N.A., Fifth Third Bank, National Association and JPMorgan, in their respective capacities as a joint lead arranger and a joint bookrunner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Assessments&#8221; has the meaning set forth in Section 5.22(g).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and accepted by the Administrative Agent, in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or any other form (including an electronic documentation form generated by use of an electronic platform) approved by the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Attributable Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on any date, (a) in respect of any Capitalized Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, (b) in respect of any Synthetic Lease Obligation of any Person, the capitalized amount of the remaining lease or similar payments under the relevant lease or other applicable agreement or instrument that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease or other agreement or instrument were accounted for as a Capitalized Lease, (c) in respect of any Securitization Transaction of any Person, the outstanding principal amount of such financing, after taking into account reserve accounts and making appropriate adjustments, determined by the Administrative Agent in its reasonable judgment and (d) in respect of any Sale and Leaseback Transaction of any Person, the present value (discounted in accordance with GAAP at the debt rate implied in the applicable lease) of the obligations of the lessee for rental payments during the term of such lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the audited consolidated balance sheet of the Company and its Subsidiaries for the fiscal year ended December 31, 2020, and the related consolidated statements of income or operations, shareholders&#8217; equity and cash flows for such fiscal year of the Company and its Subsidiaries, including the notes thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Availability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period from and including the Closing Date to the earliest of (a) the Revolving Facility Maturity Date, (b) the date of termination of the Revolving Commitments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and (c) the date of termination of the Commitment of each Revolving Lender to make Revolving Loans and of the obligation of the L&#47;C Issuer to make L&#47;C Credit Extensions pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bail-In Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014&#47;59&#47;EU of the European Parliament and of the Council of the European Union, the implementing law, rule, regulation or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bank of America</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Bank of America, N.A. and its successors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means for any day a fluctuating rate of interest per annum equal to the highest of (a) the Federal Funds Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its &#8220;prime rate,&#8221; and (c) Term SOFR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 1.00%, subject to the interest rate floors set forth therein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the Base Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.  The &#8220;prime rate&#8221; is a rate set by Bank of America based upon various factors including Bank of America&#8217;s costs and desired return, general economic conditions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate.  Any change in such prime rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change.  If the Base Rate is being used as an alternate rate of interest pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then the Base Rate shall be the greater of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above and shall be determined without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rate Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Revolving Loan, a Term Loan or an Incremental Term Loan that bears interest based on the Base Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a certification regarding beneficial ownership required by the Beneficial Ownership Regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means 31 C.F.R. &#167; 1010.230.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of (a) an &#8220;employee benefit plan&#8221; (as defined in ERISA) that is subject to Title I of ERISA, (b) a &#8220;plan&#8221; as defined in Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such &#8220;employee benefit plan&#8221; or &#8220;plan&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BHC Act Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of a party means an &#8220;affiliate&#8221; (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to a corporation, the board of directors of the corporation or any committee thereof duly authorized to act on behalf of such board, (b) with respect to a partnership, the Board of Directors of the general partner of the partnership, (c) with respect to a limited liability company, the managing member or members or any controlling committee of managing members thereof or if not member-managed, the managers thereof or any committee of managing members or managers thereof duly authorized to act on behalf of such Persons, and (d) with respect to any other Person, the board or committee of such Person serving a similar function.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BofA Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means BofA Securities, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in the introductory paragraph hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Revolving Borrowing, a Swingline Borrowing, a Term Borrowing, or an Incremental Term Borrowing, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the state where the Administrative Agent&#8217;s Office is located.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Capitalized Leases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all leases that have been or should be, in accordance with GAAP, recorded as capitalized leases.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Collateralize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, to pledge and deposit with or deliver to the Administrative Agent, for the benefit of one or more of the L&#47;C Issuer or Swingline Lender (as applicable) or the Lenders, as collateral for L&#47;C Obligations, the Obligations in respect of Swingline Loans, or obligations of the Revolving Lenders to fund participations in respect of either thereof (as the context may require), (a) cash or deposit account balances, (b) backstop letters of credit entered into on terms, from issuers and in amounts satisfactory to the Administrative Agent and the L&#47;C Issuer, and&#47;or (c) if the Administrative Agent and the L&#47;C Issuer or Swingline Lender shall agree, in their sole discretion, other credit support, in each case, in Dollars and pursuant to documentation in form and substance satisfactory to the Administrative Agent and the L&#47;C Issuer or Swingline Lender (as applicable).  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following types of Investments, to the extent owned by the Company or any of its Subsidiaries free and clear of all Liens (other than Permitted Liens)&#58; (a) marketable direct obligations issued by, or unconditionally guaranteed by, the United States or any agency or instrumentality thereof and backed by the full faith and credit of the United States, in each case maturing within one (1) year from the date of acquisition, (b) certificates of deposit, time deposits, or overnight bank deposits having maturities of six (6) months or less from the date of acquisition issued by any Lender or by any commercial bank organized under the laws of the United States or any state thereof having combined capital and surplus of not less than $500,000,000, (c) commercial paper of an issuer rated at least &#8220;Prime-1&#8221; (or the then equivalent grade) by Moody&#8217;s or at least &#8220;A-1&#8221; (or the then equivalent grade) by S&#38;P, or carrying an equivalent rating by a nationally recognized rating agency, if both of the two named rating agencies cease publishing ratings of commercial paper issuers generally, and maturing within six (6) months from the date of acquisition, (d) repurchase obligations of any Lender or of any commercial bank satisfying the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition, having a term of not more than thirty (30) days, with respect to securities issued or fully guaranteed or insured by the United States government, (e) securities with maturities of one (1) year or less from the date of acquisition issued or fully guaranteed by any state, commonwealth or territory of the United States, by any political subdivision or taxing authority of any such state, commonwealth or territory or by any foreign government, the securities of which state, commonwealth, territory, political subdivision, taxing authority or foreign government (as the case may be) are rated at least &#8220;Prime-1&#8221; (or the then equivalent grade) by Moody&#8217;s or at least &#8220;A-1&#8221; (or the then equivalent grade) by S&#38;P, (f) securities with maturities of six (6) months or less from the date of acquisition backed by standby letters of credit issued by any Lender or any commercial bank satisfying the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition, (g) money market mutual or similar funds that invest exclusively in assets satisfying the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition, or (h) money market funds that (i) comply with the criteria set forth in SEC Rule 2a 7 under the Investment Company Act of 1940, as amended, (ii) are rated AAA by S&#38;P and Aaa by Moody&#8217;s and (iii) have portfolio assets of at least $1,000,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Management Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any agreement that is not prohibited by the terms hereof to provide treasury or cash management services, including deposit accounts, overnight draft, credit cards, debit cards, p-cards (including purchasing cards and commercial cards), funds transfer, automated clearinghouse, zero balance accounts, returned check concentration, controlled disbursement, lockbox, account reconciliation and reporting and trade finance services and other cash management services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Management Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person in its capacity as a party to a Cash Management Agreement that (a) at the time it enters into a Cash Management Agreement with a Loan Party or a Subsidiary, is a Lender or an Affiliate of a Lender, (b) in the case of any Cash Management Agreement in effect on or prior to the Closing Date, is, as of the Closing Date or within thirty (30) days thereafter, a Lender or an Affiliate of a Lender and a party to a Cash Management Agreement with a Loan Party or a Subsidiary, or (c) within thirty (30) days after the time it enters into the applicable Cash Management Agreement with a Loan Party or a Subsidiary, becomes a Lender or an Affiliate of a Lender, in each case, in its capacity as a party to such Cash Management Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for any of the foregoing to be included as a &#8220;Secured Cash Management Agreement&#8221; on any date of determination by the Administrative Agent, the applicable Cash Management Bank (other than the Administrative Agent or an Affiliate of the Administrative Agent) must have delivered a Secured Party Designation Notice to the Administrative Agent prior to such date of determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Person that is a &#8220;controlled foreign corporation&#8221; within the meaning of Section 957 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CFC Holdco</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any direct or indirect Domestic Subsidiary all or substantially all of the assets of which consist of the Equity Interests of one or more CFCs, and (b) any Domestic Subsidiary that is a direct or indirect Subsidiary of a CFC (other than any Domestic Subsidiary that is treated as a C-corporation for U.S. federal income tax purposes or that is owned directly or indirectly by such a C-corporation and the income of which is treated for U.S. federal income tax purposes as income of such C-corporation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the occurrence, after the Closing Date, of any of the following&#58; (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted or issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an event or series of events by which&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to have &#8220;beneficial ownership&#8221; of all securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an &#8220;option right&#8221;)), directly or indirectly, of thirty-five percent (35%) or more of the Equity Interests of the Company entitled to vote for members of the Board of Directors of the Company on a fully-diluted basis (and taking into account all such securities that such &#8220;person&#8221; or &#8220;group&#8221; has the right to acquire pursuant to any option right)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;during any period of twenty-four (24) consecutive months, a majority of the members of the Board of Directors of the Company cease to be composed of individuals (i) who were members of that Board of Directors on the first day of such period, (ii) whose election or nomination to that Board of Directors was approved by individuals referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above constituting at the time of such election or nomination at least a majority of that Board of Directors or (iii) whose election or nomination to that Board of Directors was approved by individuals referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above constituting at the time of such election or nomination at least a majority of that Board of Directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;a change of control (or any similar event, however defined) occurs under any Indebtedness with an aggregate principal amount in excess of the Threshold Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means June 29, 2018.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CME</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means CME Group Benchmark Administration Limited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a collective reference to all real and personal property with respect to which Liens in favor of the Administrative Agent, for the benefit of the Secured Parties, are purported to be granted pursuant to and in accordance with the terms of the Collateral Documents.  Notwithstanding anything in the Loan Documents to the contrary, the term &#8220;Collateral&#8221; shall not include any Excluded Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Security Agreement, the Pledge Agreement, the Mortgages, any Mortgaged Property Support Documents, the Qualifying Control Agreements, each Joinder Agreement, each of the mortgages, collateral assignments, security agreements, pledge agreements or other similar agreements delivered to the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and each of the other agreements, instruments or documents that creates or purports to create a Lien in favor of the Administrative Agent for the benefit of the Secured Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Revolving Commitment, a Term Commitment or an Incremental Term Commitment, as the context may require.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commitment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commodity Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Commodity Exchange Act (7 U.S.C. &#167; 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.), as amended from time to time, and any successor statute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Communication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means this Agreement, any other Loan Document, and any other document, any amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to any Loan Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in the introductory paragraph hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the use, administration of or any conventions associated with SOFR, Term SOFR, the SOFR Daily Floating Rate or any proposed Successor Rate, as applicable, any conforming changes to the definitions of &#8220;Base Rate&#8221;, &#8220;SOFR&#8221;, &#8220;Term SOFR&#8221;, &#8220;SOFR Daily Floating Rate&#8221; and &#8220;Interest Period&#8221;, timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters (including, for the avoidance of doubt, the definitions of &#8220;Business Day&#8221; and &#8220;U.S. Government Securities Business Day&#8221;, timing of borrowing requests or prepayment, conversion or continuation notices and length of lookback periods) as may be appropriate, in the discretion of the Administrative Agent, to reflect the adoption and implementation of such applicable rate(s) and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent determines that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such rate exists, in such other manner of administration as the Administrative Agent determines is reasonably necessary in connection with the administration of this Agreement and any other Loan Document).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information Memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the lender presentation, dated July 8, 2021, relating to the Borrowers and the Facilities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, when used with reference to financial statements or financial statement items of the Company and its Subsidiaries or any other Person, such statements or items on a consolidated basis in accordance with the consolidation principles of GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Cash Interest Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any period, Consolidated Interest Charges for such period, excluding any amount not payable in cash for such period.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Consolidated EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, for any period, for the Company and its Subsidiaries on a Consolidated basis in accordance with GAAP, an amount equal to Consolidated Net Income for such period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (a) the following, without duplication, to the extent deducted in calculating such Consolidated Net Income&#58; (i) Consolidated Interest Charges for such period&#59; (ii) the provision for federal, state, local and foreign income taxes paid or payable for such period&#59; (iii) depreciation and amortization expense for such period&#59; (iv) any non-cash expenses, losses or charges for such period (including any non-cash stock based compensation expense for such period) which do not represent a cash item in such period or any other period&#59; (v) non-recurring cash expenses during such period resulting from restructuring charges and&#47;or Adverse Proceedings (that have been disclosed to the Administrative Agent)&#59; (vi) net losses from discontinued operations for such period&#59; (vii) fees and expenses for such period incurred in connection with any issuance of Qualified Capital Stock of the Company or any Permitted Acquisition&#59; (viii) non-recurring cash costs and expenses for such period incurred in connection with the opening by the Company or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">any of its Subsidiaries of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">de novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> facility used in connection with a Permitted Business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the aggregate amount added-back pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clause (a)(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not exceed an amount equal to five percent (5%) of Consolidated EBITDA for such period (calculated without giving effect to the add back permitted pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clause (a)(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; and (ix) the amount of net &#8220;run rate&#8221; cost savings, operating expense reductions and synergies for such period projected by the Company in good faith to be realized as a result of specified actions which have been taken or which are committed to be taken in connection with Permitted Acquisitions, other Investments permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Dispositions permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, restructurings, cost savings initiatives and other initiatives, in each case, after the Closing Date, net of the amount of actual benefits realized during such period from such actions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (A) in the Compliance Certificate required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> for such period, the Company shall certify that such cost savings, operating expense reductions and synergies (x) are reasonably anticipated to be realized within twelve (12) months after the consummation of such Permitted Acquisition, other Investment permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Disposition permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, restructuring, cost saving initiative or other initiative which is expected to result in such cost savings, operating expense reductions or synergies and (y) are factually supportable as determined in good faith by the Company, (B) no cost savings, operating expense reductions or synergies shall be added pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clause (a)(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to the extent duplicative of any amounts otherwise added to, or included in, Consolidated Net Income, whether through a pro forma adjustment or otherwise, for such period and (C) projected amounts (that are not yet realized) may no longer be added in calculating Consolidated EBITDA pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clause (a)(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to the extent occurring more than four (4) full fiscal quarters after the specified action taken in order to realize such projected cost savings, operating expense reductions or synergies&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the aggregate amount added-back pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not exceed an amount equal to twenty percent (20%) of Consolidated EBITDA for such period (calculated without giving effect to the add backs permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (b) the following, without duplication, to the extent included in calculating such Consolidated Net Income&#58; (i) all non-cash income or gains for such period&#59; (ii) federal, state, local and foreign income tax credits received during such period&#59; and (iii) all net gains from discontinued operations for such period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Funded Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Funded Indebtedness of the Company and its Subsidiaries on a Consolidated basis determined in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Interest Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any period, total interest expense (including that portion attributable to Capitalized Leases and capitalized interest) of the Company and its Subsidiaries on a Consolidated basis in accordance with GAAP with respect to all outstanding Funded Indebtedness of the Company and its Subsidiaries, including all commissions, discounts and other fees and charges owed with respect to letters of credit securing financial obligations, bankers&#8217; acceptances financing and receivables financings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Interest Coverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, for the Company and its Subsidiaries on a Consolidated basis, the ratio of (a) Consolidated EBITDA for the Measurement Period most recently ended on or prior to such date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) Consolidated Cash Interest Charges for the Measurement Period most recently ended on or prior to such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, for the Company and its Subsidiaries on a Consolidated basis, the ratio of (a) the total of (i) Consolidated Funded Indebtedness as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of such date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (ii) Unrestricted Cash as of such date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) Consolidated EBITDA for the Measurement Period most recently ended on or prior to such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any period, the net income (or loss) of the Company and its Subsidiaries on a Consolidated basis for such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Consolidated Net Income shall exclude (a) the income of any Subsidiary of the Company to the extent that the declaration or payment of dividends or similar distributions by that Subsidiary of that income is not at the time permitted by operation of the terms of its Organization Documents or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to that Subsidiary, (b) any aftertax gains or losses attributable to a Disposition permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> outside of the ordinary course of business yielding gross proceeds to the Company and its Subsidiaries in excess of $5,000,000 or returned surplus assets of any Pension Plan, (c) the income of any Person if such Person is not a Subsidiary except to the extent such income is distributed in cash to a Loan Party, (d) the net income attributable to non-controlling interests in Subsidiaries owned by Persons other than the Company and its Subsidiaries and (e) extraordinary items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Contractual Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; have meanings correlative thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following&#58; (a) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b)&#59; (b) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b)&#59; or (c) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of the following&#58; (a) a Borrowing and (b) an L&#47;C Credit Extension.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Daily Simple SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; with respect to any applicable determination date means the SOFR published on such date on the Federal Reserve Bank of New York&#8217;s website (or any successor source).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debt Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the issuance by any Loan Party or any Subsidiary of any Indebtedness other than Indebtedness permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debtor Relief Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Bankruptcy Code of the United States and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to any Obligation for which a rate is specified, a rate per annum equal to two percent (2%) in excess of the rate otherwise applicable thereto and (b) with respect to any Obligation for which a rate is not specified or available, a rate per annum equal to the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Applicable Rate for Revolving Loans that are Base Rate Loans </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> two percent (2%), in each case, to the fullest extent permitted by applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Default Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any Lender that (a) has failed to (i) fund all or any portion of its Loans within two (2) Business Days of the date such Loans were required to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">funded hereunder unless such Lender notifies the Administrative Agent and the Company in writing that such failure is the result of such Lender&#8217;s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, the L&#47;C Issuer, the Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or Swingline Loans) within two (2) Business Days of the date when due, (b) has notified the Company, the Administrative Agent, the L&#47;C Issuer or the Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender&#8217;s obligation to fund a Loan hereunder and states that such position is based on such Lender&#8217;s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) Business Days after written request by the Administrative Agent or the Company, to confirm in writing to the Administrative Agent and the Company that it will comply with its prospective funding obligations hereunder (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such Lender shall cease to be a Defaulting Lender pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> upon receipt of such written confirmation by the Administrative Agent and the Company), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity or (iii) become the subject of a Bail-In Action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender.  Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above, and the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Company, the L&#47;C Issuer, the Swingline Lender and each other Lender promptly following such determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any country or territory to the extent that such country or territory is the subject of any Sanction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the sale, transfer, license, lease or other disposition (including any Sale and Leaseback Transaction) of any property by any Loan Party or any Subsidiary (or the granting of any option or other right to do any of the foregoing), including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith and any issuance of Equity Interests by any Subsidiary, but excluding (a) sales of inventory and dispositions of cash and Cash Equivalents, in each case, in the ordinary course of business, by the Company or any of its Subsidiaries, (b) dispositions of used, worn out, obsolete or surplus property by the Company or any of its Subsidiaries in the ordinary course of business and the abandonment or other disposition of Intellectual Property that is, in the reasonable judgment of the Company, no longer economically practicable to maintain or useful in the conduct of the business of the Company and its Subsidiaries taken as a whole, (c) any sales, assignments, transfers, leases, licenses or other dispositions of property by the Company or any Subsidiary to any Loan Party, (d) the creation of a Lien (but not the sale or other disposition of the property subject to such Lien) permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (e) sales of property to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such sale are promptly applied to the purchase price of such replacement property, (f) any Involuntary Disposition, (g) to the extent constituting Dispositions, Investments permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, fundamental changes permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and Restricted Payments permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (in each case other than by reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">definition (or any clause of either thereof)), (h) issuance of Equity Interests of Subsidiaries to any Loan Party, and (i) any sale, transfer, issuance or other disposition of a de minimis number of shares of the Equity Interests of a Foreign Subsidiary in order to qualify members of the governing body of such Subsidiary if required by applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disqualified Capital Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Equity Interest which, by its terms (or by the terms of any security into which it is convertible or for which it is exchangeable), or upon the happening of any event, (a) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof, in whole or in part, prior to the one hundred eighty-first (181</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day after the Latest Maturity Date, (b) requires the payment of any cash dividends (other than Permitted Tax Distributions) at any time prior to the one hundred eighty-first (181</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day after the Latest Maturity Date, (c) is convertible into or exchangeable (unless at the sole option of the issuer thereof) for (i) debt securities or (ii) any Equity Interests referred to in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above, in each case at any time prior to the one hundred eighty-first (181</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day after the Latest Maturity Date, or (d) contains any repurchase obligation which may come into effect prior to payment in full of all Obligations&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any Equity Interests that would not constitute Disqualified Capital Stock but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests are convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem or repurchase such Equity Interests upon the occurrence of a change in control or an asset sale occurring prior to the one hundred eighty-first (181</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day after the Latest Maturity Date shall not constitute Disqualified Capital Stock if such Equity Interests provide that the issuer thereof will not redeem or repurchase any such Equity Interests pursuant to such provisions prior to the Facility Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean lawful money of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Subsidiary that is organized under the laws of any political subdivision of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earn Out Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to an Acquisition, all obligations of the Company or any Subsidiary to make earn out or other contingency payments (including purchase price adjustments, non-competition and consulting agreements, or other indemnity obligations) pursuant to the documentation relating to such Acquisition.  For purposes of determining the amount of any Earn Out Obligations to be included in the definition of Funded Indebtedness, the amount of Earn Out Obligations shall be deemed to be the aggregate liability in respect thereof, as determined in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition, or (c) any financial institution established in an EEA Member Country which is a Subsidiary of an institution described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition and is subject to consolidated supervision with its parent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EEA Member Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EEA Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to it by 15 USC &#167;7006.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to it by 15 USC &#167;7006.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means fixed or capital assets that are used or useful in a Permitted Business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that meets the requirements to be an assignee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (subject to such consents, if any, as may be required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any &#8220;employee benefit plan&#8221; as defined in Section 3(3) of ERISA which is or was sponsored, maintained or contributed to by, or required to be contributed by, the Company, any of its Subsidiaries or any of their respective ERISA Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Company, any other Loan Party or any of their respective Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law or any Environmental Permit, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any permit, approval, identification number, license or other authorization required under any Environmental Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Employee Retirement Income Security Act of 1974, and any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as applied to any Person, (a) any corporation which is a member of a controlled group of corporations within the meaning of Section 414(b) of the Code of which that Person is a member, (b) any trade or business (whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of Section 414(c) of the Code of which that Person is a member, and (c) any member of an affiliated service group within the meaning of Section 414(m) or (o) of the Code of which that Person, any corporation described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above or any trade or business described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above is a member.  Any former ERISA Affiliate of the Company or any of its shall continue to be considered an ERISA Affiliate of the Company or any such Subsidiary within the meaning of this definition with respect to the period such entity was an ERISA Affiliate of the Company or such Subsidiary and with respect to liabilities arising after such period for which the Company or such Subsidiary could be liable under the Code or ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a &#8220;reportable event&#8221; within the meaning of Section 4043 of ERISA and the regulations issued thereunder with respect to any Pension Plan (excluding those for which the provision for 30day notice to the PBGC has been waived by regulation), (b) the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Pension Plan or the failure to make any required contribution to a Multiemployer Plan under Section 431 of the Code, (c) the provision by the administrator of any Pension Plan pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section 4041(c) of ERISA, (d) the withdrawal by the Company or any of its Subsidiaries or any of their respective ERISA Affiliates from any Pension </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability to the Company, any of its Subsidiaries or any of their respective Affiliates pursuant to Section 4063 or 4064 of ERISA, (e) the institution by the PBGC of proceedings to terminate any Pension Plan, or the occurrence of any event or condition which might constitute grounds under ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan, (f) the imposition of liability on the Company or any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA, (g) the withdrawal of the Company, any of its Subsidiaries or any of their respective ERISA Affiliates in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by the Company, any of its Subsidiaries or any of their respective ERISA Affiliates of notice from any Multiemployer Plan that it intends to terminate or has terminated under Section 4041A or 4042 of ERISA, (h) the occurrence of an act or omission which could give rise to the imposition on the Company, any of its Subsidiaries or any of their respective ERISA Affiliates of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Section 409, Section 502(c), (i) or (1), or Section 4071 of ERISA in respect of any Employee Benefit Plan, (i) the assertion of a material claim (other than routine claims for benefits) against any Employee Benefit Plan other than a Multiemployer Plan or the assets thereof, or against the Company, any of its Subsidiaries or any of their respective ERISA Affiliates in connection with any Employee Benefit Plan, (j) receipt from the IRS of notice of the failure of any Pension Plan (or any other Employee Benefit Plan intended to be qualified under Section 401(a) of the Code) to qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Pension Plan to qualify for exemption from taxation under Section 501(a) of the Code, or (k) the imposition of a Lien pursuant to Section 40l(a)(29) or 412(n) of the Code or pursuant to ERISA with respect to any Pension Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EU Bail-In Legislation Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Deposit and Securities Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) zero balance accounts, (b) payroll accounts, (c) withholding and trust accounts, (d) escrow accounts (to the extent maintained by the Company and its Subsidiaries for the purpose of establishing or maintaining escrow amounts for third parties), (e) employee benefit accounts (including 401(k) accounts and pension fund accounts), (f) deposit and securities accounts not located in the United States or any political subdivision thereof, (g) tax withholding accounts (to the extent maintained by the Company and its Subsidiaries exclusively for the purpose of maintaining or holding tax withholding amounts payable to applicable Governmental Authorities) and (h) any other deposit or securities account the average daily balance of which, together with the aggregate average daily balance of all other deposit accounts and securities accounts excluded pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, does not exceed $100,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Joint Venture Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Equity Interests owned by any Loan Party in any non-Wholly Owned Subsidiary that is not an Immaterial Joint Venture, but only to the extent the granting of a security interest therein by such Loan Party in the manner contemplated by the Loan Documents (a) is prohibited by such non-Wholly Owned Subsidiary&#8217;s Organization Documents and such prohibition (i) existed on the Second Amendment Effective Date or (ii) existed at the time such non-Wholly Owned Subsidiary became a Subsidiary of the Company, so long as (A) the Loan Party attempted in good faith to prevent the inclusion of such prohibition in the non-Wholly Owned Subsidiary&#8217;s Organization Documents if such Organization Documents were adopted or amended (excluding amendments solely to reflect the ownership, name, and capital contribution of the Loan Party) at the time the non-Wholly Owned Subsidiary became a Subsidiary of the Loan Party and (B) the Loan Party did not otherwise include such prohibition in the Organization Documents for the sole purpose of causing the Equity Interests of the non-Wholly Owned Subsidiary to be excluded as Collateral, or (ii) would require the consent of any person or entity (other than any Loan Party or any Subsidiary or Affiliate thereof) and such consent has not been obtained (it being understood and agreed that if such consent is required pursuant to a binding Contractual Obligation, the exclusion set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall only apply to the extent such binding Contractual Obligation (i) existed on the Second Amendment Effective Date or (ii) existed at the time such non-Wholly Owned Subsidiary became a Subsidiary of the Company, so long as, if the Contractual Obligation is entered into in connection with the non-Wholly Owned Subsidiary becoming a Subsidiary, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Loan Party attempted in good faith to prevent the inclusion of such prohibition in the Contractual Obligation and did not otherwise include such prohibition in the Contractual Obligation for the sole purpose of causing the Equity Interests of the non-Wholly Owned Subsidiary to be excluded as Collateral under the Loan Documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in any event, the foregoing shall not exclude the Equity Interests of any Subsidiary that are already subject to a Lien in favor of the Administrative Agent, for the benefit of the Secured Parties, at the time such Organization Documents or other binding Contractual Obligation, as applicable, are entered into by such Loan Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Loan Party, (a)(i) unless requested by the Administrative Agent or the Required Lenders, any owned or leased real property which is located outside of the United States, (ii) any owned real property with a fair market value of less than $5,000,000, and (iii) any leased real property for which the annual rent payments do not exceed $2,500,000, (b) unless requested by the Administrative Agent or the Required Lenders, any personal property (including motor vehicles) in respect of which perfection of a Lien is not either (i) governed by the Uniform Commercial Code or (ii) effected by appropriate evidence of the Lien being filed in either the United States Copyright Office or the United States Patent and Trademark Office, (c) the Equity Interests of any Foreign Subsidiary or CFC Holdco to the extent not required to be pledged to secure the Secured Obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (d) any property which, subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, is subject to a Lien of the type described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> pursuant to documents that prohibit such Loan Party from granting any other Liens in such property, (e) the Excluded Deposit and Securities Accounts, (f) the Equity Interests of any Specified Entity, (g) the Equity Interests of any Immaterial Joint Ventures, (h)(i) that certain 15.3% limited partnership interest owned by the Company in Heritage Healthcare Innovation Fund, LP, (ii) all of the Equity Interests owned by (A) the Company in Alliance Home Health, Inc., (B) the Company in Amedisys PAC, L.L.C. and (C) Amedisys Holding in Amedisys Maine, P.L.L.C., (iii) that certain 22.7% membership interest in Clinically Home, LLC owned by Amedisys Ventures, L.L.C. and (iv) that certain 40% membership interest in Clinically Home of Western New York, LLC owned by TLC Holdings I, L.L.C., (i) Excluded Joint Venture Interests, and (j) any real or personal property as to which the Administrative Agent and the Company agree in writing that the costs or other consequences of obtaining a security interest or perfection thereof are excessive in view of the benefits to be obtained by the Secured Parties therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) each CFC Holdco, (b) each Immaterial Subsidiary, (c) each Subsidiary that is not a Wholly Owned Subsidiary, and (d) each Foreign Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Swap Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Loan Party, any Swap Obligation if, and to the extent that, all or a portion of the Guaranty of such Loan Party of, or the grant by such Loan Party of a Lien to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation thereof) by virtue of such Loan Party&#8217;s failure for any reason to constitute an &#8220;eligible contract participant&#8221; as defined in the Commodity Exchange Act (determined after giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and any other &#8220;keepwell, support or other agreement&#8221; for the benefit of such Loan Party and any and all guarantees of such Loan Party&#8217;s Swap Obligations by other Loan Parties) at the time the Guaranty of such Loan Party, or grant by such Loan Party of a Lien, becomes effective with respect to such Swap Obligation.  If a Swap Obligation arises under a Master Agreement governing more than one Swap Contract, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to Swap Contracts for which such Guaranty or Lien is or becomes excluded in accordance with the first sentence of this definition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following Taxes imposed on or with respect to any Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) or (ii) such Lender changes its Lending Office, except in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">each case to the extent that, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its Lending Office, (c) Taxes attributable to such Recipient&#8217;s failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preliminary Statements hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those certain letters of credit described by issuer, date of issuance, letter of credit number, undrawn amount, name of beneficiary and date of expiry as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Revolving Facility, the Term Facility or an Incremental Term Facility, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Facility Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which all of the following shall have occurred&#58; (a) the Aggregate Commitments have terminated, (b) all Obligations have been paid in full in cash (other than contingent indemnification obligations for which no claim has been asserted), and (c) all Letters of Credit have terminated or expired (other than Letters of Credit as to which other arrangements with respect thereto satisfactory to the Administrative Agent and the L&#47;C Issuer shall have been made).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fair Labor Standards Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means The Fair Labor Standards Act of 1938 (29 U.S.C. &#167; 201 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.), as amended from time to time, and any successor statute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">FASB ASC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Accounting Standards Codification of the Financial Accounting Standards Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Federal Funds Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any day, the rate per annum calculated by the Federal Reserve Bank of New York based on such day&#8217;s federal funds transactions by depository institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the federal funds effective rate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the Federal Funds Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the fee letter agreement, dated July 6, 2021, among the Borrowers, Bank of America and BofA Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Flood Hazard Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Mortgaged Property that is in an area designated by the Federal Emergency Management Agency as having special flood or mudslide hazards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Flood Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, (a) National Flood Insurance Reform Act of 1994 (which comprehensively revised the National Flood Insurance Act of 1968 and the Flood Disaster Protection Act of 1973) as now or hereafter in effect or any successor statute thereto, (b) the Flood Insurance Reform Act of 2004 as now or hereafter in effect or any successor statute thereto, and (c) the Biggert&#8211;Waters Flood Insurance Reform Act of 2012 as now or hereafter in effect or any successor statute thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Lender that is not a U.S. Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Subsidiary that is organized under the laws of a jurisdiction other than the United States, a State thereof or the District of Columbia.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">FRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Board of Governors of the Federal Reserve System of the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fronting Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time there is a Defaulting Lender that is a Revolving Lender, (a) with respect to the L&#47;C Issuer, such Defaulting Lender&#8217;s Applicable Percentage of the outstanding L&#47;C Obligations other than L&#47;C Obligations as to which such Defaulting Lender&#8217;s participation obligation has been reallocated to other Revolving Lenders or Cash Collateralized in accordance with the terms hereof, and (b) with respect to the Swingline Lender, such Defaulting Lender&#8217;s Applicable Percentage of Swingline Loans other than Swingline Loans as to which such Defaulting Lender&#8217;s participation obligation has been reallocated to other Revolving Lenders or Cash Collateralized in accordance with the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Funded Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP (except as expressly provided below)&#58; (a) all obligations, whether current or long-term, for borrowed money (including the Obligations) and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments, (b) all purchase money Indebtedness, (c) the principal portion of all obligations under conditional sale or other title retention agreements relating to property purchased by such Person or any Subsidiary thereof (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business), (d) all obligations arising under letters of credit (including standby and commercial), bankers&#8217; acceptances, bank guaranties, surety bonds and similar instruments, (e) all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business), including any Earn Out Obligations, (f) all Attributable Indebtedness, (g) to the extent constituting a non-contingent, quantifiable liability in accordance with GAAP, (i) all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Permitted Disqualified Capital Stock in such Person or any other Person, and (ii) all payment obligations arising under Guarantees of (A) reasonable indemnity obligations of Subsidiaries in connection with any Disposition of assets by such Subsidiaries permitted under this Agreement or any contribution of assets to a Subsidiary pursuant to an Investment permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or (B) obligations of Subsidiaries under operating leases, (h) all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Disqualified Capital Stock (other than Permitted Disqualified Capital Stock) in such Person or any other Person, valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> accrued and unpaid dividends, (i) all Funded Indebtedness of others secured by (or for which the holder of such Funded Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed, (j) all Guarantees with respect to Funded Indebtedness of the types specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above of another Person, and (k) all Funded Indebtedness of the types referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or joint venturer, except to the extent that such Funded Indebtedness is expressly made non-recourse to such Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Funding Indemnity Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a funding indemnity letter, in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means generally accepted accounting principles in the United States set forth from time to time in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable stature and authority within the accounting profession) including the FASB ASC, that are applicable to the circumstances as of the date of determination, consistently applied and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Governmental Authorization&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any permit, license, certificate of need, approval, agreement, provider number, registration, certificate, filing, consent, authorization, plan, directive, consent order, consent decree or other permission (including any supplements or amendments thereto) of or from any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Governmental Third Party Payor&#8221; has the meaning set forth in Section 5.22(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Governmental Third Party Payor Programs&#8221; has the meaning set forth in Section 5.22(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">primary obligor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the term &#8220;Guarantee&#8221; shall not include endorsements for collection or deposit in the ordinary course of business.  The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as a verb has a corresponding meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, (a) each Person identified as a &#8220;Guarantor&#8221; on the signature pages to the Second Amendment, (b) the Subsidiaries of the Company as are or may from time to time become parties to this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (c) with respect to Additional Secured Obligations owing by any Loan Party and any Swap Obligation of a Specified Loan Party (determined before giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 10.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">10.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) under the Guaranty, each Borrower, and (d) the successors and permitted assigns of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in no event shall an Excluded Subsidiary be a Guarantor (subject to the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, (a) the Guarantee made by the Guarantors under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in favor of the Secured Parties, and (b) each other guaranty delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, natural gas, natural gas liquids, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, toxic mold, infectious or medical wastes and all other substances, wastes, chemicals, pollutants, contaminants or compounds of any nature in any form regulated pursuant to any Environmental Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Health Care Laws&#8221; means, collectively,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (a) any and all federal and state fraud and abuse laws, including the federal AntiKickback Statute (42 U.S.C. &#167; 1320a7b(b)), the Stark Anti-SelfReferral Law (42 U.S.C. &#167; 1395nn), the AntiInducement Law (42 U.S.C. &#167;1320a7a(a)(5)), the Civil False Claims Act (31 U.S.C. &#167;S 3729 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.), the Administrative False Claims Law (42 U.S.C. &#167; 1320a7b(a)), the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exclusion Laws (42 U.S.C. &#167; 1320a-7), the Civil Monetary Penalty Laws (42 U.S.C. &#167; 1320a7a), the regulations promulgated pursuant to such statute and any comparable state laws, (b) HIPAA, (c) Medicare, (d) Medicaid, and (e) any other state or federal law, regulation, guidance document, manual provision, program memorandum, opinion letter, or other issuance which regulates patient or program charges, billing and collections, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care or reimbursement therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Hedge Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person in its capacity as a party to a Swap Contract that, (a) at the time it enters into a Swap Contract with a Loan Party or a Subsidiary that is not prohibited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, is a Lender or an Affiliate of a Lender, (b) in the case of any Swap Contract not prohibited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in effect on or prior to the Closing Date, is, as of the Closing Date or within thirty (30) days thereafter, a Lender or an Affiliate of a Lender and a party to a Swap Contract not prohibited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with a Loan Party or a Subsidiary, or (c) within thirty (30) days after the time it enters into the applicable Swap Contract not prohibited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with a Loan Party or a Subsidiary, becomes a Lender or an Affiliate of a Lender, in each case, in its capacity as a party to such Swap Contract (even if such Person ceases to be a Lender or such Person&#8217;s Affiliate ceased to be a Lender)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in the case of a Secured Hedge Agreement with a Person who is no longer a Lender (or Affiliate of a Lender), such Person shall be considered a Hedge Bank only through the stated termination date (without extension or renewal) of such Secured Hedge Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for any of the foregoing to be included as a &#8220;Secured Hedge Agreement&#8221; on any date of determination by the Administrative Agent, the applicable Hedge Bank (other than the Administrative Agent or an Affiliate of the Administrative Agent) must have delivered a Secured Party Designation Notice to the Administrative Agent prior to such date of determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;HIPAA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.), and any comparable state laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;HIPAA Compliance Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.22(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;HIPAA Compliant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means, to the extent applicable, each of the Company and its Subsidiaries (a) is in material compliance with any and all of the applicable requirements of HIPAA and (b) is not subject to, and would not reasonably be expected to become subject to, any civil or criminal penalty or any investigation, claim or process that would reasonably be expected to cause a Material Adverse Effect in connection with any violation by the Company or any of its Subsidiaries of then effective requirements of HIPAA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">HMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the definition of &#8220;Sanction(s)&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Honor Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means international accounting standards within the meaning of IAS Regulation 1606&#47;2002 to the extent applicable to the relevant financial statements delivered under or referred to herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Immaterial Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date, any non-Wholly Owned Subsidiary </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">designated as such by the Company in writing to the Administrative Agent that as of the last day of the Measurement Period most recently ended for which financial statements have been delivered pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, did not have, together with the Consolidated EBITDA for such Measurement Period attributable to all Immaterial Joint Ventures in the aggregate, Consolidated EBITDA attributable to such non-Wholly Owned Subsidiary in excess of ten percent (10%) of Consolidated EBITDA for such Measurement Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Immaterial Subsidiary</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date, any Wholly Owned Subsidiary designated as such by the Company in writing to the Administrative Agent that&#58; (a) as of the last day of the Measurement Period most recently ended for which financial statements have been delivered pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.01(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, did not have, together with the Consolidated EBITDA for such Measurement Period attributable to all Immaterial Subsidiaries in the aggregate, Consolidated EBITDA attributable to such Wholly Owned Subsidiary in excess of five percent (5%) of Consolidated EBITDA attributable to all Wholly Owned Subsidiaries for such Measurement Period, and (b) as of the last day of the Measurement Period most recently ended for which financial statements have been delivered pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, did not have, together with the Net Revenues for such Measurement Period attributable to all Immaterial Subsidiaries in the aggregate (excluding any contribution to Net Revenues from Subsidiaries that are not Wholly Owned Subsidiaries), Net Revenues attributable to such Wholly Owned Subsidiary in excess of five percent (5%) of Net Revenues attributable to all Wholly Owned Subsidiaries for such Measurement Period (excluding any contribution to Net Revenues from Subsidiaries that are not Wholly Owned Subsidiaries).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Incremental Amount&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means, as of any date of determination, the sum of (a) the total of (i) $200,000,000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (ii) the aggregate amount of increases in the Revolving Facility implemented in reliance on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to such date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (iii) the aggregate principal amount of all Incremental Term Facilities incurred in reliance on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> prior to such date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) an unlimited additional amount so long as the Maximum Leverage Ratio Requirement is satisfied at the time an increase in the Revolving Facility is implemented pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or an Incremental Term Facility is incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable, and after giving effect thereto.  For the avoidance of doubt, any increase in the Revolving Facility implemented pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the incurrence of any Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall, in each case, be deemed to have been implemented or incurred, as applicable, under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above prior to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a borrowing consisting of simultaneous Incremental Term Loans of the same Type and under the same Incremental Term Facility and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Incremental Term Lenders with respect to such Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to each Incremental Term Lender with respect to an Incremental Term Facility, its obligation to make Incremental Term Loans with respect to such Incremental Term Facility pursuant to an Incremental Term Loan Lender Joinder Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, at any time after the funding of an Incremental Term Facility, determination of &#8220;Required Lenders&#8221; shall include the Outstanding Amount of all Incremental Term Loans with respect to such Incremental Term Facility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, with respect to any Incremental Term Loan Lender Joinder Agreement, the aggregate principal amount of all Incremental Term Loans made by Incremental Term Lenders pursuant to such Incremental Term Loan Lender Joinder Agreement that are outstanding at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of the Persons identified as an &#8220;Incremental Term Lender&#8221; in an Incremental Term Loan Lender Joinder Agreement, together with their respective successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an advance made by an Incremental Term Lender under an Incremental Term Facility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Loan Lender Joinder Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a joinder agreement, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, executed and delivered in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Loan Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; with respect to any Incremental Term Facility, shall be as set forth in the applicable Incremental Term Loan Lender Joinder Agreement for such Incremental Term Facility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a promissory note made by the applicable Borrower in favor of an Incremental Term Lender evidencing Incremental Term Loans made by such Incremental Term Lender, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">all Funded Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Swap Termination Value of any Swap Contract&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">all Guarantees with respect to outstanding Indebtedness of the type specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above of any other Person&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all Indebtedness of the types referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person or a Subsidiary thereof is a general partner or joint venturer, unless such Indebtedness is expressly made non-recourse to such Person or such Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Other Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Multiemployer Plan, the condition that such Plan is insolvent within the meaning of Section 4245 of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Insolvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means pertaining to a condition of Insolvency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all trademarks, trademark applications, service marks, trade names, copyrights, copyright applications, patents, patent applications, patent rights, franchises, licenses and other intellectual property rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intercompany Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Indebtedness permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) as to any Term SOFR Loan, the last day of each Interest Period applicable to such Loan and the Maturity Date of the Facility under which such Loan was made&#59; and (b) as to any Base Rate Loan or Swingline Loan, the last Business Day of each March, June, September and December and the Maturity Date of the Facility under which such Loan was made (with Swingline Loans being deemed made under the Revolving Facility for purposes of this definition).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to each Term SOFR Loan, the period commencing on the date such Term SOFR Loan is disbursed or converted to or continued as a Term SOFR Loan and ending on the date one (1) or three (3) months thereafter (in each case, subject to availability), as selected by the applicable Borrower in its Loan Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">no Interest Period shall extend beyond the Maturity Date of the Facility under which such Loan was made.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interim Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the unaudited consolidated financial statements of the Company and its Subsidiaries for the fiscal quarter ended March 31, 2021, including balance sheets and statements of income or operations, shareholders&#8217; equity and cash flows.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of Equity Interests of another Person, (b) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or interest in, another Person (including any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor guaranties Indebtedness of such other Person), or (c) an Acquisition.  For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any loss of, damage to or destruction of, or any condemnation or other taking for public use of, any property of any Loan Party or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ISP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Letter of Credit, the &#8220;International Standby Practices 1998&#8221; published by the Institute of International Banking Law &#38; Practice, Inc. (or such later version thereof as may be in effect at the time of issuance).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Issuer Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any Letter of Credit, the Letter of Credit Application for such Letter of Credit, and any other document, agreement and instrument entered into by the L&#47;C Issuer and the Company (or any Subsidiary) or in favor of the L&#47;C Issuer and relating to such Letter of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joinder Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a joinder agreement substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> executed and delivered in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">JPMorgan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means JPMorgan Chase Bank, N.A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Junior Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Junior Debt Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Latest Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any date of determination, the latest of the Revolving Facility Maturity Date, the Term Facility Maturity Date and the then-latest Incremental Term Loan Maturity Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">L&#47;C Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to each Revolving Lender, such Lender&#8217;s funding of its participation in any L&#47;C Borrowing in accordance with its Applicable Revolving Percentage.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">L&#47;C Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the date when made or refinanced as a Revolving Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">L&#47;C Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Letter of Credit, the issuance thereof or extension of the expiry date thereof, or the increase of the amount thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">L&#47;C Issuer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Bank of America in its capacity as issuer of Letters of Credit hereunder, or any successor issuer of such Letters of Credit hereunder.  Notwithstanding the foregoing, JPMorgan shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be the L&#47;C Issuer with respect to the Existing Letters of Credit identified as issued by JPMorgan on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event there is more than one L&#47;C Issuer at any time, references herein and in the other Loan Documents to the &#8220;L&#47;C Issuer&#8221; shall be deemed to refer to the L&#47;C Issuer in respect of the applicable Letter of Credit, or to all L&#47;C Issuers, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">L&#47;C Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as at any date of determination, the aggregate amount available to be drawn under all outstanding Letters of Credit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the aggregate of all Unreimbursed Amounts (including all L&#47;C Borrowings).  For purposes of computing the amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be &#8220;outstanding&#8221; in the amount so remaining available to be drawn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">LCT Test Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of the Persons identified as a &#8220;Lender&#8221; on the signature pages hereto, each other Person that becomes a &#8220;Lender&#8221; in accordance with this Agreement and, their successors and assigns and, unless the context requires otherwise, includes the Swingline Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lender Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Administrative Agent, each Lender, the Swingline Lender and the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lender Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means each Lender, the Swingline Lender and the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lending Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to the Administrative Agent, the L&#47;C Issuer or any Lender, the office or offices of such Person described as such in such Person&#8217;s Administrative Questionnaire, or such other office or offices as such Person may from time to time notify the Company and the Administrative Agent&#59; which office may include any Affiliate of such Person or any domestic or foreign branch of such Person or such Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any standby letter of credit issued hereunder and shall include the Existing Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the day that is seven (7) days prior to the Revolving Facility Maturity Date (or, if such day is not a Business Day, the next preceding Business Day).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit Sublimit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an amount equal to the lesser of (a) $60,000,000 and (b) the Revolving Facility.  The Letter of Credit Sublimit is part of, and not in addition to, the Revolving Facility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Leverage Increase Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property and any financing lease having substantially the same economic effect as any of the foregoing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limited Condition Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Permitted Acquisition or other Investment permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that is not conditioned on the availability of, or on obtaining, third party financing, or (b) any repayment, redemption, repurchase or other discharge of any Indebtedness requiring irrevocable notice in advance thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an extension of credit by a Lender to a Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in the form of a Revolving Loan, a Term Loan, an Incremental Term Loan or a Swingline Loan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, this Agreement, the Notes, the Guaranty, the Collateral Documents, the Fee Letter, each Issuer Document, each Incremental Term Loan Lender Joinder Agreement, each Joinder Agreement, any agreement creating or perfecting rights in Cash Collateral pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and any other agreement, instrument or documented designated by its terms as a &#8220;Loan Document&#8221; (but specifically excluding any Secured Hedge Agreement and any Secured Cash Management Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Loan Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a notice of (a) a Borrowing (other than a Swingline Borrowing), (b) a conversion of Term SOFR Loans to Base Rate Loans, (c) a conversion of Base Rate Loans to Term SOFR Loans, or (d) a continuation of Term SOFR Loans, in each case pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which shall be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or such other form as may be approved by the Administrative Agent  (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of a Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Loan Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, each Borrower and each Guarantor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Master Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the definition of &#8220;Swap Contract&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a material adverse change in, or a material adverse effect on, the operations, business, assets, properties, liabilities (actual or contingent), condition (financial or otherwise) or prospects of the Loan Parties and their respective Subsidiaries, taken as a whole, (b) a material impairment of the rights and remedies of the Administrative Agent or any Lender under any Loan Document, or of the ability of the Loan Parties, taken as a whole, to perform their respective obligations under any Loan Document, or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against any Loan Party of any Loan Document to which it is a party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, each contract or agreement (a) material to the operations, business, assets, properties, financial condition, performance or prospects of such Person or (b) any other contract, agreement, permit or license, written or oral, of such Person and its Subsidiaries as to which the breach, nonperformance, cancellation or failure to renew by any party thereto, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Revolving Facility Maturity Date, the Term Facility Maturity Date or an Incremental Term Loan Maturity Date, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Maximum Leverage Ratio Requirement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means, with respect to any request pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the requirement that the Company shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate demonstrating that immediately after giving Pro Forma Effect to any increase in the Revolving Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the incurrence of any Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable, and the use of proceeds therefrom, the Consolidated Leverage Ratio is at least 0.50 less than the maximum Consolidated Leverage Ratio then permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (it being understood and agreed that for purposes of calculating such Consolidated Leverage Ratio, the identifiable proceeds of such increase in the Revolving Facility or such Incremental Term Facility shall not qualify as Unrestricted Cash for purposes of the definition of &#8220;Consolidated Leverage Ratio&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for the purpose of calculating the Consolidated Leverage Ratio pursuant to this definition, any such increase in the Revolving Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the incurrence of any such Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), as applicable, shall be deemed to be fully drawn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Measurement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any date of determination, (a) for purposes of determining compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on the last day of any fiscal quarter of the Company, the four (4) fiscal quarters of the Company ending on the last day of such fiscal quarter, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and (b) for all other purposes, the most recently completed four (4) fiscal quarters of the Company for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Medicaid&#8221; means, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">collectively, the healthcare assistance program established by Title XIX of the Social Security Act (42 U.S.C. &#167; 1396 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.) and any statutes succeeding thereto, and all laws, rules, regulations, manuals, orders, guidelines or requirements pertaining to such program, including (a) all federal statutes (whether set forth in Title XIX of the Social Security Act or elsewhere) affecting such program, (b) all state statutes and plans for medical assistance enacted in connection with such program and federal rules and regulations promulgated in connection with such program, and (c) all applicable provisions of all rules, regulations, manuals, orders and administrative, reimbursement, guidelines and requirements of all government authorities promulgated in connection with such program (whether or not having the force of law).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Medicare&#8221; means, c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ollectively, the health insurance program for the aged and disabled established by Title XVIII of the Social Security Act (42 U.S.C. &#167;1395 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.) and any statutes succeeding thereto, and all laws, rules, regulations, manuals, orders or guidelines pertaining to such program, including (a) all federal statutes (whether set forth in Title XVIII of the Social Security Act or elsewhere) affecting such program, and (b) all applicable provisions of all rules, regulations, manuals, orders and administrative, reimbursement, guidelines and requirements of all governmental authorities promulgated in connected with such program (whether or not having the force of law).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Collateral Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, (a) with respect to Cash Collateral consisting of cash or deposit account balances provided to reduce or eliminate Fronting Exposure during any period when a Lender constitutes a Defaulting Lender, an amount equal to one hundred three percent (103%) of the Fronting Exposure of the L&#47;C Issuer with respect to Letters of Credit issued and outstanding at such time, (b) with respect to Cash Collateral consisting of cash or deposit account balances provided in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, an amount equal to one hundred three percent (103%) of the Outstanding Amount of all L&#47;C Obligations, and (c) otherwise, an amount determined by the Administrative Agent and the L&#47;C Issuer in their sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Moody&#8217;s Investors Service, Inc. and any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, individually and collectively, as the context requires, each of the fee or leasehold mortgages, deeds of trust and deeds executed by a Loan Party that purport to grant a Lien to the Administrative Agent (or a trustee for the benefit of the Administrative Agent) for the benefit of the Secured Parties in any Mortgaged Properties, in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgaged Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any owned or leased property of a Loan Party listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.20(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and identified as a &#8220;Mortgaged Property&#8221; thereon and any other owned or leased real property of a Loan Party that is or will become encumbered by a Mortgage in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgaged Property Support Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any real property subject to a Mortgage&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a fully executed and notarized Mortgage encumbering the fee interest and&#47;or leasehold interest of a Loan Party in such real property&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">if requested by the Administrative Agent in its sole discretion, maps or plats of an as-built survey of the sites of such real property certified to the Administrative Agent and the title insurance company issuing the policies referred to in clause (c) of this definition in a manner satisfactory to each of the Administrative Agent and such title insurance company, dated a date satisfactory to each of the Administrative Agent and such title insurance company by an independent professional licensed land surveyor, which maps or plats and the surveys on which they are based shall be sufficient to delete any standard printed survey exception contained in the applicable title policy and be made in accordance with the Minimum Standard Detail Requirements for Land Title Surveys jointly established and adopted by the American Land Title </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Association and the National Society of Professional Surveyors in 2021 with, to the extent required by the Administrative Agent, items 2, 3, 4, 6(a), 6(b), 7(a), 7(b)(1), 7(c), 8, 9, 13, 14, 16, 17, and 18 on Table A thereof completed&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">ALTA mortgagee title insurance policies issued by a title insurance company acceptable to the Administrative Agent with respect to such real property, assuring the Administrative Agent that the Mortgage covering such real property creates a valid and enforceable first priority mortgage lien on such real property, free and clear of all defects and encumbrances except Permitted Liens, which title insurance policies shall otherwise be in form and substance satisfactory to the Administrative Agent and shall include such endorsements as are requested by the Administrative Agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">evidence (provided at least five (5) Business Days prior to such real property becoming a Mortgaged Property) as to (i) whether such real property is a Flood Hazard Property and (ii) if such real property is a Flood Hazard Property, (A) whether the community in which such real property is located is participating in the National Flood Insurance Program, (B) the applicable Loan Party&#8217;s written acknowledgment of receipt of written notification from the Administrative Agent (1) as to the fact that such real property is a Flood Hazard Property and (2) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program and (C) copies of insurance policies or certificates of insurance of the Loan Parties and their respective Subsidiaries evidencing flood insurance satisfactory to the Administrative Agent and otherwise in compliance with Flood Laws and naming the Administrative Agent and its successors and&#47;or assigns as sole loss payee on behalf of the Secured Parties&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">if requested by the Administrative Agent or any Lender, a Phase I (and if requested by the Administrative Agent based on the results of the Phase I, a Phase II) environmental assessment prepared by a firm acceptable to the Administrative Agent and&#47;or an environmental questionnaire and such other environmental diligence items related to such real property as the Administrative Agent shall request&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">if requested by the Administrative Agent in its sole discretion, an opinion of legal counsel to the Loan Party granting the Mortgage on such real property, addressed to the Administrative Agent and each Lender, in form and substance reasonably acceptable to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Plan that is a multiemployer plan as defined in Sections 3(37) and 4001(a)(3) of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Net Cash Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the aggregate cash or Cash Equivalents proceeds received by any Loan Party or any Subsidiary in respect of (a) any Disposition, net of (i) attorneys&#8217; fees, accountants&#8217; fees, investment banking fees, amounts required to be applied to the repayment of Indebtedness secured by a Lien expressly permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on any asset that is the subject of such Disposition (other than any Lien pursuant to a Collateral Document), and other customary fees and expenses incurred by such Loan Party or such Subsidiary in connection with such Disposition, and (ii) taxes paid or reasonably estimated to be payable as a result of such Disposition (after taking into account any available tax credits or deductions and any tax sharing arrangements), (b) any Debt Issuance, net of customary fees, commissions, costs and other expenses incurred in connection therewith, and (c) any Involuntary Disposition, net of (i) all reasonable costs and expenses incurred in connection with the collection of such proceeds, awards or other compensation in respect of such Involuntary Disposition, (ii) amounts required to be applied to the repayment of Indebtedness secured by a Lien expressly permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on any asset that is the subject of such Involuntary Disposition (other than any Lien pursuant to a Collateral Document), and (iii) taxes paid or reasonably estimated to be payable as a result of such Involuntary Disposition (after taking into account any available tax credits or deductions and any tax sharing arrangements).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Net Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any Person, the gross revenues of such Person, net of estimated revenue and contractual adjustments in accordance with such Person&#8217;s revenue recognition policies and in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Consenting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Lender that does not approve any consent, waiver or amendment that (a) requires the approval of all Lenders or all affected Lenders in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (b) has been approved by the Required Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, each Lender that is not a Defaulting Lender at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Revolving Note, a Term Note or an Incremental Term Note, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Loan Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a notice of prepayment with respect to a Loan, which shall be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the applicable Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party arising under any Loan Document or otherwise with respect to any Loan or Letter of Credit and (b) all costs and expenses incurred in connection with enforcement and collection of the foregoing, including the fees, charges and disbursements of counsel, in each case whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof pursuant to any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Obligations of a Loan Party shall exclude any Excluded Swap Obligations with respect to such Loan Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Office of Foreign Assets Control of the United States Department of the Treasury.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Organization Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement or limited liability company agreement (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), and (d) with respect to all entities, any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization (or equivalent or comparable documents with respect to any non-U.S. jurisdiction).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to the Revolving Loans, Term Loans, Incremental Term Loans and Swingline Loans on any date, the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of the Revolving Loans, Term Loans, Incremental Term Loans and Swingline Loans, as the case may be, occurring on such date, and (b) with respect to any L&#47;C Obligations on any date, the aggregate outstanding amount of such L&#47;C Obligations on such date after giving effect to any L&#47;C Credit Extension occurring on such date and any other changes in the aggregate amount of the L&#47;C Obligations as of such date, including as a result of any reimbursements by the Borrowers of Unreimbursed Amounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Pension Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of ERISA (or any successor thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pension Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Employee Benefit Plan, other than a Multiemployer Plan, which is subject to Section 412 of the Code or Section 302 of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Acquisition by a Loan Party or any Wholly Owned Subsidiary (the Person, assets or division, line of business or other business unit of the Person to be acquired in such Acquisition shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (a) the Target of such Acquisition operates a Permitted Business or the assets acquired pursuant to such Acquisition are used or useful in a Permitted Business, (b) the Company shall have delivered to the Administrative Agent (for further distribution to each Lender) a Pro Forma Compliance Certificate demonstrating that, upon giving Pro Forma Effect to such Acquisition, the Loan Parties would be in compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (c) the aggregate Acquisition Consideration for all such Acquisitions of Persons that do not become Guarantors and assets that do not become subject to the security interests created by the Collateral Documents, in the aggregate during the term of this Agreement shall not exceed the greater of (i) $50,000,000 and (ii) an amount equal to fifteen percent (15%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (d) the Target of such Acquisition will become a Loan Party and the assets acquired shall be subject to Liens in favor of the Administrative Agent, in each case in accordance with, and to the extent required by, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (e) no Default or Event of Default shall exist or would result from giving effect to such Acquisition and (f) such Acquisition shall not be a &#8220;hostile&#8221; acquisition and shall have been approved by the Board of Directors and&#47;or the shareholders (or equivalent) of the applicable Loan Party and the Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any business that is, directly or indirectly through a Subsidiary, the same as, or reasonably related, ancillary or complementary to, the business of the Company and its Subsidiaries on the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Disqualified Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Disqualified Capital Stock issued by any non-Wholly Owned Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such Equity Interests would not constitute Disqualified Capital Stock but for provisions thereof requiring such Subsidiary to repurchase such Equity Interests upon the occurrence or non-occurrence of certain specified events.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Refinancing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Indebtedness of any Person, any modification, refinancing, refunding, renewal or extension of such Indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (a) the principal amount thereof does not exceed the sum of (i) the outstanding principal amount of the Indebtedness so modified, refinanced, refunded, renewed or extended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (ii) prepayment premiums paid, and reasonable and customary fees and expenses incurred, in connection with such modification, refinancing, refunding, renewal or extension, (b) such modification, refinancing, refunding, renewal or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">extension has (i) a final maturity date equal to or later than the final maturity date of the Indebtedness being modified, refinanced, refunded, renewed or extended, and (ii) a Weighted Average Life to Maturity equal to or longer than the Weighted Average Life to Maturity of the Indebtedness being modified, refinanced, refunded, renewed or extended, (c) the direct and contingent obligors of such Indebtedness shall not be changed, as a result of or in connection with such modification, refinancing, refunding, renewal or extension, (d) the terms of such Indebtedness shall not be changed in any manner that is materially adverse, taken as a whole, to the Company or any Subsidiary, as applicable, as a result of or in connection with such modification, refinancing, refunding, renewal or extension, (e) if the Indebtedness being modified, refinanced, refunded, renewed or extended is subordinated in right of payment to the Secured Obligations or secured by Liens on the Collateral junior to those created under the Collateral Documents, such modification, refinancing, refunding, renewal or extension is subordinated to the Secured Obligations on terms at least as favorable to the Lenders as those contained in the documentation governing the Indebtedness being so modified, refinanced, refunded, renewed or extended, (f) if the Indebtedness being modified, refinanced, refunded, renewed or extended is unsecured, such modification, refinancing, refunding, renewal or extension shall be unsecured, and (g) at the time of such modification, refinancing, refunding, renewal or extension of such Indebtedness, no Default or Event of Default shall have occurred and be continuing or result therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Tax Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a cash distribution made by a non-Wholly Owned Subsidiary to the holders of its Equity Interests solely in respect of the income tax liabilities attributable to one or more of such holders&#8217; ownership interests (whether direct or indirect) in such non-Wholly Owned Subsidiary, in an aggregate amount not to exceed the amount that is required to be included or recognized by one or more of such holders as income because of one or more of such holders&#8217; direct or indirect ownership of the Equity Interests of such non-Wholly Owned Subsidiary.  The determination of any such holder&#8217;s taxable income for such period shall be reduced by any cumulative taxable loss previously allocated to such holder after the Closing Date and not previously taken into account pursuant to this sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individually identifiable information of any natural Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means at a particular time, any Employee Benefit Plan that is covered by ERISA and in respect of which the Borrowers or an ERISA Affiliate is (or, if such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an &#8220;employer&#8221; as defined in Section 3(5) of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pledge Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the amended and restated pledge agreement, dated as of the Closing Date, executed in favor of the Administrative Agent by each of the Loan Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Private Third Party Payor&#8221; has the meaning set forth in Section 5.22(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Private Third Party Payor Programs&#8221; has the meaning set forth in Section 5.22(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Forma Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Forma Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Forma Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in respect of a Specified Transaction, that such Specified Transaction and the following transactions in connection therewith (to the extent applicable) shall be deemed to have occurred as of the first day of the applicable Measurement Period for the applicable covenant or requirement&#58; (a)(i) with respect to any Specified Disposition, income statement and cash flow statement items (whether positive or negative) attributable to the Person or property disposed of shall be excluded and (ii) with respect to any Acquisition or Investment, income statement and cash flow statement items (whether positive or negative) attributable to the Person or property acquired shall be included to the extent relating to any period applicable in such calculations to the extent (A) such items are not otherwise included in such income statement items for the Company and its Subsidiaries in accordance with GAAP or in accordance with any defined terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (B) such items are supported by financial statements or other information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">satisfactory to the Administrative Agent, (b) any retirement of Indebtedness and (c) any incurrence or assumption of Indebtedness by the Company or any Subsidiary (and if such Indebtedness has a floating or formula rate, such Indebtedness shall have an implied rate of interest for the applicable period for purposes of this definition determined by utilizing the rate which is or would be in effect with respect to such Indebtedness as at the relevant date of determination)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (x) Pro Forma Basis, Pro Forma Compliance and Pro Forma Effect in respect of any Specified Transaction shall be calculated in a reasonable and factually supportable manner and certified by a Responsible Officer of the Company and (y) any such calculation shall be subject to the applicable limitations set forth in the definition of &#8220;Consolidated EBITDA&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Forma Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a certificate of a Responsible Officer of the Company containing reasonably detailed calculations of the Consolidated Leverage Ratio and the Consolidated Interest Coverage Ratio as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> after giving Pro Forma Effect to the applicable Specified Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Public Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">QFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to the term &#8220;qualified financial contract&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">QFC Credit Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Permitted Acquisition for which the aggregate Acquisition Consideration exceeds $100,000,000 or (b) a series of related Permitted Acquisitions in any twelve (12) month period, for which the aggregate Acquisition Consideration for all such Permitted Acquisitions exceeds $100,000,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for any Permitted Acquisition or series of Permitted Acquisitions to qualify as a &#8220;Qualified Acquisition&#8221;, the Administrative Agent shall have received (not fewer than ten (10) Business Days (or such lesser period of time as may be agreed to by the Administrative Agent in its sole discretion) prior to the consummation of such Permitted Acquisition or series of related Permitted Acquisitions) a Qualified Acquisition Election Certificate with respect to such Permitted Acquisition or series of Permitted Acquisitions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Acquisition Election Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a certificate of a Responsible Officer of the Company, in form and substance satisfactory to the Administrative Agent, (a) certifying that the applicable Permitted Acquisition or series of related Permitted Acquisitions meet the criteria set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (as applicable) of the definition of &#8220;Qualified Acquisition&#8221; and (b) notifying the Administrative Agent that the Company has elected to treat such Permitted Acquisition or series of related Permitted Acquisitions as a &#8220;Qualified Acquisition&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Acquisition Pro Forma Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the determinations of the Consolidated Leverage Ratio required in connection with (a) the satisfaction of the Maximum Leverage Ratio Requirement in connection with any increase in the Revolving Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or incurrence of any Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in each case, used to finance a Permitted Acquisition or series of related Permitted Acquisitions that the Company elects to treat as a Qualified Acquisition and (b) the calculation of the amount of Indebtedness permitted to be incurred by the Company and its Subsidiaries pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (to the extent that such Indebtedness is incurred in connection with a Permitted Acquisition or a series of related Permitted Acquisitions that the Company elects to treat as a Qualified Acquisition).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of any Person means any Equity Interests of such Person that are not Disqualified Capital Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified ECP Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, each Loan Party with total assets exceeding $10,000,000 or that qualifies at such time as an &#8220;eligible contract participant&#8221; under the Commodity </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exchange Act and can cause another Person to qualify as an &#8220;eligible contract participant&#8221; at such time under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an agreement, among a Loan Party, a depository institution or securities intermediary and the Administrative Agent, which agreement is in form and substance acceptable to the Administrative Agent and which provides the Administrative Agent with &#8220;control&#8221; (as such term is used in Article 9 of the UCC) over the deposit account(s) or securities account(s) described therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Administrative Agent, any Lender, the L&#47;C Issuer or any other recipient of any payment to be made by or on account of any obligation of any Loan Party hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, such Person&#8217;s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person&#8217;s Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Removal Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reportable Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the events set forth in Section 4043(c) of ERISA, other than those events as to which the thirty (30) day notice period is waived under subsections .27, .28, .29, .30, .31, .32, .34 or .35 of PBGC Reg. &#167;4043.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Request for Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to a Borrowing, conversion or continuation of Incremental Term Loans, Term Loans or Revolving Loans, a Loan Notice, (b) with respect to an L&#47;C Credit Extension, a Letter of Credit Application, and (c) with respect to a Swingline Loan, a Swingline Loan Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, Lenders having Total Credit Exposures representing more than fifty percent (50%) of the Total Credit Exposures of all Lenders at such time.  The Total Credit Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the amount of any participation in any Swingline Loan and Unreimbursed Amounts that such Defaulting Lender has failed to fund that have not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the Swingline Lender or the L&#47;C Issuer, as the case may be, in making such determination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, this definition shall be subject to the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Required Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, Revolving Lenders having Total Revolving Exposures representing more than fifty percent (50%) of the Total Revolving Exposures of all Revolving Lenders at such time.  The Total Revolving Exposure of any Defaulting Lender shall be disregarded in determining Required Revolving Lenders at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the amount of any participation in any Swingline Loan and Unreimbursed Amounts that such Defaulting Lender has failed to fund that have not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the Swingline Lender or the L&#47;C Issuer, as the case may be, in making such determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Rescindable Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.12(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means an EEA Resolution Authority or, with respect to any UK&#160;Financial Institution, a UK Resolution Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the chief executive officer, president, chief financial officer, treasurer, assistant treasurer or controller of a Loan Party, and, solely for purposes of the delivery of incumbency certificates, the secretary or any assistant secretary of a Loan Party, and, solely for purposes of notices given pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, any other officer or employee of the applicable Loan Party so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of the applicable Loan Party designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent.  Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and&#47;or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.  To the extent requested by the Administrative Agent, each Responsible Officer will provide an incumbency certificate and to the extent requested by the Administrative Agent, appropriate authorization documentation, in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any dividend or other distribution, direct or indirect, on account of any shares (or equivalent) of any class of Equity Interests of the Company or any of its Subsidiaries, now or hereafter outstanding, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any shares (or equivalent) of any class of Equity Interests of the Company or any of its Subsidiaries, now or hereafter outstanding, and (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Equity Interests of any Loan Party or any of its Subsidiaries, now or hereafter outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a borrowing consisting of simultaneous Revolving Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Revolving Lenders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to each Revolving Lender, its obligation to (a) make Revolving Loans to the Borrowers pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (b) purchase participations in L&#47;C Obligations, and (c) purchase participations in Swingline Loans, in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite such Lender&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> under the caption &#8220;Revolving Commitment&#8221;, opposite such caption in the Assignment and Assumption pursuant to which such Lender becomes a party hereto or in any documentation executed by such Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement.  The aggregate amount of the Revolving Commitments of all of the Revolving Lenders on the Second Amendment Effective Date is $550,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Lender at any time, the aggregate principal amount at such time of its outstanding Revolving Loans and such Lender&#8217;s participation in L&#47;C Obligations and Swingline Loans at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, the aggregate amount of the Revolving Lenders&#8217; Revolving Commitments at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Facility Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means July 30, 2026&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if such date is not a Business Day, the Revolving Facility Maturity Date shall be the next preceding Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, (a) so long as any Revolving Commitment is in effect, any Lender that has a Revolving Commitment at such time or (b) if the Revolving Commitments have terminated or expired, any Lender that has a Revolving Loan or a participation in L&#47;C Obligations or Swingline Loans at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a promissory note made by the Borrowers in favor of a Revolving Lender evidencing Revolving Loans or Swingline Loans, as the case may be, made by such Revolving Lender, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Standard &#38; Poor&#8217;s Financial Services LLC, a subsidiary of S&#38;P Global Inc., and any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sale and Leaseback Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Loan Party or any Subsidiary, any arrangement, directly or indirectly, with any Person whereby such Loan Party or such Subsidiary shall sell or transfer any property used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold or transferred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sanction(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any sanction administered or enforced by the United States Government (including OFAC), the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">HMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or other relevant sanctions authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Unavailability Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Second Amendment to Amended and Restated Credit Agreement, dated as of the Second Amendment Effective Date, by and among the Borrowers, the Guarantors party thereto, the Lenders party thereto, Bank of America, as Administrative Agent, Swingline Lender and L&#47;C Issuer, and the other L&#47;C Issuers party thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Second Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means July 30, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Cash Management Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Cash Management Agreement between any Loan Party or any Subsidiary and any Cash Management Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Hedge Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any interest rate, currency, foreign exchange, or commodity Swap Contract permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> between any Loan Party or any Subsidiary and any Hedge Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Obligations and all Additional Secured Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Administrative Agent, the Lenders, the L&#47;C Issuer, the Hedge Banks, the Cash Management Banks, each Indemnitee and each co-agent or sub-agent appointed by the Administrative Agent from time to time pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Party Designation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a notice from any Lender or an Affiliate of a Lender substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, including all amendments thereto and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securitization Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any financing transaction or series of financing transactions (including factoring arrangements) pursuant to which such Person or any Subsidiary of such Person may sell, convey or otherwise transfer, or grant a security interest in, accounts, payments, receivables, rights to future lease payments or residuals or similar rights to payment to a special purpose subsidiary or affiliate of such Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the amended and restated security agreement, dated as of the Closing Date, executed in favor of the Administrative Agent by each of the Loan Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York (or a successor administrator). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means, (a) with respect to Daily Simple SOFR, 0.10% (10 basis points), (b) with respect to the SOFR Daily Floating Rate, 0.10% (10 basis points), and (c) with respect to Term SOFR, (i) 0.10% (10 basis points) for an Interest Period of one month&#8217;s duration, and (ii) 0.10% (10 basis points) for an Interest Period of three months&#8217; duration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Daily Floating Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any day, a fluctuating rate of interest, which can change on each Business Day, equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to such day, with a term equivalent to one month beginning on that date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the rate is not published prior to 11&#58;00 a.m. on such determination date then the SOFR Daily Floating Rate means such Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto&#59; in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the SOFR Adjustment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the SOFR Daily Floating Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Daily Floating Rate Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Swingline Loan that bears interest at a rate based on the definition of &#8220;SOFR Daily Floating Rate&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solvency Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a solvency certificate in substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean, with respect to any Person on any date of determination, that on such date (a) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (b) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#8217;s ability to pay such debts and liabilities as they mature, (d) such Person is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person&#8217;s property would constitute an unreasonably small capital, and (e) such Person is able to pay its debts and liabilities, contingent obligations and other commitments as they mature in the ordinary course of business.  The amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that would reasonably be expected to become an actual or matured liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any sale, transfer or other Disposition of all or substantially all of the Equity Interests of any Subsidiary or of any business unit, line of business or division of the Company or any Subsidiary (including the termination of activities constituting a business) or any other sale, transfer or other Disposition that results in a Person ceasing to be a Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, Wentworth Home Care and Hospice, LLC, Portneuf Home Health Care, LLC, Marietta Home Health and Hospice, LLC and Tri Cities Home Health, LLC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Event of Default pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Indebtedness having an aggregate principal amount in excess of $5,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Loan Party that is not then an &#8220;eligible contract participant&#8221; under the Commodity Exchange Act (determined prior to giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Acquisition, any Specified Disposition, any Investment that results in a Person becoming a Subsidiary, in each case, whether by merger, consolidation or otherwise, (b) any incurrence or repayment of Specified Indebtedness or (c) any other event that by the terms of the Loan Documents requires Pro Forma Compliance with a test or covenant, calculation as to Pro Forma Effect with respect to a test or covenant or requires such test or covenant to be calculated on a Pro Forma Basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subordinating Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the shares of Voting Stock is at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person.  Unless otherwise specified, all references herein to a &#8220;Subsidiary&#8221; or to &#8220;Subsidiaries&#8221; shall refer to a Subsidiary or Subsidiaries of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Supported QFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swap Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Master Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including any such obligations or liabilities under any Master Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swap Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any Loan Party any obligation to pay or perform under any agreement, contract or transaction that constitutes a &#8220;swap&#8221; within the meaning of Section 1a(47) of the Commodity Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swap Termination Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a borrowing of a Swingline Loan pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Bank of America, in its capacity as provider of Swingline Loans, or any successor swingline lender hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Loan Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a notice of a Swingline Borrowing pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which shall be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or such other form as approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the applicable Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Sublimit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an amount equal to the lesser of (a) $25,000,000, and (b) the Revolving Facility.  The Swingline Sublimit is part of, and not in addition to, the Revolving Facility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Synthetic Lease Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the monetary obligation of a Person under (a) a so-called synthetic, off-balance sheet or tax retention lease, or (b) an agreement for the use or possession of property (including Sale and Leaseback Transactions), in each case, creating obligations that do not appear on the balance sheet of such Person but which, upon the application of any Debtor Relief Laws to such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in the definition of &#8220;Permitted Acquisition&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a borrowing consisting of simultaneous Term Loans of the same Type and, in the case of Term SOFR Loans, having the same Interest Period made by each of the Term Lenders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to each Term Lender, its obligation to make a Term Loan to the Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite such Term Lender&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> under the caption &#8220;Term Commitment&#8221; or opposite such caption in the Assignment and Assumption pursuant to which such Term Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement.  The aggregate amount of the Term Commitments of all of the Term Lenders on the Second Amendment Effective Date is $450,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, the aggregate principal amount of the Term Loans of all Term Lenders outstanding at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Facility Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means July 30, 2026&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if such date is not a Business Day, the Term Facility Maturity Date shall be the next preceding Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, at any time, any Lender that holds a Term Loan at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a promissory note made by the Company in favor of a Term Lender evidencing the Term Loan made by such Term Lender, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) for any Interest Period with respect to a Term SOFR Loan, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the rate is not published prior to 11&#58;00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto&#59; in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the SOFR Adjustment for such Interest Period&#59; and (b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate with a term of one month commencing that day&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if Term SOFR determined in accordance with either of the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this definition would otherwise be less than zero, Term SOFR shall be deemed zero for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Revolving Loan, a Term Loan or an Incremental Term Loan that bears interest at a rate based on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the definition of &#8220;Term SOFR&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR Screen Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the forward-looking SOFR term rate administered by CME (or any successor administrator satisfactory to the Administrative Agent) and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Governmental Third Party Payor or any Private Third Party Payor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Payor Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Governmental Third Party Payor Program or any Private Third Party Payor Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Threshold Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means $15,000,000.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Credit Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Lender at any time, the unused Commitments, Revolving Exposure, Outstanding Amount of all Term Loans of such Lender and Outstanding Amount of all Incremental Term Loans of such Lender at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Revolving Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Revolving Lender at any time, the unused Revolving Commitment and Revolving Exposure of such Revolving Lender at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Revolving Outstandings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the aggregate Outstanding Amount of all Revolving Loans, Swingline Loans and L&#47;C Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Loan, its character as a Base Rate Loan or a Term SOFR Loan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Uniform Commercial Code as in effect in the State of New York&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">UK Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person subject to IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">UK Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Unreimbursed Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Unrestricted Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, subject to the limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the aggregate amount of unrestricted cash and Cash Equivalents of the Loan Parties as of such date, not to exceed $100,000,000.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Government Securities Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Business Day, except any Business Day on which any of the Securities Industry and Financial Markets Association, the New York Stock Exchange or the Federal Reserve Bank of New York is not open for business because such day is a legal holiday under the federal laws of the United States or the laws of the State of New York, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Loan Party that is organized under the laws of one of the states of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that is a &#8220;United States Person&#8221; as defined in Section 7701(a)(30) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(e)(ii)(B)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, Equity Interests issued by such Person the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such Person, even though the right to so vote has been suspended by the happening of such contingency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted Average Life to Maturity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, when applied to any Indebtedness at any date of determination, the number of years obtained by dividing&#58; (a) the sum of the products obtained by multiplying (i) the amount of each then remaining installment, sinking fund, serial maturity or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">required payments of principal, including payment at final maturity, in respect thereof, by (ii) the number of years (calculated to the nearest one twelfth) that will elapse between such date of determination and the making of such payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) the then outstanding principal amount of such Indebtedness as of such date of determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Wholly Owned Subsidiary</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as to any Person, (a) any corporation one hundred percent (100%) of whose Equity Interests (other than directors&#8217; qualifying shares or Equity Interests that are required to be held by another person in order to satisfy a foreign requirement of Law prescribing an equity owner resident in the local jurisdiction) is at the time owned by such Person and&#47;or one or more Wholly Owned Subsidiaries of such Person and (b) any partnership, association, joint venture, limited liability company or other entity in which such Person and&#47;or one or more Wholly Owned Subsidiaries of such Person have a one hundred percent (100%) equity interest at such time.  Unless otherwise specified, all references herein to a &#8220;Wholly Owned Subsidiary&#8221; or to &#8220;Wholly Owned Subsidiaries&#8221; shall refer to a Wholly Owned Subsidiary or Wholly Owned Subsidiaries of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Write-Down and Conversion Powers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means, (a)&#160;with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b)&#160;with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Other Interpretive Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;  The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221;  Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including the Loan Documents and any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, amended and restated, modified, extended, restated, replaced or supplemented from time to time (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person&#8217;s successors and assigns, (iii) the words &#8220;hereto,&#8221; &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder,&#8221; and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Preliminary Statements, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Preliminary Statements, Exhibits and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory rules, regulations, orders and provisions consolidating, amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified, extended, restated, replaced or supplemented from time to time, and (vi) the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.  Any and all references to &#8220;Borrower&#8221; regardless of whether preceded by the term a, any, each of, all, and&#47;or, or any other similar term shall be deemed to refer, as the context requires, to each and every (and&#47;or any one or all) parties constituting the Borrower, individually and&#47;or in the aggregate.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">In the computation of periods of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including&#59;&#8221; the words &#8220;to&#8221; and &#8220;until&#8221; each mean &#8220;to but excluding&#59;&#8221; and the word &#8220;through&#8221; means &#8220;to and including.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Any reference herein to a merger, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, shall be deemed to apply to a division of or by a limited liability company, or an allocation of assets to a series of a limited liability company (or the unwinding of such a division or allocation), as if it were a merger, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, as applicable, to, of or with a separate Person.  Any division of a limited liability company shall constitute a separate Person hereunder (and each division of any limited liability company that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Accounting Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein.  Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, (i) Indebtedness of the Company and its Subsidiaries shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed to be carried at one hundred percent (100%) of the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC 470-20 on financial liabilities shall be disregarded and (ii) all liability amounts shall be determined excluding any liability relating to any operating lease, all asset amounts shall be determined excluding any right-of-use assets relating to any operating lease, all amortization amounts shall be determined excluding any amortization of a right-of-use asset relating to any operating lease, and all interest amounts shall be determined excluding any deemed interest comprising a portion of fixed rent payable under any operating lease, in each case to the extent that such liability, asset, amortization or interest pertains to an operating lease under which the covenantor or a member of its consolidated group is the lessee and would not have been accounted for as such under GAAP as in effect on December 31, 2015.  Notwithstanding anything contained herein to the contrary, in connection with the incurrence of any Indebtedness by the Company or any Subsidiary thereof, the proceeds of such Indebtedness shall not be counted as Unrestricted Cash in connection with any calculation of the Consolidated Leverage Ratio for purposes of determining the permissibility of the incurrence of such Indebtedness under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Changes in GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If at any time any change in GAAP (including the adoption of IFRS) would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Company or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Company shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Company shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP.  </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Consolidation of Variable Interest Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All references herein to Consolidated financial statements of the Company and its Subsidiaries or to the determination of any amount for the Company and its Subsidiaries on a Consolidated basis or any similar reference shall, in each case, be deemed to include each variable interest entity that the Company is required to consolidate pursuant to FASB ASC 810 as if such variable interest entity were a Subsidiary as defined herein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Pro Forma Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained herein, all calculations of the Consolidated Leverage Ratio (including for purposes of determining the Applicable Rate) and the Consolidated Interest Coverage Ratio </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be made on a Pro Forma Basis with respect to all Specified Transactions occurring during the applicable Measurement Period to which such calculation relates, and&#47;or subsequent to the end of such Measurement Period but not later than the date of such calculation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding the foregoing, when calculating the Consolidated Leverage Ratio and&#47;or the Consolidated Interest Coverage Ratio for purposes of determining (i) compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and&#47;or (ii) the Applicable Rate, any Specified Transaction and any related adjustment contemplated in the definition of Pro Forma Basis that occurred subsequent to the end of the applicable Measurement Period shall not be given Pro Forma Effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Limited Condition Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary herein, to the extent that the terms of this Agreement require (i) compliance with any financial ratio or test (including any Consolidated Leverage Ratio test or any Consolidated Interest Coverage Ratio test), (ii) the absence of a Default or an Event of Default, or (iii) a determination as to whether the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect), in each case in connection with the consummation of a Limited Condition Transaction, the determination of whether the relevant condition is satisfied may be made, at the election of the Company, (A) in the case of a Permitted Acquisition or other Investment, in each case that is a Limited Condition Transaction, upon either (1) the execution of the definitive agreement with respect to such Permitted Acquisition or other Investment, or (2) the consummation of such Permitted Acquisition or other Investment and (B) in the case of any repayment, redemption, repurchase or other discharge of any Indebtedness, in each case that is a Limited Condition Transaction, upon either (1) delivery of notice with respect to such payment, redemption, repurchase or other discharge, or (2) the making of such payment, redemption, repurchase or discharge (the dates referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (A)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(B)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LCT Test Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), after giving effect to the relevant Limited Condition Transaction and related incurrence of Indebtedness, on a Pro Forma Basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding the foregoing, in connection with any Limited Condition Transaction&#58; (w) the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the proviso to the definition of &#8220;Permitted Acquisition&#8221; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the proviso to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be satisfied if (I) no Default or Event of Default shall have occurred and be continuing as of the applicable LCT Test Date, and (II) no Specified Event of Default shall have occurred and be continuing at the time of consummation of such Limited Condition Transaction&#59; (x) if the proceeds of an increase in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Revolving Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are being used to finance such Limited Condition Transaction, then (I) the condition set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)(E)(2)(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be required to be satisfied at the time of closing of the Limited Condition Transaction and funding of such increase but may be subject to customary &#8220;SunGard&#8221; or &#8220;certain funds&#8221; conditionality and the representations and warranties required may be limited to customary &#8220;specified representations&#8221; and such other representations and warranties as may be required by the applicable lenders providing such increase, and (II) the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)(E)(2)(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall, if and to the extent the lenders providing such increase so agree, be satisfied if (x) no Default or Event of Default shall have occurred and be continuing as of the applicable LCT Test Date, and (y) no Specified Event of Default shall have occurred and be continuing at the time of the funding of such increase in connection with the consummation of such Limited Condition Transaction&#59; (y) if the proceeds of an Incremental Term Facility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are being used to finance such Limited Condition Transaction, then (I) the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)(H)(2)(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be required to be satisfied at the time of closing of the Limited Condition Transaction and funding of such Incremental Term Facility but may be subject to customary &#8220;SunGard&#8221; or &#8220;certain funds&#8221; conditionality and the representations and warranties required may be limited to customary &#8220;specified representations&#8221; and such other representations and warranties as may be required by the applicable lenders providing such Incremental Term Facility, and (II) the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)(H)(2)(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall, if and to the extent the lenders providing such Incremental Term Facility so agree, be satisfied if (x) no Default or Event of Default shall have occurred and be continuing as of the applicable LCT Test Date, and (y) no Specified Event of Default shall have occurred and be continuing at the time of the funding of such Incremental Term Facility in connection with the consummation of such Limited Condition Transaction&#59; and (z) such Limited Condition Transaction and the related Indebtedness to be incurred (and any associated Lien) and the use of proceeds thereof (and the consummation of any Permitted Acquisition or Investment) shall be deemed incurred and&#47;or applied at the LCT Test Date (until such time as the Indebtedness is actually incurred or the applicable definitive agreement is terminated without actually consummating the applicable Limited Condition Transaction) and outstanding thereafter for purposes of Pro Forma Compliance (other than for purposes of determining Pro Forma Compliance in connection with the making of any Restricted Payment or the prepayment of any Junior Debt) with any applicable calculation of the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (it being understood and agreed that with respect to any such ratio test or basket to be used to effect a Restricted Payment or a prepayment of Junior Debt, the Company shall demonstrate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance with the applicable test both after giving effect to the applicable Limited Condition Transaction and assuming that such transaction had not occurred).  For the avoidance of doubt, if any of such ratios or amounts for which compliance was determined or tested as of the LCT Test Date are thereafter exceeded as a result of fluctuations in such ratio or amount (including due to fluctuations in Consolidated EBITDA), at or prior to the consummation of the relevant Limited Condition Transaction, such ratios or amounts will not be deemed to have been exceeded as a result of such fluctuations solely for purposes of determining whether the relevant Limited Condition Transaction is permitted to be consummated or taken.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above in connection with the use of the proceeds of an Incremental Term Facility to finance a Limited Condition Transaction (and, in the case of such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, only if and to the extent the lenders providing such Incremental Term Facility so agree as provided in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), it is understood and agreed that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not limit the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to any proposed Credit Extension, in connection with a Limited Condition Transaction or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Rounding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any financial ratios required to be maintained by the Company pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Times of Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Letter of Credit Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to any Letter of Credit that, by its terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">UCC Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Terms defined in the UCC in effect on the Closing Date and not otherwise defined herein shall, unless the context otherwise indicates, have the meanings provided by those definitions.  Subject to the foregoing, the term &#8220;UCC&#8221; refers, as of any date of determination, to the UCC then in effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Interest Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent does not warrant, nor accept responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to any reference rate referred to herein or with respect to any rate (including, for the avoidance of doubt, the selection of such rate and any related spread or other adjustment) that is an alternative or replacement for or successor to any such rate (including any Successor Rate) (or any component of any of the foregoing) or the effect of any of the foregoing, or of any Conforming Changes.  The Administrative Agent and its affiliates or other related entities may engage in transactions or other activities that affect any reference rate referred to herein, or any alternative, successor or replacement rate (including any Successor Rate) (or any component of any of the foregoing) or any related spread or other adjustments thereto, in each case, in a manner adverse to any Loan Party.  The Administrative Agent may select information sources or services in its reasonable discretion to ascertain any reference rate referred to herein or any alternative, successor or replacement rate (including any Successor Rate) (or any component of any of the foregoing), in each case pursuant to the terms of this Agreement, and shall have no liability to any Loan Party, any Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or other action or omission related to or affecting the selection, determination, or calculation of any rate (or component thereof) provided by any such information source or service.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.35pt"><br><br>COMMITMENTS AND CREDIT EXTENSIONS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Revolving Borrowings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions set forth herein, each Revolving Lender severally agrees to make loans (each such loan, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revolving Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Borrowers in Dollars, from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed at any time outstanding the amount of such Lender&#8217;s Revolving Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, after giving effect to any Revolving Borrowing, (i) the Total Revolving Outstandings shall not exceed the Revolving Facility, and (ii) the Revolving Exposure of any Lender shall not exceed such Revolving Lender&#8217;s Revolving Commitment.  Within the limits of each Revolving Lender&#8217;s Revolving Commitment, and subject to the other terms and conditions hereof, the Borrowers may borrow Revolving Loans, prepay under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and reborrow under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Revolving Loans may be Base Rate Loans or Term SOFR Loans, as further provided herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any Revolving Borrowings made on the Closing Date or any of the three (3) Business Days following the Closing Date shall be made as Base Rate Loans unless the applicable Borrower delivers a Funding Indemnity Letter not less than three (3) Business Days prior to the date of such Revolving Borrowing.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Incremental Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, on the effective date of any Incremental Term Loan Lender Joinder Agreement, each Incremental Term Lender party to such Incremental Term Loan Lender Joinder Agreement severally agrees to make a term loan in a single advance to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable Borrower in the amount of its respective Incremental Term Commitment with respect to such Incremental Term Facility as set forth in such Incremental Term Loan Lender Joinder Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, after giving effect to such advances, the Outstanding Amount of such Incremental Term Loans shall not exceed the aggregate amount of the Incremental Term Commitments set forth in the applicable Incremental Term Loan Lender Joinder Agreement of the applicable Incremental Term Lenders.  Each Incremental Term Borrowing shall consist of Incremental Term Loans made simultaneously by the Incremental Term Lenders in accordance with their respective Applicable Percentage of the applicable Incremental Term Facility.  Incremental Term Borrowings prepaid or repaid may not be reborrowed.  Incremental Term Loans may be Base Rate Loans or Term SOFR Loans, as further provided herein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Term Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions set forth herein, each Term Lender severally agrees to make a single loan (each such loan, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Company, in Dollars, on the Second Amendment Effective Date in an aggregate amount not to exceed such Term Lender&#8217;s Term Commitment.  Each Term Lender shall make its Term Loan to the Company by (i) continuing its term loan outstanding under this Agreement immediately prior to the Second Amendment Effective Date, and&#47;or (ii) advancing additional amounts constituting its Term Loan (or any portion thereof) on the Second Amendment Effective Date.  The Term Borrowing shall consist of Term Loans made simultaneously by the Term Lenders in accordance with their respective Term Commitments.  Term Borrowings repaid or prepaid may not be reborrowed.  Term Loans may be Base Rate Loans or Term SOFR Loans, as further provided herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Term Borrowing made on the Second Amendment Effective Date shall consist of Base Rate Loans unless the Company delivers a Funding Indemnity Letter not less than three (3) Business Days prior to the Second Amendment Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Borrowings, Conversions and Continuations of Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Borrowing, each conversion of Loans from one Type to the other, and each continuation of Term SOFR Loans shall be made upon the applicable Borrower&#8217;s irrevocable notice to the Administrative Agent, which may be given by&#58; (i) telephone or (ii) a Loan Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a Loan Notice.  Each such Loan Notice must be received by the Administrative Agent not later than 11&#58;00 a.m. (A) two (2) Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Term SOFR Loans or of any conversion of Term SOFR Loans to Base Rate Loans, and (B) on the requested date of any Borrowing of Base Rate Loans.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Borrowing of, conversion to or continuation of Term SOFR Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000 in excess thereof (or, (x) in connection with any conversion or continuation of Term Loans or Incremental Term Loans, if less, the entire principal thereof then outstanding and (y) if the aggregate Revolving Commitments as of the applicable date are less than $1,000,000, the aggregate amount of the aggregate Revolving Commitments as of such date).  Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Borrowing of or conversion to Base Rate Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof (or, (x) in connection with any conversion or continuation of Term Loans or Incremental Term Loans, if less, the entire principal thereof then outstanding and (y) if the aggregate Revolving Commitments as of the applicable date are less than $500,000, the aggregate amount of the aggregate Revolving Commitments as of such date).  Each Loan Notice and each telephonic notice shall specify (I) the applicable Borrower, (II) the applicable Facility and whether such Borrower is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of Loans, as the case may be, under such Facility, (III) the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (IV) the principal amount of Loans to be borrowed, converted or continued, (V) the Type of Loans to be borrowed or to which existing Loans are to be converted, and (VI) if applicable, the duration of the Interest Period with respect thereto.  If the applicable Borrower fails to specify a Type of Loan in a Loan Notice or if the applicable Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans.  Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Term SOFR Loans.  If the applicable Borrower requests a Borrowing of, conversion to, or continuation of Term SOFR Loans in any such Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one (1) month.  Notwithstanding anything to the contrary herein, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to Swingline Borrowings or Swingline Loans.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following receipt of a Loan Notice for a Facility, the Administrative Agent shall promptly notify each Appropriate Lender of the amount of its Applicable Percentage under such Facility of the applicable Loans, and if no timely notice of a conversion or continuation is provided by the applicable Borrower, the Administrative Agent shall notify each Appropriate Lender of the details of any automatic conversion to Base Rate Loans described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the case of a Borrowing, each Appropriate Lender shall make the amount of its Loan available to the Administrative Agent in immediately available funds at the Administrative Agent&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Office not later than 1&#58;00 p.m. on the Business Day specified in the applicable Loan Notice.  Upon satisfaction of the applicable conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (and, with respect to the Term Borrowing to be made on the Second Amendment Effective Date, Section 3 of the Second Amendment), the Administrative Agent shall make all funds so received available to the applicable Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the applicable Borrower on the books of Bank of America with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the applicable Borrower&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if, on the date a Loan Notice with respect to a Revolving Borrowing is given by any Borrower, there are L&#47;C Borrowings outstanding, then the proceeds of such Revolving Borrowing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall be applied to the payment in full of any such L&#47;C Borrowings, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall be made available to the applicable Borrower as provided above.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Term SOFR Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided herein, a Term SOFR Loan may be continued or converted only on the last day of an Interest Period for such Term SOFR Loan.  During the existence of a Default, no Loans may be requested as, converted to or continued as Term SOFR Loans without the consent of the Required Lenders, and the Required Lenders may demand that any or all of the outstanding Term SOFR Loans be converted immediately to Base Rate Loans.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Interest Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each determination of an interest rate by the Administrative Agent pursuant to any provision of this Agreement shall be conclusive and binding on the applicable Borrower and the Lenders in the absence of manifest error.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Interest Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After giving effect to all Revolving Borrowings, all conversions of Revolving Loans from one Type to the other, and all continuations of Revolving Loans as the same Type, there shall not be more than ten (10) Interest Periods in effect in respect of the Revolving Facility.  After giving effect to the Term Borrowing, all conversions of Term Loans from one Type to the other, and all continuations of Term Loans as the same Type, there shall not be more than five (5) Interest Periods in effect in respect of the Term Facility.  With respect to each Incremental Term Facility, after giving effect to all Incremental Term Borrowings, all conversions of Incremental Term Loans from one Type to the other, and all continuations of Incremental Term Loans as the same Type, there shall not be more than five (5) Interest Periods in effect in respect of such Incremental Term Facility.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Cashless Settlement Mechanism</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Agreement, any Lender may exchange, continue or rollover all or any portion of its Loans in connection with any refinancing, extension, loan modification </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or similar transaction permitted by the terms of this Agreement, pursuant to a cashless settlement mechanism approved by the Company, the Administrative Agent and such Lender.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Increase in Revolving Facility&#59; Incremental Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers may at any time and from time to time, upon prior written notice by the Company to the Administrative Agent, increase the Revolving Facility (but not the Letter of Credit Sublimit or the Swingline Sublimit) and&#47;or establish one or more Incremental Term Facilities, by a maximum aggregate amount not to exceed the Incremental Amount, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Increase in Revolving Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers may, at any time and from time to time, upon prior written notice by the Company to the Administrative Agent, increase the Revolving Facility (but not the Letter of Credit Sublimit or the Swingline Sublimit) with additional Revolving Commitments from any Revolving Lender or new Revolving Commitments from any other Person selected by the Borrowers and acceptable to the Administrative Agent, the Swingline Lender and the L&#47;C Issuer (so long as such Persons are not Affiliates of the Company and would be permitted at such time by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to become assignees hereunder)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">any such increase shall be in a minimum principal amount of $5,000,000 and in integral multiples of $1,000,000 in excess thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">no Default or Event of Default shall exist and be continuing at the time of any such increase&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">no existing Lender shall be under any obligation to increase its Revolving Commitment and any such decision whether to increase its Revolving Commitment shall be in such Lender&#8217;s sole and absolute discretion&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">(1) any new Lender shall join this Agreement by executing such joinder documents as are required by the Administrative Agent and&#47;or (2) any existing Lender electing to increase its Revolving Commitment shall have executed a commitment agreement satisfactory to the Administrative Agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.69pt">as a condition precedent to such increase, the Company shall have delivered to the Administrative Agent a certificate of each Loan Party dated as of the date of such increase (in sufficient copies for each Lender) signed by a Responsible Officer of each such Loan Party (1) certifying and attaching the resolutions adopted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by such Loan Party approving or consenting to such increase, and (2) in the case of the Borrowers, certifying that, before and after giving effect to such increase, (x) the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the other Loan Documents are true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date of such increase, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsections (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to refer to the most recent statements furnished pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (y) no Default or Event of Default exists&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.35pt">a Responsible Officer of the Company shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate demonstrating that, upon giving Pro Forma Effect to such increase in the Revolving Facility (and assuming for such calculation that such increase is fully drawn), the Loan Parties would be in compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (it being understood and agreed that for purposes of calculating such Consolidated Leverage Ratio, the identifiable proceeds of such increase in the Revolving Facility shall not qualify as Unrestricted Cash for purposes of the definition of &#8220;Consolidated Leverage Ratio&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to the calculation referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, solely in connection with any increase in the Revolving Facility incurred to fund a Qualified Acquisition, the Consolidated Leverage Ratio test level set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to be 4.00 to 1.0&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed revised to include any increase in the Revolving Facility </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to include thereon any Person that becomes a Lender pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the Administrative Agent shall have received such amendments to the Collateral Documents as the Administrative Agent reasonably requests to cause the Collateral Documents to secure the Secured Obligations after giving effect to such increase in the Revolving Facility.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon each increase to the Revolving Facility pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Revolving Lender immediately prior to such increase will automatically and without further act be deemed to have assigned to each Lender providing a portion of such increase and each such increasing Lender will automatically and without further act be deemed to have assumed, a portion of such Revolving Lender&#8217;s participations hereunder in outstanding Letters of Credit and Swingline Loans such that, after giving effect to each such deemed assignment and assumption of participations, the percentage of the aggregate outstanding participations hereunder in such Letters of Credit and&#47;or Swingline Loans held by each Revolving Lender (including each such increasing Lender), as applicable, will equal such Revolving Lender&#8217;s Applicable Revolving Percentage of the aggregate outstanding L&#47;C Obligations and Swingline Loans.  Additionally, if any Revolving Loans are outstanding at the time any increase to the Revolving Facility is effected pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the applicable Revolving Lenders immediately after effectiveness of such increase to the Revolving Facility shall purchase and assign at par such amounts of the Revolving Loans outstanding at such time as the Administrative Agent may require such that each Revolving Lender holds its Applicable Revolving Percentage of all Revolving Loans outstanding immediately after giving effect to all such assignments.  The Administrative Agent and the Lenders hereby agree that the minimum borrowing, pro rata borrowing and pro rata payment requirements contained elsewhere in this Agreement shall not apply to the transactions effected pursuant to the immediately preceding sentence.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Institution of Incremental Term Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers may, at any time, upon prior written notice to the Administrative Agent, institute an Incremental Term Facility&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the Borrowers (in consultation and coordination with the Administrative Agent) shall obtain commitments for the amount of such Incremental Term Facility from existing Lenders or other Persons acceptable to the Administrative Agent (so long as such Persons are not Affiliates of the Company and would be permitted at such time by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to become assignees hereunder), which Lenders shall join in this Agreement as Incremental Term Lenders by executing an Incremental Term Loan Lender Joinder Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">no existing Lender shall be under any obligation to become an Incremental Term Lender and any such decision whether to become an Incremental Term Lender shall be in such Lender&#8217;s sole and absolute discretion&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">such Incremental Term Facility shall be in a minimum aggregate principal amount of $5,000,000 and integral multiples of $1,000,000 in excess thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">no Default or Event of Default shall exist and be continuing at the time of any such increase&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.69pt">the Incremental Term Loan Maturity Date for such Incremental Term Facility shall be as set forth in the Incremental Term Loan Lender Joinder Agreement relating to such Incremental Term Facility&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such date shall not be earlier than the then-Latest Maturity Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.35pt">the scheduled principal amortization payments under such Incremental Term Facility shall be as set forth in the Incremental Term Loan Lender Joinder Agreement relating to such Incremental Term Facility&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Weighted Average Life to Maturity of the Incremental Term Loans made under such Incremental Term Facility shall not be shorter than the then-remaining Weighted Average Life to Maturity of the Term Loans or any Incremental Term Loans under any then-existing Incremental Term Facility&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">all other terms of such Incremental Term Facility (other than as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.02(g)(ii)(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above) shall be reasonably satisfactory to the Administrative Agent (it being understood and agreed that the following shall be reasonably satisfactory to the Administrative Agent&#58; (x) covenants or other provisions applicable only to periods after the then-Latest Maturity Date, (y) covenants or other provisions that are added for the benefit of the Administrative Agent and the Lenders under this Agreement and the other Loan Documents, and (z) to the extent required by the lenders providing such Incremental Term Facility, customary &#8220;most-favored-nation&#8221; protection, call protection, and mandatory prepayments (including an excess cash flow prepayment), in each case, which may be applicable solely with respect to such Incremental Term Facility (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent any mandatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prepayment required in connection with the establishment of an Incremental Term Facility, such mandatory prepayment shall be applied ratably to the Term Loans and all then-existing Incremental Term Loans))&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">as a condition precedent to such institution, the Company shall have delivered to the Administrative Agent a certificate of each Loan Party dated as of the date of such institution (in sufficient copies for each Lender) signed by a Responsible Officer of each such Loan Party (1) certifying and attaching the resolutions adopted by such Loan Party approving or consenting to such institution, and (2) in the case of the Borrowers, certifying that, before and after giving effect to such institution, (x) the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the other Loan Documents are true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date of such institution, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsections (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to refer to the most recent statements furnished pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (y) no Default or Event of Default exists&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.03pt">a Responsible Officer of the Company shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate demonstrating that, upon giving Pro Forma Effect to such Incremental Term Facility, the Loan Parties would be in compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (it being understood and agreed that for purposes of calculating such Consolidated Leverage Ratio, the identifiable proceeds of such Incremental Term Facility </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not qualify as Unrestricted Cash for the purposes of the definition of &#8220;Consolidated Leverage Ratio&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to the calculation referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, solely in connection with any Incremental Term Facility incurred to fund a Qualified Acquisition, the Consolidated Leverage Ratio test level set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to be 4.00 to 1.0&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(J)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.36pt;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed revised to include such Incremental Term Facility pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to include thereon any Person that becomes an Incremental Term Lender pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(K)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the Administrative Agent shall have received such amendments to the Collateral Documents as the Administrative Agent reasonably requests to cause the Collateral Documents to secure the Secured Obligations after giving effect to such Incremental Term Facility.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.8pt;text-decoration:underline">The Letter of Credit Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Subject to the terms and conditions set forth herein, (A) the L&#47;C Issuer agrees, in reliance upon the agreements of the Revolving Lenders set forth in this Section, (1) from time to time on any Business Day during the period from the Closing Date until the Letter of Credit Expiration Date, to issue Letters of Credit in Dollars for the account of the Company or any of its Subsidiaries, and to amend Letters of Credit previously issued by it, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (2) to honor drawings under the Letters of Credit&#59; and (B) the Revolving Lenders severally agree to participate in Letters of Credit issued for the account of the Company or its Subsidiaries and any drawings thereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, after giving effect to any L&#47;C Credit Extension with respect to any Letter of Credit, (x) the Total Revolving Outstandings shall not exceed the Revolving Facility, (y) the Revolving Exposure of any Revolving Lender shall not exceed such Revolving Lender&#8217;s Revolving Commitment, and (z) the Outstanding Amount of the L&#47;C Obligations shall not exceed the Letter of Credit Sublimit.  Each request by the Company for the issuance or amendment of a Letter of Credit shall be deemed to be a representation by the Company that the L&#47;C Credit Extension so requested complies with the conditions set forth in the proviso to the preceding sentence.  Within the foregoing limits, and subject to the terms and conditions hereof, the Company&#8217;s ability to obtain Letters of Credit shall be fully revolving, and accordingly the Company may, during the foregoing period, obtain Letters of Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed.  All Existing Letters of Credit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be deemed to have been issued pursuant hereto and deemed L&#47;C Obligations, and from and after the Closing Date shall be subject to and governed by the terms and conditions hereof.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">The L&#47;C Issuer shall not issue any Letter of Credit if&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the expiry date of the requested Letter of Credit would occur more than twelve (12) months after the date of issuance, unless the Required Revolving Lenders have approved such expiry date&#59; or</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">the expiry date of the requested Letter of Credit would occur after the Letter of Credit Expiration Date, unless all the Revolving Lenders have approved such expiry date.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">The L&#47;C Issuer shall not be under any obligation to issue any Letter of Credit if&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain the L&#47;C Issuer from issuing the Letter of Credit, or any Law applicable to the L&#47;C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the L&#47;C Issuer shall prohibit, or request that the L&#47;C Issuer refrain from, the issuance of letters of credit generally or the Letter of Credit in particular or shall impose upon the L&#47;C Issuer with respect to the Letter of Credit any restriction, reserve or capital requirement (for which the L&#47;C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon the L&#47;C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date and which the L&#47;C Issuer in good faith deems material to it&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">the issuance of the Letter of Credit would violate one or more policies of the L&#47;C Issuer applicable to letters of credit generally&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">except as otherwise agreed by the Administrative Agent and the L&#47;C Issuer, the Letter of Credit is in an initial stated amount less than $500,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the Letter of Credit is to be denominated in a currency other than Dollars&#59;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.69pt">any Revolving Lender is at that time a Defaulting Lender, unless the L&#47;C Issuer has entered into arrangements, including the delivery of Cash Collateral, satisfactory to the L&#47;C Issuer (in its sole discretion) with the Company or such Revolving Lender to eliminate the L&#47;C Issuer&#8217;s actual or potential Fronting Exposure (after giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) with respect to the Defaulting Lender arising </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L&#47;C Obligations as to which the L&#47;C Issuer has actual or potential Fronting Exposure, as it may elect in its sole discretion&#59; or</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.35pt">the Letter of Credit contains any provisions for automatic reinstatement of the stated amount after any drawing thereunder.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">The L&#47;C Issuer shall not amend any Letter of Credit if the L&#47;C Issuer would not be permitted at such time to issue the Letter of Credit in its amended form under the terms hereof.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">The L&#47;C Issuer shall be under no obligation to amend any Letter of Credit if (A) the L&#47;C Issuer would have no obligation at such time to issue such Letter of Credit in its amended form under the terms hereof, or (B) the beneficiary of such Letter of Credit does not accept the proposed amendment to the Letter of Credit.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">The L&#47;C Issuer shall act on behalf of the Revolving Lenders with respect to any Letters of Credit issued by it and the documents associated therewith, and the L&#47;C Issuer shall have all of the benefits and immunities (A) provided to the Administrative Agent in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to any acts taken or omissions suffered by the L&#47;C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and Issuer Documents pertaining to such Letters of Credit as fully as if the term &#8220;Administrative Agent&#8221; as used in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> included the L&#47;C Issuer with respect to such acts or omissions, and (B) as additionally provided herein with respect to the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.18pt;text-decoration:underline">Procedures for Issuance and Amendment of Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the Company delivered to the L&#47;C Issuer (with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Responsible Officer of the Company.  Such Letter of Credit Application may be sent by fax transmission, by United States mail, by overnight courier, by electronic transmission using the system provided by the L&#47;C Issuer, by personal delivery or by any other means acceptable to the L&#47;C Issuer.  Such Letter of Credit Application must be received by the L&#47;C Issuer and the Administrative Agent not later than 11&#58;00 a.m. at least two (2) Business Days (or such later date and time as the Administrative Agent and the L&#47;C Issuer may agree in a particular instance in their sole discretion) prior to the proposed issuance date or date of amendment, as the case may be.  In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L&#47;C Issuer&#58; (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day)&#59; (B) the amount thereof&#59; (C) the expiry date thereof&#59; (D) the name and address of the beneficiary thereof&#59; (E) the documents to be presented by such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beneficiary in case of any drawing thereunder&#59; (F)&#160;the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder&#59; (G) the purpose and nature of the requested Letter of Credit&#59; and (H) such other matters as the L&#47;C Issuer may reasonably require.  In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L&#47;C Issuer&#58; (1) the Letter of Credit to be amended&#59; (2) the proposed date of amendment thereof (which shall be a Business Day)&#59; (3) the nature of the proposed amendment&#59; and (4) such other matters as the L&#47;C Issuer may reasonably require.  Additionally, the Company shall furnish to the L&#47;C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as the L&#47;C Issuer or the Administrative Agent may require.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Promptly after receipt of any Letter of Credit Application, the L&#47;C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the Company and, if not, the L&#47;C Issuer will provide the Administrative Agent with a copy thereof.  Unless the L&#47;C Issuer has received written notice from any Revolving Lender, the Administrative Agent or any Loan Party, at least one (1) Business Day prior to the requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not then be satisfied, then, subject to the terms and conditions hereof, the L&#47;C Issuer shall, on the requested date, issue a Letter of Credit for the account of the Company (or the applicable Subsidiary) or enter into the applicable amendment, as the case may be, in each case in accordance with the L&#47;C Issuer&#8217;s usual and customary business practices.  Immediately upon the issuance of each Letter of Credit, each Revolving Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the L&#47;C Issuer a risk participation in such Letter of Credit in an amount equal to the product of such Revolving Lender&#8217;s Applicable Revolving Percentage times the amount of such Letter of Credit.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the L&#47;C Issuer will also deliver to the Company and the Administrative Agent a true and complete copy of such Letter of Credit or amendment.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.8pt;text-decoration:underline">Drawings and Reimbursements&#59; Funding of Participations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the L&#47;C Issuer shall promptly notify the Company and the Administrative Agent thereof.  Not later than 2&#58;00 p.m. (x) on the date of any payment by the L&#47;C Issuer under a Letter of Credit, if the Company received notice of such drawing prior to 11&#58;00 a.m., on such date or (y) otherwise on the Business Day immediately following receipt by the Company of such notice (each such date, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Honor Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company shall reimburse the L&#47;C Issuer through the Administrative Agent in an amount equal to the amount of such drawing.  If the Company fails to so reimburse the L&#47;C Issuer by such time, the Administrative Agent shall promptly notify each Revolving Lender of the Honor Date, the amount of the unreimbursed drawing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Unreimbursed Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the amount of such Revolving Lender&#8217;s Applicable Revolving Percentage thereof.  In such event, the Company shall be deemed to have requested a Revolving Borrowing of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the principal amount of Base Rate Loans, but subject to the amount of the unutilized portion of the Revolving Commitments and the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than the delivery of a Loan Notice).  Any notice given by the L&#47;C Issuer or the Administrative Agent pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> may be given by telephone if immediately confirmed in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Each Revolving Lender shall upon any notice pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> make funds available (and the Administrative Agent may apply Cash Collateral provided for this purpose) for the account of the L&#47;C Issuer at the Administrative Agent&#8217;s Office in an amount equal to its Applicable Revolving Percentage of the Unreimbursed Amount not later than 1&#58;00 p.m. on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Revolving Lender that so makes funds available shall be deemed to have made a Base Rate Loan to the Company in such amount.  The Administrative Agent shall remit the funds so received to the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">With respect to any Unreimbursed Amount that is not fully refinanced by a Revolving Borrowing of Base Rate Loans because the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> cannot be satisfied or for any other reason, the Company shall be deemed to have incurred from the L&#47;C Issuer an L&#47;C Borrowing in the amount of the Unreimbursed Amount that is not so refinanced, which L&#47;C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate.  In such event, each Revolving Lender&#8217;s payment to the Administrative Agent for the account of the L&#47;C Issuer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed payment in respect of its participation in such L&#47;C Borrowing and shall constitute an L&#47;C Advance from such Revolving Lender in satisfaction of its participation obligation under this Section.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">Until each Revolving Lender funds its Revolving Loan or L&#47;C Advance pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to reimburse the L&#47;C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Revolving Lender&#8217;s Applicable Revolving Percentage of such amount shall be solely for the account of the L&#47;C Issuer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">Each Revolving Lender&#8217;s obligation to make Revolving Loans or L&#47;C Advances to reimburse the L&#47;C Issuer for amounts drawn under Letters of Credit, as contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Revolving Lender may have against the L&#47;C Issuer, the Company, any Subsidiary or any other Person for any reason whatsoever&#59; (B) the occurrence or continuance of a Default&#59; or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Revolving Lender&#8217;s obligation to make Revolving Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is subject to the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than delivery by the Company of a Loan Notice).  No such making of an L&#47;C Advance shall relieve or otherwise impair the obligation of the Company to reimburse the L&#47;C Issuer for the amount of any payment made by the L&#47;C Issuer under any Letter of Credit, together with interest as provided herein.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">If any Revolving Lender fails to make available to the Administrative Agent for the account of the L&#47;C Issuer any amount required to be paid by such Revolving Lender pursuant to the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the time specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then, without limiting the other provisions of this Agreement, the L&#47;C Issuer shall be entitled to recover from such Revolving Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the L&#47;C Issuer at a rate per annum equal to the greater of the Federal Funds Rate and a rate determined by the L&#47;C Issuer in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by the L&#47;C Issuer in connection with the foregoing.  If such Revolving Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Revolving Lender&#8217;s Revolving Loan included in the relevant Revolving Borrowing or L&#47;C Advance in respect of the relevant L&#47;C Borrowing, as the case may be.  A certificate of the L&#47;C Issuer submitted to any Revolving Lender (through the Administrative Agent) with respect to any amounts owing under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be conclusive absent manifest error.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.18pt;text-decoration:underline">Repayment of Participations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">At any time after the L&#47;C Issuer has made a payment under any Letter of Credit and has received from any Revolving Lender such Revolving Lender&#8217;s L&#47;C Advance in respect of such payment in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if the Administrative Agent receives for the account of the L&#47;C Issuer any payment in respect of the related Unreimbursed Amount or interest thereon (whether directly from the Company or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Revolving Lender its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Revolving Percentage thereof in the same funds as those received by the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">If any payment received by the Administrative Agent for the account of the L&#47;C Issuer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is required to be returned under any of the circumstances described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including pursuant to any settlement entered into by the L&#47;C Issuer in its discretion), each Revolving Lender shall pay to the Administrative Agent for the account of the L&#47;C Issuer its Applicable Revolving Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Revolving Lender, at a rate per annum equal to the Federal Funds Rate from time to time in effect.  The obligations of the Revolving Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.8pt;text-decoration:underline">Obligations Absolute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The obligation of the Company to reimburse the L&#47;C Issuer for each drawing under each Letter of Credit and to repay each L&#47;C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">any lack of validity or enforceability of such Letter of Credit, this Agreement, or any other Loan Document&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">the existence of any claim, counterclaim, setoff, defense or other right that the Company or any Subsidiary may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), the L&#47;C Issuer or any other Person, whether in connection with this Agreement or by such Letter of Credit, the transactions contemplated hereby or any agreement or instrument relating thereto, or any unrelated transaction&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">any draft, demand, endorsement, certificate or other document presented under or in connection with such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect&#59; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">waiver by the L&#47;C Issuer of any requirement that exists for the L&#47;C Issuer&#8217;s protection and not the protection of the Company or any waiver by the L&#47;C Issuer which does not in fact materially prejudice the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">honor of a demand for payment presented electronically even if such Letter of Credit requires that demand be in the form of a draft&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">any payment made by the L&#47;C Issuer in respect of an otherwise complying item presented after the date specified as the expiration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of, or the date by which documents must be received under, such Letter of Credit if presentation after such date is authorized by the UCC or the ISP, as applicable&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt">any payment by the L&#47;C Issuer under such Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit&#59; or any payment made by the L&#47;C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.03pt">any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, the Company or any of its Subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in the event of any claim of noncompliance with the Company&#8217;s instructions or other irregularity, the Company will immediately notify the L&#47;C Issuer.  The Company shall be conclusively deemed to have waived any such claim against the L&#47;C Issuer and its correspondents unless such notice is given as aforesaid.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.02pt;text-decoration:underline">Role of L&#47;C Issuer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Lender and the Company agree that, in paying any drawing under a Letter of Credit, the L&#47;C Issuer shall not have any responsibility to obtain any document (other than any sight or time draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document.  None of the L&#47;C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L&#47;C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Revolving Lenders, the Required Lenders or the Required Revolving Lenders, as applicable&#59; (ii) any action taken or omitted in the absence of gross negligence or willful misconduct&#59; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer Document.  The Company hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to its use of any Letter of Credit&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this assumption is not intended to, and shall not, preclude the Company&#8217;s pursuing such rights and remedies as it may have against the beneficiary or transferee at law or under any other agreement.  None of the L&#47;C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L&#47;C Issuer shall be liable or responsible for any of the matters described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, anything in such clauses to the contrary notwithstanding, the Company may have a claim against the L&#47;C Issuer, and the L&#47;C Issuer may be liable to the Company, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by the Company which the Company proves, as determined by a final </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nonappealable judgment of a court of competent jurisdiction, were caused by the L&#47;C Issuer&#8217;s willful misconduct or gross negligence or the L&#47;C Issuer&#8217;s willful failure to pay under any Letter of Credit after the presentation to it by the beneficiary of a sight or time draft and certificate(s) strictly complying with the terms and conditions of a Letter of Credit.  In furtherance and not in limitation of the foregoing, the L&#47;C Issuer may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L&#47;C Issuer shall not be responsible for the validity or sufficiency of any instrument transferring, endorsing or assigning or purporting to transfer, endorse or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason.  The L&#47;C Issuer may send a Letter of Credit or conduct any communication to or from the beneficiary via the Society for Worldwide Interbank Financial Telecommunication (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SWIFT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) message or overnight courier, or any other commercially reasonable means of communicating with a beneficiary.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.18pt;text-decoration:underline">Applicability of ISP&#59; Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless otherwise expressly agreed by the L&#47;C Issuer and the Company when a Letter of Credit is issued (including any such agreement applicable to an Existing Letter of Credit), the rules of the ISP shall apply to each Letter of Credit.  Notwithstanding the foregoing, the L&#47;C Issuer shall not be responsible to the Company for, and the L&#47;C Issuer&#8217;s rights and remedies against the Company shall not be impaired by, any action or inaction of the L&#47;C Issuer required or permitted under any law, order, or practice that is required or permitted to be applied to any Letter of Credit or this Agreement, including the Law or any order of a jurisdiction where the L&#47;C Issuer or the beneficiary is located, the practice stated in the ISP, or in the decisions, opinions, practice statements, or official commentary of the ICC Banking Commission, the Bankers Association for Finance and Trade - International Financial Services Association (BAFT-IFSA), or the Institute of International Banking Law &#38; Practice, whether or not any Letter of Credit chooses such law or practice.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.18pt;text-decoration:underline">Letter of Credit Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay to the Administrative Agent for the account of each Revolving Lender in accordance, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with its Applicable Revolving Percentage, a Letter of Credit fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for each Letter of Credit equal to the Applicable Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">times</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the daily amount available to be drawn under such Letter of Credit.  Letter of Credit Fees shall be (i) due and payable on the first Business Day following each fiscal quarter end, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand and (ii) computed on a quarterly basis in arrears.  If there is any change in the Applicable Rate during any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.63pt;text-decoration:underline">Fronting Fee and Documentary and Processing Charges Payable to L&#47;C Issuer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay directly to the L&#47;C Issuer for its own account a fronting fee with respect to (i) each Letter of Credit (other than any Existing Letter of Credit issued by JPMorgan), at the rate per annum </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified in the Fee Letter, computed on the daily amount available to be drawn under such Letter of Credit on a quarterly basis in arrears, such fronting fee shall be due and payable on or prior to the date that is ten (10) Business Days following each fiscal quarter end, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand, and (ii) each Existing Letter of Credit issued by JPMorgan, at the rate, times and in the amounts separately agreed in writing between the Company and JPMorgan.  For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, the Company shall pay directly to the L&#47;C Issuer for its own account the customary issuance, presentation, amendment and other processing fees, and other standard costs and charges, of the L&#47;C Issuer relating to letters of credit as from time to time in effect.  Such customary fees and standard costs and charges are due and payable on demand and are nonrefundable.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.63pt;text-decoration:underline">Conflict with Issuer Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of any conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.18pt;text-decoration:underline">Letters of Credit Issued for Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding that a Letter of Credit issued or outstanding hereunder is in support of any obligations of, or is for the account of, a Subsidiary, the Company shall be obligated to reimburse the L&#47;C Issuer hereunder for any and all drawings under such Letter of Credit.  The Company hereby acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Company, and that the Company&#8217;s business derives substantial benefits from the businesses of such Subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Swingline Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">The Swingline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions set forth herein, the Swingline Lender, in reliance upon the agreements of the Revolving Lenders set forth in this Section, may in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make loans to the Borrowers (each such loan, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Swingline Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each such Swingline Loan may be made, subject to the terms and conditions set forth herein, to the Borrowers, in Dollars, from time to time on any Business Day during the Availability Period in an aggregate amount not to exceed at any time outstanding the amount of the Swingline Sublimit, notwithstanding the fact that such Swingline Loans, when aggregated with the Applicable Revolving Percentage of the Outstanding Amount of Revolving Loans and L&#47;C Obligations of the Lender acting as Swingline Lender, may exceed the amount of such Lender&#8217;s Revolving Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) after giving effect to any Swingline Loan, (A) the Total Revolving Outstandings shall not exceed the Revolving Facility at such time, and (B) the Revolving Exposure of any Revolving Lender at such time shall not exceed such Revolving Lender&#8217;s Revolving Commitment, (ii) no Borrower shall use the proceeds of any Swingline Loan to refinance any outstanding Swingline Loan, and (iii) the Swingline Lender shall not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under any obligation to make any Swingline Loan if it shall determine (which determination shall be conclusive and binding absent manifest error) that it has, or by such Credit Extension may have, Fronting Exposure.  Within the foregoing limits, and subject to the other terms and conditions hereof, the Borrowers may borrow under this Section, prepay under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and reborrow under this Section.  Each Swingline Loan shall bear interest, at the applicable Borrowers&#8217; option, at a rate based on (x) the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate for Base Rate Loans or (y) the SOFR Daily Floating Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate for SOFR Daily Floating Rate Loans.  Immediately upon the making of a Swingline Loan, each Revolving Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the Swingline Lender a risk participation in such Swingline Loan in an amount equal to the product of such Revolving Lender&#8217;s Applicable Revolving Percentage times the amount of such Swingline Loan.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Borrowing Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Swingline Borrowing shall be made upon the applicable Borrower&#8217;s irrevocable notice to the Swingline Lender and the Administrative Agent, which may be given by&#58; (i) telephone or (ii) a Swingline Loan Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any telephonic notice must be confirmed immediately by delivery to the Swingline Lender and the Administrative Agent of a Swingline Loan Notice.  Each such Swingline Loan Notice must be received by the Swingline Lender and the Administrative Agent not later than 1&#58;00 p.m. on the requested borrowing date, and shall specify (A) the applicable Borrower, (B) the amount to be borrowed, which shall be a minimum of $100,000, (C) the requested date of the Borrowing (which shall be a Business Day), and (D) whether such Swingline Loan will bear interest at the Base Rate or the SOFR Daily Floating Rate.  Promptly after receipt by the Swingline Lender of any Swingline Loan Notice, the Swingline Lender will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Swingline Loan Notice and, if not, the Swingline Lender will notify the Administrative Agent (by telephone or in writing) of the contents thereof.  Unless the Swingline Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any Revolving Lender) prior to 2&#58;00 p.m. on the date of the proposed Swingline Borrowing (1) directing the Swingline Lender not to make such Swingline Loan as a result of the limitations set forth in the first proviso to the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (2) that one or more of the applicable conditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is not then satisfied, then, subject to the terms and conditions hereof, the Swingline Lender may, not later than 3&#58;00 p.m. on the borrowing date specified in such Swingline Loan Notice, make the amount of its Swingline Loan available to the applicable Borrower at its office by crediting the account of the applicable Borrower on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the books of the Swingline Lender in immediately available funds.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Refinancing of Swingline Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">The Swingline Lender at any time in its sole discretion may request, on behalf of the Borrowers (which hereby irrevocably authorizes the Swingline Lender to so request on its behalf), that each Revolving Lender make a Base Rate Loan in an amount equal to such Revolving Lender&#8217;s Applicable Revolving Percentage of the amount of Swingline Loans then outstanding.  Such request shall be made in writing (which written request shall be deemed to be a Loan Notice for purposes hereof) and in accordance with the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without regard to the minimum and multiples specified therein for the principal amount of Base Rate Loans, but subject to the unutilized portion of the Revolving Facility and the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Swingline Lender shall furnish the Company with a copy of the applicable Loan Notice promptly after delivering such notice to the Administrative Agent.  Each Revolving Lender shall make an amount equal to its Applicable Revolving Percentage of the amount specified in such Loan Notice available to the Administrative Agent in immediately available funds (and the Administrative Agent may apply Cash Collateral available with respect to the applicable Swingline Loan) for the account of the Swingline Lender at the Administrative Agent&#8217;s Office not later than 1&#58;00 p.m. on the day specified in such Loan Notice, whereupon, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Revolving Lender that so makes funds available shall be deemed to have made a Base Rate Loan to the applicable Borrower in such amount.  The Administrative Agent shall remit the funds so received to the Swingline Lender.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">If for any reason any Swingline Loan cannot be refinanced by such a Revolving Borrowing in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the request for Base Rate Loans submitted by the Swingline Lender as set forth herein shall be deemed to be a request by the Swingline Lender that each of the Revolving Lenders fund its risk participation in the relevant Swingline Loan and each Revolving Lender&#8217;s payment to the Administrative Agent for the account of the Swingline Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed payment in respect of such participation.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">If any Revolving Lender fails to make available to the Administrative Agent for the account of the Swingline Lender any amount required to be paid by such Revolving Lender pursuant to the foregoing provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the time specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Swingline Lender shall be entitled to recover from such Revolving Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the Swingline Lender at a rate per annum equal to the greater of the Federal Funds Rate and a rate determined by the Swingline Lender in accordance with banking industry rules on interbank compensation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any administrative, processing or similar fees customarily charged by the Swingline Lender in connection with the foregoing.  If such Revolving Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Revolving Lender&#8217;s Revolving Loan included in the relevant Revolving Borrowing or funded participation in the relevant Swingline Loan, as the case may be.  A certificate of the Swingline Lender submitted to any Revolving Lender (through the Administrative Agent) with respect to any amounts owing under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be conclusive absent manifest error.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">Each Revolving Lender&#8217;s obligation to make Revolving Loans or to purchase and fund risk participations in Swingline Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Revolving Lender may have against the Swingline Lender, any Borrower or any other Person for any reason whatsoever, (B) the occurrence or continuance of a Default or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Revolving Lender&#8217;s obligation to make Revolving Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is subject to the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than delivery of a Loan Notice).  No such funding of risk participations shall relieve or otherwise impair the obligation of the Borrowers to repay Swingline Loans, together with interest as provided herein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Repayment of Participations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">At any time after any Revolving Lender has purchased and funded a risk participation in a Swingline Loan, if the Swingline Lender receives any payment on account of such Swingline Loan, the Swingline Lender will distribute to such Revolving Lender its Applicable Revolving Percentage thereof in the same funds as those received by the Swingline Lender.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">If any payment received by the Swingline Lender in respect of principal or interest on any Swingline Loan is required to be returned by the Swingline Lender under any of the circumstances described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including pursuant to any settlement entered into by the Swingline Lender in its discretion), each Revolving Lender shall pay to the Swingline Lender its Applicable Revolving Percentage thereof on demand of the Administrative Agent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the Federal Funds Rate.  The Administrative Agent will make such demand upon the request of the Swingline Lender.  The obligations of the Revolving Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Interest for Account of Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Swingline Lender shall be responsible for invoicing the Borrowers for interest on the Swingline Loans.  Until each Revolving Lender funds its Base Rate Loan or risk participation pursuant to this Section to refinance such Revolving Lender&#8217;s Applicable Revolving Percentage of any Swingline Loan, interest in respect of such Applicable Revolving Percentage shall be solely for the account of the Swingline Lender.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Payments Directly to Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall make all payments of principal and interest in respect of the Swingline Loans directly to the Swingline Lender.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Optional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">The Borrowers may, upon notice to the Administrative Agent pursuant to delivery to the Administrative Agent of a Notice of Loan Prepayment, at any time or from time to time voluntarily prepay the Revolving Loans, Term Loans and&#47;or any Incremental Term Loans in whole or in part without premium or penalty subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, unless otherwise agreed by the Administrative Agent, (A) such notice must be received by the Administrative Agent not later than 11&#58;00 a.m. (1) two (2) Business Days prior to any date of prepayment of Term SOFR Loans, and (2) on the date of prepayment of Base Rate Loans, (B) any prepayment of Term SOFR Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000 in excess thereof, and (C) any prepayment of Base Rate Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof (or, in each case, if less, the entire principal amount thereof then outstanding).  Each such notice shall specify the date and amount of such prepayment, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Type(s) of Loans to be prepaid, and whether the Loans to be prepaid are Revolving Loans, Term Loans and&#47;or Incremental Term Loans and, if Term SOFR Loans are to be prepaid, the Interest Period(s) of such Loans.  The Administrative Agent will promptly notify each Lender of its receipt of each such notice, and of the amount of such Lender&#8217;s ratable portion of such prepayment (based on such Lender&#8217;s Applicable Percentage in respect of the relevant Facility).  If such notice is given by the Borrowers, the Borrowers shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.  Any prepayment of principal shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each prepayment of Term Loans or Incremental Term Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied to the Term Loans and any then-existing Incremental Term Loans on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> basis, and shall be applied to the principal repayment installments thereof, first, to reduce in direct order of maturity the next four (4) scheduled amortization payments and thereafter (after such scheduled amortization payments have been eliminated as a result of such reductions), on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> basis.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such prepayments shall be paid to the Lenders in accordance with their respective Applicable Percentages in respect of each of the relevant Facilities.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">The Borrowers may, upon notice to the Swingline Lender pursuant to delivery to the Swingline Lender of a Notice of Loan Prepayment (with a copy to the Administrative Agent), at any time or from time to time, voluntarily prepay Swingline Loans in whole or in part without premium or penalty&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, unless otherwise agreed by the Swingline Lender, (A) such notice must be received by the Swingline Lender and the Administrative Agent not later than 1&#58;00 p.m. on the date of the prepayment, and (B) any such prepayment shall be in a minimum principal amount of $100,000 or a whole multiple of $100,000 in excess thereof (or, if less, the entire principal thereof then outstanding).  Each such notice shall specify the date and amount of such prepayment.  If such notice is given by the Borrowers, the Borrowers shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.  Any prepayment of principal shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Mandatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Total Revolving Outstandings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If for any reason the Total Revolving Outstandings at any time exceed the Revolving Facility at such time, the Borrowers shall immediately prepay Revolving Loans, Swingline Loans and L&#47;C Borrowings (together with all accrued but unpaid interest thereon) and&#47;or Cash Collateralize the L&#47;C Obligations in an aggregate amount equal to such excess&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrowers shall not be required to Cash Collateralize the L&#47;C Obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless, after the prepayment of the Revolving Loans and Swingline Loans, the Total Revolving Outstandings exceed the Revolving Facility at such time.  </font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Dispositions and Involuntary Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall prepay (within thirty (30) days of the date of such Disposition or Involuntary Disposition) the Loans and&#47;or Cash Collateralize the L&#47;C Obligations as hereinafter provided in an aggregate amount equal to one hundred percent (100%) of the Net Cash Proceeds received by any Loan Party or any Subsidiary from any Disposition or any Involuntary Disposition&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, so long as no Default shall have occurred and be continuing, such Net Cash Proceeds shall not be required to be so applied (A) if the aggregate amount of Net Cash Proceeds received by any Loan Party or any Subsidiary from any such Disposition or Involuntary Disposition is equal to or less than $5,000,000 (it being understood and agreed that a series of related Dispositions or Involuntary Dispositions, as applicable, shall constitute a single Disposition or Involuntary Disposition, as applicable, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), or (B) if, at the election of the Company (as notified by the Company to the Administrative Agent on or prior to the date of such Disposition or Involuntary Disposition), such Loan Party or such Subsidiary reinvests all or any portion of such Net Cash Proceeds in Eligible Assets within two hundred seventy (270) days following the date of such Disposition or Involuntary Disposition&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for purposes of the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any portion of such Net Cash Proceeds that has not been so reinvested by the end of such period shall be applied within two (2) Business Days after the end of such period to prepay the Loans and&#47;or Cash Collateralize the L&#47;C Obligations.  Any prepayment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt;text-decoration:underline">Debt Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly upon the receipt by any Loan Party or any Subsidiary of the Net Cash Proceeds of any Debt Issuance, the Borrowers shall prepay the Loans and&#47;or Cash Collateralize the L&#47;C Obligations as hereinafter provided in an aggregate amount equal to one hundred percent (100%) of such Net Cash </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proceeds.  Any prepayment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt;text-decoration:underline">Application of Mandatory Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each prepayment of Loans pursuant to the foregoing provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.05(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the Term Loans and any Incremental Term Loans on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> basis and to the principal repayment installments thereof in inverse order of maturity, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the outstanding Revolving Loans (without a corresponding permanent reduction of the Revolving Facility), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, after the outstanding Revolving Loans have been paid in full, to Cash Collateralize the remaining L&#47;C Obligations.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such prepayments shall be paid to the Lenders in accordance with their respective Applicable Percentages in respect of each of the relevant Facilities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within the parameters of the applications set forth above, prepayments pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied first to Base Rate Loans and then to Term SOFR Loans in direct order of Interest Period maturities.  All prepayments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, but otherwise without premium or penalty, and shall be accompanied by interest on the principal amount prepaid through the date of prepayment.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Termination or Reduction of Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Optional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers may, upon notice to the Administrative Agent, terminate the Revolving Facility, the Letter of Credit Sublimit or the Swingline Sublimit, or from time to time permanently reduce the Revolving Facility, the Letter of Credit Sublimit or the Swingline Sublimit&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; unless otherwise agreed by the Administrative Agent, (i) any such notice shall be received by the Administrative Agent not later than 11&#58;00 a.m. five (5) Business Days prior to the date of termination or reduction, (ii) any such partial reduction shall be in an aggregate amount of $1,000,000 or any whole multiple of $100,000 in excess thereof and (iii) the Borrowers shall not terminate or reduce (A) the Revolving Facility if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Revolving Outstandings would exceed the Revolving Facility, (B) the Letter of Credit Sublimit if, after giving effect thereto, the Outstanding Amount of L&#47;C Obligations not fully Cash Collateralized hereunder would exceed the Letter of Credit Sublimit, or (C) the Swingline Sublimit if, after giving effect thereto and to any concurrent prepayments hereunder, the Outstanding Amount of Swingline Loans would exceed the Swingline Sublimit.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Mandatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">The aggregate Term Commitments shall be automatically and permanently reduced to zero on the Second Amendment Effective Date after giving effect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the funding of the Term Loans on the Second Amendment Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">The aggregate Incremental Term Commitments with respect to an Incremental Term Facility shall be automatically and permanently reduced to zero on the date of funding of the Incremental Term Loans advanced under such Incremental Term Facility.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">If after giving effect to any reduction or termination of Revolving Commitments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Letter of Credit Sublimit or the Swingline Sublimit exceeds the Revolving Facility at such time, the Letter of Credit Sublimit or the Swingline Sublimit, as the case may be, shall be automatically reduced by the amount of such excess.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Application of Commitment Reductions&#59; Payment of Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent will promptly notify the Lenders of any termination or reduction of the Letter of Credit Sublimit, the Swingline Sublimit or the Revolving Commitments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon any reduction of the Revolving Commitments, the Revolving Commitment of each Revolving Lender shall be reduced by such Lender&#8217;s Applicable Revolving Percentage of such reduction amount.  All fees in respect of the Revolving Facility accrued until the effective date of any termination of the Revolving Facility shall be paid on the effective date of such termination.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Repayment of Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall repay to the Revolving Lenders on the Revolving Facility Maturity Date the aggregate principal amount of all Revolving Loans outstanding on such date.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Incremental Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall repay the outstanding principal amount of all Incremental Term Loans in the installments, on the dates and in the amounts set forth in the applicable Incremental Term Loan Lender Joinder Agreement for the Incremental Term Facility under which such Incremental Term Loans were made (as such installments may hereafter be adjusted as a result of the application of prepayments in accordance with the order of priority set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), unless accelerated sooner pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Swingline Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall repay each Swingline Loan on the earlier to occur of (i) the date ten (10) Business Days after such Swingline Loan is made and (ii) the Revolving Facility Maturity Date.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall repay the outstanding principal amount of the Term Loans in installments on the last </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Business Day of each March, June, September and December and on the Term Facility Maturity Date, in each case, in the respective amounts set forth in the table below (which amounts shall be reduced as a result of the application of prepayments in accordance with the order of priority set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), unless accelerated sooner pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:102.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.788%"><tr><td style="width:1.0%"></td><td style="width:43.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Payment Date</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Principal Amortization Payment (% of Outstanding Amount of Term Loans as of the Second Amendment Effective Date)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">December, 2021</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">June, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">September, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">December, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">June, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">September, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.625%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">December, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">June, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">September, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">December, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">June, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">September, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">December, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">June, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.250%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Term Facility Maturity Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Outstanding Principal Balance </font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Term Loans</font></div></td></tr><tr style="height:16pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the final principal repayment installment of the Term Loans shall be repaid on the Term Facility Maturity Date and in any event shall be in an amount equal to the aggregate principal amount of all Term Loans outstanding on such date.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Interest and Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.08(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) each Term SOFR Loan under a Facility shall bear interest on the outstanding principal amount thereof for each Interest Period from the applicable borrowing date at a rate per annum equal to Term SOFR for such Interest Period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate, (ii) each Base Rate Loan under a Facility shall bear interest on the outstanding principal amount thereof </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from the applicable borrowing date at a rate per annum equal to the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate, and (iii) each Swingline Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to, at the applicable Borrowers&#8217; option (x) the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate or (y) the SOFR Daily Floating Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Applicable Rate.  To the extent that any calculation of interest or any fee required to be paid under this Agreement shall be based on (or result in) a calculation that is less than zero, such calculation shall be deemed zero for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">(A) If any amount payable by any Loan Party under any Loan Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, or (B) an Event of Default pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 8.01(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> exists, all outstanding Obligations shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Upon the request of the Required Lenders, while any other Event of Default exists, all outstanding Obligations (including Letter of Credit Fees) shall accrue at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon demand.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Interest Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein.  Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to certain fees described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsections (h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Commitment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall pay to the Administrative Agent for the account of each Revolving Lender in accordance with its Applicable Revolving Percentage, a commitment fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commitment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) equal to the Applicable Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">times</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the actual daily amount by which the Revolving Facility exceeds the sum of (i) the Outstanding Amount of Revolving Loans and (ii) the Outstanding Amount </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of L&#47;C Obligations, subject to adjustment as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the avoidance of doubt, the Outstanding Amount of Swingline Loans shall not be counted towards or considered usage of the Revolving Facility for purposes of determining the Commitment Fee.  The Commitment Fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is not met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period.  The Commitment Fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Rate during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Other Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">The Borrowers shall pay to the Administrative Agent and BofA Securities for their own respective accounts, fees in the amounts and at the times specified in the Fee Letter.  The Borrowers shall pay to each Arranger (other than BofA Securities), for its own account, fees as shall have been separately agreed upon in writing in the amounts and at the times so specified.  Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">The Borrowers shall pay to the Lenders, such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified.  Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Computation of Interest and Fees&#59; Retroactive Adjustments of Applicable Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Computation of Interest and Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to Term SOFR) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed.  All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365 day year).  Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any Loan that is repaid on the same day on which it is made shall, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, bear interest for one (1) day.  Each determination by the Administrative Agent of an interest rate or fee hereunder shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be conclusive and binding for all purposes, absent manifest error.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Financial Statement Adjustments or Restatements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, as a result of any restatement of or other adjustment to the financial statements of the Company and its Subsidiaries or for any other reason, the Company or the Lenders determine that (i) the Consolidated Leverage Ratio as calculated by the Company as of any applicable date was inaccurate and (ii) a proper calculation of the Consolidated Leverage Ratio would have resulted in higher pricing for such period, the Company shall immediately and retroactively be obligated to pay to the Administrative Agent for the account of the applicable Lenders or the L&#47;C Issuer, as the case may be, promptly on demand by the Administrative Agent (or, after the occurrence of an actual or deemed entry of an order for relief with respect to the Company under the Bankruptcy Code of the United States, automatically and without further action by the Administrative Agent, any Lender or the L&#47;C Issuer), an amount equal to the excess of the amount of interest and fees that should have been paid for such period over the amount of interest and fees actually paid for such period.  This paragraph shall not limit the rights of the Administrative Agent, any Lender or the L&#47;C Issuer, as the case may be, under any provision of this Agreement to payment of any Obligations hereunder at the Default Rate or under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s obligations under this paragraph shall survive the termination of the Aggregate Commitments and the repayment of all other Obligations hereunder.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Evidence of Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Maintenance of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender in the ordinary course of business.  The Administrative Agent shall maintain the Register in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The accounts or records maintained by each Lender shall be conclusive absent manifest error of the amount of the Credit Extensions made by the Lenders to the Borrowers and the interest and payments thereon.  Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrowers hereunder to pay any amount owing with respect to the Obligations.  In the event of any conflict between the accounts and records maintained by any Lender and the Register, the Register shall control in the absence of manifest error.  Upon the request of any Lender made through the Administrative Agent, the Borrowers shall execute and deliver to such Lender (through the Administrative Agent) one or more Notes, as applicable, which shall evidence such Lender&#8217;s Loans in addition to such accounts or records.  Each Lender may attach schedules to its Notes and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Maintenance of Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to the accounts and records referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Lender and the Administrative Agent shall maintain in accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit and Swingline Loans.  In the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Payments Generally&#59; Administrative Agent&#8217;s Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments to be made by the Borrowers shall be made free and clear of and without condition or deduction for any counterclaim, defense, recoupment or setoff.  Except as otherwise expressly provided herein, all payments by the Borrowers hereunder shall be made to the Administrative Agent for the account of the respective Lenders to which such payment is owed, at the Administrative Agent&#8217;s Office in immediately available funds not later than 2&#58;00 p.m. on the date specified herein.  The Administrative Agent will promptly distribute to each Lender its Applicable Percentage in respect of the relevant Facility (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender&#8217;s Lending Office.  All payments received by the Administrative Agent after 2&#58;00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue.  Except as otherwise specifically provided for in this Agreement, if any payment to be made by the Borrowers shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Funding by Lenders&#59; Presumption by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing of Term SOFR Loans (or, in the case of any Borrowing of Base Rate Loans, prior to 12&#58;00 noon on the date of such Borrowing) that such Lender will not make available to the Administrative Agent such Lender&#8217;s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or, in the case of a Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and may, in reliance upon such assumption, make available to the applicable Borrower a corresponding amount.  In such event, if a Lender has not in fact made its share of the Borrowing available to the Administrative Agent, then the applicable Lender and the applicable Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount in immediately available funds with interest thereon, for each day from and including the date such amount is made available to such Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules on interbank compensation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by such Borrower, the interest rate applicable to Base Rate Loans.  If the applicable Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to such Borrower the amount of such interest paid by such Borrower for such period.  If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender&#8217;s Loan included in such Borrowing.  Any payment by the applicable Borrower shall be without prejudice to any claim such Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Payments by Borrower&#59; Presumptions by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless the Administrative Agent shall have received notice from the Borrowers prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L&#47;C Issuer hereunder that the Borrowers will not make such payment, the Administrative Agent may assume that the Borrowers have made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Appropriate Lenders or the L&#47;C Issuer, as the case may be, the amount due.  With respect to any payment that the Administrative Agent makes for the account of the Lenders or L&#47;C Issuer hereunder as to which the Administrative Agent determines (which determination shall be conclusive absent manifest error) that any of the following applies (such payment referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rescindable Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (A) the Borrowers have not in fact made such payment&#59; (B) the Administrative Agent has made a payment in excess of the amount so paid by the Borrowers (whether or not then owed)&#59; or (C) the Administrative Agent has for any reason otherwise erroneously made such payment, then each of the Appropriate Lenders or the L&#47;C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the Rescindable Amount so distributed to such Lender or the L&#47;C Issuer, in immediately available funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A notice of the Administrative Agent to any Lender or the Company with respect to any amount owing under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be conclusive, absent manifest error.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Failure to Satisfy Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and such funds are not made available to the applicable Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Obligations of Lenders Several</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The obligations of the Lenders hereunder to make Loans, to fund participations in Letters of Credit and Swingline Loans and to make payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are several and not joint.  The failure of any Lender to make any Loan, to fund any such participation or to make any payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to make its payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Funding Source</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Sharing of Payments by Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of (a) Obligations in respect of any of the Facilities due and payable to such Lender hereunder and under the other Loan Documents at such time in excess of its ratable share (according to the proportion of (i) the amount of such Obligations due and payable to such Lender at such time to (ii) the aggregate amount of the Obligations in respect of the Facilities due and payable to all Lenders hereunder and under the other Loan Documents at such time) of payments on account of the Obligations in respect of the Facilities due and payable to all Lenders hereunder and under the other Loan Documents at such time obtained by all the Lenders at such time or (b) Obligations in respect of any of the Facilities owing (but not due and payable) to such Lender hereunder and under the other Loan Documents at such time in excess of its ratable share (according to the proportion of (i) the amount of such Obligations owing (but not due and payable) to such Lender at such time to (ii) the aggregate amount of the Obligations in respect of the Facilities owing (but not due and payable) to all Lenders hereunder and under the other Loan Documents at such time) of payments on account of the Obligations in respect of the Facilities owing (but not due and payable) to all Lenders hereunder and under the other Loan Documents at such time obtained by all of the Lenders at such time, then, in each case under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, the Lender receiving such greater proportion shall (A) notify the Administrative Agent of such fact, and (B) purchase (for cash at face value) participations in the Loans and subparticipations in L&#47;C Obligations and Swingline Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of Obligations in respect of the Facilities then due and payable to the Lenders or owing (but not due and payable) to the Lenders, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">if any such participations or subparticipations are purchased and all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any portion of the payment giving rise thereto is recovered, such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest&#59; and</font></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the provisions of this Section shall not be construed to apply to (x) any payment made by or on behalf of the Borrowers pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) the application of Cash Collateral provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or subparticipations in L&#47;C Obligations or Swingline Loans to any assignee or participant, other than an assignment to any Loan Party or any Affiliate thereof (as to which the provisions of this Section shall apply).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against such Loan Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Loan Party in the amount of such participation.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Cash Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Certain Credit Support Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If (i) the L&#47;C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in an L&#47;C Borrowing, (ii) as of the Letter of Credit Expiration Date, any L&#47;C Obligation for any reason remains outstanding, (iii) the Borrowers shall be required to provide Cash Collateral pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (iv) there shall exist a Defaulting Lender, the Borrowers shall immediately (in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above) or within one (1) Business Day (in all other cases) following any request by the Administrative Agent or the L&#47;C Issuer, provide Cash Collateral in an amount not less than the applicable Minimum Collateral Amount (determined in the case of Cash Collateral provided pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, after giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and any Cash Collateral provided by the Defaulting Lender).  Additionally, if the Administrative Agent notifies the Company at any time that the Outstanding Amount of all L&#47;C Obligations at such time exceeds one hundred five percent (105%) of the Letter of Credit Sublimit then in effect, then within two (2) Business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Days after receipt of such notice, the Borrowers shall provide Cash Collateral for the Outstanding Amount of the L&#47;C Obligations in an amount not less than the amount by which the Outstanding Amount of all L&#47;C Obligations exceeds the Letter of Credit Sublimit.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Grant of Security Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers, and to the extent provided by any Defaulting Lender, such Defaulting Lender, hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the L&#47;C Issuer and the Lenders, and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and all other property so provided as collateral pursuant hereto, and in all proceeds of the foregoing, all as security for the obligations to which such Cash Collateral may be applied pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent or the L&#47;C Issuer as herein provided, or that the total amount of such Cash Collateral is less than the Minimum Collateral Amount, the Borrowers will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency.  All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in one or more blocked, non-interest bearing deposit accounts at Bank of America.  The Borrowers shall pay on demand therefor from time to time all customary account opening, activity and other administrative fees and charges in connection with the maintenance and disbursement of Cash Collateral.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained in this Agreement, Cash Collateral provided under any of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in respect of Letters of Credit shall be held and applied to the satisfaction of the specific L&#47;C Obligations, obligations to fund participations therein (including, as to Cash Collateral provided by a Revolving Lender that is a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may be provided for herein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or to secure other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Revolving Lender (or, as appropriate, its assignee following compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)) or (ii) the determination by the Administrative Agent and the L&#47;C Issuer that there exists excess Cash Collateral&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (A) any such release shall be without prejudice to, and any disbursement or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other transfer of Cash Collateral shall be and remain subject to, any other Lien conferred under the Loan Documents and the other applicable provisions of the Loan Documents, and (B) the Person providing Cash Collateral and the L&#47;C Issuer may agree that Cash Collateral shall not be released but instead held to support future anticipated Fronting Exposure or other obligations.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Defaulting Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Such Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in the definition of &#8220;Required Lenders&#8221;, &#8220;Required Revolving Lenders&#8221; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Defaulting Lender Waterfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be applied at such time or times as may be determined by the Administrative Agent as follows&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the payment on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis of any amounts owing by such Defaulting Lender to the L&#47;C Issuer or Swingline Lender hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to Cash Collateralize the L&#47;C Issuer&#8217;s Fronting Exposure with respect to such Defaulting Lender in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as the Borrowers may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if so determined by the Administrative Agent and the Borrowers, to be held in a deposit account and released pro rata in order to (A) satisfy such Defaulting Lender&#8217;s potential future funding obligations with respect to Loans under this Agreement and (B) Cash Collateralize the L&#47;C Issuer&#8217;s future Fronting Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Agreement, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the payment of any amounts owing to the Lenders, the L&#47;C Issuer or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Swingline Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, the L&#47;C Issuer or the Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender&#8217;s breach of its obligations under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrowers as a result of any judgment of a court of competent jurisdiction obtained by the Borrowers against such Defaulting Lender as a result of such Defaulting Lender&#8217;s breach of its obligations under this Agreement&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">eighth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to such Defaulting Lender or as otherwise as may be required under the Loan Documents in connection with any Lien conferred thereunder or directed by a court of competent jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if (1) such payment is a payment of the principal amount of any Loans or L&#47;C Borrowings in respect of which such Defaulting Lender has not fully funded its appropriate share, and (2) such Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L&#47;C Obligations owed to, all Non-Defaulting Lenders on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> basis prior to being applied to the payment of any Loans of, or L&#47;C Obligations owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in L&#47;C Obligations and Swingline Loans are held by the Lenders pro rata in accordance with the Commitments hereunder without giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt;text-decoration:underline">Certain Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Defaulting Lender shall be entitled to receive any fee payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for any period during which that Lender is a Defaulting Lender (and the Borrowers shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt;text-decoration:underline">Letter of Credit Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Defaulting Lender shall be entitled to receive Letter of Credit Fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Applicable Revolving Percentage of the stated amount of Letters of Credit for which it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has provided Cash Collateral pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt;text-decoration:underline">Defaulting Lender Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to any fee payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or Letter of Credit Fee not required to be paid to any Defaulting Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, the Borrowers shall (1) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting Lender&#8217;s participation in L&#47;C Obligations or Swingline Loans that has been reallocated to such Non-Defaulting Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, (2) pay to the L&#47;C Issuer and Swingline Lender, as applicable, the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to the L&#47;C Issuer&#8217;s or Swingline Lender&#8217;s Fronting Exposure to such Defaulting Lender, and (3) not be required to pay the remaining amount of any such fee.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt;text-decoration:underline">Reallocation of Applicable Revolving Percentages to Reduce Fronting Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All or any part of such Defaulting Lender&#8217;s participation in L&#47;C Obligations and Swingline Loans shall be reallocated among the Non-Defaulting Lenders in accordance with their respective Applicable Revolving Percentages (calculated without regard to such Defaulting Lender&#8217;s Commitment) but only to the extent that such reallocation does not cause the aggregate Revolving Exposure of any Non-Defaulting Lender to exceed such Non-Defaulting Lender&#8217;s Revolving Commitment.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender&#8217;s increased exposure following such reallocation.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">Cash Collateral, Repayment of Swingline Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the reallocation described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above cannot, or can only partially, be effected, the Borrowers shall, without prejudice to any right or remedy available to it hereunder or under applicable Law, (A) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, prepay Swingline Loans in an amount equal to the Swingline Lender&#8217;s Fronting Exposure and (B) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Cash Collateralize the L&#47;C Issuer&#8217;s Fronting Exposure in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Defaulting Lender Cure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company, the Administrative Agent, the Swingline Lender and the L&#47;C Issuer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit and Swingline Loans to be held on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis by the Lenders in accordance with their Applicable Percentages (without giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), whereupon such Lender will cease to be a Defaulting Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrowers while that Lender was a Defaulting Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender&#8217;s having been a Defaulting Lender.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">New Swingline Loans&#47;Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  So long as any Revolving Lender is a Defaulting Lender, (i) the Swingline Lender shall not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be required to fund any Swingline Loans unless it is satisfied that it will have no Fronting Exposure after giving effect to such Swingline Loan and (ii) no L&#47;C Issuer shall be required to issue, extend, increase, reinstate or renew any Letter of Credit unless it is satisfied that it will have no Fronting Exposure after giving effect thereto.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.07pt"><br><br>TAXES, YIELD PROTECTION AND ILLEGALITY</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Payments Free of Taxes&#59; Obligation to Withhold&#59; Payments on Account of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable Laws.  If any applicable Laws (as determined in the good faith discretion of the Administrative Agent) require the deduction or withholding of any Tax from any such payment by the Administrative Agent or a Loan Party, then the Administrative Agent or such Loan Party shall be entitled to make such deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">If any Loan Party or the Administrative Agent shall be required by the Code to withhold or deduct any Taxes, including both United States federal backup withholding and withholding taxes, from any payment, then (A) the Administrative Agent shall withhold or make such deductions as are determined by the Administrative Agent to be required based upon the information and documentation it has received pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, (B) the Administrative Agent shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with the Code, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">If any Loan Party or the Administrative Agent shall be required by any applicable Laws other than the Code to withhold or deduct any Taxes from any payment, then (A) such Loan Party or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as are determined by it to be required based upon the information and documentation it has received pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, (B) such Loan Party or the Administrative Agent, to the extent required by such Laws, shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Payment of Other Taxes by the Loan Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, the Loan Parties shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Tax Indemnifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Each of the Loan Parties shall, and does hereby, jointly and severally indemnify each Recipient, and shall make payment in respect thereof within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to the Company by a Lender or the L&#47;C Issuer (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or the L&#47;C Issuer, shall be conclusive absent manifest error.  Each of the Loan Parties shall also, and does hereby, jointly and severally indemnify the Administrative Agent, and shall make payment in respect thereof within ten (10) days after demand therefor, for any amount which a Lender or the L&#47;C Issuer for any reason fails to pay indefeasibly to the Administrative Agent as required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Each Lender and the L&#47;C Issuer shall, and does hereby, severally indemnify and shall make payment in respect thereof within ten (10) days after demand therefor, (A) the Administrative Agent against any Indemnified Taxes attributable to such Lender or the L&#47;C Issuer (but only to the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Parties to do so), (B) the Administrative Agent and the Loan Parties, as applicable, against any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> relating to the maintenance of a Participant Register and (C) the Administrative Agent and the Loan Parties, as applicable, against any Excluded Taxes attributable to such Lender or the L&#47;C Issuer, in each case, that are payable or paid by the Administrative Agent or a Loan Party in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error.  Each Lender and the L&#47;C Issuer hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">85</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the L&#47;C Issuer, as the case may be, under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Evidence of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority, as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Status of Lenders&#59; Tax Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Company and the Administrative Agent, at the time or times reasonably requested by the Company or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Company or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Company or the Administrative Agent, shall deliver such other documentation prescribed by applicable Law or reasonably requested by the Company or the Administrative Agent as will enable the Company or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01(e)(ii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below) shall not be required if in the Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Without limiting the generality of the foregoing, in the event that a Borrower is a U.S. Person,</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">any Lender that is a U.S. Person shall deliver to the Company and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Company or the Administrative </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Company and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Company or the Administrative Agent), whichever of the following is applicable&#58;</font></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">executed originals of IRS Form W-8ECI&#59;</font></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of a Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; described in Section 881(c)(3)(C) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (y) executed copies of IRS Form W-8BEN-E (or W-8BEN, as applicable)&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">87</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:270pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN-E (or W-8BEN, as applicable), a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Company and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Company or the Administrative Agent), executed copies (or originals, as required) of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Law to permit the Company or the Administrative Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Company and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Company or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code) and such additional documentation reasonably requested by the Company or the Administrative Agent as may be necessary for the Company and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount to deduct and withhold from such payment.  Solely for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;FATCA&#8221; shall include any amendments made to FATCA after the Closing Date.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">Each Lender agrees that if any form or certification it previously delivered pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Company and the Administrative Agent in writing of its legal inability to do so.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Treatment of Certain Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless required by applicable Laws, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender or the L&#47;C Issuer, or have any obligation to pay to any Lender or the L&#47;C Issuer, any refund of Taxes withheld or deducted from funds paid for the account of such Lender or the L&#47;C Issuer, as the case may be.  If any Recipient determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified by any Loan Party or with respect to which any Loan Party has paid additional amounts pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, it shall pay to such Loan Party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by such Loan Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Recipient, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Loan Party, upon the request of the Recipient, agrees to repay the amount paid over to such Loan Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Recipient in the event the Recipient is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this subsection, in no event will the applicable Recipient be required to pay any amount to such Loan Party pursuant to this subsection the payment of which would place the Recipient in a less favorable net after-Tax position than such Recipient would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This subsection shall not be construed to require any Recipient to make available its tax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">returns (or any other information relating to its taxes that it deems confidential) to any Loan Party or any other Person.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each party&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender or the L&#47;C Issuer, the termination of the Commitments and the repayment, satisfaction or discharge of all other Obligations.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Illegality and Designated Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its Lending Office to perform any of its obligations hereunder, or to make, maintain or fund Loans whose interest is determined by reference to SOFR, Term SOFR or the SOFR Daily Floating Rate, or to determine or charge interest rates based upon SOFR, Term SOFR or the SOFR Daily Floating Rate, then, on notice thereof by such Lender to the Company through the Administrative Agent, (i) any obligation of such Lender to perform such obligations, to make or continue Term SOFR Loans or SOFR Daily Floating Rate Loans, or to convert Base Rate Loans to Term SOFR Loans, as applicable, shall be suspended, and (ii) if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by reference to the Term SOFR component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Term SOFR component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Company that the circumstances giving rise to such determination no longer exist.  Upon receipt of such notice, (A) the Borrowers shall, upon demand from such Lender (with a copy to the Administrative Agent), (1) in the case of Term SOFR Loans, prepay or, if applicable, convert all Term SOFR Loans of such Lender to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Term SOFR component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Term SOFR Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Term SOFR Loans, and (2) in the case of SOFR Daily Floating Rate Loans, prepay such SOFR Daily Floating Rate Loans immediately, and (B)  if such notice asserts the illegality of such Lender determining or charging interest rates based upon Term SOFR, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Term SOFR component thereof until the Administrative Agent is advised in writing by such Lender </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that it is no longer illegal for such Lender to determine or charge interest rates based upon Term SOFR.  Upon any such prepayment or conversion, the Borrowers shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">If, in any applicable jurisdiction, the Administrative Agent, the L&#47;C Issuer, or any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for the Administrative Agent, the L&#47;C Issuer, or any Lender to (i) perform any of its obligations hereunder or under any other Loan Document, (ii) to fund or maintain its participation in any Loan or Letter of Credit or (iii) issue, make, maintain, fund or charge interest with respect to any Credit Extension, such Person shall promptly notify the Administrative Agent.  Upon receipt of such notice, the Administrative Agent shall promptly notify the Company, and, until such notice is revoked, any obligation of such Person to issue, make, maintain, fund or charge interest with respect to any such Credit Extension shall be suspended, and to the extent required by applicable Law, cancelled.  Upon receipt of such notice, the Borrowers shall (A) repay that Person&#8217;s participation in the Loans or other applicable Obligations on the last day of the Interest Period for each Loan or other Obligation occurring after the Administrative Agent has notified the Company or, if earlier, the date specified by such Person in the notice delivered to the Administrative Agent (being no earlier than the last day of any applicable grace period permitted by applicable Law) and (B) take all reasonable actions requested by such Person to mitigate or avoid such illegality.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Inability to Determine Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">If in connection with any request for a Term SOFR Loan or a SOFR Daily Floating Rate Loan, or a conversion of Base Rate Loans to Term SOFR Loans, or a continuation of Term SOFR Loans, (i) the Administrative Agent determines (which determination shall be conclusive absent manifest error) that (A) no Successor Rate has been determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the circumstances under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the Scheduled Unavailability Date has occurred, (B) adequate and reasonable means do not exist for determining Term SOFR for any requested Interest Period with respect to a proposed Term SOFR Loan or in connection with an existing or proposed Base Rate Loan, or (C) adequate and reasonable means do not exist for determining the SOFR Daily Floating Rate with respect to a proposed SOFR Daily Floating Rate Loan, or (ii) the Administrative Agent or the Required Lenders or the Swingline Lender, as applicable, determine that for any reason the SOFR Daily Floating Rate or Term SOFR for any requested Interest Period with respect to a proposed Term SOFR Loan does not adequately and fairly reflect the cost to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Company and each Lender.  Thereafter, (x) the obligation of the Lenders to make or maintain Term SOFR Loans or SOFR Daily Floating Rate Loans, or to convert Base Rate Loans to Term SOFR Loans, shall be suspended (to the extent of the affected Term SOFR Loans, SOFR Daily Floating Rate Loans or Interest Periods, as applicable), and (y) in the event of a determination described in the preceding sentence with respect to the Term SOFR component of the Base Rate, the utilization of the Term SOFR component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (or, in the case of a determination by the Required Lenders or the Swingline Lender, as applicable, described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, until the Administrative Agent upon instruction of the Required Lenders or the Swingline Lender, as applicable) revokes such notice.  Upon receipt of such notice, (I) the Borrowers may revoke any pending request for a Borrowing of, conversion to or continuation of Term SOFR Loans or SOFR Daily Floating Rate Loans (to the extent of the affected SOFR Daily Floating Rate Loans, Term SOFR Loans or Interest Periods, as applicable) or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Loans in the amount specified therein, (II) any outstanding Term SOFR Loans shall be deemed to have been converted to Base Rate Loans immediately at the end of their respective applicable Interest Period, and (III) any outstanding SOFR Daily Floating Rate Loans shall be deemed to have been converted immediately to Swingline Loans bearing interest at the Base Rate.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Company or Required Lenders notify the Administrative Agent (with, in the case of the Required Lenders, a copy to the Company) that the Company or Required Lenders (as applicable) have determined, that&#58; (i) adequate and reasonable means do not exist for ascertaining one month and three month interest periods of Term SOFR (or, in the case of SOFR Daily Floating Rate Loans, the one month interest period of Term SOFR), including because the Term SOFR Screen Rate is not available or published on a current basis and such circumstances are unlikely to be temporary&#59; or (ii) CME or any successor administrator of the Term SOFR Screen Rate or a Governmental Authority having jurisdiction over the Administrative Agent or such administrator with respect to its publication of Term SOFR, in each case acting in such capacity, has made a public statement identifying a specific date after which one month and three month interest periods of Term SOFR (or, in the case of the SOFR Daily Floating Rate, the one month interest period of Term SOFR) or the Term SOFR Screen Rate shall or will no longer be made available, or permitted to be used for determining the interest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">92</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rate of Dollar-denominated syndicated loans, or shall or will otherwise cease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, at the time of such statement, there is no successor administrator that is satisfactory to the Administrative Agent that will continue to provide such interest periods of Term SOFR (or, in the case of the SOFR Daily Floating Rate, the one month interest period of Term SOFR) after such specific date (the latest date on which one month and three month interest periods of Term SOFR (or, in the case of the SOFR Daily Floating Rate, the one month interest period of Term SOFR) or the Term SOFR Screen Rate are no longer available permanently or indefinitely, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Unavailability Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; then, on a date and time determined by the Administrative Agent (any such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which date shall be, in the case of Term SOFR Loans, at the end of an Interest Period or on the relevant interest payment date, as applicable, for interest calculated and, solely with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, no later than the Scheduled Unavailability Date, Term SOFR and the SOFR Daily Floating Rate will be replaced hereunder and under any Loan Document with Daily Simple SOFR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the SOFR Adjustment for any payment period for interest calculated that can be determined by the Administrative Agent, in each case, without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If the Successor Rate is Daily Simple SOFR plus the SOFR Adjustment, all interest payments will be payable on a monthly basis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary herein, (i) if the Administrative Agent determines that Daily Simple SOFR is not available on or prior to the Term SOFR Replacement Date, or (ii) if the events or circumstances of the type described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have occurred with respect to the Successor Rate then in effect, then in each case, the Administrative Agent and the Company may amend this Agreement solely for the purpose of replacing Term SOFR, the SOFR Daily Floating Rate or any then current Successor Rate in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> at the end of any Interest Period, relevant interest payment date or payment period (or, in the case of a daily floating interest rate, upon the effectiveness of such amendment) for interest calculated, as applicable, with an alternative benchmark rate giving due consideration to any evolving or then-existing convention for similar Dollar-denominated credit facilities syndicated and agented in the United States for such alternative benchmark and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then-existing convention for similar Dollar-denominated credit facilities syndicated and agented in the United States for such benchmark.  For the avoidance of doubt, any such proposed rate and adjustments, shall constitute a &#8220;Successor Rate&#8221;.  Any such amendment shall become effective at 5&#58;00 p.m. on the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Lenders and the Company unless, prior to such time, Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders object to such amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent will promptly (in one or more notices) notify the Company and each Lender of the implementation of any Successor Rate.  Any Successor Rate shall be applied in a manner consistent with market practice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent such market practice is not administratively feasible for the Administrative Agent, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">93</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Successor Rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent.  Notwithstanding anything else herein, if at any time any Successor Rate as so determined would otherwise be less than zero, the Successor Rate will be deemed to be zero for the purposes of this Agreement and the other Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the implementation of a Successor Rate, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Company and the Lenders reasonably promptly after such amendment becomes effective.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, those Lenders that either have not made, or do not have an obligation under this Agreement to make, the relevant Loans in Dollars shall be excluded from any determination of Required Lenders.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Increased Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Increased Costs Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Change in Law shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender or the L&#47;C Issuer&#59;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto&#59; or</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">impose on any Lender or the L&#47;C Issuer or the applicable interbank market any other condition, cost or expense affecting this Agreement or Term SOFR Loans or SOFR Daily Floating Rate Loans made by such Lender or any Letter of Credit or participation therein&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the result of any of the foregoing shall be to increase the cost to such Lender of making, converting to, continuing or maintaining any Loan (or of maintaining its obligation to make any such Loan), or to increase the cost to such Lender or the L&#47;C Issuer of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender or the L&#47;C Issuer hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or the L&#47;C Issuer, the Borrowers will pay to such Lender or the L&#47;C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L&#47;C Issuer, as the case may be, for such additional costs incurred or reduction suffered. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Capital Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Lender or the L&#47;C Issuer determines that any Change in Law affecting such Lender or the L&#47;C Issuer or any Lending Office of such Lender or such Lender&#8217;s or the L&#47;C Issuer&#8217;s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender&#8217;s or the L&#47;C Issuer&#8217;s capital or on the capital of such Lender&#8217;s or the L&#47;C Issuer&#8217;s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by the L&#47;C Issuer, to a level below that which such Lender or the L&#47;C Issuer or such Lender&#8217;s or the L&#47;C Issuer&#8217;s holding company could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s or the L&#47;C Issuer&#8217;s policies and the policies of such Lender&#8217;s or the L&#47;C Issuer&#8217;s holding company with respect to capital adequacy), then from time to time the Borrowers will pay to such Lender or the L&#47;C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L&#47;C Issuer or such Lender&#8217;s or such the L&#47;C Issuer&#8217;s holding company for any such reduction suffered.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Certificates for Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A certificate of a Lender or the L&#47;C Issuer setting forth the amount or amounts necessary to compensate such Lender or the L&#47;C Issuer or its holding company, as the case may be, as specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section and delivered to the Company shall be conclusive absent manifest error.  The Borrowers shall pay such Lender or the L&#47;C Issuer, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Delay in Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Failure or delay on the part of any Lender or the L&#47;C Issuer to demand compensation pursuant to the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not constitute a waiver of such Lender&#8217;s or the L&#47;C Issuer&#8217;s right to demand such compensation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrowers shall not be required to compensate a Lender or the L&#47;C Issuer pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than nine (9) months prior to the date that such Lender or the L&#47;C Issuer, as the case may be, notifies the Company of the Change in Law giving rise to such increased costs or reductions and of such Lender&#8217;s or the L&#47;C Issuer&#8217;s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine (9) month period referred to above shall be extended to include the period of retroactive effect thereof).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compensation for Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">95</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrowers shall promptly compensate such Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period, applicable interest payment date or payment period, as applicable, for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">any failure by a Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the date or in the amount notified by such Borrower&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">any assignment of a Term SOFR Loan on a day other than the last day of the Interest Period therefor as a result of a request by a Borrower pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including any loss of anticipated profits, any foreign exchange losses and any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained or from the performance of any foreign exchange contract.  The Borrowers shall also pay customary administrative fees charged by such Lender in connection with the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Mitigation Obligations&#59; Replacement of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Designation of a Different Lending Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), or requires the Borrowers to pay any Indemnified Taxes or additional amounts to any Lender, the L&#47;C Issuer, or any Governmental Authority for the account of any Lender or the L&#47;C Issuer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or if any Lender gives a notice pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then at the request of the Company, such Lender or the L&#47;C Issuer shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender or the L&#47;C Issuer, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as the case may be, in the future, or eliminate the need for the notice pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as applicable, and (ii) in each case, would not subject such Lender or the L&#47;C Issuer, as the case may be, to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender or the L&#47;C Issuer, as the case may be.  The Borrowers hereby agree to pay all reasonable costs and expenses incurred by any Lender or the L&#47;C Issuer in connection with any such designation or assignment.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Replacement of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">96</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or if the Borrowers are required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and, in each case, such Lender has declined or is unable to designate a different lending office in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.06(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company may replace such Lender in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Borrower&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive termination of the Aggregate Commitments, repayment of all other Obligations hereunder, resignation of the Administrative Agent and the Facility Termination Date.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"><br><br>CONDITIONS PRECEDENT TO CREDIT EXTENSIONS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Conditions to all Credit Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligation of each Lender and the L&#47;C Issuer to honor any Request for Credit Extension is subject to the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The representations and warranties of the Company and each other Loan Party contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date of such Credit Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsections (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to refer to the most recent statements furnished pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Default or Event of Default shall exist, or would result from such proposed Credit Extension or from the application of the proceeds thereof.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Request for Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent and, if applicable, the L&#47;C Issuer or the Swingline Lender, shall have received a Request for Credit Extension in accordance with the requirements hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">97</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Request for Credit Extension submitted by a Borrower shall be deemed to be a representation and warranty that the conditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have been satisfied on and as of the date of the applicable Credit Extension.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.97pt"><br><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party represents and warrants to the Administrative Agent and the Lenders, as of the date made or deemed made, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Existence, Qualification and Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party and each Subsidiary (a) is duly organized or formed, validly existing and, as applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite corporate, limited liability company or other organizational power and authority, as applicable, and all requisite governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, and (c) is duly qualified and is licensed and, as applicable, in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license&#59; except in each case referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Authorization&#59; No Contravention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The execution, delivery and performance by each Loan Party of each Loan Document to which such Person is or is to be a party have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of such Person&#8217;s Organization Documents, (b) conflict with or result in any breach or contravention of, or the creation of any Lien under (other than the Liens created by the Collateral Documents in favor of the Administrative Agent), or require any payment to be made under (i) any Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject, or (c) violate any Law, except with respect to any conflict, breach or contravention or payment (but not creation of Liens) referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the extent that such conflict, breach, contravention or payment could not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Governmental Authorization&#59; Other Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, (b) the grant by any Loan Party of the Liens granted by it pursuant to the Collateral Documents, (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the first priority nature thereof) or (d) the exercise by the Administrative Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Collateral Documents, other than (i) authorizations, approvals, actions, notices and filings which have been duly obtained, (ii) filings to perfect the Liens created by the Collateral Documents and (iii) approvals, consents, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">98</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exemptions, authorizations, actions, notices or filings required under applicable law in connection with the exercise and enforcement of rights and remedies under the Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Document has been duly executed and delivered by each Loan Party that is party thereto.  Each Loan Document constitutes a legal, valid and binding obligation of each Loan Party that is party thereto, enforceable against each such Loan Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#8217; rights generally and by general equitable principles and&#47;or principles of good faith and fair dealing (whether enforcement is sought by proceedings in equity or at law).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Financial Statements&#59; No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Audited Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations, cash flows and changes in shareholder&#8217;s equity for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Quarterly Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Interim Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations, cash flows and changes in shareholders&#8217; equity for the period covered thereby, subject, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the absence of footnotes and to normal year-end audit adjustments.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Since December 31, 2020, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The budget of the Company and its Subsidiaries delivered pursuant to Section 3(e)(ii) of the Second Amendment was prepared in good faith on the basis of the assumptions stated therein, which assumptions were fair in light of the conditions existing at the time of delivery of such budget, and represented, at the time of delivery pursuant to Section 3(e)(ii) of the Second Amendment, the Company&#8217;s reasonable estimate of its future financial condition and performance.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no Adverse Proceedings (a) that purport to affect or pertain to this Agreement or any other Loan Document or any of the transactions contemplated hereby, or (b) as to which there is a reasonable possibility of an adverse determination and that, if adversely determined, either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries (i) is in violation of any applicable laws (including Environmental Laws and Health Care Laws) that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, or (ii) is subject to or in default with respect to any final judgments, writs, injunctions, decrees, rules or regulations of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither any Loan Party nor any Subsidiary thereof is in default under or with respect to, or a party to, any Contractual Obligation that would, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Agreement or any other Loan Document.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Ownership of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party and each of its Subsidiaries has good record and marketable title in fee simple to, or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business, except for such defects in title as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Environmental Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no Adverse Proceedings regarding environmental matters or compliance with Environmental Laws that, individually or in the aggregate would reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries nor any of their respective facilities or operations are subject to any outstanding written order, consent decree or settlement agreement with any Person relating to any Environmental Law, any claim giving rise to any Environmental Liability, or any activity relating to any Hazardous Materials that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.  There are and, to each of the Company&#8217;s and its Subsidiaries&#8217; knowledge, have been, no conditions, occurrences, or activities relating to Hazardous Materials which would reasonably be expected to form the basis of a claim giving rise to any Environmental Liability against the Company and its Subsidiaries that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries nor, to any Loan Party&#8217;s knowledge, any predecessor of the Company and its Subsidiaries has filed any notice under any Environmental Law indicating past or present treatment of Hazardous Materials at any facility in violation of any Environmental Law where such violation is reasonably expected to have a Material Adverse Effect.  None of the Company&#8217;s or any of its Subsidiaries&#8217; operations involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260 270 or any state equivalent, except in the ordinary course of its business in compliance with all Environmental Laws.  Compliance with all current or reasonably foreseeable future requirements pursuant to or under Environmental Laws would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.  No event or condition has occurred or is occurring with respect to the Company and its Subsidiaries relating to any Environmental Law, any release of Hazardous Materials, or any activity relating to any Hazardous Materials which individually or in the aggregate has had, or would reasonably be expected to have, a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The properties of the Company and its Subsidiaries are insured with financially sound and reputable insurance companies not Affiliates of the Company, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the applicable Loan Party or the applicable Subsidiary operates.  The general liability, casualty, property, terrorism and business interruption insurance coverage of the Loan Parties as in effect on the Second Amendment Effective Date is outlined as to carrier, policy number, expiration date, type, amount and deductibles on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and such insurance coverage complies with the requirements set forth in this Agreement and the other Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party and its Subsidiaries have filed or caused to be filed all federal, state and other tax returns and reports required to be filed (excluding such other tax returns and reports with respect to which the failure to pay or file would not result in the loss, suspension, or impairment of any material Governmental Authorization, and otherwise would not reasonably be expected to have a Material Adverse Effect), and have paid all federal, state and other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP.  There is no tax assessment proposed in writing (and received by any Loan Party or any Subsidiary) against any Loan Party or any Subsidiary that would, if made, have a Material Adverse Effect, nor is there any tax sharing agreement applicable to the Company or any Subsidiary. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">ERISA Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Neither a Reportable Event nor the failure to contribute the minimum required contribution (within the meaning of Section 412 of the Code) has occurred during the five (5) year period prior to the date on which this representation is made or deemed made with respect to any Plan, and each Plan has complied in all material respects with the applicable provisions of ERISA and the Code.  No termination of a Pension Plan has occurred, and no Lien in favor of the PBGC or a Plan has arisen, during such five (5) year period.  The present value of all accrued benefits under each Pension Plan (based on those assumptions used to fund such Plans) did not, as of the last annual valuation date prior to the date on which this representation is made or deemed made, exceed the value of the assets of such Plan allocable to such accrued benefits by a material amount.  Neither the Borrowers nor any ERISA Affiliate has had a complete or partial withdrawal from any Multiemployer Plan that has resulted or would reasonably be expected to result in a material liability under ERISA, and neither the Borrowers nor any ERISA Affiliate would become subject to any material liability under ERISA if the Borrowers or any such ERISA Affiliate were to withdraw completely from all Multiemployer Plans as of the valuation date most closely preceding the date on which this representation is made or deemed made.  No such Multiemployer Plan is Insolvent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">101</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">The Company, and each of its Subsidiaries and each of their respective ERISA Affiliates are in compliance with all applicable provisions and requirements of ERISA and the Code and the regulations and published interpretations thereunder with respect to each Employee Benefit Plan, and have performed all their obligations under each Employee Benefit Plan, except where such non-compliance or non-performance would not reasonably be expected to result in a Material Adverse Effect.  Each Employee Benefit Plan which is intended to qualify under Section 401(a) of the Code has received a favorable determination letter from the IRS indicating that such Employee Benefit Plan is so qualified and nothing has occurred subsequent to the issuance of such determination letter which would cause such Employee Benefit Plan to lose its qualified status that would reasonably be expected to result in a Material Adverse Effect.  No liability to the PBGC (other than required premium payments), the IRS, any Employee Benefit Plan or any trust established under Title IV of ERISA has been or is expected to be incurred by Company, any of its Subsidiaries or any of their ERISA Affiliates except to the extent reflected on the consolidated financial statements of the Company and its Subsidiaries and the notes thereto.  No ERISA Event has occurred or is reasonably expected to occur that would reasonably be expected to result in a Material Adverse Effect.  Except to the extent required under Section 4980B of the Code or similar state laws, no Employee Benefit Plan provides health or welfare benefits (through the purchase of insurance or otherwise) for any retired or former employee of Company, any of its Subsidiaries or any of their respective ERISA Affiliates.  The present value of the aggregate benefit liabilities under each Pension Plan sponsored, maintained or contributed to by the Company, any of its Subsidiaries or any of their ERISA Affiliates (determined as of the end of the most recent plan year on the basis of the actuarial assumptions specified for funding purposes in the most recent actuarial valuation for such Pension Plan), did not exceed the aggregate current value of the assets of such Pension Plan.  As of the most recent valuation date for each Multiemployer Plan for which the actuarial report is available, the potential liability of the Company, its Subsidiaries and their respective ERISA Affiliates for a complete withdrawal from such Multiemployer Plan (within the meaning of Section 4203 of ERISA), when aggregated with such potential liability for a complete withdrawal from all Multiemployer Plans, based on information available pursuant to Section 4221(e) of ERISA is zero.  The Company, its Subsidiaries and each of their ERISA Affiliates have complied with the requirements of Section 515 of ERISA with respect to each Multiemployer Plan and are not in material &#8220;default&#8221; (as defined in Section 4219(c)(5) of ERISA) with respect to payments to a Multiemployer Plan.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Each Borrower represents and warrants as of the Second Amendment Effective Date that such Borrower is not and will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">102</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be using &#8220;plan assets&#8221; (within the meaning of 29 CFR &#167; 2510.3-101, as modified by Section 3(42) of ERISA) of one or more Benefit Plans in connection with the Loans, the Letters of Credit or the Commitments. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Margin Regulations&#59; Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Margin Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Borrower is engaged, nor will it engage, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock.  Following the application of the proceeds of each Borrowing or drawing under each Letter of Credit, not more than twenty-five percent (25%) of the value of the assets (either of a Borrower only or of the Company and its Subsidiaries on a Consolidated basis) subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or subject to any restriction contained in any agreement or instrument between any Borrower and any Lender or any Affiliate of any Lender relating to Indebtedness and within the scope of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will be margin stock.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Loan Party is or is required to be registered as an &#8220;investment company&#8221; under the Investment Company Act of 1940.  No Loan Party is subject to regulation under any Law that limits its ability to incur Indebtedness.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">No statement or information contained in this Agreement, any other Loan Document, the Confidential Information Memorandum or any other document, certificate or statement furnished by or on behalf of any Loan Party to the Administrative Agent or the Lenders, or any of them, for use in connection with the transactions contemplated by this Agreement or the other Loan Documents, contained as of the date such statement, information, document or certificate was so furnished (or, in the case of the Confidential Information Memorandum, as of the Second Amendment Effective Date) any untrue statement of a material fact or omitted to state a material fact necessary to make the statements contained herein or therein not misleading.  The projections and pro forma financial information contained in the materials referenced above are based upon good faith estimates and assumptions believed by management of the Company to be reasonable at the time made, it being recognized by the Lenders that such financial information as it relates to future events is not to be viewed as fact and that actual results during the period or periods covered by such financial information may differ from the projected results set forth therein by a material amount.  The Loan Parties have no knowledge of any matter or occurrence that would reasonably be expected to have a Material Adverse Effect that has not been expressly disclosed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">103</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein, in the other Loan Documents, in the Confidential Information Memorandum or in any other documents, certificates and statements furnished to the Administrative Agent and the Lenders for use in connection with the transactions contemplated hereby and by the other Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">The projections of the Company and its Subsidiaries on a Consolidated basis that are set forth in the Confidential Information Memorandum were, as of the date made, based on good faith estimates and assumptions made by the management of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the projections are not to be viewed as facts and actual results of the Company and its Subsidiaries on a Consolidated basis for the period or periods covered by the projections may differ from such projections and the differences may be material&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, management of the Company believes that the projections, as of the date made, were reasonable and attainable.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">As of the Second Amendment Effective Date, the information included in any Beneficial Ownership Certification (if required) delivered on or prior to the Second Amendment Effective Date is true and correct in all respects.    </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party and each Subsidiary is in compliance with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party is, individually and together with its Subsidiaries on a Consolidated basis, Solvent.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Sanctions Concerns&#59; Anti-Corruption Laws&#59; PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Sanctions Concerns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Loan Party, nor any Subsidiary, nor, to the knowledge of the Loan Parties and their Subsidiaries, any director, officer, employee, agent, affiliate or representative thereof, is an individual or entity that is, or is owned or controlled by, one or more individuals or entities that are (i) the subject or target of any Sanctions, (ii) included on OFAC&#8217;s List of Specially Designated Nationals or HMT&#8217;s Consolidated List of Financial Sanctions Targets, or any similar list enforced by any other relevant sanctions authority or (iii) located, organized or resident in a Designated Jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Loan Parties and their Subsidiaries have conducted their business in compliance with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in other jurisdictions, and, to the extent applicable, have instituted and maintained policies and procedures designed to promote and achieve compliance with such laws.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent applicable, each Loan Party and each Subsidiary is in compliance, in all material respects, with (i) the Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) and any other enabling legislation or executive order relating thereto and (ii) the PATRIOT Act.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Responsible Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are the Responsible Officers of each Loan Party, holding the offices indicated next to their respective names, as of the Second Amendment Effective Date, and such Responsible Officers are the duly elected and qualified officers of such Loan Party and are duly authorized to execute and deliver, on behalf of each such respective Loan Party, this Agreement, the Notes and the other Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Subsidiaries&#59; Equity Interests&#59; Loan Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.19(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, is complete and accurate list as of the Second Amendment Effective Date of each of the following&#58; (i) all Subsidiaries, joint ventures and partnerships and other equity investments of the Loan Parties, (ii) the number of shares or ownership interests of each class of Equity Interests in each Subsidiary outstanding, (iii) the number and percentage of outstanding shares or ownership interests of each class of Equity Interests owned by the Loan Parties and their Subsidiaries, (iv) the class or nature of such Equity Interests (i.e. voting, non-voting, preferred, etc.), and (v) identification of each Subsidiary that is an Excluded Subsidiary.  The outstanding Equity Interests in all Subsidiaries that are corporations are validly issued, fully paid and non-assessable.  The outstanding Equity Interests in all Subsidiaries (other than any Subsidiary that is a corporation) are validly issued, fully paid and the holders thereof have no obligation to make payments or contributions to any such Subsidiary or its credits by reason of their ownership of the Equity Interests therein (other than, with respect to non-Wholly Owned Subsidiaries, customary capital contribution requirements).  The outstanding Equity Interests in all Subsidiaries are owned free and clear of all Liens.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.19(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a complete and accurate list as of the Second Amendment Effective Date of each Loan Party&#8217;s&#58; (i) exact legal name, (ii) former legal names in the four (4) months prior to the Second Amendment Effective Date, if any, (iii) jurisdiction of its incorporation or organization, as applicable, (iv) type of organization, (v) chief executive office address (and, if different, principal place of business address), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">105</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) U.S. federal taxpayer identification number (or, in the case of any non-U.S. Loan Party that does not have a U.S. taxpayer identification number, its unique identification number issued to it by the jurisdiction of its incorporation or organization) and (vii) organization identification number.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Collateral Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Collateral Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of the Collateral Documents are effective to create in favor of the Administrative Agent for the benefit of the Secured Parties a legal, valid and enforceable first priority Lien (subject to Permitted Liens) on all right, title and interest of the respective Loan Parties in the Collateral described therein.  Except for filings completed prior to the Closing Date and as contemplated hereby and by the Collateral Documents, no filing or other action will be necessary to perfect or protect such Liens.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.20(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as of the Second Amendment Effective Date, is a list of all Intellectual Property registered or pending registration with the United States Copyright Office or the United States Patent and Trademark Office and owned by each Loan Party as of the Second Amendment Effective Date.  Except for such claims and infringements that would not reasonably be expected to have a Material Adverse Effect, no claim has been asserted and is pending by any Person challenging or questioning the use of any Intellectual Property or the validity or effectiveness of any Intellectual Property, nor does any Loan Party know of any such claim, and, to the knowledge of the Loan Parties, the use of any Intellectual Property by any Loan Party or any of its Subsidiaries or the granting of a right or a license in respect of any Intellectual Property from any Loan Party or any of its Subsidiaries does not infringe on the rights of any Person.  As of the Second Amendment Effective Date, none of the Intellectual Property owned by any of the Loan Parties or any of its Subsidiaries is subject to any licensing agreement or similar arrangement except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.20(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Deposit Accounts and Securities Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.20(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as of the Second Amendment Effective Date, is a description of all deposit accounts and securities accounts of the Loan Parties, including the name of (A) the applicable Loan Party, (B) in the case of a deposit account, the depository institution and average amount held in such deposit account and whether such account is an Excluded Deposit and Securities Account, and (C) in the case of a securities account, the securities intermediary or issuer and the average aggregate market value held in such securities account, as applicable, and whether such account is an Excluded Deposit and Securities Account.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">106</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.20(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as of the Second Amendment Effective Date, is a list of all real property located in the United States that is owned or leased by any Loan Party (in each case, including (i) the name of the Loan Party owning (or leasing) such property and an indication of whether such property is a Mortgaged Property, (ii) if such real property is a Mortgaged Property, the number of buildings located on such property, (iii) the property address, and (iv) the city, county (if such real property is a Mortgaged Property), state and zip code which such property is located).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Regulation H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Mortgaged Property is a Flood Hazard Property unless the Administrative Agent shall have received the following&#58; (a) the applicable Loan Party&#8217;s written acknowledgment of receipt of written notification from the Administrative Agent (i) as to the fact that such Mortgaged Property is a Flood Hazard Property, (ii) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program and (iii) such other flood hazard determination forms, notices and confirmations thereof as requested by the Administrative Agent and (b) copies of insurance policies or certificates of insurance of the applicable Loan Party evidencing flood insurance reasonably satisfactory to the Administrative Agent (and otherwise in compliance with Flood Laws) and naming the Administrative Agent as loss payee on behalf of the Lenders.  All flood hazard insurance policies required hereunder have been obtained and remain in full force and effect, and the premiums thereon have been paid in full.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compliance with Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">The Company and its Subsidiaries, when taken as a whole, are in compliance in all material respects with all material Health Care Laws applicable to it, its products and its properties or other assets or its business or operation.  Each of the Company and its Subsidiaries, taken as a whole, has in effect all material Governmental Authorizations necessary for it to carry on its business and operations, as presently conducted.  All such Governmental Authorizations are in full force and effect and there exists no default under, or violation of, any such Governmental Authorization and neither the Company nor any of its Subsidiaries has received notice or has knowledge that any Governmental Authority is considering limiting, suspending, terminating, adversely amending or revoking any such Governmental Authorization, in each case, except where the failure to be in full force and effect, and&#47;or default, or violation or such notice would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, all reports, documents, claims, notices or approvals required to be filed, obtained, maintained or furnished by the Company and its Subsidiaries pursuant to any Health Care Law to any Governmental Authority have been so filed, obtained, maintained or furnished except where the failure to do so would not reasonably be expected to have a Material Adverse Effect, and all such reports, documents, claims and notices </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">107</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">were complete and correct in all material respects on the date filed (or were or will be corrected in or supplemented by a subsequent filing).</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Each of the Company and its Subsidiaries, to the extent that it is billing the applicable Third Party Payor, has the requisite provider number or other Governmental Authorization to bill under Medicare, the respective Medicaid program in the state or states in which such entity operates, any other Governmental Third Party Payor Program and Private Third Party Payor Programs.  There is no investigation, audit, claim review, or other action pending, or threatened to the knowledge of the Company or its Subsidiaries, which would result in a revocation, suspension, termination, probation, restriction, limitation, or nonrenewal of any Governmental Third Party Payor or Private Third Party Payor provider number or result in any of the Company&#8217;s or any of its Subsidiaries&#8217; exclusion from any Governmental Third Party Payor Program or Private Third Party Payor Program which individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Third Party Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Medicare, Medicaid, TRICARE, federal or state government insurers or health care programs and any other person or entity which presently or in the future maintains Governmental Third Party Payor Programs.  In addition, for purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Third Party Payor Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all governmental third party payor programs in which the Company or any of its Subsidiaries participates (including Medicare, Medicaid, TRICARE or any other federal or state health care programs).  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Third Party Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means private insurers and any other person or entity which presently or in the future maintains Private Third Party Payor Programs.  In addition, for purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Private Third Party Payor Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all non-governmental third party payor programs in which the Company or any of its Subsidiaries participate (including managed care plans, or any other private health care insurance programs).</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Each of the Company and its Subsidiaries (i) has received and maintains accreditation to the extent required by law in good standing and without limitation or impairment by all applicable accrediting organizations, including The Joint Commission, the Accreditation Commission for Health Care, Inc. or other applicable nationally recognized accrediting agency, and (ii) if applicable, has cured all deficiencies or submitted or will submit a plan of correction to cure all deficiencies noted in its most recent accreditation survey reports, except in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> where the failure to require, maintain, cure or submit would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">108</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">There are no facts, circumstances or conditions that, to the knowledge of the Company or its Subsidiaries, would reasonably be expected to form the basis for any valid investigation, suit, claim, audit, action (legal or regulatory) or proceeding (legal or regulatory) by a Governmental Authority relating to any of the Health Care Laws against or affecting the Company and its Subsidiaries that would reasonably be expected to have a Material Adverse Effect.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or as otherwise disclosed to the Administrative Agent, neither the Company nor any of its Subsidiaries (i) is a party to a corporate integrity agreement, or (ii) has any reporting obligations pursuant to a settlement agreement, plan of correction, or other remedial measure entered into with any Governmental Authority.  Each of the Company and its Subsidiaries, as applicable, has complied with the terms and conditions of any corporate integrity agreements, settlement agreements, plans of correction, or other remedial measures or demand of any Governmental Authority to which it is subject except where non-compliance would not reasonably be expected to have a Material Adverse Effect, all of which are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or otherwise disclosed to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">Neither the Company nor any of its Subsidiaries or their respective officers, directors, employees or agents is, has been, or, to the knowledge of the Company or any of its Subsidiaries, has been threatened to be, (i) excluded from any Governmental Third Party Payor Program pursuant to 42 U.S.C. &#167; 1320a7b and related regulations, or (ii) made a party to any other action by any Governmental Authority that may prohibit it from participating in any Governmental Third Party Payor Program or selling products to any governmental or other purchaser pursuant to any Health Care Laws, except where the same would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">To the extent applicable to the Company or any of its Subsidiaries, and for so long as (i) the Company or any of its Subsidiaries are a &#8220;covered entity&#8221; as defined in 45 C.F.R. &#167; 160.103, (ii) the Company or any of its Subsidiaries are a &#8220;business associate&#8221; as defined in 45 C.F.R. &#167; 160.103, (iii) the Company or any of its Subsidiaries are subject to or covered by the HIPAA Administrative Requirements codified at 45 C.F.R. Parts 160 &#38; 162 and&#47;or the HIPAA Security and Privacy Requirements codified at 45 C.F.R. Parts 160 &#38; 164, and&#47;or (iv) the Company or any of its Subsidiaries sponsor any &#8220;group health plans&#8221; as defined in 45 C.F.R. &#167; 160.103, the Company and its Subsidiaries have&#58;  (A) completed surveys, inventories, reviews, analyses and&#47;or assessments, including risk assessments, (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assessments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of all material areas of their businesses and operations subject to HIPAA, to the extent these Assessments are required for the Company or any of its Subsidiaries, as the case may be, to be HIPAA Compliant&#894; (B) developed a plan and time line for becoming </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">109</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HIPAA Compliant (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HIPAA Compliance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (C) implemented those provisions of its HIPAA Compliance Plan necessary for the Company and its Subsidiaries to be HIPAA Compliant except where non-compliance is not reasonably expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">The Company and its Subsidiaries maintain a compliance plan that is intended to ensure that the Company and its Subsidiaries are compliant with all Health Care Laws applicable to the business of the Company and its Subsidiaries, and is consistent with compliance guidance from the U.S. Department of Health and Human Services Office of Inspector General and the U.S. Federal Sentencing Guidelines that is publicly available as of the Closing Date.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">Neither the Company nor any of its Subsidiaries has (i) received any claim or notice from any Governmental Authority or patient alleging or referencing any breach, security incident, violation of its information systems or the improper use, disclosure or access to any Personal Information in its possession, custody or control, or (ii) had any breaches as defined in HIPAA or in violation of any other federal or state law applicable to the privacy or security of Personal Information, except in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, where the incident would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Labor Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as, in the aggregate, would not reasonably be expected to have a Material Adverse Effect&#58;  (a) there are no strikes or other labor disputes against the Company or any Subsidiary pending or, to the knowledge of the Loan Parties, threatened&#59; (b) hours worked by and payment made to employees of each of the Company or any Subsidiary have not been in violation of the Fair Labor Standards Act or any other applicable requirement of Law dealing with such matters&#59; and (c) all payments due from the Company or any Subsidiary on account of employee health and welfare insurance have been paid or accrued as a liability on the books of the Company or such Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Affected Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Loan Party is an Affected Financial Institution.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Covered Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Loan Party is a Covered Entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">110</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"><br><br>AFFIRMATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Loan Parties hereby covenants and agrees that on the Closing Date and thereafter until the Facility Termination Date, such Loan Party shall, and shall cause each of its Subsidiaries to&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the Required Lenders&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as available, but in any event within ninety (90) days after the end of each fiscal year of the Company, a Consolidated balance sheet of the Company and its Subsidiaries as at the end of such fiscal year, and the related Consolidated statements of income or operations, changes in shareholders&#8217; equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such Consolidated statements to be audited and accompanied by a report and opinion of an independent certified public accountant of nationally recognized standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any &#8220;going concern&#8221; or like qualification or exception or any qualification or exception as to the scope of such audit.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Quarterly Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as available, but in any event within forty-five (45) days after the end of each of the first three (3) fiscal quarters of each fiscal year of the Company, a Consolidated balance sheet of the Company and its Subsidiaries as at the end of such fiscal quarter, and the related Consolidated statements of income or operations, changes in shareholders&#8217; equity and cash flows for such fiscal quarter and for the portion of the Company&#8217;s fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such Consolidated statements to be certified by the chief executive officer, chief financial officer, treasurer or controller who is a Responsible Officer of the Company as fairly presenting the financial condition, results of operations, shareholders&#8217; equity and cash flows of the Company and its Subsidiaries, subject only to normal year-end audit adjustments and the absence of footnotes.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Business Plan and Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as available, but in any event no later than February 15 of each fiscal year of the Company (or, if earlier, ten (10) Business Days after approval </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">111</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the Board of Directors of the Company), an annual business plan and budget of the Company and its Subsidiaries on a Consolidated basis, including forecasts prepared by management of the Company, in form satisfactory to the Administrative Agent, of Consolidated balance sheets and statements of income or operations and cash flows of the Company and its Subsidiaries on a quarterly basis for the then current fiscal year.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As to any information contained in materials furnished pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company shall not be separately required to furnish such information under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, but the foregoing shall not be in derogation of the obligation of the Company to furnish the information and materials described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above at the times specified therein.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Certificates&#59; Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the Required Lenders&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Accountants&#8217; Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Concurrently with the delivery of the financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a certificate of its independent certified public accountants certifying such financial statements and stating that in making the examination necessary therefor no knowledge was obtained of any Default of a financial nature under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or, if any such Default shall exist, stating the nature and status of such event.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Concurrently with the delivery of the financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) a duly completed Compliance Certificate signed by the chief executive officer, chief financial officer, treasurer or controller which is a Responsible Officer of the Company, including (A) information regarding the amount of all Dispositions, Involuntary Dispositions, Debt Issuances and Acquisitions that occurred during the period covered by such Compliance Certificate, (B) a certification as to whether the Loan Parties and their respective Subsidiaries have performed and observed each covenant and condition of the Loan Documents applicable to it during the period covered by the Compliance Certificate (or, if not, a listing of the conditions or covenants that have not been performed or observed and the nature and status of each such Default), (C) a certification of compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including financial covenant analyses and calculation for the period covered by the Compliance Certificate, (D) a listing of (1) all applications by any Loan Party, if any, for any Intellectual Property made since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), (2) all issuances of registrations or letters on existing applications by any Loan Party for any Intellectual Property received since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), and (3) all licenses </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">112</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any Intellectual Property entered into by any Loan Party since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), and (E) any updated insurance binder or other evidence of insurance for any insurance coverage of any Loan Party or any Subsidiary that was renewed, replaced or modified during the period covered by such Compliance Certificate, and (ii) a copy of management&#8217;s discussion and analysis with respect to such financial statements.  Unless the Administrative Agent or a Lender requests executed originals, delivery of the Compliance Certificate may be by electronic communication including fax or email and shall be deemed to be an original and authentic counterpart thereof for all purposes.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Audit Reports&#59; Management Letters&#59; Recommendations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly after any request by the Administrative Agent or any Lender, copies of any detailed audit reports, management letters or recommendations submitted to the Board of Directors (or the audit committee of the Board of Directors) of any Loan Party by independent accountants in connection with the accounts or books of any Loan Party or any of its Subsidiaries, or any audit of any of them.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Annual Reports&#59; Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of any Loan Party, and copies of all annual, regular, periodic and special reports and registration statements which any Loan Party may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, or with any national securities exchange, and in any case not otherwise required to be delivered to the Administrative Agent pursuant hereto.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Debt Securities Statements and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly, but in any event within five (5) days after the furnishing thereof, copies of any statement or report furnished to any holder of debt securities of any Loan Party or of any of its Subsidiaries pursuant to the terms of any indenture, loan or credit or similar agreement and not otherwise required to be furnished to the Lenders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other clause of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">SEC Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly, and in any event within five (5) Business Days after receipt thereof by any Loan Party or any Subsidiary thereof, copies of each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of any Loan Party or any Subsidiary thereof.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Not later than five (5) Business Days after receipt thereof by any Loan Party or any Subsidiary thereof, copies of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">113</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all material notices, requests and other documents (including amendments, waivers and other modifications) so received under or pursuant to any material instrument, indenture, loan or credit or similar agreement and, from time to time upon request by the Administrative Agent, such information and reports regarding such instruments, indentures and loan and credit and similar agreements as the Administrative Agent may reasonably request.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Environmental Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly after the assertion or occurrence thereof, notice of any action or proceeding against or of any noncompliance by any Loan Party or any of its Subsidiaries with any Environmental Law or Environmental Permit that would (i) reasonably be expected to have a Material Adverse Effect or (ii) cause any Mortgaged Properties to be subject to any restrictions on ownership, occupancy, use or transferability under any Environmental Law.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt;text-decoration:underline">Additional Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly, such additional information regarding the business, financial, legal or corporate affairs of any Loan Party or any Subsidiary thereof, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender (acting through the Administrative Agent) may from time to time reasonably request.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Documents required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (a) on which the Company posts such documents, or provides a link thereto on the Company&#8217;s website on the Internet at the website address listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (b) on which such documents are posted on the Company&#8217;s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; (i) the Company shall deliver paper copies of such documents to the Administrative Agent or any Lender upon its request to the Company to deliver such paper copies until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (ii) the Company shall notify the Administrative Agent (by fax transmission or e-mail transmission) of the posting of any such documents and, if requested, provide to the Administrative Agent by e-mail electronic versions (i.e., soft copies) of such documents.  The Administrative Agent shall have no obligation to request the delivery of or to maintain paper copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Company with any such request by a Lender for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Borrowers hereby acknowledge that (A) the Administrative Agent and&#47;or an Affiliate thereof may, but shall not be obligated to, make available to the Lenders and the L&#47;C Issuer materials and&#47;or information provided by or on behalf of the Borrowers hereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by posting the Borrower Materials on IntraLinks, Syndtrak, ClearPar or a substantially similar electronic transmission system (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (B) certain of the Lenders (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Public Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may have personnel who do not wish to receive material non-public information with respect to the Borrowers or their respective Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons&#8217; securities.  The Borrowers hereby agree that it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">114</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will use commercially reasonable efforts to identify that portion of the Borrower Materials that may be distributed to the Public Lenders and that (1) all such Borrower Materials shall be clearly and conspicuously marked &#8220;PUBLIC&#8221; which, at a minimum, shall mean that the word &#8220;PUBLIC&#8221; shall appear prominently on the first page thereof, (2) by marking Borrower Materials &#8220;PUBLIC,&#8221; the Borrowers shall be deemed to have authorized the Administrative Agent, any Affiliate thereof, the Arrangers, the L&#47;C Issuer and the Lenders to treat such Borrower Materials as not containing any material non-public information (although it may be sensitive and proprietary) with respect to the Borrowers or their respective securities for purposes of United States federal and state securities laws (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent such Borrower Materials constitute Information, they shall be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), (3) all Borrower Materials marked &#8220;PUBLIC&#8221; are permitted to be made available through a portion of the Platform designated &#8220;Public Side Information&#8221;, and (4) the Administrative Agent and any Affiliate thereof and the Arrangers shall be entitled to treat any Borrower Materials that are not marked &#8220;PUBLIC&#8221; as being suitable only for posting on a portion of the Platform not designated &#8220;Public Side Information.&#8221; Notwithstanding the foregoing, the Borrowers shall be under no obligation to mark any Borrower Materials &#8220;PUBLIC&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promptly notify the Administrative Agent and each Lender of&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">the occurrence of any Default&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">any matter that has resulted or would reasonably be expected to result in a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">the occurrence of or forthcoming occurrence of any ERISA Event, including a written notice specifying the nature thereof, what action the Company, any of its Subsidiaries or any of their respective ERISA Affiliates has taken, is taking or proposes to take with respect thereto and, when known, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect thereto&#59; and with reasonable promptness, provide copies of (i) each Schedule B (Actuarial Information) to the annual report (Form 5500 Series) filed by the Company, any of its Subsidiaries or any of their respective ERISA Affiliates with the Internal Revenue Service with respect to each Pension Plan&#59; (ii) all notices received by the Company, any of its Subsidiaries or any of their respective ERISA Affiliates from a Multiemployer Plan sponsor concerning an ERISA Event&#59; and (iii) copies of such other documents or governmental reports or filings relating to any Employee Benefit Plan as Administrative Agent shall reasonably request&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">(i) the institution of any Adverse Proceeding not previously disclosed in writing by the Company to the Lenders, or (ii) any material development in any Adverse Proceeding that, in the case of either </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (d)(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, is reasonably expected to result in damages not otherwise covered by insurance in excess of $7,500,000, or seeks to enjoin or otherwise prevent the consummation of, or to recover any damages or obtain relief as a result of, the transactions contemplated hereby, written notice thereof together with such other information as may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">115</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably available to the Company to enable the Lenders and their counsel to evaluate such matters&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">any material change in accounting policies or financial reporting practices by any Loan Party or any Subsidiary thereof, including any determination by the Company referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">(i) (A) any written recommendation from any Governmental Authority or other regulatory body to the Company or any of its Subsidiaries regarding any Governmental Authorizations or any Governmental Third Party Payor Program providers&#59; (B) any written notice regarding any accreditations or supplier numbers that have been suspended, revoked, or limited in any way&#59; or (C) notification of any penalties or sanctions imposed that, in the case of any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (f)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(f)(i)(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are material to the Company and its Subsidiaries, taken as a whole&#59; (ii) notice of termination of eligibility to participate in any reimbursement program of any Third Party Payor Program that is material to the Company and its Subsidiaries, taken as a whole&#59; (iii) the occurrence of any reportable event under any settlement agreement or corporate integrity agreement entered into by the Company or any of its Subsidiaries with any Governmental Authority&#59; (iv) notice that an officer, manager or employee of the Company or any of its Subsidiaries&#58; (A) has had a civil monetary penalty assessed against him or her pursuant to 42 U.S.C. &#167; 1320a7a or is the subject of a proceeding seeking to assess such penalty&#59; (B) has been excluded from participation in a Federal Health Care Program (as that term is defined in 42 U.S.C. &#167; 1320a7b) or is the subject of a proceeding seeking to assess such penalty&#59; (C) has been convicted (as that term is defined in 42 C.F.R.  &#167; 1001.2) of any of those offenses described in 42 U.S.C. &#167; 1320a7b or 18 U.S.C. &#167;&#167; 669, 1035, 1347 or 1518 or is the subject of a proceeding seeking to assess such penalty&#59; or (D) has been involved or named in a U.S. Attorney complaint made or any other action taken pursuant to the federal False Claims Act or a qui tam action&#59; and (v) copies of any report or communication from any Governmental Authority in connection with any inspection of any facility of the Company or any of its Subsidiaries other than those which are routine and non-material to the Company and its Subsidiaries taken as a whole&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">any Mortgaged Property that is, or becomes, a Flood Hazard Property&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">(i) the occurrence of any Reportable Event with respect to any Plan, a failure to make any required contribution to a Plan, the creation of any Lien in favor of the PBGC or a Plan or any withdrawal from, or the termination, or Insolvency of, any Multiemployer Plan, or (ii) the institution of proceedings or the taking of any other action by the PBGC or a Borrower or any ERISA Affiliate or any Multiemployer Plan with respect to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">116</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withdrawal from, or the termination, or Insolvency of, any Plan.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each notice pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be accompanied by a statement of a Responsible Officer of the Company setting forth details of the occurrence referred to therein and to the extent applicable, stating what action the Company has taken and proposes to take with respect thereto.  Each notice pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Payment of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pay and discharge as the same shall become due and payable, all its material obligations and liabilities, including (a) all federal, state and other material tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by such Loan Party or such Subsidiary, (b) all lawful claims which, if unpaid, would by law become a Lien upon its property, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by such Loan Party or such Subsidiary and (c) all Indebtedness, as and when due and payable, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness, except in the case of clauses (a), (b) and (c), to the extent that the failure to pay or discharge would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Preservation of Existence, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Take all reasonable action to maintain all material rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that the Company&#8217;s Board of Directors has determined that the preservation thereof is no longer desirable in the conduct of the business of such Person and the failure to do so would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Maintenance of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear excepted.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Make all necessary repairs thereto and renewals and replacements thereof except where the failure to do so would not reasonably be expected to have a Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Maintenance of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">117</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Maintenance of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Maintain with financially sound and reputable insurance companies which are not Affiliates of the Company, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily carried under similar circumstances by such other Persons, including (i) terrorism insurance and (ii) flood hazard insurance on all Mortgaged Properties that are Flood Hazard Properties, on such terms and in such amounts as required by the National Flood Insurance Reform Act of 1994 or as otherwise required by the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Evidence of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Cause the Administrative Agent to be named as lenders&#8217; loss payable, loss payee or mortgagee, as its interest may appear, and&#47;or additional insured with respect to any such insurance providing liability coverage or coverage in respect of any Collateral, and cause, unless otherwise agreed to by the Administrative Agent, each provider of any such insurance to agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Administrative Agent that it will give the Administrative Agent thirty (30) days prior written notice before any such policy or policies shall be altered or cancelled (or ten (10) days prior notice in the case of cancellation due to the nonpayment of premiums).  Annually, upon expiration of current insurance coverage, the Loan Parties shall provide, or cause to be provided, to the Administrative Agent, such evidence of insurance as required by the Administrative Agent, including, but not limited to&#58; (i) certified copies of such insurance policies, (ii) evidence of such insurance policies (including and as applicable, ACORD Form 28 certificates (or similar form of insurance certificate), and ACORD Form 25 certificates (or similar form of insurance certificate)), (iii) declaration pages for each insurance policy and (iv) lender&#8217;s loss payable endorsement if the Administrative Agent for the benefit of the Secured Parties is not on the declarations page for such policy.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Comply with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted, or (b) the failure to comply therewith would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maintain proper books of record and account, in which full, true and correct entries in conformity with GAAP and all requirements of Law shall be made of all financial dealings and transactions in relation to its business and activities.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Inspection Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">118</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permit representatives and independent contractors of the Administrative Agent and each Lender (to the extent accompanied by the Administrative Agent) to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at such reasonable times during normal business hours and as often as may be reasonably desired.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use the proceeds of the Credit Extensions (a) to refinance certain existing Indebtedness (including certain Indebtedness under the Existing Credit Agreement), and (b) for other general corporate purposes (including Permitted Acquisitions)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in no event shall the proceeds of the Credit Extensions be used in contravention of any Law or of any Loan Document.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Perform and observe all the terms and provisions of each Material Contract to be performed or observed by it, maintain each such Material Contract in full force and effect, enforce each such Material Contract in accordance with its terms, in each case, except to the extent that the failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Covenant to Guarantee Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within thirty (30) days (or such longer period of time as is agreed to by the Administrative Agent in its sole discretion) after the acquisition or formation of any Domestic Subsidiary (it being understood that any Subsidiary ceasing to be an Excluded Subsidiary but remaining a Subsidiary shall be deemed to be the acquisition of a Subsidiary for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), cause such Person to become a Guarantor hereunder by way of execution of a Joinder Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no Excluded Subsidiary shall be required to become a Guarantor (subject to the last sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In connection with the foregoing, the Loan Parties shall deliver to the Administrative Agent, with respect to each new Guarantor to the extent applicable, Organization Documents, resolutions, incumbency certificates, good standing certificates, lien searches, searches of Intellectual Property records and substantially the same documentation otherwise required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including applicable Mortgages and Mortgaged Property Security Documents) and, to the extent required by the Administrative Agent, favorable opinions of counsel to such Person (which should cover, among other things, the legality, binding effect and enforceability), all in form, content and scope satisfactory to the Administrative Agent.  It is understood and agreed that, to the extent that, as of the last day of any Measurement Period for which financial statements were required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Consolidated EBITDA for such Measurement Period attributable to all Loan Parties in the aggregate does not equal or exceed seventy percent (70%) of Consolidated EBITDA for such Measurement Period, the Company shall within thirty (30) days (or such longer period of time as is agreed to by the Administrative Agent in its sole discretion) cause Subsidiaries that would otherwise be classified as Excluded Subsidiaries to become Guarantors in accordance with the foregoing provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the extent necessary so that the Consolidated EBITDA that is attributable only to the Loan Parties is equal to or exceeds seventy percent (70%) of Consolidated EBITDA for such Measurement Period.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Covenant to Give Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except with respect to Excluded Property&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">119</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Loan Party shall cause (i) one hundred percent (100%) of the issued and outstanding Equity Interests of each Domestic Subsidiary directly owned by a Loan Party (other than any CFC Holdco) and (ii) sixty five percent (65%) (or such greater percentage that, due to a change in an applicable Law after the Closing Date, (A) could not reasonably be expected to cause the undistributed earnings of such Foreign Subsidiary or such CFC Holdco as determined for United States federal income tax purposes to be treated as a deemed dividend to such Foreign Subsidiary&#8217;s or such CFC Holdco&#8217;s, as applicable, United States parent and (B) could not reasonably be expected to cause any material adverse tax consequences) of the issued and outstanding Equity Interests entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) and one hundred percent (100%) of the issued and outstanding Equity Interests not entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) in each Foreign Subsidiary and each CFC Holdco, in each case, directly owned by a Loan Party to be subject at all times to a first priority, perfected Lien in favor of the Administrative Agent, for the benefit of the Secured Parties, pursuant to the terms and conditions of the Collateral Documents, together with opinions of counsel and any filings and deliveries necessary in connection therewith to perfect the security interests therein, all in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Other Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Loan Party shall cause all property of each Loan Party to be subject at all times to first priority, perfected and, in the case of real property (whether leased or owned), title insured (to the extent such title insurance is required by the Administrative Agent) Liens in favor of the Administrative Agent to secure the Secured Obligations pursuant to the Collateral Documents or, with respect to any such property acquired subsequent to the Closing Date, such other additional security documents as the Administrative Agent shall request (subject to Permitted Liens) and, in connection with the foregoing, deliver to the Administrative Agent such other documentation as the Administrative Agent may request including filings and deliveries necessary to perfect such Liens, Organization Documents, resolutions, Mortgaged Property Support Documents and favorable opinions of counsel to such Person, all in form, content and scope reasonably satisfactory to the Administrative Agent.  It is understood and agreed that, with respect to any Mortgaged Property acquired by any Loan Party after the Closing Date, the Loan Parties shall have thirty (30) days (or such longer period of time as may be agreed to by the Administrative Agent in its sole discretion) to comply with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such Mortgaged Property.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Landlord Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the case of any tangible personal property Collateral located at any other premises leased by a Loan Party containing personal property Collateral with a value in excess of $2,500,000, the Loan Parties will provide the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">120</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administrative Agent with such estoppel letters, consents and waivers from the landlords on such real property to the extent (i) requested by the Administrative Agent and (ii) the Loan Parties are able to secure such letters, consents and waivers after using commercially reasonable efforts (such letters, consents and waivers shall be in form and substance satisfactory to the Administrative Agent).</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Account Control Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Loan Parties shall not open, maintain or otherwise have any deposit or other accounts (including securities accounts) at any bank or other financial institution, or any other account where money or securities are or may be deposited or maintained with any Person, other than (i) deposit accounts and securities accounts that are maintained at all times with the Administrative Agent, (ii) Excluded Deposit and Securities Accounts, (iii) deposit accounts that are maintained at all times with depositary institutions as to which the Administrative Agent shall have received a Qualifying Control Agreement, (iv) securities accounts that are maintained at all times with financial institutions as to which the Administrative Agent shall have received a Qualifying Control Agreement and (v) any other deposit or securities account to the extent that the Administrative Agent has not requested that the Loan Parties deliver a Qualifying Control Agreement with respect thereto (it being understood that the Loan Parties shall have ninety (90) days (or such longer period of time as is agreed to by the Administrative Agent in its sole discretion) after such request by the Administrative Agent to deliver such Qualifying Control Agreements).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promptly upon request by the Administrative Agent, or any Lender through the Administrative Agent, (a) correct any material defect or error that may be discovered in any Loan Document or in the execution, acknowledgment, filing or recordation thereof, and (b) do, execute, acknowledge, deliver, record, re-record, file, re-file, register and re-register any and all such further acts, deeds, certificates, assurances and other instruments as the Administrative Agent, or any Lender through the Administrative Agent, may reasonably require from time to time in order to (i) carry out more effectively the purposes of the Loan Documents, (ii) to the fullest extent permitted by applicable Law, subject any Loan Party&#8217;s or any of its Subsidiaries&#8217; properties, assets, rights or interests to the Liens now or hereafter intended to be covered by any of the Collateral Documents, (iii) perfect and maintain the validity, effectiveness and priority of any of the Collateral Documents and any of the Liens intended to be created thereunder and (iv) assure, convey, grant, assign, transfer, preserve, protect and confirm more effectively unto the Secured Parties the rights granted or now or hereafter intended to be granted to the Secured Parties under any Loan Document or under any other instrument executed in connection with any Loan Document to which any Loan Party or any of its Subsidiaries is or is to be a party, and cause each of its Subsidiaries to do so.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Anti-Corruption Laws&#59; Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conduct its business in compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">121</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other jurisdictions and with all applicable Sanctions, and, to the extent applicable, maintain policies and procedures designed to promote and achieve compliance with such laws and Sanctions.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Compliance Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">To the extent necessary, review and revise its policies and procedures to provide continuing compliance with all applicable Health Care Laws.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Maintain appropriate programs and procedures for communicating such policies and procedures to all officers, directors and employees of the Company and its Subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Provide that all officers, directors and employees of the Company and its Subsidiaries are able to report violations of any Health Care Laws.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Provide that such reported violations are adequately addressed and corrected as soon as practicable.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Condition of Participation in Third Party Payor Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable to the Company and its Subsidiaries in the conduct of their business, (a) maintain its qualification for participation in, and payment under, Third Party Payor Programs, that provide for payment or reimbursement for services, except to the extent such loss or relinquishment would not reasonably be expected to have a Material Adverse Effect&#59; and (b) promptly furnish or cause to be furnished to Administrative Agent and Lenders copies of all material reports and correspondence, if any, it sends or receives relating to any material loss or revocation (or material threatened loss or revocation) of any qualification described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.41pt"><br><br>NEGATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Loan Parties hereby covenants and agrees that on the Closing Date and thereafter until the Facility Termination Date, no Loan Party shall, nor shall it permit any Subsidiary to, directly or indirectly&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, except for the following (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Liens pursuant to any Loan Document&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Liens existing on the Second Amendment Effective Date and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and any renewals or extensions thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) the property covered thereby is not changed, (ii) the amount secured or benefited thereby is not increased except by an amount equal to a reasonable premium or other reasonable amount paid, and fees and expenses </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">122</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably incurred, in connection with any such renewal or extension of the underlying Indebtedness and by an amount equal to any existing commitments unutilized under the underlying Indebtedness, (iii) the direct or any contingent obligor with respect thereto is not changed, and (iv) any renewal, replacement, refinancing, restructuring or extension of the obligations secured or benefited thereby is a Permitted Refinancing permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Liens for taxes not yet due or that are being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, adequate reserves with respect thereto are maintained on the books of the Company or its Subsidiaries, as the case may be, in conformity with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">statutory Liens of landlords, banks (and rights of set off), of carriers, warehousemen, mechanics, repairmen, workmen and materialmen, and other Liens imposed by law (other than any such Lien imposed pursuant to Section 401(a)(29) or 412(n) of the Code or by ERISA), in each case incurred in the ordinary course of business (i) for amounts not yet overdue or (ii) for amounts that are overdue and that (in the case of any such amounts overdue for a period in excess of five (5) days) are being contested in good faith by appropriate proceedings, so long as such reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made for any such contested amounts&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Liens incurred in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other types of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government contracts, trade contracts, performance and return-ofmoney bonds and other similar obligations (exclusive of obligations for the payment of borrowed money or other Indebtedness)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">easements, rights-of-way, restrictions (including zoning restrictions), covenants, licenses, encroachments, protrusions and other similar charges or encumbrances, and minor title deficiencies on or with respect to any real property, in each case whether now or hereafter in existence, (i) not securing Indebtedness, (ii) not individually or in the aggregate materially impairing the value or marketability of such real property and (iii) not individually or in the aggregate materially interfering with the ordinary conduct of the business of the Company and its Subsidiaries at such real property&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Liens arising out of judgments, attachments or awards not resulting in an Event of Default&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Liens securing Indebtedness permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; (i) such Liens do not at any time encumber any property other than the property financed by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">123</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Indebtedness together with any accessions thereto and proceeds thereof, (ii) the Indebtedness secured thereby does not exceed the cost (negotiated on an arm&#8217;s length basis) of the property being acquired on the date of acquisition and (iii) such Liens attach to such property concurrently with or within one hundred eighty (180) days after the acquisition thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">any interest or title of a lessor under any lease entered into by the Company or any other Subsidiary in the ordinary course of its business and covering only the assets so leased, so long as no such leases, individually or in the aggregate, interfere in any material respect with the ordinary conduct of the business of the Company or any such Subsidiary or materially impair the use (for its intended purposes) or the value of the property subject thereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by the Company or any Subsidiary in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">non-exclusive licenses of Intellectual Property granted by the Company or any Subsidiary in the ordinary course of business and not interfering in any material respect with the ordinary conduct of business of the Company and its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">the filing of UCC financing statements solely as a precautionary measure in connection with operating leases or consignment of goods&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.13pt">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Liens securing Indebtedness permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) such Lien is not created in contemplation of or in connection with such Acquisition, (ii) such Lien shall not apply to any other property of the Company or any Subsidiary (other than improvements on the property subject thereto and proceeds thereof), and (iii) such Lien shall secure only those obligations it secures on the date of Acquisition, and any renewals, replacements, refinancings, restructurings or extensions thereof so long as the principal amount of such renewals, replacements, refinancings, restructurings or extensions thereof does not exceed the principal amount of the obligations being renewed, replaced, refinanced, restructured or extended except by an amount equal to a reasonable premium or other reasonable amount paid, and fees and expenses reasonably incurred, in each case, in connection with any such renewals, replacements, refinancings, restructurings or extensions of the underlying Indebtedness&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">124</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">other Liens not permitted by the foregoing clauses of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> securing Indebtedness or other obligations permitted pursuant to this Agreement in an aggregate principal amount not to exceed at any one time outstanding the greater of (i) $35,000,000, and (ii) an amount equal to ten percent (10%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Create, incur, assume or suffer to exist any Indebtedness, except&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Indebtedness under the Loan Documents&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Indebtedness outstanding on the Second Amendment Effective Date and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (and any Permitted Refinancing thereof)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Indebtedness in respect of Capitalized Leases, Synthetic Lease Obligations and purchase money obligations incurred by the Company or any of its Subsidiaries to finance the purchase of fixed assets, and renewals, refinancings and extensions thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) the total of all such Indebtedness for all such Persons taken together shall not exceed an aggregate principal amount at any one time outstanding of the greater of (i) $15,000,000, and (ii) an amount equal to five percent (5%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (ii) such Indebtedness when incurred shall not exceed the purchase price of the asset(s) financed, and (iii) no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance outstanding thereon at the time of such refinancing&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">(i) Indebtedness of a Person that becomes a Subsidiary or Indebtedness incurred to finance assets of a Person that are acquired in a Permitted Acquisition in an aggregate amount not to exceed at any time the greater of (i) $35,000,000, and (ii) an amount equal to ten percent (10%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (A) such Indebtedness existed at the time such Person became a Subsidiary or at the time such assets were acquired and, in each case, was not created in anticipation thereof, and (B) such Indebtedness is not guaranteed in any respect by the Company or any of its Subsidiaries (other than by any such Person that so becomes a Subsidiary), and (ii) any Permitted Refinancing of any Indebtedness specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Indebtedness consisting of Earn Out Obligations incurred in connection with Permitted Acquisitions&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">125</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">Indebtedness in respect of netting services, overdraft protections and otherwise in connection with deposit accounts, in each case incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">unsecured Indebtedness of the Company or any of its Subsidiaries owed to sellers in connection with Permitted Acquisitions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) the Company shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate demonstrating that, upon giving Pro Forma Effect to the incurrence of such Indebtedness, the Consolidated Leverage Ratio shall be at least 0.50 less than the maximum Consolidated Leverage Ratio then permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (ii) no such Indebtedness shall require the Company or any of its Subsidiaries to comply with any financial covenants&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">intercompany Indebtedness arising pursuant to Investments permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than by reference to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or any clause hereof))&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">obligations (contingent or otherwise) of the Company or any Subsidiary existing or arising under any Swap Contract&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) such obligations are (or were) entered into by such Person in the ordinary course of business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person, or changes in the value of securities issued by such Person, and not for purposes of speculation or taking a &#8220;market view,&#8221; and (ii) such Swap Contract does not contain any provision exonerating the non-defaulting party from its obligation to make payments on outstanding transactions to the defaulting party&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">&#91;reserved&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Guarantees with respect to Indebtedness of any Loan Party permitted under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if the Indebtedness being Guaranteed is subordinated to the Secured Obligations, such Guarantee shall be subordinated to the Guaranty on terms at least as favorable to the Lenders as those contained in the subordination of such Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">Indebtedness under Secured Cash Management Agreements&#59; </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.13pt">to the extent constituting Indebtedness, Permitted Disqualified Capital Stock&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">to the extent constituting Indebtedness, Guarantees permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">126</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">other secured Indebtedness not permitted by any of the foregoing clauses of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in an aggregate principal amount not to exceed at any time outstanding the greater of (i) $35,000,000, and (ii) an amount equal to ten percent (10%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">other unsecured Indebtedness not permitted by any of the foregoing clauses of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) no Default or Event of Default shall have occurred and be continuing at the time of incurrence of such Indebtedness or would result therefrom, and (ii) upon giving Pro Forma Effect to such Indebtedness, the Loan Parties would be in compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, Subsidiaries that are not Loan Parties may not incur Indebtedness for borrowed money under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in an aggregate principal amount at any time outstanding in excess of the greater of (i) $15,000,000, and (ii) an amount equal to five percent (5%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Make or hold any Investments, except&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Investments existing as of the Second Amendment Effective Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">(i) Investments owned as of the Second Amendment Effective Date in any Subsidiary of the Company, and (ii) Investments made after the Second Amendment Effective Date in any Person that is a Loan Party prior to giving effect to such Investment (including, for the avoidance of doubt, Guarantees by a Loan Party of the obligations of another Loan Party)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Investments made after the Second Amendment Effective Date by Loan Parties in Subsidiaries that are not Loan Parties and joint ventures of the Company and its Subsidiaries, in an aggregate principal amount not to exceed at any one time outstanding the greater of (i) $85,000,000, and (ii) an amount equal to twenty-five percent (25%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Investments in cash and Cash Equivalents&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">127</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Investments by any Subsidiary of the Company that is not a Loan Party in any other Subsidiary of the Company that is not a Loan Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#91;reserved&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">loans and advances to employees of the Company or any of its Subsidiaries made in the ordinary course of business in compliance with applicable requirements of Law (including Section 402 of the SarbanesOxley Act) in an aggregate principal amount not to exceed $2,000,000 at any time outstanding&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Guarantees permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than by reference to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or any clause hereof))&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">Permitted Acquisitions&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">(i) Investments in securities of trade creditors or customers received in connection with the settlement of debts, the satisfaction of judgments, settlements, compromises or resolutions of litigation, arbitration or other disputes, upon foreclosure or pursuant to any plan of reorganization or liquidation or similar arrangement upon the bankruptcy or insolvency of such trade creditors or customers and (ii) deposits, prepayments and other credits to suppliers made in the ordinary course of business consistent with the past practices of the Company or any of its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Guarantees of (i) reasonable indemnity obligations of Subsidiaries in connection with any Disposition of assets by such Subsidiaries permitted under this Agreement or any contribution of assets to a Subsidiary pursuant to an Investment permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (ii) obligations of Subsidiaries under operating leases (in the case of each of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, other than such obligations of Subsidiaries constituting Indebtedness)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">Guarantees of obligations of non-Wholly Owned Subsidiaries to repurchase Permitted Disqualified Capital Stock&#59; </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.13pt">any other Investment not permitted by any of the foregoing clauses of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) no Default or Event of Default shall have occurred and be continuing at the time of such Investment or would result therefrom, and (ii) upon giving Pro Forma Effect to such Investment, the Consolidated Leverage Ratio would not exceed 2.75 to 1.0&#59; and </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">other Investments not permitted by any of the foregoing clauses of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in an aggregate principal amount not to exceed at any time outstanding the greater of (i) $50,000,000, and (ii) an amount equal to fifteen percent (15%) of Consolidated EBITDA as of the most recent fiscal quarter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">128</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (in any case, net of amounts realized in respect of such Investments upon the sale, collection or return of capital (not to exceed the original amount invested)).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Fundamental Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; (a) the Company may merge or consolidate with any of its Subsidiaries (other than Amedisys Holding) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company shall be the continuing or surviving Person&#59; (b) Amedisys Holding may merge or consolidate with any of its Subsidiaries </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Amedisys Holding shall be the continuing or surviving Person&#59; (c) any Loan Party other than a Borrower may merge or consolidate with any other Loan Party other than a Borrower&#59; (d) any Subsidiary that is not a Loan Party may be merged or consolidated with or into any Loan Party so long as such Loan Party shall be the continuing or surviving Person&#59; (e) any Subsidiary that is not a Loan Party may be merged or consolidated with or into any other Subsidiary that is not a Loan Party&#59; (f) any Subsidiary (other than Amedisys Holding) may dissolve, liquidate or wind up its affairs at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) such dissolution, liquidation or winding up, as applicable, would not reasonably be expected to have a Material Adverse Effect and (ii) the Lien on and security interest in any property of such Subsidiary granted or to be granted in favor of the Secured Parties under the Collateral Documents shall be maintained or created in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as applicable&#59; (g) any Loan Party (other than a Borrower) may transfer all or substantially all of its assets to a Subsidiary that is not a Loan Party to effectuate an Investment permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (so long as such transfer is permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; and (h) so long as no Event of Default shall have occurred and be continuing or would result therefrom, any Subsidiary (other than Amedisys Holding) may change its legal form if the Company determines that such action is in its best interests and makes such change in a manner reasonably acceptable to the Administrative Agent (including with respect to the continued perfection of Liens on the Collateral, a reaffirmation by each Loan Party of its continued obligations under this Agreement and the other Loan Documents, continued compliance by the Loan Parties with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and satisfaction of customary PATRIOT Act and Beneficial Ownership Regulation requirements).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Make any Disposition unless (a) the assets are sold for fair market value (to the extent the value is greater than $10,000,000 as determined in good faith by the Board of Directors of the Company), (b) at least seventy percent (70%) of the aggregate consideration for such Disposition is received in cash or Cash Equivalents, (c) no Default or Event of Default exists or would result from such Disposition, and (d) the aggregate net book value of all assets sold or otherwise disposed of by the Loan Parties and their Subsidiaries shall not exceed (i) in any fiscal year of the Company, the greater of (A) $25,000,000, and (B) an amount equal to seven and a half percent (7.5%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (ii) during the term of this Agreement, the greater of (A) $100,000,000, and (B) an amount equal to thirty percent (30%) of Consolidated EBITDA as of the most recent fiscal quarter end for which the Company was required to deliver financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Restricted Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">129</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so, except that&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">each Subsidiary may make Restricted Payments (i) to any Loan Party or (ii) to any Subsidiary that is not a Loan Party that owns Equity Interests in such Subsidiary (and, in the case of Restricted Payments by a non-Wholly Owned Subsidiary, to the Company and any such other Subsidiary and to each other owner of Equity Interests of such Subsidiary based on their relative ownership interests)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the Company and each Subsidiary may declare and make dividend payments or other distributions payable solely in the Qualified Capital Stock of such Person&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;the Company may make any other Restricted Payment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) no Default or Event of Default shall have occurred and be continuing at the time of such Restricted Payment or would result therefrom, and (ii) upon giving Pro Forma Effect to such Restricted Payment, the Consolidated Leverage Ratio is less than 2.75 to 1.0.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Change in Nature of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Engage in any material line of business substantially different from those lines of business conducted by the Company and its Subsidiaries on the Closing Date or any business substantially related or incidental thereto.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Enter into or permit to exist any transaction or series of transactions with any officer, director or Affiliate of such Person other than (a) advances of working capital to any Loan Party, (b) transfers of cash and assets to any Loan Party, (c) intercompany transactions expressly permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (d) reasonable and customary director, officer and employee compensation (including bonuses) and other benefits (including retirement, health, stock option and other benefit plans) and reasonable indemnification and severance arrangements, (e) transactions pursuant to agreements or plans in existence on the Second Amendment Effective Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (f) except as otherwise specifically limited in this Agreement, other transactions which are entered into in the ordinary course of such Person&#8217;s business on terms and conditions substantially as favorable to such Person as would be obtainable by it in a comparable arms-length transaction with a Person other than an officer, director or Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Burdensome Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Enter into, or permit to exist, any Contractual Obligation that (a) encumbers or restricts the ability of any such Person to (i) make Restricted Payments to any Loan Party, (ii) pay any Indebtedness or other obligations owed to any Loan Party, (iii) make loans or advances to any Loan Party, (iv) transfer any of its property to any Loan Party, (v) pledge its property pursuant to the Loan Documents or any renewals, refinancings, exchanges, refundings or extension thereof or (vi) act as a Loan Party pursuant to the Loan Documents or any renewals, refinancings, exchanges, refundings or extension thereof, except (in respect of any of the matters referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above) for (1) this Agreement and the other Loan Documents, (2) customary restrictions and conditions contained in any agreement relating to the sale of any property permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> pending the consummation of such sale, (3) any agreement in effect at the time such Subsidiary becomes a Subsidiary of the Company, so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">130</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long as such agreement was not entered into in connection with or in contemplation of such person becoming a Subsidiary of the Company, (4) any instrument governing Indebtedness assumed in connection with any Permitted Acquisition, which encumbrance or restriction is not applicable to any Person, or the properties or assets of any Person, other than the Person or the properties or assets of the Person so acquired and (5) customary provisions in joint venture agreements and other similar agreements applicable to joint ventures entered into in the ordinary course of business relating to the assets and Equity Interests of such joint venture, or (b) requires the grant of any security for any obligation if such property is given as security for the Secured Obligations.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use the proceeds of any Credit Extension, whether directly or indirectly, and whether immediately, incidentally or ultimately, to purchase or carry margin stock (within the meaning of Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Financial Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Consolidated Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Permit the Consolidated Leverage Ratio as of the end of any Measurement Period ending as of the end of any fiscal quarter of the Company to be greater than 3.50 to 1.0&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for each of the four (4) Measurement Periods immediately following a Qualified Acquisition (such period of increase, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leverage Increase Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the ratio set forth above shall be increased to 4.00 to 1.0&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (A) for at least one (1) fiscal quarter immediately following each Leverage Increase Period, the Consolidated Leverage Ratio as of the end of such fiscal quarter shall not be greater than 3.50 to 1.0 prior to giving effect to another Leverage Increase Period pursuant to the immediately preceding proviso and (B) the Leverage Increase Period shall only apply with respect to the calculation of the Consolidated Leverage Ratio for purposes of determining compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the end of any Measurement Period ending as of the end of any fiscal quarter of the Company and for purposes of any Qualified Acquisition Pro Forma Determination.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Consolidated Interest Coverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Permit the Consolidated Interest Coverage Ratio as of the end of any Measurement Period ending as of the end of any fiscal quarter of the Company to be less than 3.00 to 1.0.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendments of Organization Documents&#59; Fiscal Year&#59; Legal Name, State of Organization&#59; Form of Entity and Accounting Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Terminate, amend or modify any of its Organization Documents (including (i) by the filing or modification of any certificate of designation and (ii) any election to treat any Pledged Shares (as defined in the Pledge Agreement) as a &#8220;security&#8221; under Section 8-103 of the UCC other than concurrently with the delivery of certificates representing such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">131</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pledged Shares to the Administrative Agent) or any agreement to which it is a party with respect to its Equity Interests (including any stockholders&#8217; agreement), or enter into any new agreement with respect to its Equity Interests, other than any such amendments or modifications or such new agreements which are not adverse in any material respect to the interests of the Lenders.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Change its fiscal year.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Change its name, state of organization, form of organization or principal place of business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such changes may be made so long as written notice of such change is provided to the Administrative Agent within fifteen (15) Business Days (or such longer period as the Administrative Agent shall accept in its sole discretion) thereafter.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Permit any Domestic Subsidiary that is not a C-corporation that does not hold Equity Interests of a CFC on the Closing Date to hold Equity Interests of a CFC.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Permit Amedisys Holding to fail be a Wholly Owned Subsidiary of the Company.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">Make any change in accounting policies or reporting practices, except as required by GAAP.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Sale and Leaseback Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Enter into any Sale and Leaseback Transaction.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Prepayments, Etc. of Junior Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Make any payment or prepayment of principal of or redeem, purchase, defease or otherwise satisfy prior to the scheduled maturity thereof in any manner any Indebtedness that is expressly subordinated in right of payment to the Secured Obligations, any Indebtedness secured by Liens on the Collateral contractually junior to those created under the Collateral Documents, any unsecured Indebtedness for borrowed money or any Permitted Refinancing of any of the foregoing (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Junior Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or make any payment in violation of any subordination terms applicable to any such Indebtedness (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Junior Debt Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except that&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">the Company and each Subsidiary may declare and make Junior Debt Payments payable solely in the Qualified Capital Stock of such Person&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the Company and its Subsidiaries may make any other Junior Debt Payment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) no Default or Event of Default shall have occurred and be continuing at the time of such Junior Debt Payment or would result therefrom, and (ii) upon giving Pro Forma Effect to such Junior Debt Payment, the Consolidated Leverage Ratio is less than 2.75 to 1.0.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendment, Etc. of Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">132</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amend or modify any of the terms of any Indebtedness of any Loan Party or any Subsidiary (other than Indebtedness arising under the Loan Documents) if such amendment or modification would add or change any terms in a manner adverse to any Loan Party or any Subsidiary, shorten the final maturity or Weighted Average Life to Maturity, require any payment to be made sooner than originally scheduled, increase the interest rate applicable thereto or otherwise be materially adverse to the Secured Parties.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Ownership of Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provisions of this Agreement to the contrary, (a) establish, create or acquire any additional Subsidiaries without the prior written consent of the Required Lenders&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without such consent, the Company may (i) establish or create one or more Wholly Owned Subsidiaries of the Company that are Domestic Subsidiaries or (ii) establish, create or acquire one or more Domestic Subsidiaries in connection with an Investment permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, so long as, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be complied with to the extent required by such sections&#59; (b) permit any Loan Party or any Subsidiary to issue or have outstanding any shares of Disqualified Capital Stock (other than Permitted Disqualified Capital Stock)&#59; (c) create, incur, assume or suffer to exist any Lien on any Equity Interests of any Subsidiary of any Loan Party, except for Permitted Liens&#59; or (d) own, directly or indirectly, any Foreign Subsidiary (other than any Foreign Subsidiary that is organized under the laws of a territory of the United States).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use any Credit Extension or the proceeds of any Credit Extension, or lend, contribute or otherwise make available such Credit Extension or the proceeds of any Credit Extension to any Person, to fund any activities of or business with any Person, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as Lender, Arranger, Administrative Agent, L&#47;C Issuer, Swingline Lender, or otherwise) of Sanctions.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use any Credit Extension or the proceeds of any Credit Extension for any purpose which would breach the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in other jurisdictions.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Specified Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permit the aggregate Net Revenues of the Specified Entities to exceed five percent (5%) of the consolidated Net Revenues of the Company and its Subsidiaries (excluding any contribution to Net Revenues from Subsidiaries that are not Wholly Owned Subsidiaries).</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.13pt"><br><br>EVENTS OF DEFAULT AND REMEDIES</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any of the following shall constitute an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Non-Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Borrower or any other Loan Party fails to pay (i) when and as required to be paid herein, any amount </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">133</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of principal of any Loan or any L&#47;C Obligation or deposit any funds as Cash Collateral in respect of L&#47;C Obligations, or (ii) within three (3) Business Days after the same becomes due, any interest on any Loan or on any L&#47;C Obligation, any fee due hereunder, or any other amount payable hereunder or under any other Loan Document&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Specific Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Loan Party fails to perform or observe any term, covenant or agreement contained in any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.03(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.05(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (with respect to the Borrowers only), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Other Defaults</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Loan Party fails to perform or observe any other covenant or agreement (not specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above) contained in any Loan Document on its part to be performed or observed and such failure continues for a period of ten (10) Business Days after the earlier of (i) notice to the Company from the Administrative Agent or the Required Lenders, and (ii) a Responsible Officer becoming aware of such default&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Company or any other Loan Party herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be materially incorrect or misleading when made or deemed made&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Cross-Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Any Loan Party or any Subsidiary thereof (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than Indebtedness hereunder and Indebtedness under Swap Contracts) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than the Threshold Amount (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if (and only for so long as) all such failures to pay are in the nature of a setoff against purchase price adjustments or indemnities, in each case, arising from seller financing permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in connection with Permitted Acquisitions, then such $15,000,000 threshold amount shall be deemed to be $25,000,000), or (B) fails to observe or perform any other agreement or condition relating to any Indebtedness or Guarantee having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than the Threshold Amount or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such Guarantee (or a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">134</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded, or (ii) there occurs under any Swap Contract an Early Termination Date (as defined in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which a Loan Party or any Subsidiary thereof is the Defaulting Party (as defined in such Swap Contract) or (B) any Termination Event (as so defined) under such Swap Contract as to which a Loan Party or any Subsidiary thereof is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by such Loan Party or such Subsidiary as a result thereof is greater than the Threshold Amount&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Insolvency Proceedings, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any Loan Party or any Subsidiary thereof institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors&#59; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property&#59; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for sixty (60) days&#59; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for sixty (60) days, or an order for relief is entered in any such proceeding&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Inability to Pay Debts&#59; Attachment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Any Loan Party or any Subsidiary thereof becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of any such Person and is not released, vacated or fully bonded within sixty (60) days after its issue or levy&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Judgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There is entered against any Loan Party or any Subsidiary thereof (i) one or more final judgments or orders for the payment of money in an aggregate amount (as to all such judgments and orders) exceeding the Threshold Amount (to the extent not covered by independent third-party insurance as to which the insurer has been notified of the potential claim and does not dispute coverage), or (ii) any one or more non-monetary final judgments that have, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and, in either case, (A) enforcement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">135</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of thirty (30) consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (i) The occurrence of an ERISA Event, or (ii) any other event or condition shall occur or exist with respect to a Plan, and, such event or condition, together with all other such events or conditions, if any, has had or would reasonably be expected to have a Material Adverse Effect&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt;text-decoration:underline">Invalidity of Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all Obligations arising under the Loan Documents, ceases to be in full force and effect&#59; or any Loan Party or any Affiliate thereof contests in any manner the validity or enforceability of any Loan Document&#59; or any Loan Party denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any Loan Document&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company or any of its Subsidiaries shall fail to (i) comply, in any material respect, with any Health Care Law or (ii) maintain any material Governmental Authorization, material accreditation or material Government Third Party Payor Program provider number or agreement or otherwise become no longer eligible for participation in any material Government Third Party Payor Program, and, in each case, such failure will cause a Material Adverse Effect&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt;text-decoration:underline">Collateral Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Lien created by the Collateral Documents shall at any time fail to constitute a valid and (to the extent required by the Collateral Documents or as otherwise permitted under this Agreement) perfected Lien on any material portion of the Collateral purported to be subject thereto, securing the obligations purported to be secured thereby, with the priority required by the Loan Documents, or any Loan Party shall so assert in writing, in each case other than as a result of action or inaction of the Administrative Agent or any Lender&#59; or </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.13pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There occurs any Change of Control.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if a Default shall have occurred under the Loan Documents, then such Default will continue to exist until it either is cured (to the extent specifically permitted) in accordance with the Loan Documents or is otherwise expressly waived by the Administrative Agent (with the approval of requisite Appropriate Lenders (in their sole discretion) as determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; and once an Event of Default occurs under the Loan Documents, then such Event of Default will continue to exist until it is expressly waived by the requisite Appropriate Lenders or by the Administrative Agent with the approval of the requisite Appropriate Lenders, as required hereunder in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">136</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Remedies upon Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">declare the Commitment of each Lender to make Loans and any obligation of the L&#47;C Issuer to make L&#47;C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Borrowers&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">require that the Borrowers Cash Collateralize the L&#47;C Obligations (in an amount equal to the Minimum Collateral Amount with respect thereto)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">exercise on behalf of itself, the Lenders and the L&#47;C Issuer all rights and remedies available to it, the Lenders and the L&#47;C Issuer under the Loan Documents or applicable Law or equity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon the occurrence of an actual or deemed entry of an order for relief with respect to any Borrower under the Bankruptcy Code of the United States, the obligation of each Lender to make Loans and any obligation of the L&#47;C Issuer to make L&#47;C Credit Extensions shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrowers to Cash Collateralize the L&#47;C Obligations as aforesaid shall automatically become effective, in each case without further act of the Administrative Agent or any Lender.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Application of Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">After the exercise of remedies provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or after the Loans have automatically become immediately due and payable and the L&#47;C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or if at any time insufficient funds are received by and available to the Administrative Agent to pay fully all Secured Obligations then due hereunder, any amounts received on account of the Secured Obligations shall, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, be applied by the Administrative Agent in the following order&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to payment of that portion of the Secured Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) payable to the Administrative Agent in its capacity as such&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to payment of that portion of the Secured Obligations constituting fees, indemnities and other amounts (other than principal, interest and Letter of Credit Fees) payable to the Lenders and the L&#47;C Issuer (including fees, charges and disbursements of counsel to the respective Lenders and the L&#47;C Issuer) arising under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">137</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Loan Documents and amounts payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, ratably among them in proportion to the respective amounts described in this clause </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> payable to them&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to payment of that portion of the Secured Obligations constituting accrued and unpaid Letter of Credit Fees and interest on the Loans and L&#47;C Borrowings, ratably among the Lenders and the L&#47;C Issuers in proportion to the respective amounts described in this clause </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> held by them&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to (a) payment of that portion of the Secured Obligations constituting accrued and unpaid principal of the Loans and L&#47;C Borrowings, (b) payment of that portion of the Secured Obligations then owing under Secured Hedge Agreements, (c) payment of that portion of the Secured Obligations then owing under Secured Cash Management Agreements and (d) Cash Collateralize that portion of L&#47;C Obligations comprised of the aggregate undrawn amount of Letters of Credit, ratably among the Lenders, Hedge Banks, Cash Management Banks and the L&#47;C Issuers in proportion to the respective amounts described in this clause </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> held by them&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Last</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the balance, if any, after all of the Secured Obligations have been paid in full, to the Borrowers or as otherwise required by Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above shall be applied to satisfy drawings under such Letters of Credit as they occur.  If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the other Secured Obligations, if any, in the order set forth above.  Excluded Swap Obligations with respect to any Loan Party shall not be paid with amounts received from such Loan Party or its assets, but appropriate adjustments shall be made with respect to payments from other Loan Parties to preserve the allocation to Secured Obligations otherwise set forth above in this Section.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, Secured Obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements shall be excluded from the application described above if the Administrative Agent has not received a Secured Party Designation Notice, together with such supporting documentation as the Administrative Agent may request, from the applicable Cash Management Bank or Hedge Bank, as the case may be.  Each Cash Management Bank or Hedge Bank not a party to this Agreement that has given the notice contemplated by the preceding sentence shall, by such notice, be deemed to have acknowledged and accepted the appointment of the Administrative Agent pursuant to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for itself and its Affiliates as if a &#8220;Lender&#8221; party hereto.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"><br><br>ADMINISTRATIVE AGENT</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Appointment and Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Lenders and the L&#47;C Issuer hereby irrevocably appoints, designates and authorizes Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">138</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L&#47;C Issuer, and neither any Borrower nor any other Loan Party shall have rights as a third party beneficiary of any of such provisions.  It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent shall also act as the &#8220;collateral agent&#8221; under the Loan Documents, and each of the Lenders (including in its capacities as a potential Hedge Bank and a potential Cash Management Bank) and the L&#47;C Issuer hereby irrevocably appoints and authorizes the Administrative Agent to act as the agent of such Lender and the L&#47;C Issuer for purposes of acquiring, holding and enforcing any and all Liens on Collateral granted by any of the Loan Parties to secure any of the Secured Obligations, together with such powers and discretion as are reasonably incidental thereto.  In this connection, the Administrative Agent, as &#8220;collateral agent&#8221; and any co-agents, sub-agents and attorneys-in-fact appointed by the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for purposes of holding or enforcing any Lien on the Collateral (or any portion thereof) granted under the Collateral Documents, or for exercising any rights and remedies thereunder at the direction of the Administrative Agent, shall be entitled to the benefits of all provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as though such co-agents, sub-agents and attorneys-in-fact were the &#8220;collateral agent&#8221; under the Loan Documents) as if set forth in full herein with respect thereto.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Rights as a Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term &#8220;Lender&#8221; or &#8220;Lenders&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of banking, trust, financial, advisory, underwriting or other business with any Loan Party or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders or to provide notice to or consent of the Lenders with respect thereto.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Exculpatory Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">The Administrative Agent or the Arrangers, as applicable, shall not have any duties or obligations except those expressly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">139</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature.  Without limiting the generality of the foregoing, the Administrative Agent or the Arrangers, as applicable, and their Related Parties&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing&#59;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law&#59; and</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">shall not have any duty or responsibility to disclose, and shall not be liable for the failure to disclose, to any Lender or the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Issuer any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of any of the Loan Parties or any of their Affiliates that is communicated to, or in the possession of, the Administrative Agent, Arrangers or any of their Related Parties in any capacity, except for notices, reports and other documents expressly required to be furnished to the Lenders by the Administrative Agent herein.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Neither the Administrative Agent nor any of its Related Parties shall be liable for any action taken or not taken by the Administrative Agent under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby or thereby (i)&#160;with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary), or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or (ii)&#160;in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment.  The Administrative Agent shall be deemed not to have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">140</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">knowledge of any Default unless and until notice describing such Default is given in writing to the Administrative Agent by the Company, a Lender or the L&#47;C Issuer.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Neither the Administrative Agent nor any of its Related Parties have any duty or obligation to any Lender or participant or any other Person to ascertain or inquire into (i)&#160;any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)&#160;the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii)&#160;the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv)&#160;the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or the creation, perfection or priority of any Lien purported to be created by the Collateral Documents, (v)&#160;the value or the sufficiency of any Collateral, or (vi)&#160;the satisfaction of any condition set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Reliance by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent shall be entitled to rely upon, and shall be fully protected in relying and shall not incur any liability for relying upon, any notice, request, certificate, communication, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall be fully protected in relying and shall not incur any liability for relying thereon.  In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or the L&#47;C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L&#47;C Issuer unless the Administrative Agent shall have received notice to the contrary from such Lender or the L&#47;C Issuer prior to the making of such Loan or the issuance of such Letter of Credit.  The Administrative Agent may consult with legal counsel (who may be counsel for the Loan Parties), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent.  The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties.  The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the Facilities as well as activities as Administrative Agent.  The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">141</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Resignation of Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent may at any time give notice of its resignation to the Lenders, the L&#47;C Issuer and the Company.  Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Company, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the retiring Administrative Agent may (but shall not be obligated to) on behalf of the Lenders and the L&#47;C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in no event shall any successor Administrative Agent be a Defaulting Lender.  Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Person serving as Administrative Agent is a Defaulting Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the definition thereof, the Required Lenders may, to the extent permitted by applicable Law, by notice in writing to the Company and such Person remove such Person as Administrative Agent and, in consultation with the Company, appoint a successor.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days (or such earlier day as shall be agreed by the Required Lenders) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Removal Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Effect of Resignation or Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (i) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any collateral security held by the Administrative Agent on behalf of the Lenders or the L&#47;C Issuer under any of the Loan Documents, the retiring or removed Administrative Agent shall continue to hold such collateral security until such time as a successor Administrative Agent is appointed) and (ii) except for any indemnity payments or other amounts then owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">142</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to each Lender and the L&#47;C Issuer directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above.  Upon the acceptance of a successor&#8217;s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or removed) Administrative Agent (other than as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and other than any rights to indemnity payments or other amounts owed to the retiring or removed Administrative Agent as of the Resignation Effective Date or the Removal Effective Date, as applicable), and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section).  The fees payable by the Borrowers to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrowers and such successor.  After the retiring or removed Administrative Agent&#8217;s resignation or removal hereunder and under the other Loan Documents, the provisions of this Article and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them (x) while the retiring or removed Administrative Agent was acting as Administrative Agent, and (y) after such resignation or removal for as long as any of them continues to act in any capacity hereunder or under the other Loan Documents, including acting as collateral agent or otherwise holding any collateral security on behalf of any of the Secured Parties and in respect of any actions taken in connection with transferring the agency to any successor Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">L&#47;C Issuer and Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any resignation or removal by Bank of America as Administrative Agent pursuant to this Section shall also constitute its resignation as L&#47;C Issuer and Swingline Lender.  If Bank of America resigns as the L&#47;C Issuer, it shall retain all the rights, powers, privileges and duties of the L&#47;C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L&#47;C Issuer and all L&#47;C Obligations with respect thereto, including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Bank of America resigns as Swingline Lender, it shall retain all the rights of the Swingline Lender provided for hereunder with respect to Swingline Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Base Rate Loans or SOFR Daily Floating Rate Loans or fund risk participations in outstanding Swingline Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the appointment by the Company of a successor L&#47;C Issuer or Swingline Lender hereunder (which successor shall in all cases be a Lender other than a Defaulting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">143</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lender), (i) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L&#47;C Issuer or Swingline Lender, as applicable, (ii) the retiring L&#47;C Issuer and Swingline Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents, and (iii) the successor L&#47;C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Non-Reliance on Administrative Agent, Arrangers and Other Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Lender and the L&#47;C Issuer expressly acknowledges that neither the Administrative Agent nor any Arranger has made any representation or warranty to it, and that no act by the Administrative Agent or any Arranger hereafter taken, including any consent to, and acceptance of any assignment or review of the affairs of any Loan Party or any Affiliate thereof, shall be deemed to constitute any representation or warranty by the Administrative Agent or any Arranger to any Lender or the L&#47;C Issuer as to any matter, including whether the Administrative Agent or any Arranger has disclosed material information in their (or their respective Related Parties&#8217;) possession.  Each Lender and the L&#47;C Issuer represents to the Administrative Agent and each Arranger that it has, independently and without reliance upon the Administrative Agent, any Arranger, any other Lender or any of their respective Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis of, appraisal of, and investigation into, the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties and their respective Subsidiaries, and all applicable bank or other regulatory Laws relating to the transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to the Borrowers hereunder.  Each Lender and the L&#47;C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent, any Arranger, any other Lender or any of their respective Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties.  Each Lender and the L&#47;C Issuer represents and warrants that (a) the Loan Documents set forth the terms of a commercial lending facility, and (b) it is engaged in making, acquiring or holding commercial loans in the ordinary course and is entering into this Agreement as a Lender or the L&#47;C Issuer for the purpose of making, acquiring or holding commercial loans and providing other facilities set forth herein as may be applicable to such Lender or the L&#47;C Issuer, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument, and each Lender and the L&#47;C Issuer agrees not to assert a claim in contravention of the foregoing.  Each Lender and the L&#47;C Issuer represents and warrants that it is sophisticated with respect to decisions to make, acquire and&#47;or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender or the L&#47;C Issuer, and either it, or the Person exercising discretion in making its decision to make, acquire and&#47;or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring or holding such commercial loans or providing such other facilities.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Other Duties, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">144</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Anything herein to the contrary notwithstanding, none of the titles listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, an Arranger, a Lender or the L&#47;C Issuer hereunder.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Administrative Agent May File Proofs of Claim&#59; Credit Bidding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan or L&#47;C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrowers) shall be entitled and empowered, by intervention in such proceeding or otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L&#47;C Obligations and all other Secured Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L&#47;C Issuer and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L&#47;C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L&#47;C Issuer and the Administrative Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.03(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) allowed in such judicial proceeding&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and the L&#47;C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the L&#47;C Issuer, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or the L&#47;C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Secured Obligations or the rights of any Lender or the L&#47;C Issuer to authorize the Administrative Agent to vote in respect of the claim of any Lender or the L&#47;C Issuer or in any such proceeding.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Secured Parties hereby irrevocably authorize the Administrative Agent, at the direction of the Required Lenders, to credit bid all or any portion of the Secured Obligations (including accepting some or all of the Collateral in satisfaction of some or all of the Secured Obligations pursuant to a deed in lieu of foreclosure or otherwise) and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (a) at any sale thereof conducted under the provisions of the Bankruptcy Code of the United States, including under Sections 363, 1123 or 1129 of the Bankruptcy Code of the United States, or any similar Laws in any other jurisdictions to which a Loan Party is subject, (b) at any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">145</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sale or foreclosure or acceptance of collateral in lieu of debt conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with any applicable Law.  In connection with any such credit bid and purchase, the Secured Obligations owed to the Secured Parties shall be entitled to be, and shall be, credit bid on a ratable basis (with Secured Obligations with respect to contingent or unliquidated claims receiving contingent interests in the acquired assets on a ratable basis that would vest upon the liquidation of such claims in an amount proportional to the liquidated portion of the contingent claim amount used in allocating the contingent interests) in the asset or assets so purchased (or in the Equity Interests or debt instruments of the acquisition vehicle or vehicles that are used to consummate such purchase).  In connection with any such bid, (i) the Administrative Agent shall be authorized to form one or more acquisition vehicles to make a bid, (ii) the Administrative Agent shall be authorized to adopt documents providing for the governance of the acquisition vehicle or vehicles (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any actions by the Administrative Agent with respect to such acquisition vehicle or vehicles, including any disposition of the assets or Equity Interests thereof shall be governed, directly or indirectly, by the vote of the Required Lenders, irrespective of the termination of this Agreement and without giving effect to the limitations on actions by the Required Lenders contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), (iii) the Administrative Agent shall be authorized to assign the relevant Secured Obligations to any such acquisition vehicle pro rata by the Lenders, as a result of which each of the Lenders shall be deemed to have received a pro rata portion of any Equity Interests and&#47;or debt instruments issued by such an acquisition vehicle on account of the assignment of the Secured Obligations to be credit bid, all without the need for any Secured Party or acquisition vehicle to take any further action, and (iv) to the extent that Secured Obligations that are assigned to an acquisition vehicle are not used to acquire Collateral for any reason (as a result of another bid being higher or better, because the amount of Secured Obligations assigned to the acquisition vehicle exceeds the amount of debt credit bid by the acquisition vehicle or otherwise), such Secured Obligations shall automatically be reassigned to the Lenders pro rata and the Equity Interests and&#47;or debt instruments issued by any acquisition vehicle on account of the Secured Obligations that had been assigned to the acquisition vehicle shall automatically be cancelled, without the need for any Secured Party or any acquisition vehicle to take any further action.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Collateral and Guaranty Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Lenders (including in its capacities as a potential Cash Management Bank and a potential Hedge Bank) and each of the L&#47;C Issuer irrevocably authorize the Administrative Agent, at its option and in its discretion,</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (i) upon the Facility Termination Date, (ii) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted hereunder or under any other Loan Document, or (iii) if approved, authorized or ratified in writing by the Required Lenders or each Lender, as applicable, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">to subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">146</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">to release any Guarantor from its obligations under the Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Guaranty pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In each case as specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Administrative Agent will, at the Borrowers&#8217; expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such item of Collateral from the assignment and security interest granted under the Collateral Documents or to subordinate its interest in such item, or to release such Guarantor from its obligations under the Guaranty, in each case in accordance with the terms of the Loan Documents and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent&#8217;s Lien thereon, or any certificate prepared by any Loan Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Secured Cash Management Agreements and Secured Hedge Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise expressly set forth herein, no Cash Management Bank or Hedge Bank that obtains the benefit of the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Guaranty or any Collateral by virtue of the provisions hereof or any Collateral Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Loan Document or otherwise in respect of the Collateral (including the release or impairment of any Collateral) (or to notice of or to consent to any amendment, waiver or modification of the provisions hereof or of the Guaranty or any Collateral Document) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Loan Documents.  Notwithstanding any other provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, the Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Secured Obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements except to the extent expressly provided herein and unless the Administrative Agent has received a Secured Party Designation Notice of such Secured Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Cash Management Bank or Hedge Bank, as the case may be.  The Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Secured Obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements in the case of a Facility Termination Date.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">ERISA Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrowers </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">147</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any other Loan Party, that at least one of the following is and will be true&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">such Lender is not using &#8220;plan assets&#8221; (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments, or this Agreement,</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">the transaction exemption set forth in one or more PTEs, such as PTE 84&#8211;14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95&#8211;60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90&#8211;1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91&#8211;38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96&#8211;23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement,</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">(A) such Lender is an investment fund managed by a &#8220;Qualified Professional Asset Manager&#8221; (within the meaning of Part VI of PTE 84&#8211;14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Letters of Credit, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84&#8211;14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of&#160;Part I of PTE 84&#8211;14 are satisfied with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement, or</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">In addition, unless either (1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in the immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (iv</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in the immediately </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">148</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrowers or any other Loan Party, that the Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is not a fiduciary with respect to the assets of such Lender involved in such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any other Loan Document or any documents related hereto or thereto).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Recovery of Erroneous Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation of any other provision in this Agreement, if at any time the Administrative Agent makes a payment hereunder in error to any Lender Recipient Party, whether or not in respect of an Obligation due and owing by any Borrower at such time, where such payment is a Rescindable Amount, then in any such event, each Lender Recipient Party receiving a Rescindable Amount severally agrees to repay to the Administrative Agent forthwith on demand the Rescindable Amount received by such Lender Recipient Party  in immediately available funds in the currency so received, with interest thereon, for each day from and including the date such Rescindable Amount is received by it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.  Each Lender Recipient Party irrevocably waives any and all defenses, including any &#8220;discharge for value&#8221; (under which a creditor might otherwise claim a right to retain funds mistakenly paid by a third party in respect of a debt owed by another) or similar defense to its obligation to return any Rescindable Amount.&#160; The Administrative Agent shall inform each Lender Recipient Party promptly upon determining that any payment made to such Lender Recipient Party comprised, in whole or in part, a Rescindable Amount.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.97pt"><br><br>CONTINUING GUARANTY</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Guarantor hereby absolutely and unconditionally, jointly and severally guarantees, as primary obligor and as a guaranty of payment and performance and not merely as a guaranty of collection, prompt payment when due, whether at stated maturity, by required prepayment, upon acceleration, demand or otherwise, and at all times thereafter, of any and all Secured Obligations (for each Guarantor, subject to the proviso in this sentence, its &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; (i) the Guaranteed Obligations of a Guarantor shall exclude any Excluded Swap Obligations with respect to such Guarantor and (ii) the liability of each Guarantor individually with respect to this Guaranty shall be limited to an aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance under Section 548 of the Bankruptcy Code of the United States or any comparable provisions of any applicable state law.  Without limiting the generality of the foregoing, the Guaranteed Obligations shall include such indebtedness, obligations, and liabilities, or portion thereof, which may be or hereafter become unenforceable or compromised or shall be allowed or disallowed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">149</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claim under any proceeding or case commenced by or against any debtor under any Debtor Relief Laws.  The Administrative Agent&#8217;s books and records showing the amount of the Obligations shall be admissible in evidence in any action or proceeding, and shall be binding upon each Guarantor, and conclusive for the purpose of establishing the amount of the Secured Obligations.  This Guaranty shall not be affected by the genuineness, validity, regularity or enforceability of the Secured Obligations or any instrument or agreement evidencing any Secured Obligations, or by the existence, validity, enforceability, perfection, non-perfection or extent of any collateral therefor, or by any fact or circumstance relating to the Secured Obligations which might otherwise constitute a defense to the obligations of the Guarantors, or any of them, under this Guaranty, and each Guarantor hereby irrevocably waives any defenses it may now have or hereafter acquire in any way relating to any or all of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Rights of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Guarantor consents and agrees that the Secured Parties may, at any time and from time to time, without notice or demand, and without affecting the enforceability or continuing effectiveness hereof&#58; (a) amend, extend, renew, compromise, discharge, accelerate or otherwise change the time for payment or the terms of the Secured Obligations or any part thereof, (b) take, hold, exchange, enforce, waive, release, fail to perfect, sell, or otherwise dispose of any security for the payment of this Guaranty or any Secured Obligations, (c) apply such security and direct the order or manner of sale thereof as the Administrative Agent, the L&#47;C Issuer and the Lenders in their sole discretion may determine, and (d) release or substitute one or more of any endorsers or other guarantors of any of the Secured Obligations.  Without limiting the generality of the foregoing, each Guarantor consents to the taking of, or failure to take, any action which might in any manner or to any extent vary the risks of such Guarantor under this Guaranty or which, but for this provision, might operate as a discharge of such Guarantor.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Certain Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Guarantor waives (a) any defense arising by reason of any disability or other defense of the Borrowers or any other guarantor, or the cessation from any cause whatsoever (including any act or omission of any Secured Party) of the liability of the Borrowers or any other Loan Party, (b) any defense based on any claim that such Guarantor&#8217;s obligations exceed or are more burdensome than those of the Borrowers or any other Loan Party, (c) the benefit of any statute of limitations affecting any Guarantor&#8217;s liability hereunder, (d) any right to proceed against the Borrowers or any other Loan Party, proceed against or exhaust any security for the Secured Obligations, or pursue any other remedy in the power of any Secured Party whatsoever, (e) any benefit of and any right to participate in any security now or hereafter held by any Secured Party, and (f) to the fullest extent permitted by law, any and all other defenses or benefits that may be derived from or afforded by applicable Law limiting the liability of or exonerating guarantors or sureties.  Each Guarantor expressly waives all setoffs and counterclaims and all presentments, demands for payment or performance, notices of nonpayment or nonperformance, protests, notices of protest, notices of dishonor and all other notices or demands of any kind or nature whatsoever with respect to the Secured Obligations, and all notices of acceptance of this Guaranty or of the existence, creation or incurrence of new or additional Secured Obligations.  Each Guarantor waives any rights and defenses that are or may become available to it by reason of &#167;&#167; 2787 to 2855, inclusive, and &#167;&#167; 2899 and 3433 of the California Civil Code.  The foregoing waivers and the provisions hereinafter set forth in this Guaranty which pertain to California law are included solely out of an abundance of caution, and shall not be construed to mean that any of the above-referenced provisions of California law are in any way applicable to this Guaranty or the Secured Obligations.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Obligations Independent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of each Guarantor hereunder are those of primary obligor, and not merely as surety, and are independent of the Secured Obligations and the obligations of any other guarantor, and a separate action may be brought against each Guarantor to enforce this Guaranty whether or not any Borrower or any other person or entity is joined as a party.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Guarantor shall exercise any right of subrogation, contribution, indemnity, reimbursement or similar rights with respect to any payments it makes under this Guaranty until all of the Secured Obligations and any amounts payable under this Guaranty have been indefeasibly paid and performed in full and the Commitments and the Facilities are terminated.  If any amounts are paid to a Guarantor in violation of the foregoing limitation, then such amounts shall be held in trust for the benefit of the Secured Parties and shall forthwith be paid to the Secured Parties to reduce the amount of the Secured Obligations, whether matured or unmatured.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Termination&#59; Reinstatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Guaranty is a continuing and irrevocable guaranty of all Secured Obligations now or hereafter existing and shall remain in full force and effect until the Facility Termination Date.  Notwithstanding the foregoing, this Guaranty shall continue in full force and effect or be revived, as the case may be, if any payment by or on behalf of a Borrower or a Guarantor is made, or any of the Secured Parties exercises its right of setoff, in respect of the Secured Obligations and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by any of the Secured Parties in their discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Laws or otherwise, all as if such payment had not been made or such setoff had not occurred and whether or not the Secured Parties are in possession of or have released this Guaranty and regardless of any prior revocation, rescission, termination or reduction.  The obligations of each Guarantor under this paragraph shall survive termination of this Guaranty.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Stay of Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If acceleration of the time for payment of any of the Secured Obligations is stayed, in connection with any case commenced by or against a Guarantor or a Borrower under any Debtor Relief Laws, or otherwise, all such amounts shall nonetheless be payable by each Guarantor, jointly and severally, immediately upon demand by the Secured Parties.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Condition of Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Guarantor acknowledges and agrees that it has the sole responsibility for, and has adequate means of, obtaining from each Borrower and any other guarantor such information concerning the financial condition, business and operations of each Borrower and any such other guarantor as such Guarantor requires, and that none of the Secured Parties has any duty, and such Guarantor is not relying on the Secured Parties at any time, to disclose to it any information relating to the business, operations or financial condition of each Borrower or any other guarantor (each Guarantor waiving any duty on the part of the Secured Parties to disclose such information and any defense relating to the failure to provide the same).</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Appointment of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Loan Parties hereby appoints the Company to act as its agent for all purposes of this Agreement, the other Loan Documents and all other documents and electronic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">151</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">platforms entered into in connection herewith and agrees that (a) the Company may execute such documents and provide such authorizations on behalf of such Loan Parties as the Company deems appropriate in its sole discretion and each Loan Party shall be obligated by all of the terms of any such document and&#47;or authorization executed on its behalf, (b) any notice or communication delivered by the Administrative Agent, the L&#47;C Issuer or a Lender to the Company shall be deemed delivered to each Loan Party and (c) the Administrative Agent, the L&#47;C Issuer or the Lenders may accept, and be permitted to rely on, any document, authorization, instrument or agreement executed by the Company on behalf of each of Loan Parties.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Right of Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Guarantors agree among themselves that, in connection with payments made hereunder, each Guarantor shall have contribution rights against the other Guarantors as permitted under applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Keepwell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party that is a Qualified ECP Guarantor at the time the Guaranty or the grant of a Lien under the Loan Documents, in each case, by any Specified Loan Party becomes effective with respect to any Swap Obligation, hereby jointly and severally, absolutely, unconditionally and irrevocably undertakes to provide such funds or other support to each Specified Loan Party with respect to such Swap Obligation as may be needed by such Specified Loan Party from time to time to honor all of its obligations under the Loan Documents in respect of such Swap Obligation (but, in each case, only up to the maximum amount of such liability that can be hereby incurred without rendering such Qualified ECP Guarantor&#8217;s obligations and undertakings under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount).  The obligations and undertakings of each Qualified ECP Guarantor under this Section shall remain in full force and effect until the Secured Obligations have been indefeasibly paid and performed in full.  Each Loan Party intends this Section to constitute, and this Section shall be deemed to constitute, a guarantee of the obligations of, and a &#8220;keepwell, support, or other agreement&#8221; for the benefit of, each Specified Loan Party for all purposes of the Commodity Exchange Act.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Additional Guarantor Waivers and Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each Guarantor understands and acknowledges that if the Secured Parties foreclose judicially or nonjudicially against any real property security for the Secured Obligations, that foreclosure could impair or destroy any ability that such Guarantor may have to seek reimbursement, contribution, or indemnification from the Borrowers or others based on any right such Guarantor may have of subrogation, reimbursement, contribution, or indemnification for any amounts paid by such Guarantor under this Guaranty.  Each Guarantor further understands and acknowledges that in the absence of this paragraph, such potential impairment or destruction of such Guarantor&#8217;s rights, if any, may entitle such Guarantor to assert a defense to this Guaranty based on Section 580d of the California Code of Civil Procedure as interpreted in Union Bank v. Gradsky, 265 Cal. App. 2d 40 (1968).  By executing this Guaranty, each Guarantor freely, irrevocably, and unconditionally&#58;  (i) waives and relinquishes that defense and agrees that it will be fully liable under this Guaranty even though the Secured Parties may foreclose, either by judicial foreclosure or by exercise of power of sale, any deed of trust securing the Secured Obligations, (ii) agrees that it will not assert that defense in any action or proceeding which the Secured Parties may commence to enforce this Guaranty, (iii) acknowledges and agrees that the rights and defenses waived by such Guarantor in this Guaranty include any right or defense that it may have or be entitled to assert based upon or arising out of any one or more of &#167;&#167; 580a, 580b, 580d, or 726 of the California Code of Civil Procedure or &#167; 2848 of the California Civil Code, and (iv) acknowledges and agrees that the Secured Parties are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">152</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relying on this waiver in creating the Secured Obligations, and that this waiver is a material part of the consideration which the Secured Parties are receiving for creating the Secured Obligations.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Each Guarantor waives all rights and defenses that it may have because any of the Secured Obligations is secured by real property.  This means, among other things&#58;  (i) the Secured Parties may collect from any Guarantor without first foreclosing on any real or personal property collateral pledged by the other Loan Parties, and (ii) if the Secured Parties foreclose on any real property collateral pledged by the other Loan Parties&#58;  (A) the amount of the Secured Obligations may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral is worth more than the sale price, and (B) the Secured Parties may collect from any Guarantor even if the Secured Parties, by foreclosing on the real property collateral, have destroyed any right such Guarantor may have to collect from the Borrowers.  This is an unconditional and irrevocable waiver of any rights and defenses each Guarantor may have because any of the Secured Obligations is secured by real property.  These rights and defenses include, but are not limited to, any rights or defenses based upon &#167; 580a, 580b, 580d, or 726 of the California Code of Civil Procedure.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Each Guarantor waives any right or defense it may have at law or equity, including California Code of Civil Procedure &#167; 580a, to a fair market value hearing or action to determine a deficiency judgment after a foreclosure.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"><br><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Borrowers or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders (or by the Administrative Agent with the consent of the Required Lenders) and the Borrowers or the applicable Loan Party, as the case may be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no such amendment, waiver or consent shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">extend or increase the Commitment of any Lender (or reinstate any Commitment terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) without the written consent of such Lender (it being understood and agreed that a waiver of any condition precedent in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or of any Default or a mandatory reduction in Commitments is not considered an extension or increase in Commitments of any Lender)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">postpone any date fixed by this Agreement or any other Loan Document for any payment (excluding mandatory prepayments) of principal, interest, fees or other amounts due to the Lenders (or any of them) or any scheduled or mandatory reduction of the Commitments hereunder or under such other Loan Document without the written consent of each Lender entitled to such payment or whose Commitments are to be reduced&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">reduce the principal of, or the rate of interest specified herein on, any Loan or L&#47;C Borrowing, or (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">153</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the final proviso to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender entitled to such amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, only the consent of the Required Lenders shall be necessary to amend (i) the definition of &#8220;Default Rate&#8221; or to waive any obligation of the Borrowers to pay interest or Letter of Credit Fees at the Default Rate, or (ii) any financial covenant hereunder (or any defined term used therein) even if the effect of such amendment would be to reduce the rate of interest on any Loan or L&#47;C Borrowing or to reduce any fee payable hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">change </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other provision hereof in a manner that would alter the pro rata sharing of payments required thereby without the written consent of each Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">change any provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the definition of &#8220;Required Lenders&#8221; or any other provision of any Loan Document specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or thereunder or make any determination or grant any consent hereunder without the written consent of each Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">release all or substantially all of the Collateral in any transaction or series of related transactions, without the written consent of each Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">release, or agree to release, all or substantially all of the Guarantors, without the written consent of each Lender, except to the extent the release of any Subsidiary from the Guaranty is permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (in which case such release may be made by the Administrative Agent acting alone)&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">release a Borrower or permit a Borrower to assign or transfer any of its rights or obligations under this Agreement or the other Loan Documents without the consent of each Lender&#59; </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">change or waive any provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as the same applies to the Administrative Agent, or any other provision hereof as the same applies to the rights or obligations of the Administrative Agent, in each case without the written consent of the Administrative Agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">change the application of prepayments as among or between classes of Loans under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without the written consent of the Required Lenders for the class of Loans that is being allocated a lesser prepayment as a result thereof (it being understood that the Required Lenders may waive, in whole or in part, any prepayment so long as the application, as between the classes of Loans, of any portion of such prepayment that is still required to be made is not changed)&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">154</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">change this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the definition of &#8220;Required Revolving Lenders&#8221; without the consent of each Revolving Lender&#59; </font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">without the prior written consent of each Lender directly affected thereby, change </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.06(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in a manner that would alter the pro rata reduction of Commitments&#59; or</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.13pt">without the prior written consent of each Lender directly affected thereby, (i) subordinate, or have the effect of subordinating, the Obligations hereunder to any other Indebtedness or other obligation or (ii) subordinate, or have the effect of subordinating, the Liens securing the Obligations to Liens securing any other Indebtedness or other obligation&#59; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) no amendment, waiver or consent shall, unless in writing and signed by the L&#47;C Issuer in addition to the Lenders required above, affect the rights or duties of the L&#47;C Issuer under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it, (ii) no amendment, waiver or consent shall, unless in writing and signed by the Swingline Lender in addition to the Lenders required above, affect the rights or duties of the Swingline Lender under this Agreement, (iii) no amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document, and (iv) the Fee Letter may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto.  Notwithstanding anything to the contrary herein, (A) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender, or all Lenders or each affected Lender under a Facility, may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (1) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (2) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender, or all Lenders or each affected Lender under a Facility, that by its terms affects any Defaulting Lender disproportionately adversely relative to other affected Lenders shall require the consent of such Defaulting Lender, (B) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code of the United States supersedes the unanimous consent provisions set forth herein and (C) the Required Lenders shall determine whether or not to allow a Loan Party to use cash collateral in the context of a bankruptcy or insolvency proceeding and such determination shall be binding on all of the Lenders.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, (v) in order to implement any additional Commitments and&#47;or any Incremental Term Facility in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this Agreement may be amended for such purpose (but solely to the extent necessary to implement such additional Commitments and&#47;or such Incremental Term Facility in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including amendments to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as may be necessary to include the Lenders providing such additional Commitments and&#47;or such Incremental Term Facility or implement such additional Commitments and&#47;or such Incremental Term Facility) by the Borrowers, the other Loan Parties, the Administrative Agent and the relevant Lenders providing such additional Commitments and&#47;or providing a portion of such Incremental Term Facility, (w) if following the Closing Date, the Administrative Agent and the Borrowers shall have jointly identified an inconsistency, obvious error or omission of a technical or immaterial nature, in each case, in any provision of the Loan Documents, then the Administrative Agent and the Loan Parties shall be permitted to amend such provision and such amendment shall become effective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">155</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without any further action or consent of any other party to any Loan Documents if the same is not objected to in writing by the Required Lenders within three (3) Business Days following receipt of notice thereof, (x) this Agreement may be amended (or amended and restated) with the written consent of the Required Lenders, the Administrative Agent, each Borrower, the other Loan Parties and the relevant Lenders providing such additional credit facilities (1) to add one or more additional credit facilities to this Agreement, to permit the extensions of credit from time to time outstanding hereunder and the accrued interest and fees in respect thereof to share ratably in the benefits of this Agreement and the other Loan Documents with the Loans and the accrued interest and fees in respect thereof and to include appropriately the Lenders holding such credit facilities in any determination of the Required Lenders or the Required Revolving Lenders, as applicable, and (2) to change, modify or alter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other provision hereof relating to the pro rata sharing of payments among the Lenders to the extent necessary to effectuate any of the amendments (or amendments and restatements) enumerated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (y) the Administrative Agent and the Borrowers may make amendments contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (z) with respect to SOFR, Term SOFR or the SOFR Daily Floating Rate, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Company and the Lenders reasonably promptly after such amendment becomes effective.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, as to any amendment, amendment and restatement or other modifications otherwise approved in accordance with this Section, it shall not be necessary to obtain the consent or approval of any Lender that, upon giving effect to such amendment, amendment and restatement or other modification, would have no Commitment or outstanding Loans so long as such Lender receives payment in full of the principal of and interest accrued on each Loan made by, and all other amounts owing to, such Lender or accrued for the account of such Lender under this Agreement and the other Loan Documents at the time such amendment, amendment and restatement or other modification becomes effective.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Notices&#59; Effectiveness&#59; Electronic Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Notices Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by fax transmission or e-mail transmission as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">if to any Borrower or any other Loan Party, the Administrative Agent, the L&#47;C Issuer or the Swingline Lender, to the address, fax number, e-mail address or telephone number specified for such Person on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">if to any other Lender, to the address, fax number, e-mail address or telephone number specified in its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">156</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public information relating to a Borrower).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices and other communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received&#59; notices and other communications sent by fax transmission shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient).  Notices and other communications delivered through electronic communications to the extent provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below shall be effective as provided in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Electronic Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices and other communications to the Administrative Agent, the Lenders, the Swingline Lender and the L&#47;C Issuer hereunder may be delivered or furnished by electronic communication (including e-mail, FPML messaging and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the foregoing shall not apply to notices to any Lender, the Swingline Lender or the L&#47;C Issuer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if such Lender, Swingline Lender or L&#47;C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication.  The Administrative Agent, the Swingline Lender, the L&#47;C Issuer or the Borrowers may each, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, approval of such procedures may be limited to particular notices or communications.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender&#8217;s receipt of an acknowledgment from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement) and (ii) notices and other communications posted to an Internet or intranet website shall be deemed received by the intended recipient upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail address or other written acknowledgement) indicating that such notice or communication is available and identifying the website address therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for both </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if such notice or other communication is not sent during the normal business hours of the recipient, such notice, email or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">The Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  THE PLATFORM IS PROVIDED &#8220;AS IS&#8221; AND &#8220;AS AVAILABLE.&#8221;  THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">157</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS.  NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM.  In no event shall the Administrative Agent or any of its Related Parties (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) have any liability to the Borrowers, any Lender, the L&#47;C Issuer or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of any Borrower&#8217;s, any Loan Party&#8217;s or the Administrative Agent&#8217;s transmission of Borrower Materials or notices through the Platform, any other electronic platform or electronic messaging service, or through the Internet.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Change of Address, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Borrower, the Administrative Agent, the L&#47;C Issuer and the Swingline Lender may change its address, fax number or telephone number or e-mail address for notices and other communications hereunder by notice to the other parties hereto.  Each other Lender may change its address, fax number or telephone number or e-mail address for notices and other communications hereunder by notice to the Company, the Administrative Agent, the L&#47;C Issuer and the Swingline Lender.  In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, fax number and e-mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender.  Furthermore, each Public Lender agrees to cause at least one (1) individual at or on behalf of such Public Lender to at all times have selected the &#8220;Private Side Information&#8221; or similar designation on the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public Lender&#8217;s compliance procedures and applicable Law, including United States federal and state securities Laws, to make reference to Borrower Materials that are not made available through the &#8220;Public Side Information&#8221; portion of the Platform and that may contain material non-public information with respect to a Borrower or its securities for purposes of United States federal or state securities laws.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Reliance by Administrative Agent, L&#47;C Issuer and Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent, the L&#47;C Issuer and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic notices, Loan Notices, Letter of Credit Applications, Notice of Loan Prepayment and Swingline Loan Notices) purportedly given by or on behalf of any Loan Party even if (i) such notices were not made in a manner specified </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">158</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof.  The Loan Parties shall indemnify the Administrative Agent, the L&#47;C Issuer, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of a Loan Party.  All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Waiver&#59; Cumulative Remedies&#59; Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No failure by any Lender, the L&#47;C Issuer or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof&#59; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or under any other Loan Document preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.  The rights, remedies, powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the benefit of all the Lenders and the L&#47;C Issuer&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) the L&#47;C Issuer or the Swingline Lender from exercising the rights and remedies that inure to its benefit (solely in its capacity as L&#47;C Issuer or Swingline Lender, as the case may be) hereunder and under the other Loan Documents, (c) any Lender from exercising setoff rights in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Loan Party under any Debtor Relief Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (ii) in addition to the matters set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the preceding proviso and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Expenses&#59; Indemnity&#59; Damage Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Loan Parties shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">159</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the L&#47;C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket expenses incurred by the Administrative Agent, any Lender or the L&#47;C Issuer (including the fees, charges and disbursements of any counsel for the Administrative Agent, any Lender or the L&#47;C Issuer), and shall pay all fees and time charges for attorneys who may be employees of the Administrative Agent, any Lender or the L&#47;C Issuer, in connection with the enforcement or protection of its rights (1) in connection with this Agreement and the other Loan Documents, including its rights under this Section, or (2) in connection with Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Indemnification by the Loan Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Loan Parties shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and the L&#47;C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), and shall indemnify and hold harmless each Indemnitee from all fees and time charges and disbursements for attorneys who may be employees of any Indemnitee, incurred by any Indemnitee or asserted against any Indemnitee by any Person (including any Borrowers or any other Loan Party) arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby (including any Indemnitee&#8217;s reliance on any Communication executed using an Electronic Signature, or in the form of an Electronic Record), the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Agreement and the other Loan Documents (including in respect of any matters addressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by the L&#47;C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by a Loan Party or any of its Subsidiaries, or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">160</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Environmental Liability related in any way to a Loan Party or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by any Borrower or any other Loan Party, and regardless of whether any Indemnitee is a party thereto, IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY OR SOLE NEGLIGENCE OF THE INDEMNITEE&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by the Company or any other Loan Party against an Indemnitee for a material breach in bad faith of such Indemnitee&#8217;s obligations hereunder or under any other Loan Document, if the Company or such Loan Party has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction.  Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Reimbursement by Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that the Loan Parties for any reason fail to indefeasibly pay any amount required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L&#47;C Issuer, the Swingline Lender or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L&#47;C Issuer, the Swingline Lender or such Related Party, as the case may be, such Lender&#8217;s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender&#8217;s share of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on such Lender&#8217;s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent), the L&#47;C Issuer or the Swingline Lender in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent), the L&#47;C Issuer or the Swingline Lender in connection with such capacity.  The obligations of the Lenders under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">161</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Waiver of Consequential Damages, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the fullest extent permitted by applicable Law, no Loan Party shall assert, and each Loan Party hereby waives, and acknowledges that no other Person shall have, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof.  No Indemnitee referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed to such unintended recipients by such Indemnitee through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All amounts due under this Section shall be payable not later than ten (10) Business Days after demand therefor.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The agreements in this Section and the indemnity provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.02(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the resignation of the Administrative Agent, the L&#47;C Issuer and the Swingline Lender, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Payments Set Aside</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that any payment by or on behalf of the Borrowers is made to the Administrative Agent, the L&#47;C Issuer or any Lender, or the Administrative Agent, the L&#47;C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, the L&#47;C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender and the L&#47;C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect, in the applicable currency of such recovery or payment.  The obligations of the Lenders and the L&#47;C Issuer under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Successors and Assigns Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto and thereto </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">162</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and their respective successors and assigns permitted hereby, except neither any Borrower nor any other Loan Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section, (ii) by way of participation in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void).  Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent, the L&#47;C Issuer and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Assignments by Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement and the other Loan Documents (including all or a portion of its Commitment(s) and the Loans (including for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, participations in L&#47;C Obligations and in Swingline Loans) at the time owing to it)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each case with respect to any Facility, any such assignment shall be subject to the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Minimum Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">in the case of an assignment of the entire remaining amount of the assigning Lender&#8217;s Commitment under any Facility and&#47;or the Loans at the time owing to it (in each case with respect to any Facility) or contemporaneous assignments to related Approved Funds (determined after giving effect to such Assignment and Assumption) that equal at least the amount specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">paragraph (b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned&#59; and</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">in any case not described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Loans of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">163</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if &#8220;Trade Date&#8221; is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $5,000,000, in the case of any assignment in respect of the Revolving Facility, or $1,000,000, in the case of any assignment in respect of the Term Facility or any Incremental Term Facility, unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Company otherwise consents (each such consent not to be unreasonably withheld or delayed)&#59;</font></div><div style="margin-bottom:12pt;padding-left:115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the foregoing minimum amounts shall not apply to assignments made by the Administrative Agent which are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Proportionate Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender&#8217;s rights and obligations under this Agreement and the other Loan Documents with respect to the Loans and&#47;or the Commitment assigned, except that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not (A) apply to the Swingline Lender&#8217;s rights and obligations in respect of Swingline Loans or (B) prohibit any Lender from assigning all or a portion of its rights and obligations among separate Facilities on a non-pro rata basis.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt;text-decoration:underline">Required Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No consent shall be required for any assignment except to the extent required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section and, in addition&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">the consent of the Company (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received notice thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of (1) any unfunded Term Commitment, any unfunded Incremental Term Commitment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">164</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any Revolving Commitment if such assignment is to a Person that is not a Lender with a Commitment in respect of the applicable Facility, an Affiliate of such Lender or an Approved Fund with respect to such Lender or (2) any Term Loan or any Incremental Term Loan to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund&#59; and</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.02pt">the consent of the L&#47;C Issuer and the Swingline Lender shall be required for any assignment in respect of the Revolving Facility.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt;text-decoration:underline">Assignment and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the processing and recordation fee shall not apply to assignments made by the Administrative Agent which are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire.</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">No Assignment to Certain Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No such assignment shall be made (A) to any Borrower or any Affiliates or Subsidiaries of any Borrower, (B) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (C) to a natural Person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of a natural person).</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt;text-decoration:underline">Certain Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Company and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (A) pay and satisfy in full all payment liabilities then owed by such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">165</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defaulting Lender to the Administrative Agent, the L&#47;C Issuer or any Lender hereunder (and interest accrued thereon) and (B) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swingline Loans in accordance with its Applicable Percentage.  Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to acceptance and recording thereof by the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to facts and circumstances occurring prior to the effective date of such assignment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender&#8217;s having been a Defaulting Lender.  Upon request, the applicable Borrowers (at its expense) shall execute and deliver one or more Notes, as applicable, to the assignee Lender.  Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent, acting solely for this purpose as an agent of the Borrowers (and such agency being solely for tax purposes), shall maintain at the Administrative Agent&#8217;s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans and L&#47;C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The entries in the Register shall be conclusive, absent manifest error, and the Borrowers, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by any Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Participations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Lender may at any time, without the consent of, or notice to, the Borrowers or the Administrative </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">166</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agent, sell participations to any Person (other than a natural Person, or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of a natural Person, a Defaulting Lender or any Borrower or any Affiliate or Subsidiaries of any Borrower) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in all or a portion of such Lender&#8217;s rights and&#47;or obligations under this Agreement (including all or a portion of its Commitment and&#47;or the Loans (including such Lender&#8217;s participations in L&#47;C Obligations and&#47;or Swingline Loans) owing to it)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) such Lender&#8217;s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrowers, the Administrative Agent, the Lenders and the L&#47;C Issuer shall continue to deal solely and directly with such Lender in connection with such Lender&#8217;s rights and obligations under this Agreement.  For the avoidance of doubt, each Lender shall be responsible for the indemnity under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> without regard to the existence of any participations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in the first proviso to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that affects such Participant.  The Borrowers agree that each Participant shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (subject to the requirements and limitations therein, including the requirements under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (it being understood that the documentation required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be delivered to the Lender who sells the participation)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">paragraph (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such Participant (A) agrees to be subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as if it were an assignee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">paragraph (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Section and (B) shall not be entitled to receive any greater payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to any participation, than the Lender from whom it acquired the applicable participation would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation.  Each Lender that sells a participation agrees, at the Company&#8217;s request and expense, to use reasonable efforts to cooperate with the Borrowers to effectuate the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to any Participant.  To the extent permitted by law, each Participant also shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as though it were a Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such Participant agrees to be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as though it were a Lender.  Each Lender that sells a participation shall, acting solely for this purpose as a fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant&#8217;s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">167</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Certain Pledges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note or Notes, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Resignation as L&#47;C Issuer or Swingline Lender after Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, if at any time Bank of America assigns all of its Revolving Commitment and Revolving Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, Bank of America may, (A) upon thirty (30) days&#8217; notice to the Company and the Lenders, resign as an L&#47;C Issuer and&#47;or (B) upon thirty (30) days&#8217; notice to the Company, resign as Swingline Lender.  In the event of any such resignation as an L&#47;C Issuer or Swingline Lender, the Company shall be entitled to appoint from among the Lenders a successor L&#47;C Issuer or Swingline Lender hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no failure by the Company to appoint any such successor shall affect the resignation of Bank of America as an L&#47;C Issuer or Swingline Lender, as the case may be.  If Bank of America resigns as an L&#47;C Issuer, it shall retain all the rights, powers, privileges and duties of an L&#47;C Issuer hereunder with respect to all Letters of Credit issued by Bank of America and outstanding as of the effective date of its resignation as an L&#47;C Issuer and all L&#47;C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  If Bank of America resigns as Swingline Lender, it shall retain all the rights of the Swingline Lender provided for hereunder with respect to Swingline Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Base Rate Loans or fund risk participations in outstanding Swingline Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the appointment of a successor L&#47;C Issuer and&#47;or Swingline Lender, (1) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L&#47;C Issuer or Swingline Lender, as the case may be, and (2) the successor L&#47;C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, issued by Bank of America and outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, if at any time JPMorgan assigns all of its Revolving Commitment and Revolving Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, JPMorgan may, upon thirty (30) days&#8217; notice to the Company and the Lenders, resign as an L&#47;C Issuer.  In the event of any such resignation as an L&#47;C Issuer, the Company shall be entitled to appoint from among the Lenders a successor L&#47;C Issuer hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">168</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no failure by the Company to appoint any such successor shall affect the resignation of JPMorgan as an L&#47;C Issuer.  If JPMorgan resigns as an L&#47;C Issuer, it shall retain all the rights, powers, privileges and duties of an L&#47;C Issuer hereunder with respect to all Letters of Credit issued by JPMorgan and outstanding as of the effective date of its resignation as an L&#47;C Issuer and all L&#47;C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Upon the appointment of a successor L&#47;C Issuer, (A) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L&#47;C Issuer, and (B) the successor L&#47;C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, issued by JPMorgan and outstanding at the time of such succession or make other arrangements satisfactory to JPMorgan to effectively assume the obligations of JPMorgan with respect to such Letters of Credit.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Treatment of Certain Information&#59; Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Treatment of Certain Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Administrative Agent, the Lenders and the L&#47;C Issuer agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its Affiliates, its auditors, and to its Related Parties (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (ii) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (iii) to the extent required by applicable Laws or regulations or by any subpoena or similar legal process, (iv) to any other party hereto, (v) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (vi) subject to an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Agreement or any Eligible Assignee invited to be a Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or (B) any actual or prospective party (or its Related Parties) to any swap, derivative or other transaction under which payments are to be made by reference to the Borrowers and their respective obligations, this Agreement or payments hereunder, (vii) on a confidential basis to (A) any rating agency in connection with rating the Company or its Subsidiaries or the credit facilities provided hereunder, (B) the provider of any Platform or other electronic delivery service used by the Administrative Agent, the L&#47;C Issuer and&#47;or the Swingline Lender to deliver Borrower Materials or notices to the Lenders, or (C) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, or (viii) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">169</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the consent of the Company or to the extent such Information (1) becomes publicly available other than as a result of a breach of this Section or (2) becomes available to the Administrative Agent, any Lender, the L&#47;C Issuer or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrowers.  For purposes of this Section, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all information received from the Company or any Subsidiary relating to the Company or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or any L&#47;C Issuer on a nonconfidential basis prior to disclosure by the Company or any Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the case of information received from the Company or any Subsidiary after the Closing Date, such information is clearly identified at the time of delivery as confidential.  Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.  In addition, the Administrative Agent and the Lenders may disclose the existence of this Agreement and information about this Agreement to market data collectors, similar service providers to the lending industry and service providers to the Administrative Agent, the Arrangers and the Lenders in connection with the administration of this Agreement, the other Loan Documents and the Commitments.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Administrative Agent, the Lenders and the L&#47;C Issuer acknowledges that (i) the Information may include material non-public information concerning a Loan Party or a Subsidiary, as the case may be, (ii) it has developed compliance procedures regarding the use of material non-public information and (iii) it will handle such material non-public information in accordance with applicable Law, including United States federal and state securities Laws.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Loan Parties and their Affiliates agree that they will not in the future issue any press releases or other public disclosure using the name of the Administrative Agent or any Lender or their respective Affiliates or referring to this Agreement or any of the Loan Documents without the prior written consent of the Administrative Agent, unless (and only to the extent that) the Loan Parties or such Affiliate is required to do so under law and then, in any event the Loan Parties or such Affiliate will consult with such Person before issuing such press release or other public disclosure (it being understood that the Loan Parties or such Affiliate shall not be required to so consult with such Person (x) if such consultation is prohibited by applicable law, rule or regulation or (y) with respect to filings required to be made pursuant to the Securities Act or the Securities Exchange Act of 1934, as amended).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">170</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">Customary Advertising Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Loan Parties consent to the publication by the Administrative Agent or any Lender of customary advertising material relating to the transactions contemplated hereby using the name, product photographs, logo or trademark of the Loan Parties.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Right of Setoff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If an Event of Default shall have occurred and be continuing, each Lender, the L&#47;C Issuer and each of their respective Affiliates is hereby authorized at any time and from time to time, after obtaining the prior written consent of the Administrative Agent, to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, the L&#47;C Issuer or any such Affiliate to or for the credit or the account of any Borrower or any other Loan Party against any and all of the obligations of such Borrower or such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender or the L&#47;C Issuer or their respective Affiliates, irrespective of whether or not such Lender, the L&#47;C Issuer or Affiliate shall have made any demand under this Agreement or any other Loan Document and although such obligations of such Borrower or such Loan Party may be contingent or unmatured, secured or unsecured, or are owed to a branch, office or Affiliate of such Lender or the L&#47;C Issuer different from the branch, office or Affiliate holding such deposit or obligated on such indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event that any Defaulting Lender shall exercise any such right of setoff, (a) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent, the L&#47;C Issuer and the Lenders, and (b) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Secured Obligations owing to such Defaulting Lender as to which it exercised such right of setoff.  The rights of each Lender, the L&#47;C Issuer and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender, the L&#47;C Issuer or their respective Affiliates may have.  Each Lender and the L&#47;C Issuer agrees to notify the Company and the Administrative Agent promptly after any such setoff and application, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the failure to give such notice shall not affect the validity of such setoff and application.  Notwithstanding the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if at any time any Lender, the L&#47;C Issuer or any of their respective Affiliates maintains one or more deposit accounts for the Company or any other Loan Party into which Medicare and&#47;or Medicaid receivables are deposited, such Person shall waive the right of setoff set forth herein.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maximum Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrowers.  In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">171</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Integration&#59; Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, the other Loan Documents, and any separate letter agreements with respect to fees payable to the Administrative Agent or the L&#47;C Issuer, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.  </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Survival of Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof.  Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  Without limiting the foregoing provisions of this Section, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, the L&#47;C Issuer or the Swingline Lender, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Replacement of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">If the Company is entitled to replace a Lender pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Company may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), all of its interests, rights (other than its existing rights to payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and obligations under this Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">the Company shall have paid to the Administrative Agent the assignment fee (if any) specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.06(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">172</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">such Lender shall have received payment of an amount equal to one hundred percent (100%) of the outstanding principal of its Loans and L&#47;C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Company (in the case of all other amounts)&#59;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">in the case of any such assignment resulting from a claim for compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or payments required to be made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such assignment will result in a reduction in such compensation or payments thereafter&#59;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">such assignment does not conflict with applicable Laws&#59; and</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">in the case of an assignment resulting from a Lender becoming a Non-Consenting Lender, the applicable assignee shall have consented to the applicable amendment, waiver or consent.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Company to require such assignment and delegation cease to apply.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">Each party hereto agrees that (i) an assignment required pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> may be effected pursuant to an Assignment and Assumption executed by the Company, the Administrative Agent and the assignee and (ii) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to an be bound by the terms thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any such documents shall be without recourse to or warranty by the parties thereto.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">Notwithstanding anything in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, (A)&#160;the Lender that acts as the L&#47;C Issuer may not be replaced hereunder at any time it has any Letter of Credit outstanding hereunder unless arrangements satisfactory to such Lender (including the furnishing of a backstop standby letter of credit in form and substance, and issued by an issuer, reasonably satisfactory to the L&#47;C Issuer or the depositing of Cash Collateral into a Cash Collateral account in amounts and pursuant to arrangements reasonably satisfactory to the L&#47;C Issuer) have been made with respect to such outstanding Letter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">173</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Credit and (B)&#160;the Lender that acts as the Administrative Agent may not be replaced hereunder except in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;9.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Governing Law&#59; Jurisdiction&#59; Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (EXCEPT, AS TO ANY OTHER LOAN DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT (EXCEPT, AS TO ANY OTHER LOAN DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">SUBMISSION TO JURISDICTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EACH BORROWER AND EACH OTHER LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT IT WILL NOT COMMENCE ANY ACTION, LITIGATION OR PROCEEDING OF ANY KIND OR DESCRIPTION, WHETHER IN LAW OR EQUITY, WHETHER IN CONTRACT OR IN TORT OR OTHERWISE, AGAINST THE ADMINISTRATIVE AGENT, ANY LENDER, THE L&#47;C ISSUER, OR ANY RELATED PARTY OF THE FOREGOING IN ANY WAY RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS RELATING HERETO OR THERETO, IN ANY FORUM OTHER THAN THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE JURISDICTION OF SUCH COURTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION, LITIGATION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT.  EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION, LITIGATION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW.  NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER OR THE L&#47;C </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">174</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY BORROWER OR ANY OTHER LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt;text-decoration:underline">WAIVER OF VENUE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EACH BORROWER AND EACH OTHER LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PARAGRAPH (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> OF THIS SECTION.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt;text-decoration:underline">SERVICE OF PROCESS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION 11.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Subordination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Loan Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subordinating Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) hereby subordinates the payment of all obligations and indebtedness of any other Loan Party owing to it, whether now existing or hereafter arising, including but not limited to any obligation of any such other Loan Party to the Subordinating Loan Party as subrogee of the Secured Parties or resulting from such Subordinating Loan Party&#8217;s performance under the Guaranty, to the indefeasible payment in full </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">175</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in cash of all Obligations.  If the Secured Parties so request, any such obligation or indebtedness of any such other Loan Party to the Subordinating Loan Party shall be enforced and performance received by the Subordinating Loan Party as trustee for the Secured Parties and the proceeds thereof shall be paid over to the Secured Parties on account of the Secured Obligations, but without reducing or affecting in any manner the liability of the Subordinating Loan Party under this Agreement.  Without limitation of the foregoing, so long as no Default has occurred and is continuing, the Loan Parties may make and receive payments with respect to Intercompany Debt&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event that any Loan Party receives any payment of any Intercompany Debt at a time when such payment is prohibited by this Section, such payment shall be held by such Loan Party, in trust for the benefit of, and shall be paid forthwith over and delivered, upon written request, to the Administrative Agent.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Advisory or Fiduciary Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), each Borrower and each other Loan Party acknowledges and agrees, and acknowledges its Affiliates&#8217; understanding, that&#58; (a) (i) the arranging and other services regarding this Agreement provided by the Administrative Agent and any Affiliate thereof, the Arrangers and the Lenders are arm&#8217;s-length commercial transactions between each Borrower, each other Loan Party and their respective Affiliates, on the one hand, and the Administrative Agent and, as applicable, its Affiliates (including BofA Securities) and the Lenders and their Affiliates (collectively, solely for purposes of this Section, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on the other hand, (ii) the Borrowers and the other Loan Parties have consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (iii) the Borrowers and each other Loan Party are capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents, (b) (i) the Administrative Agent and its Affiliates (including BofA Securities) and each Lender each is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary, for any Borrower, any other Loan Party or any of their respective Affiliates, or any other Person and (ii) neither the Administrative Agent, any of its Affiliates (including BofA Securities) nor any Lender has any obligation to any Borrower, any other Loan Party or any of their respective Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents, and (c) the Administrative Agent and its Affiliates (including BofA Securities) and the Lenders may be engaged in a broad range of transactions that involve interests that differ from those of the Borrowers, the other Loan Parties and their respective Affiliates, and neither the Administrative Agent, any of its Affiliates (including BofA Securities) nor any Lender has any obligation to disclose any of such interests to any Borrower, any other Loan Party or any of their respective Affiliates.  To the fullest extent permitted by law, each Borrower and each other Loan Party hereby waives and releases any claims that it may have against the Administrative Agent, any of its Affiliates (including BofA Securities) or any Lender with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Electronic Execution&#59; Electronic Records&#59; Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, any other Loan Document and any other Communication, including Communications required to be in writing, may be in the form of an Electronic Record and may be executed using Electronic Signatures.  Each of the Loan Parties and each Lender Party agrees that any Electronic Signature on or associated with any Communication shall be valid and binding on such Person to the same extent as a manual, original signature, and that any Communication entered into by Electronic Signature will constitute the legal, valid and binding obligation of such Person enforceable against such Person in accordance with the terms thereof </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">176</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the same extent as if a manually executed original signature was delivered.&#160;&#160;Any Communication may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Communication.&#160; For the avoidance of doubt, the authorization under this paragraph may include use or acceptance of a manually signed paper Communication which has been converted into electronic form (such as scanned into .pdf), or an electronically signed Communication converted into another format, for transmission, delivery and&#47;or retention.  Each Lender Party may, at its option, create one or more copies of any Communication in the form of an imaged Electronic Record (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Copy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall be deemed created in the ordinary course of such Person&#8217;s business, and destroy the original paper document.&#160; All Communications in the form of an Electronic Record, including an Electronic Copy, shall be considered an original for all purposes, and shall have the same legal effect, validity and enforceability as a paper record.  Notwithstanding anything contained herein to the contrary, none of the Administrative Agent, the L&#47;C Issuer, or the Swingline Lender is under any obligation to accept an Electronic Signature in any form or in any format unless expressly agreed to by such Person pursuant to procedures approved by it&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without limiting the foregoing, (a) to the extent the Administrative Agent, the L&#47;C Issuer and&#47;or the Swingline Lender has agreed to accept such Electronic Signature, the Administrative Agent and each of the other Lender Parties shall be entitled to rely on any such Electronic Signature purportedly given by or on behalf of any Loan Party and&#47;or any Lender Party without further verification, and (b) upon the request of the Administrative Agent or any Lender Party, any Electronic Signature shall be promptly followed by such manually executed counterpart.&#160; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None of the Administrative Agent, the L&#47;C Issuer, or the Swingline Lender shall be responsible for or have any duty to ascertain or inquire into the sufficiency, validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement, instrument or document (including, for the avoidance of doubt, in connection with the Administrative Agent&#8217;s, the L&#47;C Issuer&#8217;s or the Swingline Lender&#8217;s reliance on any Electronic Signature transmitted by telecopy, emailed .pdf or any other electronic means).  The Administrative Agent, the L&#47;C Issuer and the Swingline Lender shall be entitled to rely on, and shall incur no liability under or in respect of this Agreement or any other Loan Document by acting upon, any Communication (which writing may be a fax, any electronic message, Internet or intranet website posting or other distribution or signed using an Electronic Signature) or any statement made to it orally or by telephone and believed by it to be genuine and signed or sent or otherwise authenticated (whether or not such Person in fact meets the requirements set forth in the Loan Documents for being the maker thereof).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Loan Parties and each Lender Party hereby waives (a) any argument, defense or right to contest the legal effect, validity or enforceability of this Agreement or any other Loan Document based solely on the lack of paper original copies of this Agreement or such other Loan Document, and (b) waives any claim against each Lender Party and each Related Party thereof for any liabilities arising solely from such Lender Party&#8217;s reliance on or use of Electronic Signatures, including any liabilities arising as a result of the failure of the Loan Parties to use any available security measures in connection with the execution, delivery or transmission of any Electronic Signature.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the parties represents and warrants to the other parties that it has the corporate capacity and authority to execute this Agreement and any other Communication through electronic means and there are no restrictions on doing so in that party&#8217;s constitutive documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">USA PATRIOT Act Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">177</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Lender that is subject to the PATRIOT Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrowers and the other Loan Parties that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), it is required to obtain, verify and record information that identifies each Loan Party, which information includes the name and address of each Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify each Loan Party in accordance with the PATRIOT Act.  The Borrowers and the Loan Parties agree to, promptly following a request by the Administrative Agent or any Lender, provide all such other documentation and information that the Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the PATRIOT Act and the Beneficial Ownership Regulation.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Concerning Joint and Several Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each of the Borrowers is accepting joint and several liability hereunder in consideration of the financial accommodation to be provided by the Lenders under this Agreement, for the mutual benefit, directly and indirectly, of each of the Borrowers and in consideration of the undertakings of each of the Borrowers to accept joint and several liability for the obligations of each of them.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Each of the Borrowers jointly and severally hereby irrevocably and unconditionally accepts, not merely as a surety but also as a co-debtor, joint and several liability with the other Borrower with respect to the payment and performance of all of the Obligations arising under this Agreement and the other Loan Documents, it being the intention of the parties hereto that all the Secured Obligations shall be the joint and several obligations of each of the Borrowers without preferences or distinction among them.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;If and to the extent that a Borrower shall fail to make any payment with respect to any of the obligations hereunder as and when due or to perform any of such obligations in accordance with the terms thereof, then in each such event, the other Borrower will make such payment with respect to, or perform, such obligation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The obligations of each Borrower under the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> constitute full recourse obligations of such Borrower, enforceable against it to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of this Agreement or any other circumstances whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as otherwise expressly provided herein, each Borrower hereby waives notice of acceptance of its joint and several liability, notice of occurrence of any Default or Event of Default (except to the extent notice is expressly required to be given pursuant to the terms of this Agreement), or of any demand for any payment under this Agreement, notice of any action at any time taken or omitted by the Administrative Agent or the Lenders under or in respect of any of the Secured Obligations hereunder, any requirement of diligence and, generally, all demands, notices and other formalities of every kind in connection with this Agreement.  Each Borrower hereby assents to, and waives notice of, any extension or postponement of the time for the payment of any of the Secured Obligations hereunder, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence by the Lenders at any time or times in respect of any default by any Borrower in the performance or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by the Lenders in respect of any of the Secured Obligations hereunder, and the taking, addition, substitution or release, in whole or in part, at any time or times, of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">178</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any security for any of such Secured Obligations or the addition, substitution or release, in whole or in part, of any Borrower.  Without limiting the generality of the foregoing, each Borrower assents to any other action or delay in acting or any failure to act on the part of the Administrative Agent or the Lenders, including any failure strictly or diligently to assert any right or to pursue any remedy or to comply fully with applicable laws or regulations thereunder which might, but for the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, afford grounds for terminating, discharging or relieving such Borrower, in whole or in part, from any of its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, it being the intention of each Borrower that, so long as any of the Secured Obligations hereunder remain unsatisfied, the obligations of such Borrower under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not be discharged except by performance and then only to the extent of such performance.  The obligations of each Borrower under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not be diminished or rendered unenforceable by any winding up, reorganization, arrangement, liquidation, reconstruction or similar proceeding with respect to any reconstruction or similar proceeding with respect to any Borrower or the Lenders.  The joint and several liability of the Borrowers hereunder shall continue in full force and effect notwithstanding any absorption, merger, amalgamation or any other change whatsoever in the name, membership, constitution or place of formation of any Borrower or the Lenders.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are made for the benefit of the Administrative Agent and the Lenders and their respective successors and assigns, and may be enforced by any such Person from time to time against any of the Borrowers as often as occasion therefore may arise and without requirement on the part of any Lender first to marshal any of its claims or to exercise any of its rights against any other Borrower or to exhaust any remedies available to it against any other Borrower or to resort to any other source or means of obtaining payment of any of the Secured Obligations or to elect any other remedy.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall remain in effect until the Facility Termination Date.  If at any time, any payment, or any part thereof, made in respect of any of the Secured Obligations, is rescinded or must otherwise be restored or returned by the Lenders upon the insolvency, bankruptcy or reorganization of any of the Borrowers, or otherwise, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will forthwith be reinstated and in effect as though such payment had not been made.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Notwithstanding any provision to the contrary contained herein or in any other of the Loan Documents or Swap Contracts or Cash Management Agreements, the obligations of each Borrower hereunder shall be limited to an aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance under Section 548 of the Bankruptcy Code of the United States or any comparable provisions of any applicable Debtor Relief Law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">ENTIRE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.  THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Acknowledgement and Consent to Bail-In of Affected Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Solely to the extent any Lender or L&#47;C Issuer that is an Affected Financial Institution is a party to this Agreement and notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">179</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any liability of any Lender or L&#47;C Issuer that is an Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by&#58;</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.8pt">the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender or L&#47;C Issuer that is an Affected Financial Institution&#59; and</font></div><div style="margin-bottom:12pt;padding-left:162pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the effects of any Bail-In Action on any such liability, including, if applicable&#58;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">a reduction in full or in part or cancellation of any such liability&#59;</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document&#59; or</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendment and Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties hereto agree that, on the Closing Date, the following transactions shall be deemed to occur automatically, without further action by any party hereto&#58; (a) the Existing Credit Agreement shall be deemed to be amended and restated in its entirety pursuant to this Agreement&#59; (b) all obligations under the Existing Credit Agreement outstanding on the Closing Date shall in all respects be continuing and shall be deemed to be Obligations outstanding hereunder&#59; (c) the guarantees made to the lenders, the letter of credit issuers, the administrative agent and each other holder of the obligations under the Existing Credit Agreement, shall remain in full force and effect with respect to the Secured Obligations and are hereby reaffirmed&#59; and (d) the security interests and liens in favor of Bank of America, as administrative agent for the benefit of the holders of the obligations under the Existing Credit Agreement, created under the collateral documents entered into in connection with the Existing Credit Agreement shall remain in full force and effect with respect to the Secured Obligations and are hereby reaffirmed.  On the Closing Date, (i) the Loan Parties shall prepay any revolving loans outstanding under the Existing Credit Agreement to the extent necessary to keep the outstanding Revolving Loans ratable with the revised Revolving Commitments as of the Closing Date, and (ii) the revolving credit extensions and revolving commitments made by the lenders under the Existing Credit Agreement shall be re-allocated and restated among the Lenders so that, as of the Closing Date, the respective Revolving Commitments of the Lenders shall be as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as in effect on the Closing Date.  The parties hereto further acknowledge and agree that this Agreement constitutes an amendment to the Existing Credit Agreement made under and in accordance with the terms of Section 11.01 of the Existing Credit Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.75pt;text-decoration:underline">Acknowledgement Regarding Any Supported QFCs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that the Loan Documents provide support, through a guarantee or otherwise, for any Swap Contract or any other agreement or instrument that is a QFC (such support, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">QFC Credit Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and each such QFC, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Supported QFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Special Resolution Regimes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and&#47;or of the United States or any other state of the United States)&#58; In the event a Covered Entity that is party to a Supported QFC (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States.  In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States.  Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGES OMITTED&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">181</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_700"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Annex B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Amended Exhibits</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">See attached.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_714"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i5691bec2d7554cedbaaa8b01a446339b_727"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Form of&#93; Incremental Term Loan Lender Joinder Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS INCREMENTAL TERM LOAN LENDER JOINDER AGREEMENT dated as of &#91;__________, ____&#93; (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is by and among each of the Persons identified as &#8220;Incremental Term Lenders&#8221; on the signature pages hereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incremental Term Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Amedisys, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Amedisys Holding, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Guarantors party hereto, and Bank of America, N.A., as Administrative Agent.  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">W I T N E S S E T H</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, pursuant to that certain Amended and Restated Credit Agreement dated as of June 29, 2018 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) among the Borrowers, the Guarantors party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer, the Lenders have agreed to provide the Borrowers with the credit facilities provided for therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, pursuant to Section 2.01(b) of the Credit Agreement, the Borrowers have requested that each Incremental Term Lender provide an Incremental Term Facility under the Credit Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, each Incremental Term Lender has agreed to provide an Incremental Term Facility on the terms and conditions set forth herein and to become an &#8220;Incremental Term Lender&#8221; under the Credit Agreement in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Each Incremental Term Lender severally agrees to make an Incremental Term Loan in a single advance to &#91;the Company&#93;&#91;Amedisys Holding&#93; on the date hereof in the amount of its respective Incremental Term Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, after giving effect to such advances, the Outstanding Amount of all Incremental Term Loans shall not exceed the aggregate amount of the Incremental Term Commitments of the Incremental Term Lenders.  The Incremental Term Commitments of each of the Incremental Term Lenders and the Applicable Percentage of the Incremental Term Facility for each of the Incremental Term Lenders shall be as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.  The existing Schedule 1.01(b) to the Credit Agreement shall be deemed to be amended to include the information set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Applicable Rate with respect to the Incremental Term Facility shall be (a) &#91;__&#93; percent (&#91;__&#93;%), with respect to Term SOFR Loans, and (b) &#91;__&#93; percent (&#91;__&#93;%), with respect to Base Rate Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The Incremental Term Loan Maturity Date shall be &#91;__&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;&#91;The Company&#93;&#91;Amedisys Holding&#93; shall repay to the Incremental Term Lenders the principal amount of the Incremental Term Loans in quarterly installments on the dates set forth below as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"></td><td style="width:22.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Principal</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization Payment</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Principal</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization Payment</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.35pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Incremental Term Loan Maturity Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Outstanding Amount</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Total&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Each Incremental Term Lender (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Agreement and to consummate the transactions contemplated hereby and to become an Incremental Term Lender under the Credit Agreement, (ii) it meets all requirements of an Eligible Assignee under the Credit Agreement (subject to receipt of such consents as may be required under the Credit Agreement), (iii) from and after the date hereof, it shall be bound by the provisions of the Credit Agreement as an Incremental Term Lender thereunder and shall have the obligations of an Incremental Term Lender thereunder, (iv) it has received a copy of the Credit Agreement, together with copies of the most recent financial statements delivered pursuant to the terms thereof, as applicable, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement on the basis of which it has made such analysis and decision independently and without reliance on the Administrative Agent or any other Incremental Term Lender, and (v) if it is a Foreign Lender, attached hereto is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement&#59; and (b) agrees that (i) it will, independently and without reliance on the Administrative Agent or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as an Incremental Term Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Each of the Administrative Agent, the Borrowers, and each Guarantor agrees that, as of the date hereof, each Incremental Term Lender shall (a) be a party to the Credit Agreement and the other Loan Documents, (b) be an &#8220;Incremental Term Lender&#8221; for all purposes of the Credit Agreement and the other Loan Documents and (c) have the rights and obligations of an Incremental Term Lender under the Credit Agreement and the other Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;The address of each Incremental Term Lender for purposes of all notices and other communications is as set forth on the Administrative Questionnaire delivered by such Incremental Term Lender to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page of this Agreement by fax transmission or e-mail transmission (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed by a duly authorized officer as of the date first above written.</font></div><div><font><br></font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">INCREMENTAL TERM LENDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;INSERT INCREMENTAL TERM LENDER&#93;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BORROWERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMEDISYS, INC.,</font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GUARANTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;INSERT GUARANTOR&#93;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ADMINISTRATIVE AGENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BANK OF AMERICA, N.A.,</font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Administrative Agent</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT F</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Form of&#93; Loan Notice</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;Bank of America, N.A., as Administrative Agent</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RE&#58;&#160;&#160;&#160;&#160;Amended and Restated Credit Agreement, dated as of June 29, 2018, by and among Amedisys, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Amedisys Holding, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Guarantors party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer (as amended, modified, extended, restated, replaced, or supplemented from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;&#91;Date&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned hereby requests (select one)&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;A &#91;Revolving Borrowing&#93;&#91;Incremental Term Borrowing&#93;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;A &#91;conversion&#93;&#91;continuation&#93; of &#91;Revolving&#93;&#91;Term&#93;&#91;Incremental Term&#93; Loans</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">---</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;On </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (a Business Day)</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the amount of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Comprised of&#58;&#160;&#160;&#160;&#160;&#9744;  Base Rate Loans</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;  Term SOFR Loans</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;For Term SOFR Loans&#58;  with an Interest Period of __ months.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to such Borrowing, the undersigned Borrower hereby represents and warrants that &#91;(i) such request complies with the requirements of &#91;Section 2.01(a)&#93;&#91;Section 2.01(b)&#93; of the Credit Agreement and (ii)&#93; each of the conditions set forth in Section 4.02 of the Credit Agreement have been satisfied on and as of the date of such Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delivery of an executed counterpart of a signature page of this notice by fax transmission or other electronic mail transmission (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this notice.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned Responsible Officer of the undersigned Borrower has caused this Loan Notice to be executed as of the date first above written.</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS, INC.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT G</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Form of&#93; Notice of Loan Prepayment</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;Bank of America, N.A., as &#91;Administrative Agent&#93;&#91;and Swingline Lender&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RE&#58;&#160;&#160;&#160;&#160;Amended and Restated Credit Agreement, dated as of June 29, 2018, by and among Amedisys, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Amedisys Holding, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Guarantors party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer (as amended, modified, extended, restated, replaced, or supplemented from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;&#91;Date&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;The Company&#93;&#91;Amedisys Holding&#93; hereby notifies the Administrative Agent &#91;and the Swingline Lender&#93; that on &#91;Date&#93;, pursuant to the terms of Section 2.05 of the Credit Agreement, &#91;the Company&#93;&#91;Amedisys Holding&#93; intends to prepay&#47;repay the following Loans as more specifically set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Voluntary prepayment of &#91;Revolving&#93;&#91;Term&#93;&#91;Incremental Term&#93; Loans in the following amount(s)&#58;</font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Term SOFR Loans&#58; $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Applicable Interest Period(s)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Base Rate Loans&#58; $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Voluntary prepayment of Swingline Loans in the following amount&#58; &#160;&#160;&#160;&#160;$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delivery of an executed counterpart of a signature page of this notice by fax transmission or other electronic mail transmission (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this notice.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="padding-left:234pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Any prepayment of Term SOFR Loans shall be in a principal amount of $1,000,000 or a whole multiple of $100,000 in excess thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Any prepayment of Base Rate Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof (or, if less, the entire principal thereof then outstanding).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Any such prepayment shall be in a minimum principal amount of $100,000 or a whole multiple of $100,000 in excess thereof (or, if less, the entire principal thereof then outstanding).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned Responsible Officer of the undersigned Borrower has caused this Notice of Loan Prepayment to be executed as of the date first above written.</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS, INC.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5691bec2d7554cedbaaa8b01a446339b_730"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT K</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Form of&#93; Swingline Loan Notice</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;Bank of America, N.A., as Administrative Agent and Swingline Lender</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RE&#58;&#160;&#160;&#160;&#160;Amended and Restated Credit Agreement, dated as of June 29, 2018, by and among Amedisys, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Amedisys Holding, L.L.C., a Louisiana limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amedisys Holding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together with the Company, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Guarantors party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and L&#47;C Issuer (as amended, modified, extended, restated, replaced, or supplemented from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;&#91;Date&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned hereby requests a Swingline Loan&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;On _________________________________ (a Business Day).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the amount of $_______________________.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;At an interest rate based on&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Applicable Rate for Base Rate Loans </font></div><div style="padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;the SOFR Daily Floating Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Applicable Rate for SOFR Daily Floating Rate Loans.</font></div><div style="padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to such Swingline Borrowing, the undersigned Borrower hereby represents and warrants that (i) such request complies with the requirements of Section 2.04(a) of the Credit Agreement and (ii) each of the conditions set forth in Section 4.02 of the Credit Agreement have been satisfied on and as of the date of such Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delivery of an executed counterpart of a signature page of this notice by fax transmission or other electronic mail transmission (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this notice.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> In a minimum amount of $100,000.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned Responsible Officer of the undersigned Borrower has caused this Swingline Loan Notice to be executed as of the date first above written.</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS, INC.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;AMEDISYS HOLDING, L.L.C.,</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Louisiana limited liability company</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>amed-20233103xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i81402b323f14467e95decb6a07f5245e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard Ashworth, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Richard Ashworth</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Ashworth</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>amed-20233103xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i40d3edc2beef421f84c4076589c68b41_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>amed-20233103xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie3164c343e0541e3868ffe455f123cf7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;), I, Richard Ashworth, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Richard Ashworth</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Ashworth<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>amed-20233103xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5f63577677b14aef9b80c05e39e7ebad_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;), I, Scott G. Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>amed-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDINCOMESTATEMENT" roleURI="http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT">
        <link:definition>0000004 - Statement - CONSOLIDATED INCOME STATEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>0000007 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTS" roleURI="http://www.amedisys.com/role/INVESTMENTS">
        <link:definition>0000009 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>0000010 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONS" roleURI="http://www.amedisys.com/role/DISPOSITIONS">
        <link:definition>0000011 - Disclosure - DISPOSITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>0000012 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>0000014 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASESHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE">
        <link:definition>0000015 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS">
        <link:definition>0000016 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <link:definition>0000017 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables">
        <link:definition>0000019 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSTables" roleURI="http://www.amedisys.com/role/INVESTMENTSTables">
        <link:definition>0000021 - Disclosure - INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>0000022 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONSTables" roleURI="http://www.amedisys.com/role/DISPOSITIONSTables">
        <link:definition>0000023 - Disclosure - DISPOSITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables">
        <link:definition>0000024 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000025 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTTables" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables">
        <link:definition>0000026 - Disclosure - SUBSEQUENT EVENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>0000027 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
        <link:definition>0000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
        <link:definition>0000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>0000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSDetails" roleURI="http://www.amedisys.com/role/INVESTMENTSDetails">
        <link:definition>0000034 - Disclosure - INVESTMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>0000035 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails">
        <link:definition>0000036 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>0000037 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
        <link:definition>0000038 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1">
        <link:definition>0000038 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>0000040 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>0000041 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>0000042 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000043 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>0000044 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>0000045 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>0000046 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>0000047 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PriorCreditAgreementMember" abstract="true" name="PriorCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ReclassificationOfOperatingLeaseToFinanceLease" abstract="false" name="ReclassificationOfOperatingLeaseToFinanceLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmountReleasedFromEscrow" abstract="false" name="AmountReleasedFromEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfJointVentures" abstract="false" name="NumberOfJointVentures" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" abstract="false" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionShareExchangeRatio" abstract="false" name="BusinessAcquisitionShareExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Discountedclosingstockprice" abstract="false" name="Discountedclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_IncreaseDecreaseInAssetsAcquired" abstract="false" name="IncreaseDecreaseInAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DepreciationExpenseFleetLeasesFinanceLease" abstract="false" name="DepreciationExpenseFleetLeasesFinanceLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_PayorsDomain" abstract="true" name="PayorsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AccountsReceivablePortionDerivedFromMedicare" abstract="false" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ReversalOfLossContingencyAccrual" abstract="false" name="ReversalOfLossContingencyAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2021ShareRepurchaseProgramMember" abstract="true" name="A2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2019ShareRepurchaseProgramMember" abstract="true" name="A2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ContributionsAttributableToNoncontrollingInterest" abstract="false" name="ContributionsAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" abstract="false" name="PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_LegalSettlementPaymentLessInterest" abstract="false" name="LegalSettlementPaymentLessInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ReductionToNetServiceRevenue" abstract="false" name="ReductionToNetServiceRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19PPEMember" abstract="true" name="COVID19PPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Businessacquisitionproformaoperatingincomeloss" abstract="false" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2023ShareRepurchaseProgramMember" abstract="true" name="A2023ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" abstract="false" name="NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_TotalLegalSettlementPayment" abstract="false" name="TotalLegalSettlementPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_MajorSinglePayorCustomerMember" abstract="true" name="MajorSinglePayorCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_SOFRAdjustment" abstract="false" name="SOFRAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AssistedCareHomeHealthMember" abstract="true" name="AssistedCareHomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_A2022ShareRepurchaseProgramMember" abstract="true" name="A2022ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitsettlement" abstract="false" name="SecuritiesClassActionLawsuitsettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ThirdAmendmentToAmendedCreditAgreementMember" abstract="true" name="ThirdAmendmentToAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationAcquiredNoncontrollingInterest" abstract="false" name="BusinessCombinationAcquiredNoncontrollingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecondAmendedCreditAgreementMember" abstract="true" name="SecondAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FourHundredFiftyMillionTermLoanFacilityMember" abstract="true" name="FourHundredFiftyMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_FleetInsuranceExposureLimit" abstract="false" name="FleetInsuranceExposureLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashBalanceAssociatedWithProviderReliefFund" abstract="false" name="CashBalanceAssociatedWithProviderReliefFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PayorsAxis" abstract="true" name="PayorsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsContessaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_AsanaHospiceAquisitionMember" abstract="true" name="AsanaHospiceAquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_CashPaidForOperatingLeaseLiabilities" abstract="false" name="CashPaidForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" abstract="false" name="LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ExistingShareRepurchaseProgramMember" abstract="true" name="ExistingShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonCashAccruedContingentConsideration" abstract="false" name="NonCashAccruedContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_CompanysinsurancecarriersMember" abstract="true" name="CompanysinsurancecarriersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Percentageofclosingstockprice" abstract="false" name="Percentageofclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CertificateOfNeedAndLicensesMember" abstract="true" name="CertificateOfNeedAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_EvolutionHealthMember" abstract="true" name="EvolutionHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NonCashNoncontrollingInterestContribution" abstract="false" name="NonCashNoncontrollingInterestContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_OneHundredMillionTermLoanMember" abstract="true" name="OneHundredMillionTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AcutePhaseForHighAcuityCareServices" abstract="false" name="AcutePhaseForHighAcuityCareServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HighAcuityCareMember" abstract="true" name="HighAcuityCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CashPaidForFinanceLeaseLiabilities" abstract="false" name="CashPaidForFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_VariousAcquisitionsMember" abstract="true" name="VariousAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BusinessAcquisitionTerminationFee" abstract="false" name="BusinessAcquisitionTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>amed-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_b559c74b-9742-4be6-95e0-9b71ecc29280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_b559c74b-9742-4be6-95e0-9b71ecc29280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_198af57f-9c69-4967-8451-b06670126b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_198af57f-9c69-4967-8451-b06670126b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3b8fecb8-8822-4e10-a2ab-4fc3d2a64b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3b8fecb8-8822-4e10-a2ab-4fc3d2a64b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3a1967f1-0adc-4345-907c-26d300212de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:to="loc_us-gaap_TreasuryStockValue_3a1967f1-0adc-4345-907c-26d300212de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6dd8e53-794e-429d-8fe5-edaeeef4cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cda603cc-8e7b-4b73-a894-b92196ab8d2c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6dd8e53-794e-429d-8fe5-edaeeef4cf46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f3bf9ea4-3731-42b1-8eb8-7f0f90f21e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_AssetsCurrent_f3bf9ea4-3731-42b1-8eb8-7f0f90f21e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c526046f-654a-444f-859f-a99dbcff2893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c526046f-654a-444f-859f-a99dbcff2893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e718127-0560-4ddd-b210-8aaf149084a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e718127-0560-4ddd-b210-8aaf149084a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a36018f-398a-4c42-a668-59813eadb5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_Goodwill_7a36018f-398a-4c42-a668-59813eadb5ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_80410de1-f1ed-40fd-9ef6-58124b18e637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_80410de1-f1ed-40fd-9ef6-58124b18e637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_348ef97f-67fb-484d-948f-26605a7a1973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af875b20-2dec-4078-bbbb-c1e3acab3f14" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_348ef97f-67fb-484d-948f-26605a7a1973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98fa2db3-e943-4a64-bbea-4f4370a46430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_119ac280-b33e-40b5-9b07-1eac63f358a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98fa2db3-e943-4a64-bbea-4f4370a46430" xlink:to="loc_us-gaap_StockholdersEquity_119ac280-b33e-40b5-9b07-1eac63f358a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d8ca384f-30c9-4d82-920b-81161be6f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98fa2db3-e943-4a64-bbea-4f4370a46430" xlink:to="loc_us-gaap_MinorityInterest_d8ca384f-30c9-4d82-920b-81161be6f3f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b8b34e30-4a42-43ef-b8c3-d2fb32dce623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:to="loc_us-gaap_AccountsPayableCurrent_b8b34e30-4a42-43ef-b8c3-d2fb32dce623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c4f7d205-e404-4894-83f5-43899cb079d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c4f7d205-e404-4894-83f5-43899cb079d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5bd9fed5-2204-43fb-929b-a5d4709b2d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5bd9fed5-2204-43fb-929b-a5d4709b2d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_22b2d8c2-a142-4c6f-8e2f-4276b17c3f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_22b2d8c2-a142-4c6f-8e2f-4276b17c3f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e5f5e56-7b8b-4be6-8e82-9b2bc58ffabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23d4d3a5-5914-4290-adca-961510e8aebd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9e5f5e56-7b8b-4be6-8e82-9b2bc58ffabb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea3d26a8-3716-4529-a716-15863b3f89df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d915deb2-c127-45eb-8636-586dd3a36168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea3d26a8-3716-4529-a716-15863b3f89df" xlink:to="loc_us-gaap_Liabilities_d915deb2-c127-45eb-8636-586dd3a36168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2f9e52e-a0ac-41e6-86cf-c3f275b11d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea3d26a8-3716-4529-a716-15863b3f89df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2f9e52e-a0ac-41e6-86cf-c3f275b11d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3387ea8-84a3-42bf-86f2-062a8f221a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3387ea8-84a3-42bf-86f2-062a8f221a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_a91c1bba-da24-49ec-9f58-50f3f34c8a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:to="loc_us-gaap_RestrictedCash_a91c1bba-da24-49ec-9f58-50f3f34c8a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19401c3f-5081-495e-a472-b1d68964e899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_19401c3f-5081-495e-a472-b1d68964e899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_cd68d984-fec7-4b8c-80fd-acfd446b5de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_cd68d984-fec7-4b8c-80fd-acfd446b5de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3b6a357d-627d-4b09-869d-a5cbd6936c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_22bf66f0-2cd6-453c-be43-6feffb81414a" xlink:to="loc_us-gaap_OtherAssetsCurrent_3b6a357d-627d-4b09-869d-a5cbd6936c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d967f287-a8d0-4569-8777-b7d87854f67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:to="loc_us-gaap_LiabilitiesCurrent_d967f287-a8d0-4569-8777-b7d87854f67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1cd6d9f6-b05f-42eb-96b7-25fb28d0afd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1cd6d9f6-b05f-42eb-96b7-25fb28d0afd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb4ffc4a-f77a-4f8c-9c09-a4b902610fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb4ffc4a-f77a-4f8c-9c09-a4b902610fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c9d1c43b-ee33-4081-8a4c-2ee075410506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c9d1c43b-ee33-4081-8a4c-2ee075410506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_25c7b650-75f1-44de-a73d-f4b31e196a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dccb8e57-4ad2-475c-8321-9e664bf59c63" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_25c7b650-75f1-44de-a73d-f4b31e196a07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDINCOMESTATEMENT"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_99eff68e-ad1f-4a3d-b342-fb618185e86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_92083583-36a7-489e-bb8c-e74c2da32445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_99eff68e-ad1f-4a3d-b342-fb618185e86b" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_92083583-36a7-489e-bb8c-e74c2da32445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fbf6dc1d-d02b-40a4-98c5-1d86c30b502a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_99eff68e-ad1f-4a3d-b342-fb618185e86b" xlink:to="loc_us-gaap_InterestExpense_fbf6dc1d-d02b-40a4-98c5-1d86c30b502a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14faf661-4476-41b0-9d71-a938d214b284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_99eff68e-ad1f-4a3d-b342-fb618185e86b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14faf661-4476-41b0-9d71-a938d214b284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9517bce1-d561-4c71-87d0-05a36e45b72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_99eff68e-ad1f-4a3d-b342-fb618185e86b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9517bce1-d561-4c71-87d0-05a36e45b72c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49574538-f913-4af4-956d-0bfc1404b53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fe360cff-8dce-45f6-913b-e2d20971eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49574538-f913-4af4-956d-0bfc1404b53b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fe360cff-8dce-45f6-913b-e2d20971eb9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8ba63de2-a70a-45fa-ac86-9f0d9e41676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49574538-f913-4af4-956d-0bfc1404b53b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8ba63de2-a70a-45fa-ac86-9f0d9e41676c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c0ce3216-ae47-4486-8969-4a2fb6fbe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49574538-f913-4af4-956d-0bfc1404b53b" xlink:to="loc_us-gaap_CostsAndExpenses_c0ce3216-ae47-4486-8969-4a2fb6fbe6bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62b8e0ff-ae08-493b-9b48-538a6248def5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_392a9749-195f-4eee-8623-7022a72a77ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_62b8e0ff-ae08-493b-9b48-538a6248def5" xlink:to="loc_us-gaap_ProfitLoss_392a9749-195f-4eee-8623-7022a72a77ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16f6d321-c187-4f7c-a75b-e56ab9bfdd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_62b8e0ff-ae08-493b-9b48-538a6248def5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16f6d321-c187-4f7c-a75b-e56ab9bfdd79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_23d8cf58-d6f3-4c1e-ab53-d3dcf66b0331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_23d8cf58-d6f3-4c1e-ab53-d3dcf66b0331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_b31111a5-06af-4b86-9e55-408a245d8709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:to="loc_us-gaap_LaborAndRelatedExpense_b31111a5-06af-4b86-9e55-408a245d8709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_75146a47-c2fa-44ab-bc7f-8723ed99cc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:to="loc_us-gaap_ShareBasedCompensation_75146a47-c2fa-44ab-bc7f-8723ed99cc4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_9820f8a0-053c-419c-9d74-112f6b02c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_9820f8a0-053c-419c-9d74-112f6b02c0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b9e86f49-bf93-4935-80a0-538e0b7cb349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_352459f9-1a0c-4682-9da5-e58a33b14197" xlink:to="loc_us-gaap_DepreciationAndAmortization_b9e86f49-bf93-4935-80a0-538e0b7cb349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_70f489d8-e093-4041-aa8b-6976516213a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aa1d42eb-0fcc-481b-8acb-d89ce1a4a358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_70f489d8-e093-4041-aa8b-6976516213a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aa1d42eb-0fcc-481b-8acb-d89ce1a4a358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f893aefd-9ea1-480c-a9fa-6b0c2d8693b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_70f489d8-e093-4041-aa8b-6976516213a8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f893aefd-9ea1-480c-a9fa-6b0c2d8693b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7054f1-ca4e-4dd6-b72f-d13b9946dfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c3fa926f-8a6a-4c01-b973-416905dbb6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7054f1-ca4e-4dd6-b72f-d13b9946dfdd" xlink:to="loc_us-gaap_OperatingIncomeLoss_c3fa926f-8a6a-4c01-b973-416905dbb6ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8e7db044-09b6-4c48-8d33-25bd049735a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7054f1-ca4e-4dd6-b72f-d13b9946dfdd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8e7db044-09b6-4c48-8d33-25bd049735a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f50d5e6a-b1c1-4488-bd97-ad87f51dcb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db79395-fe8d-4c21-bbe1-95162606b587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f50d5e6a-b1c1-4488-bd97-ad87f51dcb4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db79395-fe8d-4c21-bbe1-95162606b587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a14dcf64-e9fb-43f4-81b2-c03e79c53e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f50d5e6a-b1c1-4488-bd97-ad87f51dcb4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a14dcf64-e9fb-43f4-81b2-c03e79c53e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b22674-e799-4298-8cd9-aa3d5f1780eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f50d5e6a-b1c1-4488-bd97-ad87f51dcb4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b22674-e799-4298-8cd9-aa3d5f1780eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0a132623-34b1-4415-8417-27d451bc241e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0a132623-34b1-4415-8417-27d451bc241e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e0fe6aed-2317-4996-b691-9df7cfd3eb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e0fe6aed-2317-4996-b691-9df7cfd3eb83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c5742dfc-45aa-445b-a9c4-c8c7c18132ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c5742dfc-45aa-445b-a9c4-c8c7c18132ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_243cbefe-11ff-4456-9d5c-5e91c6447e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_243cbefe-11ff-4456-9d5c-5e91c6447e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_d2117fa2-3ccf-477c-9193-e344610b39b3" xlink:href="amed-20230331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_d2117fa2-3ccf-477c-9193-e344610b39b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9c7ebbeb-f9a7-4638-9fda-84f26d4cb3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9c7ebbeb-f9a7-4638-9fda-84f26d4cb3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_fccc3b0b-cbec-4948-9a4a-bb45df03b624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_fccc3b0b-cbec-4948-9a4a-bb45df03b624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_13a58e2c-2d40-49f0-bbfd-4c806161bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_13a58e2c-2d40-49f0-bbfd-4c806161bc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_65267a21-18e3-4e0f-8767-c5b3694bc502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a501652d-9fa7-4a37-905b-a15e1ccb79cf" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_65267a21-18e3-4e0f-8767-c5b3694bc502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6759bc33-da1d-4641-8f19-31faf44a8f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_ProfitLoss_6759bc33-da1d-4641-8f19-31faf44a8f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7000e41a-1dd3-4b3e-a536-fbe70f12d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7000e41a-1dd3-4b3e-a536-fbe70f12d9f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bc78128d-519c-400c-81de-aa8f7decff50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_ShareBasedCompensation_bc78128d-519c-400c-81de-aa8f7decff50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_92e13da9-276f-4a3e-bd58-0a058a90dd17" xlink:href="amed-20230331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_92e13da9-276f-4a3e-bd58-0a058a90dd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8221905c-bfa0-49f2-a432-d5ac3e54bcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8221905c-bfa0-49f2-a432-d5ac3e54bcd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_4e9ddfe0-75d2-44bb-b368-1b2a1514fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_4e9ddfe0-75d2-44bb-b368-1b2a1514fafb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5da1c02b-0094-43cf-afa7-f572b7374a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5da1c02b-0094-43cf-afa7-f572b7374a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7d7f4c8d-3ad8-4613-abb3-ed4b18daefe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7d7f4c8d-3ad8-4613-abb3-ed4b18daefe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_151c04f9-8bb9-465e-87b6-5cf24de46f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_151c04f9-8bb9-465e-87b6-5cf24de46f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_982461a8-573a-4ce7-8bff-6b0c4b1c8f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_982461a8-573a-4ce7-8bff-6b0c4b1c8f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_788eb1c7-41d5-4840-928b-4e93c96eb42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_788eb1c7-41d5-4840-928b-4e93c96eb42c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f06f6585-0f7b-43d5-967a-e04590dbdafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f06f6585-0f7b-43d5-967a-e04590dbdafb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef18ddfc-2e8e-424c-89be-2a9f8a64feab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef18ddfc-2e8e-424c-89be-2a9f8a64feab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bfd37a66-d989-4bd0-97e4-9c090130fe20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bfd37a66-d989-4bd0-97e4-9c090130fe20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fec9054c-5ad5-451d-be3d-9078dddc1b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fec9054c-5ad5-451d-be3d-9078dddc1b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5384a9ce-764f-4c18-a33f-0d541c927105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5384a9ce-764f-4c18-a33f-0d541c927105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b2db2324-b3d0-4549-9446-38965f703701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b2db2324-b3d0-4549-9446-38965f703701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0413d140-3603-433c-a2d1-c57cce1a00df" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7326b13-c1d7-49e1-a3e2-f174657ee06f" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0413d140-3603-433c-a2d1-c57cce1a00df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_035fc7b0-5ede-4fbc-816a-987b8ebfa7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_035fc7b0-5ede-4fbc-816a-987b8ebfa7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1efc4819-51a9-4e11-aa1e-156300d96b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1efc4819-51a9-4e11-aa1e-156300d96b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_524e48cd-68f5-4fef-a756-69e231c80844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_524e48cd-68f5-4fef-a756-69e231c80844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_488fe662-da92-4c36-b7d2-60e0f6ba6af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_488fe662-da92-4c36-b7d2-60e0f6ba6af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_301ad74b-c7b8-4fd6-bc24-63076af521c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_301ad74b-c7b8-4fd6-bc24-63076af521c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_36b0e48f-9020-402a-aa5b-bbff203bdc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_36b0e48f-9020-402a-aa5b-bbff203bdc1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0c8d92f1-683a-4b0e-b686-9c67cace461f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0aa459b4-3112-4e64-9804-0665780b3720" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0c8d92f1-683a-4b0e-b686-9c67cace461f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47ac8e93-4924-4f7a-990d-20557a5c9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a16f170-e76c-4bd4-a9c6-0686984bd2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47ac8e93-4924-4f7a-990d-20557a5c9f59" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a16f170-e76c-4bd4-a9c6-0686984bd2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4d3d3454-1a95-4b4f-9854-d52463dc5e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47ac8e93-4924-4f7a-990d-20557a5c9f59" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4d3d3454-1a95-4b4f-9854-d52463dc5e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_8bd8630a-43fe-4e5b-bacc-2a96d40eed73" xlink:href="amed-20230331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47ac8e93-4924-4f7a-990d-20557a5c9f59" xlink:to="loc_amed_NonVestedStockAndStockUnits_8bd8630a-43fe-4e5b-bacc-2a96d40eed73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2e22126d-7f9d-42ff-b285-4f2cb7b1a030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3a4f8356-52af-40da-a872-eaf0d5323705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2e22126d-7f9d-42ff-b285-4f2cb7b1a030" xlink:to="loc_us-gaap_LongTermDebtCurrent_3a4f8356-52af-40da-a872-eaf0d5323705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_47eac810-f596-4f8d-9662-3653037e1ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2e22126d-7f9d-42ff-b285-4f2cb7b1a030" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_47eac810-f596-4f8d-9662-3653037e1ed9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6e324375-0fee-493e-a2ec-9367b5d880cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e104fd47-964c-4302-9a39-29200c44f461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6e324375-0fee-493e-a2ec-9367b5d880cc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e104fd47-964c-4302-9a39-29200c44f461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0fe33468-f97b-4bf1-850a-25009a82e362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6e324375-0fee-493e-a2ec-9367b5d880cc" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0fe33468-f97b-4bf1-850a-25009a82e362" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>amed-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended" id="i8ed445fa20e64b05a5b24078610d9eae_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a22d8736-c1c6-4cd9-a8fe-71c2de537724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a22d8736-c1c6-4cd9-a8fe-71c2de537724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_05110fe6-2284-45d8-b2ad-a4d448751de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_SharesOutstanding_05110fe6-2284-45d8-b2ad-a4d448751de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_52a8eb27-ce11-4049-b2ac-f11ee12ade45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_52a8eb27-ce11-4049-b2ac-f11ee12ade45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee4f94d5-25df-4614-af8c-10f7d838188d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee4f94d5-25df-4614-af8c-10f7d838188d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_64abfa27-6fef-41bd-8eab-298726a36ea1" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_64abfa27-6fef-41bd-8eab-298726a36ea1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_7285c63f-c9c6-4aba-8008-5a6690033600" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_7285c63f-c9c6-4aba-8008-5a6690033600" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_57d0c716-87ca-4aa4-853e-5c439096e733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_57d0c716-87ca-4aa4-853e-5c439096e733" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0eae493f-d294-4a18-9afd-82e240e249a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0eae493f-d294-4a18-9afd-82e240e249a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_48606b02-d26d-4ffa-85b0-f57ac43f9de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_48606b02-d26d-4ffa-85b0-f57ac43f9de3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7d420a9-270f-420c-b1b8-9c8de85d1295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7d420a9-270f-420c-b1b8-9c8de85d1295" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a7b6f462-c83c-4120-9c3e-392bfe9e9227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a7b6f462-c83c-4120-9c3e-392bfe9e9227" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_83c8b70f-7f7c-4e00-8ea8-a6d860cf2e47" xlink:href="amed-20230331.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_SurrenderedShares_83c8b70f-7f7c-4e00-8ea8-a6d860cf2e47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_6aef5ea4-e597-4fb9-802e-a61429e3ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_6aef5ea4-e597-4fb9-802e-a61429e3ed77" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_99d01edf-0e92-4f6f-b3cd-d40f4b5d338c" xlink:href="amed-20230331.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_99d01edf-0e92-4f6f-b3cd-d40f4b5d338c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ff276c66-5c97-4206-a4f1-9277a1ffe4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ff276c66-5c97-4206-a4f1-9277a1ffe4d9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_ae202c4f-26f2-426e-a4ff-c853cddc8cc7" xlink:href="amed-20230331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_ae202c4f-26f2-426e-a4ff-c853cddc8cc7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_286fcc95-bf69-4b82-a817-a2d9913e5652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_ProfitLoss_286fcc95-bf69-4b82-a817-a2d9913e5652" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_809579fb-c197-43a2-ab1d-8439a274a54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e7653580-c62b-4ba6-a83d-21f3270ba0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e338ac5-deb2-42fa-8624-05d3c30c1fee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:to="loc_us-gaap_EquityComponentDomain_3e338ac5-deb2-42fa-8624-05d3c30c1fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:to="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef7ea8fc-1db2-4874-9d58-d5bff8831986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_CommonStockMember_ef7ea8fc-1db2-4874-9d58-d5bff8831986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1fd1d6fe-9460-4ad6-9ba9-32853c898f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1fd1d6fe-9460-4ad6-9ba9-32853c898f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1537b906-9482-4729-a6ee-8a5846fc5992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1537b906-9482-4729-a6ee-8a5846fc5992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f81d9c0c-be48-48be-8f43-0d47930e8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_RetainedEarningsMember_f81d9c0c-be48-48be-8f43-0d47930e8cab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db088952-4f57-4178-b7c2-11970e282736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db088952-4f57-4178-b7c2-11970e282736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_e447e9bb-f059-4819-9d90-dc5c16988aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_e447e9bb-f059-4819-9d90-dc5c16988aaa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20230331.xsd#SUBSEQUENTEVENTTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended" id="i5b2801e58fde494b9edf2333132ddfc5_SUBSEQUENTEVENTTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7b8bff70-2b16-4ddf-be23-c5ed84115832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7b8bff70-2b16-4ddf-be23-c5ed84115832" xlink:to="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6eb835c8-a47b-40ce-a635-a113d9ec5163_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6eb835c8-a47b-40ce-a635-a113d9ec5163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7124c12-8e56-48e6-8310-e002d2d62de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7124c12-8e56-48e6-8310-e002d2d62de2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="i53d93578ecd34b93af2480801eed3c07_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c20bcd8e-8900-4422-a94b-1a1db337fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c20bcd8e-8900-4422-a94b-1a1db337fb87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_842ecfe9-640b-490b-ae50-ca695c519369" xlink:href="amed-20230331.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_amed_OperatingCareCenters_842ecfe9-640b-490b-ae50-ca695c519369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_68bef80e-2d7b-4ede-9f29-9d8f3ed8b83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_68bef80e-2d7b-4ede-9f29-9d8f3ed8b83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_98c78867-ba7b-47ed-b094-de2a25ab9cea" xlink:href="amed-20230331.xsd#amed_NumberOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_amed_NumberOfJointVentures_98c78867-ba7b-47ed-b094-de2a25ab9cea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_23ee4258-3f54-4bd1-86ad-5eea869c9326_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:to="loc_us-gaap_TypeOfAdoptionMember_23ee4258-3f54-4bd1-86ad-5eea869c9326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_91575f57-2fe9-4dae-ac12-6cdeb4c614b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_91575f57-2fe9-4dae-ac12-6cdeb4c614b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3800e08-802a-411a-ab59-6d563dfb29ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a3800e08-802a-411a-ab59-6d563dfb29ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8f40fa96-2e7e-4d1d-93a4-ff2a934e6e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8f40fa96-2e7e-4d1d-93a4-ff2a934e6e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5311e44a-1c65-4dac-9429-c55e09c1b58e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5311e44a-1c65-4dac-9429-c55e09c1b58e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_d1c3df8c-f3f8-42e1-9492-5bc886faabd1" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:to="loc_amed_MedicareRevenueMember_d1c3df8c-f3f8-42e1-9492-5bc886faabd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_aa794b3e-f6a3-455a-9d72-661599c7faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_aa794b3e-f6a3-455a-9d72-661599c7faf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d89bfbde-f49b-4094-b1f8-a22a9d35ce42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:to="loc_us-gaap_SegmentDomain_d89bfbde-f49b-4094-b1f8-a22a9d35ce42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:to="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_eadb4dff-d6f3-4015-a875-c7bc8aabc3a2" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HomeHealthMember_eadb4dff-d6f3-4015-a875-c7bc8aabc3a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e7aeb6c5-2928-428a-b2f9-a634d0a7d585" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HospiceMember_e7aeb6c5-2928-428a-b2f9-a634d0a7d585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9aae523a-2f8a-4f7f-932a-45da26407f92" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_PersonalCareMember_9aae523a-2f8a-4f7f-932a-45da26407f92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_54391275-6835-499c-be19-f76c3c1234f2" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HighAcuityCareMember_54391275-6835-499c-be19-f76c3c1234f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_407de72a-4246-4eb5-bdbe-b42c51341c09_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:to="loc_srt_ProductsAndServicesDomain_407de72a-4246-4eb5-bdbe-b42c51341c09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:to="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_6cca6672-00a2-4e55-91c0-9a694e16e392" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:to="loc_amed_MedicareRevenueMember_6cca6672-00a2-4e55-91c0-9a694e16e392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b999a18e-c579-4c36-a73f-35c39079c60f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b999a18e-c579-4c36-a73f-35c39079c60f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4e97e1cb-2977-483f-a034-c407d98c5e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4e97e1cb-2977-483f-a034-c407d98c5e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69c93f3c-0e30-498b-b115-7b318a33cd4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69c93f3c-0e30-498b-b115-7b318a33cd4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_b5d1031f-aebc-4cb9-9fdd-e89a342ff3f4" xlink:href="amed-20230331.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:to="loc_amed_EvolutionHealthMember_b5d1031f-aebc-4cb9-9fdd-e89a342ff3f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i845b5b34eb3347c6a341758245b14882_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b49250a7-b5af-45db-aed2-2a4fa37cc330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b49250a7-b5af-45db-aed2-2a4fa37cc330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_90083595-d5d9-4da4-9ee8-ca1a9a90ab1c" xlink:href="amed-20230331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_90083595-d5d9-4da4-9ee8-ca1a9a90ab1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e30a0fb6-f130-4759-bb3c-ca07cea72766" xlink:href="amed-20230331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e30a0fb6-f130-4759-bb3c-ca07cea72766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_30ed4430-6459-4af0-a0e0-96654224b9c4" xlink:href="amed-20230331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_30ed4430-6459-4af0-a0e0-96654224b9c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_f893fb48-4c45-4763-950f-d960d4deafa8" xlink:href="amed-20230331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_f893fb48-4c45-4763-950f-d960d4deafa8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_7970e881-eed1-4c8e-a4d8-5ffc34cb18ac" xlink:href="amed-20230331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_7970e881-eed1-4c8e-a4d8-5ffc34cb18ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_45b75591-fdf9-407b-abec-bc1bb02fd941" xlink:href="amed-20230331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_45b75591-fdf9-407b-abec-bc1bb02fd941" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_cb0b4529-97c8-469c-b2a4-ca512b1e3395" xlink:href="amed-20230331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_SecondThresholdOfServicesRequired_cb0b4529-97c8-469c-b2a4-ca512b1e3395" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_17ad7cf8-9acf-44e4-ad72-d2dbcdf45bf6" xlink:href="amed-20230331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_17ad7cf8-9acf-44e4-ad72-d2dbcdf45bf6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_1c4382d8-79eb-4278-aa1f-7de2369f6ec7" xlink:href="amed-20230331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_1c4382d8-79eb-4278-aa1f-7de2369f6ec7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_9539ab25-451c-4885-9212-6c3282910a62" xlink:href="amed-20230331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NonMedicareRevenueTermRates_9539ab25-451c-4885-9212-6c3282910a62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dfeb6c59-7033-465d-a085-6242df4dfeca" xlink:href="amed-20230331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dfeb6c59-7033-465d-a085-6242df4dfeca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_c776e19c-51df-4115-b6de-26ad01f77029" xlink:href="amed-20230331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_c776e19c-51df-4115-b6de-26ad01f77029" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_2ec42945-5a93-4606-926d-cc82b98cd128" xlink:href="amed-20230331.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_2ec42945-5a93-4606-926d-cc82b98cd128" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_bad5f9fa-a989-4d83-9e99-ba19f8521fda" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_bad5f9fa-a989-4d83-9e99-ba19f8521fda" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices_4475dd3d-7c31-4553-a76b-e074479eb10f" xlink:href="amed-20230331.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_AcutePhaseForHighAcuityCareServices_4475dd3d-7c31-4553-a76b-e074479eb10f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_fddcf4b9-b199-4182-a1ed-34d6c20ec3a6" xlink:href="amed-20230331.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_fddcf4b9-b199-4182-a1ed-34d6c20ec3a6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_feb32805-efba-44aa-8761-a905d71fb373_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_feb32805-efba-44aa-8761-a905d71fb373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_c9182856-a2e8-4114-841b-8c31c407ba18" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:to="loc_amed_CompassionateCareHospiceMember_c9182856-a2e8-4114-841b-8c31c407ba18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f5b1e8be-223b-4a93-9ba2-3f0196f06523" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:to="loc_amed_AseraCareHospiceMember_f5b1e8be-223b-4a93-9ba2-3f0196f06523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_06f92391-3e90-452b-a60b-b06b56ce907b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_06f92391-3e90-452b-a60b-b06b56ce907b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_efe4a1fe-3a7d-4b8d-a451-f34bbcd2d45d" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:to="loc_amed_MedicareRevenueMember_efe4a1fe-3a7d-4b8d-a451-f34bbcd2d45d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_71d99c22-961f-4fe8-a90a-6c4cf4dfbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_71d99c22-961f-4fe8-a90a-6c4cf4dfbb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4dfb945-0df0-42b3-adac-4eb4677bdc90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4dfb945-0df0-42b3-adac-4eb4677bdc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8766ef47-340c-41c5-a7dd-f502a62a0db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8766ef47-340c-41c5-a7dd-f502a62a0db2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:href="amed-20230331.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_535c0620-7023-44e9-a9d6-c06b8591aa6a_default" xlink:href="amed-20230331.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:to="loc_amed_CapYearDomain_535c0620-7023-44e9-a9d6-c06b8591aa6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:href="amed-20230331.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:to="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_dcef7f4e-11b7-4e12-8bdf-e794a531e66d" xlink:href="amed-20230331.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_dcef7f4e-11b7-4e12-8bdf-e794a531e66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eadf4bad-a83a-43c2-8c07-9d73db26fd49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:to="loc_us-gaap_SegmentDomain_eadf4bad-a83a-43c2-8c07-9d73db26fd49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:to="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7d5860d1-8489-447f-8aba-6baf98b054d0" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HomeHealthMember_7d5860d1-8489-447f-8aba-6baf98b054d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_a731f200-b024-4247-b42f-02494eee52f4" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HospiceMember_a731f200-b024-4247-b42f-02494eee52f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_279dc4e3-55ef-4d84-83d8-ed2478a9fdb3" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HighAcuityCareMember_279dc4e3-55ef-4d84-83d8-ed2478a9fdb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40b3c276-c10d-4d03-b47b-889f40cd999e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:to="loc_srt_RangeMember_40b3c276-c10d-4d03-b47b-889f40cd999e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:to="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83854370-8dc4-4b87-9fb6-63a2a51ed3a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:to="loc_srt_MinimumMember_83854370-8dc4-4b87-9fb6-63a2a51ed3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79a4653a-2701-474d-ac30-efd17d8fdd0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:to="loc_srt_MaximumMember_79a4653a-2701-474d-ac30-efd17d8fdd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80abe41f-b1f5-486a-a1cb-6b5615b4ae56_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:to="loc_srt_ProductsAndServicesDomain_80abe41f-b1f5-486a-a1cb-6b5615b4ae56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:to="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_85f38ae3-a09f-488e-a743-bdfe7ed17885" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:to="loc_amed_MedicareRevenueMember_85f38ae3-a09f-488e-a743-bdfe7ed17885" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended" id="i7b1e602443344273bbfa14b1e4c90cc3_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7bec2c96-67bc-4d2c-b8b3-f5afcb7a6445" xlink:href="amed-20230331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7bec2c96-67bc-4d2c-b8b3-f5afcb7a6445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:href="amed-20230331.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:to="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_c7f26658-f000-48f8-bcd6-4c9240826f3a_default" xlink:href="amed-20230331.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:to="loc_amed_PayorClassDomain_c7f26658-f000-48f8-bcd6-4c9240826f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:href="amed-20230331.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:to="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_1c79583d-36b3-4704-919d-d39b30295d73" xlink:href="amed-20230331.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthMedicareMember_1c79583d-36b3-4704-919d-d39b30295d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_c6383a8f-b486-474e-b837-6e05651d5a84" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_c6383a8f-b486-474e-b837-6e05651d5a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_f6908d3a-e91e-43c9-9eb8-2a0692166b7a" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_f6908d3a-e91e-43c9-9eb8-2a0692166b7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_9929bb95-bc12-44a2-99dc-fdd027e99481" xlink:href="amed-20230331.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HospiceMedicareMember_9929bb95-bc12-44a2-99dc-fdd027e99481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_05455d1b-1d13-4af4-898e-c8fec8499f64" xlink:href="amed-20230331.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HospiceNonMedicareMember_05455d1b-1d13-4af4-898e-c8fec8499f64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_c1e55e0f-20f2-4e3a-8346-d9b3864dbd8d" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_PersonalCareMember_c1e55e0f-20f2-4e3a-8346-d9b3864dbd8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_2ff8522b-1690-4fea-9090-0800c8403037" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HighAcuityCareMember_2ff8522b-1690-4fea-9090-0800c8403037" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="ic5992d8ce9e841d7a97967fb5e5d65aa_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5387a5b6-3cf6-4d51-b73b-d0042903d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5387a5b6-3cf6-4d51-b73b-d0042903d66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2b60522b-298f-49cd-99de-527f3ff5223e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_RestrictedCash_2b60522b-298f-49cd-99de-527f3ff5223e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd23633-d6d4-470d-96f0-a2f503dd76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd23633-d6d4-470d-96f0-a2f503dd76ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_7cf23da8-55e3-483c-89a6-895d86684dad" xlink:href="amed-20230331.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_7cf23da8-55e3-483c-89a6-895d86684dad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00d40630-4371-4e62-9045-4b299653ad89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00d40630-4371-4e62-9045-4b299653ad89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_193df4db-92c2-4434-81c9-e4b942864d78" xlink:href="amed-20230331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_AsanaHospiceAquisitionMember_193df4db-92c2-4434-81c9-e4b942864d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_f1d23d35-c1e9-4aef-a73d-aa19119ce0f6" xlink:href="amed-20230331.xsd#amed_COVID19PPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_COVID19PPEMember_f1d23d35-c1e9-4aef-a73d-aa19119ce0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_94cbee3e-fbe8-4ae3-8cf7-ff2c5fb25db9" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_AseraCareHospiceMember_94cbee3e-fbe8-4ae3-8cf7-ff2c5fb25db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bca04f52-564d-4473-b6b6-6432ef2ee360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bca04f52-564d-4473-b6b6-6432ef2ee360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_09354827-fe0f-43dc-81be-67bf2e59fbfa" xlink:href="amed-20230331.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:to="loc_amed_AsanaHospiceMember_09354827-fe0f-43dc-81be-67bf2e59fbfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_d8a356c8-c08c-4a89-bcc0-ebb876d43643" xlink:href="amed-20230331.xsd#amed_VariousAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:to="loc_amed_VariousAcquisitionsMember_d8a356c8-c08c-4a89-bcc0-ebb876d43643" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="ia0aca56b17c04349aff9186e3ef6249b_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b6c77a69-2883-416d-b01a-2998345c1575" xlink:href="amed-20230331.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b6c77a69-2883-416d-b01a-2998345c1575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f5c8b505-b0ad-484f-a40e-796e4a5777c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f5c8b505-b0ad-484f-a40e-796e4a5777c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d6c8394f-ea37-4d11-ac4c-837a2c7daf22" xlink:href="amed-20230331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d6c8394f-ea37-4d11-ac4c-837a2c7daf22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c5a63447-8038-4d9a-8bd2-605d28c1b007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c5a63447-8038-4d9a-8bd2-605d28c1b007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a432071a-cfc8-4b8d-b751-30595c864c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a432071a-cfc8-4b8d-b751-30595c864c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d18d8092-7f43-4177-b545-c75daa8663fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d18d8092-7f43-4177-b545-c75daa8663fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2159f7b0-2e90-4a38-848c-4ba68473f936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:to="loc_us-gaap_AccountsReceivableMember_2159f7b0-2e90-4a38-848c-4ba68473f936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b37bcfa8-5960-4159-a577-4435ee3b1661_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:to="loc_srt_NameOfMajorCustomerDomain_b37bcfa8-5960-4159-a577-4435ee3b1661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_52e99420-59b2-4434-a114-06e876e75d54" xlink:href="amed-20230331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:to="loc_amed_MajorSinglePayorCustomerMember_52e99420-59b2-4434-a114-06e876e75d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43b197e7-6449-42c3-bf3a-5572c4c8601d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43b197e7-6449-42c3-bf3a-5572c4c8601d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_4a16b8af-b5dc-4156-af7b-4589c95f7db2" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:to="loc_amed_CompassionateCareHospiceMember_4a16b8af-b5dc-4156-af7b-4589c95f7db2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i7076d702a3854d33a8261f808ddc22bc_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ae374e02-50dd-49a8-9ec1-630cd426a518" xlink:href="amed-20230331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ae374e02-50dd-49a8-9ec1-630cd426a518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a9231a1c-6565-4b57-871d-17af1cab4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:to="loc_us-gaap_LongTermDebtFairValue_a9231a1c-6565-4b57-871d-17af1cab4c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_efb2a7ee-103e-4f4b-b999-c6684174d5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_efb2a7ee-103e-4f4b-b999-c6684174d5d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a300b611-8776-4ce7-998d-a624c01ef800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a300b611-8776-4ce7-998d-a624c01ef800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74520e0e-77e5-4f3b-8f98-c228e4629760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74520e0e-77e5-4f3b-8f98-c228e4629760" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INVESTMENTSDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#INVESTMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INVESTMENTSDetails" xlink:type="extended" id="i57e6566d54ee42d4a5628d95bebcb40d_INVESTMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f66ebdb1-a5e4-4e3f-a1ae-b65dcc6337fb" xlink:href="amed-20230331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f66ebdb1-a5e4-4e3f-a1ae-b65dcc6337fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_e7158580-6ba6-4ebc-bb68-984abdf217c8" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_e7158580-6ba6-4ebc-bb68-984abdf217c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_33cbac35-f850-44ad-9a18-7eef558a1d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_33cbac35-f850-44ad-9a18-7eef558a1d3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_8530cde3-0d4d-45c5-81f9-f948ee386118" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_8530cde3-0d4d-45c5-81f9-f948ee386118" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8ac4a870-27cf-478b-b226-c1440d9afaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8ac4a870-27cf-478b-b226-c1440d9afaf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_b782156a-c962-4927-8e80-a4fc9548626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_b782156a-c962-4927-8e80-a4fc9548626f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_e0d85e71-795d-4522-b941-ce1c3d3696bc" xlink:href="amed-20230331.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_e0d85e71-795d-4522-b941-ce1c3d3696bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9651762-ef38-4425-9a60-be3f2b0ca92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9651762-ef38-4425-9a60-be3f2b0ca92f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1a016910-8bb9-4fd5-b2e6-b82d9e52e5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1a016910-8bb9-4fd5-b2e6-b82d9e52e5d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5c58f7e8-a761-4552-9254-af3672df0dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OtherAssetsCurrent_5c58f7e8-a761-4552-9254-af3672df0dd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38da438a-b732-42a2-91df-c40df3a40033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AssetsCurrent_38da438a-b732-42a2-91df-c40df3a40033" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68785c34-510b-4acf-9117-c81aef334c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68785c34-510b-4acf-9117-c81aef334c6c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4df419f8-39fc-43ef-953f-8283992beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4df419f8-39fc-43ef-953f-8283992beb2d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e118ab9a-97e4-4cea-ae15-aee09dc59cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Goodwill_e118ab9a-97e4-4cea-ae15-aee09dc59cbb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b25d9bca-a013-41ae-9a8d-3b06d18bae51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b25d9bca-a013-41ae-9a8d-3b06d18bae51" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9071a445-84d9-4737-9118-e30b6b5d3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9071a445-84d9-4737-9118-e30b6b5d3be4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9b8f7b6c-f111-480b-b90e-6fc72aa7481c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Assets_9b8f7b6c-f111-480b-b90e-6fc72aa7481c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1a197299-6695-40c4-be24-8213600c0ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccountsPayableCurrent_1a197299-6695-40c4-be24-8213600c0ff2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_899a5a5b-5641-4b6a-8110-e59dface7721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_899a5a5b-5641-4b6a-8110-e59dface7721" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ea4d8b72-54ab-4ff7-871a-960c34469141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ea4d8b72-54ab-4ff7-871a-960c34469141" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d7bbc90a-d8c7-4d64-813c-2a19289fdc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d7bbc90a-d8c7-4d64-813c-2a19289fdc8c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_5c6d383b-3474-45d4-b905-51e821e0889d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_DebtCurrent_5c6d383b-3474-45d4-b905-51e821e0889d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3b4aaee7-1cb4-42b9-88f1-2f7594c93c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Liabilities_3b4aaee7-1cb4-42b9-88f1-2f7594c93c44" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8ed539ff-1b67-4296-b5b2-953bbd67b1b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8ed539ff-1b67-4296-b5b2-953bbd67b1b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_602b0909-013d-44b7-8390-1676d2601198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_602b0909-013d-44b7-8390-1676d2601198" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i9371e013b5ff4e12b9a619f951e904bd_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_3d2c3f4b-432c-4f4b-8736-b68e5869768f" xlink:href="amed-20230331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_PercentageofSharesOutstanding_3d2c3f4b-432c-4f4b-8736-b68e5869768f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_18a596b3-b845-4a05-b3df-74be640060b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_18a596b3-b845-4a05-b3df-74be640060b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ee52337c-dd85-45ce-9ba0-9197807eb43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ee52337c-dd85-45ce-9ba0-9197807eb43f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_eaff813b-6906-4c28-89cd-9f0df568c640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_eaff813b-6906-4c28-89cd-9f0df568c640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_be81f5ab-90cc-4044-a67f-444fa13ee0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_be81f5ab-90cc-4044-a67f-444fa13ee0a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_6674556c-2380-419d-9890-e2b3eb7370a2" xlink:href="amed-20230331.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_6674556c-2380-419d-9890-e2b3eb7370a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_cce35df6-0af4-4858-a76d-01c9a5cb6e4b" xlink:href="amed-20230331.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_cce35df6-0af4-4858-a76d-01c9a5cb6e4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_90e6ccab-4de5-4fb3-b1c3-a8093ec05015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_90e6ccab-4de5-4fb3-b1c3-a8093ec05015" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_d9f0c692-91e4-4441-a3fa-70a2112f1407" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_d9f0c692-91e4-4441-a3fa-70a2112f1407" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_92f4ac0e-e608-4ade-842c-a08cdb826c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_92f4ac0e-e608-4ade-842c-a08cdb826c12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_5ecbd05a-aa02-4029-974f-e1cad77e901b" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_5ecbd05a-aa02-4029-974f-e1cad77e901b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e073c4dc-4c4a-4e32-9fbd-de2bb8c88a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e073c4dc-4c4a-4e32-9fbd-de2bb8c88a0d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_d27ee253-5a88-48ef-ac31-18747dc60de1" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_d27ee253-5a88-48ef-ac31-18747dc60de1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f6c9e799-2216-4d90-8080-c0cad8205e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f6c9e799-2216-4d90-8080-c0cad8205e6c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_5423b096-c246-409f-9f0e-8c1bee0d5e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_5423b096-c246-409f-9f0e-8c1bee0d5e2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d27b02f5-87d0-44be-8004-c3a031b2cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d27b02f5-87d0-44be-8004-c3a031b2cca5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5e9addbc-b766-40f6-8da0-a796a148c5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5e9addbc-b766-40f6-8da0-a796a148c5b1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9935354c-4825-4cbd-81a5-1a420101e4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9935354c-4825-4cbd-81a5-1a420101e4ff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_12bd7c77-91ab-413f-a239-9c01095281fc" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_12bd7c77-91ab-413f-a239-9c01095281fc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3cc7b704-5e26-4e13-bb38-794c2c70f995" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3cc7b704-5e26-4e13-bb38-794c2c70f995" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_f22f6120-ee33-4817-aef6-d046a338fa20" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_f22f6120-ee33-4817-aef6-d046a338fa20" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0a1cc847-8acd-4d2a-84e3-24925aa7b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0a1cc847-8acd-4d2a-84e3-24925aa7b782" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_a3105d51-58d5-42c8-a8b0-0d6f844e8c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_a3105d51-58d5-42c8-a8b0-0d6f844e8c64" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_561c625c-5779-4bac-9756-d0579333e827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_561c625c-5779-4bac-9756-d0579333e827" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5e04fe6a-2ad0-4acc-bc24-fe8254eb5e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5e04fe6a-2ad0-4acc-bc24-fe8254eb5e97" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_35d47004-e967-4d06-af6e-967c9258fade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_35d47004-e967-4d06-af6e-967c9258fade" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a171040f-0344-43e9-b4e4-826673ac1a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a171040f-0344-43e9-b4e4-826673ac1a9f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_afb5a441-1969-4eed-b05c-2e92d1b3c571" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_afb5a441-1969-4eed-b05c-2e92d1b3c571" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_ca378367-623a-4434-b9fa-5d561822994d" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_ca378367-623a-4434-b9fa-5d561822994d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_48716a98-08ec-476c-b7ab-d5b06c96ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_48716a98-08ec-476c-b7ab-d5b06c96ceaa" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b44d869-6808-4bfe-abff-6b7bf2dac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b44d869-6808-4bfe-abff-6b7bf2dac1e9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f1eb119-aea1-42b9-be0e-d01cbc12504a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f1eb119-aea1-42b9-be0e-d01cbc12504a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_0e5f7c58-fcd2-437a-a10d-c3132bb288a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_0e5f7c58-fcd2-437a-a10d-c3132bb288a2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_d52e867c-a24c-4f3f-a3f6-5a1451485e45" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_d52e867c-a24c-4f3f-a3f6-5a1451485e45" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_473ffd24-1396-4cdd-bac7-451ad5c54424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_473ffd24-1396-4cdd-bac7-451ad5c54424" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d0a79dd6-bb0a-4286-8050-02dcc3722e15" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d0a79dd6-bb0a-4286-8050-02dcc3722e15" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_74598fd8-3915-4fe5-b3c2-21ea9029d9d3" xlink:href="amed-20230331.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_74598fd8-3915-4fe5-b3c2-21ea9029d9d3" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_75c44496-53c7-4ec5-88ae-9db5f199899e" xlink:href="amed-20230331.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_75c44496-53c7-4ec5-88ae-9db5f199899e" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763cd4e0-6e90-4a11-8de7-4d2f9a53164b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763cd4e0-6e90-4a11-8de7-4d2f9a53164b" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5dfefd4e-69a0-458e-a3c3-d61c2927978a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_RestrictedCash_5dfefd4e-69a0-458e-a3c3-d61c2927978a" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_015424f5-cb79-4dc0-89fc-f7eafdfb6461" xlink:href="amed-20230331.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_NonCashAccruedContingentConsideration_015424f5-cb79-4dc0-89fc-f7eafdfb6461" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow_601b39a0-b58c-4113-ac15-bffc5f98d969" xlink:href="amed-20230331.xsd#amed_AmountReleasedFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_AmountReleasedFromEscrow_601b39a0-b58c-4113-ac15-bffc5f98d969" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_147574b9-41d8-4dd6-bf7f-92a700fccc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_147574b9-41d8-4dd6-bf7f-92a700fccc0b" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_5b607fbe-0447-42f8-8f78-4177838e8e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_5b607fbe-0447-42f8-8f78-4177838e8e80" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired_809bd243-66a9-40a4-8c51-20f6c0721f1c" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_IncreaseDecreaseInAssetsAcquired_809bd243-66a9-40a4-8c51-20f6c0721f1c" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_7710f67d-5cdf-449e-917e-295dff9cf5bd" xlink:href="amed-20230331.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:to="loc_amed_EvolutionHealthMember_7710f67d-5cdf-449e-917e-295dff9cf5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_23ae8812-99a4-4c27-8241-730c151e5398" xlink:href="amed-20230331.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:to="loc_amed_AssistedCareHomeHealthMember_23ae8812-99a4-4c27-8241-730c151e5398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d7c50440-fc53-4ab5-8abb-0b8a7014be16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:to="loc_us-gaap_SegmentDomain_d7c50440-fc53-4ab5-8abb-0b8a7014be16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:to="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ecf11884-5226-458e-8af2-f7618063690b" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HospiceMember_ecf11884-5226-458e-8af2-f7618063690b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cb1e83d4-5a7d-4b81-a45e-2ddff9ec1d69" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HomeHealthMember_cb1e83d4-5a7d-4b81-a45e-2ddff9ec1d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_fe620b8d-da15-47aa-9e55-a586d68dcbb6" xlink:href="amed-20230331.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HomeHealthAndHospiceMember_fe620b8d-da15-47aa-9e55-a586d68dcbb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_888c007f-dce7-43a2-9e2e-4b8ec04fd6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_TradeNamesMember_888c007f-dce7-43a2-9e2e-4b8ec04fd6c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_184c5dbb-61af-460d-ac9f-8f05749fd6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_184c5dbb-61af-460d-ac9f-8f05749fd6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_28e7d103-2f41-48b8-8a49-cd39849f0530" xlink:href="amed-20230331.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_AcquiredNamesMember_28e7d103-2f41-48b8-8a49-cd39849f0530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_1158ee18-a227-4efb-ae9b-5788c13de4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_1158ee18-a227-4efb-ae9b-5788c13de4c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_e76cc116-08ca-436e-9f0b-f4baeb0d7be9" xlink:href="amed-20230331.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_MedicareLicenseMember_e76cc116-08ca-436e-9f0b-f4baeb0d7be9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_09df78eb-beae-4419-a834-aa59371cb726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_09df78eb-beae-4419-a834-aa59371cb726" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_37001059-d615-4d9e-b374-19fad7709813" xlink:href="amed-20230331.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_CertificatesOfNeedMember_37001059-d615-4d9e-b374-19fad7709813" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_41e470ff-7aa2-4417-b8e9-f559a5f8b012" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_CertificateOfNeedMember_41e470ff-7aa2-4417-b8e9-f559a5f8b012" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_016d15d1-7e46-42db-9556-23cf32b13fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_016d15d1-7e46-42db-9556-23cf32b13fb6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_58eefe97-d859-4561-bd4e-0d14e7df522e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_LicenseMember_58eefe97-d859-4561-bd4e-0d14e7df522e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_970b4919-45ab-4fea-93ab-070c21f63ac3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_970b4919-45ab-4fea-93ab-070c21f63ac3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_23a86e10-5dd5-4a73-91ca-69dfd41f4af9" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_CertificateOfNeedMember_23a86e10-5dd5-4a73-91ca-69dfd41f4af9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_0aa83972-3cd8-4713-a52b-087f03bff0e2" xlink:href="amed-20230331.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_MedicareLicenseMember_0aa83972-3cd8-4713-a52b-087f03bff0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember_cdee91b0-cca0-4ca4-8f1d-6b4887b85d6f" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_CertificateOfNeedAndLicensesMember_cdee91b0-cca0-4ca4-8f1d-6b4887b85d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_55c95a87-ac48-4b0d-a057-741af4a7cf57_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:to="loc_srt_SegmentGeographicalDomain_55c95a87-ac48-4b0d-a057-741af4a7cf57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:to="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_b3ee4708-236f-4b2b-93fd-cf321a0966fa" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_TN_b3ee4708-236f-4b2b-93fd-cf321a0966fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_792cb278-6b78-43b7-bd63-41deec40fff0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_WA_792cb278-6b78-43b7-bd63-41deec40fff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_c0dfb492-1256-402d-91b7-d99ba9d8fee4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_KY_c0dfb492-1256-402d-91b7-d99ba9d8fee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_a115f0eb-b195-45ec-b77e-9055ff1456d0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_NC_a115f0eb-b195-45ec-b77e-9055ff1456d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_e8a122a8-283b-4d91-a908-f2a4b92f80c4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_NY_e8a122a8-283b-4d91-a908-f2a4b92f80c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_de1a83d2-b310-4cc1-8fb4-d5956deeb6c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_WV_de1a83d2-b310-4cc1-8fb4-d5956deeb6c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b10895c1-57e9-4989-a2d1-34a55fa344ab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:to="loc_srt_RangeMember_b10895c1-57e9-4989-a2d1-34a55fa344ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:to="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22ecdee1-9062-4bed-90c0-d5af237d8ac3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:to="loc_srt_MinimumMember_22ecdee1-9062-4bed-90c0-d5af237d8ac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_692f33fa-15d4-4a76-abd6-7cf0fe56d8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:to="loc_srt_MaximumMember_692f33fa-15d4-4a76-abd6-7cf0fe56d8ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONSProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended" id="i816330551364420a892ed3b8ffe1cb3d_ACQUISITIONSProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9615a79b-496c-4a7b-abc6-0ddb1c5e25e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9615a79b-496c-4a7b-abc6-0ddb1c5e25e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_861e8b1d-a069-40bc-8789-83448e6191b9" xlink:href="amed-20230331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_861e8b1d-a069-40bc-8789-83448e6191b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_279576d3-37e9-4709-a077-a81bedcfd91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_279576d3-37e9-4709-a077-a81bedcfd91b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8eb297d1-92c0-444f-a4ee-64ec03746021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8eb297d1-92c0-444f-a4ee-64ec03746021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_641cc7bf-a369-4181-939a-525261e36420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_641cc7bf-a369-4181-939a-525261e36420" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:to="loc_us-gaap_SegmentDomain_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:to="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_a5d16846-5677-4acf-af87-af3fdc9d70c2" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:to="loc_amed_HospiceMember_a5d16846-5677-4acf-af87-af3fdc9d70c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6477a76e-f1b0-4f10-9bc0-b30546b343fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6477a76e-f1b0-4f10-9bc0-b30546b343fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_d577945b-6d6b-4f8c-ba90-6739a3ead309" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:to="loc_amed_CompassionateCareHospiceMember_d577945b-6d6b-4f8c-ba90-6739a3ead309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_3c9a23a0-6886-4c08-a961-bd6195512f79" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:to="loc_amed_AseraCareHospiceMember_3c9a23a0-6886-4c08-a961-bd6195512f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d8157e56-9014-4da9-8b62-249ee8460a7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d8157e56-9014-4da9-8b62-249ee8460a7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35b0ab01-6881-49ef-9a9c-4169fcc41e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35b0ab01-6881-49ef-9a9c-4169fcc41e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_76128ddd-daec-427a-9aa2-7d930d2a699f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:to="loc_srt_OwnershipDomain_76128ddd-daec-427a-9aa2-7d930d2a699f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cbd1bb84-37d5-4840-90e6-e8ac1f1af376" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:to="loc_srt_OwnershipDomain_cbd1bb84-37d5-4840-90e6-e8ac1f1af376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4aed41cd-ec9b-477e-849d-070db8431980_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:to="loc_us-gaap_ClassOfStockDomain_4aed41cd-ec9b-477e-849d-070db8431980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da00703b-5376-4a7d-8eba-5b324a44d877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:to="loc_us-gaap_ClassOfStockDomain_da00703b-5376-4a7d-8eba-5b324a44d877" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="i074d1704f14c4a6c8b5c9f14a46d8573_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_01531c5f-38cf-4957-8208-f263e2fe62f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_01531c5f-38cf-4957-8208-f263e2fe62f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d7a92f0e-087a-4bd7-999a-19e655e03caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d7a92f0e-087a-4bd7-999a-19e655e03caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3a075355-c9b2-4971-9550-c5fed24600f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3a075355-c9b2-4971-9550-c5fed24600f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3d26607f-ed52-42b8-92e9-bd7be6d4261e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3d26607f-ed52-42b8-92e9-bd7be6d4261e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_aa46c26e-9359-4ae9-9275-84a34f5fbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_aa46c26e-9359-4ae9-9275-84a34f5fbd61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_98588c32-b610-40e4-9724-01c91df4799b" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_98588c32-b610-40e4-9724-01c91df4799b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f6ab455-88e1-44b9-bb67-0769d3819e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f6ab455-88e1-44b9-bb67-0769d3819e7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_4c3381df-f45f-417d-b94d-666a0b1b2511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_4c3381df-f45f-417d-b94d-666a0b1b2511" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_398617b6-43bc-4f62-a3f9-3ab76da12dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_398617b6-43bc-4f62-a3f9-3ab76da12dda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_610c7394-48b4-4648-aace-64ffb9799469" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_610c7394-48b4-4648-aace-64ffb9799469" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_c2940938-079c-4ba3-b74e-851c7d564d08" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_c2940938-079c-4ba3-b74e-851c7d564d08" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_376594bb-65cc-4785-a48d-e47d4215edd3" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_376594bb-65cc-4785-a48d-e47d4215edd3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1cf6e281-2e15-40cd-8968-ceeec90854ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1cf6e281-2e15-40cd-8968-ceeec90854ba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_4bb1887e-465e-4318-9bc2-14f969054b57" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_4bb1887e-465e-4318-9bc2-14f969054b57" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d065fcee-b387-4c93-a83d-fe3bfbaf73f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d065fcee-b387-4c93-a83d-fe3bfbaf73f5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_48cfbb7c-32d8-471d-b5af-04b89a801a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_RestrictedCash_48cfbb7c-32d8-471d-b5af-04b89a801a5c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_424e9693-9c0c-47f6-8737-04e59165bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_424e9693-9c0c-47f6-8737-04e59165bec6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a48501bf-f7cd-4cee-93a8-7d4eee7a72b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a48501bf-f7cd-4cee-93a8-7d4eee7a72b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_302c0679-b2d3-4d3b-ba87-ca491294460c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:to="loc_us-gaap_SegmentDomain_302c0679-b2d3-4d3b-ba87-ca491294460c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:to="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e51550b2-f0ca-440f-957e-994e4a8aec1b" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:to="loc_amed_PersonalCareMember_e51550b2-f0ca-440f-957e-994e4a8aec1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended" id="i77e1c732555a4710b4a5e1d3c5c5b60b_LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_380593ff-7882-4d7c-9bdd-c006f27ec574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_380593ff-7882-4d7c-9bdd-c006f27ec574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fbdb890f-9e6b-4e2c-89a5-a26a4b7f869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fbdb890f-9e6b-4e2c-89a5-a26a4b7f869e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d568196-c82c-4be9-b909-59f2b39d5c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebt_4d568196-c82c-4be9-b909-59f2b39d5c23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1ff02dde-d784-4595-88ee-557e216e9c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebtCurrent_1ff02dde-d784-4595-88ee-557e216e9c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fc6899f1-11c1-4b80-bb6c-3dbaacc6a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fc6899f1-11c1-4b80-bb6c-3dbaacc6a7fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4ff878f-6553-46c8-a414-4a11c18c9dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4ff878f-6553-46c8-a414-4a11c18c9dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_d9b56e1c-e19c-499f-ae36-2b9e86f4336d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_LoansPayableMember_d9b56e1c-e19c-499f-ae36-2b9e86f4336d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_16bae182-c004-4ed5-87e7-9defca5c6287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_16bae182-c004-4ed5-87e7-9defca5c6287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_2cbe724d-5b64-49e5-96e2-4be29ad9b792" xlink:href="amed-20230331.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_amed_PromissoryNotesMember_2cbe724d-5b64-49e5-96e2-4be29ad9b792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_94cf0d4e-813f-4fd4-a672-ac4852dbef90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_94cf0d4e-813f-4fd4-a672-ac4852dbef90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_73d0667a-1200-4905-849d-2cf9c87c1d08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_73d0667a-1200-4905-849d-2cf9c87c1d08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_08bf3bb9-a9e7-402a-bfd6-0ca99be84639" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_08bf3bb9-a9e7-402a-bfd6-0ca99be84639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_358d7979-c283-4a39-8b53-5018371421ad" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_358d7979-c283-4a39-8b53-5018371421ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8e13aeb0-55d3-48ff-826b-cc38fc765103" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8e13aeb0-55d3-48ff-826b-cc38fc765103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_85cf0791-035f-4748-b719-1d4dc143810a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:to="loc_us-gaap_VariableRateDomain_85cf0791-035f-4748-b719-1d4dc143810a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:to="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_811c0a7d-fb3f-4354-9761-6cc25eac9b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_811c0a7d-fb3f-4354-9761-6cc25eac9b7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i5c8a287f636c48a59f1d1288fa5f1073_LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2705fc5e-19f4-4361-9f48-dbf0fda9d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2705fc5e-19f4-4361-9f48-dbf0fda9d4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_dc646c2a-b6cc-4dbb-aa86-49acf8b192ff" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_dc646c2a-b6cc-4dbb-aa86-49acf8b192ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_202b5507-a2ac-435f-935d-2a34db732b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_202b5507-a2ac-435f-935d-2a34db732b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ff8bb37d-d16e-4194-8cb5-759ef2d16212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ff8bb37d-d16e-4194-8cb5-759ef2d16212" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_108d0013-ddf6-4db5-bdf7-ea61b27c3041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_108d0013-ddf6-4db5-bdf7-ea61b27c3041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98ff5833-01e4-4fe2-8ee4-3174cb010987_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98ff5833-01e4-4fe2-8ee4-3174cb010987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1032c8bf-a76b-401e-a601-e881884d54e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:to="loc_us-gaap_LoansPayableMember_1032c8bf-a76b-401e-a601-e881884d54e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_36c6bf6a-da7e-4a49-9c26-c2df42e987f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_36c6bf6a-da7e-4a49-9c26-c2df42e987f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_95935e58-a0f8-4bfa-9c32-09001be0e409" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_95935e58-a0f8-4bfa-9c32-09001be0e409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_a615cc82-5fbb-4acf-9a22-4855ae917f1a" xlink:href="amed-20230331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_a615cc82-5fbb-4acf-9a22-4855ae917f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c25d190f-028a-47ae-ada4-0e2d15f22e15" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c25d190f-028a-47ae-ada4-0e2d15f22e15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_cadd7e94-9822-45ce-8585-6c94029c744e" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_cadd7e94-9822-45ce-8585-6c94029c744e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_07072cbd-17b4-4557-ab5c-cf3014287005_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:to="loc_us-gaap_VariableRateDomain_07072cbd-17b4-4557-ab5c-cf3014287005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:to="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e861f667-a2a1-4876-bdfc-3c0f160c6b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e861f667-a2a1-4876-bdfc-3c0f160c6b45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="i6a06e52495f4433c86e42b5ab7b9fe64_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_7c48776f-28fe-48f7-821f-ebe93e374628" xlink:href="amed-20230331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_amed_ConsolidatedLeverageRatio_7c48776f-28fe-48f7-821f-ebe93e374628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dbf3d372-9876-4807-a58a-cbc4b528db7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dbf3d372-9876-4807-a58a-cbc4b528db7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_671b2278-b4d2-4be8-aa60-e4175bfbd21d" xlink:href="amed-20230331.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_amed_LetterOfCreditFee_671b2278-b4d2-4be8-aa60-e4175bfbd21d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_832650b9-a7e0-4808-88f0-4dfeb7e67fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_832650b9-a7e0-4808-88f0-4dfeb7e67fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11d3a2f5-f56f-4239-b15a-b32df722489d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:to="loc_srt_RangeMember_11d3a2f5-f56f-4239-b15a-b32df722489d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:to="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_524b5619-2322-4540-b072-f9c30905e940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:to="loc_srt_MinimumMember_524b5619-2322-4540-b072-f9c30905e940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e4f6c56-136c-4e17-a05e-fecae4b70c06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:to="loc_srt_MaximumMember_6e4f6c56-136c-4e17-a05e-fecae4b70c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ec834cb-20c5-4c8e-a398-74aecb94946d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ec834cb-20c5-4c8e-a398-74aecb94946d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_abb806a5-fc84-46a8-9417-093fa2d882c1" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_abb806a5-fc84-46a8-9417-093fa2d882c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_b3cb61be-73b7-4192-be80-33c026796fc6" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_b3cb61be-73b7-4192-be80-33c026796fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_82e63743-8602-4c38-adb0-1fe71e9399d0" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_82e63743-8602-4c38-adb0-1fe71e9399d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_53bb3a93-a998-48cd-ab19-2c081829a391" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_53bb3a93-a998-48cd-ab19-2c081829a391" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_26f618ab-9b92-48a9-b750-a443327b17d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:to="loc_us-gaap_VariableRateDomain_26f618ab-9b92-48a9-b750-a443327b17d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:to="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d79e49f1-3558-4661-8e80-b8ffcd51d802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d79e49f1-3558-4661-8e80-b8ffcd51d802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1578e3eb-43aa-4f40-88a0-48bc6ca6bdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:to="loc_us-gaap_BaseRateMember_1578e3eb-43aa-4f40-88a0-48bc6ca6bdfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_45c49069-71fc-4c36-acbb-ff6ad6f15bb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_45c49069-71fc-4c36-acbb-ff6ad6f15bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_f2fc9610-7383-48be-aa5f-d4c0e6619824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_f2fc9610-7383-48be-aa5f-d4c0e6619824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_626e8bd0-7bae-40a6-86b0-06b5144af1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:to="loc_us-gaap_CreditFacilityDomain_626e8bd0-7bae-40a6-86b0-06b5144af1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_01fb444c-73ca-4a48-807a-05767cc675cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:to="loc_us-gaap_CreditFacilityDomain_01fb444c-73ca-4a48-807a-05767cc675cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="i2ad537d1f51e4958bea039eda6540282_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e6b633c2-4697-4354-beb6-5492558bc607" xlink:href="amed-20230331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e6b633c2-4697-4354-beb6-5492558bc607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_99587ec9-2e29-4d9d-9897-680ec0c0223a" xlink:href="amed-20230331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_99587ec9-2e29-4d9d-9897-680ec0c0223a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_68759756-af5e-42cb-b736-78252e4394b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_68759756-af5e-42cb-b736-78252e4394b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_52ce34d3-805c-403c-b6ed-98af2974764e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_52ce34d3-805c-403c-b6ed-98af2974764e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_4fe92e4d-0f7b-4c46-8e5a-d605fb047cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_4fe92e4d-0f7b-4c46-8e5a-d605fb047cf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_41a82c4f-a252-42b2-bac8-6248fe17c4c5" xlink:href="amed-20230331.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_TotalLeverageRatio_41a82c4f-a252-42b2-bac8-6248fe17c4c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_9272f032-febf-43ee-8670-c602b042c77b" xlink:href="amed-20230331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_9272f032-febf-43ee-8670-c602b042c77b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf39ad7d-fefb-4cce-b2ef-2326a6eed842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf39ad7d-fefb-4cce-b2ef-2326a6eed842" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_f3ca1d21-51e4-41ba-9ff6-323374ba8a43" xlink:href="amed-20230331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_RevolvingCreditFacilityTotal_f3ca1d21-51e4-41ba-9ff6-323374ba8a43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5eb61f7c-2ae1-4394-adc3-e1547881b816" xlink:href="amed-20230331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5eb61f7c-2ae1-4394-adc3-e1547881b816" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_a1c4a039-6c48-4bfd-bee6-9058b15fec05" xlink:href="amed-20230331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_a1c4a039-6c48-4bfd-bee6-9058b15fec05" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_2777a126-b855-46ef-9123-82cff9c4110a" xlink:href="amed-20230331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_2777a126-b855-46ef-9123-82cff9c4110a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1cf84353-9b46-4eb1-abac-6b538b1735bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1cf84353-9b46-4eb1-abac-6b538b1735bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_56dc1229-2359-4872-bd9a-db127b0f5114" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_56dc1229-2359-4872-bd9a-db127b0f5114" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_a02a6012-9790-44b3-a0ef-86fb81cb382f" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_a02a6012-9790-44b3-a0ef-86fb81cb382f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7645e8e3-2162-4269-98db-becb58153e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7645e8e3-2162-4269-98db-becb58153e63" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_6980f642-35fa-485f-b1bb-9f0ad258f466" xlink:href="amed-20230331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_6980f642-35fa-485f-b1bb-9f0ad258f466" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_2597e32c-d18b-4fc1-b0e6-a6a63a773c93" xlink:href="amed-20230331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_2597e32c-d18b-4fc1-b0e6-a6a63a773c93" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_798cd942-a4bc-4161-b9ac-6eeb553e11db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_798cd942-a4bc-4161-b9ac-6eeb553e11db" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e5657730-e5ef-4453-832a-1b294b8de2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e5657730-e5ef-4453-832a-1b294b8de2b1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_22de4361-9e9f-4ea6-b6d8-a9b7b4478374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_22de4361-9e9f-4ea6-b6d8-a9b7b4478374" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ef055003-17c2-473c-9a89-9520c873cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ef055003-17c2-473c-9a89-9520c873cbac" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_2e27b852-5a19-472e-8c5a-127d7ddd0995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_2e27b852-5a19-472e-8c5a-127d7ddd0995" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_e12e601f-fff1-4cc7-a5da-1ba9ea6d0a62" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_e12e601f-fff1-4cc7-a5da-1ba9ea6d0a62" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1dc19beb-1a31-43d3-bd1f-f16e35e69631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1dc19beb-1a31-43d3-bd1f-f16e35e69631" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9db3e603-22ae-4c59-bb8d-20970ab2bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9db3e603-22ae-4c59-bb8d-20970ab2bd50" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease_3a30c50f-d539-4e72-a27f-5a88f8736b92" xlink:href="amed-20230331.xsd#amed_ReclassificationOfOperatingLeaseToFinanceLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease_3a30c50f-d539-4e72-a27f-5a88f8736b92" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationExpenseFleetLeasesFinanceLease_458f17a8-6d57-4cf5-a0a9-b5ca34fcb3fc" xlink:href="amed-20230331.xsd#amed_DepreciationExpenseFleetLeasesFinanceLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DepreciationExpenseFleetLeasesFinanceLease_458f17a8-6d57-4cf5-a0a9-b5ca34fcb3fc" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SOFRAdjustment_3371214c-0d55-4014-a058-0a411f5e061f" xlink:href="amed-20230331.xsd#amed_SOFRAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_SOFRAdjustment_3371214c-0d55-4014-a058-0a411f5e061f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb0e3d49-66e8-4627-ab1c-d20790d81991_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb0e3d49-66e8-4627-ab1c-d20790d81991_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4f48120-4a50-4c1c-99eb-5adef5a70b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:to="loc_us-gaap_SubsequentEventMember_a4f48120-4a50-4c1c-99eb-5adef5a70b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:to="loc_srt_RangeMember_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:to="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b93a975-150c-44ca-a449-ece2dba16bff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:to="loc_srt_MinimumMember_9b93a975-150c-44ca-a449-ece2dba16bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d0ff7a4-78fa-492e-8db1-9d37fa34b87a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:to="loc_srt_MaximumMember_4d0ff7a4-78fa-492e-8db1-9d37fa34b87a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dd51d4db-5109-4998-aeab-ab4c2cc60098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:to="loc_us-gaap_VariableRateDomain_dd51d4db-5109-4998-aeab-ab4c2cc60098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:to="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_41b8d3c3-c2e3-4a36-9dcc-cfc17b06244c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:to="loc_us-gaap_BaseRateMember_41b8d3c3-c2e3-4a36-9dcc-cfc17b06244c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_96134bfc-c1a8-46d9-945e-89b0ae410030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_96134bfc-c1a8-46d9-945e-89b0ae410030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25e667b7-608c-4d71-b9d4-e0c32e82ee88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25e667b7-608c-4d71-b9d4-e0c32e82ee88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_935bbcac-8a08-47f5-b995-e1413177ec7c" xlink:href="amed-20230331.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_SwingLineLoanMember_935bbcac-8a08-47f5-b995-e1413177ec7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_bb8fa207-13cb-4d00-9ef1-7555f638ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LetterOfCreditMember_bb8fa207-13cb-4d00-9ef1-7555f638ca6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7ce7a845-a032-40e8-a70e-dfa1594125ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LoansPayableMember_7ce7a845-a032-40e8-a70e-dfa1594125ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_09a56065-ffa6-4bbb-a14d-e42a52010627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_09a56065-ffa6-4bbb-a14d-e42a52010627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_ae500027-c642-4b59-8712-0382f3e7c194" xlink:href="amed-20230331.xsd#amed_PriorCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_PriorCreditAgreementMember_ae500027-c642-4b59-8712-0382f3e7c194" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9d0c7f90-b958-4b93-8f70-ff7869a494c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LineOfCreditMember_9d0c7f90-b958-4b93-8f70-ff7869a494c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_541e367a-2e0e-47a8-8033-843aad818188" xlink:href="amed-20230331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_AmendedCreditAgreementMember_541e367a-2e0e-47a8-8033-843aad818188" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_a9602f98-2d35-4f1c-8651-4282dcbc6d61" xlink:href="amed-20230331.xsd#amed_ThirdAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_a9602f98-2d35-4f1c-8651-4282dcbc6d61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_7421200d-a90a-47ba-8bd4-25c964999708" xlink:href="amed-20230331.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_PromissoryNotesMember_7421200d-a90a-47ba-8bd4-25c964999708" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_baf3a68c-92e0-4916-967b-b40c58eeface" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_baf3a68c-92e0-4916-967b-b40c58eeface" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember_ddfe699a-e608-4dec-a90c-d81b16c5dd32" xlink:href="amed-20230331.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_SecondAmendedCreditAgreementMember_ddfe699a-e608-4dec-a90c-d81b16c5dd32" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c6b95888-c613-4eee-9751-a8c1e1040782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c6b95888-c613-4eee-9751-a8c1e1040782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_ec092b75-7187-43b1-820b-c6da39b865ab" xlink:href="amed-20230331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_AmendedCreditAgreementMember_ec092b75-7187-43b1-820b-c6da39b865ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_7b8ad751-26e1-454b-8802-15e6f71efc55" xlink:href="amed-20230331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_OneHundredMillionTermLoanMember_7b8ad751-26e1-454b-8802-15e6f71efc55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f6b29840-306a-403e-99d4-599715bc467e" xlink:href="amed-20230331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f6b29840-306a-403e-99d4-599715bc467e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_5821a70e-3473-4a63-9f06-0923f6d6fe21" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_5821a70e-3473-4a63-9f06-0923f6d6fe21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f1117e76-892d-408e-b981-00ae6e44162a" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f1117e76-892d-408e-b981-00ae6e44162a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_241569e5-2a6b-4dbd-8915-a46903f2aa98" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_241569e5-2a6b-4dbd-8915-a46903f2aa98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_e7b27b72-dfe2-482b-b118-c3f131602b7e" xlink:href="amed-20230331.xsd#amed_ThirdAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_e7b27b72-dfe2-482b-b118-c3f131602b7e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ib7a08c98d5c140038a78ddfdbcdb441e_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_efab0eb1-95eb-4b14-bc44-665fc834cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_efab0eb1-95eb-4b14-bc44-665fc834cafa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_0d7624a1-4b0c-43f5-9431-3a1b1de6154d" xlink:href="amed-20230331.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_Numberofpatients_0d7624a1-4b0c-43f5-9431-3a1b1de6154d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_61b65bd6-ff9f-4afb-9898-63cc1ed74e6b" xlink:href="amed-20230331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_61b65bd6-ff9f-4afb-9898-63cc1ed74e6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a477806a-20b5-4b33-b730-e256e97d53da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a477806a-20b5-4b33-b730-e256e97d53da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2a30fd50-bac1-4295-b6a1-a2bab1f966b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2a30fd50-bac1-4295-b6a1-a2bab1f966b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_041c3d91-e24c-49c1-8a92-35e60e4db70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_041c3d91-e24c-49c1-8a92-35e60e4db70d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_d97ff3ba-5889-42ae-93e4-86a151fc8e9a" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_d97ff3ba-5889-42ae-93e4-86a151fc8e9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_d3ab3a6a-a21a-4e8f-a3c0-2e72bdca302b" xlink:href="amed-20230331.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_NumberOfBeneficiaries_d3ab3a6a-a21a-4e8f-a3c0-2e72bdca302b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_416dba87-2900-49ad-9d7a-f55ec7410745" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_416dba87-2900-49ad-9d7a-f55ec7410745" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4755048c-660d-4006-a16d-dab7cf3b175f" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4755048c-660d-4006-a16d-dab7cf3b175f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_c37fb9f4-02ed-46a0-ab33-0d8a92716b4d" xlink:href="amed-20230331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_c37fb9f4-02ed-46a0-ab33-0d8a92716b4d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1443a0fc-f622-4cb0-943c-7459fcf5274a" xlink:href="amed-20230331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1443a0fc-f622-4cb0-943c-7459fcf5274a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_c28a6274-ddf7-4b36-a71a-d86add504d53" xlink:href="amed-20230331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_c28a6274-ddf7-4b36-a71a-d86add504d53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_d3e20683-f074-416f-8ea6-7b57304736bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_d3e20683-f074-416f-8ea6-7b57304736bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_61cbf143-5efb-42a7-a127-7972c31485e0" xlink:href="amed-20230331.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ActualClaimsPayment_61cbf143-5efb-42a7-a127-7972c31485e0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_a3b5da51-d6b5-49a3-b14a-2ddba7eb0d62" xlink:href="amed-20230331.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ErrorRatePercentage_a3b5da51-d6b5-49a3-b14a-2ddba7eb0d62" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_63c4e16c-e6d6-4dfa-b9eb-11b34bc451e2" xlink:href="amed-20230331.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_IndemnificationAmount_63c4e16c-e6d6-4dfa-b9eb-11b34bc451e2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_11d6e5dc-9ae0-453f-99f0-1f2931b18127" xlink:href="amed-20230331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_FloridaZpicRevenueReduction_11d6e5dc-9ae0-453f-99f0-1f2931b18127" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_1169c3b9-f09d-440e-a63b-5914af4a5296" xlink:href="amed-20230331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_HealthInsuranceRetentionLimit_1169c3b9-f09d-440e-a63b-5914af4a5296" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_12c2892a-7d51-4008-931f-8b73a73bf8d0" xlink:href="amed-20230331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_12c2892a-7d51-4008-931f-8b73a73bf8d0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f7a3d7d4-b71e-4a2f-b67d-8890c83bad77" xlink:href="amed-20230331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f7a3d7d4-b71e-4a2f-b67d-8890c83bad77" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_fc89f2e3-7c9c-44d9-83ed-d5adb8fc3567" xlink:href="amed-20230331.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_fc89f2e3-7c9c-44d9-83ed-d5adb8fc3567" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_870faa41-f613-4abc-8f45-6558467a8674" xlink:href="amed-20230331.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ReductionToNetServiceRevenue_870faa41-f613-4abc-8f45-6558467a8674" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment_5e6cc778-eaeb-475e-9ee8-b87f005b49c0" xlink:href="amed-20230331.xsd#amed_TotalLegalSettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_TotalLegalSettlementPayment_5e6cc778-eaeb-475e-9ee8-b87f005b49c0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest_557274eb-98cb-45c6-a360-6281eed085a6" xlink:href="amed-20230331.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_LegalSettlementPaymentLessInterest_557274eb-98cb-45c6-a360-6281eed085a6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_dce842ce-2315-4535-b980-8c3a9d57e849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LitigationSettlementInterest_dce842ce-2315-4535-b980-8c3a9d57e849" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_6063f16e-08dd-4242-81eb-1ec95a8fc181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_6063f16e-08dd-4242-81eb-1ec95a8fc181" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetInsuranceExposureLimit_0aa09f45-822f-41ba-b746-251606bc3114" xlink:href="amed-20230331.xsd#amed_FleetInsuranceExposureLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_FleetInsuranceExposureLimit_0aa09f45-822f-41ba-b746-251606bc3114" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:href="amed-20230331.xsd#amed_PayorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_8f20a40a-854b-46cd-a9a9-2aca8d89b520_default" xlink:href="amed-20230331.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:to="loc_amed_PayorsDomain_8f20a40a-854b-46cd-a9a9-2aca8d89b520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:href="amed-20230331.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:to="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_3d0bb86e-495f-4d7f-9b74-a9b2e9c2ffb2" xlink:href="amed-20230331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:to="loc_amed_CompanysinsurancecarriersMember_3d0bb86e-495f-4d7f-9b74-a9b2e9c2ffb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dc7405d0-afcc-480a-820f-8b9d430006c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:to="loc_srt_LitigationCaseTypeDomain_dc7405d0-afcc-480a-820f-8b9d430006c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:to="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_1061ecea-d293-4997-8a72-ddd0353701dc" xlink:href="amed-20230331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_UsDepartmentOfJusticeMember_1061ecea-d293-4997-8a72-ddd0353701dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_3405a090-1f8c-4a39-858f-278e2a446214" xlink:href="amed-20230331.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_AmedisysCIAMember_3405a090-1f8c-4a39-858f-278e2a446214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_02c147fe-35fa-4a92-aaeb-2ead045523b5" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_02c147fe-35fa-4a92-aaeb-2ead045523b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_3a62e70d-e292-4134-bfd1-ae138008c1c9" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_3a62e70d-e292-4134-bfd1-ae138008c1c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_745be270-52bc-43df-a9f0-3cf6d0902fc2" xlink:href="amed-20230331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_745be270-52bc-43df-a9f0-3cf6d0902fc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_e0f7c304-323a-4c5c-a000-84b929ce2880" xlink:href="amed-20230331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_InternalAuditComplianceReviewMember_e0f7c304-323a-4c5c-a000-84b929ce2880" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ad7eff35-7aa4-4ac1-a423-abed49ef90f9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:to="loc_srt_SegmentGeographicalDomain_ad7eff35-7aa4-4ac1-a423-abed49ef90f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:to="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_b8a62bb6-0b3a-482f-ae9b-5d83d19eea33" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_MA_b8a62bb6-0b3a-482f-ae9b-5d83d19eea33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_f491b501-5fec-49bd-8895-1a2398871945" xlink:href="amed-20230331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_amed_MorgantownWestVirginiaMember_f491b501-5fec-49bd-8895-1a2398871945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_17c9edcd-88e6-4c2b-ba6c-bb5eb6136048" xlink:href="amed-20230331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_amed_ParkersburgWestVirginiaMember_17c9edcd-88e6-4c2b-ba6c-bb5eb6136048" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_04a0c11e-36cf-4ac8-8309-8b532a318d22" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_SC_04a0c11e-36cf-4ac8-8309-8b532a318d22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_1e6edf1e-d3bd-4a89-84e4-ce60b37089ac" xlink:href="amed-20230331.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:to="loc_amed_LakelandFloridaMember_1e6edf1e-d3bd-4a89-84e4-ce60b37089ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_e2d4aa30-860b-48f7-a996-dc66fd0eb534" xlink:href="amed-20230331.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:to="loc_amed_ClearwaterFloridaMember_e2d4aa30-860b-48f7-a996-dc66fd0eb534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4d2debbe-a879-4bd2-a3cc-32f540c82efa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:to="loc_us-gaap_SegmentDomain_4d2debbe-a879-4bd2-a3cc-32f540c82efa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:to="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_772d6242-7739-48bc-93d0-6b8730016231" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:to="loc_amed_HospiceMember_772d6242-7739-48bc-93d0-6b8730016231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_08e2571e-ea5d-44c7-b790-7cb933ded8f8" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:to="loc_amed_HomeHealthMember_08e2571e-ea5d-44c7-b790-7cb933ded8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_316d125b-1ad8-44da-ab9e-91c394a6fa34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_316d125b-1ad8-44da-ab9e-91c394a6fa34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_1a0fdc9c-60a3-44c6-b8e2-3e47e79204da" xlink:href="amed-20230331.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:to="loc_amed_InfinityHomeCareMember_1a0fdc9c-60a3-44c6-b8e2-3e47e79204da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_5bd94323-b3ff-4258-85b4-c2ba6374cfd0" xlink:href="amed-20230331.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:to="loc_amed_ExtrapolatedMember_5bd94323-b3ff-4258-85b4-c2ba6374cfd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_02245d0f-244b-453b-8f80-41b9b3707804" xlink:href="amed-20230331.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:to="loc_amed_UnfavorableMember_02245d0f-244b-453b-8f80-41b9b3707804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53498d88-6938-4bd0-9c76-29ef34880bfd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:to="loc_srt_RangeMember_53498d88-6938-4bd0-9c76-29ef34880bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:to="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c96fa82e-6c80-4ecb-9511-99b9b5cbed47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:to="loc_srt_MinimumMember_c96fa82e-6c80-4ecb-9511-99b9b5cbed47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbb22787-4457-4d25-9377-a2e6caac75ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:to="loc_srt_MaximumMember_dbb22787-4457-4d25-9377-a2e6caac75ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i594dd7d73a704b278ddf59348bdb3a72_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f6318924-7ba0-4172-95a1-d03f4bfa9620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f6318924-7ba0-4172-95a1-d03f4bfa9620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0cb89ed2-e6fa-457c-b0f8-7fc9f0cfdab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0cb89ed2-e6fa-457c-b0f8-7fc9f0cfdab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_28d498ee-5d63-4456-b538-d4198d6c8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_28d498ee-5d63-4456-b538-d4198d6c8db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dcf7995e-3638-4b39-93b6-4f83637418ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dcf7995e-3638-4b39-93b6-4f83637418ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e055dc30-a11e-44cd-a2a8-007947a8f936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_DepreciationAndAmortization_e055dc30-a11e-44cd-a2a8-007947a8f936" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1237783f-de8e-4a87-b42b-8ee05d9f4362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_CostsAndExpenses_1237783f-de8e-4a87-b42b-8ee05d9f4362" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_108f70ae-f2f0-4cf7-93ef-2a545bd94317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_OperatingIncomeLoss_108f70ae-f2f0-4cf7-93ef-2a545bd94317" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c0005908-6503-4a71-9b15-b4738ec7cc3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:to="loc_us-gaap_SegmentDomain_c0005908-6503-4a71-9b15-b4738ec7cc3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:to="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bc115a96-e3c6-41a2-bc56-673b410e8373" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HomeHealthMember_bc115a96-e3c6-41a2-bc56-673b410e8373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_5cfc7953-9335-4eb9-a05b-9faafbf70583" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HospiceMember_5cfc7953-9335-4eb9-a05b-9faafbf70583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_aced22dc-c713-4166-9464-e15cbfeea886" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_PersonalCareMember_aced22dc-c713-4166-9464-e15cbfeea886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_6fd73730-7506-4167-8f67-bae7583bd0a6" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HighAcuityCareMember_6fd73730-7506-4167-8f67-bae7583bd0a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_6b9d6c15-7115-4553-af5c-c153ef43510f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_us-gaap_AllOtherSegmentsMember_6b9d6c15-7115-4553-af5c-c153ef43510f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="i01f0c5f177ae4a06b7c8f378d9c05702_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca7061ea-e860-442a-b009-8f15fbf6bc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca7061ea-e860-442a-b009-8f15fbf6bc77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_07723bb4-0978-405e-a60f-b20f80b0c296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_07723bb4-0978-405e-a60f-b20f80b0c296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ec1d51cd-9f90-499a-9d72-09b865059106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ec1d51cd-9f90-499a-9d72-09b865059106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_1308f163-10de-43b5-8d68-3c0fc4fc200c" xlink:href="amed-20230331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_PercentageofSharesOutstanding_1308f163-10de-43b5-8d68-3c0fc4fc200c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4187587c-4b50-48f8-bc2f-c8a673f985be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4187587c-4b50-48f8-bc2f-c8a673f985be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_24b3d719-41be-4dc6-ba00-745ed51f28d3" xlink:href="amed-20230331.xsd#amed_Discountedclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_Discountedclosingstockprice_24b3d719-41be-4dc6-ba00-745ed51f28d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_885c65e8-2257-4643-9504-15bffa816920" xlink:href="amed-20230331.xsd#amed_Percentageofclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_Percentageofclosingstockprice_885c65e8-2257-4643-9504-15bffa816920" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4baf1831-1563-4d37-b49a-45e6ac0ce790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4baf1831-1563-4d37-b49a-45e6ac0ce790" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3ea87572-cb72-4f84-b796-befdc6cbddce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3ea87572-cb72-4f84-b796-befdc6cbddce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_0074f348-560d-4915-95cb-46d4280ab7dd" xlink:href="amed-20230331.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_0074f348-560d-4915-95cb-46d4280ab7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_a3942bc5-9b29-49ec-8796-ac437e4f137d" xlink:href="amed-20230331.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_a3942bc5-9b29-49ec-8796-ac437e4f137d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_450e10d3-c5f6-46c7-ae72-11c5ba44e9e7" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_ShareRepurchaseProgramMember_450e10d3-c5f6-46c7-ae72-11c5ba44e9e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_80265bbf-ee9a-4fed-a402-e541b1beeabe" xlink:href="amed-20230331.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_80265bbf-ee9a-4fed-a402-e541b1beeabe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022ShareRepurchaseProgramMember_4bf5e9bd-0ac8-4e65-b2c5-93bb26dfc5c2" xlink:href="amed-20230331.xsd#amed_A2022ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2022ShareRepurchaseProgramMember_4bf5e9bd-0ac8-4e65-b2c5-93bb26dfc5c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_f00680b6-1c57-4526-88bc-bf75637b4c7c" xlink:href="amed-20230331.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_f00680b6-1c57-4526-88bc-bf75637b4c7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_84889251-b6e6-4b70-8b68-cef1fde34d7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_84889251-b6e6-4b70-8b68-cef1fde34d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6309fe27-2b1b-4311-9e1e-c4c28788558f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:to="loc_us-gaap_SubsequentEventMember_6309fe27-2b1b-4311-9e1e-c4c28788558f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="i4bf1d77af85a4836b7f1009d9f008097_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_20e68555-96f8-4382-9ab7-a44cda620c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_20e68555-96f8-4382-9ab7-a44cda620c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb4f374b-38a4-4a21-924d-39cc9b74ac25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:to="loc_us-gaap_RelatedPartyDomain_cb4f374b-38a4-4a21-924d-39cc9b74ac25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:to="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6429dab2-c745-485c-a1ef-ad357403a9c5" xlink:href="amed-20230331.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:to="loc_amed_MedalogixMember_6429dab2-c745-485c-a1ef-ad357403a9c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_82af553a-9ae5-4fbb-8cc0-e89cdf79309c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_82af553a-9ae5-4fbb-8cc0-e89cdf79309c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended" id="i0b50f6cccbe74b628bc4ab09bd91601a_SUBSEQUENTEVENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionShareExchangeRatio_942832de-dcaa-44d7-a1e0-8e2b8347b6fd" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionShareExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:to="loc_amed_BusinessAcquisitionShareExchangeRatio_942832de-dcaa-44d7-a1e0-8e2b8347b6fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTerminationFee_c6ca104f-b441-44b0-98eb-bc78b04506d2" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:to="loc_amed_BusinessAcquisitionTerminationFee_c6ca104f-b441-44b0-98eb-bc78b04506d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:to="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f3c67885-8343-4649-8daf-e380b31461a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f3c67885-8343-4649-8daf-e380b31461a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_da0ad066-5c4a-419a-b7d9-1bd39b7186d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:to="loc_us-gaap_SubsequentEventMember_da0ad066-5c4a-419a-b7d9-1bd39b7186d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_45a10b29-b02b-4883-ae46-243113a807ab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:to="loc_srt_SegmentGeographicalDomain_45a10b29-b02b-4883-ae46-243113a807ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:to="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_1e013474-9bd7-491e-ab34-a4263e343925" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:to="loc_stpr_NC_1e013474-9bd7-491e-ab34-a4263e343925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:to="loc_us-gaap_SegmentDomain_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:to="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_55600896-6e38-4493-a571-817c93cb8b20" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:to="loc_amed_HomeHealthMember_55600896-6e38-4493-a571-817c93cb8b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_be253eec-6b3b-4281-8f38-689ea992d28f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_be253eec-6b3b-4281-8f38-689ea992d28f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b322cab-befd-401e-91ef-5985439244e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b322cab-befd-401e-91ef-5985439244e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>amed-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_5bb19f99-078f-4871-a29f-53c44b7a6842_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue period of care payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Period of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20230331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_c8a3c490-8685-41be-8779-342de5ce4867_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Service Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_02bc1943-2be1-471b-a95a-c6e1dafe0df9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b63fb303-eb17-4119-8986-b881e65f5697_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_21b6f740-7e55-4ca4-a837-fb6104d1d7c0_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20230331.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c288dc63-6d91-4b90-9d14-4dd64f2be97d_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_59d2defe-0ad3-4ab9-bbae-266162262213_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_54232b68-bdbc-44bd-b3a2-b1469b4a5368_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_504a2eff-b4d1-47c9-be6b-e21af06f901e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_7c3cc741-16d6-4d8b-a70f-b49ccf8eb1fb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9b3c35b0-7185-492a-8ae3-5f636db4e619_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_6e814ad5-4925-485d-a849-c4bf96d1f494_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Liabilities Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_600ab4e0-265f-434c-af4e-11cc26d0b61b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_1e90842b-7e5f-4578-8b7f-9df899afcab0_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20230331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FleetInsuranceExposureLimit_0e8070dd-3f81-4169-9217-df49debcb2df_terseLabel_en-US" xlink:label="lab_amed_FleetInsuranceExposureLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Insurance Exposure Limit</link:label>
    <link:label id="lab_amed_FleetInsuranceExposureLimit_label_en-US" xlink:label="lab_amed_FleetInsuranceExposureLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Insurance Exposure Limit</link:label>
    <link:label id="lab_amed_FleetInsuranceExposureLimit_documentation_en-US" xlink:label="lab_amed_FleetInsuranceExposureLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific fleet insurance claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetInsuranceExposureLimit" xlink:href="amed-20230331.xsd#amed_FleetInsuranceExposureLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FleetInsuranceExposureLimit" xlink:to="lab_amed_FleetInsuranceExposureLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_b4b50fb5-f4ae-4079-8c86-a8d7897a3cac_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_label_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Lease, Unfavorable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:to="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2046a6ed-ff4f-42b2-8477-a6c92838e050_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_4b2afc3d-91ce-45ea-86a2-150fa12a5f3a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_88616927-7223-49d6-95eb-2bcbe42b8599_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c7010ae4-c13a-4ee7-9f69-e0259fc3e097_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_96c83e4e-5f9a-4288-9331-903a81d84560_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20230331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_68abdb4f-2f2e-4506-9260-c61c586ce63a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_54bd46c8-c7f0-457c-a0a8-4d438fd8c1c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_7dfe6952-0d43-4389-960d-8734b6e1f3cb_terseLabel_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExistingShareRepurchaseProgramMember" xlink:to="lab_amed_ExistingShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1959ccb9-cdc4-4c41-b2b1-0f60a39473c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_dbb128e7-f666-422f-b8bb-4603a7dcdc3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_a7e72b19-d5f1-405e-ac54-9c5f6eec506e_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20230331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e188ee60-9631-4ca5-8c85-40bbfb31a46f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_77f3e348-6fc7-4c48-bc9f-dbea6abce4b6_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba3b830e-7db5-40be-a80e-1e23d9a5077e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b84caf2d-c6b6-4ec5-9865-36875e560e3a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5972a807-10dd-477d-bf97-c4d0eef7154d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_005ac3d3-cd4e-4166-abf5-45440fd91bef_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember" xlink:href="amed-20230331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember" xlink:to="lab_amed_MajorSinglePayorCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0e921f98-16d1-41aa-94d9-725f19f06e53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2129cdb0-8646-45c7-a812-7dabfc8f72e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6e2c3a8b-a4ea-4a29-93dd-08cf2432eed8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_cbca35d9-095d-4feb-8860-595e534b9138_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20230331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_5a8e875d-e85f-481a-81ec-7785f772911b_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Term SOFR rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Term SOFR Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Term SOFR Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_11322d7e-d55c-4bae-bfbf-893176fff8f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_852a860d-1854-41b2-bac3-0841ce222292_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20230331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_c5938c6d-26e2-470e-903e-f47eea6c1a9e_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20230331.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_a5763ae9-e208-404f-b716-ce49185e31e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_62562fdf-4105-4234-a7f9-152c5a6b4e35_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Liabilities Noncurrent</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb4f2db7-5e8f-49d8-bef6-bc2eefd2fd8e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_44888aac-3e8e-4fbc-a7ae-3b6999097eda_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20230331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7b77b326-9f4b-4a56-8288-a4da24431db5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_7e03c86b-0769-4e02-b857-1a67eac59a2d_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20230331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_79ffe60d-b99b-45be-be97-76347f31ddca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_a16bfa1a-939d-4c58-8776-25181e8113bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_06b808e3-bf5b-4f12-a379-a94c4fbb5eb9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_9ba95f7a-940f-4047-adc8-4642fcf8dfd8_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20230331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_32bb524d-1afb-4df8-9a20-a7c012cc071f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_1ca907be-ed99-4d27-acd2-58a37d6624bc_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7570a42e-73e1-4810-ad58-4c8129ca6df8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0c94ab6f-5288-4cbb-b4a6-5dbf55440de5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_41b28ecf-c894-4d24-83c9-05e9fe7dae6b_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_442282a4-5c1c-45da-87d4-d9c606128454_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20230331.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_c9351a2b-ccb1-421c-993b-2cb11af4e908_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_15ea5a05-ce83-40da-a9e7-a06c9e61422c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_589e816d-c214-409f-b4b1-b531c930907a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_d120d93a-9442-4a33-a2b3-7a57020073c2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_a6ecc89a-55f9-4301-ae9f-f55dad39ba2d_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20230331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_96f093e9-02b1-4944-9413-ca1ecfd121b5_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to operating lease liabilities</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:href="amed-20230331.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1036d0bc-078c-4db4-9aa3-7aacbb577187_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_78477fd4-c7a0-460b-8fa3-cd2b38324f9e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ca2b9ea5-682b-49eb-90f3-09a909c7e5ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_76a8ba7d-c3cc-4282-b50a-03d904e21080_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2ba6b0b5-d71c-4ced-91e9-ce9fb8449ab2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_990db036-5d2a-4d37-8dcf-0291c112c6ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3aa74f00-25ac-49ad-8fc1-9e133eea995d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7fc01233-14e1-45d0-a17f-a199918ba6d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4aa8383b-8099-49d2-9a7b-813549c91251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_87161543-a68c-4a1e-8ae2-ae1671d952c4_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_41c5d935-a63a-42f4-a483-c0b439a2afa3_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_276ad84e-d29b-4320-80ee-587abd2a8f7c_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20230331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_16f716cf-5bf7-469d-8c26-5645c1ae9bf6_terseLabel_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions Attributable To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:href="amed-20230331.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:to="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f68b4a56-b9a8-4d79-a1f6-3d87ea0f72a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_be55534b-6125-4484-943c-68bba8f3c93d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_516c598b-45f7-45fd-a499-7070108257d5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_bd557034-86d9-4045-8bde-346d3f4e5f3c_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20230331.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_54525bfe-3b1c-44df-8c78-8805a0cdcf03_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_98f22170-edc7-4b8a-89a7-83577f90a9cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_a7834192-63a0-4586-82de-db9157a59a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from personal care divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_0a109a64-184b-423e-b41e-1e9ac98644b4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_a5353fe8-fd60-42c2-a549-27d51af90cfd_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20230331.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1c2f56e3-cf53-46ec-9faa-85bf060dcb26_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_af900745-63ac-4b85-a435-99697c47a47e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_acbfa20d-1a24-4114-97e1-a00adc19530c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_71272dc3-49ca-46fc-8d64-368871dd4f3c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_87f22b55-50f2-4d0f-ab5e-19a7c6e14fd8_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8313f31f-df50-440b-a05b-4878691f9a1e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_b43d243d-1198-41fe-a439-082c79e1a7cb_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_690eea91-4362-42a9-863b-e2652e98a20c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5184829d-84d2-4086-ae8a-5cc4a13b7e2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_f83579e4-e667-4cc4-90a9-83405e3c1f20_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7843c1b4-1602-473a-ac48-209fa994428c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f21c0df3-23a9-40c8-84fc-5eddb299d1e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e7b4405e-dd68-419e-85fc-0578801c85be_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d1228338-573e-48fd-8ce0-e6441fa0f6bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_15af4fcf-e270-4b7c-a9e3-f0a85d3ea7e6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember_0dcdb0eb-4f46-4457-bc74-c6dfa1a4ecb6_terseLabel_en-US" xlink:label="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amended Credit Agreement</link:label>
    <link:label id="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amendment to Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amendment to Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:href="amed-20230331.xsd#amed_ThirdAmendmentToAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:to="lab_amed_ThirdAmendmentToAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_f4d3fcb2-0ea8-4159-9c4d-7b61a8b2c495_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20230331.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_9e3145da-e3e3-409b-b0cf-97808c83f92c_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20230331.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d5ec4a2f-a5d1-4157-9f42-de9e3d82072a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term SOFR Rate [Member]</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_fc8fb50d-c8cb-4db4-8e8d-f9996d66da0a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e7578f59-cebb-40c8-bc42-4dda63c1fc60_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_33dd83e4-cfa7-4358-82ae-b47012577d6f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1ce6e0f-d776-40cc-9a55-a0aaa7f51a5d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_aafe220a-dbb2-47d9-845b-55a830e8aa85_terseLabel_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Managed Care Contract Volume Able To Receive Additional Payments</link:label>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_label_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Managed Care Contract Volume Able To Receive Additional Payments</link:label>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_documentation_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:href="amed-20230331.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:to="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_bf769ae3-57ec-4e8a-9480-db68158be48f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_63a3a30e-2909-4410-a100-1f7fedff7b0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VariousAcquisitionsMember_fd37d989-181a-41dd-8fe7-92ba317b961a_terseLabel_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_label_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions [Member]</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_documentation_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember" xlink:href="amed-20230331.xsd#amed_VariousAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VariousAcquisitionsMember" xlink:to="lab_amed_VariousAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c31ce329-b1cd-40ec-afbd-f141dcf0bd91_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_322910d0-70de-47bd-8d6e-1ed591eff0d6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c3287dc4-3837-4d8c-b25f-e61a659fecd0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_b7c4ec19-4c47-4de9-85b3-393ce0645387_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_ddb7ebfc-b899-4a52-9f21-f6642ab5dc7f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_9ab550d0-110d-4d62-9e65-959bca9d5efc_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_ec846241-2204-4482-9e38-809f91d73a38_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20230331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e048eb11-eec6-4106-ab3d-b7c87c08bdd7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLegalSettlementPayment_a77e762c-cac1-4e2a-a451-8614fd0cfdb9_terseLabel_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:label id="lab_amed_TotalLegalSettlementPayment_label_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:label id="lab_amed_TotalLegalSettlementPayment_documentation_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment" xlink:href="amed-20230331.xsd#amed_TotalLegalSettlementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLegalSettlementPayment" xlink:to="lab_amed_TotalLegalSettlementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d0ffe8b1-9aea-450e-9478-657405c47cbe_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_dfafb7a3-7033-4155-a473-81c05c626b80_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_db42518b-b0bc-4a15-b2d0-a145808749fa_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:href="amed-20230331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3ee05870-e8b5-4d95-8381-ee526e73e0ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsDomain_c16b75a5-d968-4393-be19-5a35cada39dc_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_label_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_documentation_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain" xlink:href="amed-20230331.xsd#amed_PayorsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain" xlink:to="lab_amed_PayorsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_667134b3-f74e-4c7a-b2a1-1f74ea083ed2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4f120169-cd52-47a0-baef-3840f0a64f5c_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_c25b9761-3a32-4e3f-9b0a-f71ea2795352_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_5d0efe1a-bf8f-4b3d-8f95-9f82b5897c49_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a2f7075c-1876-4bbc-965c-5b04ac419782_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_4be89480-c83b-4920-90c5-f652be968c04_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Accrued Expenses Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_069968c8-c98a-4428-8099-a2e8b376ef4d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_af441a30-2e6c-4f73-be6d-72e7023e4f26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_3256bb19-972c-45d4-bf6f-810c02e50ba7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_67c32ff5-ea04-4c09-b465-999e38b84217_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_394db747-59c5-4ef2-afd1-e219096b5e0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5edd7a50-8605-49c2-aac5-aa6222da6828_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_a5e6efb0-92aa-437d-805f-e0a26daf357e_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmountReleasedFromEscrow_b7123394-3ead-4f6a-bab3-6504b79a6d25_terseLabel_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:label id="lab_amed_AmountReleasedFromEscrow_label_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:label id="lab_amed_AmountReleasedFromEscrow_documentation_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow" xlink:href="amed-20230331.xsd#amed_AmountReleasedFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmountReleasedFromEscrow" xlink:to="lab_amed_AmountReleasedFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_e34ec559-aaa7-435c-b727-1bdc5f2a244f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_8796f1f2-742e-4a77-a04f-c3ebcace0e30_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20230331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a0f38ab1-500a-4ca9-b61c-e31b4cef17fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_90fea12d-3803-4988-ab2e-17da0a37179f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_58455ff6-f75a-44be-a8eb-ee929803f9ec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_08919c98-c230-4d94-b754-bb105e120a07_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_c17f4f4e-57a4-4531-bb58-970f195960f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on personal care divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_dda0a107-d78c-4988-bad1-67905e31ca3e_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on personal care divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0accc29e-cebc-48e7-9f03-1bd7924e9db6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7ae4f513-402f-46dc-a3fd-9eafdfe51c6c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_854ed48d-df85-4065-b855-3152d6ed5615_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_34ae231c-d409-4060-b070-0070603d092e_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20230331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_dfeb63dd-0584-49e5-afb0-cbeb7577c8b4_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time that goodwill is deductible for income tax purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20230331.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a9faeab3-b906-4caa-b861-46e18a1755d1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_1f142f54-b062-4841-9c96-340255880cd2_terseLabel_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_label_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_documentation_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual" xlink:href="amed-20230331.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReversalOfLossContingencyAccrual" xlink:to="lab_amed_ReversalOfLossContingencyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_0899a66d-e4c5-46d1-b630-e551db85c2c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1b21aad6-f572-4f65-af67-472bacd3173f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7a287f37-0873-48d1-9ec2-d0722ee7a930_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_f204c43a-a15e-480d-9b2f-ef2d67bd40c7_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, AseraCare Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, AseraCare Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_7a107c0e-8f89-46f0-823c-fe1111631257_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2da9a88e-489e-4870-ab6b-28ef37df81df_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_7ce37374-9b35-456d-b11a-c8dff8d24129_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of cost method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_55e78d47-9343-478a-8ba1-ef491e45d4c5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of cost method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_ee3560f0-3447-4e84-b283-1888a0f7b025_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4a51bb4b-f889-431f-964e-21da78d56307_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_4acc3045-7f70-449b-b6df-8b093b3b5840_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8f8edb8d-e53c-4634-9faf-d757f202cb66_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_662dd33f-1a17-450c-9633-e964fea07e44_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity assumed at acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_4097833c-9711-49ca-8bbe-e29be3e973e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_76b56143-bf29-43fe-b65e-1e1506f46422_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_891b2c03-733c-4fb0-8657-8e0125c72f79_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20230331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_2384206f-a5bb-432b-b7a1-28915708ebe0_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20230331.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_fc6579e1-96d5-4b02-aa72-376b2cde9034_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20230331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ad979bbb-aa98-459f-9375-979a88c3c92d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b166265-1628-4cbd-b528-f6b327bc59ff_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e93860e-22a7-42e1-8b7c-b716b1fd9e31_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e2671c6-6299-439d-a751-d6b16baa0db6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_23c6ef24-2133-40f7-8ec8-e1030d511aac_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_d7f64b71-9141-4e92-a96d-93685f5b9c84_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember" xlink:href="amed-20230331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember" xlink:to="lab_amed_OneHundredMillionTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_45ce95c7-5e61-4b4b-ab12-000a62d17743_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_6ae517cc-9805-4d82-a61c-2faafd86528c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_fcc88135-1691-400e-b5a6-ce2bc3ba56da_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7bb2ed30-43a0-4a2e-8a6c-38f1f16adb76_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_b87c45d8-d627-4645-95ec-7c3c3c73ff7e_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20230331.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_445459e6-41aa-4fea-88ac-0ce771a8408b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_c0ff349a-f747-4468-b921-8dfd9dc4c03e_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20230331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9e6a83ed-4e2d-491f-ab38-8035dae4717f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_da2edf67-075e-4208-9437-f7f44557cb01_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_03aebe2b-b304-4b58-9bf6-6bfdd9d985b8_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:href="amed-20230331.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2ce943d0-b3c3-4fb7-89be-2aa1df78937b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ce2a5858-4dcf-4e69-b0eb-1fe92cfc996c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ce894793-6c71-458a-90d5-4099262220a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ee8f16c-0026-4f7e-836c-0faf6133457f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_07872098-e951-483e-b31c-99f3cb885506_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_bffc1c54-d144-42e7-b5fb-c088d21439cb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d78b7ef1-2453-40ae-8adc-7401dd044220_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_b7d7f258-cd2e-4862-afef-f4497e2ab990_terseLabel_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_label_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparability of Prior Year Financial Data, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:to="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8008da67-5c48-4f60-82d0-01fad1a5ea96_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f297851a-84df-4b1c-8915-bb13bed86760_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_d329d093-48b7-48d1-a0d6-e495dd2bc7e8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease_4eaae98f-d4f9-4ee9-a58f-166bc4095b39_terseLabel_en-US" xlink:label="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Operating Lease To Finance Lease</link:label>
    <link:label id="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease_label_en-US" xlink:label="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Operating Lease To Finance Lease</link:label>
    <link:label id="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease_documentation_en-US" xlink:label="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of fleet operating lease to finance lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:href="amed-20230331.xsd#amed_ReclassificationOfOperatingLeaseToFinanceLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:to="lab_amed_ReclassificationOfOperatingLeaseToFinanceLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_5b5de495-33c9-4164-94be-ecdc3623aea4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_25d510ca-777e-448c-9007-382bb0fc35a4_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20230331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_1e41584a-f951-4e0a-bf39-ae1f5ef86b1e_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20230331.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_e2c61ab8-0aae-4d91-b036-f4acc9caecd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ebd64939-37b8-44be-b5d3-b4b1b4627eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations_fa59a299-b571-4efd-97e6-10b6af6edfe5_terseLabel_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to finance lease liabilities</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations_label_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance lease, Reductions to ROU assets resulting from reductions to finance lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations_documentation_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance lease, Reductions to ROU assets resulting from reductions to finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:href="amed-20230331.xsd#amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:to="lab_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_2445d8ca-e2f8-4e69-91a9-5af04724c2ac_terseLabel_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_label_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health [Member]</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_documentation_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember" xlink:href="amed-20230331.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AssistedCareHomeHealthMember" xlink:to="lab_amed_AssistedCareHomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_c76d17c6-82ce-4470-b5ce-cd1d2ae1434d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cfb02c6b-137b-446a-8b7d-0390bc8ac1d2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5f25440d-053f-4fcd-bdcf-9533fc327545_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5a0e6bf5-b3ad-47f4-8685-97fa5aa1c661_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f9c04ce8-80bb-47f4-abb2-27dd7b5c7ad7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_f31b18b2-a429-4b8e-a4af-d8302f9d141a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0a28eb70-8217-412a-8a03-ceedea02b368_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7e0af64d-53e9-4f3a-bdae-d69817e8e1f3_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d9023f4f-7942-4325-9454-6ae10c5372b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_9ca54019-24bc-4956-b3c6-872aa46195ed_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_20e6380a-c468-4117-ab50-ce9cc4169c89_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_fe631565-92c2-4652-85e3-8aab0b278ed4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_47470ece-127c-4097-b6ee-0f63dd0e7d48_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:href="amed-20230331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_f608f64f-a403-4b7b-926c-2cf9b6a9741c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a9041860-9d27-439f-be21-351fd8d2c8d7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_828b6c59-df29-49c3-8f22-4391637a0450_terseLabel_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_label_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash, Noncontrolling interest contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_documentation_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributed in noncash investing and financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution" xlink:href="amed-20230331.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashNoncontrollingInterestContribution" xlink:to="lab_amed_NonCashNoncontrollingInterestContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0eba97e4-2b91-4403-81bd-9e70fb531423_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_d7d4da31-dbb4-4a56-8313-e2dd4994c41c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_78722ad1-7139-4253-97b6-8cc6afbd8f46_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20230331.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_d500d375-3e6a-4dc7-9079-b3e41b8d3776_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_2f40d740-d412-4575-8779-9554730d614a_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20230331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b6f9514d-882f-48a6-b540-9d9fa4819d15_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_c27b88a5-4557-4860-9f6e-664c970ee286_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20230331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_da168924-9ca2-4a75-967a-32ce432d558d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_f7f9aad3-c03b-4cd8-b407-4187f5c4c581_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_fad667c3-cc35-49b8-b458-77120f5b5536_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseProgramMember" xlink:to="lab_amed_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1c1a9e4b-4d09-4c1c-9a4c-76de04881c45_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f5b0adea-2b8d-4350-a990-95dc02d2e4e1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_bde8d238-9fdb-468c-a33e-f2ff478ddcf8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b188d91a-dd5e-475b-9240-868cc56dd270_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_43579a10-3572-4b23-b553-304930836569_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_81838746-e0d2-45a5-bcba-d62a85894ae5_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_98f83023-a12f-4be9-84ce-a34e88cdab6a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_b42fedef-71ac-4b20-b503-3d2cd11d775e_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20230331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9a2ad94-2512-4b5e-a740-3073c7cba033_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_7a4455a7-64f4-4beb-ba2d-a2cfcb192007_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cd2bef6-9873-4502-9efa-80104b807f08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_efb50f57-00a6-4d66-9fc3-dcebff8592da_terseLabel_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Accrued Contingent Consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_label_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Accrued Contingent Consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_documentation_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Accrued Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration" xlink:href="amed-20230331.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashAccruedContingentConsideration" xlink:to="lab_amed_NonCashAccruedContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_379046c7-82ac-4f4e-817e-bed62088f11a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_2ea7d99a-515c-4690-81b5-d56c76851538_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_f8639f43-b7ab-40ba-a279-b002847d9390_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_18e9dee9-cf5e-4e6f-b20a-49efd5fa5a9a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_4d3b37e1-3156-4651-a7eb-693a3f8deb0a_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20230331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9605c53e-8ef8-4098-b631-2269504654a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c2d4a3d5-f6d1-4c28-ba31-adb7e7703c07_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_74ed699e-bea1-417b-b7da-33b58fa9e8cf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a0b97af6-52ee-45cf-a232-4f1b4de6274d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0faabb20-c177-4c09-8cab-88fc5c4b48bf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2cce0175-340c-4943-b227-26f666c4827b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_1e79449a-c098-40c4-b0ad-625f8488b30a_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_0c320234-908c-45f2-b587-3f7faeb78ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_39fa05ff-771d-48c1-906b-a863c486a0d7_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_df4348b5-93d2-4fad-97df-1c69225d75ac_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_5d767e43-834f-4e4c-a60c-baf16a34ebda_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_96481466-4387-4217-8325-085ee191491e_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7569f49c-3e53-451c-998b-79374ac7a357_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9d2a4e6b-d9be-45bd-b357-e4f371ebbfba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_33962359-a482-40ae-ae84-01f5ebd175eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_cbfbdf9e-5b7e-4cfe-b176-43508b0af46e_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_19e02cde-f4ac-444c-8e6d-11d6dca76a20_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20230331.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_1bca7d9d-c7e6-4730-811b-392248f09469_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Payroll and Employee Benefits Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_3da79f79-f07f-460d-b000-1bbbc2116692_negatedTerseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Assets Acquired</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Assets Acquired</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInAssetsAcquired" xlink:to="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_46c817e4-5933-4dcd-960f-e769f7145d0f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f006efb7-14a0-40f8-9432-5a458bcb50fc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HighAcuityCareMember_68a208c5-22e7-4280-acab-d8e79f583424_terseLabel_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_label_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care [Member]</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_documentation_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HighAcuityCareMember" xlink:to="lab_amed_HighAcuityCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_21c77a92-f583-45bc-b596-e3145e86b049_terseLabel_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:href="amed-20230331.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:to="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_0f1a79d7-a866-4f38-a8b4-64b8b39e4cf6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_3472c399-3964-4f53-a0f2-c7d7d424b3b3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a35b0f63-fd64-4dfd-88f7-32fbe80c94ed_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6b1bc929-7bfe-42ab-8580-a149a1772653_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5069e42d-1002-4f00-887c-50b21e908bf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1e930203-0ae1-4809-a229-919526216a49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_bdcd9f75-5b87-468c-bfb0-020f85078a69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ffa3e13a-8e60-48b3-ad85-cc85c485de51_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1396122f-683b-4230-9f35-6b099e64060b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1b5550a9-d387-4b57-8d7c-e487d0279d2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_0887db98-1a1d-4055-8a66-5312548a5ed0_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0573d715-54a4-40e8-9782-19e0e517c97e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_db460e04-6443-4288-8fc4-0d3430b48477_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_79e48175-0554-4196-b84f-1a366c4c47ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ce84329a-58bf-4746-b681-4f604dfd4641_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_1c8d673c-0a8c-4def-8592-4fdafcb66aa4_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20230331.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_879731d2-0f21-4063-aa51-0dab259ab690_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_19c20e48-e0fe-4b84-8fe8-402e1ea840d6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_586ff50a-369a-494f-81de-d501776d59aa_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a2a60ba4-a8b2-49cb-ae26-64b6b540d39f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_adbb1353-f6b9-414b-bf86-67bd0dde59b3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4bf1b2de-87b5-4ef3-93a8-646548cf8e29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_095a9842-8797-4a15-a391-201d66b0454b_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20230331.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_377f5b38-a687-4c8d-88ad-ce4b98c0b6ef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc279158-585a-4cc8-8f0d-01cc998e7924_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_120129d8-5739-48ef-9359-0b10ee17975d_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20230331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f108b6cd-c446-430d-9560-cbe3b41dc3e4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_456edc78-e533-4927-b40b-e25a962d2488_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_1301c559-1982-45c5-96f7-1570c1f0efc4_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c9234cd-63ff-4153-ab0d-61787a6f58a9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_66dc086f-97dc-4442-80c2-86929c172679_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_73066c40-4986-4389-9591-e690ce6addac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9d75848f-1ab9-4be8-ac10-c91b32aca359_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_26933b8c-acd8-4cf9-a3b9-47001d460832_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20230331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d6999ef6-65b1-42d4-8386-6c16696c6d61_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsAxis_448cf922-75cf-42e8-afba-2ba136c9fbe7_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_label_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_documentation_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis" xlink:href="amed-20230331.xsd#amed_PayorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis" xlink:to="lab_amed_PayorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_141b4b44-738c-4218-9108-c612d1cfb4a9_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20230331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5a01d09a-39be-4a10-9515-8311e8ad3c92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_318fe661-61ef-4398-b0c9-2a392117a0bc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_f415dc33-804a-467c-9cf0-f7efb9514c39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d51d53bb-cbfb-4bcf-bd2e-900041b5c264_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_a3ceac5a-fbaa-47fa-87e5-7c9d9c073fef_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20230331.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c180e99d-7a1b-473b-a514-cc9baa388527_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9c295e9e-7194-446c-ab9e-aa68df42d82c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_022db1db-82bf-4ea4-8611-72aa4c3ebf2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cac37d72-4504-4780-9a84-864c54eb5e81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2022ShareRepurchaseProgramMember_2630d7ea-6a4f-4ba5-a60a-dd33ff998d1a_terseLabel_en-US" xlink:label="lab_amed_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2022ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2022ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022ShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_A2022ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2022ShareRepurchaseProgramMember" xlink:to="lab_amed_A2022ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_6cf1e6c2-cb3d-404f-87b5-6d3c2325f156_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20230331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_018c7d6a-6eb5-48a5-a33b-65db504e492e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fa37e012-e0c8-432b-ab74-ce3bc3b81ee9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0d708b9b-03d0-41e3-90ca-6febb2309f95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0e5aaa78-5553-4c3a-8956-682188c9ec53_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, inclusive of depreciation</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_1fda01cf-bebd-47ae-8f6f-dab7b3e41866_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20230331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f15b5329-574f-4d50-bc4f-d18d252abf11_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_595d7cd2-0f03-4e73-9334-5e6dcdccdc31_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e89f5ac-198b-4298-a175-eca9fcb0bec2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_c8a5c8c6-fe10-4a1c-99f6-c65d8bd3c1bf_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_ed7a70fc-b069-4b6f-95bc-a853b75a46ad_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20230331.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_46935d26-90e4-44ec-a6a9-1ec3975beae6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_05a535a9-2900-4583-8df2-9279464f86c3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_d7b3c3b0-70d9-4a88-ae5c-955850256277_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20230331.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_2364997a-6651-47fa-9743-83cb63b7cd63_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20230331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_b1f3e1f6-5cc2-43cd-ac19-e441c845618e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_ad4eccd1-a4e9-4e76-8a13-19b5fcce71cf_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20230331.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_e21ce1ea-8e47-4a85-a8a0-420bdf19a20b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_c2a78685-88b3-4387-8495-0309f0f525d6_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20230331.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_53f9c07e-5a6d-429a-87ee-99ecbf0f3916_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_08f2b9ea-a782-4526-8698-5acc6a4040b8_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2023</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:href="amed-20230331.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_396a2531-b9d2-4274-bed2-3f504d80611f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationExpenseFleetLeasesFinanceLease_413d5b32-ad90-4017-9a5b-e8a99deb087a_terseLabel_en-US" xlink:label="lab_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Fleet Leases - Finance Lease</link:label>
    <link:label id="lab_amed_DepreciationExpenseFleetLeasesFinanceLease_label_en-US" xlink:label="lab_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Fleet Leases - Finance Lease</link:label>
    <link:label id="lab_amed_DepreciationExpenseFleetLeasesFinanceLease_documentation_en-US" xlink:label="lab_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Fleet Leases - Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:href="amed-20230331.xsd#amed_DepreciationExpenseFleetLeasesFinanceLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:to="lab_amed_DepreciationExpenseFleetLeasesFinanceLease" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_e1f7713b-f86c-47c3-995a-4c53f8894d69_terseLabel_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember" xlink:href="amed-20230331.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondAmendedCreditAgreementMember" xlink:to="lab_amed_SecondAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b1550347-46d4-40df-b725-a299bc832e5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EvolutionHealthMember_feba89d5-f0e7-4298-8a11-a47c705ca115_terseLabel_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_label_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health [Member]</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_documentation_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember" xlink:href="amed-20230331.xsd#amed_EvolutionHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EvolutionHealthMember" xlink:to="lab_amed_EvolutionHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b953b8e3-9df0-4ee4-8bda-20ef790ff9cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_987fe0ca-cca8-46e9-b0e4-0217d5b9c937_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_d9ba87d4-f47f-4b48-8bbe-5bd22272e6d7_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_94b0fcef-097d-4845-b881-85959e2d8b6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_216fed9b-9d46-49d7-9e35-7d27492aec07_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_103e6885-3a38-47aa-aec8-7189bd9362b0_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20230331.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2031cd2f-7dd8-4ac9-b767-33285095d190_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e542f9df-14bc-4733-9471-71372df40a4d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_57422b85-3222-483a-a788-94d4aa8844b6_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20230331.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_8a294db7-4c29-4898-91a6-8bb4c8688504_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareLicenseMember_a2a33785-ed66-468d-b66f-9d53ba11664d_terseLabel_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_label_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_documentation_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember" xlink:href="amed-20230331.xsd#amed_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareLicenseMember" xlink:to="lab_amed_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_35a9db90-fb42-419d-a479-a9933f2adf6d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46220059-6f69-4be3-bb84-50383d3be674_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ae74243-551a-41d4-9845-d00029dd7332_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df0f4377-1ebf-4373-9d45-ddc6666c1b02_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_4b89b991-f2e8-41a9-aafa-23a02d00f43f_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_06ae7b1e-6f3c-4307-be15-a40804095425_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_322d224e-0f16-4ddb-850d-acb3d582daed_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_f9b367e4-9f3e-4fbd-a68e-a4db0dd764ad_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20230331.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_06734aa8-ab18-473a-b5c2-a009239a9407_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_851f5f3b-644c-4463-834d-0e11f04c7d20_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_92968d11-3f1d-4834-ba50-26b84c0ff628_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f7aa8844-1f15-4c70-86ec-d5893df4bbba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_66fe7876-51c5-493c-9822-dbeb4198eff0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_648a6703-0e74-4771-aa6f-d784407cca8f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_f0c5110f-5c0a-4c62-a9c1-47417ad5720c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_998e5ac1-437b-405e-936e-5c5a23ecdfcf_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_6eb70620-8981-453f-bd7f-83d10ed7cac2_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20230331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_2a9dc1f9-5f24-4257-af67-0a81fbb80a5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionTerminationFee_d82c65b0-2f50-402e-941a-76e3b387c01b_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Termination Fee</link:label>
    <link:label id="lab_amed_BusinessAcquisitionTerminationFee_label_en-US" xlink:label="lab_amed_BusinessAcquisitionTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Termination Fee</link:label>
    <link:label id="lab_amed_BusinessAcquisitionTerminationFee_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTerminationFee" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionTerminationFee" xlink:to="lab_amed_BusinessAcquisitionTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_090d3d35-3936-4891-8950-d388b664caec_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_22990922-7222-4e66-8106-3511e4e021a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_5589302e-f635-4909-8209-21288111573b_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2615688c-3ed6-43d7-8cd7-a14158e70c88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bd3ef845-3b6c-40dc-a3e2-cf5ea6bd547f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SOFRAdjustment_7db9db09-7c64-4bb8-8dc4-2810a9c3414e_terseLabel_en-US" xlink:label="lab_amed_SOFRAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Adjustment</link:label>
    <link:label id="lab_amed_SOFRAdjustment_label_en-US" xlink:label="lab_amed_SOFRAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Adjustment</link:label>
    <link:label id="lab_amed_SOFRAdjustment_documentation_en-US" xlink:label="lab_amed_SOFRAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SOFRAdjustment" xlink:href="amed-20230331.xsd#amed_SOFRAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SOFRAdjustment" xlink:to="lab_amed_SOFRAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_f582dbe7-33a2-490e-a6f1-f3a6b23edce2_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20230331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7f0bd00-dbb0-41ad-bc9f-2e263da70def_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d8e2efd6-33d7-495f-b807-d39ce8062735_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3dfd2dc6-6aeb-4497-91ed-7e4d91c5fd49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_fe390b3c-1c64-47ad-84ba-3d4f025db657_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_a2c6d714-1483-484a-bb97-4b9e8b7d61d1_terseLabel_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:href="amed-20230331.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:to="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_be5c6810-ce36-4ee6-944d-516599100258_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_e95d43ca-357c-4243-8d93-da9d4aa8818a_terseLabel_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_label_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_documentation_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Net Service Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue" xlink:href="amed-20230331.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReductionToNetServiceRevenue" xlink:to="lab_amed_ReductionToNetServiceRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_e5d3607e-2dd8-4513-9bd6-f3fb1f2e20ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_317fd53a-a812-4dd9-a9b3-dd4e1f0e31ae_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7505e4a5-55df-497a-aa88-af4b4d32a092_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_19ba464a-0c7c-4c5c-ac2f-0e1c4928818c_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20230331.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_eed0868c-78bb-475c-b816-2b908a35bacc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_e25cbb8b-9b86-4867-b60f-d0f63667efd8_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20230331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_36ced80b-c982-48ff-adca-39a50fa0d84a_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20230331.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_933f665b-7608-4828-adc2-9adfc2b07615_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_30300e58-8bb6-4d37-b024-487e8600fc34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_8114642f-c7bf-45a6-9cec-cefd9e06bf17_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_442837f1-ef6f-45b2-84ac-033ca8c508ab_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization (inclusive of depreciation included in cost of service)</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_fdb14303-c85f-4b37-a2fe-4928b43fd0ef_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20230331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1b649b22-f9c8-4fd9-baaf-1b792207e7f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b38bb5ca-e627-4106-b689-f67030ea44df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PriorCreditAgreementMember_89645652-b60f-4a44-aaed-331a6d1d1404_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember" xlink:href="amed-20230331.xsd#amed_PriorCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember" xlink:to="lab_amed_PriorCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_011efbac-c47f-468d-b8d1-718155359213_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_799a5455-bd69-44e0-978d-1740b613bc5d_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_968db1b0-055e-4bde-a78e-d8fc3a70a7fa_terseLabel_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:to="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0c83de22-b7e7-4c53-994a-432abe9e1ef4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ed383fb8-8b9b-4f52-af7a-f37d011615f4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e6270d4a-de62-4904-8f37-427f9304871e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $105,183 and $101,364</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8fe77b22-8d97-4ba7-a6e5-ba1499b1bda8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_a049cf8a-806f-4131-b41b-75ce83f8cb09_terseLabel_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019ShareRepurchaseProgramMember" xlink:to="lab_amed_A2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_27686df0-5958-44e2-b6bb-f9cfab47ed08_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20230331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_4685a60c-0b45-40c1-aa0b-ce602f48d69b_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2353b04a-5d12-4cf0-8568-e0b32b5fbfaf_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_2e84910c-f554-4c3a-bb93-b460e0201a81_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_d2f65dce-623a-40a0-99fb-ce83e8fc8310_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_37ba8c6f-e064-429d-b3be-1025f9c78cac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5daf0d9e-4764-4381-ac57-eab912fadafc_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d4bafbeb-ab55-4424-b0ec-1c36e388ff37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_a6e4ffed-0920-4694-b48e-c0d3f5649836_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember" xlink:href="amed-20230331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAquisitionMember" xlink:to="lab_amed_AsanaHospiceAquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_928ee471-8889-410d-956c-e97fcc7b5392_terseLabel_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_label_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_documentation_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with the CARES Act Provider Relief Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:href="amed-20230331.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:to="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7863bbaf-03d2-4198-9d91-d097ebf51f26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74270bf1-faa0-480a-8bf2-4cdf207a0975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5fcc97bd-e4b4-4ea7-a6a3-f0325fded778_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_16f16f09-b434-43e5-92d6-aed872a17660_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b6cb1ef-1989-47b0-93e0-d54096e8f1be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_360ff527-8f39-4023-817a-30cf26a7412e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b3a2a406-1b0f-460d-b029-79e7fd89c2bc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f3481fdb-5bb8-4adc-a489-762200183530_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_6b5655e5-001b-4ef7-892e-bd9f55aced4e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_d93c05c6-7a44-4e7f-bf2b-c7c17a378929_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_750ad33d-8bb6-433b-9efd-fbaa2e1be167_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_48cfb016-bff3-4d92-b841-01709a5cce4d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_7b6061ed-b620-4c94-9e37-3bf3133d9d15_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_49c5f1d5-fd97-4854-b173-a0e5a8b93c4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f26e7bee-bbd1-4edd-a2d8-e6b23538ede4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_d0af5c67-8db0-4c8f-a200-a224647e7c95_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_515bf3c4-3436-4f8f-9b3b-4a5b126ca193_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_99a660d8-82d5-40cb-b8a3-fcbd1b0f52d6_terseLabel_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_label_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_documentation_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest" xlink:href="amed-20230331.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LegalSettlementPaymentLessInterest" xlink:to="lab_amed_LegalSettlementPaymentLessInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_40c9decf-cea3-49d5-913b-c905dd59cf84_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_82c32961-5ec6-4c81-a872-a46a4aafcd82_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20230331.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_4840b29d-e99e-4543-a7a9-8d2fb27ea0ed_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a40c3ec1-c66f-4c1e-8fb7-28d13ebdc276_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_1a450efe-57fd-4d19-a546-20a2758788d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_3c7ea022-3359-48b9-b4f7-4d7852610320_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20230331.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7ec2fb7a-4780-4123-ab6f-2ce160db6c88_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_da552954-f8fd-43c8-891b-c07b8e51fe03_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_a65cf060-d9c6-4eea-aba3-86b8a3f7ffdb_terseLabel_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_label_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_documentation_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:href="amed-20230331.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:to="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_60505fad-45f7-4296-880a-149b040592a1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1c455209-2b43-4ae2-9099-370cbaac7c52_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c898dfc4-023a-48b5-9c2c-fb5bae1ddde5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_e8321e69-752a-4441-8ae9-eb69f90257ea_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20230331.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_a313fca2-50f3-4c4d-b489-31734b452c4c_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_f594f109-0140-408e-8c60-7aaf4fd7096a_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses</link:label>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedAndLicensesMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need and Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedAndLicensesMember" xlink:to="lab_amed_CertificateOfNeedAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d7d12917-0bcb-47db-a58b-56886672a2a9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_64d4bffa-fe84-4915-9600-214c25233359_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember" xlink:href="amed-20230331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember" xlink:to="lab_amed_CompanysinsurancecarriersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_75bebb74-27d0-484e-b2f3-94eb4a8b3173_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_72a715a7-b992-49d6-b596-15d1a30ef72c_terseLabel_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021ShareRepurchaseProgramMember" xlink:to="lab_amed_A2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_589fd536-7aae-48d4-b834-de427d93c98e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_7497d278-01ee-4bd2-8e19-c79be30104b1_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_1860ce1e-e238-47d8-9179-141a1896cbc0_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20230331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5db7ea2d-bdd5-4156-9d23-3266a3defc0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8566788c-023a-470b-b545-4aa6a65ca83d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_c866e013-cbbc-4b19-9c2c-1ddaaaded4a2_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_87af4f8d-6e15-43b6-8150-c4ebaae98c0d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_fb298dff-4ea0-4a38-8a9d-c73487e33476_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_2de660bb-25e1-43bb-9210-f195ce4c1fac_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:href="amed-20230331.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2b8a2937-eb21-47c5-bb04-b95ab2e6d5e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_970e64a9-bab8-46c6-ad1a-6b2dcf579b69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_279540a0-d208-41c0-b1a7-e3817e9b8cac_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20230331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9ad5da7b-e4d4-4314-9672-d57fa076140a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_75e2252d-052f-4658-88eb-d883342a3d39_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_618fd395-9566-43ab-a84c-3d397d65acab_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_a55cfa1a-27cc-430a-97a3-a6c3d8926fb3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_6c08cf90-47b0-447e-bc4c-538170cb7f3f_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20230331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4b9789e8-a38a-4321-9a71-59e92633f881_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbe1b77d-0182-447a-8624-bdf17cd6beec_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_de5389a9-c13f-47f8-ae0f-0fedad8e6d4a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_149cfe71-a463-4b35-a3fd-953942552d37_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_aedae614-3c83-4389-95f9-df5b2b41c4c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_a1b050b2-bfdb-43cc-af95-c71c478c4f99_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_145f1450-58e5-4ef1-a555-e99784509bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42dbbf23-9ed2-4ad6-b006-9e15fd49aeb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_478db9db-8948-45d9-a94b-5a8679fb6c07_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9a8f65e5-dc09-455d-9c23-6207c1617051_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 7</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_850426b6-15d9-4967-8683-04ba9f395db5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_66b4f790-bebc-40fc-b78e-203d0e6383be_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20230331.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8012c4fc-f793-4e25-bfaa-4bcd5d9b3240_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7604f10f-3e7b-4997-af66-3c1f07deefeb_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_868bed68-86c4-4191-9c71-fa080b4fd7f8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_762ded0c-d386-4430-8d15-93a618195f36_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e2bb8678-cbd2-490b-a74d-ee82bbba99b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_667b4575-beca-401e-84f1-d3e8dc066c86_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e7f39391-c81c-4ee7-b96c-b924e3d9322e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_d2b46620-8c7f-47f6-a09d-57ac6144a6f7_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20230331.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_11ee3001-dccc-41b6-a129-c610999c817e_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20230331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_ee4369dd-a469-4153-9013-3344c79546f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_0558e154-ff32-4dd0-aeb6-e74ceabd6a3c_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_0c93222a-73fc-459f-9e54-9db4bda2a893_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20230331.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5ed5eae6-c4d9-4167-99e0-9ba7e13a6946_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_dac59ca7-f837-4a8b-b495-7b9d39395613_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_58914bef-d1c4-491c-a382-919cea330e4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_56513994-73ec-463a-b99f-eea97c9e273a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionShareExchangeRatio_b66e6afd-927f-40dc-b905-779c62ac8997_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Exchange Ratio</link:label>
    <link:label id="lab_amed_BusinessAcquisitionShareExchangeRatio_label_en-US" xlink:label="lab_amed_BusinessAcquisitionShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Exchange Ratio</link:label>
    <link:label id="lab_amed_BusinessAcquisitionShareExchangeRatio_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionShareExchangeRatio" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionShareExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionShareExchangeRatio" xlink:to="lab_amed_BusinessAcquisitionShareExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_68876b79-8dbe-4488-9ef8-4f832509e303_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_3da91be2-a975-436a-89a6-2c2a6c780408_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_be157589-a693-4298-8164-ad0d83e56cfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_ff4c0b1c-d39c-4c88-99c2-6452974c06a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_7649e527-e9f7-448b-884b-827bad9796cc_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20230331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_50b5082e-4fe5-436f-9c17-7c2f3d1d4a8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_e35bcd63-49ea-49a4-835a-006c08f71ef6_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_4106879c-ca6a-4f93-be90-c18d02c003cc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_e680e46a-17dc-4a83-b8aa-0ebcd4b1bf46_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20230331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_f153f79c-3d89-49ad-a289-4afab8dfe37a_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20230331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_0e326ee9-3b8b-42e6-97cb-056ee04a63ad_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4eac8dc6-d832-4f76-9ba1-49c9ae40a682_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_91611089-9b0f-4af1-af50-50197bd55a2b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2d75bda0-502b-4a47-a761-ecf7f236fdc2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_7c6cfcd0-b735-4ca4-bc61-f6232e62abc0_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_bfcf397b-31aa-45b2-a11d-f33953423946_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_e3b2ae93-9667-4b85-bb55-908efa502d19_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20230331.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b851646-95e5-4278-b338-91bd7a677b98_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e11aee4d-de69-4b83-86de-1777aef5d346_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_500c26bc-81b5-4aa1-a456-4f2c7b99c0a3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Discountedclosingstockprice_b014d97d-4ecd-4e89-83cc-034ac50a01ea_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice" xlink:href="amed-20230331.xsd#amed_Discountedclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice" xlink:to="lab_amed_Discountedclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cc78d28b-a40d-4dc5-b587-db52568bfe8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_87ace934-b9a9-46e7-8bc2-42b72b990b73_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_e7bd21b7-4c09-46c1-954c-f8578016d881_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20230331.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c71cb1-3050-40c4-a8d0-66af2fe6708b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ce390da2-f5dd-4a9a-8ac4-606fda25b9b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b301620f-ee03-484f-8d96-8b2185bd47c2_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_651bfe21-9b7e-4437-815a-a2cf2110506d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_7e65b26a-2070-49fe-b5c4-12d60dc41943_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_02689a6a-a0b1-4cf7-bb63-6277d10479b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_066b5b90-753b-4593-bfb8-45b76b0e78df_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20230331.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9722bf62-a836-4e1b-863a-db5010a0f540_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_68843b99-b536-416c-bf19-340761873d69_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_3891d14b-1ddc-41f6-906d-c89fa6795fff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fc225536-40cc-41c9-bb9c-7a326b6e8fb3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d87a6e41-0cfb-4232-954d-a3c9e38d37c0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $16,071 and $14,604</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_06c527c8-3b36-4ec3-a331-40a06edc3e5c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_06d1cfb1-626b-4ddb-921b-c30c63493c31_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_96308484-5e6d-4c40-b3ac-8823c1a54f08_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33a7c54a-afbb-44aa-bd95-e6c724cb30d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_23c5ee5b-b274-466c-8a87-8744ef01a48e_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20230331.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_77a5e1b2-0ada-43ae-b104-e623db239e9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d6ed3ac9-42a3-4e92-85e0-53d371c382fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_6f7b95ab-669f-42cd-a155-296085f4b8fb_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20230331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f6bb6f1b-f013-43a5-8361-6ac73fcd802e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_bf91ff7e-38bf-446b-9ccb-4eb3375e8f69_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e3c1f5e0-cb4d-402b-b520-3d4e88adee29_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSITIONS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_a976571b-324f-4bea-aa90-999ec9b68fa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_a8af74c5-bcb1-4722-b695-da893d2f3a51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in technology assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_0b1c3206-92d9-499d-998f-8cd6dac2f10f_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_77a3aae8-3c83-4399-9906-4315b85fda84_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_707860f0-f418-4b41-8e4e-cbbdea583c87_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20230331.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_bdc35dbe-dfa0-4b13-b3b9-d5425bb164d1_terseLabel_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember" xlink:href="amed-20230331.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2023ShareRepurchaseProgramMember" xlink:to="lab_amed_A2023ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7d28f7d3-cc1a-4041-af9d-855d529752be_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_5c1d9bbf-55aa-4012-8c68-66bfd0f9c492_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0b75882a-8ef4-4238-86a8-ac18efdae555_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c442f2af-f778-43b4-9f6b-3c3d581503dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e35bbdd4-83f1-48b4-93fd-85dfb90c5541_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_95ad5d28-4d52-47ac-b10e-efac059ab383_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_6bc8cd02-bc65-44af-9d35-c5713ed5bcc8_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20230331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7409cba4-6064-4a77-830a-17b242d1c8e0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_fb0f4d7e-92fe-4b5a-9ca0-5ae7b463b103_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d4a6c9bd-ffb1-4fd7-9b61-75c5f7de7160_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_09cefe79-cee5-418b-8136-d617908ff8bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_e8211758-6928-4f55-b70a-86ebc1b1a6f3_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4aa4c4b7-7336-419e-aca6-cdb4a7d7ca91_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e15fb374-f9be-4036-84c2-71d2fac39217_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_084e6187-ea23-4ac7-83c7-1d775db1e712_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_4278556c-bb45-4cfa-a8a8-365ca9ec4b7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a1a67462-e112-4cde-ab80-c48335cc6a4b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_f90a54f3-4894-4e66-b27f-54cd5e263b04_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_3b651903-985d-4154-a30c-c87370bf569f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_d3fc790d-7001-4611-8ed5-1f1f48457e90_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19PPEMember_5f2d53f4-e8a1-4b6b-a839-5064aeacd3de_terseLabel_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_label_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_documentation_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember" xlink:href="amed-20230331.xsd#amed_COVID19PPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19PPEMember" xlink:to="lab_amed_COVID19PPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_fb26dfcc-3b6e-4142-9a89-d79b5ad75437_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20230331.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bbf996a9-350e-4cb3-ad5d-ab2491da5a4d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_a2e00388-b024-441c-a911-2d54e0004a48_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_95e09527-6f03-473e-8311-be997bb06448_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_dcda1835-1bab-460b-9b47-869b3c8810bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_cc6a2659-e639-46b8-89ef-16e11f15d18a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6936d121-7e3a-4483-be2b-183ab4008fbf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_e379ca5a-91c9-47ca-b44e-697b8bfde66e_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_46848b8a-d421-48ee-92e4-231bff311d9f_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_174128ad-51e5-469e-a8da-7ceb8645a12c_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Lease Contract [Member]</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_304e11f8-2d7a-4c81-8464-c500dc5eaf3f_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfJointVentures_d32445e2-f537-4339-8feb-e15277c28dfb_terseLabel_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_label_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_documentation_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of joint ventures owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures" xlink:href="amed-20230331.xsd#amed_NumberOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfJointVentures" xlink:to="lab_amed_NumberOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_3c5125e9-834d-41c8-84e5-ab8bace9fe22_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_f926a697-2c8d-4aad-8e15-bd0f8c89b91a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_2f5f1566-d658-4598-aabf-d79189c3e2c3_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of equity assumed at the acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_3de79979-90bb-474b-ba5e-479a68b63b3c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_5a63897c-da85-4387-ba66-70ddc782b043_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_4f8c80aa-faca-4be2-b0cf-016b894cc6e8_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20230331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ee954b9c-b394-44b3-bb73-39bd6aba01b2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_d8a7cdb1-5e81-4e9f-a84a-6d86c2ce62bf_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20230331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57a03ef4-d86a-42b4-b5e5-368d4ebf27a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_af281269-55ba-4194-9957-5b480e5c50f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_5ee3dc29-4016-41dc-a704-a21e95bbd192_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_d3665819-4ad6-4038-ab79-e69464ecc5c2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_aa08208b-62e4-4fb5-9b02-6777c1c3be54_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fa53a6d2-20b6-4aaf-ad10-b8c23c5741f5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_4edfacac-b513-47bb-ab86-4fe42a94b6aa_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20230331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_345ccb81-1c88-422a-9381-da18c20eab79_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6860abca-26fd-4cff-a8d6-edcc962c3717_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_96f9dbb4-389d-4b50-ae4a-34c790e35aef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb22895-8b5b-4e2a-9374-cb7b520ef0b0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a190f3ba-82d0-44fe-b81e-36f745b1bd72_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_c9fb2e06-e657-40b7-9988-3d3b2255cbc9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_99c5fb18-a54a-4127-88aa-d074f6e14644_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_80ff0c94-5b27-46e6-a7e2-78fac89b4157_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e1f94485-d3ce-48e3-a603-3213833d0ef7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_6da72e2f-3bad-4a37-a6af-04da192a5e22_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20230331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b958d5b2-6d57-4387-ba82-2d22bce71dba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c1ad4cce-7278-4a74-87b5-d7e9b79c214c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4a46eefc-38cf-4209-aad4-05f5dd6c99e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (earnings) loss from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofclosingstockprice_77f92edd-d751-4c44-8881-9b18e41b3176_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice" xlink:href="amed-20230331.xsd#amed_Percentageofclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice" xlink:to="lab_amed_Percentageofclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0dfb5f2a-8db8-498b-9b26-45eec92f5711_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_9824ac2d-af62-49bc-82af-83a4c61aea42_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_8300fc13-53b6-41b8-9d82-3e1b5b88a3e9_terseLabel_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services</link:label>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_label_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services</link:label>
    <link:label id="lab_amed_AcutePhaseForHighAcuityCareServices_documentation_en-US" xlink:label="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices" xlink:href="amed-20230331.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcutePhaseForHighAcuityCareServices" xlink:to="lab_amed_AcutePhaseForHighAcuityCareServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_07f49477-feb8-48da-9586-d5db010b4874_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_97158a11-4a7b-4599-ac97-578ea9639ec7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_c5725a18-a1c4-4edf-a93d-3e082bec1711_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_label_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents that amount of noncontrolling interest acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:href="amed-20230331.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:to="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>amed-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5fc9fd41-515c-4abe-9cff-e304f01f271f,g:64db64d4-b246-4708-ae62-d92e1d2ff13c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f0b87d64-6d8a-434e-836c-441a978ab5a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentType_f0b87d64-6d8a-434e-836c-441a978ab5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_75782416-1cc9-4255-a8fc-b3bfeb61e53e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentQuarterlyReport_75782416-1cc9-4255-a8fc-b3bfeb61e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_10f0a72a-9df6-4bf0-878f-01ed3697dea8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentPeriodEndDate_10f0a72a-9df6-4bf0-878f-01ed3697dea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_355c5d13-fa9b-4eb8-a56d-1a43e7cf5cfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentTransitionReport_355c5d13-fa9b-4eb8-a56d-1a43e7cf5cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6a568a68-3b21-49fc-aaee-9348fb460657" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityFileNumber_6a568a68-3b21-49fc-aaee-9348fb460657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3bbb6884-c92b-408f-b773-94166c446688" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityRegistrantName_3bbb6884-c92b-408f-b773-94166c446688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ab568ca8-ac09-4848-a511-b76105cd0c29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ab568ca8-ac09-4848-a511-b76105cd0c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_eb52f01e-ba63-47e5-a0a4-15958cd94a33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityTaxIdentificationNumber_eb52f01e-ba63-47e5-a0a4-15958cd94a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4f0ea7e1-ba72-4b5e-8429-19c73f109b5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityAddressAddressLine1_4f0ea7e1-ba72-4b5e-8429-19c73f109b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c541cd42-8196-4ffc-a8ec-f6574060e003" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityAddressAddressLine2_c541cd42-8196-4ffc-a8ec-f6574060e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_53d7b474-661f-4664-b0c8-9e6ad5404af5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityAddressCityOrTown_53d7b474-661f-4664-b0c8-9e6ad5404af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f0cc8cd5-3e31-4782-99a2-a781695289bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityAddressStateOrProvince_f0cc8cd5-3e31-4782-99a2-a781695289bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_00be42db-5a0c-4aeb-8ad1-12edd7093fc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityAddressPostalZipCode_00be42db-5a0c-4aeb-8ad1-12edd7093fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91364b18-360b-4361-846c-927cb5781ea8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_CityAreaCode_91364b18-360b-4361-846c-927cb5781ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_77a95511-6b99-4a2f-8b36-94a20fd43152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_LocalPhoneNumber_77a95511-6b99-4a2f-8b36-94a20fd43152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8ec2a761-f37c-4340-8e01-64fdd51954db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_Security12bTitle_8ec2a761-f37c-4340-8e01-64fdd51954db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_caea2342-23a2-48ea-889b-f2c895c95589" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_TradingSymbol_caea2342-23a2-48ea-889b-f2c895c95589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a44b1f7b-fbc7-4f73-b77f-35c330a6e540" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_SecurityExchangeName_a44b1f7b-fbc7-4f73-b77f-35c330a6e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5180a997-6edb-41ce-bdda-f4d25bd91831" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityCurrentReportingStatus_5180a997-6edb-41ce-bdda-f4d25bd91831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_098bf661-be68-4ce8-9ee5-2d7bc77fb35f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityInteractiveDataCurrent_098bf661-be68-4ce8-9ee5-2d7bc77fb35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8b02b59b-fda8-43b6-8300-b62cadaba098" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityFilerCategory_8b02b59b-fda8-43b6-8300-b62cadaba098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0e6f8d02-ddcd-4fb9-9821-a60654e7b54d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityEmergingGrowthCompany_0e6f8d02-ddcd-4fb9-9821-a60654e7b54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c03e9624-a554-43df-9e44-674a966d56ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntitySmallBusiness_c03e9624-a554-43df-9e44-674a966d56ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bada0c9f-90fe-4c07-880b-4fdc92b06f17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityShellCompany_bada0c9f-90fe-4c07-880b-4fdc92b06f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_42f9ab01-1096-4265-9998-45d2315ab11f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_42f9ab01-1096-4265-9998-45d2315ab11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6cf0a139-6af8-46e6-9cb1-e2a7c133a1e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_AmendmentFlag_6cf0a139-6af8-46e6-9cb1-e2a7c133a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a9b29c50-c443-4323-af92-6ef49890b773" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentFiscalYearFocus_a9b29c50-c443-4323-af92-6ef49890b773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_22382eb9-152f-4ab4-8104-0957bab27e2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_22382eb9-152f-4ab4-8104-0957bab27e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0d45001a-2512-48b3-8191-f5b571480262" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityCentralIndexKey_0d45001a-2512-48b3-8191-f5b571480262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9d8c9b25-19a5-4314-8895-2e13558606ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_CurrentFiscalYearEndDate_9d8c9b25-19a5-4314-8895-2e13558606ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_552747f5-fa42-4f95-9506-5174cb687925" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityVoluntaryFilers_552747f5-fa42-4f95-9506-5174cb687925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_21f1e25c-50fe-4b4f-91ea-d734d7cca95c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0af49a52-58b2-4d59-8f70-ae84b84784e9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_21f1e25c-50fe-4b4f-91ea-d734d7cca95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_229c0f25-7913-423d-b4e3-941cc21e60e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_229c0f25-7913-423d-b4e3-941cc21e60e9" xlink:to="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8be8e443-9317-48da-b3c4-7c8ebc8f90a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8be8e443-9317-48da-b3c4-7c8ebc8f90a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7131f180-f86e-435a-b91e-26e44e8d9e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_RestrictedCash_7131f180-f86e-435a-b91e-26e44e8d9e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d1149c85-f1c5-4ecc-ae53-3ab64bd9b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d1149c85-f1c5-4ecc-ae53-3ab64bd9b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_11f06a50-dcc9-4f6e-b200-0af5402bd6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_11f06a50-dcc9-4f6e-b200-0af5402bd6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3b71d8cb-2e60-4c4b-bc9e-6d26e60d0c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_OtherAssetsCurrent_3b71d8cb-2e60-4c4b-bc9e-6d26e60d0c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0733629d-1d5b-427b-988e-434986729212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15da4d89-6df9-421e-8cca-48c0b8e36870" xlink:to="loc_us-gaap_AssetsCurrent_0733629d-1d5b-427b-988e-434986729212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e2a9d63-f3a6-4219-a340-64bc29b0126e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2e2a9d63-f3a6-4219-a340-64bc29b0126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_61d002db-4367-4ca1-903e-e112f16a14ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_61d002db-4367-4ca1-903e-e112f16a14ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b6e1dd90-3367-4bf2-95e4-a2c816f05199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_Goodwill_b6e1dd90-3367-4bf2-95e4-a2c816f05199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ecd296c5-6e2d-4151-bd6b-0c5df11bd6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ecd296c5-6e2d-4151-bd6b-0c5df11bd6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d7d29be9-249c-4543-995c-cd2f91e7e17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d7d29be9-249c-4543-995c-cd2f91e7e17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_37f6a9b6-a0f8-4165-9e7d-4e88ce64a26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f7e953-d928-4bc6-a9ce-eedc8aadc393" xlink:to="loc_us-gaap_Assets_37f6a9b6-a0f8-4165-9e7d-4e88ce64a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_229c0f25-7913-423d-b4e3-941cc21e60e9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_54be7ccc-c204-4c85-91a2-dbfc72939ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_AccountsPayableCurrent_54be7ccc-c204-4c85-91a2-dbfc72939ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_358be92d-8901-4200-9f01-dd7aa2b29c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_358be92d-8901-4200-9f01-dd7aa2b29c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_24d09407-7295-473f-84b7-bb727a74e518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_24d09407-7295-473f-84b7-bb727a74e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_dc6b7bc6-9c06-4c75-81b7-4f92db4bd99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_dc6b7bc6-9c06-4c75-81b7-4f92db4bd99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b95fbd62-b8f3-4970-9e48-97f32a95e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b95fbd62-b8f3-4970-9e48-97f32a95e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5defafca-d2bb-477e-b01d-020ab707e03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6878c3b0-6582-4a01-b259-4199d0fceb73" xlink:to="loc_us-gaap_LiabilitiesCurrent_5defafca-d2bb-477e-b01d-020ab707e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9d8f8ae3-9f18-4e69-a4bf-31f4341b10b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9d8f8ae3-9f18-4e69-a4bf-31f4341b10b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fea764eb-74a0-4d89-96b6-3ad0623bd6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fea764eb-74a0-4d89-96b6-3ad0623bd6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55d26796-b009-4dbe-9d2d-cd50e7dc1b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55d26796-b009-4dbe-9d2d-cd50e7dc1b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64372ed5-4bcb-4266-b2fb-3ab313da55b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64372ed5-4bcb-4266-b2fb-3ab313da55b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af83df8f-de24-477d-b019-729766d8c17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_Liabilities_af83df8f-de24-477d-b019-729766d8c17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_70813ffa-50c2-4602-8672-2749c22ab055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_CommitmentsAndContingencies_70813ffa-50c2-4602-8672-2749c22ab055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_50a35696-b56b-4f9c-9e0b-d3a9128bc334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_50a35696-b56b-4f9c-9e0b-d3a9128bc334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_e9aa8125-7d7e-4ea9-a5da-37086ecc94da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_e9aa8125-7d7e-4ea9-a5da-37086ecc94da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_17bde551-1aa8-479b-a871-530c04b0af86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_17bde551-1aa8-479b-a871-530c04b0af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_339776c6-3af7-42af-8588-50f73030c6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_TreasuryStockValue_339776c6-3af7-42af-8588-50f73030c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_75c62030-4c8b-4040-8088-f08d4a28641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_75c62030-4c8b-4040-8088-f08d4a28641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36008ecd-bdb4-415b-bc71-e8e546ddef1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_StockholdersEquity_36008ecd-bdb4-415b-bc71-e8e546ddef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2d6383e0-b57a-4f96-a3f4-757df8500084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_MinorityInterest_2d6383e0-b57a-4f96-a3f4-757df8500084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066d878e-a900-44a8-adae-b242a3c15b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f43d02f-a87e-4572-a72e-ec09e0031e8f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066d878e-a900-44a8-adae-b242a3c15b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85a860e4-3201-468f-b4f6-1afca07c40a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a4e4445-2326-4dfd-906d-bda01482f944" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_85a860e4-3201-468f-b4f6-1afca07c40a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a680dd-030d-4da4-91d7-3859fe3326e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a680dd-030d-4da4-91d7-3859fe3326e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_85c22a27-2bb7-4def-bca2-c083ea7eae64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_85c22a27-2bb7-4def-bca2-c083ea7eae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7ccd63c6-8ad7-45d0-8576-723afb8f6b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7ccd63c6-8ad7-45d0-8576-723afb8f6b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d44e5f1b-c84c-4a80-b06d-aa25d42937b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d44e5f1b-c84c-4a80-b06d-aa25d42937b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e61a3a9a-9417-4adb-b2dd-872b0e185eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e61a3a9a-9417-4adb-b2dd-872b0e185eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f94ad01c-2d74-45bd-ab40-c944cd56a319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f94ad01c-2d74-45bd-ab40-c944cd56a319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_afa22430-9e8d-4379-9386-025e6140fa55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_afa22430-9e8d-4379-9386-025e6140fa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a9ea4e2d-5ebf-4245-a711-bd05d0574521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a9ea4e2d-5ebf-4245-a711-bd05d0574521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_81c4203b-0a63-418d-8b35-d5b694b79b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_CommonStockSharesIssued_81c4203b-0a63-418d-8b35-d5b694b79b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ad3d85fd-c639-43b5-a785-e0b30be0530a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ad3d85fd-c639-43b5-a785-e0b30be0530a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b1a4c1d5-0340-4f92-a469-6458b693e080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0680dd28-0e82-415f-b445-c5b76afa0ba2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b1a4c1d5-0340-4f92-a469-6458b693e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDINCOMESTATEMENT"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_458edf20-216d-457b-a901-68f32e25ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_458edf20-216d-457b-a901-68f32e25ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5aea266e-0943-4421-8b24-179c1259694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5aea266e-0943-4421-8b24-179c1259694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1318aa03-c5cf-449b-a034-60343118f1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1318aa03-c5cf-449b-a034-60343118f1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_6d089b17-3e58-4995-b476-cf0fafca748b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_6d089b17-3e58-4995-b476-cf0fafca748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1f5533ca-3252-475c-93b8-89f9454250ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:to="loc_us-gaap_ShareBasedCompensation_1f5533ca-3252-475c-93b8-89f9454250ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d8af2669-c2dd-42e3-88fe-6a49070d3400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:to="loc_us-gaap_DepreciationAndAmortization_d8af2669-c2dd-42e3-88fe-6a49070d3400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7c1f1656-6a3e-4192-a2aa-ecbe3b332873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_ca88fdb0-8b29-49d9-955b-3f7965610e3e" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7c1f1656-6a3e-4192-a2aa-ecbe3b332873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e4e5f3bf-ebff-45fb-ba8a-d9246f47973f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_CostsAndExpenses_e4e5f3bf-ebff-45fb-ba8a-d9246f47973f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f353143d-ba32-41a4-b4ff-771063122617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_OperatingIncomeLoss_f353143d-ba32-41a4-b4ff-771063122617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_110db885-1df8-4fea-afeb-f2e83ec4424d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_110db885-1df8-4fea-afeb-f2e83ec4424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_01b69348-cad1-416b-beac-4b120ad815ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:to="loc_us-gaap_InterestExpense_01b69348-cad1-416b-beac-4b120ad815ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b80c0bba-b022-4270-bd1e-e6dbabbad2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b80c0bba-b022-4270-bd1e-e6dbabbad2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0bc5a2e8-c531-46c3-b474-492cc6361542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0bc5a2e8-c531-46c3-b474-492cc6361542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7e42bf5d-7482-427e-8626-07e0ba4d977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9a56b8e2-a085-47d9-9141-1c9c04a83365" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7e42bf5d-7482-427e-8626-07e0ba4d977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f4b8b6c3-82cf-45db-b432-52a07f31842e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f4b8b6c3-82cf-45db-b432-52a07f31842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3eee1ece-3ce5-4fb2-aeac-efc252d8d914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3eee1ece-3ce5-4fb2-aeac-efc252d8d914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_02c455a7-c5a2-4e5e-91e5-e9a59073fea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_ProfitLoss_02c455a7-c5a2-4e5e-91e5-e9a59073fea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3dc57f70-edcb-41f2-97df-c8c5132c8a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3dc57f70-edcb-41f2-97df-c8c5132c8a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55aed772-2881-41cb-87fa-a73a729c00d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_NetIncomeLoss_55aed772-2881-41cb-87fa-a73a729c00d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_6ffe69f1-c2e5-47d8-a804-6aa619381677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_6ffe69f1-c2e5-47d8-a804-6aa619381677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a376d6b5-c84b-4c82-88c5-b7dd4f4457e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6ffe69f1-c2e5-47d8-a804-6aa619381677" xlink:to="loc_us-gaap_EarningsPerShareBasic_a376d6b5-c84b-4c82-88c5-b7dd4f4457e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbd523d6-d73b-493e-bb66-cd2186bb1098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6ffe69f1-c2e5-47d8-a804-6aa619381677" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbd523d6-d73b-493e-bb66-cd2186bb1098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_76c7d6c1-b840-4408-9d2e-95497c95bbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76dbd1d2-1d9e-4580-b397-d75530ab6d12" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_76c7d6c1-b840-4408-9d2e-95497c95bbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_00f86040-0b0a-46a2-9aca-e387eb968fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_76c7d6c1-b840-4408-9d2e-95497c95bbff" xlink:to="loc_us-gaap_EarningsPerShareDiluted_00f86040-0b0a-46a2-9aca-e387eb968fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f4624b5-909a-4d55-92fc-f0aa265c1595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_76c7d6c1-b840-4408-9d2e-95497c95bbff" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f4624b5-909a-4d55-92fc-f0aa265c1595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d534d87a-587f-4f5a-a1d8-896cc3eb4e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d534d87a-587f-4f5a-a1d8-896cc3eb4e00" xlink:to="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e338ac5-deb2-42fa-8624-05d3c30c1fee" xlink:to="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef7ea8fc-1db2-4874-9d58-d5bff8831986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_CommonStockMember_ef7ea8fc-1db2-4874-9d58-d5bff8831986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1fd1d6fe-9460-4ad6-9ba9-32853c898f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1fd1d6fe-9460-4ad6-9ba9-32853c898f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1537b906-9482-4729-a6ee-8a5846fc5992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1537b906-9482-4729-a6ee-8a5846fc5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f81d9c0c-be48-48be-8f43-0d47930e8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_RetainedEarningsMember_f81d9c0c-be48-48be-8f43-0d47930e8cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db088952-4f57-4178-b7c2-11970e282736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db088952-4f57-4178-b7c2-11970e282736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_e447e9bb-f059-4819-9d90-dc5c16988aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31b306c7-8de0-4ee6-b188-eea7f94bd264" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_e447e9bb-f059-4819-9d90-dc5c16988aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bab35771-6921-488c-b234-9596e089dc21" xlink:to="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a22d8736-c1c6-4cd9-a8fe-71c2de537724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a22d8736-c1c6-4cd9-a8fe-71c2de537724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_05110fe6-2284-45d8-b2ad-a4d448751de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_SharesOutstanding_05110fe6-2284-45d8-b2ad-a4d448751de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_52a8eb27-ce11-4049-b2ac-f11ee12ade45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_52a8eb27-ce11-4049-b2ac-f11ee12ade45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee4f94d5-25df-4614-af8c-10f7d838188d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee4f94d5-25df-4614-af8c-10f7d838188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_64abfa27-6fef-41bd-8eab-298726a36ea1" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_64abfa27-6fef-41bd-8eab-298726a36ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_7285c63f-c9c6-4aba-8008-5a6690033600" xlink:href="amed-20230331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_7285c63f-c9c6-4aba-8008-5a6690033600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_57d0c716-87ca-4aa4-853e-5c439096e733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_57d0c716-87ca-4aa4-853e-5c439096e733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0eae493f-d294-4a18-9afd-82e240e249a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0eae493f-d294-4a18-9afd-82e240e249a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_48606b02-d26d-4ffa-85b0-f57ac43f9de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_48606b02-d26d-4ffa-85b0-f57ac43f9de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7d420a9-270f-420c-b1b8-9c8de85d1295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7d420a9-270f-420c-b1b8-9c8de85d1295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a7b6f462-c83c-4120-9c3e-392bfe9e9227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a7b6f462-c83c-4120-9c3e-392bfe9e9227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_83c8b70f-7f7c-4e00-8ea8-a6d860cf2e47" xlink:href="amed-20230331.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_SurrenderedShares_83c8b70f-7f7c-4e00-8ea8-a6d860cf2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_6aef5ea4-e597-4fb9-802e-a61429e3ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_6aef5ea4-e597-4fb9-802e-a61429e3ed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_99d01edf-0e92-4f6f-b3cd-d40f4b5d338c" xlink:href="amed-20230331.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_99d01edf-0e92-4f6f-b3cd-d40f4b5d338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ff276c66-5c97-4206-a4f1-9277a1ffe4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ff276c66-5c97-4206-a4f1-9277a1ffe4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_ae202c4f-26f2-426e-a4ff-c853cddc8cc7" xlink:href="amed-20230331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_ae202c4f-26f2-426e-a4ff-c853cddc8cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_286fcc95-bf69-4b82-a817-a2d9913e5652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_ProfitLoss_286fcc95-bf69-4b82-a817-a2d9913e5652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_809579fb-c197-43a2-ab1d-8439a274a54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_809579fb-c197-43a2-ab1d-8439a274a54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e7653580-c62b-4ba6-a83d-21f3270ba0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23b4d2c4-574c-49c6-85dc-d2c7036eebad" xlink:to="loc_us-gaap_SharesOutstanding_e7653580-c62b-4ba6-a83d-21f3270ba0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f060ce8-305c-4d60-b72c-dc07d67e6f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f060ce8-305c-4d60-b72c-dc07d67e6f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_026dd421-ccad-4447-b9d2-9f13d0578fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f060ce8-305c-4d60-b72c-dc07d67e6f17" xlink:to="loc_us-gaap_ProfitLoss_026dd421-ccad-4447-b9d2-9f13d0578fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f060ce8-305c-4d60-b72c-dc07d67e6f17" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0196041d-8164-4898-96b2-76fdc2d0135c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0196041d-8164-4898-96b2-76fdc2d0135c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d53e3078-59da-40e0-bdd2-3b3c9ca1726b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_ShareBasedCompensation_d53e3078-59da-40e0-bdd2-3b3c9ca1726b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_e70a1fcd-8fd8-4e36-9acf-b4e95b127826" xlink:href="amed-20230331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_e70a1fcd-8fd8-4e36-9acf-b4e95b127826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ca0f0be6-059d-46e9-9a5a-67ece2737de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ca0f0be6-059d-46e9-9a5a-67ece2737de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_14f0a36d-86b8-40da-88c0-e3b2ba857a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_14f0a36d-86b8-40da-88c0-e3b2ba857a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b1450585-f7b5-4875-a70b-e0ef208c6326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b1450585-f7b5-4875-a70b-e0ef208c6326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f503f913-2f02-4a8c-8286-2a8748f8723e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f503f913-2f02-4a8c-8286-2a8748f8723e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_dc2cb39e-6b0e-4f2f-836b-d29af6ce89bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_dc2cb39e-6b0e-4f2f-836b-d29af6ce89bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_702edf9d-e714-4069-b1a8-e3568edafbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_702edf9d-e714-4069-b1a8-e3568edafbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3de53897-cba5-4c80-a96c-86d23e099667" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3ce1afac-9dfc-4383-8503-efa48ed6b872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3ce1afac-9dfc-4383-8503-efa48ed6b872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e509dfe3-8693-4e5e-aeca-91c408ecde20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e509dfe3-8693-4e5e-aeca-91c408ecde20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b2721ca9-2342-4c70-9412-e9fc47a806ac" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b2721ca9-2342-4c70-9412-e9fc47a806ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5604ffd8-15c3-4ef9-93e7-442bf5309517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5604ffd8-15c3-4ef9-93e7-442bf5309517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_83ec2150-69e9-44f0-b328-02d722da9601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_83ec2150-69e9-44f0-b328-02d722da9601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_403f4d3a-2f41-4901-95c0-bc4f49f4164d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_403f4d3a-2f41-4901-95c0-bc4f49f4164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_07329e9d-e41c-4483-8bb7-e90e43e311e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_07329e9d-e41c-4483-8bb7-e90e43e311e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c286ca71-5566-4971-a42d-81934aeee833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3816be46-b153-45ac-8740-ea202346fa46" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c286ca71-5566-4971-a42d-81934aeee833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1218a50-c67d-4e66-9f96-16e1c52a49fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f060ce8-305c-4d60-b72c-dc07d67e6f17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1218a50-c67d-4e66-9f96-16e1c52a49fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b409f885-bbf6-4a0f-a124-9dab33bc2ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b409f885-bbf6-4a0f-a124-9dab33bc2ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e925d748-75a7-4a11-87ec-a898ea4dcff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e925d748-75a7-4a11-87ec-a898ea4dcff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95a827e1-4ef5-4e34-a071-cf4e72998776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95a827e1-4ef5-4e34-a071-cf4e72998776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_4869d9f3-79c9-44b1-b321-24f1c1df0244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_4869d9f3-79c9-44b1-b321-24f1c1df0244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_2b02482d-af1e-4de4-acb5-469642783725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_2b02482d-af1e-4de4-acb5-469642783725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_fe79080d-904b-42e4-9d3e-a50e0c5d04af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_fe79080d-904b-42e4-9d3e-a50e0c5d04af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3828769e-b4f7-4d36-82f2-663a969b17fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3828769e-b4f7-4d36-82f2-663a969b17fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7369dc5-14f8-480c-91ac-8618bd81e1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_795f2941-cd43-42c8-a5fb-dbd3db38a8e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7369dc5-14f8-480c-91ac-8618bd81e1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3e9d663b-34a8-41e3-b996-a61e755e328b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3e9d663b-34a8-41e3-b996-a61e755e328b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ace83e57-7284-4df1-8c8f-950f90a0b3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ace83e57-7284-4df1-8c8f-950f90a0b3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_44fae6d0-db1e-40b4-a205-032e51cf101d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_44fae6d0-db1e-40b4-a205-032e51cf101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_905a3a71-f520-4394-8e9c-1fa593468992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_905a3a71-f520-4394-8e9c-1fa593468992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_71249a6c-4547-41db-a132-df4e968abbe4" xlink:href="amed-20230331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_71249a6c-4547-41db-a132-df4e968abbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9d096d79-a4bb-4478-8fc4-9470f10c9c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9d096d79-a4bb-4478-8fc4-9470f10c9c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_1253c629-a0f9-4478-ac6e-3aafb7176044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_1253c629-a0f9-4478-ac6e-3aafb7176044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ea95cabd-1974-4345-bd89-8204f83ceb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ea95cabd-1974-4345-bd89-8204f83ceb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_eaa9e1fb-adaa-4a85-a7fa-77e0844cd6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_eaa9e1fb-adaa-4a85-a7fa-77e0844cd6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd6947b-0b9c-4a7a-8cb4-73c6f549347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7bd505f-372d-4213-8c5e-9256c9846959" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd6947b-0b9c-4a7a-8cb4-73c6f549347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_fa029284-f7de-4b03-8f2e-2ed4e044fc86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_fa029284-f7de-4b03-8f2e-2ed4e044fc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b53210ba-75da-42c3-ba64-fc664d2ad391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b53210ba-75da-42c3-ba64-fc664d2ad391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2305459-934c-4e04-be05-428b112e00f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2305459-934c-4e04-be05-428b112e00f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_741d16e9-432d-45cb-9e94-1ef3d2c5d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:to="loc_us-gaap_InterestPaidNet_741d16e9-432d-45cb-9e94-1ef3d2c5d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_eddc67b4-8860-4ba7-a69c-7bd9b8ee5ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_eddc67b4-8860-4ba7-a69c-7bd9b8ee5ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities_4bb89aa3-85d7-4313-a592-ffd2f0d8d908" xlink:href="amed-20230331.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:to="loc_amed_CashPaidForOperatingLeaseLiabilities_4bb89aa3-85d7-4313-a592-ffd2f0d8d908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities_c2f28ba4-d32c-413f-a769-b31e55448f04" xlink:href="amed-20230331.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d366e44b-617d-425e-8c11-c7ceec20425c" xlink:to="loc_amed_CashPaidForFinanceLeaseLiabilities_c2f28ba4-d32c-413f-a769-b31e55448f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee7406c7-019e-4a33-b6a8-7c5fb5b12c8d" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a088577e-cf48-4821-982a-b122f0a7cf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a088577e-cf48-4821-982a-b122f0a7cf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_44c44e03-b684-4d34-afed-ba0a879992a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_44c44e03-b684-4d34-afed-ba0a879992a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_ec8ed0b1-58d8-4a5e-9c6f-d3f10b0adba6" xlink:href="amed-20230331.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_ec8ed0b1-58d8-4a5e-9c6f-d3f10b0adba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations_88375ce2-379d-4f82-86c6-6af4f9cd9b2d" xlink:href="amed-20230331.xsd#amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:to="loc_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations_88375ce2-379d-4f82-86c6-6af4f9cd9b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution_e3f1325c-986a-4db1-9dfd-c4c37762d6ff" xlink:href="amed-20230331.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4201e3cb-ae5f-4fde-936d-e0aed5f1c410" xlink:to="loc_amed_NonCashNoncontrollingInterestContribution_e3f1325c-986a-4db1-9dfd-c4c37762d6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20230331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_287a2910-f082-4d31-a21b-7520b44572a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5907ebe7-2f3f-490a-b842-35053e5182d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_287a2910-f082-4d31-a21b-7520b44572a2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5907ebe7-2f3f-490a-b842-35053e5182d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e72052e-6d31-47be-8c0f-a010f696af25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_21800e30-b6e9-4957-8fa3-e4e59f987973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e72052e-6d31-47be-8c0f-a010f696af25" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_21800e30-b6e9-4957-8fa3-e4e59f987973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INVESTMENTS" xlink:type="simple" xlink:href="amed-20230331.xsd#INVESTMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INVESTMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_570ca66f-79d7-4bcf-b38b-c11c6f525232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_47accb36-ad6c-4b69-bc37-28aac1ee8de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_570ca66f-79d7-4bcf-b38b-c11c6f525232" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_47accb36-ad6c-4b69-bc37-28aac1ee8de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_525e2d64-e57b-4973-b32a-6d1efcff3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f405cdc3-e5d2-4934-bd46-4ac2a4a3b217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_525e2d64-e57b-4973-b32a-6d1efcff3723" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f405cdc3-e5d2-4934-bd46-4ac2a4a3b217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DISPOSITIONS" xlink:type="simple" xlink:href="amed-20230331.xsd#DISPOSITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DISPOSITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_133936d3-c312-4246-8e3d-134ec27b99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_400359b5-bf2f-4e15-be6a-2a51b8954a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_133936d3-c312-4246-8e3d-134ec27b99ed" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_400359b5-bf2f-4e15-be6a-2a51b8954a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c63e0d31-e396-4fcb-a255-a52d2eeff5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d5ae236c-372b-47b1-9d61-19db8857c12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c63e0d31-e396-4fcb-a255-a52d2eeff5e9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d5ae236c-372b-47b1-9d61-19db8857c12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d15dfc3-0783-4312-a1fc-9bc4437ef5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae9ecb0a-fcce-4731-bac8-40719f790cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d15dfc3-0783-4312-a1fc-9bc4437ef5d4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae9ecb0a-fcce-4731-bac8-40719f790cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20230331.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b4a7ea90-353f-4655-828d-910093074080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e6d885d6-1b39-4e24-b9e7-c12b6c026095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b4a7ea90-353f-4655-828d-910093074080" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e6d885d6-1b39-4e24-b9e7-c12b6c026095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20230331.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6e2dc721-3ebe-4d43-85e1-5265e8efd3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_dce84fc4-4c14-4cd2-8186-e40edaf71a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6e2dc721-3ebe-4d43-85e1-5265e8efd3c0" xlink:to="loc_us-gaap_TreasuryStockTextBlock_dce84fc4-4c14-4cd2-8186-e40edaf71a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20230331.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d92fa22a-6485-4355-82ca-a352d3bd7c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e6579e2a-61d1-4317-94f2-d48546339ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d92fa22a-6485-4355-82ca-a352d3bd7c67" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e6579e2a-61d1-4317-94f2-d48546339ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20230331.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8c1d975d-509f-4141-8567-9b0274733020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_cfdcf707-0a76-4d16-82e3-94b25123c22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8c1d975d-509f-4141-8567-9b0274733020" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_cfdcf707-0a76-4d16-82e3-94b25123c22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_409932af-6413-444a-a815-d517d961668b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_409932af-6413-444a-a815-d517d961668b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_366f68a9-f912-44cd-b7c0-26f30afc3d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_366f68a9-f912-44cd-b7c0-26f30afc3d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eb485755-e1d8-4fee-aecc-8ad2f9f152f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_UseOfEstimates_eb485755-e1d8-4fee-aecc-8ad2f9f152f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData_7ef9f2e1-de27-43e4-b8d3-823f55d1f457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_ComparabilityOfPriorYearFinancialData_7ef9f2e1-de27-43e4-b8d3-823f55d1f457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bd2b895f-ca0e-4501-9b60-c8ee023f5a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bd2b895f-ca0e-4501-9b60-c8ee023f5a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_7e8713fa-afee-4cef-8624-1ce7f20fcb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_7e8713fa-afee-4cef-8624-1ce7f20fcb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c14e2c10-480f-44d3-8ff7-2d8cae405aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c14e2c10-480f-44d3-8ff7-2d8cae405aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_b03c2ce9-72a7-43b2-9f1b-f0697bab55e2" xlink:href="amed-20230331.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_b03c2ce9-72a7-43b2-9f1b-f0697bab55e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_66fcefa8-1e91-4725-a2a8-e45ba45b2d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_66fcefa8-1e91-4725-a2a8-e45ba45b2d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_84985a7c-f772-4d0f-b3ae-7b2e827156ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_84985a7c-f772-4d0f-b3ae-7b2e827156ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_3832140b-5080-4478-9f0c-0dc5900e948f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_3832140b-5080-4478-9f0c-0dc5900e948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ee2b0b27-b855-4112-b371-5779b42d4fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ee2b0b27-b855-4112-b371-5779b42d4fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e444c4dd-1aa7-47c3-92ac-43723d513b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb93d41-98d8-4a15-92bd-e48a164f50d6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e444c4dd-1aa7-47c3-92ac-43723d513b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="simple" xlink:href="amed-20230331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1652989-93b1-4a73-98dd-eeacfa0da137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_685d939c-404c-47ac-b220-ee581e4aa1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_8b79e932-53a5-4049-9801-fbf0b4c8b1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_685d939c-404c-47ac-b220-ee581e4aa1df" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_8b79e932-53a5-4049-9801-fbf0b4c8b1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_c7389e86-0ebd-4622-9814-db24690e5718" xlink:href="amed-20230331.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_685d939c-404c-47ac-b220-ee581e4aa1df" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_c7389e86-0ebd-4622-9814-db24690e5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_ddb096d0-d75d-4332-8052-6f4ef5810ff4" xlink:href="amed-20230331.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_685d939c-404c-47ac-b220-ee581e4aa1df" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_ddb096d0-d75d-4332-8052-6f4ef5810ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e53a7b60-8ab4-4601-99de-bcb49e8179e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_685d939c-404c-47ac-b220-ee581e4aa1df" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e53a7b60-8ab4-4601-99de-bcb49e8179e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="amed-20230331.xsd#INVESTMENTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INVESTMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0b1bf201-6c20-4846-bc70-013ef12a4934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3a6c4a48-c53b-40d8-8a6f-269c5e5005c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0b1bf201-6c20-4846-bc70-013ef12a4934" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3a6c4a48-c53b-40d8-8a6f-269c5e5005c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_86895f2e-911d-4b61-a7ae-3dc6224f7fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_86895f2e-911d-4b61-a7ae-3dc6224f7fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ad603c0c-1503-4205-8215-432c4b319e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ad603c0c-1503-4205-8215-432c4b319e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_d61526a7-4c9b-4a43-9a5f-efe1a4cf7429" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_d61526a7-4c9b-4a43-9a5f-efe1a4cf7429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_c403d803-a9d8-4b68-a093-456ab3e24332" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_c403d803-a9d8-4b68-a093-456ab3e24332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_95b958f7-0b6e-4071-af97-c8076d45218e" xlink:href="amed-20230331.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c386e2c2-ff4c-4be4-b3d2-f90cdd71a52a" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_95b958f7-0b6e-4071-af97-c8076d45218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DISPOSITIONSTables" xlink:type="simple" xlink:href="amed-20230331.xsd#DISPOSITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DISPOSITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_14ef798f-a840-468f-93ca-73145972e53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_29d6a8b4-ad6a-4eaf-9391-bdd8993b9100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_14ef798f-a840-468f-93ca-73145972e53f" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_29d6a8b4-ad6a-4eaf-9391-bdd8993b9100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_622e908d-48aa-4f96-848e-c55f15b806c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_80ede951-b8b7-4292-9afa-ce43a491a194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_622e908d-48aa-4f96-848e-c55f15b806c0" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_80ede951-b8b7-4292-9afa-ce43a491a194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_cdac60b7-7b77-473d-8039-9c39790fb948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_622e908d-48aa-4f96-848e-c55f15b806c0" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_cdac60b7-7b77-473d-8039-9c39790fb948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20230331.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8cfa2dc2-3463-42dc-bebf-06ab16f0ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5b2face7-0fc4-4c02-a76d-09809a6f3901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8cfa2dc2-3463-42dc-bebf-06ab16f0ec25" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5b2face7-0fc4-4c02-a76d-09809a6f3901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20230331.xsd#SUBSEQUENTEVENTTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_317882f5-ebc0-4e8f-85b2-8bc3abe8db16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_317882f5-ebc0-4e8f-85b2-8bc3abe8db16" xlink:to="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7124c12-8e56-48e6-8310-e002d2d62de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eb835c8-a47b-40ce-a635-a113d9ec5163" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7124c12-8e56-48e6-8310-e002d2d62de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7b8bff70-2b16-4ddf-be23-c5ed84115832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_09abfef5-713b-452c-8449-a660baf9802b" xlink:to="loc_us-gaap_SubsequentEventLineItems_7b8bff70-2b16-4ddf-be23-c5ed84115832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee8374c4-9e6a-42cc-9732-f402c9c520d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee8374c4-9e6a-42cc-9732-f402c9c520d3" xlink:to="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23ee4258-3f54-4bd1-86ad-5eea869c9326" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_91575f57-2fe9-4dae-ac12-6cdeb4c614b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2505291d-cdaa-4fb8-ae31-290db3322f72" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_91575f57-2fe9-4dae-ac12-6cdeb4c614b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a3800e08-802a-411a-ab59-6d563dfb29ad" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8f40fa96-2e7e-4d1d-93a4-ff2a934e6e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_075fce21-8057-4cc4-82a7-8d96d8a65c3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8f40fa96-2e7e-4d1d-93a4-ff2a934e6e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5311e44a-1c65-4dac-9429-c55e09c1b58e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_d1c3df8c-f3f8-42e1-9492-5bc886faabd1" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:to="loc_amed_MedicareRevenueMember_d1c3df8c-f3f8-42e1-9492-5bc886faabd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_aa794b3e-f6a3-455a-9d72-661599c7faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_808b1fbc-7647-40ce-96db-3f366e402699" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_aa794b3e-f6a3-455a-9d72-661599c7faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d89bfbde-f49b-4094-b1f8-a22a9d35ce42" xlink:to="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_eadb4dff-d6f3-4015-a875-c7bc8aabc3a2" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HomeHealthMember_eadb4dff-d6f3-4015-a875-c7bc8aabc3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e7aeb6c5-2928-428a-b2f9-a634d0a7d585" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HospiceMember_e7aeb6c5-2928-428a-b2f9-a634d0a7d585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9aae523a-2f8a-4f7f-932a-45da26407f92" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_PersonalCareMember_9aae523a-2f8a-4f7f-932a-45da26407f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_54391275-6835-499c-be19-f76c3c1234f2" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0393b99e-f087-4044-ae26-4b98a03706d2" xlink:to="loc_amed_HighAcuityCareMember_54391275-6835-499c-be19-f76c3c1234f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_407de72a-4246-4eb5-bdbe-b42c51341c09" xlink:to="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_6cca6672-00a2-4e55-91c0-9a694e16e392" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6a28c5f-4b69-4f90-853d-290f447b7baf" xlink:to="loc_amed_MedicareRevenueMember_6cca6672-00a2-4e55-91c0-9a694e16e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b999a18e-c579-4c36-a73f-35c39079c60f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4e97e1cb-2977-483f-a034-c407d98c5e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3ccbb2f8-2d46-4a11-a06d-e89bfa40bb31" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4e97e1cb-2977-483f-a034-c407d98c5e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_69c93f3c-0e30-498b-b115-7b318a33cd4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_b5d1031f-aebc-4cb9-9fdd-e89a342ff3f4" xlink:href="amed-20230331.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6ee2997-c203-4581-b2b9-cd1053b0f05b" xlink:to="loc_amed_EvolutionHealthMember_b5d1031f-aebc-4cb9-9fdd-e89a342ff3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98f203d0-b028-47c3-9931-4da0cf43768e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c20bcd8e-8900-4422-a94b-1a1db337fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c20bcd8e-8900-4422-a94b-1a1db337fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_842ecfe9-640b-490b-ae50-ca695c519369" xlink:href="amed-20230331.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_amed_OperatingCareCenters_842ecfe9-640b-490b-ae50-ca695c519369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_68bef80e-2d7b-4ede-9f29-9d8f3ed8b83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_68bef80e-2d7b-4ede-9f29-9d8f3ed8b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_98c78867-ba7b-47ed-b094-de2a25ab9cea" xlink:href="amed-20230331.xsd#amed_NumberOfJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_27dd3b72-f4de-4130-ada9-3fde80e536ae" xlink:to="loc_amed_NumberOfJointVentures_98c78867-ba7b-47ed-b094-de2a25ab9cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_410a875b-10e6-4899-8ebd-858fe1ed5a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_410a875b-10e6-4899-8ebd-858fe1ed5a81" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_feb32805-efba-44aa-8761-a905d71fb373" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_c9182856-a2e8-4114-841b-8c31c407ba18" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:to="loc_amed_CompassionateCareHospiceMember_c9182856-a2e8-4114-841b-8c31c407ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f5b1e8be-223b-4a93-9ba2-3f0196f06523" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f676949-6f25-4cbd-ae21-52b94d337063" xlink:to="loc_amed_AseraCareHospiceMember_f5b1e8be-223b-4a93-9ba2-3f0196f06523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06f92391-3e90-452b-a60b-b06b56ce907b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_efe4a1fe-3a7d-4b8d-a451-f34bbcd2d45d" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:to="loc_amed_MedicareRevenueMember_efe4a1fe-3a7d-4b8d-a451-f34bbcd2d45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_71d99c22-961f-4fe8-a90a-6c4cf4dfbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb10d05a-1142-4987-ae4d-942d9850679b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_71d99c22-961f-4fe8-a90a-6c4cf4dfbb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a4dfb945-0df0-42b3-adac-4eb4677bdc90" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8766ef47-340c-41c5-a7dd-f502a62a0db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b4f6256e-2987-4247-9128-9243aef6c5d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8766ef47-340c-41c5-a7dd-f502a62a0db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:href="amed-20230331.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:href="amed-20230331.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_535c0620-7023-44e9-a9d6-c06b8591aa6a" xlink:to="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_dcef7f4e-11b7-4e12-8bdf-e794a531e66d" xlink:href="amed-20230331.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_ea5285b3-71eb-4c70-ab9d-e36cbd5e7e80" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_dcef7f4e-11b7-4e12-8bdf-e794a531e66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eadf4bad-a83a-43c2-8c07-9d73db26fd49" xlink:to="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7d5860d1-8489-447f-8aba-6baf98b054d0" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HomeHealthMember_7d5860d1-8489-447f-8aba-6baf98b054d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_a731f200-b024-4247-b42f-02494eee52f4" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HospiceMember_a731f200-b024-4247-b42f-02494eee52f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_279dc4e3-55ef-4d84-83d8-ed2478a9fdb3" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ca465628-6568-4694-b821-bfb2c81f2a29" xlink:to="loc_amed_HighAcuityCareMember_279dc4e3-55ef-4d84-83d8-ed2478a9fdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_40b3c276-c10d-4d03-b47b-889f40cd999e" xlink:to="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83854370-8dc4-4b87-9fb6-63a2a51ed3a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:to="loc_srt_MinimumMember_83854370-8dc4-4b87-9fb6-63a2a51ed3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79a4653a-2701-474d-ac30-efd17d8fdd0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1322623d-0170-49b9-b2d5-3010c3b3e115" xlink:to="loc_srt_MaximumMember_79a4653a-2701-474d-ac30-efd17d8fdd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80abe41f-b1f5-486a-a1cb-6b5615b4ae56" xlink:to="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_85f38ae3-a09f-488e-a743-bdfe7ed17885" xlink:href="amed-20230331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e990306-7395-4f29-b8f5-ec090476c160" xlink:to="loc_amed_MedicareRevenueMember_85f38ae3-a09f-488e-a743-bdfe7ed17885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_875aa025-ea87-4dd8-b4d6-bb3781436962" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b49250a7-b5af-45db-aed2-2a4fa37cc330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b49250a7-b5af-45db-aed2-2a4fa37cc330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_90083595-d5d9-4da4-9ee8-ca1a9a90ab1c" xlink:href="amed-20230331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_90083595-d5d9-4da4-9ee8-ca1a9a90ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e30a0fb6-f130-4759-bb3c-ca07cea72766" xlink:href="amed-20230331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e30a0fb6-f130-4759-bb3c-ca07cea72766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_30ed4430-6459-4af0-a0e0-96654224b9c4" xlink:href="amed-20230331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_30ed4430-6459-4af0-a0e0-96654224b9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_f893fb48-4c45-4763-950f-d960d4deafa8" xlink:href="amed-20230331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_f893fb48-4c45-4763-950f-d960d4deafa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_7970e881-eed1-4c8e-a4d8-5ffc34cb18ac" xlink:href="amed-20230331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_7970e881-eed1-4c8e-a4d8-5ffc34cb18ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_45b75591-fdf9-407b-abec-bc1bb02fd941" xlink:href="amed-20230331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_45b75591-fdf9-407b-abec-bc1bb02fd941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_cb0b4529-97c8-469c-b2a4-ca512b1e3395" xlink:href="amed-20230331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_SecondThresholdOfServicesRequired_cb0b4529-97c8-469c-b2a4-ca512b1e3395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_17ad7cf8-9acf-44e4-ad72-d2dbcdf45bf6" xlink:href="amed-20230331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_17ad7cf8-9acf-44e4-ad72-d2dbcdf45bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_1c4382d8-79eb-4278-aa1f-7de2369f6ec7" xlink:href="amed-20230331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_1c4382d8-79eb-4278-aa1f-7de2369f6ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_9539ab25-451c-4885-9212-6c3282910a62" xlink:href="amed-20230331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NonMedicareRevenueTermRates_9539ab25-451c-4885-9212-6c3282910a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dfeb6c59-7033-465d-a085-6242df4dfeca" xlink:href="amed-20230331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dfeb6c59-7033-465d-a085-6242df4dfeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_c776e19c-51df-4115-b6de-26ad01f77029" xlink:href="amed-20230331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_c776e19c-51df-4115-b6de-26ad01f77029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_2ec42945-5a93-4606-926d-cc82b98cd128" xlink:href="amed-20230331.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_2ec42945-5a93-4606-926d-cc82b98cd128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_bad5f9fa-a989-4d83-9e99-ba19f8521fda" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_bad5f9fa-a989-4d83-9e99-ba19f8521fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcutePhaseForHighAcuityCareServices_4475dd3d-7c31-4553-a76b-e074479eb10f" xlink:href="amed-20230331.xsd#amed_AcutePhaseForHighAcuityCareServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_AcutePhaseForHighAcuityCareServices_4475dd3d-7c31-4553-a76b-e074479eb10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_fddcf4b9-b199-4182-a1ed-34d6c20ec3a6" xlink:href="amed-20230331.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_edd9c0d4-9727-43b3-a352-e301940b640c" xlink:to="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_fddcf4b9-b199-4182-a1ed-34d6c20ec3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_29c07a70-109e-41be-a02e-a748b93ee8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_29c07a70-109e-41be-a02e-a748b93ee8c9" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:href="amed-20230331.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:to="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:href="amed-20230331.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_c7f26658-f000-48f8-bcd6-4c9240826f3a" xlink:to="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_1c79583d-36b3-4704-919d-d39b30295d73" xlink:href="amed-20230331.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthMedicareMember_1c79583d-36b3-4704-919d-d39b30295d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_c6383a8f-b486-474e-b837-6e05651d5a84" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_c6383a8f-b486-474e-b837-6e05651d5a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_f6908d3a-e91e-43c9-9eb8-2a0692166b7a" xlink:href="amed-20230331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_f6908d3a-e91e-43c9-9eb8-2a0692166b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_9929bb95-bc12-44a2-99dc-fdd027e99481" xlink:href="amed-20230331.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HospiceMedicareMember_9929bb95-bc12-44a2-99dc-fdd027e99481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_05455d1b-1d13-4af4-898e-c8fec8499f64" xlink:href="amed-20230331.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HospiceNonMedicareMember_05455d1b-1d13-4af4-898e-c8fec8499f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_c1e55e0f-20f2-4e3a-8346-d9b3864dbd8d" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_PersonalCareMember_c1e55e0f-20f2-4e3a-8346-d9b3864dbd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_2ff8522b-1690-4fea-9090-0800c8403037" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_48f54d3b-542b-478d-ad6b-ddf716524d77" xlink:to="loc_amed_HighAcuityCareMember_2ff8522b-1690-4fea-9090-0800c8403037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_20a8a975-8688-4d90-bb9f-f9b4feed5ae3" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7bec2c96-67bc-4d2c-b8b3-f5afcb7a6445" xlink:href="amed-20230331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_57d4879a-5add-49a1-8d18-d216f62a3880" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7bec2c96-67bc-4d2c-b8b3-f5afcb7a6445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56c432ef-86e1-429b-997f-aaf5f24a39af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c432ef-86e1-429b-997f-aaf5f24a39af" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_00d40630-4371-4e62-9045-4b299653ad89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_193df4db-92c2-4434-81c9-e4b942864d78" xlink:href="amed-20230331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_AsanaHospiceAquisitionMember_193df4db-92c2-4434-81c9-e4b942864d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_f1d23d35-c1e9-4aef-a73d-aa19119ce0f6" xlink:href="amed-20230331.xsd#amed_COVID19PPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_COVID19PPEMember_f1d23d35-c1e9-4aef-a73d-aa19119ce0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_94cbee3e-fbe8-4ae3-8cf7-ff2c5fb25db9" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dacb6cfc-f813-4c69-9046-3aa62d3dfdb7" xlink:to="loc_amed_AseraCareHospiceMember_94cbee3e-fbe8-4ae3-8cf7-ff2c5fb25db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bca04f52-564d-4473-b6b6-6432ef2ee360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_09354827-fe0f-43dc-81be-67bf2e59fbfa" xlink:href="amed-20230331.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:to="loc_amed_AsanaHospiceMember_09354827-fe0f-43dc-81be-67bf2e59fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_d8a356c8-c08c-4a89-bcc0-ebb876d43643" xlink:href="amed-20230331.xsd#amed_VariousAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2dfed32e-a758-4585-87f4-20802fd6c8b8" xlink:to="loc_amed_VariousAcquisitionsMember_d8a356c8-c08c-4a89-bcc0-ebb876d43643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e9e67968-775f-4a07-acf3-a54f373a1e0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5387a5b6-3cf6-4d51-b73b-d0042903d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5387a5b6-3cf6-4d51-b73b-d0042903d66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2b60522b-298f-49cd-99de-527f3ff5223e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_RestrictedCash_2b60522b-298f-49cd-99de-527f3ff5223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd23633-d6d4-470d-96f0-a2f503dd76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd23633-d6d4-470d-96f0-a2f503dd76ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_7cf23da8-55e3-483c-89a6-895d86684dad" xlink:href="amed-20230331.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_e9a3444a-420f-48d5-befd-b7d1f46f8f01" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_7cf23da8-55e3-483c-89a6-895d86684dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c5a63447-8038-4d9a-8bd2-605d28c1b007" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a432071a-cfc8-4b8d-b751-30595c864c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a7082a0-b512-49da-87dc-947d26011add" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a432071a-cfc8-4b8d-b751-30595c864c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d18d8092-7f43-4177-b545-c75daa8663fb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2159f7b0-2e90-4a38-848c-4ba68473f936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa44d7ac-9246-4f92-a4ae-5ef790421cca" xlink:to="loc_us-gaap_AccountsReceivableMember_2159f7b0-2e90-4a38-848c-4ba68473f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b37bcfa8-5960-4159-a577-4435ee3b1661" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_52e99420-59b2-4434-a114-06e876e75d54" xlink:href="amed-20230331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a52b605-6067-4c93-81eb-8d3eb8eeb438" xlink:to="loc_amed_MajorSinglePayorCustomerMember_52e99420-59b2-4434-a114-06e876e75d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43b197e7-6449-42c3-bf3a-5572c4c8601d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_4a16b8af-b5dc-4156-af7b-4589c95f7db2" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32238528-c626-40cc-ad92-bd46d97eb536" xlink:to="loc_amed_CompassionateCareHospiceMember_4a16b8af-b5dc-4156-af7b-4589c95f7db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_633e25bb-9d75-48a5-ac76-f742a0c9627c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b6c77a69-2883-416d-b01a-2998345c1575" xlink:href="amed-20230331.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b6c77a69-2883-416d-b01a-2998345c1575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f5c8b505-b0ad-484f-a40e-796e4a5777c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f5c8b505-b0ad-484f-a40e-796e4a5777c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d6c8394f-ea37-4d11-ac4c-837a2c7daf22" xlink:href="amed-20230331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ed413913-f653-48c6-9f1f-73b8842b627b" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d6c8394f-ea37-4d11-ac4c-837a2c7daf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_6cfb64d3-98c7-4567-b371-a2f7e50ea27e" xlink:href="amed-20230331.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_6cfb64d3-98c7-4567-b371-a2f7e50ea27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_8dec5ee4-647d-47d7-ad56-32c9efa65ee2" xlink:href="amed-20230331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_8dec5ee4-647d-47d7-ad56-32c9efa65ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_d2df3d3b-b775-4d8f-bcf8-1693355dd42d" xlink:href="amed-20230331.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_d2df3d3b-b775-4d8f-bcf8-1693355dd42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_a85c5612-bca6-49a5-83d7-5bfc326e3880" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_a85c5612-bca6-49a5-83d7-5bfc326e3880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_b1a0aa95-1f2b-482e-85e4-5acbf188c4ea" xlink:href="amed-20230331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_b1a0aa95-1f2b-482e-85e4-5acbf188c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_b7af3fc1-35e2-403e-bf67-387259e528e8" xlink:href="amed-20230331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_b7af3fc1-35e2-403e-bf67-387259e528e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_30126eec-1902-4044-b38f-e5d9d5024706" xlink:href="amed-20230331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6c7fb3b-2f21-48a8-b416-0b6ef24f4721" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_30126eec-1902-4044-b38f-e5d9d5024706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8e133d7-c984-44fb-9074-c60ae8fb9e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8e133d7-c984-44fb-9074-c60ae8fb9e2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe99c4c9-fe48-41a7-b78e-f2a2bac9a5fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_efb2a7ee-103e-4f4b-b999-c6684174d5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_efb2a7ee-103e-4f4b-b999-c6684174d5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a300b611-8776-4ce7-998d-a624c01ef800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a300b611-8776-4ce7-998d-a624c01ef800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74520e0e-77e5-4f3b-8f98-c228e4629760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3ff240b-4b40-417f-b9ac-a2a2976a80e9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74520e0e-77e5-4f3b-8f98-c228e4629760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a02f415f-b6f8-45c8-b50e-f0d7982bc297" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ae374e02-50dd-49a8-9ec1-630cd426a518" xlink:href="amed-20230331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ae374e02-50dd-49a8-9ec1-630cd426a518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a9231a1c-6565-4b57-871d-17af1cab4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aedc85df-135a-47f4-9fd6-ea7e678ab2c6" xlink:to="loc_us-gaap_LongTermDebtFairValue_a9231a1c-6565-4b57-871d-17af1cab4c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_215a5044-a4c7-441a-93b6-f52956ed2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88918235-62db-4ffa-af32-24a80655d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215a5044-a4c7-441a-93b6-f52956ed2d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88918235-62db-4ffa-af32-24a80655d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b3baeb00-f429-4dcd-a92e-c7c93e96e597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215a5044-a4c7-441a-93b6-f52956ed2d04" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b3baeb00-f429-4dcd-a92e-c7c93e96e597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0d0beb66-19bf-4d4f-87f3-c605fc0b6edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b3baeb00-f429-4dcd-a92e-c7c93e96e597" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0d0beb66-19bf-4d4f-87f3-c605fc0b6edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_00030943-9fd6-4206-b92b-ed34094e27a1" xlink:href="amed-20230331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b3baeb00-f429-4dcd-a92e-c7c93e96e597" xlink:to="loc_amed_NonVestedStockAndStockUnits_00030943-9fd6-4206-b92b-ed34094e27a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0985316f-5cff-47b5-a855-e2f6df33cc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215a5044-a4c7-441a-93b6-f52956ed2d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0985316f-5cff-47b5-a855-e2f6df33cc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_115cdaef-2fe5-430f-a0c0-b33b9061b360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215a5044-a4c7-441a-93b6-f52956ed2d04" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_115cdaef-2fe5-430f-a0c0-b33b9061b360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INVESTMENTSDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#INVESTMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INVESTMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_62faf818-ff28-4399-b045-146f0f84f7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_62faf818-ff28-4399-b045-146f0f84f7f5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8ed539ff-1b67-4296-b5b2-953bbd67b1b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_602b0909-013d-44b7-8390-1676d2601198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b902c5bd-bdb6-4c97-86e9-cce107599b27" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_602b0909-013d-44b7-8390-1676d2601198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_072b96c1-ff4f-4af6-b3a6-c63bd2c8ca4e" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f66ebdb1-a5e4-4e3f-a1ae-b65dcc6337fb" xlink:href="amed-20230331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f66ebdb1-a5e4-4e3f-a1ae-b65dcc6337fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_e7158580-6ba6-4ebc-bb68-984abdf217c8" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_e7158580-6ba6-4ebc-bb68-984abdf217c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_33cbac35-f850-44ad-9a18-7eef558a1d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_33cbac35-f850-44ad-9a18-7eef558a1d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_8530cde3-0d4d-45c5-81f9-f948ee386118" xlink:href="amed-20230331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_8530cde3-0d4d-45c5-81f9-f948ee386118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8ac4a870-27cf-478b-b226-c1440d9afaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8ac4a870-27cf-478b-b226-c1440d9afaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_b782156a-c962-4927-8e80-a4fc9548626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_b782156a-c962-4927-8e80-a4fc9548626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_e0d85e71-795d-4522-b941-ce1c3d3696bc" xlink:href="amed-20230331.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_e0d85e71-795d-4522-b941-ce1c3d3696bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9651762-ef38-4425-9a60-be3f2b0ca92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9651762-ef38-4425-9a60-be3f2b0ca92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1a016910-8bb9-4fd5-b2e6-b82d9e52e5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1a016910-8bb9-4fd5-b2e6-b82d9e52e5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5c58f7e8-a761-4552-9254-af3672df0dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OtherAssetsCurrent_5c58f7e8-a761-4552-9254-af3672df0dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38da438a-b732-42a2-91df-c40df3a40033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AssetsCurrent_38da438a-b732-42a2-91df-c40df3a40033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68785c34-510b-4acf-9117-c81aef334c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68785c34-510b-4acf-9117-c81aef334c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4df419f8-39fc-43ef-953f-8283992beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4df419f8-39fc-43ef-953f-8283992beb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e118ab9a-97e4-4cea-ae15-aee09dc59cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Goodwill_e118ab9a-97e4-4cea-ae15-aee09dc59cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b25d9bca-a013-41ae-9a8d-3b06d18bae51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b25d9bca-a013-41ae-9a8d-3b06d18bae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9071a445-84d9-4737-9118-e30b6b5d3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9071a445-84d9-4737-9118-e30b6b5d3be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9b8f7b6c-f111-480b-b90e-6fc72aa7481c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Assets_9b8f7b6c-f111-480b-b90e-6fc72aa7481c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1a197299-6695-40c4-be24-8213600c0ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccountsPayableCurrent_1a197299-6695-40c4-be24-8213600c0ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_899a5a5b-5641-4b6a-8110-e59dface7721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_899a5a5b-5641-4b6a-8110-e59dface7721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ea4d8b72-54ab-4ff7-871a-960c34469141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ea4d8b72-54ab-4ff7-871a-960c34469141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d7bbc90a-d8c7-4d64-813c-2a19289fdc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d7bbc90a-d8c7-4d64-813c-2a19289fdc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_5c6d383b-3474-45d4-b905-51e821e0889d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_DebtCurrent_5c6d383b-3474-45d4-b905-51e821e0889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3b4aaee7-1cb4-42b9-88f1-2f7594c93c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e9d41a8e-bad0-4962-9846-b2933358886b" xlink:to="loc_us-gaap_Liabilities_3b4aaee7-1cb4-42b9-88f1-2f7594c93c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6fb8335a-9b7b-4e0c-89b1-cbdf8addc939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6fb8335a-9b7b-4e0c-89b1-cbdf8addc939" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7283104a-4c0e-4f52-8bb3-94d1c56bbaa3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_7710f67d-5cdf-449e-917e-295dff9cf5bd" xlink:href="amed-20230331.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:to="loc_amed_EvolutionHealthMember_7710f67d-5cdf-449e-917e-295dff9cf5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_23ae8812-99a4-4c27-8241-730c151e5398" xlink:href="amed-20230331.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cc0a664-c6f9-40c3-afe8-ce8bee75b94b" xlink:to="loc_amed_AssistedCareHomeHealthMember_23ae8812-99a4-4c27-8241-730c151e5398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d7c50440-fc53-4ab5-8abb-0b8a7014be16" xlink:to="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ecf11884-5226-458e-8af2-f7618063690b" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HospiceMember_ecf11884-5226-458e-8af2-f7618063690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cb1e83d4-5a7d-4b81-a45e-2ddff9ec1d69" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HomeHealthMember_cb1e83d4-5a7d-4b81-a45e-2ddff9ec1d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_fe620b8d-da15-47aa-9e55-a586d68dcbb6" xlink:href="amed-20230331.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_19e2277f-d1e3-454e-9b86-d041013a4132" xlink:to="loc_amed_HomeHealthAndHospiceMember_fe620b8d-da15-47aa-9e55-a586d68dcbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e37c66f1-14f8-4105-bc04-a39a0a6f0e7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_888c007f-dce7-43a2-9e2e-4b8ec04fd6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_TradeNamesMember_888c007f-dce7-43a2-9e2e-4b8ec04fd6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_184c5dbb-61af-460d-ac9f-8f05749fd6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_184c5dbb-61af-460d-ac9f-8f05749fd6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_28e7d103-2f41-48b8-8a49-cd39849f0530" xlink:href="amed-20230331.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_AcquiredNamesMember_28e7d103-2f41-48b8-8a49-cd39849f0530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_1158ee18-a227-4efb-ae9b-5788c13de4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_1158ee18-a227-4efb-ae9b-5788c13de4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_e76cc116-08ca-436e-9f0b-f4baeb0d7be9" xlink:href="amed-20230331.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_MedicareLicenseMember_e76cc116-08ca-436e-9f0b-f4baeb0d7be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_09df78eb-beae-4419-a834-aa59371cb726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_09df78eb-beae-4419-a834-aa59371cb726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_37001059-d615-4d9e-b374-19fad7709813" xlink:href="amed-20230331.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_CertificatesOfNeedMember_37001059-d615-4d9e-b374-19fad7709813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_41e470ff-7aa2-4417-b8e9-f559a5f8b012" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_amed_CertificateOfNeedMember_41e470ff-7aa2-4417-b8e9-f559a5f8b012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_016d15d1-7e46-42db-9556-23cf32b13fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_016d15d1-7e46-42db-9556-23cf32b13fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_58eefe97-d859-4561-bd4e-0d14e7df522e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88444331-4c40-4b5b-8b38-a4ae2c002280" xlink:to="loc_us-gaap_LicenseMember_58eefe97-d859-4561-bd4e-0d14e7df522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_970b4919-45ab-4fea-93ab-070c21f63ac3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_23a86e10-5dd5-4a73-91ca-69dfd41f4af9" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_CertificateOfNeedMember_23a86e10-5dd5-4a73-91ca-69dfd41f4af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_0aa83972-3cd8-4713-a52b-087f03bff0e2" xlink:href="amed-20230331.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_MedicareLicenseMember_0aa83972-3cd8-4713-a52b-087f03bff0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedAndLicensesMember_cdee91b0-cca0-4ca4-8f1d-6b4887b85d6f" xlink:href="amed-20230331.xsd#amed_CertificateOfNeedAndLicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8546db8d-0811-4af9-a359-76fd295da4bc" xlink:to="loc_amed_CertificateOfNeedAndLicensesMember_cdee91b0-cca0-4ca4-8f1d-6b4887b85d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_55c95a87-ac48-4b0d-a057-741af4a7cf57" xlink:to="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_b3ee4708-236f-4b2b-93fd-cf321a0966fa" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_TN_b3ee4708-236f-4b2b-93fd-cf321a0966fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_792cb278-6b78-43b7-bd63-41deec40fff0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_WA_792cb278-6b78-43b7-bd63-41deec40fff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_c0dfb492-1256-402d-91b7-d99ba9d8fee4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_KY_c0dfb492-1256-402d-91b7-d99ba9d8fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_a115f0eb-b195-45ec-b77e-9055ff1456d0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_NC_a115f0eb-b195-45ec-b77e-9055ff1456d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_e8a122a8-283b-4d91-a908-f2a4b92f80c4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_NY_e8a122a8-283b-4d91-a908-f2a4b92f80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_de1a83d2-b310-4cc1-8fb4-d5956deeb6c9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72c4c10a-c8e7-498c-ba63-ff4f735fc3dd" xlink:to="loc_stpr_WV_de1a83d2-b310-4cc1-8fb4-d5956deeb6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b10895c1-57e9-4989-a2d1-34a55fa344ab" xlink:to="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22ecdee1-9062-4bed-90c0-d5af237d8ac3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:to="loc_srt_MinimumMember_22ecdee1-9062-4bed-90c0-d5af237d8ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_692f33fa-15d4-4a76-abd6-7cf0fe56d8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6a06019-8600-4a94-94a3-6d3b116ad6e0" xlink:to="loc_srt_MaximumMember_692f33fa-15d4-4a76-abd6-7cf0fe56d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9befa398-dc15-49e2-b940-bc58df7b0eba" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_3d2c3f4b-432c-4f4b-8736-b68e5869768f" xlink:href="amed-20230331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_PercentageofSharesOutstanding_3d2c3f4b-432c-4f4b-8736-b68e5869768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_18a596b3-b845-4a05-b3df-74be640060b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_18a596b3-b845-4a05-b3df-74be640060b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ee52337c-dd85-45ce-9ba0-9197807eb43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ee52337c-dd85-45ce-9ba0-9197807eb43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_eaff813b-6906-4c28-89cd-9f0df568c640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_eaff813b-6906-4c28-89cd-9f0df568c640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_be81f5ab-90cc-4044-a67f-444fa13ee0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_be81f5ab-90cc-4044-a67f-444fa13ee0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_6674556c-2380-419d-9890-e2b3eb7370a2" xlink:href="amed-20230331.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_6674556c-2380-419d-9890-e2b3eb7370a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_cce35df6-0af4-4858-a76d-01c9a5cb6e4b" xlink:href="amed-20230331.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_cce35df6-0af4-4858-a76d-01c9a5cb6e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_90e6ccab-4de5-4fb3-b1c3-a8093ec05015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_90e6ccab-4de5-4fb3-b1c3-a8093ec05015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_d9f0c692-91e4-4441-a3fa-70a2112f1407" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_d9f0c692-91e4-4441-a3fa-70a2112f1407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_92f4ac0e-e608-4ade-842c-a08cdb826c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_92f4ac0e-e608-4ade-842c-a08cdb826c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_5ecbd05a-aa02-4029-974f-e1cad77e901b" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_5ecbd05a-aa02-4029-974f-e1cad77e901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e073c4dc-4c4a-4e32-9fbd-de2bb8c88a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e073c4dc-4c4a-4e32-9fbd-de2bb8c88a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_d27ee253-5a88-48ef-ac31-18747dc60de1" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_d27ee253-5a88-48ef-ac31-18747dc60de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f6c9e799-2216-4d90-8080-c0cad8205e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f6c9e799-2216-4d90-8080-c0cad8205e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_5423b096-c246-409f-9f0e-8c1bee0d5e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_5423b096-c246-409f-9f0e-8c1bee0d5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d27b02f5-87d0-44be-8004-c3a031b2cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d27b02f5-87d0-44be-8004-c3a031b2cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5e9addbc-b766-40f6-8da0-a796a148c5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5e9addbc-b766-40f6-8da0-a796a148c5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9935354c-4825-4cbd-81a5-1a420101e4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9935354c-4825-4cbd-81a5-1a420101e4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_12bd7c77-91ab-413f-a239-9c01095281fc" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_12bd7c77-91ab-413f-a239-9c01095281fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3cc7b704-5e26-4e13-bb38-794c2c70f995" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3cc7b704-5e26-4e13-bb38-794c2c70f995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_f22f6120-ee33-4817-aef6-d046a338fa20" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_f22f6120-ee33-4817-aef6-d046a338fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0a1cc847-8acd-4d2a-84e3-24925aa7b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0a1cc847-8acd-4d2a-84e3-24925aa7b782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_a3105d51-58d5-42c8-a8b0-0d6f844e8c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_a3105d51-58d5-42c8-a8b0-0d6f844e8c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_561c625c-5779-4bac-9756-d0579333e827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_561c625c-5779-4bac-9756-d0579333e827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5e04fe6a-2ad0-4acc-bc24-fe8254eb5e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5e04fe6a-2ad0-4acc-bc24-fe8254eb5e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_35d47004-e967-4d06-af6e-967c9258fade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_35d47004-e967-4d06-af6e-967c9258fade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a171040f-0344-43e9-b4e4-826673ac1a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a171040f-0344-43e9-b4e4-826673ac1a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_afb5a441-1969-4eed-b05c-2e92d1b3c571" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_afb5a441-1969-4eed-b05c-2e92d1b3c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_ca378367-623a-4434-b9fa-5d561822994d" xlink:href="amed-20230331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_ca378367-623a-4434-b9fa-5d561822994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_48716a98-08ec-476c-b7ab-d5b06c96ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_48716a98-08ec-476c-b7ab-d5b06c96ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b44d869-6808-4bfe-abff-6b7bf2dac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b44d869-6808-4bfe-abff-6b7bf2dac1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f1eb119-aea1-42b9-be0e-d01cbc12504a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0f1eb119-aea1-42b9-be0e-d01cbc12504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_0e5f7c58-fcd2-437a-a10d-c3132bb288a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_0e5f7c58-fcd2-437a-a10d-c3132bb288a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_d52e867c-a24c-4f3f-a3f6-5a1451485e45" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_d52e867c-a24c-4f3f-a3f6-5a1451485e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_473ffd24-1396-4cdd-bac7-451ad5c54424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_473ffd24-1396-4cdd-bac7-451ad5c54424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d0a79dd6-bb0a-4286-8050-02dcc3722e15" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d0a79dd6-bb0a-4286-8050-02dcc3722e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_74598fd8-3915-4fe5-b3c2-21ea9029d9d3" xlink:href="amed-20230331.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_74598fd8-3915-4fe5-b3c2-21ea9029d9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_75c44496-53c7-4ec5-88ae-9db5f199899e" xlink:href="amed-20230331.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_75c44496-53c7-4ec5-88ae-9db5f199899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763cd4e0-6e90-4a11-8de7-4d2f9a53164b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763cd4e0-6e90-4a11-8de7-4d2f9a53164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5dfefd4e-69a0-458e-a3c3-d61c2927978a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_RestrictedCash_5dfefd4e-69a0-458e-a3c3-d61c2927978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_015424f5-cb79-4dc0-89fc-f7eafdfb6461" xlink:href="amed-20230331.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_NonCashAccruedContingentConsideration_015424f5-cb79-4dc0-89fc-f7eafdfb6461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow_601b39a0-b58c-4113-ac15-bffc5f98d969" xlink:href="amed-20230331.xsd#amed_AmountReleasedFromEscrow"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_AmountReleasedFromEscrow_601b39a0-b58c-4113-ac15-bffc5f98d969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_147574b9-41d8-4dd6-bf7f-92a700fccc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_147574b9-41d8-4dd6-bf7f-92a700fccc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_5b607fbe-0447-42f8-8f78-4177838e8e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_5b607fbe-0447-42f8-8f78-4177838e8e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired_809bd243-66a9-40a4-8c51-20f6c0721f1c" xlink:href="amed-20230331.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1bbaea13-6048-45bc-a9dd-529642960050" xlink:to="loc_amed_IncreaseDecreaseInAssetsAcquired_809bd243-66a9-40a4-8c51-20f6c0721f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#ACQUISITIONSProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_27ee5fa0-4946-4111-808c-c36f313a6def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_27ee5fa0-4946-4111-808c-c36f313a6def" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f3fb8edf-7f5b-40a6-a530-3fd38137e6a9" xlink:to="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_a5d16846-5677-4acf-af87-af3fdc9d70c2" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b16c3114-8199-4dd7-97b5-5cda87075e30" xlink:to="loc_amed_HospiceMember_a5d16846-5677-4acf-af87-af3fdc9d70c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6477a76e-f1b0-4f10-9bc0-b30546b343fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_d577945b-6d6b-4f8c-ba90-6739a3ead309" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:to="loc_amed_CompassionateCareHospiceMember_d577945b-6d6b-4f8c-ba90-6739a3ead309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_3c9a23a0-6886-4c08-a961-bd6195512f79" xlink:href="amed-20230331.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1133d8ee-8269-41c0-a420-86d7ae115c2a" xlink:to="loc_amed_AseraCareHospiceMember_3c9a23a0-6886-4c08-a961-bd6195512f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35b0ab01-6881-49ef-9a9c-4169fcc41e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d8157e56-9014-4da9-8b62-249ee8460a7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35b0ab01-6881-49ef-9a9c-4169fcc41e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cbd1bb84-37d5-4840-90e6-e8ac1f1af376" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_76128ddd-daec-427a-9aa2-7d930d2a699f" xlink:to="loc_srt_OwnershipDomain_cbd1bb84-37d5-4840-90e6-e8ac1f1af376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da00703b-5376-4a7d-8eba-5b324a44d877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4aed41cd-ec9b-477e-849d-070db8431980" xlink:to="loc_us-gaap_ClassOfStockDomain_da00703b-5376-4a7d-8eba-5b324a44d877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b4fe488-3be2-4c7b-a5fe-1bfb47a879f2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9615a79b-496c-4a7b-abc6-0ddb1c5e25e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9615a79b-496c-4a7b-abc6-0ddb1c5e25e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_861e8b1d-a069-40bc-8789-83448e6191b9" xlink:href="amed-20230331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_861e8b1d-a069-40bc-8789-83448e6191b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_279576d3-37e9-4709-a077-a81bedcfd91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_279576d3-37e9-4709-a077-a81bedcfd91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8eb297d1-92c0-444f-a4ee-64ec03746021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_8eb297d1-92c0-444f-a4ee-64ec03746021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_641cc7bf-a369-4181-939a-525261e36420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_434a9846-6051-4473-b22b-4e4ebd800cbd" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_641cc7bf-a369-4181-939a-525261e36420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d66b0f7f-c9d5-4a18-956e-ad5546ff3c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d66b0f7f-c9d5-4a18-956e-ad5546ff3c9d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_302c0679-b2d3-4d3b-ba87-ca491294460c" xlink:to="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e51550b2-f0ca-440f-957e-994e4a8aec1b" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a8b005fe-2654-4f48-a4e8-e06d4acd231f" xlink:to="loc_amed_PersonalCareMember_e51550b2-f0ca-440f-957e-994e4a8aec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9bcfbc20-31fd-481f-a3a0-463c9db7a667" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_01531c5f-38cf-4957-8208-f263e2fe62f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_01531c5f-38cf-4957-8208-f263e2fe62f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d7a92f0e-087a-4bd7-999a-19e655e03caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d7a92f0e-087a-4bd7-999a-19e655e03caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3a075355-c9b2-4971-9550-c5fed24600f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3a075355-c9b2-4971-9550-c5fed24600f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3d26607f-ed52-42b8-92e9-bd7be6d4261e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3d26607f-ed52-42b8-92e9-bd7be6d4261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_aa46c26e-9359-4ae9-9275-84a34f5fbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_aa46c26e-9359-4ae9-9275-84a34f5fbd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_98588c32-b610-40e4-9724-01c91df4799b" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_98588c32-b610-40e4-9724-01c91df4799b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f6ab455-88e1-44b9-bb67-0769d3819e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f6ab455-88e1-44b9-bb67-0769d3819e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_4c3381df-f45f-417d-b94d-666a0b1b2511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_4c3381df-f45f-417d-b94d-666a0b1b2511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_398617b6-43bc-4f62-a3f9-3ab76da12dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_398617b6-43bc-4f62-a3f9-3ab76da12dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_610c7394-48b4-4648-aace-64ffb9799469" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_610c7394-48b4-4648-aace-64ffb9799469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_c2940938-079c-4ba3-b74e-851c7d564d08" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_c2940938-079c-4ba3-b74e-851c7d564d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_376594bb-65cc-4785-a48d-e47d4215edd3" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_376594bb-65cc-4785-a48d-e47d4215edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1cf6e281-2e15-40cd-8968-ceeec90854ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1cf6e281-2e15-40cd-8968-ceeec90854ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_4bb1887e-465e-4318-9bc2-14f969054b57" xlink:href="amed-20230331.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_4bb1887e-465e-4318-9bc2-14f969054b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d065fcee-b387-4c93-a83d-fe3bfbaf73f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d065fcee-b387-4c93-a83d-fe3bfbaf73f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_48cfbb7c-32d8-471d-b5af-04b89a801a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_RestrictedCash_48cfbb7c-32d8-471d-b5af-04b89a801a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_424e9693-9c0c-47f6-8737-04e59165bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_424e9693-9c0c-47f6-8737-04e59165bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a48501bf-f7cd-4cee-93a8-7d4eee7a72b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0bc90523-0a70-4629-a44f-3cd995ddd600" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a48501bf-f7cd-4cee-93a8-7d4eee7a72b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fb5b93e7-9787-4bff-a7b4-c843d938cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fb5b93e7-9787-4bff-a7b4-c843d938cc91" xlink:to="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4ff878f-6553-46c8-a414-4a11c18c9dbb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_d9b56e1c-e19c-499f-ae36-2b9e86f4336d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_LoansPayableMember_d9b56e1c-e19c-499f-ae36-2b9e86f4336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_16bae182-c004-4ed5-87e7-9defca5c6287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_16bae182-c004-4ed5-87e7-9defca5c6287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_2cbe724d-5b64-49e5-96e2-4be29ad9b792" xlink:href="amed-20230331.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_amed_PromissoryNotesMember_2cbe724d-5b64-49e5-96e2-4be29ad9b792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_94cf0d4e-813f-4fd4-a672-ac4852dbef90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3207c042-4001-41de-80a6-043abed51ab7" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_94cf0d4e-813f-4fd4-a672-ac4852dbef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_73d0667a-1200-4905-849d-2cf9c87c1d08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_08bf3bb9-a9e7-402a-bfd6-0ca99be84639" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_08bf3bb9-a9e7-402a-bfd6-0ca99be84639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_358d7979-c283-4a39-8b53-5018371421ad" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_358d7979-c283-4a39-8b53-5018371421ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8e13aeb0-55d3-48ff-826b-cc38fc765103" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff32784-09e9-4429-b9e3-c81bcec421cb" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8e13aeb0-55d3-48ff-826b-cc38fc765103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_85cf0791-035f-4748-b719-1d4dc143810a" xlink:to="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_811c0a7d-fb3f-4354-9761-6cc25eac9b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d6d3b9f6-04d8-4efb-ae77-79fd0e8b1c5e" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_811c0a7d-fb3f-4354-9761-6cc25eac9b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81d1681a-778c-4ca0-84e8-d43fd1988d61" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_380593ff-7882-4d7c-9bdd-c006f27ec574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_380593ff-7882-4d7c-9bdd-c006f27ec574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fbdb890f-9e6b-4e2c-89a5-a26a4b7f869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fbdb890f-9e6b-4e2c-89a5-a26a4b7f869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d568196-c82c-4be9-b909-59f2b39d5c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebt_4d568196-c82c-4be9-b909-59f2b39d5c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1ff02dde-d784-4595-88ee-557e216e9c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebtCurrent_1ff02dde-d784-4595-88ee-557e216e9c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fc6899f1-11c1-4b80-bb6c-3dbaacc6a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e9868075-04e8-4a42-9f4e-6e6234e96895" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fc6899f1-11c1-4b80-bb6c-3dbaacc6a7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b6799458-9c8b-4477-8307-dbd8e1b2348c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6799458-9c8b-4477-8307-dbd8e1b2348c" xlink:to="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ff5833-01e4-4fe2-8ee4-3174cb010987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1032c8bf-a76b-401e-a601-e881884d54e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:to="loc_us-gaap_LoansPayableMember_1032c8bf-a76b-401e-a601-e881884d54e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_36c6bf6a-da7e-4a49-9c26-c2df42e987f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ef1081cc-c85a-494f-b45e-938075b152be" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_36c6bf6a-da7e-4a49-9c26-c2df42e987f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a61aea32-c8a9-41ef-a8a5-0189bbf5db1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_95935e58-a0f8-4bfa-9c32-09001be0e409" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_95935e58-a0f8-4bfa-9c32-09001be0e409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_a615cc82-5fbb-4acf-9a22-4855ae917f1a" xlink:href="amed-20230331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_a615cc82-5fbb-4acf-9a22-4855ae917f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c25d190f-028a-47ae-ada4-0e2d15f22e15" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c25d190f-028a-47ae-ada4-0e2d15f22e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_cadd7e94-9822-45ce-8585-6c94029c744e" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf1aab5-3080-4b89-8943-a51012c27c09" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_cadd7e94-9822-45ce-8585-6c94029c744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_07072cbd-17b4-4557-ab5c-cf3014287005" xlink:to="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e861f667-a2a1-4876-bdfc-3c0f160c6b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_72be5416-b233-49c3-8557-74976b02a324" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e861f667-a2a1-4876-bdfc-3c0f160c6b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f1ea96ef-a44f-4fe2-b1e6-a3171a4a24db" xlink:to="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2705fc5e-19f4-4361-9f48-dbf0fda9d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2705fc5e-19f4-4361-9f48-dbf0fda9d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_dc646c2a-b6cc-4dbb-aa86-49acf8b192ff" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_dc646c2a-b6cc-4dbb-aa86-49acf8b192ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_202b5507-a2ac-435f-935d-2a34db732b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_202b5507-a2ac-435f-935d-2a34db732b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ff8bb37d-d16e-4194-8cb5-759ef2d16212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ff8bb37d-d16e-4194-8cb5-759ef2d16212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_108d0013-ddf6-4db5-bdf7-ea61b27c3041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83466a3a-64bc-4f52-b7e8-b94e5656c32e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_108d0013-ddf6-4db5-bdf7-ea61b27c3041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f63eda4e-7938-4851-8f14-e156d0bb0c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f63eda4e-7938-4851-8f14-e156d0bb0c2c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_11d3a2f5-f56f-4239-b15a-b32df722489d" xlink:to="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_524b5619-2322-4540-b072-f9c30905e940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:to="loc_srt_MinimumMember_524b5619-2322-4540-b072-f9c30905e940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e4f6c56-136c-4e17-a05e-fecae4b70c06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1c64401-e1dc-403f-907e-6baf06eb1780" xlink:to="loc_srt_MaximumMember_6e4f6c56-136c-4e17-a05e-fecae4b70c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ec834cb-20c5-4c8e-a398-74aecb94946d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_abb806a5-fc84-46a8-9417-093fa2d882c1" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_abb806a5-fc84-46a8-9417-093fa2d882c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_b3cb61be-73b7-4192-be80-33c026796fc6" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_b3cb61be-73b7-4192-be80-33c026796fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_82e63743-8602-4c38-adb0-1fe71e9399d0" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_82e63743-8602-4c38-adb0-1fe71e9399d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_53bb3a93-a998-48cd-ab19-2c081829a391" xlink:href="amed-20230331.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69ced321-8d40-4d1e-a23f-990ff7a85266" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_53bb3a93-a998-48cd-ab19-2c081829a391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_26f618ab-9b92-48a9-b750-a443327b17d2" xlink:to="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d79e49f1-3558-4661-8e80-b8ffcd51d802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d79e49f1-3558-4661-8e80-b8ffcd51d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1578e3eb-43aa-4f40-88a0-48bc6ca6bdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_55dcda6e-4bd8-4e3e-899b-069cb8442868" xlink:to="loc_us-gaap_BaseRateMember_1578e3eb-43aa-4f40-88a0-48bc6ca6bdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_f2fc9610-7383-48be-aa5f-d4c0e6619824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_45c49069-71fc-4c36-acbb-ff6ad6f15bb0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_f2fc9610-7383-48be-aa5f-d4c0e6619824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_01fb444c-73ca-4a48-807a-05767cc675cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_626e8bd0-7bae-40a6-86b0-06b5144af1d2" xlink:to="loc_us-gaap_CreditFacilityDomain_01fb444c-73ca-4a48-807a-05767cc675cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d4de0654-b218-4bce-8dab-f41f51311ef0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_7c48776f-28fe-48f7-821f-ebe93e374628" xlink:href="amed-20230331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_amed_ConsolidatedLeverageRatio_7c48776f-28fe-48f7-821f-ebe93e374628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dbf3d372-9876-4807-a58a-cbc4b528db7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dbf3d372-9876-4807-a58a-cbc4b528db7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_671b2278-b4d2-4be8-aa60-e4175bfbd21d" xlink:href="amed-20230331.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_amed_LetterOfCreditFee_671b2278-b4d2-4be8-aa60-e4175bfbd21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_832650b9-a7e0-4808-88f0-4dfeb7e67fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_64015028-7ae2-4eb7-8416-b7e8413d2589" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_832650b9-a7e0-4808-88f0-4dfeb7e67fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a9461af9-3b0e-47e3-8c48-6afc0b945d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9461af9-3b0e-47e3-8c48-6afc0b945d07" xlink:to="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fb0e3d49-66e8-4627-ab1c-d20790d81991" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4f48120-4a50-4c1c-99eb-5adef5a70b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e4eacb1f-03bb-4c25-82eb-731d88ce997e" xlink:to="loc_us-gaap_SubsequentEventMember_a4f48120-4a50-4c1c-99eb-5adef5a70b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aae2817e-18cb-47f3-b6cf-d4e54a4e30a7" xlink:to="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b93a975-150c-44ca-a449-ece2dba16bff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:to="loc_srt_MinimumMember_9b93a975-150c-44ca-a449-ece2dba16bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d0ff7a4-78fa-492e-8db1-9d37fa34b87a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0dbf6e27-9940-40fb-83a9-d8eb5fb65846" xlink:to="loc_srt_MaximumMember_4d0ff7a4-78fa-492e-8db1-9d37fa34b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_dd51d4db-5109-4998-aeab-ab4c2cc60098" xlink:to="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_41b8d3c3-c2e3-4a36-9dcc-cfc17b06244c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:to="loc_us-gaap_BaseRateMember_41b8d3c3-c2e3-4a36-9dcc-cfc17b06244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_96134bfc-c1a8-46d9-945e-89b0ae410030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_752dc3db-987a-4a1b-9431-11d014b43b25" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_96134bfc-c1a8-46d9-945e-89b0ae410030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25e667b7-608c-4d71-b9d4-e0c32e82ee88" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_935bbcac-8a08-47f5-b995-e1413177ec7c" xlink:href="amed-20230331.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_SwingLineLoanMember_935bbcac-8a08-47f5-b995-e1413177ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_bb8fa207-13cb-4d00-9ef1-7555f638ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LetterOfCreditMember_bb8fa207-13cb-4d00-9ef1-7555f638ca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7ce7a845-a032-40e8-a70e-dfa1594125ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LoansPayableMember_7ce7a845-a032-40e8-a70e-dfa1594125ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_09a56065-ffa6-4bbb-a14d-e42a52010627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_09a56065-ffa6-4bbb-a14d-e42a52010627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_ae500027-c642-4b59-8712-0382f3e7c194" xlink:href="amed-20230331.xsd#amed_PriorCreditAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_PriorCreditAgreementMember_ae500027-c642-4b59-8712-0382f3e7c194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9d0c7f90-b958-4b93-8f70-ff7869a494c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_LineOfCreditMember_9d0c7f90-b958-4b93-8f70-ff7869a494c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_541e367a-2e0e-47a8-8033-843aad818188" xlink:href="amed-20230331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_AmendedCreditAgreementMember_541e367a-2e0e-47a8-8033-843aad818188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_a9602f98-2d35-4f1c-8651-4282dcbc6d61" xlink:href="amed-20230331.xsd#amed_ThirdAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_a9602f98-2d35-4f1c-8651-4282dcbc6d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_7421200d-a90a-47ba-8bd4-25c964999708" xlink:href="amed-20230331.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_PromissoryNotesMember_7421200d-a90a-47ba-8bd4-25c964999708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_baf3a68c-92e0-4916-967b-b40c58eeface" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_baf3a68c-92e0-4916-967b-b40c58eeface" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember_ddfe699a-e608-4dec-a90c-d81b16c5dd32" xlink:href="amed-20230331.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af42001f-6fec-439d-b3a9-135414f0f779" xlink:to="loc_amed_SecondAmendedCreditAgreementMember_ddfe699a-e608-4dec-a90c-d81b16c5dd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6b95888-c613-4eee-9751-a8c1e1040782" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_ec092b75-7187-43b1-820b-c6da39b865ab" xlink:href="amed-20230331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_AmendedCreditAgreementMember_ec092b75-7187-43b1-820b-c6da39b865ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_7b8ad751-26e1-454b-8802-15e6f71efc55" xlink:href="amed-20230331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_OneHundredMillionTermLoanMember_7b8ad751-26e1-454b-8802-15e6f71efc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f6b29840-306a-403e-99d4-599715bc467e" xlink:href="amed-20230331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f6b29840-306a-403e-99d4-599715bc467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_5821a70e-3473-4a63-9f06-0923f6d6fe21" xlink:href="amed-20230331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_5821a70e-3473-4a63-9f06-0923f6d6fe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f1117e76-892d-408e-b981-00ae6e44162a" xlink:href="amed-20230331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f1117e76-892d-408e-b981-00ae6e44162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_241569e5-2a6b-4dbd-8915-a46903f2aa98" xlink:href="amed-20230331.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_241569e5-2a6b-4dbd-8915-a46903f2aa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_e7b27b72-dfe2-482b-b118-c3f131602b7e" xlink:href="amed-20230331.xsd#amed_ThirdAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_574ea478-d9cb-435d-95f1-49c78a55a20e" xlink:to="loc_amed_ThirdAmendmentToAmendedCreditAgreementMember_e7b27b72-dfe2-482b-b118-c3f131602b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2991788d-a0fc-41a2-8fcc-762e9421977b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e6b633c2-4697-4354-beb6-5492558bc607" xlink:href="amed-20230331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e6b633c2-4697-4354-beb6-5492558bc607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_99587ec9-2e29-4d9d-9897-680ec0c0223a" xlink:href="amed-20230331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_99587ec9-2e29-4d9d-9897-680ec0c0223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_68759756-af5e-42cb-b736-78252e4394b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_68759756-af5e-42cb-b736-78252e4394b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_52ce34d3-805c-403c-b6ed-98af2974764e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_52ce34d3-805c-403c-b6ed-98af2974764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_4fe92e4d-0f7b-4c46-8e5a-d605fb047cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_4fe92e4d-0f7b-4c46-8e5a-d605fb047cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_41a82c4f-a252-42b2-bac8-6248fe17c4c5" xlink:href="amed-20230331.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_TotalLeverageRatio_41a82c4f-a252-42b2-bac8-6248fe17c4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_9272f032-febf-43ee-8670-c602b042c77b" xlink:href="amed-20230331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_9272f032-febf-43ee-8670-c602b042c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf39ad7d-fefb-4cce-b2ef-2326a6eed842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf39ad7d-fefb-4cce-b2ef-2326a6eed842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_f3ca1d21-51e4-41ba-9ff6-323374ba8a43" xlink:href="amed-20230331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_RevolvingCreditFacilityTotal_f3ca1d21-51e4-41ba-9ff6-323374ba8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5eb61f7c-2ae1-4394-adc3-e1547881b816" xlink:href="amed-20230331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5eb61f7c-2ae1-4394-adc3-e1547881b816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_a1c4a039-6c48-4bfd-bee6-9058b15fec05" xlink:href="amed-20230331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_a1c4a039-6c48-4bfd-bee6-9058b15fec05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_2777a126-b855-46ef-9123-82cff9c4110a" xlink:href="amed-20230331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_2777a126-b855-46ef-9123-82cff9c4110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1cf84353-9b46-4eb1-abac-6b538b1735bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1cf84353-9b46-4eb1-abac-6b538b1735bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_56dc1229-2359-4872-bd9a-db127b0f5114" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_56dc1229-2359-4872-bd9a-db127b0f5114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_a02a6012-9790-44b3-a0ef-86fb81cb382f" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate_a02a6012-9790-44b3-a0ef-86fb81cb382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7645e8e3-2162-4269-98db-becb58153e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7645e8e3-2162-4269-98db-becb58153e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_6980f642-35fa-485f-b1bb-9f0ad258f466" xlink:href="amed-20230331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_6980f642-35fa-485f-b1bb-9f0ad258f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_2597e32c-d18b-4fc1-b0e6-a6a63a773c93" xlink:href="amed-20230331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_2597e32c-d18b-4fc1-b0e6-a6a63a773c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_798cd942-a4bc-4161-b9ac-6eeb553e11db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_798cd942-a4bc-4161-b9ac-6eeb553e11db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e5657730-e5ef-4453-832a-1b294b8de2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e5657730-e5ef-4453-832a-1b294b8de2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_22de4361-9e9f-4ea6-b6d8-a9b7b4478374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_22de4361-9e9f-4ea6-b6d8-a9b7b4478374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ef055003-17c2-473c-9a89-9520c873cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ef055003-17c2-473c-9a89-9520c873cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_2e27b852-5a19-472e-8c5a-127d7ddd0995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_2e27b852-5a19-472e-8c5a-127d7ddd0995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_e12e601f-fff1-4cc7-a5da-1ba9ea6d0a62" xlink:href="amed-20230331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_e12e601f-fff1-4cc7-a5da-1ba9ea6d0a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1dc19beb-1a31-43d3-bd1f-f16e35e69631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1dc19beb-1a31-43d3-bd1f-f16e35e69631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9db3e603-22ae-4c59-bb8d-20970ab2bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9db3e603-22ae-4c59-bb8d-20970ab2bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease_3a30c50f-d539-4e72-a27f-5a88f8736b92" xlink:href="amed-20230331.xsd#amed_ReclassificationOfOperatingLeaseToFinanceLease"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_ReclassificationOfOperatingLeaseToFinanceLease_3a30c50f-d539-4e72-a27f-5a88f8736b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationExpenseFleetLeasesFinanceLease_458f17a8-6d57-4cf5-a0a9-b5ca34fcb3fc" xlink:href="amed-20230331.xsd#amed_DepreciationExpenseFleetLeasesFinanceLease"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_DepreciationExpenseFleetLeasesFinanceLease_458f17a8-6d57-4cf5-a0a9-b5ca34fcb3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SOFRAdjustment_3371214c-0d55-4014-a058-0a411f5e061f" xlink:href="amed-20230331.xsd#amed_SOFRAdjustment"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7118e8af-fa25-4adb-b069-53578c5b6629" xlink:to="loc_amed_SOFRAdjustment_3371214c-0d55-4014-a058-0a411f5e061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_90eaf9dd-465b-45d4-8c1d-e35c67ce1097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_90eaf9dd-465b-45d4-8c1d-e35c67ce1097" xlink:to="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:href="amed-20230331.xsd#amed_PayorsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:href="amed-20230331.xsd#amed_PayorsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_8f20a40a-854b-46cd-a9a9-2aca8d89b520" xlink:to="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_3d0bb86e-495f-4d7f-9b74-a9b2e9c2ffb2" xlink:href="amed-20230331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_d26d125d-7019-4c72-bd1f-6ac538556a1d" xlink:to="loc_amed_CompanysinsurancecarriersMember_3d0bb86e-495f-4d7f-9b74-a9b2e9c2ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_dc7405d0-afcc-480a-820f-8b9d430006c2" xlink:to="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_1061ecea-d293-4997-8a72-ddd0353701dc" xlink:href="amed-20230331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_UsDepartmentOfJusticeMember_1061ecea-d293-4997-8a72-ddd0353701dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_3405a090-1f8c-4a39-858f-278e2a446214" xlink:href="amed-20230331.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_AmedisysCIAMember_3405a090-1f8c-4a39-858f-278e2a446214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_02c147fe-35fa-4a92-aaeb-2ead045523b5" xlink:href="amed-20230331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_02c147fe-35fa-4a92-aaeb-2ead045523b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_3a62e70d-e292-4134-bfd1-ae138008c1c9" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_3a62e70d-e292-4134-bfd1-ae138008c1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_745be270-52bc-43df-a9f0-3cf6d0902fc2" xlink:href="amed-20230331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_745be270-52bc-43df-a9f0-3cf6d0902fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_e0f7c304-323a-4c5c-a000-84b929ce2880" xlink:href="amed-20230331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e99c677-24aa-4175-a73b-c989c0278c2e" xlink:to="loc_amed_InternalAuditComplianceReviewMember_e0f7c304-323a-4c5c-a000-84b929ce2880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ad7eff35-7aa4-4ac1-a423-abed49ef90f9" xlink:to="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_b8a62bb6-0b3a-482f-ae9b-5d83d19eea33" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_MA_b8a62bb6-0b3a-482f-ae9b-5d83d19eea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_f491b501-5fec-49bd-8895-1a2398871945" xlink:href="amed-20230331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_amed_MorgantownWestVirginiaMember_f491b501-5fec-49bd-8895-1a2398871945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_17c9edcd-88e6-4c2b-ba6c-bb5eb6136048" xlink:href="amed-20230331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_amed_ParkersburgWestVirginiaMember_17c9edcd-88e6-4c2b-ba6c-bb5eb6136048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_04a0c11e-36cf-4ac8-8309-8b532a318d22" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_SC_04a0c11e-36cf-4ac8-8309-8b532a318d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2a676af5-ae09-41ba-9346-c09345040377" xlink:to="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_1e6edf1e-d3bd-4a89-84e4-ce60b37089ac" xlink:href="amed-20230331.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:to="loc_amed_LakelandFloridaMember_1e6edf1e-d3bd-4a89-84e4-ce60b37089ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_e2d4aa30-860b-48f7-a996-dc66fd0eb534" xlink:href="amed-20230331.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_feceb1c6-6c34-4489-ab96-522a566c45b8" xlink:to="loc_amed_ClearwaterFloridaMember_e2d4aa30-860b-48f7-a996-dc66fd0eb534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4d2debbe-a879-4bd2-a3cc-32f540c82efa" xlink:to="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_772d6242-7739-48bc-93d0-6b8730016231" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:to="loc_amed_HospiceMember_772d6242-7739-48bc-93d0-6b8730016231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_08e2571e-ea5d-44c7-b790-7cb933ded8f8" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e1961c70-13d3-4de4-8001-eed1a04b0025" xlink:to="loc_amed_HomeHealthMember_08e2571e-ea5d-44c7-b790-7cb933ded8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_316d125b-1ad8-44da-ab9e-91c394a6fa34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_1a0fdc9c-60a3-44c6-b8e2-3e47e79204da" xlink:href="amed-20230331.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9e134fd-3916-4500-ad5f-60e5e62496e3" xlink:to="loc_amed_InfinityHomeCareMember_1a0fdc9c-60a3-44c6-b8e2-3e47e79204da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_db3b816e-b4c5-4c8d-a1cd-a36319a2a0d0" xlink:to="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_5bd94323-b3ff-4258-85b4-c2ba6374cfd0" xlink:href="amed-20230331.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:to="loc_amed_ExtrapolatedMember_5bd94323-b3ff-4258-85b4-c2ba6374cfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_02245d0f-244b-453b-8f80-41b9b3707804" xlink:href="amed-20230331.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_893c793b-833d-4e81-a7b1-0a39bbf2e0ed" xlink:to="loc_amed_UnfavorableMember_02245d0f-244b-453b-8f80-41b9b3707804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_53498d88-6938-4bd0-9c76-29ef34880bfd" xlink:to="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c96fa82e-6c80-4ecb-9511-99b9b5cbed47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:to="loc_srt_MinimumMember_c96fa82e-6c80-4ecb-9511-99b9b5cbed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbb22787-4457-4d25-9377-a2e6caac75ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_deae8059-e675-408d-924e-3d2e10c2232c" xlink:to="loc_srt_MaximumMember_dbb22787-4457-4d25-9377-a2e6caac75ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_924f33fa-5548-4007-9305-edca678ca97b" xlink:to="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_efab0eb1-95eb-4b14-bc44-665fc834cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_efab0eb1-95eb-4b14-bc44-665fc834cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_0d7624a1-4b0c-43f5-9431-3a1b1de6154d" xlink:href="amed-20230331.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_Numberofpatients_0d7624a1-4b0c-43f5-9431-3a1b1de6154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_61b65bd6-ff9f-4afb-9898-63cc1ed74e6b" xlink:href="amed-20230331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_61b65bd6-ff9f-4afb-9898-63cc1ed74e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a477806a-20b5-4b33-b730-e256e97d53da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a477806a-20b5-4b33-b730-e256e97d53da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2a30fd50-bac1-4295-b6a1-a2bab1f966b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2a30fd50-bac1-4295-b6a1-a2bab1f966b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_041c3d91-e24c-49c1-8a92-35e60e4db70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_041c3d91-e24c-49c1-8a92-35e60e4db70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_d97ff3ba-5889-42ae-93e4-86a151fc8e9a" xlink:href="amed-20230331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_d97ff3ba-5889-42ae-93e4-86a151fc8e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_d3ab3a6a-a21a-4e8f-a3c0-2e72bdca302b" xlink:href="amed-20230331.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_NumberOfBeneficiaries_d3ab3a6a-a21a-4e8f-a3c0-2e72bdca302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_416dba87-2900-49ad-9d7a-f55ec7410745" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_416dba87-2900-49ad-9d7a-f55ec7410745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4755048c-660d-4006-a16d-dab7cf3b175f" xlink:href="amed-20230331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4755048c-660d-4006-a16d-dab7cf3b175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_c37fb9f4-02ed-46a0-ab33-0d8a92716b4d" xlink:href="amed-20230331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_c37fb9f4-02ed-46a0-ab33-0d8a92716b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1443a0fc-f622-4cb0-943c-7459fcf5274a" xlink:href="amed-20230331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1443a0fc-f622-4cb0-943c-7459fcf5274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_c28a6274-ddf7-4b36-a71a-d86add504d53" xlink:href="amed-20230331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_c28a6274-ddf7-4b36-a71a-d86add504d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_d3e20683-f074-416f-8ea6-7b57304736bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_d3e20683-f074-416f-8ea6-7b57304736bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_61cbf143-5efb-42a7-a127-7972c31485e0" xlink:href="amed-20230331.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ActualClaimsPayment_61cbf143-5efb-42a7-a127-7972c31485e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_a3b5da51-d6b5-49a3-b14a-2ddba7eb0d62" xlink:href="amed-20230331.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ErrorRatePercentage_a3b5da51-d6b5-49a3-b14a-2ddba7eb0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_63c4e16c-e6d6-4dfa-b9eb-11b34bc451e2" xlink:href="amed-20230331.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_IndemnificationAmount_63c4e16c-e6d6-4dfa-b9eb-11b34bc451e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_11d6e5dc-9ae0-453f-99f0-1f2931b18127" xlink:href="amed-20230331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_FloridaZpicRevenueReduction_11d6e5dc-9ae0-453f-99f0-1f2931b18127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_1169c3b9-f09d-440e-a63b-5914af4a5296" xlink:href="amed-20230331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_HealthInsuranceRetentionLimit_1169c3b9-f09d-440e-a63b-5914af4a5296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_12c2892a-7d51-4008-931f-8b73a73bf8d0" xlink:href="amed-20230331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_12c2892a-7d51-4008-931f-8b73a73bf8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f7a3d7d4-b71e-4a2f-b67d-8890c83bad77" xlink:href="amed-20230331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f7a3d7d4-b71e-4a2f-b67d-8890c83bad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_fc89f2e3-7c9c-44d9-83ed-d5adb8fc3567" xlink:href="amed-20230331.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_fc89f2e3-7c9c-44d9-83ed-d5adb8fc3567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_870faa41-f613-4abc-8f45-6558467a8674" xlink:href="amed-20230331.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_ReductionToNetServiceRevenue_870faa41-f613-4abc-8f45-6558467a8674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment_5e6cc778-eaeb-475e-9ee8-b87f005b49c0" xlink:href="amed-20230331.xsd#amed_TotalLegalSettlementPayment"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_TotalLegalSettlementPayment_5e6cc778-eaeb-475e-9ee8-b87f005b49c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest_557274eb-98cb-45c6-a360-6281eed085a6" xlink:href="amed-20230331.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_LegalSettlementPaymentLessInterest_557274eb-98cb-45c6-a360-6281eed085a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_dce842ce-2315-4535-b980-8c3a9d57e849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_LitigationSettlementInterest_dce842ce-2315-4535-b980-8c3a9d57e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_6063f16e-08dd-4242-81eb-1ec95a8fc181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_6063f16e-08dd-4242-81eb-1ec95a8fc181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetInsuranceExposureLimit_0aa09f45-822f-41ba-b746-251606bc3114" xlink:href="amed-20230331.xsd#amed_FleetInsuranceExposureLimit"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_604ac4d6-bc5f-4b58-8d32-63c247c4b998" xlink:to="loc_amed_FleetInsuranceExposureLimit_0aa09f45-822f-41ba-b746-251606bc3114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f0256796-d0e7-48d2-867c-612c65b2528b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1684817f-4594-42aa-ad77-b21ce2b9f524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f0256796-d0e7-48d2-867c-612c65b2528b" xlink:to="loc_us-gaap_NumberOfReportableSegments_1684817f-4594-42aa-ad77-b21ce2b9f524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ece165a4-2882-4c64-b64c-90474d243668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ece165a4-2882-4c64-b64c-90474d243668" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c0005908-6503-4a71-9b15-b4738ec7cc3c" xlink:to="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bc115a96-e3c6-41a2-bc56-673b410e8373" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HomeHealthMember_bc115a96-e3c6-41a2-bc56-673b410e8373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_5cfc7953-9335-4eb9-a05b-9faafbf70583" xlink:href="amed-20230331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HospiceMember_5cfc7953-9335-4eb9-a05b-9faafbf70583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_aced22dc-c713-4166-9464-e15cbfeea886" xlink:href="amed-20230331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_PersonalCareMember_aced22dc-c713-4166-9464-e15cbfeea886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_6fd73730-7506-4167-8f67-bae7583bd0a6" xlink:href="amed-20230331.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_amed_HighAcuityCareMember_6fd73730-7506-4167-8f67-bae7583bd0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_6b9d6c15-7115-4553-af5c-c153ef43510f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_397f2683-2b06-4ab7-ba87-9cb9c09296d8" xlink:to="loc_us-gaap_AllOtherSegmentsMember_6b9d6c15-7115-4553-af5c-c153ef43510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_917ff7a6-5e1e-4266-99ff-924d5cba00ac" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f6318924-7ba0-4172-95a1-d03f4bfa9620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f6318924-7ba0-4172-95a1-d03f4bfa9620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0cb89ed2-e6fa-457c-b0f8-7fc9f0cfdab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0cb89ed2-e6fa-457c-b0f8-7fc9f0cfdab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_28d498ee-5d63-4456-b538-d4198d6c8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_28d498ee-5d63-4456-b538-d4198d6c8db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dcf7995e-3638-4b39-93b6-4f83637418ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dcf7995e-3638-4b39-93b6-4f83637418ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e055dc30-a11e-44cd-a2a8-007947a8f936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_DepreciationAndAmortization_e055dc30-a11e-44cd-a2a8-007947a8f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1237783f-de8e-4a87-b42b-8ee05d9f4362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_CostsAndExpenses_1237783f-de8e-4a87-b42b-8ee05d9f4362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_108f70ae-f2f0-4cf7-93ef-2a545bd94317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1a871e49-e36f-4baa-a781-a34187645eee" xlink:to="loc_us-gaap_OperatingIncomeLoss_108f70ae-f2f0-4cf7-93ef-2a545bd94317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_79395c6e-2637-4ef7-9069-72d6abadaeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_79395c6e-2637-4ef7-9069-72d6abadaeb1" xlink:to="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3ea87572-cb72-4f84-b796-befdc6cbddce" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_0074f348-560d-4915-95cb-46d4280ab7dd" xlink:href="amed-20230331.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_0074f348-560d-4915-95cb-46d4280ab7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_a3942bc5-9b29-49ec-8796-ac437e4f137d" xlink:href="amed-20230331.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_a3942bc5-9b29-49ec-8796-ac437e4f137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_450e10d3-c5f6-46c7-ae72-11c5ba44e9e7" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_ShareRepurchaseProgramMember_450e10d3-c5f6-46c7-ae72-11c5ba44e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_80265bbf-ee9a-4fed-a402-e541b1beeabe" xlink:href="amed-20230331.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_80265bbf-ee9a-4fed-a402-e541b1beeabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022ShareRepurchaseProgramMember_4bf5e9bd-0ac8-4e65-b2c5-93bb26dfc5c2" xlink:href="amed-20230331.xsd#amed_A2022ShareRepurchaseProgramMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2022ShareRepurchaseProgramMember_4bf5e9bd-0ac8-4e65-b2c5-93bb26dfc5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_f00680b6-1c57-4526-88bc-bf75637b4c7c" xlink:href="amed-20230331.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df1177b7-b055-4f5e-96e7-156aac56000b" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_f00680b6-1c57-4526-88bc-bf75637b4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84889251-b6e6-4b70-8b68-cef1fde34d7f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6309fe27-2b1b-4311-9e1e-c4c28788558f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2903e85a-d010-4f9e-80d3-0f7ea1a6108c" xlink:to="loc_us-gaap_SubsequentEventMember_6309fe27-2b1b-4311-9e1e-c4c28788558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:href="amed-20230331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_ff17f5bb-90c8-4e87-9547-54bbb95ad230" xlink:to="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca7061ea-e860-442a-b009-8f15fbf6bc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca7061ea-e860-442a-b009-8f15fbf6bc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_07723bb4-0978-405e-a60f-b20f80b0c296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_07723bb4-0978-405e-a60f-b20f80b0c296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ec1d51cd-9f90-499a-9d72-09b865059106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ec1d51cd-9f90-499a-9d72-09b865059106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_1308f163-10de-43b5-8d68-3c0fc4fc200c" xlink:href="amed-20230331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_PercentageofSharesOutstanding_1308f163-10de-43b5-8d68-3c0fc4fc200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4187587c-4b50-48f8-bc2f-c8a673f985be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4187587c-4b50-48f8-bc2f-c8a673f985be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_24b3d719-41be-4dc6-ba00-745ed51f28d3" xlink:href="amed-20230331.xsd#amed_Discountedclosingstockprice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_Discountedclosingstockprice_24b3d719-41be-4dc6-ba00-745ed51f28d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_885c65e8-2257-4643-9504-15bffa816920" xlink:href="amed-20230331.xsd#amed_Percentageofclosingstockprice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_amed_Percentageofclosingstockprice_885c65e8-2257-4643-9504-15bffa816920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4baf1831-1563-4d37-b49a-45e6ac0ce790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_19bdb157-5d87-4554-b030-b1a929750c22" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4baf1831-1563-4d37-b49a-45e6ac0ce790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9092b87b-0792-4c70-ba46-75542bd83473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9092b87b-0792-4c70-ba46-75542bd83473" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb4f374b-38a4-4a21-924d-39cc9b74ac25" xlink:to="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6429dab2-c745-485c-a1ef-ad357403a9c5" xlink:href="amed-20230331.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5e93e045-ab0d-47a7-a075-8b59636b9447" xlink:to="loc_amed_MedalogixMember_6429dab2-c745-485c-a1ef-ad357403a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_82af553a-9ae5-4fbb-8cc0-e89cdf79309c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cff4bf7e-93b6-4d5c-91d8-b72a9dd9fc16" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_82af553a-9ae5-4fbb-8cc0-e89cdf79309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8eaf3afc-c813-4dc4-beca-746dbbf619cd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_20e68555-96f8-4382-9ab7-a44cda620c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e7e4ec4d-aec3-4d0a-af14-fe6ebf22a304" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_20e68555-96f8-4382-9ab7-a44cda620c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20230331.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ad081a36-4638-46dd-957b-2c29a995161a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ad081a36-4638-46dd-957b-2c29a995161a" xlink:to="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f3c67885-8343-4649-8daf-e380b31461a4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_da0ad066-5c4a-419a-b7d9-1bd39b7186d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f369f666-314c-438f-afe1-fe305f021a69" xlink:to="loc_us-gaap_SubsequentEventMember_da0ad066-5c4a-419a-b7d9-1bd39b7186d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_45a10b29-b02b-4883-ae46-243113a807ab" xlink:to="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_1e013474-9bd7-491e-ab34-a4263e343925" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f3e058a5-1d6e-486e-b839-3a2b31e3332b" xlink:to="loc_stpr_NC_1e013474-9bd7-491e-ab34-a4263e343925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93f2d5ec-7c93-4bdf-9478-7b7a57bfcaf5" xlink:to="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_55600896-6e38-4493-a571-817c93cb8b20" xlink:href="amed-20230331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3532904b-03d3-45d0-8d3f-59925fc99635" xlink:to="loc_amed_HomeHealthMember_55600896-6e38-4493-a571-817c93cb8b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b322cab-befd-401e-91ef-5985439244e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be253eec-6b3b-4281-8f38-689ea992d28f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b322cab-befd-401e-91ef-5985439244e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07a70b65-b971-40f4-ac89-6d0ab4564118" xlink:to="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionShareExchangeRatio_942832de-dcaa-44d7-a1e0-8e2b8347b6fd" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionShareExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:to="loc_amed_BusinessAcquisitionShareExchangeRatio_942832de-dcaa-44d7-a1e0-8e2b8347b6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTerminationFee_c6ca104f-b441-44b0-98eb-bc78b04506d2" xlink:href="amed-20230331.xsd#amed_BusinessAcquisitionTerminationFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_84552af1-245d-4cb1-9b77-87b79f18ba45" xlink:to="loc_amed_BusinessAcquisitionTerminationFee_c6ca104f-b441-44b0-98eb-bc78b04506d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>amed-20230331_g1.jpg
<TEXT>
begin 644 amed-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***;+*D$32S.J1H-S,QP /6@!7=
M8T9Y&"JHRS,< #UKS[Q-XZ>??9Z(Y2/H]R.&;_=]![]:S_%7BV76)&M;)FCL
M5/T,I]3[>@_R.8K@K5[^[$XZM:^D0)).3R:***Y#E"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH M:=J5WI5VMQ8S-'(.N.C#T([BO4/#GBNVUV,
M1/B"\4?-$3PWNOK].H_6O):?%+)!,LL+M'(ARK*<$&M:=65-^1K3J.#/=J*Y
M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
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M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
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MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
M]<15X7XF5A_B9JT445WG:%%%% '*>.?$$NEVD=G9N4N+@$LXZHGM[FO,223D
M\FNH^()<^)_G^Z(5V_3G^N:Y>O+KR<INYY]:3<V%=5X(U^2PU..PG<FUN6VJ
M"?N.>A'U/%<K4EN76ZB,7WPX*X]<\5G"3C*Z,XR<7='NM%(N=HSUQS2U[!Z@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
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M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
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MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
M"BBB@ KE/B!J?V30UM$;$EVV#_N#D_K@5U=>2>,M4_M/Q%-L;,5O^Z3GCCJ?
MSS6%>?+#U,:TN6!@T44H!9@J@DDX '>O,//.S^'6E^=?S:C(ORP#9'G^\>I_
M ?SKT6LWP_I@TC0[>UP X7=(1W8\G_#\*TJ]6E#D@D>E3CRQL%%%9NOZLNBZ
M--=M@N!MB4_Q.>G^/T%:-I*[+;25V87C'Q:VFYT_36Q=$?O)!_RR![#W_E7F
MS,SN6=BS,<DDY)-.FFDN)GFF8O)(Q9F/4D]Z97E5*CF[L\Z<W-W845>TG1[S
M6KOR+&+<1R[GA4'J37H.F> -,M(U:_W7DW?<2J ^P']:<*4I[!"G*>QYA17M
M<>B:7$FV/3K4#_KBO^%5[KPMHMXI$FG0H?6)?+/_ ([BMOJLNYM]7EW/'**Z
MWQ)X(ETR-KO36:XMEY=#]^,>ON/\^]<E7-*$H.S.>47%V9N>&O$UQH-T%),E
MFY_>19Z?[2^A_G7K-O/%=6\<]NX>*10RL.X->%5WGP[UEB9-)G;( ,D&3T_O
M+_7\ZZ</5:?(SHH5&GRL[VBBBN\[ HHHH **** "L_7-+36-'GLVP&=<QL?X
M6'(/YUH44FDU9B:NK,\MT'P3>ZG+OO@UG;*<$L/G?'8#^O\ .O1-,T:QT>#R
M["!8\CYG/+-]35ZBLZ=*,-B(4XPV"BBBM30**** "BBB@ (#*0PR#P0>]>=>
M,O"2V2MJ6F)B#/[Z%1_J_<>WMV^G3T6FRQI-"\4JAT=2K*>A!ZBLZE-35F1.
M"FK,\(HJ_KFFMI&M7%F>5C;*$]U/(_2J%>4TT[,\UJSL=K\.M5,5]+IDC?),
M#)&/1AU'XC^5>B5XCI5Z=/U:UNP<>5*K'W&>1^6:]N!STKOPTKQMV.VA*\;=
M@HHHKJ.@**** /%-;_Y#^H?]?,G_ *$:HU>UO_D/ZA_U\R?^A&J->-+=GE/<
MO:7?/ITEQ/$X24P-&G7)W8''T'/X51HK:\+Z&=<UA8G!^SQ?/,1Z>GXTTG)J
M*&KR:2-7PAX1_M/;?ZDI%H#^[C_YZX_I_.O2$1(HU2-51%&%51@ 4(BQQJD:
MA44 *H& !Z4ZO4ITU35D>C""@K(****T+"BBB@"CJ^DVNLV#6MXF0>4<=4/J
M*\?U339M)U*:SN/O1GA@.&'8CZU[=7&_$/2A/IL6HQ+^\MVVR$=T/^!Q^=<V
M(IJ4>9;HYZT+KF1YQ5G3[V33M0@NX#AX7##W]1^(XJM17G)VU.+8Z#Q=KRZY
MJ49MR?LT48" ^I&6/]/PKGZ*VO"VB'6]92)Q_H\7SS'V]/Q_QJ_>J2\V5K.7
MJ:W@_P (C40NH:FG^B@_NXS_ ,M#ZGV_G7I"(L:*D:A54855& !Z4(BQQJD:
MA54850, #TI:].G34%9'H0@H*R"BBBM"PHHHH J:GIEMJUB]K>1AT;H>ZGU'
MO7C^L:5-HVIRV=QSM.4<='7L:]KKDOB!I0NM&6^C7][:M\Q]4/!_7!_.N;$4
MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
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MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
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MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
MKQGQ'IYTSQ!=V^,()"R?[K<C^>*]FKB?B)I'FVL6J0KEH?W<N/[I/!_ G'XU
MSXB'-"_8PKQO&_8\\K>\':H-+\11&1L0SCR7/IGH?SQ^M8-%>=&3B[HXHMQ=
MT>\T5S7@SQ"-7TX6UR^;RW7#9/,B]F_H?_KUTM>O&2DKH]*,E)7044451044
M44 %%%% !1110 4444 %%%% !1110 5F^(; ZEH%W;*,NT9*#_:'(_E6E12:
MNK":NK'@U%;/BO2CI/B">)5Q#(?-BXXVGM^!R*QJ\>2<79GEM-.S.W^'.IB.
MZN--D8 2CS(\_P!X=1^7/X5Z%7AEG=RV-[%=6[;9(F#*:]FTC5(=8TR*\MSP
MXPRYY1NXKNPT[QY6=E"=UREVBBBNLZ0HHHH **** "BBB@ ID\T=M;R33-MC
MC4LQ/8"GUP?C[Q",?V1:/SP;A@?R7^I_"HJ34(W9$Y*$;G&ZI?OJ>J7%Y)P9
MG+ 9^Z.P_ 54HHKR&[NYYKU"O9/#'_(KZ?\ ]<17C=>R>&/^17T__KB*Z\+\
M3.C#_$S5HHHKO.T**** ,_Q!_P BYJ/_ %[2?^@FO%J]I\0?\BYJ/_7M)_Z"
M:\6K@Q7Q(X\1N@KT7X;?\@N\_P"NP_\ 0:\ZKT7X;?\ (+O/^NP_]!K/#_Q$
M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
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M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
MU>MUY)X)_P"1PLO^!_\ H#5ZW7;A?@^9UX?X HHHKJ.@**** "LG7_#MIKUK
MMF'ESJ/W<ZCE?8^H]JUJ*32DK,32:LSQ?6-#OM$N?*O8L*3\DJ\J_P!#_2LZ
MO=;BVANX&AN8DEB;JCKD&N+U?X=QR,TNC3>4>OD2DE?P;J/QS]:X:F&:UB<<
MZ#6L3SZBKVH:-J&EL1?6DD0SC>1E3]&'%4:Y&FM&<[36Y;M]5U"TXMKZXB'H
MDK ?EFM"+QAKT0PNHN?]]%;^8K$HJE*2V8U*2V9OOXVU]QC[=M_W8D']*I3^
M(M8N 1+J5R0>H60J#^ K-HH<Y/=@YR>[%9V=BSL68]23DFDHJ6"VGNI1';0R
M32'HL:EC^0J1$52VUK/>W"P6D3S2MT5!DUU.D_#Z^NBLFIN+.+^X/F<_T'^>
M*[W2]%L=&@\JP@"9^\YY9OJ:Z*>'E+5Z&T*,I;Z'/^&/!4>FLEYJ@66Z'*1]
M5B/]3_+]:ZZBBO0C!05D=L8J*L@HHHJB@HHHH *;)&DL;1RJ'1AAE89!%.HH
M \S\4>#)=.9[S3$:6TZM&.6B_P 17)5[S7*Z]X&M-39I[ K:7))+#'R.?<=O
MJ/RKBJX?K Y*E#K$\PHK1U+0-2TF0B\M7"CI(HW(?QK.KC::=F<K36C)[>]N
MK0YM+F: _P#3.0K_ "K3C\7Z[&@5=1D(']Y5)_,BL6BA2DMF-2:V9N'QCKQ&
M/[0;\$7_  JC<ZUJ=V"+F_N)%/53(<?ETJC13<Y/=@Y2>["BE56=@J*68] !
MG-=/H_@34=0*R7G^AP'G+C+D>R_XT1C*3LD$8N3LCGK.RN-0NTMK.)I97/"K
M_/V%>J>&/#$6@VQ>0B6\D'SR=E']T>W\ZO:1H=CHD'EV,6&(^>1N6?ZFM"N^
ME04-7N=M.BHZO<X_XD?\@.U_Z^1_Z"U>;5Z3\2/^0';?]?(_]!:O-JYL1_$.
M>O\ &%>R>&/^17T__KB*\;KV3PQ_R*^G_P#7$5>%^)E8?XF:M%%%=YVA1110
M!G^(/^1<U'_KVD_]!->+5[3K_P#R+FH_]>TG_H)KQ:N#%?$CCQ&Z"O1?AM_R
M"[S_ *[#_P!!KSJO1?AM_P @N\_Z[#_T&L\/_$1%#XSM****],[PHHHH 1T6
M1&1U#*PP01D$5Y=XL\*2:/,UW9*SV+GMR8CZ'V]#_D^I4CHLB,DBAD8896&0
M1Z5E4IJHK,SJ4U-69X/17H6N_#Z.8M/HC")^IMW/RGZ'M]#^E<->Z=>:;-Y5
M];R0/VWC@_0]#^%>=.G*&YPRIRAN5U8JP9200<@@]*T8/$>L6R[8M2N0/1I"
MV/SK-HJ$VMB$VMC:_P"$OUXKC^T9/^^5_P *H76JW]\"+R\GF!_A>0D?ETJI
M13<I/=C<I/=A1170:1X-U352KO$;2 _\M9A@D>R]3_+WI1BY.R!1<G9&+:6D
M]]=);6D;2RR'"JHKUSPWH$6@::(AA[B3YII /O'T'L*DT30++0K?9:)ND8?O
M)F^\_P#@/:M.O0HT>35[G;2I<FKW"BBBNDW"BBB@ HHHH **** .<\;Z5_:7
MA]Y(US-:GS5]2/XA^7/X5Y37O! 92&&01@@UXSXATW^R=>N;1?N*VZ/_ '3R
M/YXKAQ4-5(X\1'7F,VBBBN,Y3K_A[I?VG5GOY%S':KA?=S_@,_I7I59'AC2_
M[)T"W@9<2L/,E_WCV_#I^%:]>K1AR02/2I1Y8V"BBBM30**** "BBB@ KG?%
M?A=-=MO.M\)>Q+A"> X_NG^AKHJ*F45)69,HJ2LSPF:&6VG>&>-HY$.&1A@@
MTRO8=<\,V&NQYN%\NX PLZ?>'L?45YWK'A#5-(9F,1N;<=)H1GCW'4?R]Z\Z
MI1E#S1PSI2CZ&%5FUU*]LO\ CSNYX!Z1R%1^55J*PNUL9;&ROBW75Z:E+^(4
M_P!*BG\3:U<KB74KC'HC[?Y8K+HJN>7<?-+N*[M(Y9V+,3DDG)-)15NPTN]U
M27R["VDF;N5' ^IZ"I2;>@M65*[3P5X5>YFCU348\0(=T,;#_6'LWT_G6EH'
M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682616480176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,559,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682615960816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,436<span></span>
</td>
<td class="nump">$ 40,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">19,664<span></span>
</td>
<td class="nump">13,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">294,122<span></span>
</td>
<td class="nump">296,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">18,754<span></span>
</td>
<td class="nump">11,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">23,581<span></span>
</td>
<td class="nump">26,415<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">405,557<span></span>
</td>
<td class="nump">388,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $105,183 and $101,364</a></td>
<td class="nump">33,353<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">85,211<span></span>
</td>
<td class="nump">102,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,244,679<span></span>
</td>
<td class="nump">1,287,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $16,071 and $14,604</a></td>
<td class="nump">99,929<span></span>
</td>
<td class="nump">101,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">78,230<span></span>
</td>
<td class="nump">79,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,946,959<span></span>
</td>
<td class="nump">1,976,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">40,017<span></span>
</td>
<td class="nump">43,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">122,723<span></span>
</td>
<td class="nump">125,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">137,899<span></span>
</td>
<td class="nump">137,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">26,958<span></span>
</td>
<td class="nump">15,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">25,453<span></span>
</td>
<td class="nump">33,521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">353,050<span></span>
</td>
<td class="nump">355,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">373,202<span></span>
</td>
<td class="nump">419,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">59,826<span></span>
</td>
<td class="nump">69,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">22,752<span></span>
</td>
<td class="nump">20,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">4,781<span></span>
</td>
<td class="nump">4,808<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">813,611<span></span>
</td>
<td class="nump">869,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 7</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">758,669<span></span>
</td>
<td class="nump">755,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock</a></td>
<td class="num">(462,508)<span></span>
</td>
<td class="num">(461,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">782,918<span></span>
</td>
<td class="nump">757,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">1,079,117<span></span>
</td>
<td class="nump">1,051,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">54,231<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">1,133,348<span></span>
</td>
<td class="nump">1,106,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,946,959<span></span>
</td>
<td class="nump">$ 1,976,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682618796528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 105,183<span></span>
</td>
<td class="nump">$ 101,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 16,071<span></span>
</td>
<td class="nump">$ 14,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,938,354<span></span>
</td>
<td class="nump">37,891,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,544,145<span></span>
</td>
<td class="nump">32,511,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">5,394,209<span></span>
</td>
<td class="nump">5,379,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682618844176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED INCOME STATEMENT - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 556,389<span></span>
</td>
<td class="nump">$ 545,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">315,010<span></span>
</td>
<td class="nump">304,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">126,339<span></span>
</td>
<td class="nump">123,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">8,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">64,945<span></span>
</td>
<td class="nump">53,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">514,010<span></span>
</td>
<td class="nump">497,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">42,379<span></span>
</td>
<td class="nump">47,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,517)<span></span>
</td>
<td class="num">(3,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings (loss) from equity method investments</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="num">(682)<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(7,670)<span></span>
</td>
<td class="num">(4,230)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">34,709<span></span>
</td>
<td class="nump">43,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(9,800)<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">24,909<span></span>
</td>
<td class="nump">31,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">337<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 25,246<span></span>
</td>
<td class="nump">$ 31,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,558<span></span>
</td>
<td class="nump">32,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">32,643<span></span>
</td>
<td class="nump">32,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682616518576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2021</a></td>
<td class="nump">$ 976,323<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 728,118<span></span>
</td>
<td class="num">$ (435,868)<span></span>
</td>
<td class="nump">$ 639,063<span></span>
</td>
<td class="nump">$ 44,972<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(4,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ContributionsAttributableToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">9,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">31,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,671<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2022</a></td>
<td class="nump">1,020,652<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">736,536<span></span>
</td>
<td class="num">(440,550)<span></span>
</td>
<td class="nump">670,734<span></span>
</td>
<td class="nump">53,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,763,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2022</a></td>
<td class="nump">1,106,573<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">755,063<span></span>
</td>
<td class="num">(461,200)<span></span>
</td>
<td class="nump">757,672<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,891,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(1,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">24,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,246<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2023</a></td>
<td class="nump">$ 1,133,348<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 758,669<span></span>
</td>
<td class="num">$ (462,508)<span></span>
</td>
<td class="nump">$ 782,918<span></span>
</td>
<td class="nump">$ 54,231<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,938,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ContributionsAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ContributionsAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612482240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 24,909<span></span>
</td>
<td class="nump">$ 31,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization (inclusive of depreciation included in cost of service)</a></td>
<td class="nump">5,694<span></span>
</td>
<td class="nump">8,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">8,622<span></span>
</td>
<td class="nump">10,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on personal care divestiture</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in (earnings) loss from equity method investments</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity method investments</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(7,476)<span></span>
</td>
<td class="num">(18,618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">7,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(918)<span></span>
</td>
<td class="num">(749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,457)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">7,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(7,960)<span></span>
</td>
<td class="num">(9,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">25,961<span></span>
</td>
<td class="nump">48,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from the sale of deferred compensation plan assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Investments in technology assets</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchase of cost method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from personal care divestiture</a></td>
<td class="nump">47,787<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">45,896<span></span>
</td>
<td class="num">(16,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(1,308)<span></span>
</td>
<td class="num">(4,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Noncontrolling interest contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distributions</a></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(55,313)<span></span>
</td>
<td class="num">(3,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(56,890)<span></span>
</td>
<td class="num">(7,402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">14,967<span></span>
</td>
<td class="nump">25,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">54,133<span></span>
</td>
<td class="nump">45,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">69,100<span></span>
</td>
<td class="nump">70,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,654<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">8,878<span></span>
</td>
<td class="nump">9,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashPaidForFinanceLeaseLiabilities', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">7,083<span></span>
</td>
<td class="nump">11,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">20,790<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Reductions to right of use assets resulting from reductions to operating lease liabilities</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations', window );">Reductions to right of use assets resulting from reductions to finance lease liabilities</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashNoncontrollingInterestContribution', window );">Noncontrolling interest contribution</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for finance lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance lease, Reductions to ROU assets resulting from reductions to finance lease obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashNoncontrollingInterestContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashNoncontrollingInterestContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682621696864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 72% and 75% of our consolidated net service revenue derived from Medicare for the three-month periods ended March 31, 2023 and 2022, respectively. As of March&#160;31, 2023, we owned and operated 348 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 9 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 16, 2023 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682620929296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 72% and 75% of our consolidated net service revenue for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, CMS implemented a new Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three-month periods ended March&#160;31, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of March&#160;31, 2023, we have recorded $4.1 million for estimated amounts due back to Medicare </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2022, we had recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2023 and December 31, 2022, we had $19.7&#160;million and $13.6&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of March&#160;31, 2023, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% of our patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617229472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $38.9 million and $40.5 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of March 31, 2023, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. Our high acuity care segment also includes one admitting joint venture with a health system partner that is accounted for under the equity method of accounting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:61.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682621606512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Acquisitions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, we acquired the regulatory assets of a home health provider in West Virginia for a purchase price of $0.4&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $0.3&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $16.7&#160;million placed into escrow, $1.0&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, reduced the purchase price by $1.3&#160;million from $67.8&#160;million to $66.5&#160;million. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of March 31, 2023, $5.7&#160;million of the $16.7&#160;million has been released from escrow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15&#160;million of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTg4_24315a26-40ac-43a0-9b7d-1ad27911f76d">two</span> to five years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. During the three-month period ended March 31, 2023, total assets acquired decreased $0.2&#160;million (primarily patient accounts receivable) and total liabilities assumed remained flat as a result of our review. These adjustments resulted in a $0.2&#160;million increase in goodwill. The total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names (less than $0.1&#160;million). The acquired names will be amortized over a weighted average period of one year. The entire amount of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682621688144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSITIONS</a></td>
<td class="text">DISPOSITIONS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestiture closed on March 31, 2023. We received net proceeds of $47.8&#160;million and recognized a $2.2&#160;million loss during the three-month period ended March 31, 2023 which is reflected in miscellaneous, net within our condensed consolidated income statement. The net proceeds of $47.8&#160;million is inclusive of $6.0&#160;million that was placed into an escrow account in accordance with the closing payment and indemnity provisions within the purchase agreement; this amount is recorded as restricted cash within our condensed consolidated balance sheet as of March 31, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposition of our personal care business did not qualify as a discontinued operation because it did not represent a strategic shift that has or will have a major effect on the Company's operations or financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617201632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate (6.1% at March 31, 2023); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 10, 2023, we entered into the Third Amendment to our Credit Agreement (as amended by the Third Amendment, the "Third Amended Credit Agreement"). The Third Amendment (i) formally replaced the use of the London Interbank Offered Rate ("LIBOR") with the Secured Overnight Financing Rate ("SOFR") for interest rate pricing and (ii) allowed for the disposition of our personal care business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Term SOFR Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Term SOFR Rate plus 1% per annum. The &#8220;Term SOFR Rate&#8221; means the quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%. The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2023, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Term SOFR Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:9.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term SOFR Loans and SOFR Daily Floating Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Third Amended Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net proceeds received from the divestiture of our personal care line of business were used to pay a portion of our Term Loan during the three-month period ended March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Third Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Third Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Third Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Third Amended Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Third Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, we had no outstanding borrowings under our $550.0 million Revolving Credit Facility. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 6.1% and 1.7% for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our consolidated leverage ratio was 1.6, our consolidated interest coverage ratio was 10.3 and we are in compliance with our covenants under the Third Amended Credit Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our availability under our $550.0 million Revolving Credit Facility was $519.2 million as we have no outstanding borrowings and $30.8 million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing or arising after the respective effective dates of the Joinders, under the Third Amended Credit Agreement pursuant to the terms of the Joinders and the Third Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Notes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding promissory note totaling $0.2&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of 6.5%.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding finance leases totaling $20.1&#160;million relate to leased equipment and fleet vehicles and bear interest rates ranging from 2.2% to 7.7%.</span></div>Effective January 1, 2023, the master lease agreement for our fleet leases was modified to remove the residual value guarantee provided by the lessor on each of our fleet leases. The modification resulted in a change in the classification of our fleet leases from operating leases to finance leases. In connection with the modification, we reclassified approximately $15&#160;million from the operating lease asset and liability accounts to the property and equipment and current/long-term obligations accounts within our condensed consolidated balance sheet. Additionally, following the modification, expenses associated with our fleet leases will now be recorded in depreciation expense and interest expense within our condensed consolidated income statement as opposed to cost of service and general and administrative expenses which is where the expenses were reflected in prior periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617263824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2023, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. </span></div><div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4&#160;million to $25.2&#160;million, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3&#160;million ($22.8&#160;million extrapolated repayment plus $11.5&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7&#160;million ($2.4&#160;million extrapolated repayment plus $1.2&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $1.5&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9&#160;million and have recorded this amount within other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation, professional liability and fleet. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $2.0 million per incident. Our professional liability insurance has a retention limit of $0.3 million per incident. Our fleet insurance has an exposure limit of $0.4&#160;million per accident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682620882304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATIONOur operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our reorganization initiatives, management has revised its measurement of our reportable segments' operating income (loss). Effective January 1, 2023, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function in order to realize operational efficiencies. Additionally, effective January 1, 2023, we transitioned from the high acuity care segment to the home health segment the operations of a home health care center that was contributed to the high acuity care segment by one of our health system partners during 2022. Prior periods have been recast to conform to the current year presentation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617291280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022 (the "2022 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. We did not repurchase any shares under the 2022 Share Repurchase Program during the three-month period ended March 31, 2022. The 2022 Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, </span></div>repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617333392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $2.4&#160;million during each of the three-month periods ended March&#160;31, 2023 and 2022 in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617263824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2023, Amedisys, Option Care Health, Inc., a Delaware corporation ("Option Care Health"), and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Option Care Health ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides for, among other things and subject to the satisfaction or waiver of the conditions set forth therein, the merger of Merger Sub with and into Amedisys (the "Merger"), with Amedisys surviving the Merger as a wholly-owned subsidiary of Option Care Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Amedisys&#8217; common stock issued and outstanding (excluding shares held by Amedisys as treasury stock or owned by Option Care Health or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time) will be converted into the right to receive 3.0213 (the "Exchange Ratio") fully paid and nonassessable shares of Option Care Health common stock (and, if applicable, cash in lieu of fractional shares) (the "Merger Consideration"), less any applicable withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Merger Agreement, as of the Effective Time, each outstanding time-based vesting Amedisys restricted stock unit award (each, an "Amedisys RSU") and Amedisys option to purchase shares of Amedisys common stock (each, an "Amedisys Option") will be converted into an equivalent restricted stock unit award or option, as applicable, of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted RSU" or a "Converted Option", as applicable) equal to (1) the number of shares of Amedisys common stock subject to such Amedisys RSU or Amedisys Option immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, rounded to the nearest whole number of shares of Option Care Health common stock. A Converted Option will have an exercise price per share equal to (1) the exercise price per share of the equivalent Amedisys Option immediately prior to the Effective Time divided by (2) the Exchange Ratio, rounded to the nearest whole cent. In addition, each Amedisys performance-based vesting restricted stock unit award (each, an "Amedisys PSU") will be converted into an equivalent restricted stock unit award of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted PSU") equal to (1) the number of shares of Amedisys common stock subject to such Amedisys PSU immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, assuming achievement at target performance with respect to any Amedisys PSU for which the level of performance-vesting has not yet been determined, rounded to the nearest whole number of shares of Option Care Health common stock. Each Converted RSU, Converted Option and Converted PSU shall have the same terms and conditions (including any double-trigger protections but excluding any performance-based vesting conditions) that applied to the corresponding Amedisys RSU, Amedisys Option or Amedisys PSU immediately prior to the Effective Time (other than any other terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement or other immaterial or administrative or ministerial changes).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The completion of the Merger is subject to certain conditions, including: (1) the adoption of the Merger Agreement by Amedisys&#8217; stockholders, (2) the adoption of the Charter Amendment (as defined in the Merger Agreement) and the approval of the issuance of shares of Option Care Health common stock in the Merger by Option Care Health stockholders, (3) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the receipt of other required regulatory approvals, (5) the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger, (6) the approval for listing of the shares of Option Care Health common stock to be issued in connection with the Merger on the Nasdaq Global Select Market and the effectiveness of a registration statement with respect to such common stock, (7) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (8) performance by each party of its respective obligations under the Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amedisys expects to incur certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, as well as other customary payments. If the Merger Agreement is terminated due to a recommendation change by Amedisys&#8217; board of directors or under certain circumstances where a proposal for an alternative transaction has been made to Amedisys and, within 12 months following termination, Amedisys enters into a definitive </span></div>agreement providing for an alternative transaction or consummates an alternative transaction, Amedisys will be required to pay to Option Care Health a termination fee of $106,000,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682616457424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div>This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 16, 2023 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComparabilityOfPriorYearFinancialData', window );">Reclassification</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 72% and 75% of our consolidated net service revenue for the three-month periods ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, CMS implemented a new Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three-month periods ended March&#160;31, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of March&#160;31, 2023, we have recorded $4.1 million for estimated amounts due back to Medicare </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2022, we had recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321">five</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830">seven</span> days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2023 and December 31, 2022, we had $19.7&#160;million and $13.6&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of March&#160;31, 2023, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% of our patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComparabilityOfPriorYearFinancialData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124429468&amp;loc=d3e288-107754<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComparabilityOfPriorYearFinancialData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682616515456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Net Service Revenue by Payor Class</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617326096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:61.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617326096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock', window );">Schedule of Business Acquisitions, Evolution Health</a></td>
<td class="text">The total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions, Evolution Health</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617315504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682621579904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate (6.1% at March 31, 2023); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:9.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term SOFR Loans and SOFR Daily Floating Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617260592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text">Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, inclusive of depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682615901184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>state </div>
<div>numberOfJointVentures </div>
<div>care_center</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfJointVentures', window );">Number of Joint Ventures | numberOfJointVentures</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer [Member] | Product Concentration Risk | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of joint ventures owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612655552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments', window );">Percentage Managed Care Contract Volume Able To Receive Additional Payments</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AcutePhaseForHighAcuityCareServices', window );">Acute Phase for High Acuity Care Services</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AcutePhaseForHighAcuityCareServices', window );">Acute Phase for High Acuity Care Services</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember', window );">Cap Year 2016 Through 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenue from Contract with Customer [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AcutePhaseForHighAcuityCareServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AcutePhaseForHighAcuityCareServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612637600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682620931184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,436<span></span>
</td>
<td class="nump">$ 40,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">19,664<span></span>
</td>
<td class="nump">13,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">69,100<span></span>
</td>
<td class="nump">54,133<span></span>
</td>
<td class="nump">$ 70,909<span></span>
</td>
<td class="nump">$ 45,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember', window );">Various acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682613227280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617851376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 383,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">374,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612528192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,558<span></span>
</td>
<td class="nump">32,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">32,643<span></span>
</td>
<td class="nump">32,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617932448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum ownership percentage for cost method investment (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchase of cost method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment Owned, at Cost</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">49,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">294,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">23,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">405,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">33,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">85,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,244,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">99,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">78,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,946,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">40,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">122,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">137,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">25,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">813,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612186832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | WEST VIRGINIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price for acquisition</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="nump">$ 66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Non Cash Accrued Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AmountReleasedFromEscrow', window );">Amount Released From Escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Business Acquisition, Goodwill, Expected Tax Deductible Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Goodwill, Other Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsAcquired', window );">Decrease In Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Business Acquisition, Goodwill, Expected Tax Deductible Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Certificates Of Need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmountReleasedFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Released From Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmountReleasedFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time that goodwill is deductible for income tax purposes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashAccruedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Accrued Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashAccruedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617471248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 19,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from personal care divestiture</a></td>
<td class="nump">47,787<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on personal care divestiture</a></td>
<td class="num">(2,186)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from personal care divestiture</a></td>
<td class="nump">47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on personal care divestiture</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612610224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 403.4<span></span>
</td>
<td class="nump">$ 438.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">400.1<span></span>
</td>
<td class="nump">434.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(26.9)<span></span>
</td>
<td class="num">(15.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">373.2<span></span>
</td>
<td class="nump">419.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">383.1<span></span>
</td>
<td class="nump">435.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617470640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 403.4<span></span>
</td>
<td class="nump">$ 438.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 383.1<span></span>
</td>
<td class="nump">435.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility | Term SOFR Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612919936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Term SOFR Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Term SOFR Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Term SOFR Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Term SOFR Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682610643808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassificationOfOperatingLeaseToFinanceLease', window );">Reclassification Of Operating Lease To Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_ThirdAmendmentToAmendedCreditAgreementMember', window );">Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate', window );">Additional interest rate above Term SOFR rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SOFRAdjustment', window );">SOFR Adjustment</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Term SOFR Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">Term SOFR Rate [Member] | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">Term SOFR Rate [Member] | Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">Term SOFR Rate [Member] | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Third Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Third Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Term SOFR Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReclassificationOfOperatingLeaseToFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of fleet operating lease to finance lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReclassificationOfOperatingLeaseToFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SOFRAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SOFR Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SOFRAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_ThirdAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_ThirdAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_ThirdAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_ThirdAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682612950272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FleetInsuranceExposureLimit', window );">Fleet Insurance Exposure Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Accounts Receivable, Allowance for Credit Loss, Writeoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLegalSettlementPayment', window );">Total Legal Settlement Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LegalSettlementPaymentLessInterest', window );">Legal Settlement Payment Less Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation Settlement Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLegalSettlementPayment', window );">Total Legal Settlement Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LegalSettlementPaymentLessInterest', window );">Legal Settlement Payment Less Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation Settlement Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FleetInsuranceExposureLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific fleet insurance claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FleetInsuranceExposureLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LegalSettlementPaymentLessInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlement Payment Less Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LegalSettlementPaymentLessInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLegalSettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Legal Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLegalSettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682621686816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682610484528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 556,389<span></span>
</td>
<td class="nump">$ 545,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">315,010<span></span>
</td>
<td class="nump">304,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">194,600<span></span>
</td>
<td class="nump">184,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">8,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">514,010<span></span>
</td>
<td class="nump">497,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">42,379<span></span>
</td>
<td class="nump">47,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">343,300<span></span>
</td>
<td class="nump">335,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">197,000<span></span>
</td>
<td class="nump">185,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">89,100<span></span>
</td>
<td class="nump">83,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">287,200<span></span>
</td>
<td class="nump">269,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">56,100<span></span>
</td>
<td class="nump">66,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">193,400<span></span>
</td>
<td class="nump">193,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">101,400<span></span>
</td>
<td class="nump">106,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">47,900<span></span>
</td>
<td class="nump">51,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">149,900<span></span>
</td>
<td class="nump">158,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">43,500<span></span>
</td>
<td class="nump">34,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, inclusive of depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">50,900<span></span>
</td>
<td class="nump">43,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">52,800<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (52,800)<span></span>
</td>
<td class="num">$ (49,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682616534144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2022ShareRepurchaseProgramMember', window );">2022 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember', window );">2023 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember', window );">2023 Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2022ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2022ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682618765792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682617296304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Narrative (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 03, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessAcquisitionShareExchangeRatio', window );">Business Acquisition, Share Exchange Ratio | shares</a></td>
<td class="nump">3.0213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessAcquisitionTerminationFee', window );">Business Acquisition, Termination Fee | $</a></td>
<td class="nump">$ 106.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionShareExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Share Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionShareExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>amed-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20230331.xsd" xlink:type="simple"/>
    <context id="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6fb8bbe31c8d4d68ae6e3368641dacfc_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i585e48375f81452ca5c935a0f065bef9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5472f8016b234c9baa7f6b92667e2fc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibae6bf17ed294532b75bf96bee0338d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5843cd49ba0a4334b1931cf4711be4c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i657094f859994e9fbdfefe4e999a8f7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic03af0315b2e4303b57c3cb1aba7e7ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a54c309d06045c6a14dd53174c211ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ee19286cb774518ad12dae14f165205_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f6600d688c04ae3a1a2ff7f2efeb29c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iadff83126f1146d38e7ed86ddbf9557e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b484011fea4455cbccfb47a9d0aa132_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1606c535e6b347d68dcc0de266b16147_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iacba65ec8491499e9686e3381410fabe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i71ad24f8b9a043c19e668c1f83237ee0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1eff4d47f36149c99910fdb01ba03dcb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i961ed8ba937246e8bc366e595df4bda5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa99208e33a5497b97b9ff4d09865d65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10644ac975cd41d899b6ab34ac1c632b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7eadcd74787f4d9f97ed1b8cb8b481f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32337689aea04d268b36f9d550c54a4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1e116f3558448349842abb6755ed247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea60378b78054b2fac50a824142a5da9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i895883f4f0404807a2543d994b1d240e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i451c109a997045aba66d6e6f5f7a5b9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab0efa54710f40b2adb0bf8a574fa295_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd4a52b5e404494a99fb252c273edde2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb59d0a96fa84c18aa8e014c4d01bf7b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib188ac253c154843ad5c1a8d5049ca12_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic06fb355109d402d9d8eb2a57521c878_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4dd566e0c30743bf921e7b51a845e441_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45d65acc48b54ea4920cbeb26d75cd99_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e66fad7247f4614bb05acb8bacd747f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib066174649554b6aa169bff0a92b837c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie0e0b0dcad1b459fbea67c1673d384bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8e00191bd0ce47ae90a1b68b4dba7fbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i392b34a2cbe44843ba2061fbdd365ff8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9b0c93dea83646f48e87329ba7bd8c58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0a2828517b0d45a29ac576ac753e94b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if12394786d4c4d53b3346da0a457c35f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic91c656ae45745a298a5b5024aef1f6d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i49bceefe212449c7998aae8bb17d3e36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44c3d28d3fe1472b8e434cb3e3faf3ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic7decd3ddff141e79829e8d0ac8e68e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i457334445c94411eb7f7acd978196cee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0228a33ce76d4c2a9d5a57c7a7ee513c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36f354bf9afa4fe39ba362e4a560be60_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12658449a4884e519551b1d2d371a76a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i65c6c1787206460dac3d072a59137173_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iffb50bbe21d045c2a7ea675b3d961273_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i81ec104e809d413fb7d22fa2c4dd41d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id17ad04ba345428b8e033676549332db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e38279713af4551b387f31072d970c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idae72a9173c944f7a4f1774565c96ca2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i844b80bb13084f3b83010b9b474a966d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60919be84a16478885dd33d5c2ce0245_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief1c33a09cd14865bd58df0e8caa349b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i73e5cae45c3e4926b672d2954605b617_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c2ada7611794e0da3ad8606cb9d5fcc_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i7d005834749b442bb9d70d938394e533_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83d541af44184deb951b6a071ab45e26_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i59444987df584e7690a09dcbaa54b67d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i288ea770324347e580e9797adb70ccbe_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if5b723d973d441aaa74151c4d5f39cbc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4151a2c302cb444998f63b2e8f93e9dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf465ab991ea4ad1a42917b2b2e56157_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ie22b0a888f0d4dbbb0def16d61c7e330_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i67866a4322944973b5d992071251c8d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ida4e25adb7824b9094d7319f338e24c2_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ic67042e4013b4e38b79944277c4dd150_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4fb46cbc81ad49b3b6d2fb087cadcb23_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i963c4518f769492dbf4ac0527afcbf9d_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i1e851f9c134745c698fdeeff9b69831f_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ie4834125dbb44494abec45d7f5e2ac7b_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="id9c951c93c98441a93062a5cc5670551_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i58bb9667d6ae49158d64d74c1293836f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie474c65087de4fcd9f03f6114faa2034_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id96882539f8d4eed92cde59a1e4c6c16_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if7ad22f782c84a46af3f9772a7af2667_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32bd8ed3d02c453cbb170444b858f3c3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3159160953145aebe0e174490333355_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8d2e1865d544d56bc61bafc92378512_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81cebef82b22470c9b04463e506d3f78_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i40995d245e1849f6a663395f8252db2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93b451bfc136446abd99c9651bda4093_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide7e815971ae49ee868e7a75f749208f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia55b972867c94e8bb889ae04e28fdb15_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ia492b736de1e47179438373b2738ee0a_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i96d5def30a27419ab88f280a1a8227a2_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="if0e2df2ee5cb4b85b62420ced1fb93c9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c32b0de3217439f96df3b34a22fb3cf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id60579582fb34f4ca10b3cc4b36399dd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i46f6956ee4104b5cac9dcd8b0e43e85c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i870058a53843477c9351bc8199925557_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia33e2d83e5d1461081b910b52e23d2bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2aa0ee06acc245068f9ee47a8f9534fd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbf2a36d31e3405891903d3fee681e78_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia25ced89f8d94908bec90fa9845fe731_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i278de941823643d5a9ebedb448bfe966_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifd1d1bf51b1148e0aca183be9b4f10c1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ed24a55c79b48a9a4f962dcbc7f923c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81fc1915a4e5409f9acf5b031d0f164e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae944944b29040f5a2b123f79d05d2cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ida89fe95351140f6b7664868c8647802_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ec5894fd66b4d3f82b50f315effcf79_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1960f86c82bb4f3b9b446612846b3561_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6924c05d92fe48d08e15de81fa474e53_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic74251b39fdf4162865cb8772044613f_D20210730-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="ie62968d493c546e9be2fb5e44a2238d0_D20210730-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i1414dda84f1a4039b0c9c62176b05341_D20231001-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="i7d3cbf205560418db36bba9e6b1a9d42_D20230310-20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="icc2bd5dd04d541069c60eda0585eb542_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2beea370526f4c58885810023a334383_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d894bb39c82450382991fab6b6370d0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i99635620a5d140d8a4a7b0b502e0957d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e7a39871825490a8097d1f9e1694885_D20230310-20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="ic0910412b19c4213a4ffb7e02eb82775_D20230310-20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:ThirdAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="ibbca5f3a4ed84661b6142d602c23319c_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="ideb0213b931749a29f65d87002bd3697_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="i4656df3498d04d67889bc6a6d94519c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id73cbf69d99243349bd20c6351ede631_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="id8de4359d28d41ae8006eb4ac5462691_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4649b57d4264b6487be77b0ddca78b6_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i32b13a5963884c508a47edd37af0affe_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ib3eba185d82244d6b36d702c87bd4b49_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="if0503aff1b6d474d8e740e5f1f22aa0f_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i54da14b3e36b46ce878e835cb8028e7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie009f517271a4d76847c8f3d3582e49e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4ec2786358a4520ab9eae39cdb96053_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6e5ad00097724ab594a7deaf5d111fef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2bca8c668b9c4f898b4b708846df0658_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i942ca593c3da41b39bd5dd41b049950e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1057256597bb4a308e0432e8942b8883_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iecea7797edce4d7f827be77680105619_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i018c88178e264896b3969b9ef2af4756_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i375e7e760e9d4aa1a92757ae86a0d210_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="i830c428bb89b41599cc12c2881b394b5_D20210802-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5be9befb4f734cae91c1a764171dddf2_I20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="ic23b318b43a44f01bf8a8c58852671ce_D20230202-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i0ebd4093f9e54759abfee45439a836a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="numberofjointventures">
        <measure>amed:numberOfJointVentures</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segments">
        <measure>amed:Segments</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV80LTEtMS0xLTY3MTI0_2de4cf07-620a-4013-8a80-a481d8e9b271">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV82LTEtMS0xLTY3MTI0_97220ac9-872a-497b-a7b8-8a36bcda53d4">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV83LTEtMS0xLTY3MTI0_a38646e0-dcf5-4ad0-affc-0e576739d6de">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV85LTEtMS0xLTY3MTI0_0f40e9d6-aa4b-4f2f-b0f0-6d1eecd71ece">AMEDISYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV8xMC0xLTEtMS02NzEyNA_30f4b8fb-a550-45ec-8cb9-9e912ee7fddf">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180L2ZyYWc6YzBlYjJkNjc5NDY1NDYzNmJmZDM5MTQyOTdmNDYwNTkvdGFibGU6OTFlYWVkNmZiZTc5NGY4NjgxMmEwMGE1MGVkNjA3NzUvdGFibGVyYW5nZTo5MWVhZWQ2ZmJlNzk0Zjg2ODEyYTAwYTUwZWQ2MDc3NV8xMS0xLTEtMS02NzEyNA_02852408-c6f7-4e0d-9e15-d57c75d2c027">--12-31</dei:CurrentFiscalYearEndDate>
    <amed:AcutePhaseForHighAcuityCareServices
      contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321">P5D</amed:AcutePhaseForHighAcuityCareServices>
    <amed:AcutePhaseForHighAcuityCareServices
      contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830">P7D</amed:AcutePhaseForHighAcuityCareServices>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ief1c33a09cd14865bd58df0e8caa349b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180Ni9mcmFnOjI1MDVmNmU4MDU4MjQ4NDU4ODU5MjcyYzg2NmRmY2NmL3RhYmxlOjFhODMxNjUxNTZhMTQwMmM5MzU5YzNiNGViZWI3YjNjL3RhYmxlcmFuZ2U6MWE4MzE2NTE1NmExNDAyYzkzNTljM2I0ZWJlYjdiM2NfNC0xLTEtMS02NzEyNA_e9a79bb8-3aa0-4325-8911-8a8b0205ed7c"
      unitRef="number">0.005</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="iaf465ab991ea4ad1a42917b2b2e56157_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTg4_24315a26-40ac-43a0-9b7d-1ad27911f76d">P2Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i8e7a39871825490a8097d1f9e1694885_D20230310-20230310"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182MS9mcmFnOjJmZmIxNDhmYWM5NDQ3MjJiMWEzOTNmZmMzZmU2OWU5L3RleHRyZWdpb246MmZmYjE0OGZhYzk0NDcyMmIxYTM5M2ZmYzNmZTY5ZTlfODA5_468cada5-febe-4cab-a001-4ca7537f348b">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Term SOFR Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="ic0910412b19c4213a4ffb7e02eb82775_D20230310-20230310"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182MS9mcmFnOjJmZmIxNDhmYWM5NDQ3MjJiMWEzOTNmZmMzZmU2OWU5L3RleHRyZWdpb246MmZmYjE0OGZhYzk0NDcyMmIxYTM5M2ZmYzNmZTY5ZTlfODEw_f35a034c-b590-4898-900a-15ca84cb3bb5">Quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <dei:DocumentType
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQy_d6878cd0-d4a4-4a57-aa35-abc9121fb355">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6MTNlYWE1NmI0ZTVhNGI0ODhmZjM3MzEyZDBjMmViODMvdGFibGVyYW5nZToxM2VhYTU2YjRlNWE0YjQ4OGZmMzczMTJkMGMyZWI4M18wLTAtMS0xLTY3MTI0_0cbb76dd-bdc0-4c30-a9a8-c0d59d6b5e48">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8xMzg_5c6fb71f-04ce-468b-b5e8-4248a617bd18">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OTE3ZjE0MmVhYmYzNDY4ZWIyNTk1NzNjMzZlODNhNDEvdGFibGVyYW5nZTo5MTdmMTQyZWFiZjM0NjhlYjI1OTU3M2MzNmU4M2E0MV8wLTAtMS0xLTY3MTI0_2a8ff22d-1419-4404-a8d9-639130886d14">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM1_041e67df-9288-4396-b40b-b458521d048f">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6M2RjYWIyYWFhYWUwNDEyYThkMGMzNmYxMmM2ZTNlNGEvdGFibGVyYW5nZTozZGNhYjJhYWFhZTA0MTJhOGQwYzM2ZjEyYzZlM2U0YV8xLTAtMS0xLTY3MTI0_1a0849c3-2f77-4862-9af5-d9509a2c8914">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6M2RjYWIyYWFhYWUwNDEyYThkMGMzNmYxMmM2ZTNlNGEvdGFibGVyYW5nZTozZGNhYjJhYWFhZTA0MTJhOGQwYzM2ZjEyYzZlM2U0YV8xLTItMS0xLTY3MTI0_5848c6c7-19a6-4482-95c3-5c3f48b5e255">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQz_ceb70962-27b9-4c42-84a0-010a4e8e7075">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM3_951213c4-912d-4326-8f4f-26bbfbb93c8f">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM4_022ff803-7415-4c13-b0d1-8d1aa4a37c76">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM5_53756b60-6568-4835-af42-3e6c2255c282">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM2_78b7c380-2437-4f82-9201-004c760706d0">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjMy_69bd6913-cd15-4984-b355-ba061bb396c4">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQw_829a3dd7-b695-47e6-a6bb-e48018bce24e">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTAtMS0xLTY3MTI0_aeacc973-965c-4b3e-9d39-a6531a943ec0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTItMS0xLTY3MTI0_2625f8b0-76de-4879-a53b-c1fd97a5edd0">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6OGMxNTA5YTFjMGE1NDhlMTk0ZTJhMTdlYTQ5ZTBlYWYvdGFibGVyYW5nZTo4YzE1MDlhMWMwYTU0OGUxOTRlMmExN2VhNDllMGVhZl8xLTQtMS0xLTY3MTI0_c7cc709b-e468-4ba9-b951-5017f61ed1ef">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjMz_e700b4bd-95fc-4aa3-836e-af559b3251c3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjM0_aa1790d1-e549-40a5-b465-924ed3f7c62b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl8xLTAtMS0xLTY3MTI0_62382cb4-ea43-4c70-be60-a31ca7151748">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl8zLTYtMS0xLTY3MTI0_e27b110e-b256-4067-8b55-756c64607824">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGFibGU6NzE5OTczMjRlYzU2NDI0MGI4ZmU2MDk0NzdlMGY4MjYvdGFibGVyYW5nZTo3MTk5NzMyNGVjNTY0MjQwYjhmZTYwOTQ3N2UwZjgyNl81LTItMS0xLTY3MTI0_3d40d50d-25a7-4eb3-bbe1-ccc1bb3ddbaa">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMjQx_505f0b6d-804f-4cc7-901c-33fd69e44ce9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6fb8bbe31c8d4d68ae6e3368641dacfc_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xL2ZyYWc6ZTI2N2UxYThkYWY4NGRmZWI0MDNmZjgzZDIyMzc2NzYvdGV4dHJlZ2lvbjplMjY3ZTFhOGRhZjg0ZGZlYjQwM2ZmODNkMjIzNzY3Nl8yMTk5_ddd90900-a7e0-424d-99ec-49cf43386e56"
      unitRef="shares">32559388</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMy0xLTEtMS02NzEyNA_7cdef2d1-1248-46ac-948f-48fc0d968040"
      unitRef="usd">49436000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMy0zLTEtMS02NzEyNA_877c663f-d90c-4b1a-a9c1-c5ed38e5391d"
      unitRef="usd">40540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNC0xLTEtMS02NzEyNA_845821d2-3375-4dc5-9388-de084411ca91"
      unitRef="usd">19664000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNC0zLTEtMS02NzEyNA_c9fb73d3-38d6-41c3-add8-e2abda7826f9"
      unitRef="usd">13593000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNS0xLTEtMS02NzEyNA_163ec406-1981-403b-953c-6f522fe4928d"
      unitRef="usd">294122000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNS0zLTEtMS02NzEyNA_989cde00-d615-479b-9756-18c3c13df856"
      unitRef="usd">296785000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNi0xLTEtMS02NzEyNA_543962bb-f375-4618-ae69-03ff17adec52"
      unitRef="usd">18754000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNi0zLTEtMS02NzEyNA_5680fc88-34ac-4ba8-badf-0be38842cedd"
      unitRef="usd">11628000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNy0xLTEtMS02NzEyNA_32101992-e99d-457e-8640-f79ee299678f"
      unitRef="usd">23581000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNy0zLTEtMS02NzEyNA_0c319b5e-841d-4cfb-a44d-f3e98aaabeed"
      unitRef="usd">26415000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOC0xLTEtMS02NzEyNA_c8259b60-1226-4099-a2d4-340b01764ea1"
      unitRef="usd">405557000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOC0zLTEtMS02NzEyNA_b72822ea-b8b9-4947-8fd6-3d693097b32e"
      unitRef="usd">388961000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJlOWVmOTA0NGQ3ZjRjNTBiMjUwNDQxYmE4MmMwMjUxXzYz_e89989f6-8a03-4020-8939-e2b19434c2ce"
      unitRef="usd">105183000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJlOWVmOTA0NGQ3ZjRjNTBiMjUwNDQxYmE4MmMwMjUxXzcw_a4bf0871-a19d-47aa-801e-b86108462b16"
      unitRef="usd">101364000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0xLTEtMS02NzEyNA_a5baaa62-4f66-47b2-9ea0-7e0c41e9da42"
      unitRef="usd">33353000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfOS0zLTEtMS02NzEyNA_1a27ad8a-52c0-4a49-a2fa-5e7366a219df"
      unitRef="usd">16026000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTAtMS0xLTEtNjcxMjQ_d00ea250-619a-48bd-a00b-06801c912d39"
      unitRef="usd">85211000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTAtMy0xLTEtNjcxMjQ_28df709a-b47c-4f12-acaa-1a5653b4d2d2"
      unitRef="usd">102856000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTEtMS0xLTEtNjcxMjQ_5c9b5a6f-9485-456b-9c4a-51dc1a80b507"
      unitRef="usd">1244679000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTEtMy0xLTEtNjcxMjQ_a494e507-6a3a-4449-8918-55287a6a5046"
      unitRef="usd">1287399000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmZDVjNDgwY2QwMmE0NDVkYTRmNWI1YTcwZWZjNDI5MV81OA_3c4c11ae-7e34-4695-9bda-79124fc1e6f8"
      unitRef="usd">16071000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmZDVjNDgwY2QwMmE0NDVkYTRmNWI1YTcwZWZjNDI5MV82NQ_b833d5b0-4c56-495d-a53d-abd2e9127ded"
      unitRef="usd">14604000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMS0xLTEtNjcxMjQ_5c1d266a-fe98-40e7-a6da-2f984a43718f"
      unitRef="usd">99929000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTItMy0xLTEtNjcxMjQ_ac61f867-1d07-4844-b9bc-8b17df25f7c0"
      unitRef="usd">101167000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTQtMS0xLTEtNjcxMjQ_ea373dbc-dc5c-4fcf-8798-aab96650737d"
      unitRef="usd">78230000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTQtMy0xLTEtNjcxMjQ_8b076ed8-8c82-494c-abd8-5e44a632d3d2"
      unitRef="usd">79836000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTUtMS0xLTEtNjcxMjQ_7ffb60ed-499d-46e3-8ef1-fbc0c717e5c7"
      unitRef="usd">1946959000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTUtMy0xLTEtNjcxMjQ_38c26e93-041f-469e-a663-938d11c2b698"
      unitRef="usd">1976245000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTgtMS0xLTEtNjcxMjQ_617dcef5-104a-4025-b2f6-a1cb99b98ece"
      unitRef="usd">40017000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTgtMy0xLTEtNjcxMjQ_c8886a89-6c49-4d2d-93da-4032ed739fcb"
      unitRef="usd">43735000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTktMS0xLTEtNjcxMjQ_737b6682-e1da-470c-b97b-f062a019951d"
      unitRef="usd">122723000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMTktMy0xLTEtNjcxMjQ_60a90bfe-1ea5-42eb-9432-eab0490fcdfd"
      unitRef="usd">125387000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjAtMS0xLTEtNjcxMjQ_23282a72-af02-4628-8479-e1b4e228f3bb"
      unitRef="usd">137899000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjAtMy0xLTEtNjcxMjQ_f91aac2e-e0bc-4c96-9788-b75f6e26f484"
      unitRef="usd">137390000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjEtMS0xLTEtNjcxMjQ_7e1e6114-0d25-4110-84f1-bddef0ca52e9"
      unitRef="usd">26958000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjEtMy0xLTEtNjcxMjQ_812cb676-f334-4713-9db7-a74325fded02"
      unitRef="usd">15496000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjItMS0xLTEtNjcxMjQ_52f3b85d-ecdd-40cf-a4a3-5160c76bde07"
      unitRef="usd">25453000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjItMy0xLTEtNjcxMjQ_4f245621-5507-4116-a79f-1920fa65604e"
      unitRef="usd">33521000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjMtMS0xLTEtNjcxMjQ_daec6061-9acf-4001-abc0-1d2c65330310"
      unitRef="usd">353050000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjMtMy0xLTEtNjcxMjQ_4057e1ed-ad92-4d73-bd01-fde87c2679b6"
      unitRef="usd">355529000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjQtMS0xLTEtNjcxMjQ_d74bc8b1-bd99-4493-b5ad-fb57956ca82f"
      unitRef="usd">373202000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjQtMy0xLTEtNjcxMjQ_b5649d9a-2ee7-435e-ab53-28e4bb1496a0"
      unitRef="usd">419420000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjUtMS0xLTEtNjcxMjQ_3be768f0-13ee-4821-aa8d-894e64bf3749"
      unitRef="usd">59826000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjUtMy0xLTEtNjcxMjQ_beb62766-4b06-487b-9d92-14eb6da8e3d2"
      unitRef="usd">69504000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjYtMS0xLTEtNjcxMjQ_755c4659-cfaa-4d5d-858c-41fd04623671"
      unitRef="usd">22752000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjYtMy0xLTEtNjcxMjQ_4c746d7f-181a-4781-8a7c-e40c87635ad0"
      unitRef="usd">20411000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjctMS0xLTEtNjcxMjQ_11a49d37-fded-4092-8477-1f569b454999"
      unitRef="usd">4781000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjctMy0xLTEtNjcxMjQ_2ef257f8-4070-4f49-be2b-a3e87c6e19af"
      unitRef="usd">4808000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjgtMS0xLTEtNjcxMjQ_a36029f9-20e8-4a3a-88bd-f3a74e083e0b"
      unitRef="usd">813611000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjgtMy0xLTEtNjcxMjQ_93ae99de-08d0-4cc2-8dcb-ccad25c16c5c"
      unitRef="usd">869672000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMjktMS0xLTEtNjcxMjQ_cb5d49b8-2d37-45d4-88a2-fd0806a917ce"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18yMQ_7e638054-fd45-419e-9b26-44683f8f9be2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18yMQ_ff192d10-2b4d-495c-8687-905f0058a4d7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18zNQ_7426c61a-dae0-4091-a5b8-d377b377c8de"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY18zNQ_8a22ee97-dd34-4176-acfe-c4b895bbffe2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_6c30d627-27aa-49ff-a66c-93d2820206a2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_8de9bbe4-fd63-4c12-bd80-c737a9e634c5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_988fb724-c7db-49fc-bd93-589a1f0cca23"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpmMTQ2YmM4Nzk5ZTQ0OTMzYWFlYzcyZWYwN2Q2MzYyY181Nw_efd009a7-ed79-44d1-85d7-aaa2710fe15d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMS0xLTEtNjcxMjQ_ac18568a-8a49-4cca-9343-429d16b12a0e"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzEtMy0xLTEtNjcxMjQ_11187aaa-1028-4f8d-be47-f704ab49df26"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8xOA_15167204-cfdf-4903-bfe7-68587f6c5ab7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8xOA_c82ae63f-7cf9-4f60-9d3d-221a33b15c87"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8zMg_180b46ba-59ae-46df-9bb2-2e6b85f02e46"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl8zMg_a6a4b7fa-18ec-4ed9-8692-200d652f1a8d"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl81NA_6c58b570-35da-4760-9ce4-183f5fa5707b"
      unitRef="shares">37938354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl82MQ_2f2a0006-766c-4253-8409-6275af4ab729"
      unitRef="shares">37891186</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl84Mw_d8bf58d1-db6a-4f4d-a6df-12ba94f5af97"
      unitRef="shares">32544145</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjpiNWYzYmJiZmRmMGM0Y2FhYjU3NDlhODg1MDExYjJjNl85MA_d475b8bf-972b-411a-9f9c-8f372cecc6e9"
      unitRef="shares">32511465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMS0xLTEtNjcxMjQ_ef7fcb70-84b9-4afe-807d-f1c9b7170019"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzItMy0xLTEtNjcxMjQ_d8a3f101-ec26-4ccd-8d2a-eff29c6ca9ed"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzMtMS0xLTEtNjcxMjQ_8f77368c-6397-4bf4-bce3-fa2a19b10da0"
      unitRef="usd">758669000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzMtMy0xLTEtNjcxMjQ_0c3e93aa-fb9e-4780-a362-5035501722d0"
      unitRef="usd">755063000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjowMzE2MTE3NWZiMzQ0NWIwYWM0ZWFhOTYyZTIyZDUyZV8yOA_a615113a-58f1-46a4-8700-f435340a2424"
      unitRef="shares">5394209</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMC0xLTEtNjcxMjQvdGV4dHJlZ2lvbjowMzE2MTE3NWZiMzQ0NWIwYWM0ZWFhOTYyZTIyZDUyZV8zNQ_4e58a949-9216-4087-8d90-ac37cb9fd54b"
      unitRef="shares">5379721</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMS0xLTEtNjcxMjQ_900c49d4-690e-4178-8d48-a88fc19c557b"
      unitRef="usd">462508000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzQtMy0xLTEtNjcxMjQ_93fb48d0-eaab-44db-9a4d-e24074ed26e0"
      unitRef="usd">461200000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzYtMS0xLTEtNjcxMjQ_4ff5d9e6-4f5c-459d-af63-af3c27904e94"
      unitRef="usd">782918000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzYtMy0xLTEtNjcxMjQ_92a26257-9fcf-4102-861c-9bb4c81cb2fd"
      unitRef="usd">757672000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzctMS0xLTEtNjcxMjQ_3b57f677-d61e-4552-bb4d-0606079688c3"
      unitRef="usd">1079117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzctMy0xLTEtNjcxMjQ_1360aebe-8fd2-46bd-8f91-7c14199f8c36"
      unitRef="usd">1051573000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzgtMS0xLTEtNjcxMjQ_9dcf5087-17b1-4f59-8015-00fd5bff6d4e"
      unitRef="usd">54231000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzgtMy0xLTEtNjcxMjQ_79c73a7b-4887-451e-a0e8-e205c2503d35"
      unitRef="usd">55000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzktMS0xLTEtNjcxMjQ_9953090b-454b-4523-9fed-b4f83a38689d"
      unitRef="usd">1133348000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfMzktMy0xLTEtNjcxMjQ_bff4ac6b-ccc9-44df-a0d2-c611e3f888ae"
      unitRef="usd">1106573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNDAtMS0xLTEtNjcxMjQ_f9b1ddd2-5c08-433a-b8d6-c745adbcbcbb"
      unitRef="usd">1946959000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xOS9mcmFnOjk4NzZkYjU1YzM4YTRmZTU5YWM2Nzk5ZjE1OTBiM2I2L3RhYmxlOjJjZWUxNzJlMWVkYzQzYzU4M2ZjYWNkZWNhNzc4ODc1L3RhYmxlcmFuZ2U6MmNlZTE3MmUxZWRjNDNjNTgzZmNhY2RlY2E3Nzg4NzVfNDAtMy0xLTEtNjcxMjQ_a747ac6b-59e1-43f3-9a0e-a7020aac615f"
      unitRef="usd">1976245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMi0xLTEtMS02NzEyNA_6f76652b-94b7-4ebd-bdb0-3074fd8efeb7"
      unitRef="usd">556389000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMi0zLTEtMS02NzEyNA_1247d595-5889-498a-bdf4-d17d5ce6a854"
      unitRef="usd">545257000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNC0xLTEtMS02NzEyNA_86f15fa1-c3f3-499d-bb73-cf31b1eb5cda"
      unitRef="usd">315010000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNC0zLTEtMS02NzEyNA_4d6e64b6-ca43-4fb8-a7c9-9453a9d78192"
      unitRef="usd">304820000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNi0xLTEtMS02NzEyNA_795281be-cc3f-41b7-9a24-377db4a6bcba"
      unitRef="usd">126339000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNi0zLTEtMS02NzEyNA_269c8553-7a0e-4be2-9d72-3427ad8485b9"
      unitRef="usd">123480000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNy0xLTEtMS02NzEyNA_ba93d79e-826b-4b80-9558-78b4c5398d0e"
      unitRef="usd">3273000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfNy0zLTEtMS02NzEyNA_edd7d22c-66bd-453c-b92d-ccec1e151a16"
      unitRef="usd">7347000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0xLTEtMS03NDg2Ng_8c9e4d0b-1eba-4b19-96c6-333f4317c241"
      unitRef="usd">4443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0zLTEtMS03NDg2Ng_67e9c163-d903-4311-ba50-8b904e42b4ed"
      unitRef="usd">8008000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0xLTEtMS02NzEyNA_0e177dec-236b-4ca5-b973-cbdb4f323f28"
      unitRef="usd">64945000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfOC0zLTEtMS02NzEyNA_901c947f-4aaa-4d6b-b2ed-287f13230240"
      unitRef="usd">53640000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTAtMS0xLTEtNjcxMjQ_f79c83d6-6fb9-4984-bec6-cc814d2561f0"
      unitRef="usd">514010000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTAtMy0xLTEtNjcxMjQ_96ab3ebc-ea11-4a16-a1a1-f1d9358199dd"
      unitRef="usd">497295000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTEtMS0xLTEtNjcxMjQ_6bc86bb9-4909-48ed-82b5-cb772825c452"
      unitRef="usd">42379000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTEtMy0xLTEtNjcxMjQ_9b191c29-e530-4c2c-81e2-ad2dcae3bf12"
      unitRef="usd">47962000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTMtMS0xLTEtNjcxMjQ_8c6696e9-8d17-4777-a640-19a9571631e6"
      unitRef="usd">406000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTMtMy0xLTEtNjcxMjQ_030c0c79-6a0c-4397-ae32-43736faed919"
      unitRef="usd">13000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTQtMS0xLTEtNjcxMjQ_9a0a6a84-650f-41fe-9439-5c77b74e72fa"
      unitRef="usd">7517000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTQtMy0xLTEtNjcxMjQ_187b3184-aff3-4a4a-b47f-430ed2cb448d"
      unitRef="usd">3173000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTUtMS0xLTEtNjcxMjQ_24be7743-be68-4359-ac60-bfbbc287b169"
      unitRef="usd">123000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTUtMy0xLTEtNjcxMjQ_b6eb7fcd-f953-4024-ae85-4abab53a7bd0"
      unitRef="usd">-1403000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTYtMS0xLTEtNjcxMjQ_ef57566e-66bc-4f7c-871a-d94540a26c83"
      unitRef="usd">-682000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTYtMy0xLTEtNjcxMjQ_e563d5a7-a02a-4fe7-b885-fcc73024221b"
      unitRef="usd">333000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTctMS0xLTEtNjcxMjQ_4d964097-1551-404a-9a7a-b113b125761a"
      unitRef="usd">-7670000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTctMy0xLTEtNjcxMjQ_799ff0d0-b503-4fdd-a708-2e82f0895628"
      unitRef="usd">-4230000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTgtMS0xLTEtNjcxMjQ_e2572c23-68cf-4ef5-ae87-515034ec4ea5"
      unitRef="usd">34709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTgtMy0xLTEtNjcxMjQ_a99af12c-39ec-44e9-814b-90240b76cd6a"
      unitRef="usd">43732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTktMS0xLTEtNjcxMjQ_c1e1b148-ad71-480f-bd72-342b81fc12c5"
      unitRef="usd">9800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMTktMy0xLTEtNjcxMjQ_cc2832c0-ab46-4a4d-99d0-6f7be971d34b"
      unitRef="usd">12019000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjAtMS0xLTEtNjcxMjQ_d392ec1b-4e97-4636-a41b-f511b129dc5a"
      unitRef="usd">24909000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjAtMy0xLTEtNjcxMjQ_c2c26047-07c1-4d50-87c6-151153f29fce"
      unitRef="usd">31713000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjEtMS0xLTEtNjcxMjQ_d1477a73-3823-40b2-acec-81d8cc2743ed"
      unitRef="usd">-337000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjEtMy0xLTEtNjcxMjQ_bb98933e-38e1-4614-9fdc-ad0b6e4ae3c5"
      unitRef="usd">42000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjItMS0xLTEtNjcxMjQ_3ac35e6b-610c-4681-b3e8-a2502c611e19"
      unitRef="usd">25246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjItMy0xLTEtNjcxMjQ_ea323238-47c5-4ff8-a4db-0225c227771e"
      unitRef="usd">31671000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjQtMS0xLTEtNjcxMjQ_194d936f-8699-494f-832a-f3e2fa5d2e1c"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjQtMy0xLTEtNjcxMjQ_6f03339a-3af6-42ab-b8f5-fcd5690b37ae"
      unitRef="usdPerShare">0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjUtMS0xLTEtNjcxMjQ_35f629c5-8d27-451c-9e4a-9a942a95993d"
      unitRef="shares">32558000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjUtMy0xLTEtNjcxMjQ_c6245bd3-2d77-46e4-8202-e75e7afef630"
      unitRef="shares">32555000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjctMS0xLTEtNjcxMjQ_1e72df11-7f00-4b04-a48d-936daa4e4b12"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjctMy0xLTEtNjcxMjQ_23bca33f-e0c4-4f8e-ab15-94cef8b040be"
      unitRef="usdPerShare">0.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjgtMS0xLTEtNjcxMjQ_bb2eba00-0c6d-41f1-8f95-3b824cfe7328"
      unitRef="shares">32643000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yNS9mcmFnOjAxNzAyZjEzMmZlYzRhZGY5Nzg4Y2QwNTVmMjY0MDU2L3RhYmxlOjYwZTg0ZThiMmNlYzQ4ZjM4Yjk5N2FhNzAzNTFlOTBiL3RhYmxlcmFuZ2U6NjBlODRlOGIyY2VjNDhmMzhiOTk3YWE3MDM1MWU5MGJfMjgtMy0xLTEtNjcxMjQ_62fad8b9-7d89-4b68-9bcc-fdc9ef6fe166"
      unitRef="shares">32766000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xLTEtMS02NzEyNA_1d1012df-052c-40d1-a9d8-e00b421a0120"
      unitRef="usd">1106573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ibae6bf17ed294532b75bf96bee0338d2_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0zLTEtMS02NzEyNA_9b443b88-9d3e-4f0d-85c0-7b46cc6af540"
      unitRef="shares">37891186</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibae6bf17ed294532b75bf96bee0338d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy01LTEtMS02NzEyNA_be82e71f-3339-4132-899b-23486de0e25d"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5843cd49ba0a4334b1931cf4711be4c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy03LTEtMS02NzEyNA_c6ca677c-be43-4f36-aa80-864ec3867503"
      unitRef="usd">755063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i657094f859994e9fbdfefe4e999a8f7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy05LTEtMS02NzEyNA_cd17feeb-76c4-4489-9b1e-63f1ff6fb079"
      unitRef="usd">-461200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic03af0315b2e4303b57c3cb1aba7e7ff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xMS0xLTEtNjcxMjQ_f8bf61d2-8b11-44ee-ac0e-e79f747dc3bc"
      unitRef="usd">757672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a54c309d06045c6a14dd53174c211ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMy0xMy0xLTEtNjcxMjQ_466f3951-e744-4431-87af-6541fbd134e6"
      unitRef="usd">55000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC0xLTEtMS02NzEyNA_0645deea-768f-49aa-8cc4-28b7e081602b"
      unitRef="usd">816000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC0zLTEtMS02NzEyNA_d5f51944-ebcf-419e-8ae4-f8669ea53091"
      unitRef="shares">11498</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNC03LTEtMS02NzEyNA_d621d3b0-5b44-416f-8ecf-013d718bf1fa"
      unitRef="usd">816000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS0xLTEtMS02NzEyNA_61314bd3-f0ab-4093-ad27-ec8b4df3619d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i95bb001f4cd34e469fe954be0a024b4a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS0zLTEtMS02NzEyNA_3a7c1e4b-094e-4bf9-8cd1-de4b7e474f5d"
      unitRef="shares">35670</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNS03LTEtMS02NzEyNA_4bc51cc8-cc90-462d-86cb-21ceac675a06"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNy0xLTEtMS02NzEyNA_01f5f849-896d-42c7-9700-2835446de214"
      unitRef="usd">3273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfNy03LTEtMS02NzEyNA_84b76ffd-a48b-408f-ab89-52fa75380c02"
      unitRef="usd">3273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOC0xLTEtMS02NzEyNA_7001b132-9a27-4043-899c-a2e1cb112e05"
      unitRef="usd">1308000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i7f6600d688c04ae3a1a2ff7f2efeb29c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOC05LTEtMS02NzEyNA_2dc1963d-76d4-4816-998b-d186b56a2049"
      unitRef="usd">1308000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS0xLTEtMS02NzEyNA_6a17076f-567a-4016-bef0-6d6a2e2a894e"
      unitRef="usd">630000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6ee19286cb774518ad12dae14f165205_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS03LTEtMS02NzEyNA_35b69ad7-f9a3-45cf-b44e-befdb1854608"
      unitRef="usd">483000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfOS0xMy0xLTEtNjcxMjQ_db86521d-587a-46c5-bf12-132260922569"
      unitRef="usd">147000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTAtMS0xLTEtNjcxMjQ_9380b313-fc33-4a92-a95f-25fa3c19df20"
      unitRef="usd">285000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTAtMTMtMS0xLTY3MTI0_19085811-d443-46bd-9d90-c2ee438c09a2"
      unitRef="usd">285000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMS0xLTEtNjcxMjQ_4a6dfd47-5aa1-42b5-9341-067edfdef6ab"
      unitRef="usd">24909000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iadff83126f1146d38e7ed86ddbf9557e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMTEtMS0xLTY3MTI0_3fb786a1-7e53-48b6-a6b8-dc2d461c8f25"
      unitRef="usd">25246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if562ad27d3be49ed9ec1424a9b8696e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTEtMTMtMS0xLTY3MTI0_db47246e-558b-4898-98ce-f24c621081d3"
      unitRef="usd">-337000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMS0xLTEtNjcxMjQ_495be912-3506-459b-b2c2-fd719c65fd10"
      unitRef="usd">1133348000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0b484011fea4455cbccfb47a9d0aa132_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMy0xLTEtNjcxMjQ_e4f270bc-860e-420f-b0bf-e3082be3f55d"
      unitRef="shares">37938354</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b484011fea4455cbccfb47a9d0aa132_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItNS0xLTEtNjcxMjQ_9d965ce6-75a8-4fe9-9cfc-c4b7d94fbc17"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1606c535e6b347d68dcc0de266b16147_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItNy0xLTEtNjcxMjQ_0a50f494-8aec-4f06-ae40-ad01162f210f"
      unitRef="usd">758669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iacba65ec8491499e9686e3381410fabe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItOS0xLTEtNjcxMjQ_811ceef9-43d7-4710-82a2-e28f2ae8618a"
      unitRef="usd">-462508000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71ad24f8b9a043c19e668c1f83237ee0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMTEtMS0xLTY3MTI0_0b58040e-2d2e-49ba-be66-e07c188e0e7b"
      unitRef="usd">782918000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eff4d47f36149c99910fdb01ba03dcb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTItMTMtMS0xLTY3MTI0_835ea900-74ca-42b6-b9aa-3071fdd47f9e"
      unitRef="usd">54231000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i961ed8ba937246e8bc366e595df4bda5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMS0xLTEtNjcxMjQ_0a6225b2-0d01-4623-8e5b-83827313a027"
      unitRef="usd">976323000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifa99208e33a5497b97b9ff4d09865d65_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMy0xLTEtNjcxMjQ_e4310780-3ee3-4f53-8520-a2af02ae9e1c"
      unitRef="shares">37674868</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa99208e33a5497b97b9ff4d09865d65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctNS0xLTEtNjcxMjQ_6a97be9f-5254-4560-b674-ea1628d9e319"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10644ac975cd41d899b6ab34ac1c632b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctNy0xLTEtNjcxMjQ_bf343ab5-0acd-41f9-bc7d-00dc7801df18"
      unitRef="usd">728118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7eadcd74787f4d9f97ed1b8cb8b481f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctOS0xLTEtNjcxMjQ_9c9e971b-947d-4717-9bf8-d3305ce1a08a"
      unitRef="usd">-435868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32337689aea04d268b36f9d550c54a4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMTEtMS0xLTY3MTI0_effc533b-4eed-42d1-b0d7-8e1afb93c46f"
      unitRef="usd">639063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1e116f3558448349842abb6755ed247_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTctMTMtMS0xLTY3MTI0_46f0ffb9-560c-4450-a370-ca2667f0ec22"
      unitRef="usd">44972000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtMS0xLTEtNjcxMjQ_49afa916-6c94-4503-92fd-5c293750847d"
      unitRef="usd">985000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtMy0xLTEtNjcxMjQ_1feddd22-4054-4aca-8728-096880d424d4"
      unitRef="shares">7161</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTgtNy0xLTEtNjcxMjQ_b4ee7803-52b5-46a0-80b1-7ea52f8c740e"
      unitRef="usd">985000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktMS0xLTEtNjcxMjQ_cc322fec-b8ea-4841-8363-6ba6418c9ba5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktMy0xLTEtNjcxMjQ_c7b251ce-e566-4f47-88a4-1f6e6501cfde"
      unitRef="shares">80494</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktNS0xLTEtNjcxMjQ_8d052e3f-9d14-4d1c-bd01-d5d99a433d9e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMTktNy0xLTEtNjcxMjQ_f8768ead-2a2a-4b79-a029-8012225cb9cf"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtMS0xLTEtNjcxMjQ_0abb1ef5-3814-48d2-928f-1e5cd585707a"
      unitRef="usd">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iea60378b78054b2fac50a824142a5da9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtMy0xLTEtNjcxMjQ_4f6d5ffd-6321-478b-99cd-9a7d2ec27226"
      unitRef="shares">1182</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjAtNy0xLTEtNjcxMjQ_1641ebd7-8eef-4752-9cf1-f6bff04cedc4"
      unitRef="usd">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjEtMS0xLTEtNjcxMjQ_0d48a6f5-d415-42dd-8487-ff6c0e528d6d"
      unitRef="usd">7347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibfea3fb5753b43a18f1d39273d0b9769_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjEtNy0xLTEtNjcxMjQ_5723322d-839d-475e-bd84-a83fc9dac4cf"
      unitRef="usd">7347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjItMS0xLTEtNjcxMjQ_f1439ac4-72e1-48ce-86b2-981b0f072efa"
      unitRef="usd">4682000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i895883f4f0404807a2543d994b1d240e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjItOS0xLTEtNjcxMjQ_40929ed1-d96d-4a86-b2ad-758f37c12b4b"
      unitRef="usd">4682000</amed:SurrenderedShares>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjMtMS0xLTEtNjcxMjQ_976f97e1-e672-4491-a4b7-efc1aa5126a9"
      unitRef="usd">9552000</amed:ContributionsAttributableToNoncontrollingInterest>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjMtMTMtMS0xLTY3MTI0_8f0f376d-8cb8-4dad-8cb7-98a6cbf48bb2"
      unitRef="usd">9552000</amed:ContributionsAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjQtMS0xLTEtNjcxMjQ_159c0a26-5f99-400e-8eef-2256b0e1c273"
      unitRef="usd">672000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjQtMTMtMS0xLTY3MTI0_96af0c3d-7988-44c5-9d8c-01e6bc477031"
      unitRef="usd">672000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMS0xLTEtNjcxMjQ_67de6076-7638-4fef-9238-214cb0c31600"
      unitRef="usd">31713000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i451c109a997045aba66d6e6f5f7a5b9d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMTEtMS0xLTY3MTI0_362052f6-57e8-4f11-b2f9-60a643758f19"
      unitRef="usd">31671000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i428fac0ce3424cfaa438c2105888e391_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjUtMTMtMS0xLTY3MTI0_0b632f73-1a72-4b63-9f4f-53f72dd704f2"
      unitRef="usd">42000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab0efa54710f40b2adb0bf8a574fa295_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMS0xLTEtNjcxMjQ_b13525fa-c292-4f6f-b579-d4bbd5bbaa5b"
      unitRef="usd">1020652000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ibd4a52b5e404494a99fb252c273edde2_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMy0xLTEtNjcxMjQ_665b1da6-535f-4f4f-8043-33a65dcecf8e"
      unitRef="shares">37763705</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd4a52b5e404494a99fb252c273edde2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtNS0xLTEtNjcxMjQ_315af71c-4d05-4a69-9fdd-01cdaea1ef39"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb59d0a96fa84c18aa8e014c4d01bf7b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtNy0xLTEtNjcxMjQ_5c128922-48c2-468a-8e84-f172888c0b9f"
      unitRef="usd">736536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib188ac253c154843ad5c1a8d5049ca12_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtOS0xLTEtNjcxMjQ_52f1842d-d524-4387-b449-85ed30792309"
      unitRef="usd">-440550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic06fb355109d402d9d8eb2a57521c878_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMTEtMS0xLTY3MTI0_90c9dd69-b080-426a-8025-ac67430c7a79"
      unitRef="usd">670734000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4dd566e0c30743bf921e7b51a845e441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18yOC9mcmFnOjVhNjhlODE0MzZmZDQ4YmJiNTgzZjVmYzE2ZjI1Nzc2L3RhYmxlOmU3YTQ2MTAxYzllYzQ0ODc5ODBmZGUxNDEwYWE5ZWM2L3RhYmxlcmFuZ2U6ZTdhNDYxMDFjOWVjNDQ4Nzk4MGZkZTE0MTBhYTllYzZfMjYtMTMtMS0xLTY3MTI0_786875b7-d0d8-456d-95b1-957bbddefce2"
      unitRef="usd">53894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMy0xLTEtMS02NzEyNA_58a0484b-cb42-47ea-93ca-d340b7b7496b"
      unitRef="usd">24909000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMy0zLTEtMS02NzEyNA_051047aa-ad74-4982-8876-46d2eec1a506"
      unitRef="usd">31713000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNS0xLTEtMS02NzEyNA_ef8c8f51-d3dd-4096-8cb7-b314da2b27b6"
      unitRef="usd">5694000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNS0zLTEtMS02NzEyNA_eb28b9de-ab27-4340-a7de-0789045d9b44"
      unitRef="usd">8008000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNi0xLTEtMS02NzEyNA_3330a162-7a1c-43e9-8da5-ded7033d67e1"
      unitRef="usd">3273000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNi0zLTEtMS02NzEyNA_33628ede-87f0-4ab2-8a28-cec20a5fe163"
      unitRef="usd">7347000</us-gaap:ShareBasedCompensation>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNy0xLTEtMS02NzEyNA_450c7cc6-7868-4720-bfa3-3dac6f42ae0b"
      unitRef="usd">8622000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNy0zLTEtMS02NzEyNA_d7b99b61-c35c-4889-ab0e-85c83607a1d1"
      unitRef="usd">10096000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOC0xLTEtMS02NzEyNA_4adc4dfe-2bfa-4512-b9ef-3ee1052e7fef"
      unitRef="usd">70000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOC0zLTEtMS02NzEyNA_6c5d4efd-fd38-41b6-9f4d-0f18d8cdaf27"
      unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0xLTEtMS03MzU0MQ_e77fc917-d86c-411e-b89b-bd1243d7b8e0"
      unitRef="usd">-2186000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0zLTEtMS03MzU0MQ_2bb8cf41-59b6-4517-a58f-be73b041cd8a"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0xLTEtMS02NzEyNA_babd5840-af57-4152-a3e4-9e0373cd6fde"
      unitRef="usd">2772000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfOS0zLTEtMS02NzEyNA_d0c08809-0062-439b-96e2-a0957b632e17"
      unitRef="usd">3205000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTAtMS0xLTEtNjcxMjQ_5fda6826-5125-4b04-85db-a5eaa19b4809"
      unitRef="usd">123000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTAtMy0xLTEtNjcxMjQ_6270fd15-b1c1-4655-b4ad-d35d408b0b93"
      unitRef="usd">-1403000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTEtMS0xLTEtNjcxMjQ_574bf53a-d9eb-44f7-bda9-52efab005eed"
      unitRef="usd">248000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTEtMy0xLTEtNjcxMjQ_483a21b1-e2cd-4790-8f20-6cf85729808b"
      unitRef="usd">248000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTItMS0xLTEtNjcxMjQ_7861151c-3f17-4e22-bb7f-a24060ac5fe8"
      unitRef="usd">1787000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTItMy0xLTEtNjcxMjQ_6d359291-1641-44e3-98ee-ac593762de6d"
      unitRef="usd">1710000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTQtMS0xLTEtNjcxMjQ_379b962e-ee26-4f95-a7ff-5e7fa0a8f328"
      unitRef="usd">7476000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTQtMy0xLTEtNjcxMjQ_afd86372-6a8c-4f2a-9519-e19602eaa4e0"
      unitRef="usd">18618000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTUtMS0xLTEtNjcxMjQ_2b01094f-883c-44e6-840d-e3911cc571fa"
      unitRef="usd">4128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTUtMy0xLTEtNjcxMjQ_a57938bf-fad6-446c-a024-baa0958a3afc"
      unitRef="usd">-7882000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMS0xLTEtNzIwNTI_17e9d0c1-58e0-42ee-bb0e-62cdfc0aec6b"
      unitRef="usd">-918000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMy0xLTEtNzIwNTI_ac4ee5fa-57ec-444e-9ff7-18df64a9b9eb"
      unitRef="usd">-749000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTYtMS0xLTEtNjcxMjQ_16b8bd9e-1202-40ec-ab1b-f02d24ffa75b"
      unitRef="usd">111000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTYtMy0xLTEtNjcxMjQ_f4e875ef-6069-49d8-9e79-7c34ff178c7f"
      unitRef="usd">-247000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTctMS0xLTEtNjcxMjQ_1a48c012-f725-42ab-ac3a-5a0f5e7966ca"
      unitRef="usd">-3457000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTctMy0xLTEtNjcxMjQ_45e1c1eb-57b1-45dd-a96a-888a938830fa"
      unitRef="usd">-2115000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMS0xLTEtNjcxMjQ_03ce37f9-711d-4162-b40b-f99458dec708"
      unitRef="usd">741000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTgtMy0xLTEtNjcxMjQ_c196cc79-538d-4ca1-9ec4-905da211ca45"
      unitRef="usd">7483000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTktMS0xLTEtNjcxMjQ_fbec93f0-9d2e-4a66-bfe0-226930777911"
      unitRef="usd">-28000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMTktMy0xLTEtNjcxMjQ_b1ccb4f6-f573-4217-a3ec-efc609e9edb9"
      unitRef="usd">-57000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjAtMS0xLTEtNjcxMjQ_b3d51a3a-fe4f-42d0-9c0a-7e383465b1ee"
      unitRef="usd">-7960000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjAtMy0xLTEtNjcxMjQ_59a014f7-5c4f-43a2-a5d6-2d39381f5477"
      unitRef="usd">-9187000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjItMS0xLTEtNjcxMjQ_03288072-9a14-4f8d-a787-4e0604032a86"
      unitRef="usd">25961000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjItMy0xLTEtNjcxMjQ_8b1e9317-891d-4391-987b-308885c87edf"
      unitRef="usd">48621000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjQtMS0xLTEtNjcxMjQ_554a14b2-7841-43bb-9d2e-b0aeb636f2ef"
      unitRef="usd">19000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjQtMy0xLTEtNjcxMjQ_4130c96c-d4c8-4a22-9c08-6412103e08b9"
      unitRef="usd">22000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjUtMS0xLTEtNjcxMjQ_48b47638-0fb0-4bf8-9057-a53de72e1184"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjUtMy0xLTEtNjcxMjQ_169f98fb-a481-450f-9acc-1dc72198618a"
      unitRef="usd">37000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjYtMS0xLTEtNjcxMjQ_e0b5df63-1543-4ae4-b7ba-24f3d2a86047"
      unitRef="usd">1350000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjYtMy0xLTEtNjcxMjQ_3a48f9f3-7ba9-4f8a-a566-46425a553568"
      unitRef="usd">902000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjctMS0xLTEtNjcxMjQ_838a0808-674d-4142-a4d4-0ff8b7bd6ae7"
      unitRef="usd">210000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjctMy0xLTEtNjcxMjQ_1636b1c5-e9fe-44ff-848d-fc5bb33e2de0"
      unitRef="usd">236000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjgtMS0xLTEtNjcxMjQ_849de6b1-4499-40c6-9c28-9f36fe1efafc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjgtMy0xLTEtNjcxMjQ_783c8d64-ca4e-4cda-b96e-155de4a0917f"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMS0xLTEtNzM2MDE_2dda0ed9-5b8f-4c03-b2ec-478a1bf704ed"
      unitRef="usd">47787000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMy0xLTEtNzM2MDE_d686df59-342c-4933-9e93-e3da99e2eb8c"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjktMS0xLTEtNjcxMjQ_ec3577f8-d73f-4163-974f-ade0f6680bd6"
      unitRef="usd">350000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMjktMy0xLTEtNjcxMjQ_fd3c764e-d067-4b2c-b9cb-7dc7cfdfa5cb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzAtMS0xLTEtNjcxMjQ_262fa48d-bc4b-4883-ad84-9eae8dd4cea4"
      unitRef="usd">45896000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzAtMy0xLTEtNjcxMjQ_5b98cd29-166e-45e6-8c73-a92551e7b425"
      unitRef="usd">-16079000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzItMS0xLTEtNjcxMjQ_b56d7ee6-a6b3-427a-8bd9-2ce3ecdba449"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzItMy0xLTEtNjcxMjQ_be85c204-7f56-496f-a42c-a4335d274d30"
      unitRef="usd">86000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMS0xLTEtNjcxMjQ_178c9201-900e-4efd-887a-1388802b8fa2"
      unitRef="usd">816000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzMtMy0xLTEtNjcxMjQ_539fdae7-87dc-4115-8c32-203c637d674a"
      unitRef="usd">985000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzQtMS0xLTEtNjcxMjQ_2f82ba52-56b8-4983-860e-3c36cdb79c3c"
      unitRef="usd">1308000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzQtMy0xLTEtNjcxMjQ_7f39ea6d-1b25-4070-868a-33130862b3bc"
      unitRef="usd">4682000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzUtMS0xLTEtNjcxMjQ_53c4e0c7-9c05-496b-bf5a-38e417433ad1"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzUtMy0xLTEtNjcxMjQ_e3ae9937-63f9-4924-b90b-e12559d1ba92"
      unitRef="usd">652000</us-gaap:ProceedsFromMinorityShareholders>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzYtMS0xLTEtNjcxMjQ_b09d4f60-535b-4dd0-aa51-b0fd3562cb56"
      unitRef="usd">285000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzYtMy0xLTEtNjcxMjQ_3eec4a24-d555-4e90-8d38-1ff158105f8e"
      unitRef="usd">672000</amed:CashDistributionToNoncontrollingInterest>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzctMS0xLTEtNjcxMjQ_a2a0d9a4-a0e8-4ffa-af88-470f9f7dd186"
      unitRef="usd">8000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzctMy0xLTEtNjcxMjQ_021e020d-3d54-40bb-92aa-fccc4ec8b1c6"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzgtMS0xLTEtNjcxMjQ_e04f0ee2-c2e4-41d1-ad61-b206ae2ebffa"
      unitRef="usd">8000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzgtMy0xLTEtNjcxMjQ_70542acf-887e-444e-aab8-c41d7776d212"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzktMS0xLTEtNjcxMjQ_0123e04f-b82a-41fd-8a0e-637a10569c50"
      unitRef="usd">55313000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfMzktMy0xLTEtNjcxMjQ_8f8f1553-9d33-4216-a2bd-d3081a81190f"
      unitRef="usd">3771000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMS0xLTEtNzM2NDk_f731e010-429a-43ab-9dfc-2632e810f2e1"
      unitRef="usd">800000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMy0xLTEtNzM2NDk_0f8e1286-113f-421b-8734-e1bc02196f74"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDItMS0xLTEtNjcxMjQ_a6dcea89-2654-4e8d-89a8-e1e73366c0d4"
      unitRef="usd">-56890000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDItMy0xLTEtNjcxMjQ_597a9f01-9109-459b-a016-6b6f200f8579"
      unitRef="usd">-7402000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDMtMS0xLTEtNjcxMjQ_962d746d-6f7a-45f8-b8c8-c0370b0725ef"
      unitRef="usd">14967000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDMtMy0xLTEtNjcxMjQ_787830b8-974c-4668-a10f-748e49ccfef7"
      unitRef="usd">25140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDQtMS0xLTEtNjcxMjQ_b68b202f-e780-4fcf-8640-1901763769bd"
      unitRef="usd">54133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i961ed8ba937246e8bc366e595df4bda5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDQtMy0xLTEtNjcxMjQ_167a5235-a7c2-461b-ab03-c9c64b8d5fb7"
      unitRef="usd">45769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMS0xLTEtNjcxMjQ_1a311ece-1483-45d4-a3e4-8e472cdcd64d"
      unitRef="usd">69100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab0efa54710f40b2adb0bf8a574fa295_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNDUtMy0xLTEtNjcxMjQ_3fabf5cf-f15b-473c-a628-dd3509ee8946"
      unitRef="usd">70909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTMtMS0xLTEtNjcxMjQ_5bad44cb-44f2-4fc8-8ee8-0c473aeb353d"
      unitRef="usd">6654000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTMtMy0xLTEtNjcxMjQ_217f9811-8ae4-400e-8a0f-821e21f0d7c1"
      unitRef="usd">1864000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTQtMS0xLTEtNjcxMjQ_f19c5f3e-48dc-44ce-80e6-f231c9ec042a"
      unitRef="usd">352000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTQtMy0xLTEtNjcxMjQ_2d8e9a44-d9f9-4e9f-a4bd-3d1713d45180"
      unitRef="usd">551000</us-gaap:IncomeTaxesPaidNet>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTUtMS0xLTEtNjcxMjQ_214145c6-fce5-47ce-86b0-98f9695fc297"
      unitRef="usd">8878000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTUtMy0xLTEtNjcxMjQ_b8276f52-290f-4e7f-a88e-dc36b9aa1213"
      unitRef="usd">9936000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTYtMS0xLTEtNjcxMjQ_740270d5-3a81-47da-a88b-8c56659ca69e"
      unitRef="usd">2457000</amed:CashPaidForFinanceLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTYtMy0xLTEtNjcxMjQ_b69422b7-bde4-4eb7-9dbb-e66e9a50d82b"
      unitRef="usd">357000</amed:CashPaidForFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTgtMS0xLTEtNjcxMjQ_3e9bd92d-021d-4376-9aa3-9846d0f3d1f8"
      unitRef="usd">7083000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTgtMy0xLTEtNjcxMjQ_307d9795-b060-4137-b9da-d8cccd19b20a"
      unitRef="usd">11203000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMS0xLTEtNjcxMjQ_c65733b7-9cb2-4331-b692-288986e3ba37"
      unitRef="usd">20790000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMy0xLTEtNjcxMjQ_054d986a-9e68-4530-839d-a94e07c0c246"
      unitRef="usd">216000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjAtMS0xLTEtNjcxMjQ_8897a8d2-9d2f-490c-86ce-86fa7019767c"
      unitRef="usd">141000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjAtMy0xLTEtNjcxMjQ_3b304436-e55c-44f1-b47d-b48ae119418b"
      unitRef="usd">299000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMS0xLTEtNzIzOTI_5cb867ad-2bb9-4301-b0c0-7ea5e9405b03"
      unitRef="usd">369000</amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations>
    <amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNTktMy0xLTEtNzIzOTI_30e41102-6190-40f4-8a19-4a67b943302a"
      unitRef="usd">0</amed:LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjEtMS0xLTEtNjcxMjQ_2421b46b-ef33-462c-bc5f-3cae142451b5"
      unitRef="usd">0</amed:NonCashNoncontrollingInterestContribution>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zMS9mcmFnOmY2MDhhN2EzYzBhZDQ1ZTQ5NGM0YjBiY2I5YWU4ZWZkL3RhYmxlOmVhMDE3Njg5MDZkMTRiOWI4ODdlMzZmNjdlMTg5NDEyL3RhYmxlcmFuZ2U6ZWEwMTc2ODkwNmQxNGI5Yjg4N2UzNmY2N2UxODk0MTJfNjEtMy0xLTEtNjcxMjQ_8715f3dc-d041-47a4-b198-0e08a0b0b802"
      unitRef="usd">8900000</amed:NonCashNoncontrollingInterestContribution>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM3MA_abb0d9a7-a36b-454e-a17a-16adda1539ee">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 72% and 75% of our consolidated net service revenue derived from Medicare for the three-month periods ended March 31, 2023 and 2022, respectively. As of March&#160;31, 2023, we owned and operated 348 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 9 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 16, 2023 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTQ5NzU1ODI1MzY4_02ff7236-9bf0-4498-b972-c08e42085ec5"
      unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfMzQx_e94f58f5-1d7e-4e8a-a73a-6cbac5110aee"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i45d65acc48b54ea4920cbeb26d75cd99_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNDg0_3f65908e-093c-4fc8-b9e6-a5ae7dd8d7d3"
      unitRef="care_center">348</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i3e66fad7247f4614bb05acb8bacd747f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTMy_b446ab44-04bf-45a8-bf83-2f0b38f247b3"
      unitRef="care_center">165</amed:OperatingCareCenters>
    <amed:NumberOfJointVentures
      contextRef="ib066174649554b6aa169bff0a92b837c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjEw_e7d22a93-1f6c-44dd-a40b-f6661309b429"
      unitRef="numberofjointventures">9</amed:NumberOfJointVentures>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjQ4_c1bb6eb7-9a78-433f-8b2f-c0dbe46fe2ac"
      unitRef="state">37</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM2NQ_047e80fa-4c2a-477a-86c7-1ae83ba56ead">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 16, 2023 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM1NA_489ee842-3fae-4a1d-9b54-f97e76a5971b">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComparabilityOfPriorYearFinancialData
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNTQ5NzU1ODI1Njkx_fc67be19-b3ea-4e43-9193-96761ff5f248">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComparabilityOfPriorYearFinancialData>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18zNy9mcmFnOjUyYTBhNzg0ZDNiMzQwM2RhNzA3NzBmODMyYzBhY2Y3L3RleHRyZWdpb246NTJhMGE3ODRkM2IzNDAzZGE3MDc3MGY4MzJjMGFjZjdfNjM2Nw_6fe8615c-679c-460a-85cb-e002c9049414">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTA_efb261d3-5d4b-4748-82f0-eb773bd1ac6b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 72% and 75% of our consolidated net service revenue for the three-month periods ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&amp;lt; 1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, CMS implemented a new Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three-month periods ended March&#160;31, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of March&#160;31, 2023, we have recorded $4.1 million for estimated amounts due back to Medicare &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2022, we had recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321"&gt;five&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830"&gt;seven&lt;/span&gt; days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2023 and December 31, 2022, we had $19.7&#160;million and $13.6&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of March&#160;31, 2023, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% of our patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTM_71435544-2367-4f09-9e40-32607f4b1e12">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represented approximately 72% and 75% of our consolidated net service revenue for the three-month periods ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&amp;lt; 1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, CMS implemented a new Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three-month periods ended March&#160;31, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of March&#160;31, 2023, we have recorded $4.1 million for estimated amounts due back to Medicare &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2022, we had recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NjU_0ecfa5d4-d1e7-45c9-beaf-9975878d0321"&gt;five&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTU0NzE_507c5ced-0968-40b2-bbb0-0b75fb455830"&gt;seven&lt;/span&gt; days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2603907d9d324524894ab0a9ee3e8e7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NDQ2_02ff7236-9bf0-4498-b972-c08e42085ec5"
      unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c85f81485684d46aed10cc1ef751e9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0MjA3_e94f58f5-1d7e-4e8a-a73a-6cbac5110aee"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMzg2Mw_0c391a4c-34f9-488c-a319-6453396f8a81"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDU_640d48b0-afe6-4c31-91cb-46a6ecd74e76">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&amp;lt; 1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ie0e0b0dcad1b459fbea67c1673d384bb_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMy0xLTEtMS02NzEyNA_10c36aa5-1768-40dc-bc74-e279948d1309"
      unitRef="number">0.39</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i8e00191bd0ce47ae90a1b68b4dba7fbd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMy0zLTEtMS02NzEyNA_6260e0e8-54d0-446f-8ddd-4ca932dc647b"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i392b34a2cbe44843ba2061fbdd365ff8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNC0xLTEtMS02NzEyNA_60684c30-b865-445c-9970-d1221218825b"
      unitRef="number">0.07</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9b0c93dea83646f48e87329ba7bd8c58_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNC0zLTEtMS02NzEyNA_662e29df-de23-4a5c-99d2-059792bc6c7b"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i0a2828517b0d45a29ac576ac753e94b0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNS0xLTEtMS02NzEyNA_712ba55c-7edf-46a6-a3b1-38c83650d878"
      unitRef="number">0.15</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="if12394786d4c4d53b3346da0a457c35f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNS0zLTEtMS02NzEyNA_1085d34b-5d0a-43af-9c65-ef5722ac0c2e"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic91c656ae45745a298a5b5024aef1f6d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNy0xLTEtMS02NzEyNA_efd893a0-9625-4eb6-af89-762afc1d3609"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i49bceefe212449c7998aae8bb17d3e36_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfNy0zLTEtMS02NzEyNA_70cc9b2c-69b6-46b3-a845-3c5d1f4c6837"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i44c3d28d3fe1472b8e434cb3e3faf3ed_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOC0xLTEtMS02NzEyNA_f13b9dcf-d928-4128-91a0-d39bc132d6ae"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic7decd3ddff141e79829e8d0ac8e68e4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOC0zLTEtMS02NzEyNA_ed9e1e6a-6740-4c12-9bfe-d26058484699"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i457334445c94411eb7f7acd978196cee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOS0xLTEtMS02NzEyNA_8096eb18-378a-44fa-8799-aa35e535b414"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i0228a33ce76d4c2a9d5a57c7a7ee513c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfOS0zLTEtMS02NzEyNA_9df1c5ab-a31d-4b49-ba7d-7bd6446e9b14"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i36f354bf9afa4fe39ba362e4a560be60_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTAtMS0xLTEtNzMyOTk_31b676df-0b90-43ce-9341-42464c438575"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTEtMS0xLTEtNjcxMjQ_96944923-9623-43ac-abc6-41aa42147f3c"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmI1OTkwZjE2MTgzOTQyYjM4MzNkZTc2NmNiODU3NTU5L3RhYmxlcmFuZ2U6YjU5OTBmMTYxODM5NDJiMzgzM2RlNzY2Y2I4NTc1NTlfMTEtMy0xLTEtNjcxMjQ_5fc3c495-cf39-4882-aed5-bc7f76684be9"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NzE0_faad6dfe-34cf-4474-9a36-284cf4b04c84">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQxNQ_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTU0NA_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjAwMQ_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjA4Mg_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjM1Mw_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjU0Nw_3f714d69-693b-4c0a-9ef3-769f91df7b4b"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i12658449a4884e519551b1d2d371a76a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjczNw_e99fe821-01cc-45a8-b1f2-8470d1e18c3d"
      unitRef="visit">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjc0Mw_67dbebbe-8df7-40e7-8aeb-a75e753e2d46"
      unitRef="visit">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNjkwNw_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNzA0Mg_324f14d9-1109-49e9-b081-b65ea73d8720">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNzM2MA_d39311a4-81c8-4c9a-a2fa-d1926a30ed42"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQyNDIy_ee36713c-8346-4552-a2e4-4029a12194fb"
      unitRef="number">0.30</amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments>
    <amed:NonMedicareRevenueTermRates
      contextRef="i12658449a4884e519551b1d2d371a76a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfOTE3Mw_002b3337-e2db-4743-897d-9b169b2a0872"
      unitRef="number">0.95</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="ibaf54e3a14c249378c7e53ab9297d3c9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfOTE3OQ_b9dd15d2-551b-4142-9b1b-9dee6d54b32e"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTAzNTc_2d70d148-8405-4c0b-b5e6-52480d1b305f"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTAzNTc_f5fd6941-bb51-477c-b523-20dac9bb0ecf"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTEzNjY_2847f001-10a1-4d9f-83b2-bb82ff957c69"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="iffb50bbe21d045c2a7ea675b3d961273_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTIxMTM_c799c361-4e12-4534-9c98-29b484ba224d"
      unitRef="usd">4100000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i81ec104e809d413fb7d22fa2c4dd41d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTIyODI_80839cd1-8c28-4760-8faa-78ad1963c61e"
      unitRef="usd">4300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTQ4ODc_630520d4-38ec-4416-adf9-82e2a385ad27">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTQ5MDM_4ccb15f0-da47-436f-ba74-f788a108dca7">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUwODE_630520d4-38ec-4416-adf9-82e2a385ad27">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUxNjk_4ccb15f0-da47-436f-ba74-f788a108dca7">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i47cc2c3becfc48bf95f833d311d1b9c3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUzMzU_630520d4-38ec-4416-adf9-82e2a385ad27">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ie90f74a87c314aac94da9b53865f0f39_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTUzNDU_4ccb15f0-da47-436f-ba74-f788a108dca7">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDE_f79c6b32-5a11-4455-85e5-48f7a3ece54c">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2023 and December 31, 2022, we had $19.7&#160;million and $13.6&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="id17ad04ba345428b8e033676549332db_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfNTQ5NzU1ODQ0NjU0_a8c07e16-3831-4d66-b1c7-853f467f411d"
      unitRef="usd">19700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i3e38279713af4551b387f31072d970c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTgzNjI_a3b2e5ab-d38c-4ef2-8c73-b9787f7dbfca"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDc_c4b231c9-e9f2-445c-a49c-d6d11ff1104b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMS0xLTEtMS02NzEyNA_95bef3cc-c2b2-4d24-afaa-b136439d95d9"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMS0zLTEtMS02NzEyNA_a16893db-375c-4f75-ad6e-0063e2c414dd"
      unitRef="usd">40500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMi0xLTEtMS02NzEyNA_63065369-c5f2-4f05-a36f-8b44cb73f54c"
      unitRef="usd">19700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMi0zLTEtMS02NzEyNA_b2538fd1-4301-498f-8d1f-ae64b1b932f6"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMy0xLTEtMS02NzEyNA_5ef87dc0-d948-4217-a821-b2b97296ad8e"
      unitRef="usd">69100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmQ2ZjRjOTk0MWIwMjRlMTliMmRjMzExYjE4YjRhZTRhL3RhYmxlcmFuZ2U6ZDZmNGM5OTQxYjAyNGUxOWIyZGMzMTFiMThiNGFlNGFfMy0zLTEtMS02NzEyNA_d99af4f6-26f9-4165-8ed3-72149d2cc636"
      unitRef="usd">54100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTQ_9e2f62c9-52bf-4a8c-8d4f-3bccf98359d1">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of March&#160;31, 2023, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% of our patient accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTkyNzY_d96bd6ba-ff1e-4189-8654-8d1cb761b4e1"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk3MzU_cbfffdc2-628d-4c28-930a-a7711fb45921"
      unitRef="number">0.67</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk3MzU_de2cddec-f19f-4d2a-b537-97e6a5eaa26b"
      unitRef="number">0.67</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMTk4NTg_0e5c5650-a112-46c8-9d8b-d4745c725a0b"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDI_6bbc8ecb-94e0-4e40-a461-193bb4a70b2b">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTc_65990e8c-a3cd-4b9e-b4b6-ebb27da76a7e">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQzOTc_b83e2305-6b51-4e14-9da3-9b5b291ec15f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi0xLTEtMS02NzEyNA_7e3c6544-48a2-4130-bdc8-18fd7a9bfbcd"
      unitRef="usd">383300000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="idae72a9173c944f7a4f1774565c96ca2_I20230331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi0zLTEtMS02NzEyNA_3d36c7f3-a374-462c-9569-e8131a8fbe13"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i844b80bb13084f3b83010b9b474a966d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi01LTEtMS02NzEyNA_5b9561af-14dc-4aa2-9003-e7dc300926f4"
      unitRef="usd">374700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i60919be84a16478885dd33d5c2ce0245_I20230331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmIwZTYwOWMyNTIwNDRjN2VhYWFiNGY3MjQ4ZjgwNGEwL3RhYmxlcmFuZ2U6YjBlNjA5YzI1MjA0NGM3ZWFhYWI0ZjcyNDhmODA0YTBfMi03LTEtMS02NzEyNA_6337b68b-a633-4c73-bb1a-5c52b0778e3d"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MTU_14c2e001-f2e3-4da4-8f13-2d27c700cd0c">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RleHRyZWdpb246ZGIyZTVkM2YxOTYxNDU2YmI1NzQ0ZGU5YjhmOWQyMTBfMjQ0MDQ_ef0822cf-b46f-4d74-892e-8bd238309653">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfMi0xLTEtMS02NzEyNA_d288203e-347d-4dbc-b76a-934724c4fd50"
      unitRef="shares">32558000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfMi0zLTEtMS02NzEyNA_c3f01ecb-dd2c-4ecf-97e7-f01140bf3a98"
      unitRef="shares">32555000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNC0xLTEtMS02NzEyNA_2de4686c-b690-4d8e-a227-24a9d5d96d71"
      unitRef="shares">13000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNC0zLTEtMS02NzEyNA_d35fe982-ea3e-487f-88ee-2403928863b0"
      unitRef="shares">65000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNS0xLTEtMS02NzEyNA_65d36a12-9f26-4d1c-893f-74109dfeccc9"
      unitRef="shares">72000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNS0zLTEtMS02NzEyNA_133af7c2-4f0a-4249-8b14-02212e5c8ebf"
      unitRef="shares">146000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNi0xLTEtMS02NzEyNA_cee4c67e-6218-48f2-b876-73a0afea419e"
      unitRef="shares">32643000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNi0zLTEtMS02NzEyNA_8c39dc09-093b-43cf-8b92-d7fe333f2ca3"
      unitRef="shares">32766000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNy0xLTEtMS02NzEyNA_4907ee38-91bd-4335-8646-d89906615ffb"
      unitRef="shares">323000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM180My9mcmFnOmRiMmU1ZDNmMTk2MTQ1NmJiNTc0NGRlOWI4ZjlkMjEwL3RhYmxlOmNmNmQ2ZmM5ODQxMDQzNzRhOWY0Zjc2NDhkNjIyYmZmL3RhYmxlcmFuZ2U6Y2Y2ZDZmYzk4NDEwNDM3NGE5ZjRmNzY0OGQ2MjJiZmZfNy0zLTEtMS02NzEyNA_852f0ce3-7b78-411c-af3b-bd31fda63406"
      unitRef="shares">188000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTg4Njc_983eaa6d-c95a-4e25-a3e8-ba21695722d2">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $38.9 million and $40.5 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of March 31, 2023, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. Our high acuity care segment also includes one admitting joint venture with a health system partner that is accounted for under the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQxMTQ_46c4b3b1-01ea-45df-a3ce-0db199ee3afa"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ0MTU_1f3d0523-a28d-4892-b12e-b9a5cee62724"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ2MDg_c3e46375-788e-42b1-8704-3125fe6f5340"
      unitRef="usd">38900000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ2MTY_dd8f80ed-413b-49be-9399-09cb7e7c51d1"
      unitRef="usd">40500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <amed:MaximumPercentOwnershipForCostMethodPercent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTQ4Mjk_b16e39bd-08b9-4a69-9019-4bebd42b25e6"
      unitRef="number">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUwMzM_792c5663-756d-41ef-9fb6-95ca50129821"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUxODg_1714bc42-09fa-4a22-b711-2896cb3f3832"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTUxODg_25ae3f55-bb17-4d84-971a-ed24e50c49fd"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGV4dHJlZ2lvbjpiNTk2NWYyNjQ1NTk0NGIxYjFmN2FjZDZjNjYwOWUxZl81NDk3NTU4MTg4ODE_00e91b9c-b79b-465c-928d-407ad04e0b76">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8zLTEtMS0xLTcwOTg3_667f64d7-687b-4b79-97e3-a449a911d4f4"
      unitRef="usd">7300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8zLTMtMS0xLTcwOTg5_aca28e1b-79a0-4a7d-a526-afc9058e67ae"
      unitRef="usd">15600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF80LTEtMS0xLTcwOTkx_4abd18e1-7f1e-4061-8e5e-b3d9c68044a3"
      unitRef="usd">6900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF80LTMtMS0xLTcxMDIx_c7fca60b-a761-40a1-80e4-fac1a15f53cf"
      unitRef="usd">6100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF81LTEtMS0xLTc2NjA1_2b783b43-1ca8-439b-85b4-119d2409bedd"
      unitRef="usd">500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF81LTMtMS0xLTc2NjA3_d908069b-0bd3-4a3d-877a-e7c039275857"
      unitRef="usd">600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF82LTEtMS0xLTcxMDEx_92f21546-f28b-4d85-94dc-523f4e3fd6af"
      unitRef="usd">14700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF82LTMtMS0xLTcxMDAz_23b2eabb-b54b-4803-84cd-684584b07775"
      unitRef="usd">22300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF83LTEtMS0xLTcxMDE5_c147c2f7-3558-4fc1-9b55-5a5b74db39d7"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF83LTMtMS0xLTcxMDA1_3dc36772-d7c8-40f8-a7ae-4b5c356327fd"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF84LTEtMS0xLTcxNDc5_5466a456-44df-47d6-bd00-8246c6eae5bc"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF84LTMtMS0xLTcxNDgz_0efaa7a9-58d6-4be8-b4c9-eb8abe434075"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF85LTEtMS0xLTc2NjEw_5db9550c-8e5f-42fc-8387-3c4d5885ce87"
      unitRef="usd">8500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF85LTMtMS0xLTc2NjI3_0cbab964-1b01-4229-a5eb-16afcc4d435a"
      unitRef="usd">8500000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMC0xLTEtMS03NjYzMA_5dec613f-8cc9-4d43-bba7-e2fdcd6ef70f"
      unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMC0zLTEtMS03NjYzMw_693212c1-add9-4260-aff5-9f47966d93f4"
      unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMS0xLTEtMS03MTAyOQ_f9c68d26-dfbd-40fc-aa7d-e4830107ac5f"
      unitRef="usd">200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMS0zLTEtMS03MTAzMQ_fc1798be-de56-4c83-9fe1-ace2952d0f6e"
      unitRef="usd">200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMi0xLTEtMS03MTAxMw_acd1bbb3-756e-42fe-958b-ce726134848c"
      unitRef="usd">24000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xMi0zLTEtMS03MTAwMQ_22ce2b1a-248e-409e-8461-69ed411e614c"
      unitRef="usd">31600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNS0xLTEtMS03MTQ4MQ_f127784d-bedc-485d-b974-19f4af35ead4"
      unitRef="usd">300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNS0zLTEtMS03MTQ4NQ_89024bb1-9efe-411f-9726-ba4221c66dd6"
      unitRef="usd">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNi0xLTEtMS03MDk5NQ_01cfc798-bb47-4e7e-8cd3-f2f0b4c01fb3"
      unitRef="usd">600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNi0zLTEtMS03MTAxNQ_b9338ddc-68e2-404e-bc75-dcb3bdd2659f"
      unitRef="usd">500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNy0xLTEtMS03MTAyNQ_eb1dc3c9-9cbc-43ab-a9a9-819326869166"
      unitRef="usd">6400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xNy0zLTEtMS03MTAyNw_f10d0d1f-37a6-490c-b70d-733ab482d8df"
      unitRef="usd">5800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOC0xLTEtMS03MTQ4MQ_ee984db2-943c-425f-a684-78fa81596342"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOC0zLTEtMS03MTQ4NQ_93852ae7-92d5-4096-b363-a9106afd2f60"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DebtCurrent
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOS0xLTEtMS03MTAyMw_d448c10e-e2c0-47f0-bd05-1845fb1a3217"
      unitRef="usd">200000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8xOS0zLTEtMS03MTAwNw_62c86b8d-978e-49b1-9691-27d679f2aaab"
      unitRef="usd">200000</us-gaap:DebtCurrent>
    <us-gaap:Liabilities
      contextRef="i29c9958dd3bd44e6b9ad42a21569b9bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8yMC0xLTEtMS03MDk5OQ_1db9d0ce-b306-4ac1-babb-3eb57b40f4b5"
      unitRef="usd">7500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i73e5cae45c3e4926b672d2954605b617_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMjE4L2ZyYWc6YjU5NjVmMjY0NTU5NDRiMWIxZjdhY2Q2YzY2MDllMWYvdGFibGU6NWJjMGE1Y2Y2M2JkNGEzNzhjYWM5MTUyNDk3Y2I3ZjQvdGFibGVyYW5nZTo1YmMwYTVjZjYzYmQ0YTM3OGNhYzkxNTI0OTdjYjdmNF8yMC0zLTEtMS03MDk5Nw_023133ac-5722-4886-a43b-9eeee6e8ca70"
      unitRef="usd">6700000</us-gaap:Liabilities>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfMzc0Ng_f2324910-3796-4ea9-92b8-386a81043b08">ACQUISITIONS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2023, we acquired the regulatory assets of a home health provider in West Virginia for a purchase price of $0.4&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $0.3&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our condensed consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our condensed consolidated balance sheet related to these contingent consideration arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total $16.7&#160;million placed into escrow, $1.0&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, reduced the purchase price by $1.3&#160;million from $67.8&#160;million to $66.5&#160;million. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of March 31, 2023, $5.7&#160;million of the $16.7&#160;million has been released from escrow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15&#160;million of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTg4_24315a26-40ac-43a0-9b7d-1ad27911f76d"&gt;two&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired and liabilities assumed. During the three-month period ended March 31, 2023, total assets acquired decreased $0.2&#160;million (primarily patient accounts receivable) and total liabilities assumed remained flat as a result of our review. These adjustments resulted in a $0.2&#160;million increase in goodwill. The total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our condensed consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names (less than $0.1&#160;million). The acquired names will be amortized over a weighted average period of one year. The entire amount of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i2c2ada7611794e0da3ad8606cb9d5fcc_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjIx_07a17976-9b33-433e-b329-e74da00bdb45"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7d005834749b442bb9d70d938394e533_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjM1_b0686d36-4e17-45f4-86fd-d5a2fda21c68"
      unitRef="usd">300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i83d541af44184deb951b6a071ab45e26_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjQ5_ce96b7e8-26e4-4966-9499-82eac93c3501"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjYz_7e8694fb-f330-4208-8d90-ce0d685eab37"
      unitRef="care_center">15</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MjY3_d8848800-91cf-43be-8c3b-f45d63120890"
      unitRef="usd">67800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mjgy_3e9e0f3c-feeb-43fa-87cd-8efbc9dbfed2"
      unitRef="usd">51100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RestrictedCash
      contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mjk3_b07eb59a-507a-48c9-8e6f-561cd5009f3c"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzEy_739dfb20-0d66-42bf-af01-d55af0be58bb"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzI3_5657039b-1a6c-4707-b533-30c5b0418529"
      unitRef="usd">1000000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i288ea770324347e580e9797adb70ccbe_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzQx_2105a857-6aef-414f-9f95-683c04d798ba"
      unitRef="usd">1300000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2MzU1_80fc5bc2-6b42-459c-ad47-1986cd7ca38e"
      unitRef="usd">67800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="if5b723d973d441aaa74151c4d5f39cbc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mzcw_b9765004-e5ce-47ed-9136-3254126c5969"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i5b74ff0335714f87898f2b1588a41cca_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Mzg1_aeb6872f-eaa3-4e24-a22d-dbd179d52ef6"
      unitRef="usd">15700000</amed:NonCashAccruedContingentConsideration>
    <amed:AmountReleasedFromEscrow
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDAw_73aa7ec6-bec4-41bb-be65-4a5157e9b840"
      unitRef="usd">5700000</amed:AmountReleasedFromEscrow>
    <us-gaap:RestrictedCash
      contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDE0_98d21ca1-10d3-4b55-ba69-08a5fc156f29"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i59444987df584e7690a09dcbaa54b67d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NDgw_97d5cd43-19c1-4969-9948-a996e0904d30"
      unitRef="usd">15000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="ie22b0a888f0d4dbbb0def16d61c7e330_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI4NTk1_52428589-c3e6-4642-a4d4-6cc667d8739b">P5Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <amed:IncreaseDecreaseInAssetsAcquired
      contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI3ODU1_6b5fe187-549a-4255-be67-14906857335d"
      unitRef="usd">-200000</amed:IncreaseDecreaseInAssetsAcquired>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI3ODY5_111bc294-419d-467a-bcf0-22d29af7e00f"
      unitRef="usd">200000</us-gaap:GoodwillOtherIncreaseDecrease>
    <amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njk0_075373f7-e097-46bb-8662-d1c04e78f585">The total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDc4_1b35a10b-766e-40f9-948e-16670c12eb92"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMi0xLTEtMS03MTQ2Mg_1e7f3849-93b2-4119-bf74-ccbdd9c5905c"
      unitRef="usd">7300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMy0xLTEtMS03MTQ2Mg_ead66a08-cbe7-42b7-bef0-03ba70d4f625"
      unitRef="usd">200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNC0xLTEtMS03MTQ2Mg_3bcb59be-9528-4b11-ac81-dbd64aabe8ab"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNS0xLTEtMS03MTQ2Mg_f28e4c1e-1f12-4b2d-8ecf-2326852b80af"
      unitRef="usd">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNi0xLTEtMS03MTQ2Mg_d307ff51-ef62-4a48-99ef-2a4c8f6a9324"
      unitRef="usd">3200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i67866a4322944973b5d992071251c8d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfNy0xLTEtMS03MTQ2Mg_43f69630-031e-4ced-8e62-da59cb880432"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOC0xLTEtMS03NjU4NQ_690add1f-37a1-47fe-8033-4bdd1630e54f"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOC0xLTEtMS03MTQ2Mg_87bf5941-73d6-4f53-89d4-0784293ea33a"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfOS0xLTEtMS03MTQ2Mg_1108d9f5-b945-4218-b6cc-1353173ff701"
      unitRef="usd">14200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTEtMS0xLTEtNzE0NjU_41715d9e-4d92-4059-abff-1acfa08646ce"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTItMS0xLTEtNzE0NjU_4e768112-4bcb-424c-bf7b-ad4d7d84b10b"
      unitRef="usd">2600000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTMtMS0xLTEtNzE0NjU_bff46a34-2b41-4b23-9c28-893d7a682a86"
      unitRef="usd">2600000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTQtMS0xLTEtNzE0NjU_b29ea3de-67fb-4179-8cc7-c88e324ac03b"
      unitRef="usd">2800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTYtMS0xLTEtNzE0NjU_fb6097f2-8504-49ba-a2d0-b107bd3d74f5"
      unitRef="usd">-600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTctMS0xLTEtNzE0NjU_40907ef6-70e2-46da-8a9f-74073b95d4c8"
      unitRef="usd">9400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTgtMS0xLTEtNzE0NjU_2e91ef67-ae93-4250-81ea-ec1f1e0b4133"
      unitRef="usd">4800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i51daf29f800b44f28bc18d8b539c2581_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMTktMS0xLTEtNzE0NjU_50d2cf2c-afe5-4e0c-9f5c-99a07f1d8d54"
      unitRef="usd">61700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4151a2c302cb444998f63b2e8f93e9dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RhYmxlOmU1NDc4MmFjMzliZjRiZDJiNTJmOWFiZWE5NmFhYTk3L3RhYmxlcmFuZ2U6ZTU0NzgyYWMzOWJmNGJkMmI1MmY5YWJlYTk2YWFhOTdfMjAtMS0xLTEtNzE0NjU_93afaeba-5eec-44c4-b229-75ad4a2e1ded"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njc0_72884334-a66d-4de9-81f6-2e3682ca880a"
      unitRef="care_center">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NDkz_458e8e63-ed47-483c-bff2-1acdea47b0bd"
      unitRef="usd">24700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTA4_005d8191-5713-40f6-96c3-08dee58c9e93"
      unitRef="usd">22200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RestrictedCash
      contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTIz_778f8989-f5b1-41fe-8733-83ee87f9dde1"
      unitRef="usd">2500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTM3_168c1ba4-ffaf-418b-b455-00bae728f7e6"
      unitRef="usd">2500000</us-gaap:RestrictedCash>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTUx_538d21ad-ca31-4438-a837-ed718d456518"
      unitRef="usd">24000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic67042e4013b4e38b79944277c4dd150_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTUx_7fd24982-35c0-48e0-a559-1dfbe4b591c9"
      unitRef="usd">24000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ida4e25adb7824b9094d7319f338e24c2_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTY2_4517e2ba-a9b0-421b-91e8-f981e11bf3d2"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4fb46cbc81ad49b3b6d2fb087cadcb23_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTgw_5c4e14f3-42d0-4c84-a091-fe6a9ddd8f63"
      unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i963c4518f769492dbf4ac0527afcbf9d_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NTk0_e6abbffa-2d79-419c-b68d-9a4c20bf8893"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1e851f9c134745c698fdeeff9b69831f_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2Njgx_f09691c4-612e-4eb6-b70c-b100e2ad6c35"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie4834125dbb44494abec45d7f5e2ac7b_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NjEx_e3c59526-1faa-484b-a277-6dd51a1a9e0c">P1Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i5de143a3fca648fba48b1af47b9984f0_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181Mi9mcmFnOjE4N2UwOTM5N2QwNDQzZmFiMTJlNTdjMDMzNWVjMWQ5L3RleHRyZWdpb246MTg3ZTA5Mzk3ZDA0NDNmYWIxMmU1N2MwMzM1ZWMxZDlfNTQ5NzU1ODI2NjMw_bf96ff90-857a-4c81-9e85-be9efe6df932">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTUxMTM_48c5ffca-c690-4fda-839a-53a9281e9b34">DISPOSITIONS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestiture closed on March 31, 2023. We received net proceeds of $47.8&#160;million and recognized a $2.2&#160;million loss during the three-month period ended March 31, 2023 which is reflected in miscellaneous, net within our condensed consolidated income statement. The net proceeds of $47.8&#160;million is inclusive of $6.0&#160;million that was placed into an escrow account in accordance with the closing payment and indemnity provisions within the purchase agreement; this amount is recorded as restricted cash within our condensed consolidated balance sheet as of March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disposition of our personal care business did not qualify as a discontinued operation because it did not represent a strategic shift that has or will have a major effect on the Company's operations or financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTgxNzI_55a6dec6-0bcd-4a04-a761-b2f6e92e7da0"
      unitRef="usd">47800000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTc4NTg_f496f599-814e-465f-b283-23487d782fc2"
      unitRef="usd">2200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTgzNzE_55a6dec6-0bcd-4a04-a761-b2f6e92e7da0"
      unitRef="usd">47800000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestrictedCash
      contextRef="i58bb9667d6ae49158d64d74c1293836f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTc4ODc_9368b2e0-8493-4b39-9386-0229f951b52b"
      unitRef="usd">6000000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGV4dHJlZ2lvbjplOWYwNjBmNThiMWM0ZmY3OTAwMjZmYTkwMGUwMzQwNl81NDk3NTU4MTUxMTQ_55427fdd-f460-48b3-ba5c-f71d5d70f706">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8zLTMtMS0xLTcxMTgw_281422c0-558f-40ff-9add-bb5f90a4802e"
      unitRef="usd">9600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF80LTMtMS0xLTcxMTgz_b75aedf4-1bc5-4f93-ad72-f75ef4276434"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF81LTMtMS0xLTcxMTgz_863ad7e9-217f-43ec-8086-22a9c111fe57"
      unitRef="usd">9700000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF82LTMtMS0xLTcxMTgz_bf31d856-c9c1-484c-a4fe-e1a42e5afc23"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF83LTMtMS0xLTcxMTgz_19640fd2-cf99-4baa-80e4-3db5ea764e0d"
      unitRef="usd">2500000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF84LTMtMS0xLTcxMTgz_d5aefcf1-5cf0-4450-b759-62dfa5f57973"
      unitRef="usd">43100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xMC0zLTEtMS03MTE4Mw_8e9ab4a8-f127-4282-845e-d77aca43c9aa"
      unitRef="usd">55400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xMy0zLTEtMS03MTE4Mw_b14fee25-6f9a-4141-b177-788bb3aaabed"
      unitRef="usd">400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNC0zLTEtMS03MTE4Mw_eb268ec4-40db-4a2d-87ca-894958f89726"
      unitRef="usd">600000</amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNS0zLTEtMS03MTE4Mw_129edca7-2a67-451f-94a7-f815460b07d8"
      unitRef="usd">1800000</amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNi0zLTEtMS03MTE4Mw_8b3b8a72-f9dd-4d4e-96b3-9641a609f6ab"
      unitRef="usd">600000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xNy0zLTEtMS03MTE4Mw_45fc8a40-5b20-45a0-a522-f0c4046e4022"
      unitRef="usd">3400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xOC0zLTEtMS03MTE4Mw_a2025b1c-2892-49fc-901d-0cabe86122cc"
      unitRef="usd">1900000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i7c3425ad117b4bc4bc6c90ff6489367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM18xMTk5L2ZyYWc6ZTlmMDYwZjU4YjFjNGZmNzkwMDI2ZmE5MDBlMDM0MDYvdGFibGU6Y2MyYmY2MTc5NjAwNDU4NGI2ZDI2YjM0NTQyMDViNTQvdGFibGVyYW5nZTpjYzJiZjYxNzk2MDA0NTg0YjZkMjZiMzQ1NDIwNWI1NF8xOS0zLTEtMS03MTE4Mw_746052cb-ebc1-48ed-88d6-613ab7661e3e"
      unitRef="usd">5300000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2NA_95ef58c8-18ed-4a8e-a78c-ea461c4497b9">LONG-TERM OBLIGATIONS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate (6.1% at March 31, 2023); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Second Amendment to the Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Third Amendment to the Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 10, 2023, we entered into the Third Amendment to our Credit Agreement (as amended by the Third Amendment, the "Third Amended Credit Agreement"). The Third Amendment (i) formally replaced the use of the London Interbank Offered Rate ("LIBOR") with the Secured Overnight Financing Rate ("SOFR") for interest rate pricing and (ii) allowed for the disposition of our personal care business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Term SOFR Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Term SOFR Rate plus 1% per annum. The &#x201c;Term SOFR Rate&#x201d; means the quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%. The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2023, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Term SOFR Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term SOFR Loans and SOFR Daily Floating Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Third Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net proceeds received from the divestiture of our personal care line of business were used to pay a portion of our Term Loan during the three-month period ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Third Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Third Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Third Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Third Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Third Amended Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Third Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and 2022, we had no outstanding borrowings under our $550.0 million Revolving Credit Facility. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 6.1% and 1.7% for the three-month periods ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our consolidated leverage ratio was 1.6, our consolidated interest coverage ratio was 10.3 and we are in compliance with our covenants under the Third Amended Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our availability under our $550.0 million Revolving Credit Facility was $519.2 million as we have no outstanding borrowings and $30.8 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;Contessa and Asana Joinder,&#x201d; and together with the CCH Joinder and the AseraCare Joinder, the &#x201c;Joinders&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;existing or arising after the respective effective dates of the Joinders, under the Third Amended Credit Agreement pursuant to the terms of the Joinders and the Third Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding promissory note totaling $0.2&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of 6.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding finance leases totaling $20.1&#160;million relate to leased equipment and fleet vehicles and bear interest rates ranging from 2.2% to 7.7%.&lt;/span&gt;&lt;/div&gt;Effective January 1, 2023, the master lease agreement for our fleet leases was modified to remove the residual value guarantee provided by the lessor on each of our fleet leases. The modification resulted in a change in the classification of our fleet leases from operating leases to finance leases. In connection with the modification, we reclassified approximately $15&#160;million from the operating lease asset and liability accounts to the property and equipment and current/long-term obligations accounts within our condensed consolidated balance sheet. Additionally, following the modification, expenses associated with our fleet leases will now be recorded in depreciation expense and interest expense within our condensed consolidated income statement as opposed to cost of service and general and administrative expenses which is where the expenses were reflected in prior periods.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2MA_94a113ae-005d-4b5f-8f71-568a5ecf9e2a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate (6.1% at March 31, 2023); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie474c65087de4fcd9f03f6114faa2034_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzQ_7f8c3c28-78ee-4c17-b221-ae8d47563390"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="id96882539f8d4eed92cde59a1e4c6c16_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzEwNw_b41899f7-76a3-4c01-bffe-05c10242a1a9"
      unitRef="number">0.061</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOjhlZTI0ZTUwNWMyMjQ1YzNiMWQ2M2FiMTIwNTQ5MzM4XzEzNA_59b55cf5-9f22-4901-ab3a-28563c397d93">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie474c65087de4fcd9f03f6114faa2034_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0xLTEtMS02NzEyNA_259a519e-0a01-49c2-b835-91a8ed406a50"
      unitRef="usd">383100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if7ad22f782c84a46af3f9772a7af2667_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMS0zLTEtMS02NzEyNA_54c6e45f-5fc8-4795-b9a2-b521a1e1c552"
      unitRef="usd">435900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOmRmM2EwZWU2YTRjMjQ4NmJhNzM3MTBlYWJkNmVjN2RhXzQ_090c8ce4-e55c-4608-ab69-747fb86681c7"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ic3159160953145aebe0e174490333355_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0wLTEtMS02NzEyNC90ZXh0cmVnaW9uOmRmM2EwZWU2YTRjMjQ4NmJhNzM3MTBlYWJkNmVjN2RhXzE1MQ_299eaaec-6a18-4bb0-a218-fbd4f7cf995a">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0xLTEtMS02NzEyNA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0xLTEtMS02NzEyNA_cd24514f-9698-46c2-a531-38d14f54e65e"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i81cebef82b22470c9b04463e506d3f78_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMi0zLTEtMS02NzEyNA_6e769c77-818b-4474-9df8-95535aa198ea"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMy0xLTEtMS02NzEyNA_1fdbaea0-f1fb-4fbe-8bf7-18b6d35154bf"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i40995d245e1849f6a663395f8252db2e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfMy0zLTEtMS02NzEyNA_b68431ac-3ba7-42a1-b463-f10467c6e5bd"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93b451bfc136446abd99c9651bda4093_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNC0xLTEtMS02NzEyNA_4ae2c2a8-fe5b-47a1-abbf-d248ec5a6b74"
      unitRef="usd">20100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ide7e815971ae49ee868e7a75f749208f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNC0zLTEtMS02NzEyNA_3b7df7b4-f3c1-449a-bd9f-08fd67b0a4e5"
      unitRef="usd">2300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNS0xLTEtMS02NzEyNA_ccea9b53-c46f-4288-ae4d-711313094816"
      unitRef="usd">403400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNS0zLTEtMS02NzEyNA_5d640868-9f83-4849-ad86-903eb8ae078d"
      unitRef="usd">438400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNi0xLTEtMS02NzEyNA_de21fe4a-aba2-471b-9b66-71505aad92dc"
      unitRef="usd">3300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNi0zLTEtMS02NzEyNA_16cf296c-49e8-4f72-9186-4392f65238f1"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNy0xLTEtMS02NzEyNA_d2e5661d-16a3-465f-8524-7f00bf1352c9"
      unitRef="usd">400100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfNy0zLTEtMS02NzEyNA_6a7e6c98-11cb-4c35-8170-53444c54ddd3"
      unitRef="usd">434900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOC0xLTEtMS02NzEyNA_0fb9e1ee-0869-410d-af61-ba300f985a0c"
      unitRef="usd">26900000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOC0zLTEtMS02NzEyNA_da90259f-c57b-4821-9068-ef996928edb2"
      unitRef="usd">15500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOS0xLTEtMS02NzEyNA_6b72b756-a6fd-4aec-8104-87e6b6b4736f"
      unitRef="usd">373200000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5472f8016b234c9baa7f6b92667e2fc2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOjVlY2E3NzJlYTBjNDQzNjM4NGFkMDM4MzY5M2I3YTRiL3RhYmxlcmFuZ2U6NWVjYTc3MmVhMGM0NDM2Mzg0YWQwMzgzNjkzYjdhNGJfOS0zLTEtMS02NzEyNA_441a14f7-fae1-46cc-92c3-61eb9e853ba8"
      unitRef="usd">419400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia55b972867c94e8bb889ae04e28fdb15_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDUx_4bed4a33-bb63-49ca-8527-053d17a77a43"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia492b736de1e47179438373b2738ee0a_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDcy_c5a3d8c2-9ae7-4328-9c5c-3ac1143b0326"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i96d5def30a27419ab88f280a1a8227a2_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTU5_14ae1298-f3e8-4ae5-abb5-96295ecc3680"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTA5Nw_28dd0405-c19d-4a22-946b-051e7033c346"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate
      contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTIxNg_763627ad-e9c6-498b-bac5-32ed429b0679"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate>
    <amed:SOFRAdjustment
      contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI2NzE5_144cd41c-948f-4864-b59b-88bdfe8339a8"
      unitRef="number">0.0010</amed:SOFRAdjustment>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if0e2df2ee5cb4b85b62420ced1fb93c9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTYxMw_20ee2767-d7ad-4aae-8c1f-c8cfdbde246e"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6c32b0de3217439f96df3b34a22fb3cf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTY1MA_b74fcf0a-44e9-458e-a876-5f607d6b3af0"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNzg2MQ_24a15ee9-eeeb-4d1a-942e-259648721257">We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term SOFR Loans and SOFR Daily Floating Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="id60579582fb34f4ca10b3cc4b36399dd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjlkYTAxNTY3YWVkMDQxMDQ4Y2RjMmZjM2VjZTcyYzMyXzY_1d8f1148-c4e6-494f-9dc3-73696fddc33e"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i46f6956ee4104b5cac9dcd8b0e43e85c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0yLTEtMS02NzEyNA_dfbf82c1-80b2-4aae-954a-326af043bc0e"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i870058a53843477c9351bc8199925557_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS0zLTEtMS02NzEyNA_397430a4-e569-41ec-8b76-020672222c26"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS00LTEtMS02NzEyNA_28943e4c-7419-44db-b910-0f04647aada6"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i7e7041d740c243b09674fbf8633620bb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMS01LTEtMS02NzEyNA_44166588-f63c-422a-bc36-18e1927ae9cf"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="ia33e2d83e5d1461081b910b52e23d2bf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJhZWI3MWQxMzZiODQ3ODE4MDYxMDU1MzM0MjVkNTc3Xzc_f8956068-7d8e-4512-93fd-9865ff7221b2"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i2aa0ee06acc245068f9ee47a8f9534fd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjJhZWI3MWQxMzZiODQ3ODE4MDYxMDU1MzM0MjVkNTc3XzIz_d872eab3-0a59-4791-9278-0adf9fe51207"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibbf2a36d31e3405891903d3fee681e78_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0yLTEtMS02NzEyNA_98dba5db-77dc-4025-87ad-9ea7ce39bfce"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia25ced89f8d94908bec90fa9845fe731_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi0zLTEtMS02NzEyNA_071ee9f7-812e-4d44-9ef7-c60241295783"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i278de941823643d5a9ebedb448bfe966_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi00LTEtMS02NzEyNA_0eaf824b-0425-4ad4-8c46-971f8b8a7dda"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i278de941823643d5a9ebedb448bfe966_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMi01LTEtMS02NzEyNA_4415f890-6ae6-4fcb-8e6f-f5a66206d817"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="ifd1d1bf51b1148e0aca183be9b4f10c1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOmUwMTk0NmQ0MGRmMTRhZjE4MDBhOTdiY2U0ZWMxNmVlXzY_9e1ac79e-1bfe-4c9c-a3e9-a570b470fbf9"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i5ed24a55c79b48a9a4f962dcbc7f923c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOmUwMTk0NmQ0MGRmMTRhZjE4MDBhOTdiY2U0ZWMxNmVlXzIy_dcbd3747-0e5e-432a-a871-2b23817f4a5c"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i81fc1915a4e5409f9acf5b031d0f164e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0yLTEtMS02NzEyNA_b06b8b3c-d4c1-47ce-8cf6-4b955adc6991"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iae944944b29040f5a2b123f79d05d2cb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy0zLTEtMS02NzEyNA_982cf95f-78fb-4e3c-b0a5-c5e6ec8eb5f6"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ida89fe95351140f6b7664868c8647802_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy00LTEtMS02NzEyNA_d0d047fd-1125-49b2-a7a0-d8dfaa72382a"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ida89fe95351140f6b7664868c8647802_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfMy01LTEtMS02NzEyNA_6f441abb-dc80-44c1-bb34-62d6cc795209"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i6ec5894fd66b4d3f82b50f315effcf79_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0xLTEtMS02NzEyNC90ZXh0cmVnaW9uOjg1MTVlMjQ4MDhhZTQ3ZDk4ODU0Y2E3MDgxOGVhM2MzXzY_674ce663-95ed-437f-9b38-7bc714749b74"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1960f86c82bb4f3b9b446612846b3561_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0yLTEtMS02NzEyNA_ff4d176c-2e33-4945-a3cf-bbc5defa36ba"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6924c05d92fe48d08e15de81fa474e53_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC0zLTEtMS02NzEyNA_ea838e36-8a06-4ad6-9356-81cc2443c977"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC00LTEtMS02NzEyNA_4c6e3f45-9e20-4583-8736-e4e31634db72"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i53aa3070f0704a41abfa22982efbf40b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RhYmxlOmQ1YzMyOTlhMDg4OTQ4ZWJiYjk2Y2JiYTMyYzkyMGZjL3RhYmxlcmFuZ2U6ZDVjMzI5OWEwODg5NDhlYmJiOTZjYmJhMzJjOTIwZmNfNC01LTEtMS02NzEyNA_4ddbbfaf-1369-4686-a7aa-3daa68b02262"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ic74251b39fdf4162865cb8772044613f_D20210730-20260730"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMTkwNQ_4a2ebe52-ba17-49c9-a2c7-eef56140235d">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="ie62968d493c546e9be2fb5e44a2238d0_D20210730-20230930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjEyMA_0f99c84c-b970-4159-8450-55baf19d0e72"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i1414dda84f1a4039b0c9c62176b05341_D20231001-20260730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjIwOQ_412fd664-f956-40fe-b6d8-694a2dd74add"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="i7d3cbf205560418db36bba9e6b1a9d42_D20230310-20230310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfMjgzMA_d827e0ee-46e0-4345-aa3e-11622fdce31d"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDEyNA_05735839-d38a-44aa-9cc4-fa8328401a40"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="i856133d3d1d84153b658b1350b845ff4_D20230310-20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDMwNw_b245beab-3760-420e-af70-d7f787d0b486"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDQzNA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDQzNA_cd24514f-9698-46c2-a531-38d14f54e65e"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ic3b5b10ea4234f539036fd7ad857982a_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDc0OA_ce9226e8-8466-473d-a889-de8de874b10b"
      unitRef="number">0.061</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="icc2bd5dd04d541069c60eda0585eb542_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDc1NQ_5d91543a-00c1-4ac6-bce3-f846678ce361"
      unitRef="number">0.017</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDg3Nw_f44f2724-8706-4d65-9a6a-7329ad4ae8f4"
      unitRef="number">1.6</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="i585e48375f81452ca5c935a0f065bef9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNDkyNg_b81c1b72-d152-449f-94bf-b1049c501939"
      unitRef="number">10.3</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTMxMQ_f73d6297-d63e-4aa8-b38d-98870d1cf8ea"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM0NA_5ef72104-1f09-42eb-9b69-c23d6830599b"
      unitRef="usd">519200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32bd8ed3d02c453cbb170444b858f3c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM1OA_afd657bd-e137-41b5-9a17-a7aa2d4c5564"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id8d2e1865d544d56bc61bafc92378512_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM1OA_cd24514f-9698-46c2-a531-38d14f54e65e"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i2beea370526f4c58885810023a334383_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTM4OA_7bb130df-008e-43c3-9995-28c3a95d03d5"
      unitRef="usd">30800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTI2_738bf91f-69b6-4832-bde0-f4397a6bef74"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib05f8f52b3fc429faaeeed257c8f97cc_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTQw_a8548e79-cb1f-435b-88e9-0a639288a469"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93b451bfc136446abd99c9651bda4093_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTQ2_83feb233-9883-42c6-86fb-707b6b74c114"
      unitRef="usd">20100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d894bb39c82450382991fab6b6370d0_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTYw_5ea31edf-3ae3-4860-9d8e-e3c5136e00fd"
      unitRef="number">0.022</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99635620a5d140d8a4a7b0b502e0957d_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTY2_4f7a1204-840c-431c-871e-3fd379956b34"
      unitRef="number">0.077</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amed:ReclassificationOfOperatingLeaseToFinanceLease
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM181OC9mcmFnOjg5YjMzNWE1NTNkYzQxYmZiOWJiODcwMTk4OWFiNTUwL3RleHRyZWdpb246ODliMzM1YTU1M2RjNDFiZmI5YmI4NzAxOTg5YWI1NTBfNTQ5NzU1ODI0MTcy_9ea13c22-4ff9-490e-b8e6-a40739d9e95a"
      unitRef="usd">15000000</amed:ReclassificationOfOperatingLeaseToFinanceLease>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAyNDQ_7b6ea667-dc88-4016-8bd6-4344f2c87df6">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;), Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;) and the Office of the Inspector General (&#x201c;OIG&#x201d;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2023, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4&#160;million to $25.2&#160;million, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3&#160;million ($22.8&#160;million extrapolated repayment plus $11.5&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7&#160;million ($2.4&#160;million extrapolated repayment plus $1.2&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $1.5&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9&#160;million and have recorded this amount within other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation, professional liability and fleet. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of $2.0 million per incident. Our professional liability insurance has a retention limit of $0.3 million per incident. Our fleet insurance has an exposure limit of $0.4&#160;million per accident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amed:NumberOfBeneficiaries
      contextRef="ibbca5f3a4ed84661b6142d602c23319c_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMzY2OA_e2863147-2689-4374-ba2a-85dd3f67afad"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDExMg_01921a21-70d7-4d37-8728-2b62a2d76d0b"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ideb0213b931749a29f65d87002bd3697_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDkxNQ_3257c30c-6bcc-4e86-9955-3307ad3a508b"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="ideb0213b931749a29f65d87002bd3697_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDk0MQ_5538678b-b717-46d8-8499-88bfd7bed15a"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNDk3NA_f007d240-1600-4746-b133-257831c8b6dc"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="ibb5a92e696fd44df9e881f2ecf855749_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTAwNQ_7cf600df-1125-471a-8b80-77063f5ea4fc"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i3830d79bc7414b9383b0b67f22b8dd83_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTA3OA_d3978267-a04d-44df-8f63-c611d739eb3e"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="i4656df3498d04d67889bc6a6d94519c5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTMyMw_c764338b-0712-4155-863d-fb2a77da4556"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <amed:IndemnificationAmount
      contextRef="id73cbf69d99243349bd20c6351ede631_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTgyOA_3082b3a4-761f-4fe7-977e-f81008b635c8"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="id8de4359d28d41ae8006eb4ac5462691_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTgyOA_f1de5489-0e8a-4582-baa9-1bf1fb76f73c"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjY3Mw_3b086ee1-f216-4e48-9cc8-541019c49d59"
      unitRef="usd">34000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i32b13a5963884c508a47edd37af0affe_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjcyMw_a4368477-dd29-4ca3-8b70-8e41f61e5599"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjc1MQ_60ee6093-5477-4124-8d6a-8b10eafaa997"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="ia4649b57d4264b6487be77b0ddca78b6_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjc4OA_13537f3d-17bb-4008-9ac8-e77cdc4600be"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjgyNA_251a036f-af90-4ae5-bf3e-eacb27068508"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="if0503aff1b6d474d8e740e5f1f22aa0f_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjg3NQ_0f0f9e86-1a42-4ce9-8003-26aeb819bedf"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjkwMw_ee272856-790c-4251-b00e-7dd30cb53dda"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="ib3eba185d82244d6b36d702c87bd4b49_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNjk0MA_f05fcb88-0a5c-46fd-be09-5ef921a8de73"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i54da14b3e36b46ce878e835cb8028e7d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNzMwNA_6919803f-51b8-4429-b61b-a6f2151b88b5"
      unitRef="usd">26000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ie009f517271a4d76847c8f3d3582e49e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNzM4Ng_60cbcb10-2e4b-467f-b7d8-8d1dbcd64634"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ie4ec2786358a4520ab9eae39cdb96053_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NjE5_18fec538-a5e7-4c64-b6aa-2ddcefd993de"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i6e5ad00097724ab594a7deaf5d111fef_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NjM0_9a836208-d134-44ec-90e0-5c85a5468910"
      unitRef="usd">25200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:TotalLegalSettlementPayment
      contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Njkz_f80b9c90-3bc9-4da5-a30d-94e5a22304a6"
      unitRef="usd">34300000</amed:TotalLegalSettlementPayment>
    <amed:LegalSettlementPaymentLessInterest
      contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzA4_1a90de83-ae2b-4b16-a42b-36b9b6f31897"
      unitRef="usd">22800000</amed:LegalSettlementPaymentLessInterest>
    <us-gaap:LitigationSettlementInterest
      contextRef="i0952a158e25d49b8a28ca0baa4a76cea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzIz_efdfb088-e47c-436e-b1c0-8e1eca4149cb"
      unitRef="usd">11500000</us-gaap:LitigationSettlementInterest>
    <amed:TotalLegalSettlementPayment
      contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzM4_52fa45f1-d220-49a8-81df-5d0c9574d098"
      unitRef="usd">3700000</amed:TotalLegalSettlementPayment>
    <amed:LegalSettlementPaymentLessInterest
      contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzUy_9719209c-cbe3-4b01-9eb7-d318d2308b9b"
      unitRef="usd">2400000</amed:LegalSettlementPaymentLessInterest>
    <us-gaap:LitigationSettlementInterest
      contextRef="i8c6f3d0d44a34e76b833cb81aa75c127_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0NzY2_6cb7f492-5d8d-4163-aac6-677480577387"
      unitRef="usd">1200000</us-gaap:LitigationSettlementInterest>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i2bca8c668b9c4f898b4b708846df0658_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Nzgw_d79ab183-64b4-4361-997e-bb482735a62d"
      unitRef="usd">1500000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i942ca593c3da41b39bd5dd41b049950e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM0Nzk0_469d7ae2-64f6-40d8-b15e-5ab7102dc133"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAwNDc_74c4214b-6a37-41ff-b3b5-c78cdd05a37f"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAxNDQ_789af391-c965-41c5-b794-9abe237edaaa"
      unitRef="usd">2000000</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfMTAyMjY_cd0d35c4-a6ec-4128-a218-c2c1789e0c56"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <amed:FleetInsuranceExposureLimit
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM182NC9mcmFnOjgzMGY1NWE2YTRlYzQ1NzM4YjExMGQ5ZDI2ZThlOGE5L3RleHRyZWdpb246ODMwZjU1YTZhNGVjNDU3MzhiMTEwZDlkMjZlOGU4YTlfNTQ5NzU1ODM1Njgz_06a184de-c2ba-4c72-b33f-e1a5d5afa7e8"
      unitRef="usd">400000</amed:FleetInsuranceExposureLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfMTU5MQ_0db4af87-7c8b-4375-8ff1-11f3ba8b9578">SEGMENT INFORMATIONOur operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and SNF care to patients in their homes. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our reorganization initiatives, management has revised its measurement of our reportable segments' operating income (loss). Effective January 1, 2023, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function in order to realize operational efficiencies. Additionally, effective January 1, 2023, we transitioned from the high acuity care segment to the home health segment the operations of a home health care center that was contributed to the high acuity care segment by one of our health system partners during 2022. Prior periods have been recast to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, inclusive of depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfODI_39a565dd-0f20-4caf-8cf4-2627d1c67488"
      unitRef="segments">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RleHRyZWdpb246NWY0Yjk3MjJkNDNkNDAxYzk0OGQxNjMwNmRmMjkzZjlfMTU5NA_d0145448-5af0-4391-9131-ea03e8e4546c">Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, inclusive of depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0xLTEtMS02NzEyNA_8bd4740b-9234-48e1-8269-a30d5e257fac"
      unitRef="usd">343300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0zLTEtMS02NzEyNA_1a6c2250-5fc1-41c2-9d36-3da574cc4ada"
      unitRef="usd">193400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi01LTEtMS02NzEyNA_24230851-d088-4b67-a05d-42169e8a5025"
      unitRef="usd">15000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi03LTEtMS02NzEyNA_1fabe4d4-b13b-4726-a984-187efe49f6f2"
      unitRef="usd">4700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi05LTEtMS02NzEyNA_6ef23a09-5a4e-4ce8-b106-184f285d9fe6"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMi0xMS0xLTEtNjcxMjQ_6f545113-7fe6-4fd6-aadc-88578531173b"
      unitRef="usd">556400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0xLTEtMS02NzEyNA_b02f9dc0-5354-4902-9593-99615884f501"
      unitRef="usd">197000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0zLTEtMS02NzEyNA_892b78e6-1c6a-4c1a-ae0d-96d020c1ed22"
      unitRef="usd">101400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy01LTEtMS02NzEyNA_fe62e19d-040d-46a2-ba28-0aa432708008"
      unitRef="usd">11100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy03LTEtMS02NzEyNA_7a66e0d2-8f28-4157-aaff-309dbc358626"
      unitRef="usd">5500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy05LTEtMS02NzEyNA_3372a8a0-8631-4693-8e37-5b7650cc6fb6"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMy0xMS0xLTEtNjcxMjQ_3f55abe9-b6ef-48f3-845e-79ea0291f62e"
      unitRef="usd">315000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0xLTEtMS02NzEyNA_6a57dfbd-374a-4f92-8441-6cca8dd266dc"
      unitRef="usd">89100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0zLTEtMS02NzEyNA_39d23323-d3e8-408f-a84f-9c01fbee845c"
      unitRef="usd">47900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC01LTEtMS02NzEyNA_ac34e3af-7b27-4167-917f-6b2f65458de6"
      unitRef="usd">2300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC03LTEtMS02NzEyNA_907f0e93-780f-48c7-8104-5103c6a6b9f9"
      unitRef="usd">4400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC05LTEtMS02NzEyNA_f7392758-1125-44ae-817b-d4657048ae3c"
      unitRef="usd">50900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNC0xMS0xLTEtNjcxMjQ_67a83ea9-1351-45c8-bbf5-276b6f150e67"
      unitRef="usd">194600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0xLTEtMS02NzEyNA_d321224e-dc7b-4e2d-9eda-cb55b00d3605"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0zLTEtMS02NzEyNA_085f5c8d-46c7-418a-9189-48bd1672ef2e"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS01LTEtMS02NzEyNA_b3e7e45e-bc63-449e-83bc-1e0b92ae18ec"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS03LTEtMS02NzEyNA_cca87762-deb5-4aa7-bb92-82011b8036b0"
      unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS05LTEtMS02NzEyNA_7ce1656c-23a4-48d8-b26f-564bf9f74716"
      unitRef="usd">1900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNS0xMS0xLTEtNjcxMjQ_1a7e8cf8-b9b5-44cb-8bfc-76b8f72ef403"
      unitRef="usd">4400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0xLTEtMS02NzEyNA_c24433d8-a636-482c-b213-a1cacfce2daf"
      unitRef="usd">287200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0zLTEtMS02NzEyNA_dd3804df-5459-4294-95a9-1f7d82faf363"
      unitRef="usd">149900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi01LTEtMS02NzEyNA_2efd1868-0f3a-4950-820c-0a53f20e2c5b"
      unitRef="usd">13400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi03LTEtMS02NzEyNA_29730a41-b43a-4043-b7b7-a37654284a30"
      unitRef="usd">10700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi05LTEtMS02NzEyNA_d0491ba2-d0be-4faa-aa48-9e4334bc5ba8"
      unitRef="usd">52800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNi0xMS0xLTEtNjcxMjQ_a430ed15-409e-4303-832c-e88469c13607"
      unitRef="usd">514000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9586417a8e5141c2ae000c740a130d80_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0xLTEtMS02NzEyNA_38a3775d-6eb6-4b46-8441-28546fd4793e"
      unitRef="usd">56100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65c6c1787206460dac3d072a59137173_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0zLTEtMS02NzEyNA_8c42d027-881c-438d-82c0-abe738d01ffb"
      unitRef="usd">43500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9c951c93c98441a93062a5cc5670551_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy01LTEtMS02NzEyNA_47ac3941-f6e1-47c6-a3fa-0ba78e2e6702"
      unitRef="usd">1600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1057256597bb4a308e0432e8942b8883_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy03LTEtMS02NzEyNA_c824dff9-d32b-4db6-831c-e884b01b0ac0"
      unitRef="usd">-6000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iecea7797edce4d7f827be77680105619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy05LTEtMS02NzEyNA_b12299ed-28bc-4f56-9617-338e7ed2c001"
      unitRef="usd">-52800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfNy0xMS0xLTEtNjcxMjQ_caa79fa1-7963-490f-8e1f-1d49a2eecbe3"
      unitRef="usd">42400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMS0xLTEtNjcxMjQ_9a8cfe65-2ee4-41c8-a6ed-3b37b23670ff"
      unitRef="usd">335700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMy0xLTEtNjcxMjQ_2bbcd07e-a97e-43ba-8bd5-c799eb6278e2"
      unitRef="usd">193100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtNS0xLTEtNjcxMjQ_3c44da34-41d2-45d1-8c0b-8460b17febdf"
      unitRef="usd">14000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtNy0xLTEtNjcxMjQ_90034899-4761-4beb-8d98-c38070a43bd3"
      unitRef="usd">2500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtOS0xLTEtNjcxMjQ_1ba23e3f-cc39-481b-abd3-a6c0f97b4361"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTEtMTEtMS0xLTY3MTI0_018bc5bd-0889-4c54-9e26-11e90d47bb97"
      unitRef="usd">545300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMS0xLTEtNjcxMjQ_e6a3389c-9bd0-48bc-8e49-cd15de16315e"
      unitRef="usd">185200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMy0xLTEtNjcxMjQ_f69846e6-2dad-4cbd-8435-c63f17ae67c2"
      unitRef="usd">106400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtNS0xLTEtNjcxMjQ_f4113744-c147-40d6-96f1-c34e39a7439c"
      unitRef="usd">10800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtNy0xLTEtNjcxMjQ_f664df6a-9841-44b3-bdc6-8160766f60fb"
      unitRef="usd">2400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtOS0xLTEtNjcxMjQ_74f9e29d-dd57-4b30-a546-f5998f5f58c6"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTMtMTEtMS0xLTY3MTI0_a647859a-12e1-4dff-8c0a-ffc7ae25ba1e"
      unitRef="usd">304800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMS0xLTEtNjcxMjQ_2a512ae4-51e4-4033-88d9-2fa192f0c4cf"
      unitRef="usd">83200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMy0xLTEtNjcxMjQ_4257fd79-81c1-486a-ac5f-2c5fb8175507"
      unitRef="usd">51300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtNS0xLTEtNjcxMjQ_304369d6-5edb-4a7c-85db-30eb0177d9bc"
      unitRef="usd">2200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtNy0xLTEtNjcxMjQ_da88e9d5-4f31-4ae5-918e-615751d21c09"
      unitRef="usd">4300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtOS0xLTEtNjcxMjQ_a8143f42-bb53-4a66-b94f-c20a933b7109"
      unitRef="usd">43500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTQtMTEtMS0xLTY3MTI0_0df6125c-f537-48a9-b04d-4ebc92135b1a"
      unitRef="usd">184500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMS0xLTEtNjcxMjQ_4c4aada5-60fb-4ee8-ae6c-7b8c54e130b3"
      unitRef="usd">900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMy0xLTEtNjcxMjQ_975b669e-b841-40f9-a809-beda9b1c1265"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtNS0xLTEtNjcxMjQ_4eb107ef-df3b-4ff5-a6e1-336650d04ea0"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtNy0xLTEtNjcxMjQ_9a856e90-63e9-440f-8840-97f9cce5e0fd"
      unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtOS0xLTEtNjcxMjQ_144eeb1f-cda6-46ee-be9e-ba497c2b60fb"
      unitRef="usd">5600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTUtMTEtMS0xLTY3MTI0_75e6a6aa-ed4d-4517-a49e-af8c2aa6ff33"
      unitRef="usd">8000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMS0xLTEtNjcxMjQ_21dcea2d-7013-49b3-9501-174844416af8"
      unitRef="usd">269300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMy0xLTEtNjcxMjQ_b746ba65-3bd1-4ac8-9d75-e164136ab5a5"
      unitRef="usd">158300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtNS0xLTEtNjcxMjQ_93f20e7d-8e5a-41d3-9ce6-82b7e8af2f04"
      unitRef="usd">13100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtNy0xLTEtNjcxMjQ_0b53950f-fd8d-4675-ba0d-25226c96c924"
      unitRef="usd">7500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtOS0xLTEtNjcxMjQ_6d73c7e4-6e29-4d73-972a-01519f933f11"
      unitRef="usd">49100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTYtMTEtMS0xLTY3MTI0_83b7acdc-0cd5-404e-b65f-efeed9d8b3f3"
      unitRef="usd">497300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5f4d90288f204db8b386807f8b4ff6df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMS0xLTEtNjcxMjQ_9f7b2f2e-f3b0-40af-b4ea-edf030049fc7"
      unitRef="usd">66400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i018c88178e264896b3969b9ef2af4756_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMy0xLTEtNjcxMjQ_1a7da9a8-c4c0-42e5-8ad2-0e335e458685"
      unitRef="usd">34800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2d9c9396c11a499f868a2526d19b7310_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctNS0xLTEtNjcxMjQ_95fdca3a-a608-4a76-aa35-cf0fbc350545"
      unitRef="usd">900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iddce62c4a3e1416e8ad819b022575b96_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctNy0xLTEtNjcxMjQ_c23c8220-b11e-4bf9-8bfc-a6f60cdde4fd"
      unitRef="usd">-5000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e28ba2eefd0412fa6a92d9a6dc6d0cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctOS0xLTEtNjcxMjQ_f3cbcd3c-1699-4acf-963c-91bfebf8864d"
      unitRef="usd">-49100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icab9c6d648bc4aeab284f7c4d006fadf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183MC9mcmFnOjVmNGI5NzIyZDQzZDQwMWM5NDhkMTYzMDZkZjI5M2Y5L3RhYmxlOmYzNjYwZDNiYzA2NjQ5YTRhNDE5YTkxYjYyN2QxOGVkL3RhYmxlcmFuZ2U6ZjM2NjBkM2JjMDY2NDlhNGE0MTlhOTFiNjI3ZDE4ZWRfMTctMTEtMS0xLTY3MTI0_62792af8-d465-4e47-9c63-ddacc9b897fb"
      unitRef="usd">48000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:TreasuryStockTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMjE0Mg_5b9032b1-d946-4ebe-977e-f5fa70d0c475">SHARE REPURCHASES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022 (the "2022 Share Repurchase Program"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. We did not repurchase any shares under the 2022 Share Repurchase Program during the three-month period ended March 31, 2022. The 2022 Share Repurchase Program expired on December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, &lt;/span&gt;&lt;/div&gt;repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of March 31, 2023.</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i375e7e760e9d4aa1a92757ae86a0d210_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMTI4OQ_c0b2d9fc-b94b-4cf8-a2e9-2bab93999da0"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i830c428bb89b41599cc12c2881b394b5_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfMTMzMg_72f2ec09-1451-445c-b064-fb943afbd6f6">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5be9befb4f734cae91c1a764171dddf2_I20230202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfNTQ5NzU1ODIwNzQ1_ea67c1e0-cf8a-4167-b6bd-137bb11efb1c"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="ic23b318b43a44f01bf8a8c58852671ce_D20230202-20231231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM183OS9mcmFnOjgyYTk0YzM0NGE3ZTQ3NThhMzM0MzNhY2M4YWFiNzZmL3RleHRyZWdpb246ODJhOTRjMzQ0YTdlNDc1OGEzMzQzM2FjYzhhYWI3NmZfNTQ5NzU1ODIwNzU5_96958522-3e49-424d-ad17-ac0bbb899c66">2023-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfNDQ2_1d614c04-63ff-4b5b-9707-ffee4cc8c58e">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $2.4&#160;million during each of the three-month periods ended March&#160;31, 2023 and 2022 in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i0ebd4093f9e54759abfee45439a836a5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfMjYz_1f4af896-3e36-4ce2-a002-39352371e7c1"
      unitRef="usd">2400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184Mi9mcmFnOjFmMGU4MTY0MjQxZTQwZjA5YTE5MTEwNjBlZDY3MmFjL3RleHRyZWdpb246MWYwZTgxNjQyNDFlNDBmMDlhMTkxMTA2MGVkNjcyYWNfMjYz_243708b9-4e2e-4c25-b8af-b26a0a313842"
      unitRef="usd">2400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ifffa4741db0645459f158c3d99d750ce_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTY4_fc0c6c21-458d-4549-894e-6bcf11f0be48">SUBSEQUENT EVENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 3, 2023, Amedisys, Option Care Health, Inc., a Delaware corporation ("Option Care Health"), and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Option Care Health ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides for, among other things and subject to the satisfaction or waiver of the conditions set forth therein, the merger of Merger Sub with and into Amedisys (the "Merger"), with Amedisys surviving the Merger as a wholly-owned subsidiary of Option Care Health.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Amedisys&#x2019; common stock issued and outstanding (excluding shares held by Amedisys as treasury stock or owned by Option Care Health or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time) will be converted into the right to receive 3.0213 (the "Exchange Ratio") fully paid and nonassessable shares of Option Care Health common stock (and, if applicable, cash in lieu of fractional shares) (the "Merger Consideration"), less any applicable withholding taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the terms of the Merger Agreement, as of the Effective Time, each outstanding time-based vesting Amedisys restricted stock unit award (each, an "Amedisys RSU") and Amedisys option to purchase shares of Amedisys common stock (each, an "Amedisys Option") will be converted into an equivalent restricted stock unit award or option, as applicable, of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted RSU" or a "Converted Option", as applicable) equal to (1) the number of shares of Amedisys common stock subject to such Amedisys RSU or Amedisys Option immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, rounded to the nearest whole number of shares of Option Care Health common stock. A Converted Option will have an exercise price per share equal to (1) the exercise price per share of the equivalent Amedisys Option immediately prior to the Effective Time divided by (2) the Exchange Ratio, rounded to the nearest whole cent. In addition, each Amedisys performance-based vesting restricted stock unit award (each, an "Amedisys PSU") will be converted into an equivalent restricted stock unit award of Option Care Health relating to the number of shares of Option Care Health common stock (each, a "Converted PSU") equal to (1) the number of shares of Amedisys common stock subject to such Amedisys PSU immediately prior to the Effective Time, multiplied by (2) the Exchange Ratio, assuming achievement at target performance with respect to any Amedisys PSU for which the level of performance-vesting has not yet been determined, rounded to the nearest whole number of shares of Option Care Health common stock. Each Converted RSU, Converted Option and Converted PSU shall have the same terms and conditions (including any double-trigger protections but excluding any performance-based vesting conditions) that applied to the corresponding Amedisys RSU, Amedisys Option or Amedisys PSU immediately prior to the Effective Time (other than any other terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement or other immaterial or administrative or ministerial changes).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The completion of the Merger is subject to certain conditions, including: (1) the adoption of the Merger Agreement by Amedisys&#x2019; stockholders, (2) the adoption of the Charter Amendment (as defined in the Merger Agreement) and the approval of the issuance of shares of Option Care Health common stock in the Merger by Option Care Health stockholders, (3) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the receipt of other required regulatory approvals, (5) the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger, (6) the approval for listing of the shares of Option Care Health common stock to be issued in connection with the Merger on the Nasdaq Global Select Market and the effectiveness of a registration statement with respect to such common stock, (7) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (8) performance by each party of its respective obligations under the Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amedisys expects to incur certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, as well as other customary payments. If the Merger Agreement is terminated due to a recommendation change by Amedisys&#x2019; board of directors or under certain circumstances where a proposal for an alternative transaction has been made to Amedisys and, within 12 months following termination, Amedisys enters into a definitive &lt;/span&gt;&lt;/div&gt;agreement providing for an alternative transaction or consummates an alternative transaction, Amedisys will be required to pay to Option Care Health a termination fee of $106,000,000.</us-gaap:SubsequentEventsTextBlock>
    <amed:BusinessAcquisitionShareExchangeRatio
      contextRef="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTQ5NzU1ODIxMzg3_ff4ee86e-5ae3-4573-baca-d910e45a191f"
      unitRef="shares">3.0213</amed:BusinessAcquisitionShareExchangeRatio>
    <amed:BusinessAcquisitionTerminationFee
      contextRef="i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZlNzc1NGUwNzRjNjQ1OGJiNGJjMTYyZWZiODg0NzEzL3NlYzo2ZTc3NTRlMDc0YzY0NThiYjRiYzE2MmVmYjg4NDcxM184OC9mcmFnOjNhNGMwMTI1Yzk5NjRlODRiMzUyMmJkY2IxOTliYjAyL3RleHRyZWdpb246M2E0YzAxMjVjOTk2NGU4NGIzNTIyYmRjYjE5OWJiMDJfNTQ5NzU1ODIxMzk1_6e04d26d-ae07-4835-838e-cb8318d71583"
      unitRef="usd">106000000</amed:BusinessAcquisitionTerminationFee>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #00*16"/9HQ,\%  "7'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6977.C-AB%_XK&[?1J'9"P'6?K>,8A2>MILLW&V^YL.[U00#;, J)"Q/&_
M[RNPP<D*09EU+F+S<8[U( D=2;,M%U^S@#&)7N(HR2X'@93I>\O*O(#%-#OC
M*4O@RIJ+F$HX%!LK2P6C?B&*(XO8]L2*:9@,YK/BW(.8SW@NHS!A#P)E>1Q3
ML;MB$=]>#O#@<.(QW 12G;#FLY1NV(K)/](' 4=6Y>*',4NRD"=(L/7E8('?
MNXZC!,4=?X9LFQU]1PKEB?.OZF#I7PYL52(6,4\J"PH?S\QE4:2<H!S_[DT'
MU6\JX?'W@_MM 0\P3S1C+H\^A[X,+@?3 ?+9FN:1?.3;7]D>:*S\/!YEQ7^T
M+>\=C0;(RS/)X[T82A"'2?E)7_8/XEB &P1D+R!O!+CI%YR]H'AR5EFR NN:
M2CJ?";Y%0MT-;NI+\6P*-="$B:K&E11P-02=G+O\F0DT1%E !<MFE@1/=<7R
M]OJK4D\:] ZZYXD,,G23^,Q_K;>@+%6!R*% 5\1H>$_%&7+P.T1LXFC*XYKE
MBQ3D9*J3ORJ.4ST?I_!SC,_G[\53)@4TN7]T3ZAT&.D=5#]\GZ748Y<#Z&@9
M$\]L,/_I!SRQ?];A?2>S5["C"G9D<I]?<R^'+BK1IUW*=*1F.;:''W5(1E5/
MI'&%-.Z&]#&G0C(1[= C2[F0.CRSE12Y[J&X1E5/O$F%-^F&]\!$R'W5"Q&\
M![259W:J^EUCQS/J>W*>5YSG'5NFH#"$%"- <SV:O=8TRK05:93U!)Q6@%-C
MH6X2&<H=N@TCAC[D\1,3.C"SASTD(S*Q=6A&84^TBPKMH@O:(]N$ZB4*E?B!
MQMH6:O99W-]<+U=?5FCYP=4Q&M4]&;%=CZ-V%\IEXG$![9*J)OH.K21T1L0%
M<GF>2+&#3U^+WN)^?:,C-HOZ(A]%!]P%^1-]04L?.F>X#KV"V]""6RPQ'CK8
MP>>VMA6;Q7UY2<U+NO N?!_<,U6Y0@7MIM;<XN9,QR.TB.&][=$$?:8[+;'1
MHR]Q'7ZP,6Y\2YR'^K&EQ:?0H866\!2!!]>)!YLSRUM"%XZT@&:;*RK5B,3S
MC79D,:O[0M89")N3R[<-MR$BM/C<Z6OP% $(UPD(FX/+6[@'GDD:H;_"M/EE
M:W8\MZ=XHB4]103"=0;"YN#B%IPP66\&,QL0,M9BG2+XX#KY8'-LN>,>U-=#
MP!-3]&DQ(1=D2&P':_E.D7YP'7^P.;=\"B6$.KY&C'H!\B*:Z>?99A>7QS&\
M8E:2>U_?H90*]$RCG*$?[3/;QBB%66HQA]<^@%-$(U)'(V(.+Y#9_3#9H-4N
M?N*1CKW%0"4_[5+ *?(/J?,/,8<5-?!7]<I>O( F&SB1H&T0PAE1!%XFWBZ+
M[)%;O!>KZX5V-FT6]H6N0Q#I%(+<7 @U'RLG847MPJ"2:UMVB^,7[;J3:U;U
MY:RC#^D4?98)U&"YUJ@FUO0 KN4T.S9QGB( D3H D4X!2$T\898"N6##A38!
MM?C<40&-?^%Y#(S QB\MM<2G2$.D3D.D4QJZ@>B]40WW%W"0 8RI<4H3/;K9
ML'%!P:SK"UHG(](I&:UB&D7H*L_@LG[H:?%IYCM%'B)U'B+F.'/@"QCPF:JO
MYWJ06=<7K\Y%I-.2T.N!?U6LTZ/?<PDI-U'#JI;X.R6>_7,HW<:%F]H7>IX[
M9#R^<*;3F?6L8ZRS$6E9TXE9XA<+>[<1U:.8#9HK[Q29QZDSC].R8'-8L+P-
M,Q5OOS!(;+=P4ML!6\R:5F3-LKZ,=?YQS!GE+>-^#;J9TFSW41O>S:*^C'7<
M<;K%'< 4@+A,?/:"?F/:]TR+E0U_TXL)F1 MYRGBCG.TS64.)X<\=]Q<39L)
M+7;#(29#_6S,K/R_H-;1UJ<:T(L=X0QY:KFUW 6MSE:[SHMBK]6J;R^WK.^I
MR@,9BM@:I/;9.;SP1+D+7!Y(GA8;J4]<2AX77P-&?2;4#7!]S;D\'*@?J/;B
MY_\!4$L#!!0    ( -! I%;IZ*3N3@<   D>   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULK5EK;]LV%/TKA%<,&Z#&?(AZM(F!U,G6 ET;--GVF9'I
M6*@D>A*=U/OUNY0<RQ8I.AWZH8UE'U+G7EW><TB=/ZGZ:[.24J-O95$U%Y.5
MUNLWTVF3K60IFC.UEA7\LE1U*31<U@_39EU+L6@'E<648AQ-2Y%7D]EY^]U-
M/3M7&UWDE;RI4;,I2U%OW\E"/5U,R.3YBR_YPTJ;+Z:S\[5XD+=2_[F^J>%J
MNI]ED9>R:G)5H5HN+R:7Y,V<Q69 B_@KET_-P6=D0KE7ZJNY^+"XF&##2!8R
MTV8* 7\>Y5P6A9D)>/RSFW2ROZ<9>/CY>?;?VN AF'O1R+DJ_LX7>G4Q229H
M(9=B4^@OZNF]W 7$S7R9*IKV?_2TP^()RC:-5N5N,# H\ZK[*[[M$G$P@(0C
M ^AN 'WI +8;P-I .V9M6%="B]EYK9Y0;= PF_G0YJ8=#='DE7F,M[J&7W,8
MIV?SSY]N/W_\<'5Y=WV%WEU^O/PTOT:W[Z^O[V[1:_3G[17ZY=6OZ!7**W2W
M4IM&5(OF?*KASF;\--O=Y5UW%SIRES]$?888"1#%E#F&S_W#KV2V'TZ/AT\A
MWGW0=!\T;>=C8T%OZEI6&HFFD;IYXXJGFR!T3V#6UIMF+3)Y,8'%T\CZ44YF
M/_]$(OS6%=T/FNPH5K:/E?EFG\U%LT+PU%!F/LA_-OFC*"!XYU/LIHK:J4P#
M>)R%:<BB\^GC83@.%.8AWJ..>(9[GJ&7YQ?9Z#K/M.R8NMAU$_"#^Y(TBL(!
M.P>*\92YV?$].^YE=R-TWE9,EJD-) \Z6"8AD_>%=#'E%@>:AL34[A%5%RR*
M$^[F&NVY1GZNM5R+?('D-^CUC70^Z,A.4A+S82H=*!+1Q$TOWM.+O?0^ZY6L
MH;4=+D$7Q=A.#N,)&5!TH**0C&0PV5-,O!3OE!;%"R@FULUA(7 >#SC:,)8D
M:43<)-,]R?3$8P8MK_6V7=QF7:]!776 *M!^M325NBDWA3 +:B&AL62Y:(43
M?GM%, ](PMJA<$$"9I:1'6!J,V>,LT%\-@IZ%XW<X1'<*Q/V%PJ$!Y2K!U1(
M$&I4&T4V]#=P,?Y0=K,>TDDX)</"<< (I@D?HWT@J,1+^W>E%D]Y43BY$?NF
M- RC.!VR<P&3F*7I"+U>^HA7;68?*BVJAQP:URZ'SHH1I:IU_N]!Q40!CLFN
M8,(@PLYZV=W[D'::IM2*SH9!$9(H'@FNUSKB%[NNMWAJ@UDWCA/*\)"? Y8F
M;*PT>HDC?HWK^HJ'GDOAPBCE5@)=P#BBX4CC([W.$?XB:U3DXCXO<E ]MS\B
M7KW\7H/THV8[#KH73.)7S,MG55^+[9BD$UL,0XS)L->[8"QF8\^E%TWB5\T;
ML:U5473-OEP7:BLENI>57.8CM60K(QB0F Z;MQ/'63*V%GL-)7X1A:36&^FW
M(<261L+B)+7JW8ECZ8CG)+V&$K^(/I?[VK2[KM45JGIXK65=(G5?Y ]M"W23
MMW6/PEI-AMP=\LC#=*29T%X>J5\>'=350#$/%K%SCV-+(.6A)>\.&)@ .F)?
M:"^4U"^4QR[K%%=;$,&(8#YLW4X<YW1$-^G!EM&OFQ]=91% HIMF'\/N43CY
MVY('!0S[V2%_&Q>"!M"12J>]--(3TCA>&]\1A2V,/$WH<(/H@,'"P.%(#+U^
M4K]^7LFE!(X+E%>9*B72XMO)NK&5$KH@M]+N@.&0C-5X+Z?4OV_L#,F+6PJU
M=X1A;.UY7*@$CVS+:*^"U*^"W7H\E4];WQ+"(LM>NW 1;&[I",M>"*E?".>J
M+'-MMCI-*X9S59FJEE4&C'_^*:&$OOVDM$2QD[YW<K?10,XCG?\QT4G'0GMQ
MI8G7IEW#?D]OW2=77EG^[J.K'S3;<9R]/M-3F]SG)=]HE7T-T"M\!JX+C%J-
M'D6QD0'B <;8_$/-2@ ')#9ZI>K\7[EXBRI5290WC3$BJD9JHQO8_BR@8)RI
MLZ7:TA<?Y/B KE=R=D+)H:1!P$<CC+ O1!8'*4L"QL-V/<!EDA+8W4?/X"Y\
M -* AV% 0MX!X9*0((SX,_!$=IC#!PS-CA]SG)_>*#"_4;A<+'+3,J$[F8.M
MUWF%,K'.H5LY:=H.(.9)% T]I1/'<31R4LAZI\#\3N&N!H'=U-OG!RHTRE2C
M3:6R- PH3MO\PU6<!C$E^_0O ==7@C,VVQV\#B/*L?4<G$!"\5BQ'APG^WW$
M%ZD%? 6^7M055(K['-FYSTZ)1=.!X_&H2K#>*;"7[+0O2[G(FRT8G ]5=M:E
M=:6*A:P[I8C?M@=G>NN,P;''QG%*K"V?$\@)C\<JJ7</S.\>/BGP.94V&S]C
MW/(*/(1L1H[N;5/ 0\J&NNR"<3Q:%KUY8"\Q#YYLNLZ2&6.A51(N(([&L]D[
M!^9W#I:_V9^<CE".K?<<[M,8)]!U&C,]>$]G7I+^(>J'O&K ?B]A)#Z+(>JZ
M>^_876BU;E_=W2NM5=E^7$D!]6L \/M2@=/979BW@?NWO[/_ %!+ P04
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MV^5 LDUQ0SQG4K*L>%Q3 N%5 O!]R9C<#]0"]3\9)O\"4$L#!!0    ( -!
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M9HVL>(,$NSF=G.-W%TFN&FB+_U3L7@[^1LJ5!><_U8?/R]-)I!2QFI6MZJ*
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M2*W#*O+('6 =/[-\;Y@0>A5V&UOQP-RXQK;$+!M/!X=53")?4(E128(J/\)
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MM::$;48A*<<>[8:3Y!E.CDXC/FNF'W :05Z4@"_5VWX4# '),P04O&1LV<<
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MNP7>?6CY1E^D7O"VY6O]YXH54-@J _C^AO/VZ8/Z@=U=_+/_ U!+ P04
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M/%QV6A<]*5W6-,T^EQ(,W&Y2\"SOOQW$./[:D&V0W,UL[AI8>'S&[2;>)K?
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M#N[;M(%P0W_G22UTK-*VH[$$"MYY; L"3"[0#J\"0'F+IB2;TJPQ28RN,-L
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M*$@./0HPPJ'T:.3U);Q"YOV^TXPM-J9M:DD9#/(VH&;=VI(7+1\1!M..A$0
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M16CFV#4PN"Y=KX?YAHVU/P#@CB.Z7)>TCF@2N(?\K72T>]X%E4K9ON;SCSN
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M4J(H!M#WLYKLC+[! OY779[_/U!+ P04    " #00*16*,W=\(H'  !9$P
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ME"\\-G([YJ7DBBSP?N0C!U*"?#*"?9RBB=BJ5<<&7.8E3]*5"9KYF2Z)O6G
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M(=A"3J$TD \>@.<+:T-[P0MLOZ;=_@Y02P,$%     @ T$"D5M+=0HN-"@
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M5L[R+>\QEO<52 W"$NDR,0>QPJ+)QBI"($E,7=(R-LJU]@8AM 1>S6MD+D<
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M"EG'+H\C>]*QT$@<&^ASJXQ>K,6G$O/['M%E)LTY5RW8Z="9.8X%)/J0M(K
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M7SX-@4O9*S-\:J?)\3.0F7'4=01#L20M=X;(B(G/"-AFKI%46)L6Q%,^.V7
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M(M"YLK0 OR\-\C1^H0/:OY,Y^P]02P,$%     @ T$"D5E=FA.DP!P  !A$
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M2:/!XF(8C4\OK_K>/AC\D+AR.S+X3.;&/'OE+AM&74\(%:;D$03_+/$:E?)
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M(5XM+*.>IC#E&A!5$+F2Y#[KF@:/HE>.DLIDQEK2(DE;)TL!/IFF18.7"?8
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MMZD#[A_$Y\0$D)AD5I->W+=)>(DE44(=EUA^TB3OE,,(Z!+V@AB1/E3B^[_
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M. ]Z,.'UEWO1F^&\3X7U@GIV -2Q2FU4@?J7QM*\Q%_3>/[[(^H=4>@=4?5
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MA\I4?7>U<+KPO>Y<.^J<_6=*/U70, &=+S1E?+U@!9L?/\/_ 5!+ P04
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M_:BL NUG4IK3PCKH_DS,_P502P,$%     @ T$"D5NC!6NN3 P  G@<  !D
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M:!R^I[ZOVY>AG5A5^6Z<*DN]W0\+>DQ1NP#:WREECQ.7H'^>Y_\!4$L#!!0
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M08ESL:KMK5J?XX9/QGB%JHU[PKK;F\4>%"MC5;,QI@@:V79O\;3)PRN#//S
M(-X8Q"[NSI&+\JNP8CK6:@V:=Q,:#QQ59TW!R99%N;.:ODJRL].[L^^79U?W
M<''U[?KV\OC^XOH*]N_%K$9S, XL>>!]0;%!.^G0X@_0$KA4K:T,G+4EEF_M
M XJL#R_>AG<2[P2\%-J')/H"<1@G._"2GF[B\)*/Z.*"*LK"+2Z5MK)=P)_'
M,V,U%<=?[]'MT-+WT;AA#LU2%#CQJ",,ZD?TII\_18/P:$>L:1]KN@M]>D<-
M6*YJ!#6'ZR5JX>*]: O5N+6. TL%&UKF/0H[G;Q/89LE80Q: T(CM,I2#SY2
M4V )LV>P%0(%LA3M\^=/>1P-CPP4E<0YJ#[4$@OIFK<1#ZA!M"6;4=<I MR"
MEM(4M3*,RB<$[(M&K8@*2+*3=4WVYL ':D'G\[[2B+^Y*H,;U%*57:T!54I1
M]:4"YYRD<V66LD#>:%0K:CBG'H7C8B7M,YQR!-<<$-PK2Q^OZ CD!+ %4<5V
MA; '29KX";VC4>*G_,[\D%ZI/Z2GHQX?T2C+!O3Y5!G+TFQ@OA")HEX9.G=X
MM41*<2&%.XZBT9" HC BLRCR(\C\K,=+G)?OV%(J:Y<X45+S2ZY4/L4 G^A4
M-F@@'Y%I.O1'$%.8*8%E(4VB4>H/X.MKAPZEX:K_N8F +$/:M74:^CFMC1S(
M2[WUGN)\Z,<0I2.&YUQ$(>4@B\DJBU(*]\5&=C6Z3[J: T[.@%Q1SA*B2!DD
MGWNP/_!#_K;/"#Q(8\+\;S+'_Z/,2>8499DY5L=HCY*:O94YS2C-O\@,49YQ
M:L)!EY4<F$JO99C2RK_2,B&4+"(',0U2UI,S%N4I/7=KR9JSEJ'3E!2A<?Y&
MDQ<=!R-"CK*<GTQV2.BI*R,JR62'C(.!ZX"$^>PYERS?1D9&<#*RV_=.O^#5
M)=6@7KBKF X-[O;NONI7^]O^N+OD7K9WOPI4! O9&JAQ3J94AID'NKM^NXE5
M2W?ES92E"]0-*_IC0<T;Z/M<*;N=L(/^'VCZ#U!+ P04    " #00*16Y5AD
M42D$  ".$@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6S-6%MOXC@4
M_BM65AKM2K,-"05*%Y HI2JK<A%T9A]&JY6;',!J8C.V@9G5_/@]=D*X3)J9
M5JFZ+TE\.9_/=R[.L5M;(1_5$D"3+W'$5=M9:KVZ=%T5+"&FZDRL@./(7,B8
M:FS*A:M6$FAHA>+(]2N5NAM3QIU.R_9-9*<EUCIB'":2J'4<4_GU"B*Q;3N>
ML^N8LL52FPZWTUK1!<Q ?UA-)+;<#"5D,7#%!"<2YFVGZUWVO+H1L#,^,MBJ
M@V]BJ#P(\6@:@[#M5(Q&$$&@#03%UP9Z$$4&"?7XG((ZV9I&\/![AWYCR2.9
M!ZJ@)Z*_6*B7;>?"(2',Z3K24[&]A910S> %(E+V2;;IW(I#@K72(DZ%48.8
M\>1-OZ2&.!"HG3\AX*<"_HF ]Y1 -16H6J*)9I;6-=6TTY)B2Z29C6CFP]K&
M2B,;QHT;9UKB*$,YW1EU[S],^V1\0\:3_K1[/QB/9N])#Y_CN\&U;9/NZ)I,
MIOU9?W2?=.#LF\&H.^H-NG=DAIW](8[-R.]D1*6DQC'DUVO0E$7JMY:K44^S
MFAND.ETE.OE/Z%0E0\'U4I$^#R$\EG>17T;2WY&\\@L!AU2>D:KWGO@5OTJ4
MIAH(7\</(,?S/P7C^B-PO9:@2$ E_!-@"V2.WKV?7\8O4+N:^:9J\:I/X(WE
M@G+V+S7QCCX17(F(A30)?QZ2"6J,JB8=8DYN&*<\8#0B,T,1DTTK\ND.4<D
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MT)AG]G,)- 1I)N#X7 B]:Y@%LBNHSG]02P,$%     @ T$"D5K]" DOX!@
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MX?H"]?\;QN3B0!=0_[9C^#]02P,$%     @ T$"D5J9!YS%P!   UAH  !D
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M\[Y(C1:'*,6 DS0_AU@0SDF<7ZX!!T S _%\20C?#;( U5'6^#]02P,$%
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M+7O27(AC&Z(2(-[/".%O';EOSP^"[A]02P,$%     @ T$"D5F$YST0* P
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MTAC@_%H(?>B8!>K'7/@O4$L#!!0    ( -! I%8T'^;'80<  -(L   9
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ML+S^N*)D07EU@?S^@3'Q>E )[+8Q3_X%4$L#!!0    ( -! I%8H<RYE$@P
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M'Q#OWY1E_?BD:>"^Y)_;U3[Y/U!+ P04    " #00*16R/S2U&8%   :'P
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M(0GB&5K37W_Q^IW?ZE+A$HPX MM+4[=,4]>&/GT J00+E.8RH')91UP.T,\
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MJ82Y9U?FU]LW=DHW3:]K.\39O+A$(][Q5T(S*Y5J]T[(=KH1/(KR]ANG$=\
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MPMR@KR\X5]L3,T&Y'3[]!U!+ P04    " #00*16R!B;87$$  !]&   &0
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MQM=[W>L3R1;E[N^82<FR\G".T01S':#N3YE:&*L3O:%<_\=A^#]02P,$%
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MYTF]*IMS=L<OO$7#O?W@!$,;0:A&H1J#:OR56_''5;9/0N\#(8$71+VAA9:
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MY_.BJ)^^:09X*,K?U[M]\G]02P,$%     @ T$"D5B>.4@J&"P  [90  !D
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M(O@L*DCY%/21?)/'6#R;SUL3!NUV0#4;JCE0S85J7J4U+CUUK(;?A\Y)H5H
MU4*4I@:L[FR8^BMJ=%NON&;?><S2V<>7E8M-VRKAI+K4FJY:I=^0SO&#5CV@
MF@/57*CF034?JE&H%D"U$*6I,:VK'N8)?$$#>O$.J&9#-0>JN5#-@VH^5*-0
M+8!J(4I3\U870$QP :0U@=!+>T UN])&^ZVOQI&S YW1;9G1;#1?/.B,/E2C
M4"V :B%*4R]E73<XK/]]@T,_1=>P0#7;>MTN&3=6HQSHC"Y4\Z":#]4H5 N@
M6HC2U%C5%0Y+7^&XG!9K%K]DJGKN:<T.M(D!U>Q*4X[W!\VU7 <ZIPO5/*CF
M0S4*U0*H%J(T-3UU$\/2-S$<(3)!!"LX^;#B8BJST_;^#U=ZIG-XH$6+2CO=
M7RMK)@?:GH!J'E3SH1J%:@%4"U&:FIR]MR;17Y;C2U;(IYUKOI#_WO.BB/GF
MH.=.\P2$?6\2[)N38-^=!/OV)-CW)]EJ2DW1&C:OH.U#)Z50+8!J(4I3<U2W
M(JQW6A%O)$A&*\\W2^SBC=>)Z.'.>8)V)*": ]5<J.95FGHAN%=7@O.ADU*H
M%D"U$*6I>:JK%):^2G$=%=%B>Z&UO5!I<P0M54 U&ZHY4,V%:I[55OAX?<X7
M.BF%:@%4"U&:FJ.Z5&&]<\&,3N=\)S%GXDD>1HE?.>NKWY3."826+J": ]5<
MJ.9!-1^J4:@60+40I:E!K<L9%OR"&A:T90'5;*CF0#47JGE0S8=J%*H%4"U$
M:6K>ZI:%]7^XH(9^CLX)A/8NK):+?0R;!S0.=$[W94YE5:*Y*.%!Y_2A&H5J
M 50+49J:F+HG8>E[$I SO]":!%2S*TTY\SMHQ@5:DX!J'E3SH1J%:@%4"U&:
M^K[%=:%BJ"]4''SF5^]TS0Y4LROMG3._T#E=J.9!-1^J4:@60+40I:GIJ7L3
M0WUOXM SOWJF<WB@M8E*TYWYA4[H0C4/JOE0C4*U *J%*$U-3MV9&.H[$]W/
M_.K!SAF"MB>@F@/5W$IK'!4U+BGC0>?TH1J%:@%4"U&:&J.Z0#'4%RA^_<2O
M'NX<)VB1 JHY4,T=ME0?S.9+P3WHG#Y4HU M@&HA2E/C5/<HAN_T*#J?]]6#
MG6,$[4] -0>JN976>'&NV8P1<DX?JE&H%D"U$*5M8]3/EYP7-BO8Q5G"Q8)/
M>!R75V%9IY(O=_EV]Q+!Y^5%;S]=FKW^J_L=XY-GE/?W:^;B;,46_(:)193F
M).9S20Z.QL<](J+%<G>CR%;RT=(C#UE19,GFPR5G,R[*+Y"?GV=9\7*CG. I
M$]\WFWWQ7U!+ P04    " #00*16H7["=#@"  "R!   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q]5$V/FS 0_2L6E:I6:@,!=ENE@)3L9KLY)!LE
MV_90]6!@ &N-36V3;/]]_9'05$IRP1Y[WILWPXR3/1<OL@%0Z+6E3*9>HU0W
M\7U9--!B.>(=,'U3<=%BI4U1^[(3@$L+:JD?!L&MWV+"O"RQ9VN1);Q7E#!8
M"R3[ML7BSPPHWZ?>V#L>;$C=*'/@9TF':]B"^M:MA;;\@:4D+3!).$,"JM2;
MCB>SV/A;A^\$]O)DCTPF.><OQEB4J1<804"A4(8!ZV4'=T"I(=(R?A\XO2&D
M 9[NC^P/-G>=2XXEW''Z@Y2J2;W/'BJAPCU5&[Y_A$,^-X:OX%3:+]H[WSCT
M4-%+Q=L#6"MH"7,K?CW4X0001A< X0$06MTND%5YCQ7.$L'W2!AOS68V-E6+
MUN((,S]EJX2^)1JGLNW\ZW*^>D:+U</39CE]7CRMT$>TPD)@4R[T[AX4)E2^
M3WREPQF07QRH9XXZO$ =H25GJI%HSDHH_\?[6N:@-3QJG857"9=8C% T_H#"
M((S0%FK='$I>(8Z&(D26.+I4!$>%-M!QH0BKT<]I+I70+?/K7-Z.+3[/9L9H
M(CM<0.KI.9$@=N!E;]^,;X,O5[3&@];X&GNVZML<!.*5'@FC%N<44-Y+[28E
MDF>+XE0[WAO+:V9UE\6)OSN5XI_T40NBMM,B4<%[IEQ+#:?#0$Y='_YS=].L
M_U5-F$04*@T-1I]T7.$FQ!F*=[8K<ZYTC]MMHQ\5$,9!WU><JZ-A @S/5/87
M4$L#!!0    ( -! I%9?/9Y6@ 8  ($G   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;+6::V_;-A2&_PKA%4,+M+5XD6QECH%<VB; D@9)NWTH]D&Q
M&5NH+IY()^U^_:A+3"L\9*U$_I+8\N'KE\?D>4A1DX>\^"Z6G$OT(TTR<3A8
M2KDZ& [%;,G32+S/5SQ3G]SE11I)];98#,6JX-&\:I0F0^)YP3"-XFPPG537
MKHKI)%_+),[X58'$.DVCXN<Q3_*'PP$>/%ZXCA=+65X83B>K:,%ON/RZNBK4
MN^%&91ZG/!-QGJ&"WQT.CO#!"0O+!E7$7S%_$%NO4=F5VSS_7KXYGQ\.O-(1
M3_A,EA*1^G?/3WB2E$K*Q[^-Z&#SG67#[=>/ZA^KSJO.W$:"G^3)W_%<+@\'
MXP&:\[MHG<CK_.&,-QWR2[U9GHCJ+WIH8KT!FJV%S-.FL7*0QEG]/_K1)&*K
M@=*!&Y"F 7G:@%D:T*8!K3I:.ZNZ=1K):#HI\@=4E-%*K7Q1Y:9JK7H39^7/
M>",+]6FLVLGIS8=/%Q\NOZ#SRX^?KR^.OIQ_OD3OT.<5+R(99PMTGLWRE*/\
M#EWS55[(Z#;AZ(8OU"\I!7I]RF44)^*-:O/UYA2]?O4&O4)QAKXL\[6(LKF8
M#*5R67[7<-8X.JX=$8LCBB[R3"X%^I#-^;S=?JAZM^DB>>SB,7$*7D3%>T3Q
M6T0\0@$_)[LW)PX[=)-Q6NE16\;KY#7YK'-<3\=R6'_[4X6C<\E3\0^4NUJ;
MP=KEG#\0JVC&#P=J4@M>W//!]/??<.#] 76\)[%6&M@F#<RE/KU4):K4C&=<
ME8-[GJTYU-]:)*A$RI)T/_7]@([#R?!^NR= &/.)/]J$M3SZ&X^^T^-)+F0Y
M]!N?;]7(GB5KH>I.>77.55IF<?6[0=9K;7_+$\6^A[TGUH$PCXV)!UL/-M8#
MI_5//%-3.$%J#J)HK@I'+&0YI95U_D,Q0'!P:@:&&1RRP'OJ&0@;,]^S>!YM
M/(^<GD^W$EH;3\L9\I\UPR/#!F.,/O%J!HT];PP['6^<CIU.=7UT)7-L?+./
MF3D S# 6CDCHPQ;#C<5P1XMQ7<)?)[D0;R"?H6F T-'3*09$C<* P"ZQI_GC
M.7V>E=[.>)3()?IVP=-;7H"%SRW3M?+UI=;N]!9T\1X9T(CWE8J>U-JI(#H5
MI \.-"JM,LDH-2H3%$?]D:TT84UM[*3A"UG0B+<+JW)EV ?BQCZQVM>TQ6[<
M/I,'C6JK>H;8M V$4;MKS5_L!G!G(F"3IABP:T:%5K.:N-B-W-V@@$UVDO&(
MF!Z!N""D5IL:LMA-V0Y@P"8[_0!(IQD6!,SJ5$,6NRE[EHM561:<6'!*=*Z%
M/:FU.ZR1C<-]8L&Y(.B<BI[4VELVO2P@[F7!CEAH5-IUE3)CB,)QV#9&B28Y
M<>+QA5AHQ%NV/ S8A^+L4XQH^A(W?9^)!6)25BT&3=MFF(^M)8QH%A,WBSMC
M@9A8-3<UOPAJ>]7@)6[P[D8%8@(4LQ#(*!#GC^TIU:0E;M)VH (QZ<FH;UH%
M-K9L;'6J,4O<F+WBA<@S-69/HL+-!K=0UX+8EUJ[VQK;9+1'-A#GFJ!S*GI2
M:Z="KPN(>UVP*QO,C37VS24W%,8\ZSC5,"?N#?@+R6!NMS&PDH7"/.LDHQJ_
MU(W?9W*!FI@EYAX-BK)N%JA&,76CN#,5J$E5PRH$7IM335WJINYN3* F/3&P
MM '#[":W;E.[(=N!"!38M9I\!:*LNRZJ^4K=?#V+%TMT-%O'\F=%!-"?4Z+S
M7?.>U-H=UJ2F_C[/#YS+@,ZIZ$FMG0J]%*#NI<".(*#F5IJ-S.$);+BMM[2I
MYC9U;[=?A@$*[,#-I1801:R; ZHY2]V<?2X$@!O:0-D"HJSK6*JI2]W4[0X!
MDZ!CTZP[J'T IB'+W)#=#0,,V+IZYO %PD;6X<LT5)D;JATHP$Q6O@O,]184
MYEO76TQ#E?T"JG+)"]"7LUW7DM>76KN7FLILGZ?'K-?CX[[4VJG8.D#NYP39
MW#(;0](5TG:G,<WV>7;,S,VS8=H5TC:M@<KV<FK,3'3ZGGGS @AKWSAHN]:(
M93V?&S.3EQBP"]W]MKK55&5]G!TSX/"8F& "PEAH7?PSC5'6V^EQHQ2TZCED
M%8B#O ZW'F9*>;&HGO$2:):O,UD_]+.YNGF.[*AZ>NK)]6-\<%(_#:9EZH?3
M+J)B$6<")?Q.27KO1RI_1?V\5_U&YJOJD:G;7,H\K5XN>33G11F@/K_+<_GX
MIOR"S5-WT_\!4$L#!!0    ( -! I%:% ^%7B ,  ,L4   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;+6876^C.!2&_\H1.UK-2#/E(VGZL4FDM'C4
MD;:C*%%G+D9[X<!)0 7,V";IKO;'CPV4AHK0IO+<! Q^']OGC7V,QSO&[T6$
M*.$A33(QL2(I\TO;%D&$*14G+,=,O5DSGE*IBGQCBYPC#4M1FMB>XXSLE,:9
M-1V7S^9\.F:%3.(,YQQ$D::4_WN%"=M-+-=Z?+"(-Y'4#^SI.*<;7**\R^=<
ME>R&$L8I9B)F&7!<3ZR9>TE<3PO*&M]BW(F]>]!#63%VKPM?PHGEZ!YA@H'4
M"*HN6[S&)-$DU8^?-=1JVM3"_?M'^N=R\&HP*RKPFB7?XU!&$^O<@A#7M$CD
M@NUNL![0J>8%+!'E+^RJNB/58E (R=):K,IIG%57^E '8D_@C@X(O%K@O58P
MJ 6#YX+A <&P%@Q?*SBM!>70[6KL9>!\*NETS-D.N*ZM:/JFC'ZI5O&*,_U'
M64JNWL9*)Z?+F]F"P(+,[Q;7-[,E@:^4<ZK-@_<^2AHGX@-\@KNE#^_??8!W
M$&=P&R>),EF,;:EZH#EV4+=V5;7F'6C-=>&693(20+(0PP[ ]0N LQZ K<;>
M!,![#,"5UTOT,3B!@?L1/,<;='7H]7*O0^[WRS_CZ@0<[V#KI%\^*S:-W.T)
MQJ#Y-PQ*WO  3P\"EA'E" O,"QY$:@["G+,-IVF7W;TXO<A=BIP&.+'4*B:0
M;]&:_OF'.W+^ZHJT29AO$D8,P5J>#!M/AB5]<&B&/K?CQ]^J!GR1F(I_NCP9
MFO3$),PW"2.&8"U/3AM/3GOGR5*RX+YCBGR$62$CQN/_,(19RHI,=CG4"S_6
M(9,PWR2,5+!1"=,;ENW4=9RQO>T(_*@)_.A-@0?RD,<Z;ZF]A\J#V!7U7O*Q
M4>_O9I,5#J8%DYTAAF M1\X:1\Y>2AF#HU)&+^Y8&TS"?),P8@C6\N2\\>3<
M;,HX-^F)29AO$D8,P5J>7#2>7/S.E-$+/]8ADS#_HG>5KP)OJ,%6X%WGZ1/'
M>?L2!?_#LE@)_%E@)H%LL3O^_4T<:X!1FF^41DS1VF;M?8^Z9M>NFF?*&9,T
MWRB-F**UG?&>G/%^V][K!71KO]3Y%=X/.-H7DS1BBE;Y8N\=YJ3(-^4IFH!
M9X;J7*=YVIS4S<KS*?NI>G7,=TOY)LX$)+A64N?D3.W(>75R5A4DR\NCH163
MDJ7E;80T1*XKJ/=KQN1C03?0G%].?P%02P,$%     @ T$"D5A]MQHB* @
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ML%7 <@?BN^- 3KDY80BKBGG#=C".Q#&&0"ZZ<S2*D-F)X.M>'VR7A&$<NQ'
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M_7>E7>-:E<W1GW6_L.:?4$L! A0#%     @ T$"D5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #0
M0*163JRYU>\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #00*16F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -! I%8(]FC$
MSP4  )<?   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #00*16Z>BD[DX'   )'@  &
M@($3#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ T$"D
M5G(9 O"E P  3@P  !@              ("!EQ4  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( -! I%99?QK5\ 4  ' 8   8
M      " @7(9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #00*16D95>KXT'  "!.0  &               @(&8'P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ T$"D5JQW&@SY"0  ER\  !@
M             ("!6R<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( -! I%: N+1/>@<  .(2   8              " @8HQ  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #00*168+HJ7(<>  #A
M90  &               @($Z.0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ T$"D5BC-W?"*!P  61,  !@              ("!]U<
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -! I%;2W4*+
MC0H  -<<   9              " @;=?  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ T$"D5J4U'Q3S!   (PL  !D
M ("!>VH  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #0
M0*16W0ZV/CX-  "K*0  &0              @(&E;P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -! I%:=W$XU&@T  #,C   9
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M970Q-RYX;6Q02P$"% ,4    " #00*1664;Q-F@@   P;P  &0
M    @($QH@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M -! I%;!1>#\504   @-   9              " @=#"  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ T$"D5E-D<WWM P  6 @  !D
M             ("!7,@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #00*16Z,%:ZY,#  ">!P  &0              @(& S   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -! I%;U:\QH=P,
M *H'   9              " @4K0  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ T$"D5J*)1<)V!   9PH  !D              ("!
M^-,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #00*16
MDQ4V?@@$   /"0  &0              @(&EV   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( -! I%;E6&11*00  (X2   9
M      " @>3<  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ T$"D5K]" DOX!@  YS$  !D              ("!1.$  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #00*16ID'G,7 $  #6&@
M&0              @(%SZ   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( -! I%8 GIK//@,  !0.   9              " @1KM  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ T$"D5F$YST0*
M P  A @  !D              ("!C_   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #00*16"G(Y-@\#   ?"P  &0
M@('0\P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -!
MI%8;U'FA/P,  -@)   9              " @1;W  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ T$"D5C0?YL=A!P  TBP  !D
M         ("!C/H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #00*16*',N91(,  !7@0  &0              @($D @$ >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -! I%;(_-+49@4  !H?
M   9              " @6T. 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ T$"D5L@8FV%Q!   ?1@  !D              ("!"A0!
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #00*16+9GY
MOU $  "E%@  &0              @(&R& $ >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( -! I%8X'4'$D04  )<L   9
M  " @3D= 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MT$"D5FU^@O'##P  D],  !D              ("! 2,! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #00*16)XY2"H8+  #ME   &0
M            @('[,@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( -! I%:A?L)T. (  +($   9              " @;@^ 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ T$"D5E\]GE: !@
M@2<  !D              ("!)T$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #00*16A0/A5X@#  #+%   &0              @('>
M1P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -! I%8?
M;<:(B@(  ,<&   9              " @9U+ 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ T$"D5NUC38A1 @  [00  !D
M     ("!7DX! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M" #00*16!@CZ55X#  "2%@  #0              @ 'F4 $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( -! I%:7BKL<P    !,"   +              "
M 6]4 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -! I%:BB0Y/Z0,  (P=   /
M              "  5A5 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #0
M0*161QQ@N:0!  ";&@  &@              @ %N60$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #00*16+M+XP*X!  #*&@  $P
M            @ %*6P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -  T
+ ",.   I70$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED INCOME STATEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT</Role>
      <ShortName>CONSOLIDATED INCOME STATEMENT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INVESTMENTS</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - DISPOSITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DISPOSITIONS</Role>
      <ShortName>DISPOSITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INVESTMENTSTables</Role>
      <ShortName>INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/INVESTMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - DISPOSITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DISPOSITIONSTables</Role>
      <ShortName>DISPOSITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/DISPOSITIONS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INVESTMENTSDetails</Role>
      <ShortName>INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/INVESTMENTSTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: amed:AcutePhaseForHighAcuityCareServices, amed:GoodwillDeductibleForIncomeTaxPurposesPeriod, amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue, dei:EntityRegistrantName, us-gaap:DebtInstrumentDescriptionOfVariableRateBasis -  amed-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="amed-20230331.htm">amed-20230331.htm</File>
    <File>amed-20230331.xsd</File>
    <File>amed-20230331_cal.xml</File>
    <File>amed-20230331_def.xml</File>
    <File>amed-20230331_lab.xml</File>
    <File>amed-20230331_pre.xml</File>
    <File>amed-20233103xexx311.htm</File>
    <File>amed-20233103xexx312.htm</File>
    <File>amed-20233103xexx321.htm</File>
    <File>amed-20233103xexx322.htm</File>
    <File>exhibit101_separationagree.htm</File>
    <File>exhibit102thirdamendmentto.htm</File>
    <File>exhibit21_equitypurchaseag.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="558">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 558,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 172,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 609,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://www.amedisys.com/20230331": 4,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 12
   },
   "keyCustom": 77,
   "keyStandard": 231,
   "memberCustom": 33,
   "memberStandard": 25,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - ACQUISITIONS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - DISPOSITIONS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.amedisys.com/role/DISPOSITIONS",
     "shortName": "DISPOSITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - LONG-TERM OBLIGATIONS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - SUBSEQUENT EVENT",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INVESTMENTS (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.amedisys.com/role/INVESTMENTSTables",
     "shortName": "INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ACQUISITIONS (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - DISPOSITIONS (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.amedisys.com/role/DISPOSITIONSTables",
     "shortName": "DISPOSITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenuePeriodOfCarePaymentRateDuration",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "id17ad04ba345428b8e033676549332db_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "div",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "div",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:MinimumPercentOwnershipForControllingInterestPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - INVESTMENTS (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.amedisys.com/role/INVESTMENTSDetails",
     "shortName": "INVESTMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:MinimumPercentOwnershipForControllingInterestPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i83d541af44184deb951b6a071ab45e26_I20230120",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i7c3425ad117b4bc4bc6c90ff6489367a_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i7e7041d740c243b09674fbf8633620bb_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i7e7041d740c243b09674fbf8633620bb_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i585e48375f81452ca5c935a0f065bef9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED INCOME STATEMENT",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
     "shortName": "CONSOLIDATED INCOME STATEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i375e7e760e9d4aa1a92757ae86a0d210_I20210802",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i375e7e760e9d4aa1a92757ae86a0d210_I20210802",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ie03bf9db30cf49f29a703a25b4404670_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "amed:BusinessAcquisitionShareExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i1565dfe172bf4cfaae7e54ea733b358f_D20230503-20230503",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "amed:BusinessAcquisitionShareExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i961ed8ba937246e8bc366e595df4bda5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "i961ed8ba937246e8bc366e595df4bda5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - INVESTMENTS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.amedisys.com/role/INVESTMENTS",
     "shortName": "INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20230331.htm",
      "contextRef": "ifffa4741db0645459f158c3d99d750ce_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "amed_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Repurchase Program",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Repurchase Program",
        "label": "2021 Share Repurchase Program [Member]",
        "terseLabel": "2021 Share Repurchase Program"
       }
      }
     },
     "localname": "A2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2022ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Share Repurchase Program",
        "label": "2022 Share Repurchase Program [Member]",
        "terseLabel": "2022 Share Repurchase Program"
       }
      }
     },
     "localname": "A2022ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2023ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2023 Share Repurchase Program",
        "label": "2023 Share Repurchase Program [Member]",
        "terseLabel": "2023 Share Repurchase Program"
       }
      }
     },
     "localname": "A2023ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AcutePhaseForHighAcuityCareServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acute Phase for High Acuity Care Services, Duration in which majority of care coordination services and direct patient care take place",
        "label": "Acute Phase for High Acuity Care Services",
        "terseLabel": "Acute Phase for High Acuity Care Services"
       }
      }
     },
     "localname": "AcutePhaseForHighAcuityCareServices",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Four",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche One",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than 3.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Three",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Two",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmountReleasedFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Released From Escrow",
        "label": "Amount Released From Escrow",
        "terseLabel": "Amount Released From Escrow"
       }
      }
     },
     "localname": "AmountReleasedFromEscrow",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice Aquisition",
        "label": "Asana Hospice Aquisition [Member]",
        "terseLabel": "Asana Hospice Aquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAquisitionMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AssistedCareHomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssistedCare Home Health",
        "label": "AssistedCare Home Health [Member]",
        "terseLabel": "AssistedCare Home Health"
       }
      }
     },
     "localname": "AssistedCareHomeHealthMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionShareExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Share Exchange Ratio",
        "label": "Business Acquisition, Share Exchange Ratio",
        "terseLabel": "Business Acquisition, Share Exchange Ratio"
       }
      }
     },
     "localname": "BusinessAcquisitionShareExchangeRatio",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_BusinessAcquisitionTerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Termination Fee",
        "label": "Business Acquisition, Termination Fee",
        "terseLabel": "Business Acquisition, Termination Fee"
       }
      }
     },
     "localname": "BusinessAcquisitionTerminationFee",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationAcquiredNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that amount of noncontrolling interest acquired at the acquisition date.",
        "label": "Business Combination, Acquired Noncontrolling Interest",
        "terseLabel": "Business Combination, Acquired Noncontrolling Interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity assumed at the acquisition date",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities and equity assumed at acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19PPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 PPE",
        "label": "COVID-19 PPE [Member]",
        "terseLabel": "COVID-19 PPE [Member]"
       }
      }
     },
     "localname": "COVID19PPEMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]",
        "terseLabel": "Cap Year 2016 Through 2023"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashBalanceAssociatedWithProviderReliefFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balance Associated with the CARES Act Provider Relief Fund",
        "label": "Cash Balance Associated with Provider Relief Fund",
        "terseLabel": "Cash Balance Associated with Provider Relief Fund"
       }
      }
     },
     "localname": "CashBalanceAssociatedWithProviderReliefFund",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for finance lease liabilities",
        "label": "Cash paid for finance lease liabilities",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "CashPaidForFinanceLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need and Licenses",
        "label": "Certificate of Need and Licenses [Member]",
        "terseLabel": "Certificate of Need and Licenses"
       }
      }
     },
     "localname": "CertificateOfNeedAndLicensesMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ContributionsAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest",
        "label": "Contributions Attributable To Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "ContributionsAttributableToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Term SOFR Rate",
        "label": "Debt Instrument Interest Additional Interest Above Term SOFR Rate",
        "terseLabel": "Additional interest rate above Term SOFR rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveTermSOFRRate",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DepreciationExpenseFleetLeasesFinanceLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation Expense Fleet Leases - Finance Lease",
        "label": "Depreciation Expense Fleet Leases - Finance Lease",
        "terseLabel": "Depreciation Expense Fleet Leases - Finance Lease"
       }
      }
     },
     "localname": "DepreciationExpenseFleetLeasesFinanceLease",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Accrued Expenses Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Liabilities Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Liabilities Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Payroll and Employee Benefits Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EvolutionHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolution Health",
        "label": "Evolution Health [Member]",
        "terseLabel": "Evolution Health"
       }
      }
     },
     "localname": "EvolutionHealthMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExistingShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Share Repurchase Program",
        "label": "Existing Share Repurchase Program [Member]",
        "terseLabel": "Existing Share Repurchase Program"
       }
      }
     },
     "localname": "ExistingShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FleetInsuranceExposureLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific fleet insurance claim.",
        "label": "Fleet Insurance Exposure Limit",
        "terseLabel": "Fleet Insurance Exposure Limit"
       }
      }
     },
     "localname": "FleetInsuranceExposureLimit",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FourHundredFiftyMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Hundred Fifty Million Term Loan Facility",
        "label": "Four Hundred Fifty Million Term Loan Facility [Member]",
        "terseLabel": "Four Hundred Fifty Million Term Loan Facility"
       }
      }
     },
     "localname": "FourHundredFiftyMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time that goodwill is deductible for income tax purposes",
        "label": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
        "terseLabel": "GoodwillDeductibleForIncomeTaxPurposesPeriod"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HighAcuityCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High Acuity Care",
        "label": "High Acuity Care [Member]",
        "terseLabel": "High Acuity Care"
       }
      }
     },
     "localname": "HighAcuityCareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice",
        "label": "Home Health and Hospice [Member]",
        "terseLabel": "Home Health and Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Assets Acquired",
        "label": "Increase Decrease In Assets Acquired",
        "negatedTerseLabel": "Decrease In Assets Acquired"
       }
      }
     },
     "localname": "IncreaseDecreaseInAssetsAcquired",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LegalSettlementPaymentLessInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Settlement Payment Less Interest",
        "label": "Legal Settlement Payment Less Interest",
        "terseLabel": "Legal Settlement Payment Less Interest"
       }
      }
     },
     "localname": "LegalSettlementPaymentLessInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance lease, Reductions to ROU assets resulting from reductions to finance lease obligations",
        "label": "Lessee, Finance lease, Reductions to ROU assets resulting from reductions to finance lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to finance lease liabilities"
       }
      }
     },
     "localname": "LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare license",
        "label": "Medicare license [Member]",
        "terseLabel": "Medicare licenses [Member]"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Period of Care Payment Rate Duration",
        "terseLabel": "Net service revenue period of care payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NonCashAccruedContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Accrued Contingent Consideration",
        "label": "Non Cash Accrued Contingent Consideration",
        "terseLabel": "Non Cash Accrued Contingent Consideration"
       }
      }
     },
     "localname": "NonCashAccruedContingentConsideration",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonCashNoncontrollingInterestContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest contributed in noncash investing and financing activities.",
        "label": "Non-Cash, Noncontrolling interest contribution",
        "terseLabel": "Noncontrolling interest contribution"
       }
      }
     },
     "localname": "NonCashNoncontrollingInterestContribution",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "label": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "terseLabel": "Number of Consolidated Entities Classified as Variable Interest Entities"
       }
      }
     },
     "localname": "NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of joint ventures owned by the entity as of the balance sheet date.",
        "label": "Number of Joint Ventures",
        "terseLabel": "Number of Joint Ventures"
       }
      }
     },
     "localname": "NumberOfJointVentures",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met",
        "label": "Percentage Managed Care Contract Volume Able To Receive Additional Payments",
        "terseLabel": "Percentage Managed Care Contract Volume Able To Receive Additional Payments"
       }
      }
     },
     "localname": "PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReclassificationOfOperatingLeaseToFinanceLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of fleet operating lease to finance lease",
        "label": "Reclassification Of Operating Lease To Finance Lease",
        "terseLabel": "Reclassification Of Operating Lease To Finance Lease"
       }
      }
     },
     "localname": "ReclassificationOfOperatingLeaseToFinanceLease",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ReductionToNetServiceRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to Net Service Revenue",
        "label": "Reduction to Net Service Revenue",
        "terseLabel": "Reduction to Net Service Revenue"
       }
      }
     },
     "localname": "ReductionToNetServiceRevenue",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReversalOfLossContingencyAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Loss Contingency Accrual",
        "label": "Reversal of Loss Contingency Accrual",
        "terseLabel": "Reversal of Loss Contingency Accrual"
       }
      }
     },
     "localname": "ReversalOfLossContingencyAccrual",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SOFRAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR Adjustment",
        "label": "SOFR Adjustment",
        "terseLabel": "SOFR Adjustment"
       }
      }
     },
     "localname": "SOFRAdjustment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, AseraCare Hospice [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, AseraCare Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, Contessa [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Contessa"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsContessaTableTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Business Acquisitions, Evolution Health",
        "label": "Schedule of Business Acquisitions, Evolution Health [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Evolution Health"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block",
        "label": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amended Credit Agreement",
        "label": "Second Amended Credit Agreement [Member]",
        "terseLabel": "Second Amended Credit Agreement"
       }
      }
     },
     "localname": "SecondAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program",
        "label": "Share Repurchase Program [Member]",
        "terseLabel": "Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdAmendmentToAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Amendment to Amended Credit Agreement",
        "label": "Third Amendment to Amended Credit Agreement [Member]",
        "terseLabel": "Third Amended Credit Agreement"
       }
      }
     },
     "localname": "ThirdAmendmentToAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalLegalSettlementPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Legal Settlement Payment",
        "label": "Total Legal Settlement Payment",
        "terseLabel": "Total Legal Settlement Payment"
       }
      }
     },
     "localname": "TotalLegalSettlementPayment",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VariousAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various acquisitions",
        "label": "Various acquisitions [Member]",
        "terseLabel": "Various acquisitions"
       }
      }
     },
     "localname": "VariousAcquisitionsMember",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20230331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r247",
      "r447",
      "r448",
      "r452",
      "r453",
      "r510",
      "r572",
      "r646",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r247",
      "r447",
      "r448",
      "r452",
      "r453",
      "r510",
      "r572",
      "r646",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r316",
      "r593",
      "r653",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r416",
      "r521",
      "r546",
      "r573",
      "r574",
      "r590",
      "r599",
      "r606",
      "r651",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r416",
      "r521",
      "r546",
      "r573",
      "r574",
      "r590",
      "r599",
      "r606",
      "r651",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r316",
      "r593",
      "r653",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r312",
      "r522",
      "r591",
      "r604",
      "r643",
      "r644",
      "r653",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r312",
      "r522",
      "r591",
      "r604",
      "r643",
      "r644",
      "r653",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r408",
      "r416",
      "r420",
      "r421",
      "r422",
      "r517",
      "r521",
      "r546",
      "r573",
      "r574",
      "r590",
      "r599",
      "r606",
      "r639",
      "r651",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r408",
      "r416",
      "r420",
      "r421",
      "r422",
      "r517",
      "r521",
      "r546",
      "r573",
      "r574",
      "r590",
      "r599",
      "r606",
      "r639",
      "r651",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r592",
      "r605",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r592",
      "r605",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NORTH CAROLINA",
        "terseLabel": "NORTH CAROLINA"
       }
      }
     },
     "localname": "NC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r603"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r106",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activity:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r629",
      "r630",
      "r631",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r251",
      "r252",
      "r253",
      "r254",
      "r263",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r423",
      "r424",
      "r425",
      "r430",
      "r431",
      "r432",
      "r433",
      "r442",
      "r443",
      "r444",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r524",
      "r525",
      "r526",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r127",
      "r128",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r284",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Writeoff"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r395",
      "r488",
      "r588",
      "r589",
      "r622"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r42",
      "r151",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r176",
      "r188",
      "r220",
      "r245",
      "r296",
      "r302",
      "r308",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r447",
      "r452",
      "r469",
      "r603",
      "r647",
      "r648",
      "r663"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r213",
      "r228",
      "r245",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r447",
      "r452",
      "r469",
      "r603",
      "r647",
      "r648",
      "r663"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r104",
      "r108",
      "r211",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r440",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r440",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquired entity.",
        "label": "Business Acquisition, Name of Acquired Entity",
        "terseLabel": "Business Acquisition, Name of Acquired Entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Business Acquisition, Goodwill, Expected Tax Deductible Amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r140",
      "r141",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price for acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r72",
      "r215",
      "r576"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r73",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r72",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r166"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r245",
      "r266",
      "r270",
      "r272",
      "r274",
      "r278",
      "r279",
      "r325",
      "r364",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r469",
      "r575",
      "r614",
      "r624",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r181",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 7"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r357",
      "r358",
      "r562",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r629",
      "r630",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComparabilityOfPriorYearFinancialData": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.",
        "label": "Comparability of Prior Year Financial Data, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "ComparabilityOfPriorYearFinancialData",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r162",
      "r163",
      "r316",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r162",
      "r163",
      "r316",
      "r559",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r162",
      "r163",
      "r316",
      "r561",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r83",
      "r84",
      "r162",
      "r163",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue",
        "verboseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r85",
      "r162",
      "r164",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r162",
      "r163",
      "r316",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r47",
      "r522"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, inclusive of depreciation"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r81",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r244",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r389",
      "r396",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r177",
      "r178",
      "r187",
      "r247",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r489",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r178",
      "r187",
      "r400"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r168",
      "r170",
      "r373",
      "r489",
      "r586",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r34",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r229",
      "r585",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r35",
      "r247",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r489",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r35",
      "r118",
      "r119",
      "r120",
      "r121",
      "r167",
      "r168",
      "r170",
      "r186",
      "r247",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r489",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r169",
      "r652"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r129",
      "r429",
      "r435",
      "r436",
      "r627"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r70",
      "r105"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r70",
      "r291"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization (inclusive of depreciation included in cost of service)"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r104",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r103",
      "r108",
      "r211",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r104",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r14",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSITIONS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DISPOSITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r236",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r264",
      "r266",
      "r272",
      "r273",
      "r274",
      "r276",
      "r463",
      "r464",
      "r541",
      "r544",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r236",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r266",
      "r272",
      "r273",
      "r274",
      "r276",
      "r463",
      "r464",
      "r541",
      "r544",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r117",
      "r207",
      "r232",
      "r233",
      "r234",
      "r248",
      "r249",
      "r250",
      "r252",
      "r260",
      "r262",
      "r277",
      "r330",
      "r407",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r462",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r503",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r44",
      "r65",
      "r70",
      "r196"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r65",
      "r94",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r387",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r467",
      "r514",
      "r515",
      "r516",
      "r586",
      "r587",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r387",
      "r409",
      "r414",
      "r467",
      "r514",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r387",
      "r409",
      "r414",
      "r467",
      "r515",
      "r586",
      "r587",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r387",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r467",
      "r516",
      "r586",
      "r587",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r387",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r514",
      "r515",
      "r516",
      "r586",
      "r587",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r218",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r346",
      "r348",
      "r349",
      "r351",
      "r523",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r97",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r451",
      "r622"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Loss on personal care divestiture",
        "terseLabel": "Loss on personal care divestiture"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "(Gain) loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r217",
      "r336",
      "r540",
      "r584",
      "r603",
      "r636",
      "r637"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r338",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Goodwill, Other Increase"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r174",
      "r183",
      "r198",
      "r296",
      "r301",
      "r307",
      "r310",
      "r542",
      "r583"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r44",
      "r70",
      "r93",
      "r182",
      "r196",
      "r293"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in (earnings) loss from equity method investments",
        "terseLabel": "Equity in earnings (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r11",
      "r12",
      "r13",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r246",
      "r261",
      "r262",
      "r294",
      "r428",
      "r434",
      "r437",
      "r545"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r621",
      "r661"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r274",
      "r418"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $16,071 and $14,604",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r169",
      "r185",
      "r235",
      "r290",
      "r487"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r238",
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Investment Owned, at Cost"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r245",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r448",
      "r452",
      "r453",
      "r469",
      "r582",
      "r647",
      "r663",
      "r664"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r180",
      "r193",
      "r603",
      "r626",
      "r635",
      "r660"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r214",
      "r245",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r448",
      "r452",
      "r453",
      "r469",
      "r603",
      "r647",
      "r663",
      "r664"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r104",
      "r108",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r103",
      "r108",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r29",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r29",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r29",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.",
        "label": "Litigation Settlement Interest",
        "terseLabel": "Litigation Settlement Interest"
       }
      }
     },
     "localname": "LitigationSettlementInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r178",
      "r189",
      "r386",
      "r401",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r35",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r359",
      "r360",
      "r361",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r359",
      "r360",
      "r361",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r359",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r359",
      "r360",
      "r361",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r179",
      "r192",
      "r245",
      "r325",
      "r364",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r469"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r122",
      "r147",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r45",
      "r71",
      "r184",
      "r197",
      "r212",
      "r230",
      "r231",
      "r234",
      "r245",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r271",
      "r296",
      "r301",
      "r307",
      "r310",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r464",
      "r469",
      "r583",
      "r647"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r150",
      "r158",
      "r230",
      "r231",
      "r261",
      "r262",
      "r619"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r145",
      "r407",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable Lease Contract [Member]"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffMarketLeaseUnfavorable": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.",
        "label": "Off-Market Lease, Unfavorable",
        "terseLabel": "Off-market Lease, Unfavorable"
       }
      }
     },
     "localname": "OffMarketLeaseUnfavorable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r296",
      "r301",
      "r307",
      "r310",
      "r583"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r227",
      "r603"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other Operating Income (Expense), Net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r55",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchase of cost method investment",
        "terseLabel": "Purchase of cost method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedTerseLabel": "Investments in technology assets"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r226",
      "r334",
      "r335",
      "r577"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from personal care divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from the sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r212",
      "r230",
      "r231",
      "r239",
      "r245",
      "r251",
      "r261",
      "r262",
      "r296",
      "r301",
      "r307",
      "r310",
      "r325",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r446",
      "r449",
      "r450",
      "r464",
      "r469",
      "r542",
      "r583",
      "r600",
      "r601",
      "r619",
      "r647"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r107",
      "r194",
      "r543",
      "r603"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $105,183 and $101,364",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r415",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r173",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r203",
      "r506",
      "r507",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r415",
      "r506",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r505",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r616",
      "r623",
      "r671",
      "r672"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r122",
      "r191",
      "r553",
      "r558",
      "r603"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r207",
      "r248",
      "r249",
      "r250",
      "r252",
      "r260",
      "r262",
      "r330",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r462",
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r316",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r497",
      "r602"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r497",
      "r602"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r35",
      "r118",
      "r119",
      "r120",
      "r121",
      "r167",
      "r168",
      "r170",
      "r186",
      "r586",
      "r588",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r11",
      "r12",
      "r13",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DISPOSITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r75",
      "r175",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Net Service Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r447",
      "r448",
      "r452",
      "r453",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Term SOFR Rate [Member]"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r355",
      "r356",
      "r584",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r296",
      "r299",
      "r304",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r210",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r353",
      "r355",
      "r356",
      "r584",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r245",
      "r266",
      "r270",
      "r272",
      "r274",
      "r278",
      "r279",
      "r325",
      "r364",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r469",
      "r575",
      "r614",
      "r624",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r117",
      "r207",
      "r232",
      "r233",
      "r234",
      "r248",
      "r249",
      "r250",
      "r252",
      "r260",
      "r262",
      "r277",
      "r330",
      "r407",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r462",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r503",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r277",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r117",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r19",
      "r20",
      "r117",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r117",
      "r122",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r117",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r117",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r117",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r23",
      "r24",
      "r92",
      "r603",
      "r626",
      "r635",
      "r660"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r145",
      "r146",
      "r157",
      "r207",
      "r208",
      "r233",
      "r248",
      "r249",
      "r250",
      "r252",
      "r260",
      "r330",
      "r407",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r462",
      "r478",
      "r479",
      "r483",
      "r503",
      "r550",
      "r551",
      "r626",
      "r635",
      "r660"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r484",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r484",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r484",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r484",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury Stock Acquired, Average Cost Per Share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r20",
      "r117",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r38",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r251",
      "r252",
      "r253",
      "r254",
      "r263",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r423",
      "r424",
      "r425",
      "r430",
      "r431",
      "r432",
      "r433",
      "r442",
      "r443",
      "r444",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r524",
      "r525",
      "r526",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r152",
      "r447",
      "r448",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INVESTMENTSDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r265",
      "r274"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r264",
      "r274"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDINCOMESTATEMENT",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429468&loc=d3e288-107754",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/subtopic&trid=2208821",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0000896262-23-000045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-23-000045-xbrl.zip
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MV<Y7;__C/_[CST$^:/NW42W3L3K^^:KZ\<]75=&FYT[?_NGRHZ0_.&W[OY9
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M&;"CBF34(>"!XAD*=#H#4E,1KE1<2AI80 PQB3)-.(OSK9G! *G(/S_A/OV
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MMZLB^I<TZV\0W]]>MP>MV9TM<XY?T02^1HV]!<3*UERZX<%01KV(J\8SPK+
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M5)),99CJP&+FA<HL4 S$V*D,S</!/[,EF<EY8J<]1"<*(I,XHA RS0*.9R=
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ML[UWTESJ-YW8$;F88>:<EBQ@S1!5!EEE!<&9,(A3-N+[&%7N<8&;"_W^!5Z
MT3UYP>3P.W/4FD 0YP(Q+)VAPABMO#!8*\?(8G'<?(P"/?VR.VN)<=PYQ!QG
M& F 1>2=1EQR;_A(<RZ.;YK+P&$F$&H*NV ^Z!BGB4U@,=YKFB%.1&"62RFY
M!,=*J*8T[@0P^UN;S,7R_XOCH[I^,U1OGKPZ/<KV*M1)Q0P$L5;&&;]4$J5P
MT$88 7H#P<;,:\AC;*\R4W[I4>2NE*!<$*3C2@'DI&8Z,\AP1#Q2/'.S*_?'
M'ZR9O0U[)B?WN'D253+#DG"FD)9(90X'Y;%0#-S#')'3.UW#[[>N?PI4%2D,
MT0TQ6%E&,-4L!)-Y@ \C29;-DQ[-WQC+C,364U [8ZSF ;3-.QD'B8W C#B!
MB"7@JE0YTQ+)480$3'=&_=?YH33KOK=?Z,-6;G5[Y,\&A\7K[=5?UY[['5#6
M/\SM(P,4DO<.?6*VYN=#GV$WK]3$^*X/T )=G)Y+OP/^&HRY:O>E&\9EC:^/
MO\?"[E!!KA7Q0HG@&'/@.J7$@7@;).<9*^>[8 C>D4C''Q8J^*LJ^ #NUN^O
M@K@ I#U M>^_.VWH 0@6XK+SGT\OO;]V,H#6]]I0TQ\=K/J+=H#!" 3\?Q\[
MN';KKTS#\P:!?S:*8E!.3500W,7-"(AQ5*CR( PLX(URH:6SJZ4[W:"/>L5C
MG[*!181J+">16) 4N4P9FS',3#S&#\)+D05"C'1.EI-P*KU+%PKXFRO@%92\
MIH+?0\EKM_XD6[!MG7=NYPGEI0<S!"9XW.6,*1DS^2*3$LQ :.$4X\!1^6SG
M5A8:_Z20.\FMLK,X\"B44XHP"OIG'$%64(Z]\X+BTM6KR$D7>C>%F.B2FU4E
M<$UB)U8GG6>4*T>D8UA[B9#PANDX=8@(A1=8,R,RGZ"=:R; MGGF&!',""8S
MX[/,(.>LSJ0I#_C$&9)S)_-2%A_T-]_67?>^W2MRIR<Q4O,A'XS2]*NZ?V5+
M:!W\_E 7;J_7]1^+6)_.!O3T?@&]%=U"H>V@-['I^/=3Q<<[M_T2 F4IDA,[
M3@]3S96@4C++D=0L\\[13 >D0RB7KD9MK%)R"[5<J.5WZ7^IF/=+%E[3X5])
M*U-O-);<24(84'9#A<L0L8"LCAFF9AM1IZU']S&?U;;7Q3'<4TS(@&9%>1\%
M4P/BB )X8B,<RYB3/F/(\X #B5NTA3G!U(5B_M:HRIG3F &V4F&8L%YFTDL:
M%\D@ AKM9O?HI@4AF!%,G>!151XA%3C.2(8U<YF0+!Z#2!WEDL23Q69;&Z>M
M&K\UE#Z./C)O228%Z)]FG"!ME->>*NN,$HC3V3WV]SZ9F_<?9AH*?U4))I7*
M$9YK!\)164:8-EPQG3FO W<8X^!'IQLB,7M+H!9*$(?H)W*:%E*<:,RE)]PQ
M9:0FTFID=)R3"[1)CY9]9.-E'S.XX'-!F&:&ZT?%S.Z_TF1"BSJE%<"ED&-,
M4^8S822E0/2QUAFWF%3'6Y#QHLX%S5K0K!]J\;V7;E[C9+^T7LIJT&0AC;(L
M2"4-,QF2D@D7D.!R_I'XF?KEZ0.@8L1JKJBE3K.X*TBYDA,^(:841WZ^!V*?
MG\9,:F3V?!K1Z.7]VV<2C:%T7,J])Q-AQ#/"!5>9,>!;D?2(4>(EZ)N14L[3
M9E;W\B_Y?FO%#J/P=?$L=R?SP.BS3&7>6<]<%B0IA^]%7+7 !9Z'_1+O*=#Q
M;2OM]N:@Y8OQU><H51Z84XC$\[(1<T8:*D&B(%W#0@#V,$=+]V>,!DYAV3S"
MTDJ),XC(!8,.!F\NE%$^$!U8QL6S$^83K *:T@8(3ED%TK,8:^!A 8Q2$TZ$
MP\ID%*-G)LF/ONCWNKK]!+YS*N)TX#,%L<"#/&98>*F=!$G"*WC&C7IVAOF4
M9&@J A6>2*.)]\'%U<1!"ZW 9K5P5CAD[?,1Z)3(T%2D2C/N,Y\)Y)5C6F.0
M:<8S[:70R!%<;2J"D41D9H79 H/;\H?#PK8@8!T%II?W/XT==OM=CQJKXG(B
MQT5;?V$G"(HL ^LS4AF&N5+68F*!P<;D!3-\M,TD"&EF,[:S*:WK.RQ>EM?3
MI#%Y/+S*!P@],LJL]@I;K#/!<(:=<X&,<E%DSNV/3L'^(&(DD[$_2ZBA&.)#
MJAD+")L@M8Q[= $]S; ='_E#*ONC,VU_4]H&<[:TY'H2@MS3[NG$[!YYXQA2
M-"C/(4Y5V@3O&6=4:4F%YG/$IK9\N2+_(W3;:=Q'O*]MN<W2N]/+5RZ)NNZ=
M;O?V\Y/G2*@\HB8H9\!E!Z8"43I#% )9PQAB(D-SE#.<6<%.Y^P3+K@+'F?$
M!&:#UL";.?,ZH^ <N!P?V,[A?>,/LRK8"3N!"8B3@YCN*<[+M]Y7G*_RD]>%
M[_? K_A^];7EM2LK[_*CMW_"7^,H-\M JBAC5C .E)L9BT4\#D)*EF'Z-5KK
MQ3/]P6D;Q-?)NVG+Q]VE7C.RG/'#P9OCW U:KS%"_[U4WOKVS_ZA[K[]TQ2O
MH(#J\WDY=U^\^2I=[,/;!KW#UY@<#J#P05SW/+YL>@4T*[6]=EL?]OWK\8<W
M+N\?MO4IT* VA+QI^=";46&F-QCT.J]CM8]\,8@#BJENY_O=U['[1I='+5)J
M67(:&S6 WANX\8M'[5TNV_MJX&Y>4W)9H;LOHV5\?NU5678QOF'4M;1JKDN@
M4;&/_EJB2]?:/6H)/APD_5X[=\E_HO*_-Z/K9;?=N'BHG<N[^Z]1@LM77-3A
M5=E/WQ<#@VXK^ZGJ,@MZ[XNE2J3CVZ'&O>+U^'T!]#(-NI.W3U__;Q/LLY\T
M_'&RU>OH[O^^[ /2IGW0Y%#=V,_/_&LLX2WEU^.J,S(HIY3DJ',PB5V[T]AH
MUM:2[>9*L[9]0\W&M9F5VF[75G>V-IH;M>UDI;&6U/YO]>^5QGHM6=VLUS>V
MMS<V&U-L KE7$[[H?@M49]#K)FO+J\L)09RI*=8:7:LUN[76__.?6* WXVH^
M+8!@M<P8FW$ (1/&"#I#&/%^<ZN>_ DNL-OK-H8=*,0F(T^YY4-<TA;*X[>P
M,PA\(.,J8"XM=4JYC"-[ZPFW25=''N-\_GJM9X>=$:U8&@T&T,^G9JUW](%L
M'>W2^M =U([VUM7!YL%>NW%F<6-]Y[AQMG70./B$-]?_R1OK_QS4F[NG>U_V
M\LVU?=0XJYU]H(WV[EF/[#4M;32WVO4UBW;/=E&CV<IW#[;RW;,:J7<^=W8/
M]EECS9[4L3SY0/9.=[]8L=?<( VR<[+;;'W;_;++&NM;G;TO&ZB^UNCL'>R?
M[:UMG-;/+&F<[1ZY]<_,_?U/>X^TC\S!8;M^L$OWFN];F^M;+;@7[:WOM7</
M/AW7R5YG<ZWQK7ZP<0;/0>WD:?W@T^E7)V0FK4.I8YJE3/,LU9KR5!NK,,$!
MV")?>HM1^JDD(A=2>)O<"1SW4*6%%3^Z%9<^X>DQ_'8S?E'7Q;=DL^O_F Z.
M_SP1),M$9/=2@ ?I%5_FE#Y$K^Y2HK&2D,.3J"8W)7Z]<ZI^N;\>K!2Y;B<[
MW=SVG$_JVS_MS"L[>GPH_S2$D,P7;0C\#WO%8"D)O:*C!_ "Z!D(6*$'>FVC
MV^W>P/1.YA+TW^=F?4?4F_"^+S7<Z&R@O>;G5F-] VVNM>#^.JV?U4[WUMX=
MP/N@?O71,Y_A7;R[U^R=U,GGUFYSAT"]VHTO-01.@FVN[W7@'6?UYC_?ZNMU
M:-L&@SH>?VBN#.K;Z.1#$WJFN8&^(FM,)IQ+C;,H99:B5"LM4XL<5T[$0\5D
MY&TJ8^+-=;]Q[C9&BO\PG6[[<-/<>X=/3ZA+;?ZTL[+5K&U]V$VV:A\WMYK)
MQYVM[9V51C-I;B80,#0A*D@P33:W$LQ?N#^2S?=)\^]:<BF6.(\C5E:;\3)6
ME%WIHN\#_ET ?T?L/CUN?P>]ZQ7)H.63?X]M-JFR(DFY\?13$+^/Y?MJ56[F
M"E:\=O!+VH%WMN)CJ=.GZ:G71>J[<PD:/\T43^IG^U^Y%<%D.*2(69\R(4T*
M=BY31IC4 F?&Q8TVP<W;5A6P4?PRB1W_4[QQILA+KY@::<E0]C.D!2^K3#T&
M:9'D[D=GB;1,*@'Q5)RE'+'(!^5!0\^;M&PV:W3OH(:@S-9N9_>LL;;+X)G3
M1O,;;IPU#NIG>VW GU9CK7:=M/!ZTW7JS4]0__<YD!S4.&@!9FW@S>8.K9/Z
M6:.SP^H$ROY\"VDA6H9 B$LQPRJ- URIEDZE@BI,D93"838B+>Q9DY;FUDIC
M>Z.D)M-B+;.*]&,Z,C@WQS$?"46O<^ZYGKYJ50\Y;WM%N=KI]1#X41'O&N='
MG_[OZ?7&TMMDT%M(XU9IS(VMK?8ZG;P?QWJ3]SFP*H!:XXO7C\GY:^4@;WQ;
M];*Y=*._DO"MXZ^(82\R%U)%)+!WJD1J& (RS[CD!#O$9%AZBU+"B$!WN<'I
M#P/]E)HOLLY3&SO*._M)O[!_+<6Y-^?&^74?+Q\<[B\ENAVI;D?O>U3]<+4]
M$DC53XE H,.3I5?32( 0=B\47*G7UC:V=[=?)AN-U>69S]>\J)UH.T@:(,6D
M%Y(MOY_W(UD:)+J?;!]Z&R?[N"3O)OF@GZRVRJS.'S/4K,40\_1@8OJ0_//#
M0$S>>\#F(=?(,I<_]^1W*RN6F12_H!B8?T<S;I7\X]PZZ3328P3=/P3.Q\XA
M5:QVHPO1R.$H("G7C*WVAMU!<;K:<_YF.JD?[S@L>D>QG#E-:(]&P<C6P>Z7
M#7C^?6OW"]1OK78:GZ^OQX30[DF] URXV6@WUF\DE,[VUANMW8-_6O'9O>8*
MJC?_ 2;]Z7CW#)XY@'+.]MIULH-V/T,=KR>4L$:2*4M3$K(L!8,CJ=*!ITYQ
MI#2Q4L6$TIIOZV-=^,?/*$TU1WJ-G?]4HWX[FVWJDXW1#&E;VNT<AZ5/;8P;
M5XV12R:ML%F*E18I8Q*,D8-MPI_ I.&>E/.8<$HQQ2#N[YKC?(Q>_' "7:G$
M+TI?D/2*I!>7!R<'PR+ON[Q<' $4OAPFSB_[CO+68E]W\[/R^Q_S@E37^^.I
M@6JJ4MY8WEK>7DYJG<-V[]07I5BO8DO2Z"W_\0QR](^.RBO.%;[?'_WS 2J
MYQ*1?VEFZ-E7ZTV&%) :DAF5,LM(*IF.>R<BS;ST&<H 4:GD+%DI10&J\$6?
M7@?6EX^?T+TI,/+;":Q.ORJ."::6I0H3ES)*1"H#"RD1Q@1C%+4QL[L]S,$=
MK$Q/3*OP<;-H]H[G,^CX)2&QKXB0$"2B*?0F!ZO"-#7(X50Z'/=EIIG-Q-+;
M=SJNT=CJ#?=OQ U/)ZB2.&P6'R%(!(+P^\V.K_.OG&9<&(%2P86$$"].C \
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M/&<DH/B>2+"ZLOUW\O[#YI<%$_AM[#\J!U_8_[.V?[;TMK'9K&TGS<W2J.\
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M@<\5.=X'I .U*.U.:KSTUB2[JUEZ^D E>-^^]%+XKGI+IQ>@-WI*\1,JEA;
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M3H*]95XKO17J7#U1JQ/J.Y96IV*ZDJX]'<+3BP>_7Y1#=7K5YU5O^GURB$T
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MT @P=IP2FU[$&YND3;!L"[4R_:=+Z_F%P<6U>2/.@G21* C4<,&H4\)%(QT
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MTRK'@M@&/P [A!>#_LGV99G<A&+_&<^\+'@U%UZ]FG%H$&$\ME0B$8U!::?
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MC@2;;#LF8H*/1!DUY@PQ9J4('GS4D&P[U5:2M146!3^NXD=A;X6]U=U%^4Y
MNCCV5@C:7 B[/T70&!$V*N(1#U@@;J5)EGD("!,?+%@"D67OF2[(6I"U(.MB
M4UN<, %;(Z/5W!-MK09,>,YM(2XJ5^SB%8;=Z>;SGE!M*,UM4-,/J2W2H#F*
M1%&MM<?.Y.;S3+8%JVM(7\'>@KV/"GOG27)V1&OKJ6">"*XYLR&IJ-5!8&Z\
M)3^@M<-TF^E10>'FH_!T@T=!(]&<!A0$Y8@SK9!+1@W2 @+#RE"&$_GE'+>%
MP/=/@2X 7 #X40'P/.07R^B8$ 2;P#$-)FAPU HE*/%:Z4)^5Q=V9U)V#/8F
M!&F0PQHC3F5BOY@*9+U4G&&OK#*Y[ 2W%>.%_1;P+>"[V-RI$(24@'TB/9RY
M:"@!Y43BOUP YZ2 [RJ#[U0NEM)2*^$4"CAHQ(4,R A'T@_E7 @0/="-3<':
MVJP/]E;97+]5VR[]&SJ?-O^=?EQ<^*7/\I!WX41C-__M!K]M?KO;V[ZM-D4G
M^&>:3K.F'QU#R_H\9-OVSG/GHUY_E#[=#M+3O:H-TH>![;9.[6#4ZL?6Z!B&
MD $@0&\(^5#J50MN1^F7V.G9GN^D/Q^.TA/5<,LG-Z[ Y#+X$Y$N]+0_K&97
M/AU UXXZG^#WSYTP.KZ HTMOFVP$_/TMUJ5+.!O=_):FK#6_NA:7?^:KK2!)
M@E*"0\)2+[G0SG'GB:00G=9<$?8^%]5.WG0\N+B#4_L!D!N _0?9F&[PJ>U^
MMN?#C=^NK,-)IW=Q09P^47G=IY?LAWOWYA<;L+W5M4N^M;>SO7OX]K#=VMU_
M_J2UM;_=.GSS['!W>W?K]>[.88/4\_KK?WZ0\'S_<&>[E1X='ORYN[UUE'XY
M/$K_[.WL'QVV#EZTGF\=_J?UXL^#OYM_/[]LG22,'PT3LB0LZ9^ESPK#7YM_
MV6]Z-E&1!'+S76MU:'Q'KNJ@2M?<M:=#>'KQX/?0&9YV[?G33J_ZYNI-OY_8
MP8>DKQ.XR[HZG?V;OV_\\D2-N:)/!*X(_R3Y>/+-$RU_@J\S!L8O,J&>4''S
MZS]\\P]?%&.HJ?^#R8(^=YX+GF1Z3YUI1(V%<*W1-F>2]W(KU:YC;-_NR=SF
MGL:ZL)R[FE'FZJY>] ?C&TMD9OS@Z'@ @/;2.X\GMYR/N/%@[>'XF9W$>,+W
M?/<K:W+#)B"/8A-<\D;,0<2;O4.2Q<KJNN$;TW+7=.'H;52#_D U&MR)Y>=L
MH5J%YW9XW'K1[7\>MN*@?](Z.(5!,FJ2<;65+.%/R6J!X=/;[*^;5J*VC7?G
MBL&%7&0MFZ4QI50_-PI_TK?GWIW#'NXDN>6]SNUO;8+']);W-H?+--V9Y8J3
MX'"R\;DPD0CM\VC'H 3VX\&.[*+<E*U=O?C7O<.)__/D+=W;/C[>ISM?WWY]
M=OQN^Q5Y=_1*[/^QA]]^?-9Y2W?%V[_?\/1]_WSW?_YUO+>]P_8_?A![V^_^
MV3MZW3GX>Y<?;(=N]J'N?TS_'GT0R6X^G_%__KWS>>_(TX/M?S[OG[SZLO]'
M^OQ\7?3-U_UT+>G?+^DUO'?TWWA13K!WB&FZS_/]K?="6\PU=\@[3A%78)%A
MWJ+ .';**6ZD2V<@;QML:O)^KE#LJ,!1D^ZMM$5;.SCZ.@5'6!#,E;7(!L41
M-YHBK95$7 8*X(D56-;5%:U&.%ISD^!Z==P*'\^&HRHBTAKU6P-(&N@[76CU
MOM&__'S^S6?KX730_]3)'@=WWNI_,Q]L/>9#4RR$.8P RFLP L:'DFGR/MF&
MT[0W.K;";-L++7N2@]]?QT_\TLDA\6'G$^187+C\M]4K><-T>FF)AE6P+EW#
MIXZ'F5S#>2J#FU3;NP),_++\TN,N5(D+O;!U28SE4*SK4+PH2+MT*$+47D=!
M$BD/ 7%LY'BZDF.$!TL=52X=BJ(M:TM0:!!%+XJ],$Y;%/N!%7N:[4(2H3,!
M4)*E0CR9W,BJ]"M6VF N@G&<;VSJ-L9UU9LVG.RN )O9[_=016=S?A'TAI66
MK$M[\A5@(U7'D6=V".'Y)0$4F*H-ICHS_(,QABV1%"F;"^,9&*2#%6EY@TH"
M"U(!249YFZK2J7R-5;EV_E%4>>&J/,TX&)-40Z(86D6,>)(ATI9JY,%3;$4$
M(MG&IFHSKAJDR@L,HJX X[A,QRO_2>?DU'8&V?&6/2+?76G=/#2H5:UG?N$L
M_6*'0QBMS8S7!M.3:BSU94DE0>U^DU,_?LN7^#,+Z76^VH/X9@A;64 %\FJ#
MO-D()T]R5-Y+E L]$%<4(Q<M0RQ8+R.G%K#+1I:D=;5;+-Z3!FIZ;>RE:'I3
M-'V:W 3EC'&2(,]$LE.T-BCWUD5:>,TD3M9+2'8*P6ULZNHATQAVL[+^E%_^
ML)W>KZUN?SAL)0W.=0/]H>UF G,ZR-QF=%Z1'OC?6><T:]@C\[7,T[2E=F=+
MEDW.>3CH'29@.H@O)Q)YV;6]T<Z%1 INS8%;!\]G&8H-Z1R*@&@B)H@+0I$S
M$!$#(%A04!%R\ZO[=%PI?I6U9B8W]%PJZKL(]9VF'=*+P"$&%$.>Y$B<S,,\
M L*1Z*!]L)&JC<U[]V(N_I2:5///"=5(JC!,[+W;\KDR/'0^P7#4&9T-[C9L
M]E$84340C%M"U;.S8;K0DFU9(W)]3RQA>U_?X+U7[T&IZ U1*&B9#"9" #EM
M''*!4,Z2.:4!;VS2-M%-LI>*:Z1Y!.0NRAP[7R"@KS#H%SV>3X^_3NDQ=4[[
MR D2)I&/9$ H9(6.R(%B#G/B@[;?9G0V2),?M^=C&R(,!E5ZZSA7VGZ!NX5J
M'H69M("\UO'Z[U;+?V2_['S)06AX!CV(G>*J703SN+"9G'5!Z)SO%H5*S$-0
M9!EP9  SQ7R0,4!F'DHU:09B<7TTG7D4G7YX%O(M_((]UAH;E(1'$6?)D# 2
MDF+CW$I/,@I$56EB]Y]+57PA->GJN"ME+K#Y!>R@ERY^.(G%5%T>8/SR"8R.
M^YFG9!=)5?#UR%PD2PW"C+$LVU,ODDS&$MNK)++[72 %O.8I/#W:FIG,*6*P
M4E.)!*$"\60V(2V"2X846$N,XSKWOB=T-L5U[K[WQ0FRGE3D!M?F+?6W,),:
ME7MZ;B95. 8BD".>("Y%>L1M0(&)P+%VV!F6Q^YR_$BJRE> FEQ)>ZU*@R?N
MD@!NU.H,AV=Y7GM5&%R\)@_'1BZ+Y2"^&+='[GUXGL6PU0O;G:&ONJ$6S)H+
MLW9F"8GB+@IF43#@$$^'$7+!&B0H1.LP%@ A=^:Y=VE@<9 T5WUK=Y 4]5V4
M^DY1#JZ9I<01!-0'Q)7!2$>*D?11"T6-3K2C:>K[N'TAKV%T-NCES)#B]E@^
MS[C>3MKNY!9"O3 \&"2H&L].25=6S*<:L6QWAHHH+0D1Q",6B4(<*$7.J8@L
MY5ABZT4$G<TGI>]=-5A<),W5\=K)2-'Q)>KXM(LD,&&H(8A(3I*Y 0P9#8"2
M=ANF) T@0Z7C9#8/?2U=),TE*L^/;>\#5/-&+O71JRI]JU*9;L>Z3K?JJ=>N
MVN_U8U4S[*M'UB>M&X\9>G0M]QX+E7V9]D0N#\]3L*K1- /PT/F4A[ \,@J[
M[,C=(!>!;L/XW]W>UD0@K[_)HYQJ]9UJKV:8*U/&&4D! 5")>#0"614C$J"B
MQ59'1G7N=\'5;(9SB>NMA5;7SEJ+5C^X5D]Q51N#EDQ1)*WV2:NI1480@X 8
MB2E8RW/= M%M26;=:TM1Z\<=RCL8'<.@Y<\&@XJ4W+TGS>KZ_!O&0UX.X-1V
MPD6ZY"1+<JL7*E%5K2J*O5TCAKV982;4)0$:'I'6S&=[6R+-<4# #"'>"T6B
MW=CD;4+O V$EMK?6[K2;,XZ*OB];WZ<YBU"&:1?3M@O)$N'2(XLI1\[F_&AM
MF8T^6R):-ZGBX7&[40Y*:[WETI@I?*M:;\V"VT\Z;A7@F@.X/GPG*E]W/^\?
M[;XG"DS GB"A 2-. 9#+7;4D]2%Z;,'G"6&F*996<: TT(%2]'@)>GQ^58^M
MYP B6B049(.# S(Q*D1TB));XPPD/59\=LQ?\9@LR6-2/"7+]Y14DOB&3!>6
M4L&B.;#H[8SS@TBG73" 2!(+XC@!DG7$H8AIH#P)58F$1820XOI8'<5MJ.NC
M*' ="CSES8@<M!(0D<32(&Z"1@:40<JSI+Y$::]BSFXN4P2:PB@N8I2M4WM>
M\D"6U.7NYM#QR[%4B@^V/M3RL[3#<NTQH2BJ7.--K4/6LV0161Q%@B\IO<T=
M*KB8Q:WBS%@+W7Y(YE%T>Y&Z/5UO)8!X @X)Y0CB(@1DC;1(:VT-TYKA'$^E
M;4)FN\\4!\<RZ,C@#$(+QI'(Q^;D:):/8R*,/[_GC1<XNFO49 )'F'E@*B:+
MB)" >)Z>Z#AV*!K#A4[B43@GGO)9#T>IWEX;U7V8U-,9U2TT8P%1E(E>>V*D
M]\H@P732:V\),N Y,E@$2PGQEHLJH5PW:1;JXW9]C(,IW7[O QK!X*35=^F"
MJ@X()7VC&5Z02D+[_=XD1;@0D;L"UC\S1"0Z\(9%C$R@@+B5$KD(&%$J#<-*
M*4-(LHM*]L::JO&#AUJ*&M>BQE.\PQ'O'8\21:$8XC2W^&?@$40OL0$#P9F-
MS:;X+1^W;V,Z;?12/?8C<W,TEF]<R32[P*GS8CK5!F$?9SOL.A8$L<RB"#PF
M" N)DWALD0*F&9?"$8!L.AE9)AVNJ8X_*!DI.OX .CY%4X2QF.16E<)G'6>6
M(BN"1#0PPS2)@BNUL6G:Y)I.44O1\05Z1II+4/9AU/)V>)PG+.=>2Z'ESB^W
MDDGR^'1WNC)9#=<?!!B@=)=/LW"&_6XGM/*]K2+(+3->DZ3U/ GKY416S\[?
M#/. D^\I;=_$5;"M/FR;[8*'&=4:*XJ,)1SQJ .R2N=^>%ABGEZU6FYL4I$(
MS+VC.G/IT HY6QXK*-0>"2J@L"10F"(\.EDMAA&%M,EQ7F8(,EHYQ+#66GBM
M(,2-3:[;DJX&**QY1SUU?4>]3(9>=/N?)W./QLTH,Q?ZKD?WZI5WH\PNBVW9
MC?3FO\A'R9X3YJ;U"I.M,CJ&UC!!Z)41%;Y_DM.:QK,K3KOI&A]EM?@R6?.%
ME/+,G?$4XM>0F\GZ$92Y67<^ &<[[ G!$QUV%"F=^\8RY\:11H<M.,EDI) .
M0#);55H:0Z^-\M;.;HOR+DAYIY.F"</>2(\"]QIQ2VEVR6LD.:$$,\ Z1Q7I
MO3O2K$9H<14IQ^D@^^U&YU7CYSRWXC1KQB,+,S:+9[R<B.1EXGVCK5[8N9#*
M54L\=KY 0%]AT"\P-A>,S?;22^<.5Y)IA*/#B+NH<SZF0E:P (H"(9IO),S2
ME-#?&Y2660*,JT=$?J#=18OGT^+SZ:80)AH=';)<YPHN')&QWB,2O*+$:$ET
MKLY\)"7E#28C9P-_;(?I ^OE'ZMK*BVU9<U+>UX90T?]K3S98P"WY!\E$G ?
M^)KM:0/8B1 E0T1PEFPIX,@I9Q'ED84<&\1<Y0$Z3-PGO:FX01JLV_73CSET
MNZCO?.H[Q3Y88AW11(:2SIH<W;?)?) 2<<FIL$(P(?7&IL&SOI!UR[!N+O.X
MY/K+PZ]&X(][Z:L_G)=.>4ND'=OP";K]T\-^''VV RA(-!<2S7:IT4Q;K+,7
M5O%<.LYILH@"1SA&G1A%D!82D:#7S.$K6=)KH:L+I!%%5^^IJS,^"R8=\0*!
MB8 XCQ%IK@.*7CC'&-"0)Q%1=I_I8L5?48^_(KLK?'\XFIWK_<C<%<V@#1.+
MIJH9O1+3+4&2&J!JMB.-YB: S+VQN$D&#O82&4\U2C:/C$ @5@-(:@J2%#?%
MX^07MU+JXGF\IV9/D1"EF==)G,A;GDB(#Q8Y(P$1(0)PBPW)S7B):*<M6+P7
M#4GB.(7!L-^SW99//+P5.E7"\>AL<+?&O*MK&#4E=V/[NP0.XK.S8;K0X;!4
M3]2(7%_W+LT6VDO7N?.>AF Q!(.$TS$A%V;(T3R=1&E+7%280]C8Y*JMKJD7
M+7D;:Z/9]V4DXMZ:70R-NROU^56E#E++$(5!C-.DRH8Q9, P!"Q88X""T_49
M&L4Y<M\^O(FP#SM5,[SL(''?]*/=ZD$U[+"J%+=C8A\>F:ND(2&6B5GU';SV
M8700<]7:Y)504&LN(VJV3QYX)I2*&@7%8F[8FU!+\8AL !REU-@%N;%9DC=6
M2GT;Y13YH?86+E*/5D_/*0K,*\D!!2P5XBX1DB1FAU3PRL<0K?"NB4[/1^D@
MN;8MS2]G0\BQFE\G\9H:&M3,4^Z\GF#W4#UJOM71EW84B["]9GOL44F39'5
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M'JYM1MYZXMT;[OX2.7@'('R+#IJ_\%([D7^/A.P;^%=GWS?_+_R8F1>+-V@
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MS70B_O%$_'SC\8A[-/)T0)B(?8"X6J"(ER1601@&B1)A8M8VZ3H/'JHLT>I
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MIXL"/AY:N'U2B'[O7!36HCTZ-:5!CM5F6&+3:5!CL:N*P [4SHR=P>7E"#[
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M\&GG$!C??0!7+Q8*4U0UPSOP7354N_5N1Z\=[C+V":=UM+-Q.<K2RR<Z;+=
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MSTQW]>TA(ULRPMU&65B>&RSN ](#4+:M^F,O=CI[?<=Z[\+T\@M,J\5[78J
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M <!A9W1\!/9"K_\NQ_@<XSRRE0=%U\:WCJQ6CZQ^;GGWMD&TO 7/SUXPB29
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M?11H>!U&RN3H/!T7Z'ELW.7VG*Q,KBGR6Y6)TQ0::0J%N'<NNL8*BRIT#C^
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MNP]CN;#"4]600E>1-E69 /OV20N>FO*PL';=L4"[R#C<B2KI&(,*[ I>VXZ
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M%)TT!=C: L-D]FJ=%4:-^I>8J0>K7OVUWBO'&.1;]OYGBK9LUF25N5?1$79
MGY#1^LP-&-U546$S"MOUW%$H9G[:850B:,%(\1H%,Y(H%(LBE[D+UY:7[8NJ
M,&0M1L(-<BPQO7&4V4IS5KZ.,<_2NGI<Y/;"\7=L\.S8@#5LT'9SSE%4.3['
MF!M'.;#9(T=:P[P)84>2Q-3@.EVBG6U:)>Y.1^;?E(IF8="2W"6Z2CD^BY/G
MKHW WL2<96U24Q0VK61P;H:E>\!Y'TO(58=/86QJ1:'G,COJU6\A(.&P2H_6
MB ;]91N].F_<29"%D:GKK<2&NDGSPJZCZU>5JEJ??'@N+MTG\ NF6KC$[,%Y
M/[\T6 !O:-*L3LI0JAC#Z+$ Z+ T+A&C3GF8#I:M8V%M%L4/=T$+M,UG,-^H
M7M&J)\,]<O;%CB@PHZ;\8(K#4Z HEV[QBF/0O;VCS\<^5]1XL&PI-:!T:L%)
MG/J,4$TC!?NDM*=F\RZ,]A(N?"-DY',9)K$748]+WTN5$KZDLS'K_]A=-IIL
M@:HH3DS/KG_9:U4TG5<-GUD.Y&+Y>.U*;>[#25.E5YUC*=%3JW6-1D4FQR[J
M'8Z:K8'167D)(F-WJ#90C YRG"&0[6G>!Z%88H.;/E9:&$TJ#H\**QTOW855
MXM7ZC":*I3_=[O1$M3NN!AX>:*7;IW9M"#TNZJPP5\)HH31Z7$X^5*=&C_OF
M(*TIJR*L?3OR@]31UVO/,?'VMC\>F]0#P*92(GF(11PCX.^$&A)+35G,O"0,
MV"Q_2^![:9!$8]@J(1/-1!B -. Q8W$\EU<UG1Y2Y6I4BB86JZDS)1W!E%:O
M4$BIZS6%60M%DX4Z *36U#6IR9/4Y#E/E'6)6%L:N[)U-.S@RA6)$NC0I0-B
M50[=&T[X[O;<-I6M EPU!LFA;;K* TJQA0+EVJWYU;DRON=M>,XZ?=MDF8AN
M1&SYUW?.DO W0C]YC)2.1QKL#?-/[IX"\)0!J7=*ZDA6?59+<CHJ.7>$]E3B
MXLGAIE,LTH6"SWZR,T0=IXGJ?_99'G?:X!L$63^O".O[YF8\2%SZLULR^KJB
MR_^Y%=(F#K7<J4?U@SC^GY$#W"W?PY;M)FQ6[[A2VV@ILW_@ODU[R6&GB<YM
MYAL^OG&5L^>IEE2N\GWX_T?Z=; 7'&Q__ 'JQD\8X^G!/U_0W4WWMT^_[9_M
M7GX9?!W,N<KI%XK=Q+[\_ 9CV;G8W]YC^W_N!%_//@WV8<P'?WZD>V?_G7T=
M?%T4N*UI'%./&<)XI$&KD8K(*!0D@;\I5SS5@;>VR>AZ$,3/Q5/^0,% G7RX
MJ7Q0H#ZI4(<\EHH+(R2->1HIKCTO3(5.K7R@M7R@G7Q87?DP&_>L6.KY6$).
M:ZH(-RK%KA41@4]][LF4B22NY$/P7.3#K>'1XC[AJPN/=M(4R[L"&K)&&O0'
MET:-"^M">WL3='W=$MP$7/_R9SP0['42.EGE#3ZT=NC\?&%6Y6W.K1=_-#TX
M=-T=*N<FQ;8S:,]TA])6R_1YE-O/_D#?P =79'ZK*,3PQ%7\ZXZD6QQ)^^_F
M("O5AH=Q"$ U3#R K+$A@M*(4"X2'>@DU!%VK'NH1,-GBDA?/&<_..CL./M7
M<_9<6VL6I":)*3$"-%(>1RF)8V. LSV6@*(:,@G*:/A00'.%L.2-,<>3,BAV
MT?AN;%-+YPFW;0WL;\BK=T,B"Q;D1<JK!T,BML0!;,7?=B<L%-P:NG\_XRYT
M4N@V4NAP#E^$@6:A\"E)4AH"OO 5B1.6$M@[+]&@62F5K&U&]+Y2Z I)\%CX
MXJ8:6,>O#X@O.GY]6'Z=10T^8P(VAA*>>H)PRA,22Y\3V\36!"HV,@5]@(<K
MQ+"=AV[&0U=%$W4^NB>'%]?8X+?=1LV9XCLK_(.)N'DO'1 X5V%D2$C]&!2C
ME!(91R&)F/!$:@3W$V.M\"%_;?65.@FQ:EZZ3D+\ @DQ"X) U"=:>0GQ$B8)
M9RH%$)10HJ/4,,92J@2S$B(*[XV#.C_= _'OUG"4D04NNOO84:I=J2*/&2R]
MSL<8QUQ/I[5M"[Y]\5+PP7$2;F*]AX?-%KHRDT:_+_+!NTD<_D$ZFSSEJE)V
MXN\VXN]R#B#QQ(N,83%)?*E!_+& Q"$/B8Z3Q M#/TA3B>+OWNCHX;GL&=E\
M.MGRBQ%6)UN>0+;,0:N IG P,!+)")0OWU=$I "RI&9^JD7(N!>N;?KQO>,C
M5T>VS-4:FN[R/$F^[[H_-]V?V4QI@M9/'*[EO-!$4<"-%X$VSX-82BZ5'U*3
MRCCFD<^.?=#OUS:[IM%=T^B7US1Z22V%^&F2SQ=/@6T\=LKUSO^,L]'EGDTA
MWQVB-]V&CFQGI>KG6()C1?*L?\#IR_^B7R^__*/"+V>?@_VSOP=[9W@/_+X-
M)_@_NS^^GNG3+_0CA6?1O>U^?^^?+]_UGW]S_9__[G^E_>_R[!Q.]6]T_Y\O
MES@^^!U.^-T?7\[>#_;I^S,XE6'<6"/P\X^O_=C?W_X&X_O,]XY@'&?J.(F9
M$2*$$S()!.&&!D0P$Q,IJ!\F042IIK,YU[Z7>%S&($BYQ^-0Q2PP+ T8#30U
M<>+-YESO[O^]<WA4<=A56<<+TXBO?]OTZ*)8RRCR(E^EE+-0Q[&DD?#2F)HD
MY299>Q8U&OXQ[<;&O6Q"Q]BQT%5#P*IH(UNN3]@.N7677=L\M_[VS=K?NSMK
MO]E D@MC\\YM?GL!D+BXK,J^J Q_QS):F,3>.Q7?[>OG._*Z)/+ZU74R.XS
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M@#XX&F64#4YA[UVL4$"-4<"P:S:8:A1X?!1X?[9/"196"X6DC6 < U(CDXQ
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M%B093QA77'AI= HY2L,X^)&15(O;\Q2W+P=G^PD;";2.(TEH1#PZB9S"/I^
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ML.'XW,LX2@90<2[W6A^D/V-5@:17%1D4,._\P1/S$CR.KBDHXI+ MPDV;CX
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MA(8_TAN<DN0:S%%ERWBVVT\<S-#NFUGWN'!9JS^*PQS0UH>N?IB(W@JE+WD
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MP%Y<5OY9TF/"":PQ5O-$+,?,..R-EQ0L<8<%XY7'!+@%F4*^6G >(#C;ISN
M>H1F3R]'R8!1QW&*R,F@D32@L2$H,/A":=XM2A1^H^#L^%$_BT956V!.=&:
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MZPNZ]7KC+=:I6Z^IT1GU1<I5)'@8T2P-1 P_2KFD(HW9W%NOJR6-]7<0"+:
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MLA$$%@5Q]XPGBFN+8>7]*;S3,@>XM+PLQ[V%66+13R <V,U3O-4  JPGI@H
M"P^9P1.VAB.:@RC!G0&)F'\B!I8;A5>([EGG^@AM!C0$U.7*6T^&:3,I0L,$
MUPKK;= LHCQ0D1_( &R-5*(!XB>E 4+]FR[][UOO\8'YLWYAL[K<(U_T__G6
MQX\OP<'FL0Z2B%$>DR!*4NQ;S$DF D&24"EFHE@8H? BT]5K3%ES&['4X9A&
M:HJJ?2P-(FR4=B[+.>.U!.<'=1X:ZPSUDSI+X,H5>NI/9&"7<.9ZTM38!:A2
MJVMU&JC%"]M)'$.#XXEVM2WJ#18+>B@<3@YT!3U5J5('0VXF_S02Y7'4BIL:
M:MQ$UGM>E"@T3FQHKC;]HZJW/UZ*JY91.,%;E8[) ,!@[VV%9NL?L=E:-N_U
M L"X.,W/QA6,KTZJG'VM6^-+D9=QVVC\!VK./6?'($O?B6E#L UUE$9&<:Y,
MJI.$FD!+DX1AS&VW<TK]R(](]4?+M+=EVOUM&._DV*=I0$5 2>RKF'#%8I+$
M04*"+ I$H.)(81$J>K4TRR33CN]\6$4<=(&S_H2ZWC#/K@B+Z2!")3F:K)Z!
MB835@L<</T'?ZZYM44\[FHPL:U,7 ZE9<"IK?:RSC!6>S:V:Z:NB2XU)5*GK
M: 662@RR5<7::*/B[ :5YN@B$Y."TVH4N"7ZI*S_7?[<ZB38@F(TU"7/50RT
M7F;+#V9NS:FP1JJ+56@@_8F<J(-!?F+[B]3;<(@)%Z@G;I:/6Y=#8:WIQM4=
MU+;+!<$96NMT"$<WGI6=_' T !-VP]OL3;M7.^+"^SK"VQ.OUC;?_[WVVCO5
MPIX>!II.=<=Z!> C4#&JV!4<6K@!ILT4B"?V.*,J..,D@RBON98WFR9^X<X_
M0L>M'I1=K^RE@?=_U[- H"BL][X\Z.91EB<]BZA< *O^-2[&7E6R-KZ]HV%]
M"M9+#I2"*-T8>-R_;Y%0DM*9'U"6I8P"[HD@-5&H$K 6@TRQ*(TQ, U3I#2Y
M/H)DR=)EL1R8@_&T]H321_TGUASD$2#SV_?]C\<,L_N8+TF424FX3B*2IF%(
M&/-CH9@(_00@D\V(5-?WM4OBJ%NI76BUZB2Q6QG&53Y#2R-S:,3?^W@<ABR)
MXB0C68P-2[%K7\+3E"1)9E2<:44QL!C.*'GFU2FN8U=$%2I;Q[X$#I;F4HH5
MM-,)3 D#Z9YF,N:4 \4D+/.S*#9!D"5*)<PJ4I96R"RBF:=(;5F9#B3B&MC\
M>=D$D!>K5GUC^YO'QO=C%7"?P&[ZA,<\(AEEC !T)(S*)(N47'N37CW]4@%0
ME<+TJE_*;Q NK0J]8F=]M(G-B6-IX)"5(90&(9PU!9,W2WP2QW[$3*@%-W*F
M"OW:JGREZM8KM;<J+6"LM99:VA9 M,P[E:4U;LC90L'*D@<[V#Q6+(V3((J)
M\+DBR(0D,1$C,J)4Q2S5&=.W@H*Z$Y 8G(RLJ\"%GVP^!-Z]0G]L5X.2KNK>
M6(7NZ-*W6?K/4%]%M^>YZ.2J-.'W^YC?,1J@,H+MB7J8Q'$"6K:M&59=KLJ[
MY>VNAG/T6DJM=&2P#N;7+ZQ_C68,ZD76,J@<M8MJ13P*(V483Q,L= P2. %2
MCT2D4A[25(8WY7]/:$5.5^^;AOZ.E0F&_;'Q5<OH2D17*VBUH]DLL7>Y=W$L
MXX@S!MJ1'], .V*')(F8(B8+1!PKP<,P0NWH&@WZU5@[:G24JD[AM5=:9>/[
MZ$5E]=I&=&J$W8+ZKAE?7MC:P=5=^ J(SYQ9; DSTQKS% 5VX+2)A#9)Z!PM
MNM)61IZJ@LGH !B=N9%G6/IU-,O>7.\X3LVT[:+6[;FTP](5XI*-G#NNFE[E
M/VGOH%]S!YVV=]#;.^@O]P[ZW9.D5BH$V8B H)?.">0R%:1T3#:"/PXLX;,9
M,9&F5]&COJN"MF[5[D&6#]U;0&3T0 S4H:9-F\0&S_P%\F!XZKT7%Y<(Q)ME
M,BS^9)S',U;(FJC]/XW4W]+3F _&4%_EM==YO0M7ZP4=4F9PPEA: *0J3S,5
M^#)B(=5*1XQ:1U"*QMTU*L_NY'R>T$6W1]!A3BY!K6=^$F1,<!)'>/G4Z)BD
M<:R)P0J:8-^S4":+EF;5G(6I"A+%J< *$I'.N) ACX(HI;<NQMDOBG%Z[*5K
M!(V:R7Z_;,39'NQU!VNHTB%/4N)K;/$7)@')A$@)S0PU61P9X#>\<7:U'.=<
M;15#!J@*.M^_#=^6"?*BO(-NN:]N,%X'$# =W@:;RU),"V3Y/_&,DVA]7!BS
M=]F,^C3S1+IE%E*5+V*1&Q.AWME$J,,RPKCNO=]XO[$USDRJGFC4:[2AZ_5F
MEN',^&31,'RMV>I4@V(,_M64ZY"^G=1NS^3VA/_" ;!N53DI%TXJX_EGC6 ]
M3N)NT?J)B4U$9IOU^+9A2]%Y,Y$-$5KCIBR6 /^.YQS#)W<(3BQ_TE5TRR[U
M@^AT-5@.WKL_-V&1[V'?UZK/UEXW<GJN[@DNX+WX!F?04]5/JW^[![;<JM9<
M0MGL$3X 874ZHJA&V.IH,;C O-KF&%A_$;>^GFY5-=?N5.UH%Q/NE7%HVZH+
M>H! ZBAC3'9NPRO##]BH&0!<T*$A> 02/8P5#R*>13R),QW'F:^4%#&(&2O=
M8S^YE4.CC?S=531\A=5='+/,3R*M*3$!C0C7/,'NKPG!AEHTE3Q58;KVAO'K
MVC14T>:99.T(#L@!DW6NSW6;Z=P-,LI$F$8L2;@,_43P6"O%8F%\88R]9H/$
MXK+<KE!-Z]Q=A"(D>K($9U'"XY@H%:2$2\%(DL4^232G)J(Z#%.@B'A&4X;:
M[UEZ=^]4[F(IZ+ IAR/1<8?\P:%"BP)SSISN?3R.?*TC/V7 ]C$V9<#&5BK"
MH \V4S2@*Z;Q[!I&-0C@16>[Z]7IU_[ND:N;MF#A@KO1P32_[PP&_0&6*5C!
M @6/<=A8G9^RD,6&*4+C+".@M@+D"X!\V%ZI)(]\/]/8O6I6RV2-^^GJ2EF%
M[5Z*0,9T)F@2*M!8.5=1QB(5^WBG+U,\XVFK"/P<JCC!-O!!2 5V2R7"I#[A
M0H<D,TP3+606Q'Z4@.Q=>\.O:]E0Z0&SE=-[*@+&#WT&$I]FD>(Q5XF.N:]#
M,&"#0 C?M(K ,BF"[7\\]HV/R141H8('H CHE"2^ST@0"9TE-,VT,C,[JR]'
M$5@*.K2*P*W/_-L%*']:!W&0A!&)4RQ9 Z! ,M_7) :5VY=9R)02/UD1N!L=
MM(K ]8?M[V%&5VADEB3$%R$<=F04R;2?DE ;S*!/E,9R/#<I D_0*7?4-%8_
M-9QO8[=/Y:\J:3C3PPN,E]=9W=:UQ*T2-&X]09E+TG9>F(88O,<[0ON.RK/E
MI=4;-@OK.,0+TBA+Q_G:Q4ABC-^,.MY[FP*P:T<H_]Z]4NC>9;@XI]B,R/X-
MUCV&=F -(^D<C(L ?,B5H!S8FT49CZ1.XD0G+ 2*] .0[JXT64"#5OU[4"SX
ML7<!ZE^4TC3QF2$AS1+".9C^640S(B(34/PLR<*U-T%TG1^HN@]['17-T0WO
M04;:]U,3TCB(04]1,?HN9 +F#0N30/-4MV3TD\B([Y\<1Z DR(SZ!+8>;,LH
M-B2+,5-<495)%?$(2]ZQ68V1&X&EL7?>99)6V#4?O.J.)^/;,,VKML.; ;\:
MX4;4MK[TZJ[/YMD@[]B^]+?L-H,"Z@S3NWHGI*/-\/=@(P@;GPV<F*+NTY62
MF%<B)F49O:I$QY7]OX'GJQV?ZS9V7<-</Z? /FX_8;[[9+U1@;]SZ>@&WU_E
M:+H)V!C3G6=A#WO67:AJ;96%@Z&RLK 6AKVP!$HV&I:%MQH!EG+(T1E2T(04
MMRET>4\.7$58C()9NPF+H@U&-B)8Q_'<7;JJ4H@-42T$F5S+($XB@$C!P\ 7
M6:J%9JE461KY(;MMR]2IN/RFF^AF75SX/UA:L<7+V9'YJF[?GK__=2<\IHG1
M,F0)$:&."=9, P$L! F4DMJH-&4*O7+Q!K^A<M^"XC/2H5  'FD<!UQD8<I%
MK+0PH:*4&FU*6HC8G%R;EA:63 M[_G$J$A8%?D(491R4,2U)ZFN?A#()1<BC
M)*4^*&/AS3T%]/?I"U=5</YVZOV=/#=^&@:"AHD.0L73+!%!(H6?":P]#'J^
ML*7Q C]VI?$"/YU'6U8U.\(IV*))AWHX=-5:6E?.K<GIVX]CD_A9*E.?L$RF
M!*RND CF*Y)RX/T@8#X7D8WQ7M7*)J'EU>-1P6P"> ^&;GMY\];$\&.3'U.1
M^@KL;")T !IZ1K$T+/P%1GB:18;1!$-]P:QDL$EBF"B),,:3L\YHL63/I=%)
M+8GRJD31F%Y:(KD]D>S^. :%PV1^DA -QC3A+-(DHQ)S *B6@E.>2BRA06?T
M(9DD$JN[:M6XQ6)+<F,SU$;=B^'I0&O2!:HXK?+%7$>K1E?74NF?)[[F:/=W
MDE^)!#Y0ON)<,*[C*$L8DUE"A8A#28/8423U2XJ\P;70RJ][4>,>/PX# V:*
MH40!^Q,.VA%)J#(D5+Y,PY@K/TUF5R>XA_A:+A&TXFL9M/#Y\CB-:0HR0!*9
M8?.,#+8_U5E,% @N!:I, E(,4YEOLI*6);V61B:M]%H.C7P)CB.9Q8:G 0!$
MH@BG$2@[0D8DBF.>^&$<LP14''J3]71?X57';,J;P<%TE?H+[5T,^K8N[V*)
M,T$F!1!>!,0NN4G2).-9#.*:1\KX49@LK#)M8KE\3+1_VQ]L]T?9T(PZFV4M
M_O%MBW\&^5 ?&%.T='@S'9Y<'*LX%1D%53OB&4<M"K JC4&5RG@2Q"P44:"0
M#F]2HOJF<8FBZ6MT]93KJ[5CEZ"MPH#%@UU]O9LOXJY[HS.+BJ<"_<SNI?8A
MU[+^?ZH;Q-8_7:R[NVMW[B.2\D"*,&62*= F,Y9F*E0*_O)YFH:^;B\&_51:
M_>8?\RA5,9B$0*LF(M@I"C3^4)-09#'U R4IL[D &U>K.DR!9D^YRFKUA:!A
MXZ+0O6\ W2[*LN)=#G=[966*)U?JNBR"7][MQ)M 6(U=#[!SJ6U6,KNM2EXM
MN"Y@W:P%I;MGG?ZEQJ@:WDD%P=@?? -0*JMNPKA=+(->]F^!$0SHS:XZ0J,'
M3=4W#[#O-,?+9HB&(+IQ9E4M[:OS<$U6SEWQ4P#005Y\:]3FUAU#[(_*I0I;
MI7 H7!'FL_Z@V<)I7)W9184L"B,;G/1@B]V]IF:SFZF-<A.PFXAP;.]K 8([
MS%88'!_F&'KJY-U\6+<;*%6.NLZA<"_'*WE5Q?CF7MLWE7$S*QKZ]M^XDLFR
M+.6?U1@VFH4%(:IGK2%>S==Q?-F8!F2!K2V!I:*[)0^7-X\ "8;]@;UV9&M;
MEQM7O@L%UB#'6I ;WN$(UE*-T CPNEB9*TF)M]GL=XVPFWUP=%9BQR4V0;!Y
MI_\=@2##PK8XF?PIWB3$WJ*.01ID?.IN6\+.V68QCC86S<->;E<O=[&\AKA/
MVC)%O_<>I]9*XSF];B[@W<<QESR@/".18'@-PQB2L2PD,L8Z!WX(GQI4&.=G
M3SB0ZEVBOI>?NP9W59I9)S? 6$A&U^#K-&T!8Y7GMPJT]8^;^%9CPBVA+49H
MWVU3I205AJ648"-A(#09DBQ..0%[10<LUDH(@5Z4:Y*]L/< " ?;FL!1U1S!
MO-($]:$QY_?5E%N26K!/U][7+\=2^8J%DA,1:8E7R!(B IH0&4@*Y*9]B06P
M_.NPZRI)N79\*RWNWN(4:XK9*6?6$LQM3$^Z#^\\]B-!$ZXTD$HF")=Q %*/
M&:*I"%4HC(AU@I1SDTL7R4?(DGQN4TGL=FT*8W]6F\+'M#:OM2V3!V];>*A/
MT"G]R1H"H(FO7*]"ME>3]'^Z^^]V@=QV+__=_O@#_G.Q]\]>N+]]^@W>\V-O
M^]]O_W[=#?>"+U=(>O^?+_Z7K]_8WM>_O^UO[\-_-K]_^?'-/WCW\?O^U[V+
M_>ZG[M[7;S_^_8H8^#G<^WCLJXP+D\0DEDF&W4)"DAA#":6&92+)TC!.IEO_
M^9D*?<$S;JCA8<S2+ F!&R*MF8$S,=.M"@]WWF&)+V]W_^W!I[W-H]V#_>L;
M%#X!I\+L>E\W[\SD3J9^&,%X*&?@5U@)5@@@;)91*5**50Q0HC3*;Y6=_,JB
M*&A2GL$W]J92U6T C=.YDJ5P?% L5[PT+BY5#%?=570<A^[-P_K5#0D#VR]1
MREQ@W1C=6Y7KBS^=&P^V=X]9*L(H5(KX!D/&4AB22,-)$ 6QHC**>0(RQ<#Y
M7E5'!O4VU\W:O.JL?_=.L2Q+Y:@JZU:NH^PIK-YKKSU:'R@0.(BC$:K ^*%3
M:!J_KL:$L^_8.[&@&U^ \/(&MEGXN.EO[>K!']M,Z[%QYUH+=<5EU:,8!D)*
MMBG! ,DG>G"Y7O5AE$#5/1 (*B\JY1RS)VRM-ZPTVNG8M<)G/6T+.14YNKID
MV?D!S<2.MKZ7O&NW""8_%,6WHEI;U03%K:MNI74F0$"[A/UZ>V P(%W7_:><
M0.<2IS!FPM+EDX,:B*B3Z_(]DWL]XVWE[UU'@JE%V(3LHBC]='CDYSD&.'!;
ME0!L YWR')98+FGJ$*^>V>1XVL5KRT,J9^(V9B@ZZ\V=L#?']M^Z86$7ZFF[
MP\X=K92]Y<LB3]9M7A9X@AWLC+J]BC8:':]=E B=Z'GAIN)\=,T2@_J[EB,[
M#T!O<:+K*Q!3'4^*T1F>M&=&O:H!Z-D D&J .]7L/%K4=:G*'MZVP6C9KG[=
M]KJQES_MT7<ZNAK-]KQ<=[25NV?1!=N8EO7XRM&@_ >\^YMVHTL8TOH2FY-&
M%S'\8>N( ^6/8"!T%0*G(R=-+['?F]'N>JX ?7DU9X.VYFQ;<_;EUIR]6:=\
M"OKU+H;F>CV'N>.@W$#W!R>BE_^H'+\ 3A;)BO6F5#@5KC<?AG P[M35HBC1
MN(K?-#2F2E'ZGTK3ME</;&W]5V D%J\WO!UCW*6M<?':JG+^A4;L[CF8M)'@
M 8R,U69J =1(?SC#:?5'A15%91_J*L!\G? N2^R.!Y^6<C8D/5 V?Q1+I'=L
M^*ZR'%#.8\=7C%19I60RJT???GEU5=Z;ICI+;;3]O1I=L0UH>,WG&A43RST3
M5BL8#O)L-+Y'-O_=&:B'/5V=<?7VRV*HNS8MQ!9P+Q.A7'K3!YM14E5WM%IG
M665>BF+H0JU69ZB/P.5H>)=:H/]8HQ[EI/+M;U.N#)OMC7E&GXO." .753U%
MJX"Z;A>=OK3?C)62K-EN\@K;E(DX,WBLJH-9$G]1=N'K5P6838/$RT[B<& Y
MG,806$8,'254%?YM0PT7;Y8U#;BNO^7P ^P.,*JT*%#571J'TRX7&O?A?538
MU6#4T0=FVENU.U9:_[PLOWS)?JO]S6/E4]AFGI!0&#"6,2Z44D:)%C[3B8;O
M(CGM;:&9'TKX+O5CSIDOLM@83E.NP?#6TESU6U4$Y7)^JO82==B^S$F3[HYQ
MW6]5GN;:-'BB[E'8%=_&EW<'90G9<E#E')(XJ@:CR'M5%5D'6"^=Q2"'[N(V
MFP\X,]6'&S?IS?^6'%U9"BAT"!I(XJS0OU=__(%]<SKB\O>\9V''_NB/<EZE
M>8$V"3:O1(.HG)V=J/NZU+;3>",-&2K<PP'\1U4O+G7Q#:N+_S945[_CX49*
M^=RO_0TZ][OKAHTWJ)_<:=3KOP.2;>?:SO6ESY7>;M3?+!HX1 #,01S\_];8
MVMB^M[4I?@_.OGMT$@"QA,4T[#C$6;82EMRD@UE'@HL(UE!>+GR\IELMRBG-
MC[.L*[:K7=;;\I;;D;UKL&?O&I1=T'?L70/;AZRZ:, FUO]R#K=>4RE'K<0^
M&WHVF=BKIO>D#AZ+P%N_E\NJ6];:?5SYVHO90QN7:/?N#GOWH8RU6!K$B[7M
M+MZ% M'%LNE<+.TFWG$3#]#0:W?N#CMG;Z OHA-D0GX[&8#-K$@Y12FU-N:Z
M9<]2%F#O?KXOSBYY7P^KD&3EMIHFG9O6>NOS][U'U9UNN2._/-SZF^NV]P-7
M:N&+7$L,DXC36"0ZI)S*0&B8FHRY+RCS5>+?.C.T<D,ZK0TA_Z 1:OGD"!)H
M],!\<&'_LJU3^<T'S&6P)>Q6)4OTKJ[)TR_=[YV#[I<?^U^_7/R[O0]C;P8P
MM_#+T:?3_>T=^-]OW[]\_7*Y'WS\?O#N/]^JW\"[1O\&GZ-_O^[!\W]^VPM@
M'=M?@OWMSNG^NQU_[ZAS>G#T-M__NLO^W=[A__[SR>SE_O?W1SO#O4,_@'5B
M5?LDPV+Q?D;2 "MI)9J2)(A26_\HU$$8&R&Q]-&LBI2SS8VEL0U^NR#[7">M
M;H+L:8G7PE\+?].E $,98;)^'/@1CWR%H6X_#D284A;3F+7PM^KP]V,*_JB(
M9!"$/@F-I'C/)R"I8A%A2H0QEY(++.=/4S8WN;Z%OQ;^7@C\J52F(94IDVG"
M.14I\R, /RG#*/;#D+;PM^KP1Z?@+^!8$2JD1&$M.YY%,1%^J @/:)3J1(1^
M$ +\A3/N.;;HUZ+?BT(_ZH=Q$$9A&F<9!_,HT3YG@4Y2'F1)DK3*W\JC'YM6
M_HS(-%><9)1EA,=!1 1(-D*36!O-4Q.9 #NZS2N;V()?"WXO!/RTU"*.TU@K
M"1P3FR2PW4:C!/ NC&CZ&.#7O#MN\N]:D1]ZT&]!<3%0#*= ,=(F8 *;G FN
ML:DAUCGS(P!%;H(D5*G1$68:) $-_FB!L07&EPV,2ZN5T6J%CQ41 ?"S49']
MKS#OKQ^/(P/G2"DC,4 =X4:!6BB4)$D2QDG(*(U9MO8F#*.GXQ-<.)QM[/\]
MG7#V5K\8-FZ$EP7]"KQDA/>6]=E 8R5!.**Y"1+!8MLQ$\*?-)0M/;B+AW)@
MWO7[JMCLJ1*OBL-^1[48M0A&75Z)VF9^8%(E?1*RD!.>^@%)PY21-(U _("F
M%OH4PQ;Q_1UWLY'@0;6PJ5?.345Z\1R[]'ADR['+XMCI0&.2!EF<@#Y!980U
MO*@@@*^*I)'R U]2K8( RT?3^RL5+<>N+L<N/836<NRR.'8Z-@;*?Z!IJHC/
M@4]Y) *2B0![P0O.@MA/?#^Q+9YHR[#/EV&7'O5I&799##L=SHE%%(%(#4AB
M@$TY#6.PVXTAS$]5)AE8-T$$=OO<;B(MOSX#?EUZH.(Z?FTC$,O@X^D(!&-@
MPB3")TG$* A>L&L3S6(29G$4^E)&)EM>!*+EY=7EY:7[UEO9NS2'U+33G)DP
M%)E.219I0WAB@&EYJ$F<:N$'*36@3*^]8<M()5LBRS[[:U[O7,>9694KJX)'
M=W*(S]B'YX<_2W>(EZ<!V+,Y<18[[BA:$%H A/:WKGC%(Q'&RF2*L)@+PDT*
MI@#GE$12BD2I((J47'N3I/>WV&?#P&.F)K1<^V!.\99KE\JUTYYQEJJ L8 1
MQ328[7YBB$BX(:GTJ<FT!C4"N);'<QLKMES[#+AVZ8[QEFN7RK73WG% 5:Z9
M,"3. NS$%L4DI;$A41:8"&RU1&&:8+"T6\,MTZX@TR[=.=XR[5*9=MI#GOJQ
M\77*2)SX:*3+F"34YR2D/I.1B++4I'CA85EY;2W3KB#3+MU#WC+M4IEVVAUN
M8I8&<9@02H.0<"XT,&V<$<6C,/9Y(C0#_3B<WWB\Y=IGP+5+]X6W7+M<7]25
M+/)8)$R+E% 64@(V;$*RS(0DB*,L@L/S=11CBB;?B%:(;Y]]HOAV(Q7<><6[
M6/;^1YL;_G-=X<US0 QJG$(+/8M S^$5-[AB 0T"KHF2H"9P'2B2:B6(S,(P
M\WW%(A^+.K1Y:\^989?N!6\9=FD,.^T!]Y/0@'Z 2:82?6F)("E-4C#0,T6C
M.- &8^?^_16%EF%7EV&7[@"_EF';S+5E,/*T4SQC.M:8]9+)B(&IGH*ISC))
MJ/:S%'0FFFC99JZ] &9>NF.\E;Y+8]IIIS@FA\1Q%!"ELY!P(6(PU#%U)/ I
MS1*?19F/TC=I&?;Y,NS2G>(MPRZ-8:<=XK'4- HC20(FL&2U2D@61(:$$<],
M:F(>TPCMVWO[PUN&75V&7;H_O&78Y3FDIGWA5,0ZD0;X-$41RV5&DLQ($D=9
M8M"^Y3Y;2MRY30V_/;,=U#U#EY$)/K>$S3/'H0<IFH*W4\HX7%O.:2'PN=K@
M0@:<,P8Z@HA8!-I"($%;H(P(*H4T4@=*F+4W01)O! ]=S>FI1M9?*F\_2'F5
MEK?OSMO3CG.E6.)S!:H_*("$!RDG:8@A=Q.K)##"L CT"LK3I>7&M+S]3'C[
M00JQM+Q]=]Z^TII &T63*"&^88+P-/31(R>)+T)F E\',LR MW]"8Y:6M9\6
M:S](R9:6M>_.VM,>]R"-F2\X)1E'UH;3(5F<Q42P. IYD."A82VTAR^\W[+V
MTV+M!ZGNTK+VW5E[VC>O?)[23 1$^9DFW A!A. )2348X3P#F2V2M3=A</]H
M6LO:SXNU'Z382\O:]W"D37OQ!6>^5C0$B9T";\,1D(0%DN@DX5$J*8O\&'B;
M\H?O%M;FNB_FX<][LM_5WJM.ORA>+QI-N0<B/>&6%HLM_MG \-+C&341[EH:
M? \4V"+Q(DA\M?H[2\!2BD-%(IU%A&<\<G5N@B3DD5$\3ID&((Z6EN&_&DK6
M#;D1+8RU,/9PH9L6QNX-8U=*XDL>*#^(29)0"?IDHD@22)\(,.GA'SXU)EM[
MP]G2"O:V,-;"V JL^C&C5"V,W1O&I@-5/ ;ADH+Z92)-"8]E1 0S@OB9B!,=
M:#@I[.RQM-M;+8JU*+8"JW[U<R-R!2P8_FKQ;.EX=N4^3!)P94Q*% LRPA68
MF FCSLV7^33SA?37WD0SG'P/Y%EJH:R%LI6!LB5$(%LH>R@HFXY&9C0(TE0K
M$B096)@FC$@:T9@PEF@X03 VL4WBS&ADBV4MECU%+'O,B&N+8/=W]4\'7:40
M<6H$)7&*)052WY!$4T.HXJD(M):9QJM3P=+N3OV4F&LUBXIT XM2LT'NQJ2*
M!AZ.Y\Y@@JH_RCIZ<O*W&*5]8?O":UYX0]K @MD!#R,LDEO)BMD ,5[3K18E
M-8B4P>,L*YZYK+?]@3<\U=[1Z4!KL@?/GWH?8*2^\G9Z2BMO3PSDJ<?HN@=R
M+9A8_\LYW%GT/PGX,S!_M0_^+U Z_C<;_/;F+RTZP]-EK7TQ#'GR>UB<Y5*W
M>W>'O0.0*?H]T;$TN"4&[2[>B0+A;V]3CO+AI==NXATW\0 $X*#=N3OLW%%_
M"!R\@$[P]"M![&LX,=<,TQOH<]T;76&Z.V?J/G??T<+K?S;NH]!PE?I!DIC
MYRI+,I9$B1^;)./&1,I8]U%0N8^"F]U'3FM#R#\8G(A>67SGDR-(H-$#\P$^
M < H&[>6WWP8],_S IYLG4T+-7%UKO()9U,J$FET%)) :TXXE5@U0RO",A9G
M 8MBWYBU-XR%#W\S[V<[SF^XP=/B7XM_4_CGTT0F"<4<GX@G:92Q-$JS5)M
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MB"Y_62UM'<Q'N8%:VS;(L@L'.X.SO@L5>*_6KOYD[;7U@WJ?\]Y0G +T#4Y
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MTCY70:2(T'Y,>,)"DK!$$YDEC"8JIF'",,\Y6@=>P?]<B;#<*MGHQ0KD<+Y
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M?0#5D44BJ"0K_7[+>.)KMM&*S?7*LS?802 91;LCN% #U1K2-0"AO0".T[&
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MD *%G[QX3$4](Q9&#TX@XX4M+_!BCQ(*>,-Z8E8<P914R(DA3XNF"!MFC9*
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M)L#=8%QM,:YE,,Y@W-N*U7ZO>5KYW(/R&D.O5&1FHZN'$MG(9I5FE:_J%JE
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M $#U:]S#P F^6S>C$>WF%FGWZ-V7ZU]N;M\=9XA])\D?ZZ,%"!OKLQ<X0%6
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M7%Q1J,&ED0F8GOCBMT(83ITH%B $UH&&IX A>13373=PBBA\E&8M<D0X)N#
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MD_T%C+:;]IOQB.6ALJON!D:C5]N^6)S+AJ%@G!_(!8Q/P9J<0IM<VFH?][Y
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MY,3L@_6[,Q/GU!55+9>Z5-[2K5<:#UYWN0?O_2!T9_#/.)[X?_O_4$L#!!0
M   ( -! I%83GO^!_Q@  -,4 0 1    86UE9"TR,#(S,#,S,2YX<V3M/6MW
MXCBRW^=7^.;+G7O.TGEUSTSWF>X]A$"'71*X0+IWYLL<80O0MK$8V4["_/I;
M)=M@\$.R QW=)7O.; =;57I4J50OE7_]^]/"M1ZH\!GW/IZ<OSD[L:AG<X=Y
MLX\G]^-.XY>3OW_ZX8=?_ZO1^-?5L&==<SM<4"^P6H*2@#K6(POFUE>'^M^L
MJ> +ZRL7W]@#:30^2: 67ZX$F\T#Z^+LXG+WK?CP;FJ_GSIOSQOOSM_9C;=D
M0AOO[>FT02_/WD[/SJ<7/Y]/_S;[\--;9P+_O6U,+M[^U'C[\]DO#4)_NF@X
M[R_HN7,QG9Y?VA+ID__!M^=T02R8F.=_>/(_GLR#8/GA]/3Q\?'-X^4;+F:G
M%V=GYZ?_NNV-9-.3N*W+O&];K9\FPDW:7Y[BZPGQ:=*<+*BSU1P?,'_EO['Y
MXA2G>W9Y>9ZT1ERL!#OS_(!X]AJ[$XA&L%I2/Q\&7I_B:^SGK'%VWKC8ZLD)
MUF#I;MZ=1B]/+!($@DW"@':X6%S3*0E=  F]/T/BLBFC#O"!2Y'26PU2KP,B
M9C2X@TG[2V)3C97X](-E(8'88LE%8'D9T"GQ)W*HO@@0[.+$BHC9XS8))(=B
M2S^95:;]*74#'W\U\->;)]\Y.=7O-?0;,T*6E7I.PT2]QT^JC"#%F>?OW[\_
M?4)6RQ]!+N_(]@W\LW%^T;@\K]!M$1/J]PV_&@G</L:PV6;5QI# /7,,N1NK
MB!=4D/*WKSF,_(VJN0@) ,[^794.?6J_F?&'4X<R'<;?;8Y_5&'U+21^L!15
M.EVWEW_E=$L\CP<2 SZ)GRV7S)ORZ $\0C[YD##+D$X3J9F1_CD[4O[S@0A;
M<%>Q?4^7@B^I"!CUTR>'1# 7=/KQ!(5D(Q&.?[AD\@9&DC3)=+#-\?CZ%$"H
MV]O,)(%%IOMXX@,-7!JMC<D37PI:=>( XL/)) G]_W[^-G&KSA] [-#]SYB^
M0Z=5IP\@S&,U9H_08WAO,5#<6AS4WA,+G]T/N\7JB^PR:IQ@2_!M!O+I3/[O
MW&IL-.2&):%^/=UMNX,E]*G3]S[)OW<Y.P:.FY0 [K"$-MSV6N:"Q0^3Q2M;
MTO[=J-_K7C?'[>NK9J]YUVJ/;MKM\4A[F0L1*)?^ M9[! M'D[5/H;)B7%:$
M[)4BX]& ")C5G 8,QOEL\FQC4]+J4I]6UH];N/_G2&G7O6OU;]NC,?Q]V[X;
MUR'8+@HEE=Z642G"9JW1'2E=UO,?]3NC<;_USYM^[[H]'+7_][X[_FV]>G7H
MI8M:2<=W973<]&+U.U:ZG_^VHIXVL*\T[K2:HYM.K_^UUHF6CTA)OY_TZ8=8
M+8GVB&AUUQS?#]O]3G_0'C;'75B=S0K!K^;=]6#8'L$2R9_]3J<+SUK=9F^S
M=KK4W$=72GK_C$HD\VV7^Z&@\"/J%>F[Z?=OUE;/%G1MI?O&UNO>4UQR1'PQ
MNK^];0Y_ ^G9_7S7[71;35B;5JM_?S?NWGT>P-JUNFUMTFMB4U+WEUWJQHBE
M^-V@MC:XK03Y$=&N>_<%5)5*>S,-HJ3"^UTJI*"/:)F;+3CB1UTI4737>0M&
MM=#G9[L+G08_HI6^[HX&_8HKO06C7.GSW95.@Q_12O?Z=Y_'[>%M_ZK7_=RL
MM.!YH,IUO]A==\320#16"L\1$0 ,P]MN)$I!*P$U!0^Q]EV5P[8,A9(@E[L$
M26&3>M(6OB,BS*C]&1>A>]?I#V\E6VHK/UE()1G>9A2="(F5PG),BW_3'+:'
M[<']L'73'+5W?FH3HAR+DBCO,D1!#-8&1>;!$9%HV.ZA33UH#L>_C8?-NU&S
M)65WT7-=HE7&JR3C3[MDC%%9$I>51E;RZHA(.[J_0L<9B)_VEPK^TUTP)6$R
MMOL&@R51'-6:ZUC, ^XRFU%_OW;X&JN28L^PQZT?DVZ.*2RQ!Q_8F$Q<?8KO
MKT,E,V3< OMTO0&Z'Z.!'!.[Z.W7:AQ1":>*Z!<9%T45"7!\!$UYRJI1+0NH
M)$W&IY'"<8QKGW:>55O\'$CEZF<\&VDDQ[C\:8]:M>7/@50N?\:/D49RC,N?
MXY[+>52-,)5P*DF6\7GD^@(+GAXA1;-^I8J*0!&\DE)91TC6.W64%-FV>*OJ
M97G 2EIDO!F[1O,Q$F(/5L\=$0)F\4"O:4"8^ST-KDS72B8X:-8#HDM&9/T8
MC^F8N$G/8AK2!^J%=$AM/HNZKLM">^M/R3?/\=\TK'@$5FH(KYRB3[G):D!6
M7+1<XON'Y)"\?I2<D7'FU.*,R<J2?5NR\U>6*"15B_ASXCGX3_O/D#T0%V9\
M&*XH[TK%&)?/<?@T+.S5@MZC/U+]O_)&L3L>1@ES;-HV#V&E0-I26#50Z0Y[
MONAWJ^29C">J$L_$ [&2D5B;H;P>-QJ$[! FOA WI'S:81[Q;$;<KN<'0MZT
M.HR0T>Q3R3D9+UHESL%16'(8%I]:ZX%8J9&\\DTA#;]2+#U!G>8#%61&1W,"
MD^Z' =Y6QQ(7!V$<W4Z5G)-Q %;BG&08C7@<5C00*S62H^2<5 BA(OES()4T
MS'@$MR(81[C\Z1A"W=._%(>2)!G7WU98X]@]!>G%& B.U5_(,\BSBT))G8PS
M<(<Z@-"2&(^2.K@RW L86*9.?TF%'(X/TAQ>++E/W,^"A\NJ"E%%K$H:9GQY
MZ0ZL30_2C$KZL*).CI*L.2$G+$WEA"YHGSWNS<84BS!-@HJ$K8Q72=J,NRT_
ME@6Z2MP/JJW84P.[LK"O5PIK4.*/\T/1^(_S5RJ_.)6;CB/[1)-RBJ<9_CC4
MYB[M3,D+&3=J#5[8C,!*#>&51:*UZU"*A^V0!-2_]QPJ6@)H'72(S5R&A72>
MSQC:7:C8X6W&>5K$#MBE/.!EIY;LU8JZM3;]OO) \UFFD XJ)4TSSLTBFAZW
M:51R*ZTN^:J@5)(QXVDLO?AV].3,)@_5CD:H,2F)EW7VY20DO9)L=Z%C8]*;
M=3T@!R@^0XJ5)S&R,J*S6M&!Y_2A)+/.K4AXNN[2BOI$G6K3JY5T>YQ,L'WI
ML?:F5:!1DE)]E_*X-VO1]<:Z!-/&IZ1<E>N3QTW#G8S.^N'Z<C1*BBGO51[3
MT?CKZ799X^CW5NEC+'P<UV^7=$22_#%ZA ,%NJ(]3KQ;NIA@_5,R\0-![.#C
M22!">B)+-@/=\YIZS'7Q^$F:RI+V'^"D8MP9R[*K3AAY=D\L/P2\+ CQEW3L
M?CR)FK. +DZLJ$KKNL;]!X<O"/.Z\ X1;0HZ9^8P@,YBX[4Y$U2^+9]*&80)
M,QI2&S/+V)1%M:_[T_7AWZ/$IV,>1?VI_)6>Y92X_GJ:5=%4F7KT;D)<A(<7
M=,("S06)GBRX!SM2K#26XRY$TO2G+9>PA3\*)PL6!-2Y6L&?/G,88"E< RW8
MO=,\?N(%=$:%Q@R;"U#CV%^R"^(YW<62,(%-^ [)AAC [T_O?=KT?1H43KL^
M0E.9X 94WAM*W&!^"_O6)H*6[_'B]B;L<*!/Z 5#> XT<#J"+]J^+?AC&4$+
M -33B3[%$'Q?>EV%/IP5OM_BBPE(&40>9U3_19VN VU!+N&X)=_Y3?O/D(%$
M;GI.#Q['KD!X%P*R?C"GHA4*K/I;SO<'[O4_:ZU)WJSC":=?V#9,UFD_+:GG
MX\V?_:Y]W5'4IX4M3_Y#GU;_X"#_O\ KT$Z+%ZV@=87)'>1 Z@$=*5T?%5+J
M#*D3VC)('_!A_YY(*L)H0Q>;X)>>1*J%!.$3E\VBP'[A"ARBJV<<8H=ECA99
M_D:)N);G1-'1M=/(A/,J?9KJGKKFG+88<-QDQ[; *%P!&T5':OO)=D/,?$SK
MPL7<6@>5J9)J*Y6GZ\6#S\W\V9&^L7@N7J7G8S9UT;J>M-!7R.DMI19:U-J$
M79&<U_(@]J730>8# QO/B3>C0^Q?>=HKH ]D6ODR<5EKZR\%M5G$:IZ3MHLZ
M7+0B=@3>W&2@E6S]ZJC,MZ9@)C?<7S);VY[*0IC S1V7"^:0WV%<ZSNDL8I0
M2-%2&%-)U_2!O5"6:)&MJ+4))-L^2[N@G,*>WDI-BI],^ /M4 =FXG;"*&5%
M\X"NBO2 RP)(;!R1>EW&C_P&1@3'V"T,1YI1#]Q] -&RE:*S*J=\52PF<,1A
M3<@!60D.D_2<]F+I\A6E5]2C4Q:\E$U;-B!3]1^IQ(&R2QV,O  W@0%F?UL*
M9I?LR3*8PVXYJ9/H'!_9^WQQQ$C6&1G3I^#*A4$7GR7:" XXX2#I14N1!48!
M ^6:1O]VO6T>+IRI&M#4HS.MP<4&1\>E-(@,-:V82A44IGLAX(08SWF(6: C
M]A10ZHWGT,=LGGHQ?@3(%3RG"D7C>3A-.'Q QB\Q7 9:0D!3*E.KVU1,70UH
MPOQZ- AD*"PZ_FDQD^>T-$(Q2E7\*'6@9=N9L/Y-^.E09UM!O5KU:'095QK,
M8P'[?TX[/!0*O;X>,B/6(3XGY'?B%;/,:VK"'# /8KT_8D5Z8V-<<2$XIDN
M4(2707%XNC(>4]7"V'YN.O\._0!?C7D2=XU?E:0IJ$%-U2AV3"GRQ!;AHNFZ
M_!%'V^*>SUWFP+'@;.W,6PQDX->(B];DV7@/$T!:AEK*M)2_.C+:*/D\HG8H
MI%TFCXZF] /UR*,?,D4^D0ZD"3,L\ ",>8 ?_"W>GB5 ILJC$9G264B$\SO
M# 2?";) U\\,Z+1"7RW.E"L.V8I(3"!QK(8WGYBOT-2C)GL8LQ-\<!B, A7@
M;M93'PA,DU>/?!T!1@VZ1=%-5^R7R6_\TE'S;%6I <8(\&:E8 ]1VDYRM!5G
M^E1"LN\IUU'+I8]E2.%PL.>85HCC*=Q2N6WWPX7S%8XYG-!G<"%J',(G;G_:
MX^CVPZ#.C'KV2L8IR\6D M#0Y*'FQ=G%^0Y98EFG4,[5@"9(Q![Y1M'%&@=[
MRN=4T-B$>=S18$3% [,3K7@@NP?K 2@ VA2VQB#&]7HD12E'E1$=*(B; .G$
M*V7D$2S=$&U:&'B KG?,DE^PXC0$!92I1@5LK//W-7>D"M $3DZJ O2G.4D$
M?AO43=EE1#U-]_NS<!KBD8_W'IS\+EIV8SXF3^7IKB40QCJ?*^0&Q?&Q9C8^
MML<$)(U.3#5R<EB]%0788L;8^%2JY/$4X_A/8*KM^P^I:.P=]^S]L956-Z8R
MUHC"A!R,T/AS[H)J$"L,(&@4P4$-R!>_;2,M=S:12/UF$/TMCP2.Q,&W(!#D
MY>XH5Z3835<=D[%;*'8R#B*SK__H@3DS9\L.%UC0&O-$@CEWXM>%*U(1BPGF
M:XN*(+HC!]K#':6.(MI7U-P$U2I>6#*#L4D/W9"RQ204OFS7G_;#P&54Q**]
M6*^HB,:,Z&!JT'%U[8T/)5UM5VO:"@Q&S'@H>1 E*X@6V&)-.(1LMD15,";-
M^L(CO.WBQ6+BIJV]8F_&\S$;L4)@_2R8[W.QNN.!*MI8T-B$?1T)3[S&:0>R
MV$ALW?%IQ1.K.B)3K63,PWN@8D7DW0L^Q1_+B#<7Q*$!]]<W?%FBJ;%X5H\L
MF,^I6ZS&[ >YJ1X_GWA$,WLXV]*$[9 6U$GXV /)TR;"P_3"*SKE@B8\#$8Q
M5K,KSMZ'??\5M%5WA?J*L[X9SDKN 7W'$9@A2-?SO066F%%'!E[B$-@7[H8+
MVI1Z;W1@TDT20^*CT%C*^JB-6*-8][TF*W_,H_,1$P+=*Q@<4O@:CL^R(_4K
M\0>$%0NEO>$WP (32PX]T'4T=5V' RN$EMA;"KB7]U0?(&,\:CD0= G4BY-.
MOV?&>G[_AAYN(SEF!\2N$WW=HMA5D6UIJJZ3"=FTE\SGSO/"/F4X7GX?C?"*
M0!?XD#HP+'1'RLXC2F%*X^]4\+Y'_QE[;<4M">QY,;%KHGOI^XN;N 9^6VSG
M\V:@10PIAK;M@,I/GVT'-BJ'3I[?A2&1E!Z=$7=$@R!Z$;,X5AI0&D@ZH*:*
MB7U6/TD_\9S(;/PN95?R.S;54YYDXO1 KL*Q6&Y.%30VP:*ZY6(&J\<?O:_
MXE^8 '.6*9(ERF%,F%7+I40\PLDFM+(_"IN;,)>=M*+4EPO7 :5U&#BJ1^%_
MC3T1LMX=/ UGH1]<G)V]+Y9^>^W$4!5Q<Y4=9I7L2?@S4HB8?84EMG1OPVN@
M,(%[!H+;E#IQ5F&418B%' =$!*O^5*.27@4,IIZ/Z]O]8Y[1ADM<@65 QH;S
M]FD';A=G$E@RD$]#GT9UF;Z+*:H:@J&BIM7_TKT^?S\8M!4G3Z:="4(C]ORF
M1)Q**A:U-V$V"3N23:;+4G#YZ1F><!>3I=5=. 657*V+QE@)@?F[EW43?Q6
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M/7SV&8Z P!]PE]DKM1]."6>(JVWGTUH*\R._L0ETVAQHSRGB7;EV^+ZZ,N*
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MUP9$:*Z*=K/ ?!^GIZ FXW3JG4CEL'A+$Y(MY)P[15 4T5<8PW2P%(;9UK[
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M(P.?+8?@I<N"*XJ76F_O7PI8G^*2KDC26C]MW=$[1JVYC0DY9%V!)8+C;&;
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M]?26G /'4$L36M^>;T:S_RW0M2>_)@.$?A'>(Q\DP6+*#L%Y1GZL$@(">3_
M \]12ENB:QWY?AN>P[OWC5AP\X*HD= ;WA7-8QM/R?PD4*/W3\($GV ]:I@.
MG!*8"GHPBM&>X>E+0,T@!>,U[1A>&G_70KCQZ8]>IVWDUH-U].JBRN&TS*^U
MIR]&?_\P3!^>C6;#V><%7"1SP$4L-#,0N9H#2+/V1=0C)%<D.9ED++3VM#O
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M2^_AC*"=8AI6;_@"[DHKK"Y@OM7NIELIZM9>E[M(N??NIBDHHPTY&_1U7A-
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MA,'1LE_C:\B.KJ5TC0PB:(Y9ADY)#7=H[LJ@A^U;M;/8QRUDUKAEY2_ACTM
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MML4M!"3K+3-E@I2N!,$.3N>-<+_3N"_=]E%6IZ>SH,M39(&GY)0%%U(&E44
MIU""4%[H$&SMG?. +?'ULSH"EC]0"O116*A?#^/E>/3^'4[.:RFE09"<Z:PY
M:)?)O1#)07"1 <NF.*6PYHT\8+;?/KOOK.^;$GV47&HYU:]GH9MFJPU/1N@$
MVEH/*H8$WNJZHVE;"Q.AZU9>XYY>@#LG^/T=.  QUKP&#^J^<^UL%P&4&IDJ
M: *(>5FND!+$)!04FI]6&#7Z1\?_[S&TO5-A#>,?U%7HE1J".BM;+[S0U[)!
MF1D(Q2#03XD,.G):<NO:?#U-Y3NGFRI[#8G[N.R\)+O3\I+^5N-J.&/+8B#K
M,^R>A^%DT2DQ<,N98@685*IVP/$0%=;:Z,98&1(/_@!70_M-XKB)>T %KZ'L
MSC>=S0/?%SWK!Z%$'6J*$?>&+"?$#)&1(270B\RC3-KV&A9["[8CX.%#T-H:
M%M[+1>-=N\$R*IUFEX*T3M*.8(0,H)2LM:)+ ')T#7=">*_RP3FY#NEWAO:@
MT35\?5 YC;4%HG*6F^ =,(<)E#4U\B5$R#HRD[Q)&,(#ME+OI5_EH[!.MU7N
M&K+NW:MB%<6] OKT8D*F"-DGPW$>N*A4=K3H&U=S*&-!"+$4,-'&(C(9(.@;
M,^\V/$=$HV9B7U.QZ;[NTK[,:1/76>$8.?=0Q;8HV1^1(63&4TQ<:*8>R$)V
MUU2.B(D/0=EK2-S'55EUL-Y/EE.<5S9Z,I[.I@.&NMBD'924!;E9-D#@+$.2
M7(H8A7/7"T/UP<L-Z(Z;:BU4LH8].U\U7;%0+PG@[^/)/VF!?A(^#F?A["3_
M]\5T-L]HS5J@,Y:D(&HH9JG1:+(8T($KS973J+8+T>HPZ!%0HE<YKR'$WI<N
MIZ7\$B;_Q-D\\N7740F?QI-Y'*ZRLI0L%'#I:WU%FGD,M;64YB'KI)42S?N\
M;@)S!,QH*_ U5-BOO.":^3XY&T^K\;8HFG>9LRQ8FJZ!&!DYHL(9<#1C8"*G
M)*T0>+U,6/>U8=.@1\" 7N6\AA#[525\BA\GF(:+X]Y1/CD?3V;#_YG_^'P\
M>3(F^VET0;"7H7/CT71@E?:NY-JYGM>Z85C+-2<!@F/P3/CLL^S$B^W'/A9Z
M]"SU-2S9[S!]92X_Q7R19C6;FF"^&*7Q.;X+?[R^F'P<3W&Z]/^L3DHI6MNT
MK,L:)@UD[R#X''7AWCOO[^S,L/6HQ\*,WB2]AA-[=Q=>8Q'7UB7#O&3MNTD8
M31>1B'Q@C4Q9(0.#OM["<PXN8[W*%,4'+;FY7LVT#S=E([XC(%#O:EG#H;V/
MF]_@=#89INHZA>F'@<X%"^$!XP/!T0[)4$X2LN%)>&&]=:T/6:XB."(>["':
M-9K>+T7C%7%P7O)_GC:RV.'>D_5SA9@#QC59OT5#BC4V+2<&SI<$Q6(HN42C
M3+<;UD[#'8&J>Y+MFJKF.Q_+SB&2A7,QFKW!>26B><.'9U.2W.\#PWB4E8]1
M.W*,.4T_)#)P8BE)%^^R-[Z3QC>-<"Q*;B+!-7IM=E)Y:;IDIJ0/!/,UK3YX
M<C9_!OUZ9=O4I+&Z*I%!\]7,6<QOP)755D4B*"=;5\W=HF(+>!$L8R6EQ/JR
M$II,X CH=O^*74/3O:/O5QCG(:%D4$_J>_04%_\=Z&B8+1&!*54[,!8'KEC"
MR:UUTB']KW5CEUL!'1&-V@E^#2UV/AB=KZG7T;P87;TE&CCF8Q:*YFT",9<%
M!2YI3LHL)C$K>.'=TO7O&ND(]-U>HFOTO7<L]M=.S&L$,/WY\Z6?%BV9?<02
MI'>0ZZ:J/ J(7M%NF[3+Q4:&L;5#LBW&0W5"[VV)Z%4I]]T/_1;IS9O_6N$D
M9[6>;"WW30:Z !>C!*\R3]J06(/LW^)Y&-W1^U#_W5;-UFKHH0GA.EB+-1.7
MG7^[ -RF:?J>?+D"[K!]U)NJL@,]]M?#O1!&D$D=C%&03*E;;6WM4M!!0A<1
MK:97Y@"NU"&(LJ'G^OWR9!OQ-^3'W Q[]FE\=E$Q_0W#V>S#LJ&WM9RL+$M[
M<LJUFYU'\-PB"*]S*3X5';O%BJ]]_(,P8??1P;BI !OV,5Z<_TRGP^G\*'>"
M?QN?XQ5@0@9TC@OPG@QJE80%)Q0'*QGMD!RU_-JJ_?93M%M&.2H%-Q-G#TO[
MVUF8S6W/U?S?+BS0Z7S5RC9I<I89E*0EJ! UN! CL.B"95Q%Y*:U0W(;H&_"
M:FRGDAX:%B^Q+%^)+F!ZLA.O +D?F["AHJY38&\I][%47 '%B=/"V@*9(X'2
MJC;.=O,J5IQQ&127K2.!#Z#R.ZR[0VE\&^&VMN?^-IY^'"9<;D^8"N?.*="B
MUMJK%[DN% '%&NZ8D<9?OR/9L-M?>>SAM_<]Y#MN(IS6-MH-0R)%CDYF A/(
M:E31<0A*D\&8J[V(B>>.MYOW;XLU4]8>(FK_6JW G(SR51H5-(+6B PY5&/!
MA@ >M8:@G<G&Y12CV5)SU\<X AWN);8>+*%;VKW__/F7\-_CR9.S,%WL#"AM
M,J9PX*K4^R:FR1)D"D*]3 ^F,+2M#_:W@/=-6-5]J6M-]%*/S/H*]!6]'LN7
MJPO<GJSP+:'>CYW>F^J[4ZR9WGJPZ[>%30:/4K3OU,Z$C'91'<'5\LM!!12)
M$46:QR\\")K=X1L\5)9MHZX>V/5N$C)6.-/EMNV<HU&K*9!JZ*\,@K9M@=4<
M0Y)!R2:UIL]U#(>WAGI5VKBAQ!NZ*2L\\])-YQ]QAB?O)SAWGU?(N%-)9W*1
M#0\%E&$90O(%7&':*E^1M6Y!M!G-<;.BD19:NT6K8)W+?!4.;>9,@BB*YNJB
M([=:>4B9;#_"P[3L5OQ^S<./4\E-1-F#C_0E,_7Y*B5UGJ*ZXAW7#I'3U,@W
M!(4E0D ?05M:L+C,J%+KLJFW CI.;K3714.79T[<7S /4YB0'%)M\+$Z7+,F
M)<X-,)<"[5JU_F1A$8J* 2/+-EZOJ+-A%5C[^./4=2-QK@F&["&$I,[UM*Q6
MK6>C6:U(QCPY\@XC1 QDH:A:%<5)LHR#]M+R%*UH?>/8$=IQ,J9/_=RDT7[Y
MXT]P4BOLT&=P>EI>(>8EMZ5EC'PH7]/+=&VKC!"E5<!]"=E:YAWOEB6^:83C
MU'T[H=[4]'XYX)= 7<&D."K+2@$;R(DA]ED@'\9#T=H'75QD7&RKZ&]/SSN+
M]*::]T[K?H?IPVA\-G[_^>>::W9#!@N0C)O,=>9@L3:8%CF"U]J D*E($;DL
MUV](]C\SZ +L./G2GVYN$FCOG.ZK5DXU8@MZ"]G1RJ6TX1!K&C++7)$G5+00
MK<O4?P-FY?ZROJGXO<MQOA@MQ=OQS-5;%I7G%6EMAEDP@)?T';,L"5Z,#*EU
M[L.6$+^)>[@^U=:#WW('W+6O6!?(/=W'[0#W?N[D>J7!=I1KIL,>;D]V@>ZT
M,KG&13#':9D/A5PT22NT-277Z/&@8CI6VMUQ1_?06;>-ZEJ?Q&]R$(0,SB!G
MH'-M91>L!,]3 .-SR8J7BO)Q^5R]:Z:+W[6-6%O'#JX_(60A..FM )EJU01;
MBWMH061WMC 92V'8S;E^( >N!U7S_B+M_7V>UY^>HUNY;BDC>AX9I%2K-*6:
M(%]X!A.5<S8ZG4W9[=6^,=:1J[^QL!M>Q4TGLZ]AZW_%\?M)^/B!@)[--SBM
MD]?!60BI9M+'>O7+M 6K>* ER*:B.UW!T2B7[ 3ZZ:N-<"N HW9YVHF^X4GZ
M'-0B-O<RI.4+T 74-J[+7;S8!.2P3DE#18W[DG+#[>%V<%8DE3@+D%R-%O(N
M00Q&0BFJ6*E+DCD_/M5O< P.K?EMA-M2X[./D\&[5X,HL9[V.Q#2%)H0F2)>
ME@SUI)8'YHTIM\6A3S']Z?WXTT_U<0O=UN\NZ74QS.'V^H;"'N\NJ8;F^7SX
MOY\,K!<I"NMJ(QMBGHP68B;HBI,5D10K9#KNJZB_GSQZ16TIJ=9OU'_^8Y!8
M+E%Y 5QH XJ)3&X<8<C>Q^"S*T2C?17UG_]X](K:4E(M[=\Z_*LG@\"Y)G<K
M0N2>##B-M7N81?!,ZU*XTB;O_4:]>O+H%;6EI!J&@BV&_\< 7>!"!%IYG8PU
M[H!#\+00%T'>EQ?%L;3W&_7J\;]16TJJX=7(8N7]C0Q4'IS,Y A)7AW:Q,FA
MC0JR]D01Q&C2;2WONNU1OSUZ16TIJ<:NWILP>H]S8S9RYKRFH;5%7R?@(8C,
M0:I [W602H5.)9KNL.N_#'CTKOUNHFT8*O4%Q/*$J0N,AL[[I:$/[Z[O*/SK
MZMM#<HT=\LMPT 1F&/?@#*M]$KP"KX($DV7DW(1LL%.*U'TK\!:GNZW^MA%8
M8[W]0I(ZOSA?W>H(K.>\G(PE(\AM1#)R66*TTH<BI,VN8Y#)'9J[,NAA=\B=
MQ3YN(;.6KG8%$OZX!,20S21E"<!U5O5*SD @7Q)L*JP@[=0NM#CYNC+H(U3>
MSC+;^.;]^T_79O^2?IS_8?[[.KLW6'ZH__WUS8LODOC]]]__5&]?AM//TS^E
M\?E/<S&<//FO7U^\??'NQ>FKMZ\GX^?CR7EXBK,P/)M>!3(=GG\\N[,[U&V/
M^^DKQJO8E\^\HK<]T>(?,QQE)&$.\U]^'#INI"2'C$NCE&#!>8&D.%<*\A1E
M'MSVX.:I'"^_E&96M&Q[IPP8ICDH925$(<@[084Q.\;2];J/?>1O?,'30]K*
M="7--_@)1Q=D/QJN@_4T1V]2?04BO0+) ,LY\J11:&R=Q-H!UH.HH+@;+SKD
MINREA-;A%"M\X2N^CY-QJ?#&BZ9ZH_?#>5NUL_%T.G"&HXN\WB686D<R)G"6
MK!Y'IHY#PSV/W0)JMAOW" C1M[0/4SKY"W=?X6S1;>]E!2JLUY8V7Y!S.]@R
MLH.9M1 <)Y,HE4Q(#[B,7 %W!-SI5R$]Y$ZO:XFSQ/DL3$;$\MJ:\>V',,&?
MPW28!@ZC\)8\)R_(>E9*%0@*$8S"Q*15AHD#[$.W8CQN'K533P]%I;; ^W1X
M=C&CE=8HGI*-M7UX73JY(^S2!]!""UI5R?(4K2NU;(_RVZ34+BKJ(3MBZ[-6
M%55!Y1S(B.3KIVJFZ8+ 8XG*!F=]:5XU]C%VN-F'1KTJY:%TN+F]$F^1)3K,
M!6S1L79^,C0CR4"6+!VG_=R$VZZFOMVZY5M18:NZY=NHI/?BU5W ?*MUR[=2
MU*U5K'>1<N^JC]PDR;D"QWUM39LM>!MU;;-!]&96X_7B4H]!Y7O5+6^G\6V$
MVV_=\J S-W4#U89<-A42F4BE1G+29'/RN29P=3ID>5!EE+>2[^:ZY=L(IX>"
M@)MZ)!EE;; &H=0T"54X Q_)5XJ2:66B5+*T3MY_[-WI]MFO6ZCA,.<>UQKQ
M= 'XO3O=UJK<NNO8+GJXE^YTG$N9'2(X,?>2"6,@QQB<R38@YSJ)UN77'U=W
MNGYYLHWXFV=!CL\_AFD5#EE BP9<EW?"K*WUBJP>DTU-\)Y']7D&QDH?)(8L
M6<?DYEO'>1"'5/MH9=R/2-LWKL-)N E))A^$#(3!.5,[,#H(?EZNQG"O-1?%
M=M/R^N<?E78;B+"7.ACU6N:+&_.R_H/5XI4=UQ:U <_(,E8Y>'#1"!#*(Y*5
MRX)M?7%V"YQOPG1LI8X>[CDV0%NU4NL KK?2/+< NZ\B/(W4V(T>>^C@<$O*
M$J34D87(>%WO> T*+^"#3[22&E]24AQ]>?P$N;-<SGWP8QO1-P[F/?U]A)/I
MA^''1<]FPX7+N3:80AI>V$! @@";O619!..[<>".>- K@Q[U]K&?B%NF,%T&
MLDKPZ0"E8?;$M>$/GT&QAR+6J7,/*?;U$B\AI9AYC$Z!M+72DE/DW#(T@"XD
M7G@HTG8J'OL0%'I+1D4_^MQ&>'VVIYY7ZCDM;V?C],_Y!%7 3&Y-!DPUZK,F
MJ#KE<RW-E@FOY+YY%ZJ-8(YZT6ZKBH;IC2M@E_$L6=L%44]F_DTT]WS)NY^Z
MQKW(NH>58@VR'!B!D!$T+5(U)CR#PQA 1RE44"H[V[J_S*&TW_6^MV_E;R/B
MPZ3_/!U.:\C1<'2!^701#TYK81AE^L/'\32<_74ROO@XW2,C:,L1&B0)[3.G
M:WE#S*K,+5.%JZ2"22[JY.F'H$QVVLK!EF,U]<%_#F=AE/#M!\39R2B?Y#P7
M5CBKH,[&TXL)TJYV%0@]XNPB#T?OUP-_^26DCL7DF182R#-EH(SP$&H0KDS9
M>TVFDF&M#88#3F_?Y?/*J+</^H3&'>;E#P/&M>1)DQQ=*N2M:PM.S(M0&(FB
M]FAN'M&Y*];[J$'Y,/E]?64_B/9[B"39 O=)2N.+T6SZ:CS#::W..0ZCZ1M,
M./Q43>-7.!MD&[PH#&MYU@ JUN@:[P-PCT9K9#*%UF=^32?PG=\-^-V8)SU8
MNEM,YO4$/X9A+49[.ON DT7EVR<7DPDI:R #LUIJ#60)DC/H+:^-6QC0ZXQ9
M*!+GK37F>J;[;="_$[T!T9MQHX<8L 68T[+-OK1"GH4QM=DQ9DW(173@!7J(
MM<.AR:JFQ31F]>YHOQ-Y$Y$/Q( >+J"W>@5KQO+L\VM20A7_LW]=##]6M=1F
MS<O9!/+,DJC=.FLA<G+?/<W&:O+:@U1%EQJ <9^K])TS^,[Q)HMU6Z8TO$N;
M1PUM,97359+^O/WPF^'[#[/3\NMT69;_TGR\T\XE*2":6C6/H0)OA0+&D^>Y
M*.M]O.NLIB]PWTF]-GCLOFG0P^W"%E/ZZWB<?Q^>G5T";XH)49$=Y1S6/,Y(
MVU T%I@UOB;7>+3WZ%+>!/R=UPT6ZSUYT+!"Y"[^[_7W3R5) '.!HG0!Q6VN
MY3$S&&,"BSP*S>_1 /F^,/=Q!K(/!WIH$KS#\<WK\+D>UWSQ";PSW$93"\0G
M4,4("+)XD"%:DP,7.;?. -D;]'<J-SS.VX,/#9L6;VLD$6K2WUDU^,\_GHT_
M(_Z,(R+"UX,:LHF2E5Z!<I&^&.4@A%2KRI02/=E&RG1+;6B)ZCMS][6.VRJ^
M8??E;2="[]^$?G[VQ\=Y+[05^B2\8EXZ,H!J9&\,$J)5"$[S9+,V*C/7FK;K
MH7SGZKY<;:#B-;<D^R6"[>R(OAR&.#PC#7R=B+1&>Q4C&)UH(M9IDJ'+@,IF
M);C&G&6_YQ W07UG;=OSASW5OH:_>U_S78*TTS$X3\6@<!P$UK8&+&5PWCA(
MB$CB=5K%UB;OGI"_DWJ3P7M(+JSA\L[W><U>RLN^:(S<.8LD0DU?)'<U5UT
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MN] 9EDH2+G(KR61H+.=G. YG)YEL'H>S"Z$#3#OJ-ZHI6$%6!5UF24"-O^5
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M8$>O(L.)88 ^$:M!WH-X/='AU\LTK6D7O^#U[R,)BI=L.(N0:NY4,"Q:.MU
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M3$X+[G2WY_,=%CT-N0_%<L,4Z5UQDK5R<55G#BYG 8VT,X9KGYBUO#[:<,N
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M. Y[@[:0SUI1]R2WX9&]$9O#$))UCDD-0!Z7,ZR^K+(4?$A<DF;+3OV#GY7
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M<QV9@.QK/PBHEB.R()(*&FR!A[9P[Z-T#903LJ):D-WP>743K/KC%)>/RUT
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M"WB_S%IKPETHR4,H3O.8'>KHN@07V=B\GFZZBPRNO8P[IMF?]04LP%4T$QS
MC1'OX&Y#R!JV-6S)K3],06UUB/S+D9CO_W!# Y,E4WB@8'/Y7.#;:99!EYP]
M\ 47D6F>DU^KVJ#^K'(X8\-BM?2^;D&UN;X51VKU%R-G\X0G/OF<J&>:M[J
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M4$;Q2(Y,QB\\:3W] M/G:[>HW1N2_"KGG-]-J75Y^:4ZRZ4F_RX-K Y+AN6
M<"@1X#;F$AAUA<9PI;E_U1K<&G^*\"=!.?F!)"(M1_:PH_K<.<GYPX<2/N1V
MF'O?,T/O[YGA7I(G+:U/Q^YK3]R%;XB$1M<N]-\SPR_I8</D<6Z:TU+E;\(
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M579*RJ.0LOLM5#$+VZU)S\L4D@J^U;._BZ9 <O<;UY -H*&L58Y$H)R?"*A
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M]MTM5ZT+6&BO;W':KR832<%85DC/A;K,Z#>^3U0/Y)KNI4/K?A5<::.S&$J
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M4B,6:&@<!BTVM.MNOGP'6U_7(.75/N'*/S;HI3+QO_QX4>:TQ*+Y.TJ>3;,
MUFY>QK4O9P?+.^@/;NQ*_C_M?6=44UN[;BR(@H(%D!X1D!(!*:%#1 0$A @"
MD19$$*0+&#I$14 CH2,*!*1))]*[B&AHTDLHTHMT0A,((3G!_>WOTWWVN6?<
M,^ZXY_PX8V3^6&,D*VNM.>?[/&][UF@(*>E>[427];6PE-A@NL@(M8?$[88U
MWE)<L.&)Z6&YCQ3 XZ0QU5W\*3.%45HN+3&O)*167E-]1.Q=M^.R%]]5%U:]
M3VSP/1IQ Q*$9R/Z]#(W%K85UF;N=)B\_[@''3J-I/FCO"ZSA\P[I!W4ZV3]
MI*Z.;;0N3H^(Q^B9X$JFBJ70QHW9RZ_DVS'9X9L<3>\@(Z>"J=85"O:HX3R;
M1Q=%I5I#5:<$<%5EKPWYXI8CPL=?3X>G(<B('D[]O1NCLD$_(A>9C*1#)M$0
MLUOO(;&NH25G_5<;>HW:$#@MK;GYOTB#<GX/+=U(L[L'LODRTFYX?"&P&AE"
M 9C4I$=I"D3YQ ^M.:<BQ,Z.*+MSZDPW;L(AMZ-W^D6\$9D=DNVYRG8T=G/Q
M-"O5[C-#EP9ZR>LV>]ED@:&WW8_FP4[Z]()>$F7T5BMAZ63#I3(6::)3C$?9
M\[.".,"*?T>M(3N\:V3)4-B/6!NJ)/EQ2.=I<$7H:.O(N[VZIYND#?.3M[X<
MM;SPXJ)*E]Y58(8R:I.7M=': R>L0+UH@UM!JB>O'/4Y8VC37;(7^?(EAQUD
M] 5T,_>1?I$OJOGU[1U)E62^@6?*A=5B\XE&.F,-OFP2CJN7GA%O' F?-\<P
M,\1PSX7H,J9,#WT/7"U1N(W@>]\&N%L=$:'NCW;?6OB@1#5A^A;$N>3VFIP:
M8N>MV,A&(V&)HK]C"@+_8@HE!TPA#X)SH=+K.:[Z@\ %ZC=J4$MU89N0MR@
M[!O()J^! ^[5TGK2=YUQQEWV:')%K0_&V_8Q9-H>2IS<6D#,67XX4LU(H/G)
M1W]M6 [U"B&KZZB2/P!W^YWL?CWP6M]Y,]/J\0A.0[W^LN']Q@/OQ:?66^,)
M<MJ)RJ)=J:!\#HXUWW%Y3&4'U)/!-']G!Q3 R[IIAP]4T"72X?*3SR.;\/YD
MZH^8T7 U*#K)FGS)Q4N K$$O]@<_0/R5'WA,_,H/&M;BV11Y_ #-ASC6$>!I
MP^6JTL*:+JQ(S/V,H+Z BJDM[-F"D_K;T;*%]*,W0?V*IRX@CP\]Z6/KI3(
M:^H:7/>AFOUMR\W6ZFO>*+T+Q"N-Y%9BKR4FYYS*T,_T=+IGT/^IA^FAQ;ES
MLSW)O3>H$+)*-51HI]D'$6:,NU;2C%W4-7['"-PW7RS<0K"-[V0X+G6@B,0]
M<_]*Q?ORUX^B^%UW0GNW7HSOU7M/.*@FEFC/7-D<_K@O;HI84AL52DHW[[;\
M.ZEDU[JS?$?42\.KS9Q),10 VON+!^0,]FA5:6UJ\M:9%<N5L?V[H#"L:'6M
MNO<69O8_;-3 TZ])$/[_1)K_'%][_10R["ME7KF6A)!-Q%K&7B_NX,6R_*1I
M13)&I[H5GE  Q8R$@A54NT&*2-?93#;G<,Y>1?'<^4H9%GT)QEV[\^UUF5!<
MD<.H@XP>X4=<SE.7RU.BR)E4=/YN6!W:79N>E/?]%7#7>(H)9E&P0S?[Q<1?
M*'[E3'-H^*C8S'8=@W]N!"\M;;Z;UMG 8KF,\^=M[!_X;(T&>?&7.76)[T_S
MD0H@*=M8X^XM;2<+J':U=(O,4>XLW\!5.+_Y^:=;9=VEZ<'J%(!Z%0\G-VKL
MTU@R4-6T,V=R%X[KM9>M5@J'I:) 70I/#T QX;*=E!A3H)M\[%W?0-W4QXK0
M.ST)6OVBE\?(QG4M_@;KC#.H#/B3-0ZM$2;V1.V6@ 5])<@SLC?P.1:"O90G
M=ZEKMC?\<IZCEZD!N7GMZ#G)>P+*9G4K213 DWJL)?88UH) 1;O<B0$^FZ^%
MC,+0K-6=4/;Y3QU>"1,S/W1R!-]I"ZO0MX*<KNM_A=X%E2S* I\/)>V]])>6
MGA2?;5+J4-FUW2C@SE_P[,A>B#L?92LI=Y?1<B#@< XL4M]LW7%#0-1.&F ]
M#BO:<=$F-W7F+[]Q%95I):\MDH%!WAV!4G7+D#/7S=U/U:U:$.8@\ELY"Y\:
MO+EDO?;?4I]!R<*O).]B96EYS;,OGB?=U9'!:B<A)K.EC"%$PWZ3KO1B]_V>
M2B0O&=RGIR>H;IIZG[7UD;=SRC@7O$?$D;>&RMP4AT_M N?COSN+9);&-").
M1E0L% G=)N*K#& L9=NNK"LI8=:0AHO!P'SW5OKSA.(3ECT#A"I0]Y9+2+^,
M5K==J!/_TK-7JOL:NY,5I[2U:KI%T;6D2S+D<[U7MFAKW71C4BK;Y-V"9PP\
MPM2\!M*R?^J9=_OQ3%( RTIE[-&'/&A7IN?X?QQDP#>T'KDI2N1%BFM<8[O#
MK<(UEZE7/W+TTOA*N&=J$4DA%^UP/7AN7'N;_TAQ6%VR!:X4U$=%0A^A=P74
M)?'N2M8*_[I31AS;0% =C[Z!S'/K0@RM$3ID7G.)-KB8Y=Y7-\UFY9(8/;CX
M-*:NP=30=WCX'2?N)3L%\/&% )61,L\9?O23>G-]Z!D?Z6MA!7?#0\A7&!*>
M!-QYL"E(.A 8^:7PFCIF2;Y4XIM>M]4%P7@;(C[(K DOP("#/Z )=TQ%Q]=X
MJ3R# E#*C<)*U,1DIGSOCXK9_!-\[O\]^&#IU^JN47<\6RW5,+[U_!G1$?H=
M;^Q__%X"BF4W+6[QQ<C\"W-FDOY9_YF-3PG>85B"?/QW6DC<XI/ 738P(W$'
M^=VX-./7@ZG62=LXD<$NK_-D]6&7;>!!'=+"U@SW[WCD.?'A2/$?R"9P]=?N
MMBFR*/6+!7O[%, <B+W,SYP"X#7?WJ/^R@CLS:PL[1V]\Z9V/'F7\W+=.))X
M!):/C_H-CH:#=I1MX<!QZL*N"GN,95OC3GK4<=I\>.HXW^7DE7+>W<G:^(KD
MY_$:"0XLV70S*?O?*LCSBL"/B0'@CN<A4F(#GVI<.'XHKI?7<.6<$ONLQ\9Q
MNETQ3OG-'%(QH#10S;LK^F65;.HW\ZY5*1AXO.,TVD*7!2^6T(IHL-ZX^,-E
M#DG<ZL9C#[3TNT-C8CNI-$#M/P0GFYW@CPLF-"-%H=7J6HP_0GAWC6*9XJO>
MQU<5CO<:=: VT])WGGK%NIX,:7L9)ITT]J0ISWYM.M'\S4Q)3[$",D3^==C"
ME$[DX[/A$HH4@!<"& <)\F'VNH_Y5B93:&Y:-GCQ;HO#8 E:G\OJ)FK]&V'J
M9.4,1T7!DM0JMY''+0Q>Z$#?LSC]UT4I%-W&55H3?7/8"JTMKO0X$T\[M7HZ
M%&EM E'D"*9=MUA TJ&B;Z$'ST4]<W:MRMA;\,GX,IW(EOB>;2_M/8G&(!6U
MSE%=.5M[[3]"M0-MQKG?^@\E27]Q &LS?_<0 YG7>,//5-'][@!BY7]W$#L8
M2=?5&$.7J7>QV4[XH_U&':%V>8E90U\7\)8F-;6\JKQ:W==XZHUAV2MT \!?
MEMA;\L_X&0Q#4NGB+4U2TA\\?'FYZ"XM!S&8]! IYK.I]=W/(\>/_Z%I3A4S
M<078 T8_R%9Y8XAZ:!MSBT%>3\W;-M'7.=S#I<14X9V<G:61RW9AQV)\Y9V
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M^1C:>5@#/V\,;NDQ35P&5_P#EH!_P%)-5*U+/61=X X%, S=9^WK"=H92_D
MG)+)HFY5A@.-YR-?P+^6><'[*8!I2!82_S69>"8'/*7MX0UU?T>@):&I--<,
M7JM;4_P1N X6V'?UV9+?O#)V:.0/=R/ZX2_==T=PBJI4[+B40@%8,)(6I4MJ
M?CNL\?:[N3Y3+2]VF(J/PT[D*2K>7*J%UZ1]K%N7'D964 !4@@TK(,E\]+ D
M4\\'2I_[E3,I(K^,K8/'D'7[-%9&';]X3-B+F;B?0=2:<]2_"XHC,5( 5^VW
MJM:A!\@]047N(U0L8Z]UKGY81_MU\0\73*^3F>OSF1'3YJ-SW'),N4(KIS2I
MGABN-JTUU;[(I#4JV4> 3/P!3H W3HH<XT+JKIO](\*E'#* CQP=A&:.:CIX
MLH7=:6>#;A!A<2;1@3U6';G0R%T:S#31?]I3.HIU)G3F#C(I=N$#YYI.0?7Q
M:T8<7X"*?%O;%GJDW*;YIE5.U%HQ[T]Z97<[9[Z.YW;6>(=G:LV4^DZ@NV,N
M Y:M,O0A_TU:(+QQLZ!'=XT[-@<@(L8[BIQ)P.3O<M<%^9S./;'4/M ;6B8U
MEXKJ[?R)*%FBV'Q'JS%O=R;Z1=Z@-G?VS,]<RKU,/7I8/O+:[JT O^36M:R8
M*:[!@P9@^<IW87^VLV+" $"3C3$FKQ$L<]ZFS8-Q1<5]MOV0M_L.F+[2?0V3
M:)GBJ,<S]W3/(!D7O/.&)G.?NW4+\&NUFUS?M*#UJENVE!K1AVX^^2PI3@$8
M+_E3 ,EXK!V<X<1).H+OO=J7#6+9FBF?$+&?*8!/T%'00'G=[J+)Q$*E;UXW
M6D,,$=^KIX; '*C.TLI-Z9S;,U67^)A0X%0T'Y97BR>2F6? J^#943"A^LXW
MY<Q[;\HBBX4/D?/#D2D%BFH*>W,S6%WRNBQQB(!__JY3K-SM1_=I_G#\-]]^
M$>8O;++5:9'2F*X5(U@9$9UJ-MA2]'DJ&-A$9$^JL=# NSQ22)9N@<9^(.FT
MU/4B339%!!I-X&]31!.6;GL:,QCL<Y!<X6CYM5=$R2KF-)%M>7NA[(M:*6D(
MA!)=8J!N02!U"\@CJ):RM;=&,\/./J#'(ZB15!RZ8K7#D(Q^./0];!4,Z+1K
M<;J@R-+1WK X3" M"O4_DY&,O?-YSL]X<F>S:;15%^&+8[7E?([<$W/NFW5>
MYBVN9K&1NZRK*?7L>S[T_GWE%&^N_%0V_H@)C2TB#*.?GG-C(O';( MNO759
MX5"]HVNREI,G-ZC[8I<BAY4="[U_NE0![9A3?K29DE!]_2!*;\;#$MX\$;[+
MO$G=9I,@W.*@(G6>+GY(IFYOM4>6 9><0G;>Y![42PP=>-2V?TG%^D)_3]4>
M TUJ</,^8OXM%PM'_):II=+PYR@@VQ 5?N<Q![$4VL2=N"\^,Z\*W>]%952I
M#]SFM+J<&>'F/MQ=J9"[6-T_XNTN]9T<+^<8@!CS4^D<FAP$FR):/TK?!"Q@
MPL>1R:7>?=ZQE3%#CAL+&T+&&+&GI*M5RNEWJYS*XOB.W0N8\G#)M*( ^K$&
M1T\?EZ--81[OZ]UQQY6S7^//7RAM2R540!2MAGM]V:N88_P''<W9:SXLA=]*
MS;*K&L7DJK/CYOD<K1L398G9LUB\CUUN6J'4EHH:4VB]0?%I !M?4@Q.Y&'=
MF5+#T_49GP?=1ATKEN0%2=Z0Q[G$[3#'O(L/2AI-JPN>Q,5 W7SW:;Q+V[[B
M/<5<W7DU+X>X*R N52SV&\V\:#7)*1>^F(H:('R(&&JO/'FY\JGD[$U?)ZXZ
M[M@O3--+8=<3/#2RO )Z![T\<,=8[P=I,U[SAF3GLPMB+4$@[E2C ]1^_5.\
MH8BDD8&VN%91=D3"R@_^50Z8#,65"J93,5G'W#B)0<6()_BX[(5NF-J4$VA/
MYO-9>5&>*FY[7^ D,!F"=B^=UA*5L$NRCGY9B-^Q^CQUD["2X@(BK_./.3.Z
M?;,BR$(P;I>_#!1S1KEIKFJJG4V(TMSDB+83Z 1U!G#.^UZHZ)V!6RL;&&]R
M%I+6=F$T+D?C8'JFGV0T0<_T5G1!PU*+@IO+TO0W I8$SR_X)K=77>FLJ:QF
M[T3/!'R)%TRM/5+Q)_VM7_/(1:;-@Q"9EVVWG_")5@X='P_S]R(YM*TJ:N:.
M39LMG&-6,N2X1U9E7JP*"C5YA5%*I #<K(6AF2DD1O 4>U#HD!.I/PY4=B.!
M=JPSW*J_PE6Q>93(&;L;7;MY,=A;9(4WZ1*(SY'+M#,P$5_X0/Z;_,KK./'3
M10S\X8IIR) ,KS:S[BW36FZ"V4!S8>-)1N&&3A0.;6%#"LTVF [0*.LR:T=/
MH67T#,/6@F)Q<F>!$<DV%  G3"NO("4B6%_BN-RQ6L$6"9C&(^OT@J!4E#"*
M+C]K[,L[NQZX&2>?EBEWYGL2E)DA,W^>>-T76Z OC;M^=V9XCA8\"^=;4\+5
MR=XZ*1V9V,CBD[PJ4[>>9]]W"VYC*"PH)LD^Z5E9^<I;%PX3;?R6&!]V\'Z&
MJ>(=%WL+@^HJWIFPTV^VK9+W7]6ROZ_A2>?BO8J^9%[\U6]09>'$'.10>".X
M&I[/NE[/VYW!?8>/NJGM'QSL;(D[:4GG4=:,'-E&1IRG?6&Q.VF?BA^XOQD_
M)?(R.9;XF@(8=%E;A6-UHJ3B+X49P#18[UM&:&3<UX_/"EVX?5OCF9XYN9*P
MJ2!%Y A2TJD)"=^A1ZKNXL_Y9L+MNG<]^[NOCI07'")R;WW734RIK!=V"YNQ
M[RS%;YGRTSMEZ:+D14E/=KA!RJAG0P,Q0P-C4 X'JL<B-ARRIR>P<YM_[57M
M%9[28WKDS_9U349<S/!N_Y;O<6YM_6F^5-<=&.<.#7NJ26^UD=-KF" BOZ&7
MT%)8'N6Y6N@%O-T9 )8OT\V/S4TA= 0Y@YO[[0+5[F7.1H2>_V&QMFS.$$C8
MY[E?T3]XW[*I7'4]?#L<286VLNMWNO3!=#E7F-4!S'AMAM%B>;M.WZ;O?E9'
MC4:/5SX=.>JJSFMH.'=L"RN$-5EK)+W83K[S,\G*G_69Y-"9J/&9>3'@(!PK
MWTH>0L[AL'Q84P*4]*(?\J.' E '*XKA]H_\9VGL*_:_E]O/UQRB,AE])/X\
M]C;V\B\LK/:DS$?/?Y"CWQI\U\)/4[E.,Y7 41TU^;9\L=\.L=P6YQ0KG=M?
M_L:TL(($,1*ZC )8@5"=OK[%@^SXZY_9\?G?L^/ -4\2VG-LE>H"WNG[1_9Z
M,?._&)[^V8XL8$%8?E?K4&8YTYZV[9XUXQ^>]2/?7D@J_:=3L>9OI?JA2]0O
M=^!].BD**TP!J.Z#Y&O[)X<X*M@Y7D?=2<B1GV:?W$*&N#:UB:)E8GQVST;!
M",YI:QW]%?:6\?T"G'/@/*AR*M:>73HEH_!\?]1U2?3T?6A7"+-Z);N#NGM)
M_TRU/^Q6R>00<9)G+NH]\)7#-3%6AZZ3HJG?]S>-R/<*!7/THP;16MHV+G7H
MTFW6/8^Q[7LJ^\(QY(O]HH?.+L#XN%.LA1G'0=(HSNGMN]\%JIDQF)<*+%:]
MT5%V@MEWRY(6]+A*)'1XY@JSK7;I(L\8E/47CWZ[S!*IV%VNIA)MKAM-(!+G
M\N(37LK652C;0CJ12:#:[DU3+G9&X4^ -WOMWC;$^+G,D)A2'XYKH1D?0B 3
MX30:[XK@]D_N5W&F^QOQ[D/7]QT*J'R>EX;F($7SLXC[#UVN!#Z[RTZ<.5RL
MEK'!*DP+@D>^DO3&FQ_-^K:)LYOJYK/.I%*]6K-8WS:WJNTG^6!INR6Z(;,H
M[9-^8?Z-+EFD7%0!,(]!*T;^\P8=2$._$RQRZ9J8B)G@_$5T$Y*]O4 ZWL,6
MI/.@>7G5.9_!2=3F,070(T=' 0CWA'\A+CU@1K =!XX:"FQ<+'R00GV"X$ME
M-A-K837JD!(.@AH%0)?FGF_O>?=EPMX+IJW;!^(R65TZ[5 /!GW?]ZFQAIBG
MJ:^L.@\EXJ%I.^?T>NF:O<DAA[Z+2DS[BNUTL;;H-A^]1P5*G_:6J5O5V@ZR
M\<9FA%S2?I!/9K"B.$N@(_P:?TV$W[J'WG[7,FGA1V3*P%R$MX>XY?/=:6=C
M\KL2T(=8FE/P[T[RPO*U[7^K^#/V#\6? D>--0:?_QL9B7]7T+9( ?P_"*L<
MXF*Y;HTXF7=%A>TH+,ZK^%/4@PWP2%3Q0.5R\W,BT$65#,W6E[_\O/EBL/J_
MK'7>UX,6(MO +GA0 4DY[%[/7.C%@'<C'2T!(>6=Y-@&^#P^WG'4<*LF N(T
M%;BIQ#@!?S3?PI$HD2GH##,2KH^)4&FZL)G/JJB19RHZ4 J*4&*_-D!UXPXL
M-_4S1 $\JX.#PI?9(*NQU$E-0>2,C1T6$Q-X#9SP/@&,T\I6DQ%2&OB6OFVI
MQMQIQWVJ#ZQ?L,9Q@Y%4^OINY%(M='T[@[52X8*>FX>Z2$;Z-E[3R8Y#^W((
M70X(KRCS5NVM72I/2$7T;/Q5Y;5-[D_I75+T(G1C]U.=(T-6+[E0G]VX4JYN
M+9V4-]@74Y+M9K]]$'[4^577BL$=1X3]B L9O8&7-$D&^]\@\^RZ[\!B\#6G
MV6Y81J@?!T\I\_0@BQ"+"6I[J.$T"N#1.B0)%,)\RB!,\3IB5O)!*FI*3K=N
M8B7N!\9X==JLT;["PA,R+DF$91AI!$O5+6$.CQXSTVKX&K<_-4R8WS&J]2FQ
M;#X:KA7C;767:J)O7_W3.2[P_!)P7L=CN+W\$_QSQ34O!D@5U7-!H=ZH:1I'
M"V:#)#_9!)O:C;+]*8G; QI =)P<<"B<G?"K?GRE.'.4N[$7AEGD/MTG%6PC
MSI'@VOU W6N;2V-]&RN?P:;:QBF9(4AD-;3!Z]<640#A"I7CW)%-!@&&)JA/
MRX[W"XL^B.!A[S+$)IDH "T4\IP##/0" 0KUX5TFW\FK$JZ<^>;7O0*JOC&#
M>2DNQY<8K:EF^KY[%:'I5TUO=\EY1N/(@@]=3((/O9%!04\]G-GW35H?F'7M
M,%<GKF'?<FD,^MW$A/9Q:@FBLI_-F9\S#]0BM$W>7B?B;8X=H_'H:JC>N+F0
MH3:Z3IVB:MW?WI;X3IO)'6<5#XYD-$0T08*448"/-02C$ ]M_^@FJU$6$/'1
M/DC4(KA?A)Q*G(",T8U-F&.8$S)HJR0?C1,Y>79LJBOZ=)64.ZBLQ:#+#UQR
M4G'YFBW7IPL6:P7]J&1+Z/O:4 56E@"ZSB5"0(LS*Y)IN7ISGF@T?>O+T7NR
MO#<Z'QG< I!HE%'=XJ$>:ED9!ZUG6:ERRQ-50:F5+RZAJ])1;-!Q^\P?+)$4
MP-5<,1(ME)"[J6^G],6Z!3A@HK%_.*^.P 7YE%]_5+HS3[J+3UQLY$ \=)]&
M4^T$_WOC?^K$9UQ"OVOEU>0/*JZ.^MIV-DIS58?<T%TWQ^%  03 2,+[3)4P
M2[>"+Z;^$KANJ$1_^W$+UA%.2UWEU'P]-19MRZ6_E@H)M:;;];1TMUDZKHNW
M2EX_(;!X\V].F)K_(<[202S!R?:HA!5'U!7&6>$^)CWK,NZ_OEKX</J0+L95
M4EL)71,E,^KY_"R2/7R/48L*X$[8_5V+@YN>,0^R-@C4ZEE^9YR_E#\9&;"8
M?O7,3E^58 I?&5?>7Z_O3(Q$[-WCBJ<U3)JK" 4O/*-%,6>C1Q4SR8$H?&HT
MRO=%^K8<*#S$Q.#-%1WW$YO?6 /2(/GZ+L&N% !#5L/B,>0/^Y6L/ R[2TIR
M4>#<PUQ"&^U8WYW]"XWD-B.>':>[=6MKOJX">T]@1/:EK+2!VTO<.*Y0#@N:
M!T8#$*N-UYZQK0$8B-9@>>G3;HAH__$)Z KNB<:\?I>)($[A8J_^X,]ZAK^K
MZCQ]_$)H8"][4RVA !V@&8\#NZRJK0-[\AVZ-+\H?>[V3?2K8Y#JY_N"< <6
M"E_=%SY"Z![;00C1]O.0P<-=QK[L_J'[,0J<)G[@8N"BV'>7[5MTU2[CIUC.
M[,W$CU, Y3Q (@,H,S4^3><1>P9-9Z9M^CS1ZW!+.^L-,K]*]<8B3#"U1%/D
M99'I09#16L;( U_X?/5"V"/:A\9,5VCQR?F&Y/INY!_S;%0BF&&]S1PM20&\
MEPHG'CLHXHO-[<)%X H_HYZG46DM(%/OFJ8CRXV?G2;4:6&?B\)U->7,?0PV
M8COJ<\8 .0'LH@#FSMM2SW:>!+J&TA&HB(>Z0\AG]H'D)Q[([0GDISRJL1](
M$\&4&"TT7KYXM1(2!%7CS'9\VOQ'&/0?-1(WXX\7\(I_NQZ5LE"0\H1TBKJ5
MZVL(\! /S3V!B,::R["#?6>6?"KOA++A<DO8\-/D.5!1:O&CM]OJSHE U>?
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MW,N/AJQ'")EZ)NKB84U=:B(1>FK,JO_M;\[Z;QUY'6<6D(/RI]HZ9:.=FRB
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M-JA#<].9F.XZ[EF0/6[O,4-\6$IIG$ZZ*:W1^^_::%T7V@B]3U<+3V(O\82
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M=7RC%6^$>.9N! 9Z[8]T,NDKWZWH\]?]Q-5#Q!M7>==XXOD>E0AR/Z0029E
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M/!(DC#2WA12B0"%($0XA]Q@*"0VHHJ$UMPTCT]P8L0J+TO9%4>M5'1:G6\W
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MS@*K8.XIA9X;&;<Z@QVE3;F]5FVPJS>HU0&MYE7VRAW=0:/\)KB@N:%JL$7
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MZ&&G#'AUB&4C^D[>L+\-DI^M:USL#(!QT1Z9:D[D:SN$^RB>P?X@CIO"K4N
M.:1RLP#(,J6;34O]&/%&\KLL7^:W3V]HU=5*/X'I9D.W<8(H<WZ:2 1E'"<0
M:>J#YBPUQ"'R(AER7P6>"PE:]3HWWML*#2NIP5;L)GC#C?3LH+?CN<$!'9G:
M3F,Y0K%5)Y &HBZ[/B=E*R<8GA.4V\U]2[OOE(VORQ?N% Y=)!AIQF$(^K&G
M+;(DI)!RA#7V1%%"$ JPE45FU]W<6*B6&-0B@TKFB][E52T1[^:@X7$<F7S.
MA;!'*7@;9,XH"-_9_,1EX6U4?5D<WNJN,TO$?Y;4)%8SZ\IR\^7?4UGH)N^>
MFK0F*O"Y)U0(@Y":)(@<ZY6?XC"20K" $.%+I\-#3KW/C6RVQ=#!1M(J(N&W
MRS]Z)I5Q&PT[ZV<TC$<FHO/@[5]LW@6FH<O/6_7].@7I76 Y6J+>J9'>H6SY
M\E$3X_Y)]&;!(!.&S*H,"A&;_20B(8XT@7E1@K'G<QPQIY,=G;W-C; VPH):
MVK[1 G90V['38 ".S$9G8-<GV.PT)L-%EW7T-74XV6FU#\2/6=S4-P56$X>V
M8WE]+,NU% OA!P$.0PRC))00865*8DD/RA@A7U%/Q<PIE=[QKN9&(AM)05FO
M#=)*3/!C60GMF$JT V([_A@&N)')8XO9_GJJ%G3(=%:GP!@LB]71CB9.7G5*
MX9<YJT[>X>Z7>==$G]WH6Q=^1)5>$RDH@\2#B"4<4B)#J#R*(Q%*FMBMD9XW
M/#<B:&4#1CA[C\H>5J=])WT1&/F-ME/>R1=R2-->7H^]AB;S;QP2?]>3<?#W
M'H'<-W=I(2YU2Z)J+:_^E**>_B]O"UFM+AH;U!-<,$\RB!2*(4)1 AE/$.2Q
M4-2G2')F7[G2I>>YO:R5[*"1N#5A-S([! D[P=_]>H\*ZMA;-%L\ZW+Q^5%P
M^X1B.Z'L$(0]%MH3A5\[H#Y0M'4?P#KCK)T:G"["NH^>>['5O1KH0?]U'>1<
M/>A'S7B1%@J)4'$60$^:\I!^1"#A2,"$Q3[%+."(1-84_[SUN='X;YLR]:V$
M#J3R CH+>CX'D)$I>%@L'$CT'$PF(DH';-SX\)CNG9SWXJ;I>.V8O'O<=?2B
M'OQD$@+^7=+EZNXR$W_/RX>4M_DD]2+01Y&@4(9Z.8@\PB#S]#J1)-C#'(>*
MV 5+GNAG;IQE) 6UJ-7V32-L'[.H UP++AL&LI%9;1JT'-AN&-0FXKTCZ U$
M?J>AZ*3!CMNG(\33.NQ1H\7E_7SK7R5?:]OPRA072V_O5A_2C&8\S6Z_T)7\
MFJMB\\M';4=^__J-/IA?VN<WDAS10$$:"=\8?0DD"@502$VR @=>$E 7]_M9
MTLR-<*LSJ%^O/GP!1L:>>WOGC8^=[WXRU$?F[$8/L!$7;#2IA^!',QH_[?Q>
MZ0.,0I9CY+P5, BV ^T6G"?+I!L*@\#V?,]AF$;[\>R[M'S(2[K\M<C7#Q^S
M)G&3_K:N$+C68M4E=?.L#E+=25^E.%8L\@3DF#.(!$,02RR@(H3$(HX%]9Q8
M]@Q99L>QU6%=VB.P_9P!L:/5B6 >>X>ET0)4:ER C2)@5Q.P4>5BDQQYJ\YP
M=#H I@.1Z3F23$JE T#VG$B':+(?C;XU.F>KNNTO:?G7&YGQNWM:_-7$8LHD
M2K"*".22L3HREG%DT@8)&ILS0#QV.@1TJL.Y$>*>O, (##82]PR&/8FY'1T.
MB>3(G'<>B,ZD9HO,0,QULKM)Z<E6^><<9'U?/Z*Y%*+*@F:JQ99WYB#Q^V4=
M+ZL7X%_7#P_UI^W/'S.5%_<UY[7'?\-0"!Q*!+FB"41AA"$.J"F1EGA^$"6)
MB)4+&0TAU-P(:U?LRJ2H"\N7QFFNIPU8G2UN3I0^.9[8'F00[=AMZJ$9F0&W
MZH#-27K0:E2Y]/;&;7O-CEJC'/,>$N>!^'00D2;EW"%!?,[+@[;=\RR5*0DE
M/Z6/!XY^TO_(B[=+O6 TA0D;^X7[7,;24U D26QL1@X)C2*HE]64)BKR:>04
M1.S8_]P8N18?5O*_//)\ 2H=0*5$4]ZQWQDKQU&RX^$1L1^9<H>'W?WL53_P
MACI]Y=C[M.>O^D'SX@16SV9Z[(!?R\(8R/16?J:9_E>8^GC::JX8]H]\N;Z7
ME[KSF[RN"B2WQ'U-GRK"7E"J9!!X% K&S"%V02!&$8-11''H24PIMH_I.5^>
MN1'E5B/0J 2J4HZM4J#6"ABUP$W>5 O3G[?&5:N:PW;R .-JL4D_[6B-3*W_
M90?*(3Y@V@&;*(Y@9^#T<O"^&3MNQHZW8_=8C]VMUBD#^8.I&[*N2JNN<E T
M TFW _G0: M2!;@L5IIEP;U<%2G7ZQK=KOY[H#"%X4:D,YQA@&ZF"WL8#I.]
M\(@!F^T91M'F FQK$7V5M_6BQR259"J)"94AC!+)(3*9^0C"GIY68^Q'F$F$
MG?Q G;W-;99L97-*TFF'JV5XPU!HC1Z^8 >4>PR"#0!#Q1AT]C5M#(&-VB]B
M!*QNZAD#(-EJZ^&\D=]7;[2\?RWBD.K_]20,B$<@0KX'J>]YT%>)DD*IA+D5
M 3O2S]R(X=/5;[_"F_=?/H.K-Y\^_GIY\_'JMZ^.F_A'$+7<H#\?I[$WW[6$
M.TYQ\*<1$E12#L@/)W 8:L/\2"_3;H9WJ_IBH_O$Y3V6Y7_0(LW7=1'"LC)"
M-ODK1:A7V)A '_L4(E\(B)5,( D8#?V$D=BW"O/I[F9N+- ("NB.I Z+K.-P
M6BQR!P%I9 HXA$^?*/3C0#DL,@<!;**UH].#Y;:R.PE#YX+M^-W3K<-.:K"W
MO#I]M7LY@^LB%VM>[PK)XC'ELFRW8T*?RS @D/E<0.3I)1-53$#E:T[DRF."
M^+;E#([V,C<:; 2MMU9K21WW5;I![6;#P: :VY'7!R6G @<G43BCP,'QMB<K
M<'!2O=T"!Z<O[ILZ]^N=7"[?YO</-'M:A$% ?$]X,/&$A"C1KSH6L82^%!'Q
MI5*>L$[4\K+YN;WHM82@$A$T,KKFP=V#K_O-/A^4D5]I)SQZ)+4]I/8926SW
MFILX:>TA55XFJ3UX55^'19VCZ6/&\WMY0[^___X@LU*^D9E4Z4K/U %.!$<P
MQ&$"D< <LB!24.J52AP1);EP"K8]T=_<7N5-Q=NTDA>LZ'?7:F&G$+9U9 R&
MV^@.C0:R6E2@906-L.#'1MSCJ>MZ>#:L@!G,P]'=V\2>#BO57WH\[&[K1RBZ
MU4+24KZ3]7\_9I><%VLI]FH-)AQ)[A.(.#*L(@G$$0MA2$(NO1A%(4Y<6,6F
MT[E12R,AD#7ZCJQB!;,=M0P-WLC\THH+?FP%_DFS,VCA'*6HH0M$ S&-59>3
MTHT+",\YQ^G>@<X-W5"VE LA6"*9TF8+)IIO:!1 H@(?JCA& 661X(G3QNSA
M;N9&+@>.M_Q9"7KNP: :5#MB.1^JD:FD!TKGG_S9 V&L\SYU)Z][RF=/T9-G
M>_:O[K'K\EF*U(0-?3$%I]>;3$#Z%8^,Y\'W/:$MC5B__C*.((D(XY2(2"K[
M3$ 'NYC;J]\*"1HI^^PD',;28KOE;(1&?N/' \=AB^5LD";:7G$'RVV/I1.'
MSOV5PW=.M[?2*?G>ODKWE3UH[E.:R2NUGX)_&^OV)B^*_)O)T4_UH.J?%I)C
M% ?(AT'@(8@0-@088H@]HH@ODI"&V)H '3N?&S4VF4M5(_D%N*??T_OU_6[P
M*&N5 +S1PH$:7 ?'@E%'A'QDKC62@ROUHHK'3LCU1GSP=GRP'1AZ1- GXNYA
MP7?C]9[H=3*^:YO3S04]M=V;)?JVT3.2><U*^<^U?@C?ZTFIS6TM/80E\WTH
M)8\A\KT84A8*R!*.$^YA)H233^Y@+W.;$;9"@DI*Q]#E@T#:+8[/AF=D]GZ.
MS!B)T[H@&"I8^6 ?TP8I=ZGY(CBY\^(^11Q,^JQ/\I8NO\K5JCZ9W9R(6- D
MD4D<<,@I]R&2 84413[$L8^4\+@2C-C7;#C>T=S>^CJE6"4KV K;'@!S*1[0
M :Z%;3<09",SP21HN516& :UJ0HI]$//L7;":4BZ2R5TW#]A98336NP70K"X
MOG^%J6M9I+EXGXEW="47PE-*8N9#0B6%*/(D)"C!,(X2Y$4<)=RNFN71'N;&
MD9NR2[640(L)C)SNY:?V@>RFQ4'@&9D/G9'I59OJH/9G%:G:;W'R:E4'%3I4
MMNKPA3U,GRH9;+6U6.5<,!FF\NP3_5:NTU6Y88R%4%2QA(8PT:1H,EQ'V@I*
M0HA]KM_L.(@9M@IQ<NAS;B_[5NHF^T@M-V@$!UO)+T#6<7JZ]QA8&$O#(SOV
M"LH:U.'Q=#"GAL=U(LOJ[1TM;B4HY%+SA#"Y  9 W,WN<L.NTP2S;&HZ:\Q-
MMSW#S/'6'M3>'MW=.?GS4.15EK&\SDN;W=8AF\N\+!>"H2#RL:D"PSA$U(\@
M"X0Y@XLB[.$$$65_[LZM[[E1_54K8A/2ZL ]CJ!;</IX4([,[:W@NT?/@!8=
M5+*#_!G(P(@_'M(.;#\>XI,5)I1=0/]HQ/[)_ I6YLK:1*=5+ACS!6L'3E_-
MTJR._-$7[WPLP1T5@$F9F6\?EM+,+G15WRXU.IGI+U> -LW_/-!LTF]L.F<5
MQR:GFUWZZ;HWR_1LHM^>2=O9V^US\D7R_#9+_U.*CT(_]ZE*Z2;36W6.LI#B
M,MN-<-2_Z5=$_"97BU!*+\*)!R5F$42"1!"'V&R^1$$LDU!ZTBDL<6#YYC9K
M;?AV1[\+L-40[*K8Y%,$K9+56<(=-4&CYP7XS78M,]9C8+=7](J#.]4\.MVX
M.F]3C83^0!M<0TLWZ=;82- ^WU0;JYL^*3OI4UYLCL'[,4LB&D%!8@Q12$+(
MI$]@1,.(4T%#(NR#4W=;GAM]U[(YGG9_B9?%BJ(O"B/SW$  N"2+[ G$1&9\
MBT1EJ;?H#)04[:C^W4D6=V^8,%WB 3GW$Q\>NJ!GQ8N*WA9QG/@A8B%4"9(0
M\81"%E#?)"-#DGHXE")8K*K--2OSI&[6B7,VC8^]\=JG;E@#$U)^X/DQ@5Q$
M)C4R]2"C4L$0(T]Y-$8J<LK9U@.F69=7:V"R,V'=E1^9D2^[-7:O6K&GX%!U
M)^I&IZT<L:?(B]H/^[^.7RF1\WR=K4K-@L9 >]N4Y^-!Q$@2^S"DH7XW9:@@
M81[5C.9+&B0D"J-@K'J)!R6:VVO=2FF2(1LQQZN<>'B [%AA4MA')I0>513;
M,6ITN@!O7[.88B? KU!2\; \LRVLV G?.>45NQON:0DNE_DWJC'XD!?O\C5;
MJ?6R[:A.H&WZ^D>1KN254N4B$IY4TM>&HL(*(A,7CA6)(%$X8!$F"4=6D:(]
M^Y\MNVYEU:]SJU.UIFD.7GS*R_("5(KD2CD:6(Z#9&F)C0?]V";;T*B[&WG]
ML!O*&G3L?5JSL1\T+^S+GLT,D:Y[4P^0!BKQDHA#'YMJ88QQ2&+],6(>HASY
M),%NUN7!;N9&:B\R49^N[><"JJ5%>#948YMY[BB=F:U[I)J&1SIYQ5S=I^H.
MGKBZAS?>S0PS^6J:7%EEN\Y!3.*JT ?'(8.(!!XD'H^@BJ. 21)C[B%K%_[9
MXLR-4OKEN!IH:"QV"R8%?-+UY\GEYR9A5JO1R<7G&&/DL*$QZ5A-M MR>6\,
M&\!-E&2J4EE%*M%G+PV@JU61LO6JV@-?Y4"T(WU;C?2=7(K*^-5?21/+5/^N
M6\C51=4*;^)CF=S]#7Q+5W=I!O),@B=)"]#$3&4F@F:Y$UK%G[BQM%,%EGEV
M*XNAXIT&&]'.?9WS>YEN,V@P1/9VD(9KM9^5?5-0(2\S<:6?KN*E,7^=+U/^
MM/!B8J9+##G!%"(45#E*"*2!Q"Q,8JF04XE>JU[G-F%>ZU$P1XL.+'7=C' [
MS.UL\L&1G-Y/ /ZLI02C5-=Q F@@\]VNSTFM>2<8GAOW;C?WSDV;W\M-_:]/
M9F -Z9E"<U0AY-/0@X&,.40J,;$XL8!)(!,]ITBD JL4]19]S8UTFD3-&UE!
M*VRO>GY=(-OQS4#0C<PRO5'KDWWV%![#)9T]VM/4N69/J7P@Q>S)6\Z+_=XI
MCG-=Y!^,F?R>%N8T0'DMBZ]WM)#OTN5:&]N+,(ABQGP"21)H-HD$@DS%"F+?
MXUX@(X]1IV0Z[B+,C60:L8!LQ#5G)T!I!.X7@>TP&':L,R[$(Y/1)HYZ1_H+
MH.4'E0*@U<"<60>5#A>@T6+X0&EW! >.A780X%7"G=T!.A;1W*.EGAO&+])U
MMRZ<..%AH%0$)34))KE'($,FPRXQ>2891H'O1'5'>YH;HYV7P/\XH);;N$/
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MO<3V%\13DOJ!@"'V0H@(QI R;?'ZB: >#1,_(4ZK7\M^YT8BE=A@*S=H!+\
M6]%!+;MC/4S+<;"CEQ'0'9EKA@#6O8JF&TQ#U=6T['7:2IMN4+RHO>EX>S^R
M>G__L,R?I/Q2UZTY$  :811%2L50)9$Y"<DDI%@R*"4)B&8N1:13XLF3/<Z-
MH*[ID^YK6>7WEHWP>GV0296Z)JD\C;8=&0V*X<@TU,H*V])(X\;?6D,S$/6<
M[F]2TK%6_SG=V-_8<P=@IZAX4YK:P\0GG&#(]2K65)U D"61_H?Y7B3]P*.>
M4ZS^RR[F1B5&PLH[5"<&.UG$VA9)2Z__6?B,[?)WA,;=WW]4^Z&<_2\[F-;3
M?U3!%V[^XU?V>[E_I6EFLMQ=95_I4C?='@A:<#]12"$)HX0BB*+0UV]WA"%)
M/.63B,2>BGM$X!_KS^IYGCX,WX@*3$DNW5=N_(R5_U&DC[)<I:NUZZ'#HV@+
MLW#TO02*!/-Z1<FH\&&<$$VHH<]I:!4*. C,DVZI3H.O'<T.@=K(9&M$!#]^
MJHJ3:=SJE"QI>T2D%7@X[CT%R4 ,?+2;27GXE++/V?CD]>>DES -&X_XVSJY
M3IK=;K+KE&^DR@M97W=#O\OR_?=5074?:4:+IX\K>5_^IE76=YKUC[ZU#9-;
M>)1S'A )N305++%,(%%>: (W$A(@202+78Y,C"BK$U=-<,:B2=3 *GW:.H$K
MHU&?Q!;C#*\=S\UDT$:FRF:\&K*L-A:WJFX3V)7MB#;75^I>@'WU-K&^0V?C
M&'40!LWF,8ZDKY -9%3(#V<3&;?+GIL=\M;L_#<5H1(JD8K\$"(O4!#%@D,:
M*@&)I$HH&?D\=O(5[K4^-ZNS$<ZUCM9AY"PW(?KB,?96@S44[AL*AU0>:MM@
MK^UI-P<.J?5B"^#@13T#&.[-&?#_K-CB2FU.JKW-RU5YF8DJ_Z))<K; $9("
M80&%PI%^D>,(,AQ%,/2C0,121+%O=3[!M>.YO=Z[<E>!15+)PM3Y%.8 3UJ6
MZRK//S=Z.(8ZV Z%'2F, ?#(?/$<V_I,5 MI)7FUW;*1?<#("$>TAHJ3L.UV
MVJ@)1S!>Q%"XWM_K()7,A!2UM_+RMI!50K7&\1TB*H/0YU @CQBR\B#S$@]Z
M^I_8"X5' OO#KUT]S8^=*EE;=_E&6L<]A=,(=W/0H+B-3CH30>9TT&H8Z"8[
M;-470M<C5Z=A.7'LJJ.!*8]>G=;CV?$KBQMZD.BO>2Z^I<OE.RG6?)6RI:EH
MLUDM7J\+DX:]K.-E%WJEQN)0".A%&$%$9 2I23# F61)E"0<,_LJ$BX]SXUD
M761W( ^GP;#@W[$@'GL38@;H.E#U6"A/1-TW>P<@5JGQ.M_1%;AMU-(K&KVR
M:56K*CALG=/@H5%O('[O@V4GWSLU.!W_]]%S;S[HU8#;_% 6J\5G^A]Y\79=
MKG2[15EG(">*2I.7@!$O-J<:*&0X]B&*I8^IGT21\&TF@</-SXWI6^&<<HP?
M0:Z;L<_'8V1:MH7"^HWOUKAK?:WOW%E;ZT_;=?611B=YM;L5:M_?$U?U,.*^
MR$?="EU>*;,34.\"W,J,/U4Y->ERX2L?!<I$T'EQ !%&/B2<Q#!$7A!%&'M<
M6%4*M.IM;J]P*Z^9WJJ D!V102.S@QEQ$FP+PVQ("$=^ZZ=&S\'P&A+%B8RM
ML]!T,Z5LT>DTGTXV,IW)9*O/GIED?5._O9//:987Z>JIW3-])WEA\J.8S=@O
M4LC[ZDQR:0*:"8UC 24R^89CX4.]D/:@C")?,!SQ@),>T8Z6W5N]!],'/UZW
MQX_TNY#MAT.DI\(ASAH-N]V3(<&=*)GHX9B2"]"*7D>I[ AO:NGM#D-[RX#;
M*HXP#K2K8MOKI)LJCE \WU-QO;UW=&#5:MOZQ^RJK;#XR7QNSW\\+7P6^)2*
M&*HH"4R^.N,-C!.(DH!1+D(_"9V.J5KW/#<#<R,FJ))C@>7VB(QSZ)XE]G84
M-@JB(Y-8*S/XL97Z)Y.08XMQ)?GFK-C3H!%S;F@-%_]FV>_4T6QN<!R(37-L
MH!]C-0?3KFFQ>KHI:%::E.1Y]BG-9!7>MDAH@!,5)M##2:A7O]KZ(I('4'A)
M$$B94&*7-\JVP[GQ4R,OJ 0&.Q*#/XW,H!+:,4CM).AV##4DE*,OA,]"T9F.
M;*$9B(5.=C<I^=@J_YQSK._KX67[RN^D6.\>Q-@I:U5>EIK;3#ZAO^?E0\KE
MC2D':LJX5E5<%RKP$$<AA=2/I.8@3T#" @6E"D2<,($\;G6D]6Q)YD9.K2Z[
MYXMVR\.5%V"C$&@T<O WG35H%IZ\J89B9'+K,PK@STH=JUK% P^,@Y-PJ@&:
M:K>6LO62%D"D)5_FY;JHAFP[-JP=/)[?LS2C34Z\^X>E-).76!=M9KQZS_?"
M;.;6E=:!7K7]=5ODZTQ_NTKO]5<75;!E(7E^FU5986A9RB8$<V>5\S.XN4M+
ML*H>!Y'+$F3YJFE8+X>,#X[>FMHFZZ=\O2J'2I4WQ-!V>C_/ZF ZS^@0..QY
M30=IL)\Q?UWD7$I1ULGZ='O7^O$W)KSO)=R3$"M,((J5!W$0<JBDK_\G#OT@
M<LH(<;B;N<V-K92UWVX36:Y?^+)*X;3*MWEGZF\V*9T>=$-N%OT1Y.WL^//Q
M''F"VX>RSH!5R3B<P=Z-P4!F^I%.)C7.NQ5];I*?N+HG3="GZES135XQ4R%;
MHI+EKT5>EHM 4$(Q-J8V,?\D'J0L9C# 4H6)4-@73L[)4QW.CCH:>0U'T%KB
MC6W@R NGH+9DB $!')LK=K!KA 5;:2] )>^ O&&)S% ,<JJ[:;G$4OD7K&)[
MWT#\<J5-YN)C9A*'5#\L$B[#)$R07L:'$411+"#S?0HY%DIA$2 _Z+.E>[+C
M_P*;N>;D&[B7J[O<5#%L)3^3=5X,0!3)! N40!*B$*($4X@9]:%4B/@210)Q
MI^.(PR _)<5/#GE/IC\'R%>@^DI<L"/OB%1_#)JQN/Y%?Z]+]L?4/\GV1V_L
MX==M9XZW6X_)EXW'XZ/0S:<J-6O<R\KYT4@@:+:;"U'_MM:--2D1ZRNO"_E
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M]5C>Z!%KQK)5$%0:5K^\_E@Z>!E>:TPG\BB\PMBZN1S&P+_3O3!HA].Y$L;
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MC4O:RK&__,C-?Y;+:O;^J<DX#\WQ8;W&JU(G]=@W.F?D'/:4)AJ/2?:;:EU
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MHI^Y$4^3S;*5%=3"@D9:UXR?AZ'MYI<! 1N94GIBU2/W9R<29^3_/-SNQ#E
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MJ74N(^OBM?8O^1>%^?+;<[X27S=5G!-E08+]*(51&A'U<C.=;.5QZ/F,J4=
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MCGC">  ]Z:E-A4A"B,,0P4C$G'&F_C]4*Y2OU:-U\Q7:2C'A"JVV/>E.UPK
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MSX(-0 /Y!(RFG'0W;P/"\3[<ZEX'(_3SBHN7E<[RJ8_0JO2A!>%(,,9]2)#
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MPE823KH>MIIP&\+-.W2_[9+T8TU6G!2\_.V5D[4(/#_V@B8&-R"8,U]B&,D
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M=Q>L<*@V'Z1Z.-0//[[[_/CAOCX.?]J0@JS46P+^J)2%N=86E'OJJD%>Z^H
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MU[O10E4LMRZ3^V&C#YV4D9;EO#JU^OCRNLS?A*BN^::>I6=2BF_JP5B$7/*
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MA]5"T]97N9CFHC(P/NKOZC_E(K^?R]]N7UYG^9M<?*9+_CS)>,H5%P%D69Q
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M&C8)AI7\;47=#A_N0(YUGHKYDSD0NI'&MUM,9,PB*DD,29IF$#&<0,:2!)(
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M51!2A*5U%IJC78R.V]<E6=FVF [1[,>1;.=C/_CTS*!]0>,0['\Q1 ,%_)^
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ME,$T)4IS !>0ADD"(Y(&.%&(86659_XB*<9F0M1ZF+NMI2:@5.5H+8:22TS
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M,.Q%@\X [5U Z-Z2&R->T5+OORUO97GW2$MY6\RF_/6M+OV$AEF0QXQ"$HD
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M0)2GY= 0 K$^,<(XI&2H$SG6"%XVO;L;/!K.?582Z\#@*%;O8 9^2;=C0LO
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MV,(5,KO:R B7B3I)#<$5H8@T(A,K@R$A&&Z\D:!8;4P]2<RPN<+^C%,%T3>
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MTO5PN65'# ^>:PV$.HE.I.0,G4@N"3,N,JX<>I+5F\$]2]&P1XY]0*ZB!AK
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MW2V+?% -.4K69_0$'8GEN%QR$ 3%!41[Z:BA24A:.U_U##G#.E"O@:A:NF@
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M$JJ2B()&EJO7"SY+4"-8VD'33X%F;[$W@*$'/+R97OKQ9"18$!0]!&(3H'<
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M[$38L/<SF\-F?64VL6O?=:*/\]LQ>M(1A7<XG2_F!Y/T9CR/TZO"68H\!N&
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MQ)OQ4G9E+,OM+1X,]3,81RU-Q%$94&Y0W%D!*#P*-*I$I<\].GY/D#7L4<F
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M2CE:9+SVG(<G2!G8\.RO_T?VI8+(6S4;A\<?/KQ;I60./KXY/%XF?X\^[IK
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M7JY0W$: #:23M[:M[V^NL$-*+M(DB3,<[:LH!2Q"<0*X+3MTT36ZXOV48^Q
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M8AR+8X< EQA#S]9AP;6+1D8*+KEAQ2HM&-9,&HN:]HF,X(IWD(1PJ$P5TR'
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M[8BOY/4)OUQV-ZO6-=M4NS(R*$E+4"%J<"%&8-$%R[B*R%O/GWJ2H+&T*SF
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M9';)%.,F<YTY6%1UY&^.X+4V(&0J4D0NR]W7D_WOA+H0-FQOPX->%#77TPC
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M5+>M<3R/N^-$PR^V/:X,!/J0<ZS%L:8:B&+ Y< @6&\"5R[IV'I037LNNFV
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M);GQD'722HG6J2"/$M,-5<?WA-9&^B.T22_.YLOJVUYVD[VY/5BP)!T#,;)
MI[PSX$A P$1.25HA\&Y/R^XVZ;%%NZ'G>%Z:>A7ZT&!ZB;1LFEZJ9Y9/SN>+
MU?2_UK]]/5^\F)-[.;L@+C<YL//9<F*5]JYD!]+7238%Z\R')$!P#)X)GWV6
MG3"U_=K=H'4\KSF'4,'0"+N*1%YBODBKVOR"N'HS2_-S_!S^_'"Q^#9?XG(3
MEEN=E%)D@K6LUA>3!G('$7R.NG#OG??8"5O;K-H-54?VL-*;V$?@13T0;- V
M64[S9H-\7H39\I(R/K%&IJR0@4%?$UHX!Y?K!-<LB@]:<G.WU7@?X>"C]'4#
MW_&\>_2NHQ'@[R,N5XMIJA%M6'Z=Z%RP$/E@?"#JM4.*09*$;'@27EAO7>M+
MM-L4=!OQ<GR/"'O(>>A3[SW!?3WK:%TM=WF(?R%9WMH#$\8U!19%0XHU.34G
M!LZ7!,5B*+E$HTRW;(-.RW6#R?%<]/<DZ*&A0P[@Q6SU$==-]M93LEXM2<Y_
M3 SC45;H1^T2*$[2"G689"PEZ>)=]L9W0LMC*W0#R/'<H;<3YP@.G0>D0UY<
M^DI<?2 CB2=GZV_0'U^Y?K5&MQI/\O=^>H&7XIAP9;55D?8"IS!"K:/58@MX
M$2QC):7$^O**FC#0#:K'>X]^>"V/ .)7+*TST2E66=0M^Q(O_SW1T3!;(@)3
MBEQ#41RX8HDM;JV3#NE_K:?J/4E0-P@>S]U[>RT,?9+>)?[-[/8CZ<0Q'[-0
M)"83:).PH, ES0D(Q21F!2^\6X.7YU;JAI7CN5%O+][6*<7__6_W1$TL_WO]
MH_5/ZE_^B.6_U7___O'-K64J>]/EC^5_I/GYY2HG+_[7[V\^O?G\YO3]IP^+
M^>OYXCR\Q%68GBUO<["<GG\[>_:.ZJG/_>TGC7>IWWSU'C;VH!?_7.$L$T*;
M7\DL3R*%;R&M)K4OM"XU9O.UA2>OX3TCGRM)4R27P60\0"'!-3W['E-;SWY7
M4154SH&,*$ E&R'H@L!CB<H&9WUIG9&P+8WCF(J^-WKNGF6]JFH$'M,GTA'6
M1Z<K]C[AE_5 R9,_I\M)D24ZK..XBX[5_AIB1C*0)4O'I44RRZUQ]Q1!PX*L
M7RS<!5XSQ8P!99>TOYR?A^EL$KE)DG,ZR[FO=RG9@K=1@TZ99,*L1MG:#[]%
MP, H:J?8NY#96<I#^]G_F"^_46SZ#NM([DG0F1M'IEH;:VL%<8%0G*5_D!22
MSY:E;I. ;WUV8*WOKIMY$T&-P H\8#77F#?*VF -0N&1#NG"&?B8&$3)M#)1
M*EGZJI&^0TJW&J)?XGQIH8R18NHR>L3-7N-<RNP0:QUJO<<B7FJ36G FVX"<
MZR3ZRE!_E*AQ.,M[J;X#G';7P]#G$841W\)R24S06?V"A'K;[N;:"D;1^6RR
MH4.Z4"P1@V=@K/1!8LB2=7M'>7J=\:%D#XW.^Q'OT$@Y6>(BW&=!)A^$I)#3
M.%?309F#X V'F WW6G-1;,>7M@>_/^PYU2,R&HAS!(?299;4M:/_=O/@LC:R
MV7%M41OPC/P_E8,'%XVHW0P1R9=CP;9^-WN"G&[)0[^$P]-**>/%UV;S21U9
MB(S7S<*!."C@@Z\/U,:7E!3'YEU7GB1HV&.LF=J[P6D''0P(J.5B-3G]8T;?
M^3K]MA:)-5RXG#/D4,NDA0U$>!!@LY<LBV!\-_#0EV\ AW[W$S3W%NWVMG74
M1F@_08\%(1MPIYAYC$Z!M+6IJ%,4)S T@"XD7G@HTIJ6&!G2C.RIN(?4OX,4
M1W#F7%NZ%V?DNI^63ZMY^O=:("I@)A<O R9/[KJU=9J]S\ LR\2?Y+YY6L6C
MQ'0"26^OY,,\$.RED!$@ZR;]F[V1 R-B901-FP!4L!D<Q@ Z2J%";;Q@6_<6
MO4_%2)X)]E/OO*FL1X"6)S-1E%3!UPMQPS2Y7<I*B$*0D%!AS(XQ,KK]W_5=
MT],)0;W5,0Y]G;R;6L8)L>55"LQ'_(ZS"YQXPW6P=?]YD^JN(5G%9(#E''G2
M*/3=Z?1](.TN6:.[,=P1 \^#:R^%#'UI>,5/^,G/M\6\5';F5Z-BINOX\FR^
M7$Z<X>@BSQ!8O4UC,8&SCF)5J91#PSV/W2X3MUMW=)>,^X&I;\F/W'"]Q]7E
ME<7;RIBP7EN3)04?2(Q9YHE%:R$X'C&GDHFS YJO6\0->R<YB!';73GC1-T5
M7Z_"8D8[JE8)?_I*XO\M+*=I0NZE\#9S\"+5B=.J0%"(8!0F)JTR3!S@['R2
MQF&OI Z)P7:J.BXHOIR>7:SH1# 42I&G6[O^K)^J'/$J/84_0@NR_M*HNZ/V
M#@G&#97#7FN, 8Z[J*L9(!N7 KR<+M-E4X[KT8!T%H19IA]\FR_#V=\7\XMO
MRSVJ [9<H4G!P#Y<-:HA>)B$D[LD7">&9V,BJ^5LR=<KV, =>&T00M9:F5(D
M_7GCO;\EB8U?"G\+9V&6\--7Q%7M%)/S>M.%LTH6>;P7I/W??MPFA3YQ=I%I
M+SY,^N75@8^IQ"082%YRG6-9-VC-N#=5AM$&8UI?V!V(M6%#ZCX1_<R+YBBP
M,@*?XNE\;<G(,3+6TZ%'#KO*,D(,SD(*RG/A%7E(J3'P1UPA,4H(;558L8T^
MQP#.6VGE=;0CJS>VPF@%JBA7O74'R$Q6(65!XOJK%E9LI=@G"RNVD?+0-XWD
M/B_KAJLI=9M<.M1<:Q8%%);JQ =6Z(BP"-Z3RQY<P'3WZN>1V\3[WQY3B<56
M6IJW$]D(C$+_5OAG^,=B\DP+"2S8:G^%)S&K C)E[W7.V;#6X?,!V1OV"OP8
M3M.Q8FT$V_ 6ET\S>:_7E.1)$V,N%5!D:L )YJ ((U$4-*)YM?>NM/[J[N:.
MX)L/@(3C0OQ)2K7!T/+]?+4>1_5V'F;+CYAP^KW:I#I@(MO@16$(S%DZ=6,M
MDO0^ /=HM$8F4VCMS39EX%<_/ Z^-QICYK@VS(<%?@O3.M]JW5;ILE'.B\L9
MS!,ZK:V66D/RY*4J;SDYJ)H!F0[,@D(;5EI[88U('_:Q]Q?<),UP,H+M<4G\
M:=GF_+SB- M3^XP!9BWJ="('7M2)M-E&I BP/A8UWA&[4SOL:_.Q;((#H6$$
MN-]JN]>\I=6/#Z2TU6:LY[>JQCJM><-]",HD44>/2^U!!6+<"ZO!J2!5T:56
M40YY.CS+P;#/W\>R/P9$S=#7G%NP?GJ5YK<>X?-Q^N7KZK3\OMQ,O[O!OW?:
MN20%1,-)%0P5>"L4,)X\ST59[[O=D_9 W+")Y6/?$*. Q'$=(U<M6V\P:XH)
M4>DZR -K8D^=[QB-!6:-K[VH/-H!P^_[!'?:$[U-]AG[GC@\)HYK ]S;ZRI)
M8B@7*$J7VIPX0_0J@S$FL,BCT'Q IVFG Z&W 42_(/CWPL.107]SK?8A_*C7
M:-<QDW>&VVA R5@'8QI1!V-ZD"%:DP,7.;?NF[4WT9VV06^CD'[%;; _-HXH
M-B N:>4Z\OK5^;>S^0_$WW"&9?KS HW\OF2E5Z!<I'^8FE404LV'+R5Z\O]4
MQPDJ+:GJ]@C7V_2FL<-^6!0<$?PW(Y#J/)#9$J^Y3<(KYJ4C+Z]VL(E!0K0*
MP6F>;-9&9>9:8_YA4KH!_2_[W#R OH\(W;>C_+?3$*=GI+"??$MKM%<Q@M&)
M^+9.D\A=!E0V*\$UYJYC:=L1U0WQ?]E'Y$$Q, (O_P8'.[V+\%0,"L>A3I0&
MQ5(&YXV#A(BD#:=I]S?V\?<DN=N&^,L_&!\2&+_"&7 ST(^1.V>1)*[I'[*6
MT,0D@*OB#2E$16T/=@QL></#_[*/Q$,CX8@/@QL<9V9TH3T.43H+*GD)P<D,
M!64L,10KBQ[)>;#MSOC+/P\?&!XCV!!WIC\KETJ,-H$4=9:EY1FB#@68BLX'
MQWC0K4OU=IBRS?^RS[8-U#8"T'U8S&F'Y&6=$_QR^IUXF:Y(E#^;L.%RHH1"
M.D$D^,1JE%$,."LML83:<Z,CIDX-5+= 8@>RNL'S+_^"VEK!(\#LW\-T5CL/
MG<X^A9O] B<4^VK&8X%B*0)0U?1[&1Q0,$R!@ U6W.T\MO_$W$=HZ8;.O_P3
M9Q-5CK5QRMO3]W___.KCN]/?WK[Y^\EZ-.E5D\MY>3N???F,B_.7&%=[M$[9
M>HTFS5/VXZQ5^Y3Z_6O\7O>4*%%'+[&.**M>7RP%@HT*DE,R>^E2\LTS(1ZD
M9.\W<?KJFQE]ZZ)NX<O:1\?K"#4>P%I'ECH%!JZ6"6<E2^;>N1YR8^^3,7"3
MD?WU?N^)>4]1C^!0K+MNM=EUG^GOK+L(1%6*LZZ T5J2:4ZUJKS.C@B<)^YJ
MN6SKOHD/T3$\7O92[MW(=%])CQ M5W- !+.)*0&*,0Z*9P179WHR)>D;6?,0
M6_=%>IB281&SOX:?@<P.XAX%:,+L*K7F:O:9C]H@3X"\/KYZ3T87I0'RSM"9
MHJ0TK5N2W:=B7&#91;?WX+*7H$< E8_X?7[VG8*'%[3V=/4ZI'J7]V/###<Q
M('<"$F.T@4@:%&_6DSMC24$G(UQK,_,D0<.6/O< H';B'_JU[ .):[I<SA<_
MUF74&PY$BFB%RJ"C475>E09OZA" B,('VBO6=QNY_.#GARWR;0B'1A(<@3UY
M$;Y-5^%L_?IU&L^F7RXO(3;,>)4*RS7GA\L"JF0%P5@!(2FG18Y8?.MZ\B<)
M&K9 M@=[TD[\(\#2[7C@<DB6S,P8&X#3@K0;F+Z<42-2\<G9Q._E##8.JX>?
MYMTZ2MI3RJ/#R7LRIE?C8DN1PCH%S->&]TIX("],0G(\)DQ*\-0ZJGZ,EC%%
MUMOK^$G(["CPH1V6TQG^XV*6:=5/==3+ZL?KZ7=\-ST[(YW46]'JV]_QQYB+
M1<;H(7CRPA03 6+)9)E3\#[6R9ZR6Y;^]FN/"3^[*GQ^..D/#:[*S8:_U]-"
M+%QR]K2[+[7+UEL/23@)*L@Z-E9+T(P[:3D),^1.\-IE]3$=:BT UKL&!H?8
M_&+Q (./;!Z'7 :,#+2N;6I=*76&>H24I"O)&LU9MR3TK98=-D#K 52]R7P$
M;M0_PV):O<F/875YD>HTA0O6<V"REJ9:Y2!:[H%GE1-7TG'6.HO[+@UC M#^
MKO9>$AX90JZF?)HLHR\U.JU95%@B!+06K"^9U1EG2;?NAW6?BF&=H_VT^@1$
M=A#Q"$#R"=,%K7KZ'1>SVO+D]7069HE.W,K2IWE97/_DS2SCGY_^"-_J3ZYL
M)N>)U5FQ)=8K"JEK*Q3#P:0D-(;DHVT^]V ?@L<#O5W0<J\?_:%4-P*<WC;N
M;Z^SI- [XYC5-:F.!!B4 %\4@D$C9$V_<[YUKOHCI Q[.]GO/=-N\AX=;%Z$
MQ>(';9"3\]K.8"(=TUZ2GV>=$Z"R3>!CSO7]QA1A,6FK>L7.;7K&=&FPH\*?
M!-$>TA\%DBZ7O;2R^&*^7"UKK^$2<W2^SH) 4^?=B03.!PU!F*"B+<[XUB[5
M(Z2,Z4Z@%7[VE_GVT/&7T)GA%SHM\^>FR4%7"9P3E3699F\HBA6UO+ZV(?7,
M@_9%1.FS3D(VALW-]<<4J;7!RL[2W=VVS.O;76MD7-?>EL)$S@BY7GTH[=?M
MUA"TMBBX09]$Z\/I 3+&Y-2TQ\DNLAZG/;E1GE<2L>\+AYH_1]AWK';G2R!S
M#"$E$VQI?2 ]3,FP_7K[QLZ.$O]5BBHF=Y*T^RFKH%4&*:RXR]UU:<7?>I?O
MSR*B-[-29R#7WQRBDN7)A0^KA>XRZ+?F)9K:Q4L[\,G%.M7:@I/,0H[9(8]D
M+USKZZW#U;P4CL$;+)=59:J@@,C10)#<\J""4+G?=(OQUKQLH_<N-2_;B'H$
MH>Z#>?K>E:*=E, XJDL>R$520"RH%!EGOGER\7'4O&REW"XU+]M(>H1HV=QL
M8^',\90H!-,!E"?91*5KN6GUOB+7(O;AAAY%S<M6&NY6\[*-N$<!FGNE&)Q)
M0>:VEA?62QT2#03#.*!SW#F*Z!6V;H=P)#4O6^GV^9J7;00] J@\DP-DDHG%
M!,BAMF@*RM.A+0PDD8L2%.S9YE,R1YR8U0. VHE_!%AZ(+,V&!XP2$&R"1X4
MKP>Y"YI,L_,Q%ITC;UUJ=PPYZOMX-7M*>70XN9&+ED+A(40-DCE6KWH\.*\D
M!,T9%TG8Q%JW0CF:'/6M=-PU1WT;@0^=X[E#EK377FJD2#.PXFIWA4#VDT3(
M/&,\(D-U%T^_>H[Z5@K?,T=]&^D/#:[/?\PW['7*C:;-J%-R G2)Y.2%5, '
M(4 YK0-Z;DG*G8"UW;IC.LA:@*I'J0\-J)U2[I/0F=>7=R8<>9(V4.R0@P*&
M(G-=1&T4/&S1P^'STW<&5^\:&!QB6R7@IY"S1:_ N[IE=*K#!IP&D[QBPB>K
MU+.O'3T5/1SHA;L)J'J3^0C\\GO)V\PR*U+,P&M/*J6U!1(:!;I%,JZ$LXRU
M3O\<?]'#/K';7A(>&4(V6\F*B%IQ U%("8H\/,(XL6&5MR8R02%+ZTR:T1<]
M;*75YXL>MA'Q"$"R7^8\.L.+,20Q$3BY=I;8SB6!3*QPPY*)JK7-^;6*'K9"
M2].BAVU4-P*</I;#Y*0R)L@ 1JT'[VDR\!9='46)VFA#,6S[G.,C*7IH=W&Y
MF[Q'!QOR^'"3<B\LTR5I!.X+67UI>,U]<Y!C824'GU5HW=#G,5K&=/NTHZ*?
M!,^.4A\Z8KO-Q)L9?1:7JVI!P^H#+J;S_&J6)SD995+MZ&#J?*P<(X3@#)GR
MD(J+W(MR9RCX8\-QNBPWICNE_:#2DXA'9W+>A=7%@H+,E\34A+0>M6;K,S?5
M0L,"7FI"0Y#$EI4BBM8OM(]3,Z9@K0^SL[/D1X>A.]5BA4 ?I<V0N4%0W"MP
M*6JPVF,1](>"]XNB'6KU#EX7T0Y'>TA_=$CZ+2RGRT]$2\BGLYOA")]PYC)C
M7$+.Q50KJVL\8 &#X5'8))GJM^_[X[2-LWJB'<(::>6(ZBE>(R[#+%<>E[]3
M<+JX=;\_Q67;+/_.R_65V[\;OSU/L3 2<U (MHXV5DYS<(4K0*Y-9C&R)(XC
MH[]NR=-R^X7H,@#.*B,S6D$4O#YJURO]'"(4Q8OFDG,LK8.\1XD9/LK;$P/W
MQ^>U$/N 1^1RL9I\#+,OE]? G&<91-%0M"F@A/00N::@0PHRN$(HYSLEO]%7
M;^"$?O<3([<6'#B]MHWRYOM*<@SJWUR(%DYQIJK)OSS3><XDA0C,(I@8"C,8
MN76=C$47  QY&[V'LNZJ>P?)#:SP=]/9]/SB?$.X%BIJPST(N7[R50PBLP**
M)\?*,XU>M5#YK44'5OHN*INWD-_0B@]_WB#<H"HF:0-<&F(?N85 Y$+!%%!%
MRQ+K5&#QG.)O+CK,W5TSQ>\LO]$%P6N[)S%1 )<B*2QI4,DA!.D=6!4P40CG
M5?.Q,F/+=6_K S22]>C0<B,1R?B$60KRD3-9.I5KM9"H&\BS4FQP6IC695E'
MD_&^E8Z[9KQO(_"AGXM.SM>Q^IV;G1]O\3LNPI=ZG3.=?UZ$6?J*I[,K:QQB
M=,P$\KY2[;9B@@.OR)@R+TL0V3F1[ERZ/?)ZM,OJ8\+0KDJ?'U(#1P2QSW_,
M-PQ&F:+AD4)\&6V]KQ80T3&0,C%AK#?E[FCM_2%VO?J8WBL/#+'=-'!,$".T
M7'=0%6BD51*<810().D@Y,B %[0<O?0^L^8@^[G^F)XR#PVS';5P1$"K:=Q7
M :>,408O(7A?[RM3AA!K_)F8XTYX<CF:GY<_EQ_32^>!8;:C#D;@S=_+]Q6F
M&.XHFO'1UW*DX"%:S6J2G)3"4@2<6S^?CRM/OI^X;R\YCPPGFXVE=4XYU%?^
MN.Y(+DD<WD=@M..B4THXTWIFV^BSY;?2ZO/9\MN(> 0@V2_E.EN/JC9'E%H3
ML\:0R:Z.8'2EI*QY=JRUY?FULN6W0DO3;/EM5#<"G/X6EGB#>JZM(V%%4#($
M4(7<!.<"^0HN)I."B;EY']3;% P;!S9&TA["'0$T'CK]UY9=Z:0\\0^6ESHB
M01H(*=+A7TS(IG =XR&2)3K[1_U-M^W%/VHB]Y'BYVV-(Q:;K55$2=YP!E;6
M470N4C@2=(&L$D,RG-ZU[];]#$WCR[787O,=X+2S&D8 JP?$8X1!%S-Q$ ,9
MZCI)VIG(R$9'S94*A3</U'8T1;WEGO9CBO:4]>C0LD$\XR4JI1(A/H7:@,V!
M8S8 T];8E(S5S8<F/T3'L,9F7]T^"94=!#T"L#QH*J_3N(UB7#/AP :D@!:C
M!;<NR+5(_Y99:->ZC=F3!'6"CSDN@]-. T-?6[^8SY;SLVFNXRMNW9-.;%+.
M6E- N()U9BIQ(7@!C.@E2JN,N'-9],C5]*-+C,^+V5&'\^8"':F5>3$_/Y^N
MUC6PB!]PD:K"OM!>BD5F:07X6G:O7*U+TRY BDE%+5PFL1W YCQ"WOBRDO;#
M6=\:&MHFO<45?>F:,\2)L3P*81U$E46=^>3(]S<,4'&K8XE9W&WD^H@MNO?I
M\;U<-+!!^PEP!+:G<SF9D\)H%CT$B_6&BI'GYDI]-"PD+C2VY-+8\#0M\COH
MG4\;J].+;HZHU.]]6"SHN]^Q;4G?O<_V5;KW-/W]EN@%KPP/Q8.,C%P@BQ(<
M>45@0DF$%*4S:SUHY'!#=X3WW#J7:\?9!(H' :XD"BJ-0*\$]];^58?N;*/W
M+D-WMA'U"(ZS3Q=QB?_G@LA_5;L77\\**20-F94'8^J\.B-JIS:>( MF/<N.
M^[O9/_N_GSY,RO"HV4O%=Y]&&\A[G+"Y&OJ@,*1(L2.3M1=Q$II"28Q@)<_.
M)?2^>;SU*#'#0J>)JI^'SPYR'Q^ KC+$55&."W+$@J9_))**]\2$#AF+#I9%
MU=IG?I"0T0%G%R4_#9T=)#Z& N++D0\4&CAN$;A+) 9;9.U75=_;4*N@4++0
MR5=K6C]^T#DINQQ!N\MP#(K?X)7E6 R2R?2^)N"R$L')X"$[C+I$HYUJ44TZ
MLLKQK93U2.7X-I(;NH#X5N6SCY[HM!JX9H1UE4+-@/2 "46.@9MXM^W?KU(Y
MOI7*'JT<WT9^0RO^5N6SRNND>@76E3H_3-1GL,C!9VE+D"HZ&UHH?GR5XSLK
M?F?YC< EO)?_G&NRI\KDC'#FB7[O(&"(Y"V3YY.28<SWF1,^?/5 Z^!S+PF/
M#"%73;VUR$D2!Y[ 3$XLIU\IR8'SS+B*2D;1YR2&,<29^VFU0Y?]+40\ I#<
M21E6/+HLDX0D4!+UTI#]JS,I2^(V,B/H0!P^'_N@??"WT>?3^=C;"'<$T-BO
M+L$;3F<F&=W$0[VWR9[DIFLR>V0!%2>"6R=M]U]2<LA"@'V =SC5C0"G#T[O
M%AJ-L=&"8:ZVYK8<HL\*D-7NITX@NM;>T$-TC*DP=W^/:&])CQ MF]T6BJ+5
M> %3L+;A]AEJ+3%PJ157A15KFR=;/DC)N(:;;Z_A9R"S@[B'SF+Z] <9SK?3
M&=;1;%<F4NH84TC@ G/UBDF32+P&Y(I+;BTF>\=/>B2/Z8&/CPL!NRALWE!Z
M8S 9M[*PKGJG1%>"8)8D4"\9,V/@L7"P6NMBI$NA>9NVA^@8Y2C[7<#23-AC
M  Q!??DA_*@'[H8#F] &IS0=NU* 8C5OSS*$7 +77G&A4Z?;N:W.E[M4#)PC
MV0-8]A/T"*#R]!Q9YH,VS&@H)1A0L0Z8X2H#*A&T8)QBQM9I5OL/]^TO%;(]
M@-J)?V@OY<-B.M\T[S_YLD \O_%JC9HQ)BPDHVK.L/;@+!? I!-%HDW<JT[.
MRN-K#%R,V-AG:23+$9B7MS>RAZ^<K\R2+9Z1RU4;1D0O*0"TC#!NG?%!>76W
M[5[3$H\M\-)?+5D/)]%^@A[:>FP:;CV,>>(>I;$!!*Z3/D.MJI3$3>TKD1VG
M_W4K('MJE4Z(L$> B+;R'!H8G[].%WG-S?H*:?XD8\$;)HIW(++4H JG",]H
M#DHXD5-,)IMN3?"V6;43<-RQ *<W>0\-I \DNNER.5_\>#]?X?+*6U>"TU(9
M@F>!MD(,X&)60%ZZ-\I[;UDWT_+@YSM!PQ\+-/:7X @<DA?AVW05SMYB6.)I
M/)M^6:OCBID8B@S&)?"B5AIY;L ;&R$JEK1#+"&U3H=^DJ!N5W'L"!#47OY#
M&Y1/F.:S_*1]S+F@\3X FGK/F$E:M$L2T!D;N4DZ9RDZ69?GU^J&E..YM6TK
MW!$8G@<F R13/7/G*);C$A0B@K=T? :7.'*FF'7]CBL=OHU/ZQ?"/:4\.IS<
M:&:LK<*@K(/LZQUTG='K=2%GRR?K@M9!L-9GT]',V-A*QUUG;&PC\*$/HR<M
M)2;F1;0:+'>6&(D<G&"1A)6#])%<]A ['4/['T"'P<2N2NP<06\CT:&A<3K#
M?US,,JWZ;GIV1OKX3.?TC<=0&UW(=;,(@[R.*HO@'!/ -9IB.9:D=2=T/+/0
MF,IR6@"DI5R'QLCG/^:W>7GZ7:*8*+Q3#"0SH8Y*(W-;$S(T17M<QZ3,W:K1
MQ^Y9MEIW3.G=+1#4H]2'!M3KZ?>KW?%Z6HB%+@QJ)_CZK50J6_-3C01?F &R
MM;*83#&$Z'9]M\OJ8\J4:P&NWC4P-,1^VM]/6$MD?U2.[YCBNSN(<V[1&G!>
M9-I!#B%ZQX&Q@ :5XD:$+8^ZKFN/*<QJ>_KU(OVAP56GNCRP>Q[A3"BNC4<-
M(IB:'A0S\<@U!&4\DT6$<+?TZ3'#M<VRP[YA]F"Q>I/YT&C:ZE$%;10V6@&Y
MU)9:3D2(G%-H*PN7W#!QKP7BH1ZQ>GO][,&UZDOBH[LA>GO=B\T2S>A"@1*$
MIL,[$QNUA[J6VKJDHS&B=0KY(Z2,R3*UOE/<3=Y#6Z#;/'S Q72>I^E#^+'Y
M[55W3S312)EH%QA?+S9J5V.,!K3R0NLZM^-N7[5'C$_'!<=T:[2C9N<]BWEH
MZ'Q8S!-B7G[$A.3CY=<DQGH>?PB+U8_34AO53/,T+'Y,O-?.8O(@4'@ZDCU9
M:T?\&<<PL43&0W9SKSLO.:8[I0;PZ4?4(SBR-CM@>5JN*P%?S)>KY<0XJ[W5
M!D+1"$K0*1^M-&"=T *5]"JV+I-[C)8QW2[MAZ6F4A\!>F[+AN( /#F?7\Q6
M$RT22I4E.*93O1%+$ W6K1"*\%99H_I]$OM)RYBNC]J@IXG41X">FIKP>9.:
M\"^L-<>83R[;Z;^9T3*X7-7:XUJ1_'EZCA-5T-,FR,"*K5W;E &'.D V3)?(
ME$VECTK,+4@<TUU2&ZSUJ:.A_:?/\W6^T\T!#A1_.)%4 9(4^8 B"H@A.3!"
MN8+<)I6Z/;G=__:80J\&'M&>PAM:]S=G>%P!^<7\)C=>6%%JI5C!6"@20 1G
M+(-4KQT8'<WW>CUW&([RX%)CNN)I@(RVHAW#.?5 H_U-A[#?YHO%O-8QOPC?
MZ">K'Y-8I _99N*M5 .8$*+  D(*$PS%$$ZU3AW;AKYA<^)[.:'ZTL[0)NJ1
M!\&UX9T4F0+/@H/FJ$#Q&,"78D **:V*P04E.UFGIU89-DN^N6%J)M"AD?$0
MY$\R_88T$\[NHUYC-+S8!"+4A!>*(B'D) &Y5M8Y'ATWG<"RY<(#)\DW!U"?
M<A\:4P\:T).SL_D?]9K^T9%G[R[.5M-O9S@)/*G I =3ISZH6#)$1 .>:1>Y
M+IA8-\]Y3T(&3K=O[TT=4"_CP&#9\'I^R6NXXC7=X/5LP^MB[4\*:VW@PD!T
MFH1KZ$#W7$B@:*04GQ3GK-OU]HX$=,/<\=QV'T(/(_#K;\OM75A=+.K 6.)K
MPE-Q2FH)/BI3IV=Q"!3+@HE:TK:Q4L=^AX[=I*8;O([J KR1Z(<V6+?9N IV
M?[H$UW\2*?Y]C:2H</;Z8I;KE=E$FYRX$)Z"#^U!.2L@9A\@1RYL9$5SWJWY
MQCY4=,/645R/'U8C1P6]>H/[Z?3UQS67@8E@&!?@K6>@5)00&)EJ9PHYI"G6
M?B7M<7>3A&Z@.XI[\@/J8G0GYA.#(:U1&AU*$-S4JV"2HG=5GIBB=EQ+-++7
M\W//H9W\*"[B>U7+T ;N9U+.:?E8,YDO\&263\NKL)A1D+W\#<M\<?T(]3G\
MB<N72)2FZ:4R:Y'R?+&:_M?ZMS5AXU]?YV=G/T[_F&&^3MB8XG)BO&.E-FV2
MNLYW<+I Y#'6!/M0YZ069;I=CQR,Y&X8/IXG@W'J>DP[8'=)W&)?:&]1B@29
MNPBJ)$X:0@/!!".#M3+Y;M?&[6GKANFC>)H8@_;&XBTLEQ=AEG"=WG3S_O1D
ML:B#>M9I4']?S)<D:>]2]K0U@XHU$]C49M(U\$.,FHXFSG,OPW4[4]@-H4?Q
M'G( %8T @ _=UW_$6K] F_'^=3UJHVD3,4!-+KA26H*3(@"/HN;=912Q]:S>
M[2CLEE1[%.\I!U#1" !X6V(OPF+Q@[C99.L)D5%)VD(>/?&"P4 TV4'PT4:E
MK)-6]1HCW::G&[B.XN&DN?A' *7+[N?+J[UR>K%:KL(L_^0'"].:%@9N:_D"
M.0/@@Z, 3PN6'/TVAM8#FIZCJ1NDCN)=I!<UC !6MV7T$I=I,?U6-71:;EX=
MK.\4)@*%C4X+T(%[XJT.0DR:K*^PV>:<F?>MA\1M0U\WN!WQ.TE#]0P=VSY\
M95IY"9OJK%>S/$$NT-0N=:74VM*4+ 2=ZW$?/!GLS(+IUJ:OTW+=\'/L;R'[
MR'@$!NMGZ<R]V&7"<^(^8@0>9,VWR1)BKIQQ@U*C\4:V=N"?(*<;G([BE:.U
M\$> H\<WQZ=5S6RX41/J<Y2T120($9!VB/80*=8@,'C+0A0QZ]8#"[M3UPUE
M1_R<T4PU0Q]Y'S&=A>5R6J8I7![AI]_6B3.S+^NFNY_GE\6 N/[=1 ;)DF8%
MLI9TFJ,5$(0M=+@[5\B1--%W._NV6[<;GH[G::%'J0\-J)M7QZ_^_(:S);X^
M0URM.5G>8DMI5W@=)V"RMK1/2IV"%&BSZ!2D*BG*TFTJ7?<UNP'I>.[S>Y+V
MT""JJ0@G^3\OEJLJIXF4E@NN$K!<4_@85T2Z=L""XKQH9(9W2PZY_=UN8#B*
MJ_-]I=9,X?_];_>$29S]>_VC]4_JW_J(Y;_5?__^\<VM[U<NILL?R_](\_/+
MS[\X???NS>=WK]Y__G3R_N6+T_>?W[S_^ZOW+]Z\^O0^+*K%_(XO<16F9\O;
MK"RGYS7O^AE0;//YO_WDX2YWFU7NH:,A/_CG:MV2Z/_;<Y[!_/Q\NH;'\F26
M7\QG]<C!69KB\N5TF<[FRXL%GD0"94BKB6<8BL\9E-$1E,Z*8G>>@5SG9&Q"
M3@Y-8Q]S*P+WK_5>+F\M<=G]QPM5I"P!M*[9Z8Q9\))IP)R"H2T8_-TBRP8E
MW0]1,FR[F_ZP<K^>>V\]#'UB41 Z7RS7W<5=$61B60!7F_@JD^JP$SIH14C!
M9>>C%JS3:?7SFT//V-U?/?/]934.%6]:S65A,A<Z@V7U6C.MLW+KY(J0M'1:
MF\#S%DH>LE'^7CJYK]<=!#2T9LG2?0NS'\OIC$Q:]9@3G<53^O:FXY_,C )X
M0[&\UZ5.%"_@HU7U54Z@3Z*4V"WJ?6:AP?6_B^[F/0ER0% L%ZO)V^EJ,VWH
M!45/ZXV1DU5,9P:A]@)4KFX105&YJ^/E)6/,I$Y5]/3Y&SX!_>ZG/_#PRD-/
MS6YF_AL(=E2PN#&[R*+WY.A8$"H$4-Q2>&UEA.2=3TR00$2GYE);@>/G^L.8
MCA;Z?!0:.PIWZ,/D]YH]&19KQ_FT_ ^*QJ?I:MHWIY@;$P;(PDLR@MZ""[63
M;,Y,:DGF-G>[\7IBD;$@85?US7N0Y="8.-E<!+QX<W)U$M(&"<PSX,71%@G2
MD[OE"I P4 2EC.A89W?OT\,<%OWH?S^Y#:WUM3>T7-9JJQ6^(/']8[[\1@#^
MR0T3B2M;<)/X'[R $#""P)"9TEK(V+$_P7-+#=.NLA]4M)7KT"CYA*G6&9-?
M]:*^"9VD]:UB^&-Y<3V:6P8CT+(,*(@3Q:6"6#*'@%PZQESBR7>"R?-K#=.8
MLA^<-);LX$ )!;]<A$7^_^<S_+"8?UF$\_H._:56J5<'O=[#S1?7@W9U1&$9
M:%&SXF4N%&45!C(5D\F BG(W6'D,,]LL.TROR9[@TYN\AT;2.GMA%LY.+O)T
M5:WIV;0&ZQ_Q^Q3_N)IRP(I-DJG::RK4)(8$@3QW<"IZX1,*Y[K=8G98;)@N
ME/V@IK5L!XYWU\DMU?W^.]8-\.WK-!%O-<@+V6(I4H,-0=$9F\AJ*B&!_GY6
M'HMGW1K?/A/P/DK L VX&U^*M!'ST%C!+W=9V.PF0<R;4#,.D/E-'SNI#"1&
M_]),,6D[/20^AY7'"!@N)FZDV'EK*0\)E=6WQ>3=R20Z<KYB-,!BM8).T(F)
M/H+.3F;N$8-\JAW#$M-_?)E__UO]W"4HZJ]N .)RF0%5WT91\]VE-K2?\8Z^
M&F:K^1^S?^%R]<_IXLMT-@U7\]V4YU$S#GH][-W7B5S.:^!!2.^<Y5YUBWV?
M6F6XRY"VVF\KSJ%Q\2$L_DU?BA>++P]PPFWR=%Y6^M&0=U3G:P63(,9UZTII
MF.HV'N_)98:[$.D!&>T$.O2Y\.G%A*G $N<(TJ12#T8'3I(\7-12!,E=%D\]
MLW4Z%SZ]&.ZBHX=S84NI#:WDUV\G9*0P\F3 )$G>CW*>'!]O*'H601N3*)I^
M:I)/)R6_?CO<=40/2MY2:D,;^;?AWW@69OGUV7PQS=>V" WF0C#-DDXH58M0
MG4(%"0TY-)8Y?[<@^+&NSP]]?B!G;Q?MS)N*:FAEOSC#L/B#0IW%;1Y09!6"
M9."(9O)6BX7@220Y&5,R0S).W9ZY'EE@(/]N7X6W$-<(RM6N@]O?+I;3&2Z7
M&ZMWF4>FLL@8(T)PE@Q=S *"3 FD*%JQY 26\(2)WR6-]DF"AIVYU?#"J+WX
MQX"E2]HWAR1R;WBR#'@MV529S)YC%-P@9AZ8BHR)UD7]MP@8-N&VH6+O0F9G
M*0]]PFS>>*]>6ZS(1B@!UM:*.!<3;9O,P$1G);%@Q-VBZD?.E5N?'5CKN^MF
MWD10PZOX'/^!X6SU]>H9WZ'0ECP@#)H\()4LQ-J2UJ;HI<R87>EV$W#WR\,F
M5#93]![B&H'%OS)N)^G_7$R7ZZ[$:_LF^3K[N-;L9SH250[5JT+P/$FO@BGA
MKL^XM^U_A)1A)R?VX#&T$/E(D5-_N<"KYULBGDM5,DC/#5!8S2!D7< PU$CV
MT!MLW>KY6:*&/5V:J+X#G';7P]#'SYM9F<ZFJQ_5KM:LLJLP/+"2DT]$<Y#5
MJM9)(BA HK)HO6 DLHZ)$ ]]?WRHV$.#\[;B'(&IN6>$?_OQO@X&J?TAK__X
MQV76>Y1U=A9"5$F#2BY#X+5X2AK)?1"!Y=8=6;I3-^R@UQZ.LIX4,SK(;;C:
M[$;G9;)>1G#DT(%"QR'8R('VDH^Q"&28>\78+7)&5I;:" %/ FUW=0Q]O+WZ
M<[4(W^9GM5G1QA;KF+V20D*4I8 2VH'344$2,1AI52IW+=8C1]O];X\)&GOH
M;-Y.@$/K__=9"=_GBVIXK[/DA=*9%1"J%OKJ*I/B6'V3\O6!P3K6[7+^WJ?'
M5+#82/O[B6_@S+R/M67ZVA)JJ;S+SH'QLDY>S Q\L@:$QR*5<RR63@?(,YEX
MUPL..T:\<9;F;F(<@^XWD,T8T#'M 8VM+8'H'"19(,@LD+,DA!2=VC%WT?[0
MU8@[*NNNNG>0W, *?T=AU_G%^8;PY"F$=P+!I&J;,$7PFG/PGJR43C79M$7J
M[:U%!U;Z+BJ;MY#?T(J_G(EZQ7Z,0EAGZT "^D<6FHR<M1 $FA1"LKI;Z_7G
M%']ST>'2+9LH?F?YC2YJI*/N[75#.<-42"H;B*EVW8C52\U2@)%)*)M4]/ZI
M7*LF%Q/7U'2"2&\-& ]Q$;&;X$< H:M&RJ_GB[?X)9Q]PM7J['+2S@1+B*R.
MO?4:R=F-7!%32H$QNB0G50K-DSF>(&=,T>7N&G^DC_6^XA\ZT'Q_4>WGO'PC
MA:R)9]D:H0(GNEDMC2QD297D( .//*/A6G7KE77WRV,*,_>&P?ZR&UKQ+^:+
M;Q0AK_"Z2O;DR^+_5G=MO6T=2?I]?\5BWVO2]PNP6$")E<1 8GED98+=%Z(O
MU38QDNB0E,>>7[_5)'67J$.RC\_1BQU;\>FZ?%U=5=U5A2L$U_FR$\.CT9&D
M4DH=;A,*N5+.NRJ5Q#%;A29VPL$+"XVL,K !+%I*=@0'S8,$S5%*\ZMP?G0S
M#.D?X?P*)T%9ZY@)!(!(;ER4$N)JRI;0!KW-6CZ\>&N=ZWZ:L)&](VQS^+17
MR6AQ=H^E]<B1MY=I7IMDO\'U[Q,1)"M9,XBU+E,)KR$:LL)!Q!!Y\<;$UF]0
M]B9V9*]4^L1C:]6-#Z.GF'#ZI08E/UW-J_PG3/$DL^>TR50M[".F7&UH4\>7
M,%0Y6M;SE=\CFD9VF=P+X@Y3Q-"NV+;6-XN;N&*2O2U%1HI[G?.T5P)2W%L?
M(-*&T9PB"_3=WK9T6V]DEP$-'+,>Y#PT=-8AR$GY$2^Q3--FRG.6(<I )W\0
M/-1[LU(?G3,0:$7,B6RNZ.:[/_GYD26%F@5RATAQ:!R0 9Q]P?FW]0C)DW)"
M?_B\3E'\'C*>S6ZF@'^;*&YR#,Z"\(R1:0P9?+8!BM:8K.+,=JSEWV'13ICI
M;7A''YCI2^*O"$GDS9U?U<&EUP.V)LIJS91+8 S+-35K(!#OD$.TB6PJM[K;
M[)=#J.B6;^QMQO7 8#M,*4.C[]H2TP$]O5@05Q?3Y1+SC]_N[*8D;8F^*& "
MZP2+P"#4X);EZN%93B'#+AG*K8MUP])K25[W(N*A(7.]-\)J;\S*['9O7-#>
M6,X6-WQ-K_?&=+,W_C5=?OJ$YWG"E9*!E03%" $J158SMPG(,/N2BA96=?.M
M6U#3#72O*E7^W94T-"J?#5#?S2[3.D8]Q=7KQ+/9VJHO_MSP^7X^G<WI;Z\^
M7BV61)B?)%'[2%D%.1=;,WEDP2WYI)E"DIS)N&<M.Z&S)57=4/JJ,O>#*6W,
MJ:U;WBDB0L&,DU#(8P7R:@LX# 9LU%8R56=;/G#O^LMNW9+5#8BO/,=_L#Z&
M-HA':5ESPBNG8W-Y/C$\Q<*5!(TEUDR+)<]46+#>BB2Y<AJ[/6E_XN/=4/%:
M,NU-1#@T!([G\]F\#F&^,WXYR*AST!RRJ9=4/DB(7 40F2)FBY'EV]GQVZL:
M'G^\&P1>2^J[B0B'AL#;RXP7ES>CE->'Z(385LA- C0D$Y5+@.CK''@>I8I)
M:8[=0/#DY[O!X%5EL@\7X]! V+12^K_/TW2*7_#R"D\Q7ZTR\A/.LT&=$_B
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MF /2I^2C52'=#DKJ>6\^IFXL;7![@\KLN^AM9(C<7%UJ]!*9TA!B??5M@X7
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M9>RT("'-PD3LLDQC..KP&3IJ&+.?N(&5<$2Q8#>EFN<D)A0%?^G@):&P8ZF
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MPE#S_N\PK<)\Y3WU4<L^JO/?8-#H4=/3U]RT/R-9156>P_" ":):B"J4A",
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M71T+K1X'1*2ULPC5,N#7]&R49*S&3A"\1-0))MH' 3&? (D=GFI]BJ BU+6
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MAQ'1VS21D4V S+A"!I80*$&^HDJ?@1Q#USH%3$QAS8&>0+_/PRH&DL)LYH6
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MNIB!T I=VJFA.V)WY";&5+I]E=^]=;OPSZ=_6K?+3Z;];4NG./$_J@;D_4<
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M</IP=P;OQGCLW2?AO+HKNN_USIODB:NYOCF]L3=ZTX'QO@J\_COXGZFQ=_8
MA=ZV3(.]3CK%>Q1<EVT';X3@7S^$5,0.%:TW'*ZERIAWJ,K>?3FAQPTGLPY_
MAODM<(JP5<K55W)! J,J!I?=#E[8,<E4RAIGW^7"%N*C9U5I=(4U*%U: YS8
M-]:D9ZWU"NOS*J55%W7D;.B)J<G%:?$5(H8B5M&^.F*/,XB<[&?$+<0<)Y(*
MO #(*1&X-C0J;J9U6<K(]C?;M@_,BW/ZTWMQOBM3G(ARB74W"\QZTT>=CS<Y
M>FT9MHW1$)O"O9Q,-GOE9!ULLQF&CCUIWUXKK-X(+F53E<I95XW*L50_@. K
MS''=<Y!V*AJ(]_)B#@9Z=:6UB]>B\LC=O>*$C?5@-&5&KQ4 N>4^^R9;(ER@
M!G'6DC3K?@8WB%"6VNW  7PVOIU2FHF%%\T0">.&B%1)?K>$"PX'\R=#+\+=
MFJS4_V$AOWCO%0;8=.!0S51KDSNC=, +OKQ#C[Q["6MTDR?*EMENGS_B"W@1
MQ5J^JYIQ?6O-"G5GF%]Y09C!@'WX*'(RE;J@PC4)1='(\PQO_G%B"LPU(522
M'&AH8SD)+O<.7Y[9T!.6"38XDU:AMM0JZWH.4FTJZ68 KM<3FCH=5KRI\K@3
MK%8) FSAAH92?B=\L/H57AO*!*-/-U[ALI8Y2N5\L?!CKCXLE&16X%+[ :%K
M16QILE#MF#X*-OBU?1"Z\!C>SXW[#A^9JF2J-HS.!9DI%88O%]>2.1=ZA6'(
M4E5%PY F]J[P6M+BJ,M3N>RPWA%&N!0Z9V[T(W5A/:O:B6)OWT&WRK%;V!A3
M@TF'T'#@1*8JME^5HM:95VK+< #Z4IMLNN&Z=#3M;[@R7=_.<X>88GU9CJ[,
MDFO?! .-SO6YYA)T.( 42@O$M*AR()FBCO7M.O&S2<)5ZB;(&Y4_Q@E;PQOP
MJ,[K4MW)[D;VY#;>ITYS-UX7?Q<4M>$6QRVDL&K:0]T<MUGE_&=Y:\FLAUWH
M^6A;X\788GSW!)+U1;B\?\.JU?E :9A 7"#W](7&5 R%*B>80 5Z!*\SP6MO
M3/Y<21$14V\L4J1'X62(6CL*]:AHEDESR:&75UCFZ^%1QK&3Z_0C'$\M1T\.
MGG?NXW02NZW=NH:GT5P3MPA7Y%*VZ:?K&6^N=PTK[WP&DZ D"\0W+GO.&N?+
M,8VCVE>AR2215!7VJ=?3QWR(^DXE**A(ZQNJ=C(L%HWS#.,Q2UT39HR!415=
M?:-O!G5KX!D2(]O<NZHD$Y@LBHHT;YUQ?8>2V$HGMJ^Q!7[P&].W6[]'O<<F
MR ;3J0I^I13?QOU!*NS4/2#VRJ Q:R-PKF@7:DO:SFYN83#N:_:] &N54,XN
MEJ%7I5LL -/J9(6O@<S9WXEUX-3X=<BL[D;-@?1#.%5@0W+$UMH&8WF#^B/-
M/(BP=B%[/>IK+O >U%!'[)H;VU4"% Y1ER6PUVFX+^\[Y9-4Y9J54WS)N>O,
MR<RNU7)I&;/',ZH_GX2DW%$QQ2M3X,BU[<PF4O4<IW0/!6%C;%L<&KW*%/%9
MB3!O%/&I?R=3YPY(72%>9:]3F61=K8GU47U32GU95 5ECGMV>^=!AW3&6:.<
M9Q72N !Q(%5Y^T9GRJ^M2FFZW?FJD@55\Z%2.F@^^WHW%"$8J,%8.(W!ZNMC
M="E'2LG31S5&^X20OVF-)>HCBX2B[#,\7@K%;#T[&^*J-(+:#*9:WVSGPH 5
M70<@*>>WQ9'?<B>+3IK3%R,T>/K&U"+/W#5S"T_?PJ'\\]D6#OT2=8-4 1FJ
MZ#V_3:@K/*#(])G3&@0URVRABC+\S)7IV"CE$J:@-G"X]'R1V<L67=EF2_GE
M3N!=K?Y64:KK6/FJ/S>:[N'HR=LR%8Z*CD7LF '?AXK^80:<&]$[+*(L2<DC
M 7A3 =!-:I_R.*1XS5A8:.YN]%"4$]=P#./6H%*?JC_*V\N/RH)C[+E['0]L
M+H>1Z4WOT+>QJ=X)$*:)V&%R D!-\NOB@/IE*G1.O8H\&EJ55Y^%IF@C&!^A
MI+$XO>C)Y<XC&^HZ/F2D:5M%PREG4Q&Q@45Z3_E$;>BWND&/M;TE5ABSHU2,
MQ-R.8KA&C'T@, 7G'Y3U%*_ )1T2O1OF\3*[8MA9UXDS#@?T6F@_7!'.D7H1
MZWJ@-+*MMV C8TSF[B7G$>.O7>,N-:?W/NBG@W@!)C-C9W!BXRJJY;Z8PO9(
M/^R>7:NDM*' <*9+1PLE$R= A::Z2MTE2]$TVG&HRL82-D56J2:QPM:4;7&$
M?3,:V]:37?OY_*>W >^7/6*@Y65G..X%(V\T[E!\+8>X?N10X99H:XK.Q&C?
MUP,,]<5/-D9$>[W^..A3Y/&KP'LU>,?-A\%X0"[<+SKCWS,[3T>?WJOPV'3J
MO_7/[Y\,68^"_F%/Q:L5!Q[\0:&-!?WTNK-<%F6V0&5LO.^]!GLUC_^@?QMW
M4'7T1ZVC_Q9I*J?0R^LJ^B3RTGL-@YS*] _S;R/;7X0Q8BE[B9B6+XX.@8W4
M^,H>??2-.,N&]%;0/'FQ6M=GT\*,\>((;D>^*#EO"U>"=3W&GG5X+*),.=TE
M=:_' SU)*@.?=O0Y_3PZ.#J^)\K\JNSHQ^$6S74^/# +?;/RI<C!I88[FS,1
MJ9[;5MM6VU;;5C]MJZT1N?;S\.#GM2)K._ZO2M_F,K9)WYL!)BY V/GBL_H]
M1MZT,CSX_1)32H?!""Q62D8TZ85WT[11S]8?4-3#"Z-YNY.LZ>)'IUN8YXLI
M]'!+H5^50E_]H!3*6=Z8;WPY'(Q5ZG%W\#[H=_KCT0WD^<\2U);8UHGMZ)\C
MML>3+%[!?[-RGOS^_U!+ P04    " #00*16CMOEG]H8 P!#=B$ '@   &5X
M:&EB:70Q,#)T:&ER9&%M96YD;65N='1O+FAT;>R];7?:RK(U^OW^BG[6&G<]
MR1G$RW;>DWWV& J6;:U@\ &<K)PO=S30V-H1$ELO=MB__E9U2T)@($YBFP;F
M'FL[-A)2OU3/655=7?6/_W/4JG>_G+OB*AT%XOSB0\.KB]^>_?GGY^?U/_\\
MZAZ)T^Y90[S8VS\0W5B&B9_Z42B#/_]TF[^)WZ[2=/SNSS]O;F[V;I[O1?'E
MG]WVG_RH%W\&492HO4$Z^.V?_^!/Z*>2@W_^/__X/\^>B:.HGXU4F(I^K&2J
M!B)+_/!2?!ZHY*MX]BR_JQZ-)[%_>96*P_W#Y^)S%'_UKZ6YGOIIH/Y9/.<?
M?YJ___&G?LD_>M%@\L]_#/QKX0_^^S?_Y:NW!SW5/QR\?OGR15\->E+*-[W]
M _GBQ:OGS]_V_K\#:N2?=+OY3I). O7?OXW\\-F5XO>_>WTX3M_?^(/TZMW!
M_O[_^]O,?:GZECZ3@7\9OM.MI:O#B/J67^Y'012_^WU?_^\]7WDVE",_F+S[
MOUU_I!+15#>B'8UD^']K"8WPLT3%_M#<F/C_4>\.^.7ZSQO3FA?TG, /5=$Z
MTR3WVY7?\U-QL+]W^(\_^?X%?5K25AJQ^)\_^J7[Z^!!T4']Q'=^2B_KSW3Y
M]>(N_^W6+[I>JRD^N>T._3O;A=LS*N-+FM1>E*;1R(QKI6]]$B05/USG5LR>
M:<9 ]:-8\@)[EX4#%?-=O_VS>^JUCX1SYC:/Z/]=T6V9/USZL'DDVFZGZW3I
MCWK;/?*ZPCEINR[?N'0Z5X_"O[(D]8<3\Y%/S0C3=\]?C1]PTE=*-?6^(WYV
M",23],I/Q!^_OSD\W']?#(A=T^M<QDH9#%M7\W[[IQZA@_=/:V*@X5@F(AJ*
M,QGWKPA/:@9_:3"5W6/9O?+C@7!H- >:7=SA4/53_UJ)(^J6'0-,\JAQAD;9
M#]-(R%%$S$?B?.1UOG1JPFO6]VI"BB,5R!L9*T$='>=]W8 IJ$>CL0PG=HQU
M,:KBM-4X\IHG-='8:^R9\6U$F9_X,I0B\$<^"WW@RYX?^.F$AEQW0CRQ>JA)
MS@=^,DG$:10,2'VR8,S_^/WEV_=BOF$UD4:7BD0W%C=^>B58B',YJ0DE"6.D
MW4+](8KCZ$;%%HRPD.& Y#,(#+ %-(+68T(Q?(D%X_?4C-=))LF:2:,X$6,9
MTY(GX51I9"XV%+=]_LH'I_E1M(X95-I>W:F)YI[#2)((9T"F@I^DW'/B&N>2
M +XF.C<D^MR._'EZYAI__/[B]?NZ\)(D4W%-?\:OC/3JF+TZVX"]G]3G+-5J
MVV[=ZSJ-SG9HJ9]/W;;K=(SXE.*^1-321;(VC*.12*E-A)7FW[F;/\CP*RME
M!*ZQWY>/)WYE"ZXD/7U&=TFO))GP*DZE'QJUBW5'>F9;):E6).MT+]FDI9([
MHU_^E5'K#M^R>GGP1CRA#Z5Y1DV,HH$_]/DWFN#\LSA_*/\V#F2??XMBD63C
M<: ?3@]>,(RQ3S?IQBJQ6D'< "AUO]%$LZMD?F!M@%;-_MN\H,T2\,-A%).*
MHZ\M6GQF7<QH.4Z21'U?R_YI1%)9)\V^JHV>R20A12A+5)HFRS52LV)+_>J<
MVL3>N.)QC?J,Y;#B,;,F2"C<?V=\_3PCBT\F:BI7LQ;AL>K%!&>333(*S^N-
M!?VR8;W4C#I\&M&TLW.S5)@3/9<;,+8?LHD56O%3,<[B)).\]B)Q<^7W9ZP,
MO6I\6EB=K)?X U_&/C7AQ@\"<>0GXX@$@X2;OS N5E3?+*!07^FQ>UHE";-1
M/\AXBO3=Q]1)?R!%1%_38\.4;YA&C\P&S""O#C,&VK-OPUP:(Y*G;/NY)%;_
MSDBMT622<\92BA<]52A(#,=$%8*(B "DIX+H)M?E\H<4:F6?9%*95<$?S\UV
MC92GWK]( RJN$RF,DMS$# ?Z'GK16/6U,D9L(;1#M6S2SQHEELU0L_6Y)KH\
M3<>MMEOC?O+ ^8-\69?H$*N1GZBDU)M'69HQ6$37*B3PT>/-RC"-%6O-?F@(
MFZ8I5[$OH\AHR-<RR&0O4+,O,C(2J[[RQZF^+\F&0[_OJ[ _X588:&-LXN?W
M"-GZ7\/H)E"#2U:'=2-):V=X,VJ[D#Q7+"_#*" Q26AUO=D2)>U@[X_?#U[M
MO[_]TTZL/5)#+1I=7F7K1-HM6;9U.=9;A?]A^-3(18I4L?+TZ@FCU"R\&UJV
M8I"/?WY#<B5) = PK->RDB'K7N*2%/F0$3')6(W0#];(MPJ;V<9D<R#'YUO7
MV;HMWJ_Q^JFVW279KF3-$Q#LB2VAN\,-6Y6E-R#A.5\ZPT8K,0X#PP=5(C17
MFY'P2.'TX^E'70YP,!(RG#[<S>)H0'@L8]$F\THT(NK:QB#"6 Y8!7X6J*&1
M-(NE\8E\NDP<NRL7M%]ZHWCQL_% G_I$J1,6$YK500$*[ T0,DW)?L_!A6DW
M$9:*>QBJ;\)9I[ 9LZAO1ER6(XXA_($A["F6VE@-5<Q^'!JN@O82^[V8RUC2
M!NMS>Y&PMQ0)\]"Q1-1KXK@F3K3N]+$P"I=C)-LA!4@N ,5DTY;T!U#P0PA>
M?R4%+[17V9%1$Y'1XHWO^:[[-\;.U2XZ#EB5_=R+H;7]'EL!:F3D->KWLUC(
MC$:5!*)/UR?&)1MEJ1AFL;;8S?<%F]KA9&9'5EO2XHG_]#NKQ+QYYC555\Y=
MM(N\^\MPLT:MH&;P:UH]$@'CBQ1:OK]GMV1IDM(@\\4?'.Z\8\PY]$^LV$]$
M'>EIGP:]+>-G:A_&[:&G/ZHMK;9BVNJ5W<V'/=]=I9F)HVN?[ZYZ@N\R,;$:
M\?8E_3?,Z$\:[[[2S59&U]<^^KQWQ3,[BB2'WE7M@_8Q)X5?AJ9P.&1#8&!<
M0$_\:S-!2U=Y-=2X<-"]BU6@-Y:6!A_GH+ __8KL)5&0I<N_\O#! ?MW<]_<
M&HJEP<C5GU=QT="QO%3/>C327Y_)(?7CG0QNY"3Y[8>BN+_SSE^'X36A;D.E
M*7N :2GG@K]XD:V AI^"@_EEOKH=/_J.[X/#GJ N]16[3PE4OXUIY28$N$5
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MW@FY8BV6>513=575*@J)EI@@Y3@HC0X<7<$"QE_7_N,)-7U2-%,_< 88IDA
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MR34[(Z>NT^B>\O[(-M='0&(*@"Q =GM =L/45S(WVD[C:%M#?9I1C(I@@%A
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M;K3:WM&F%T\ &@(-@89 PY]%PS//.?/$D7/D:O>+_=UDYT,.W>*C6_CJ@-_
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M;C0*GOE)$F6Q#P0$ @(!@8"K^L>ED;<+_;!M"?0#^@'][M*_:O6M[4)!6,)
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M ,*V74A-(1="@:0FZE%(2*+S"NC\I/1WZH>9_HX.I 2[@]T!6TO9_0W8?7>
M\Q I!\#NM@NI":5,IK&4(&^0-U!I 2J]1,Z!'<+%0^0< 'G;+J25"I*PNT'=
MP*0EF/0*.7MW"!4/D7H U&V[D)[':BPG7-41M W:!AXMI.T7H.W=0<1#9!X
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M96&0N-U".I\[&?F20>  IJ4$CJ)%.X2-1. H+0P"MUM(/T31UT3(<"#:?'T
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M=DMI)XNO_6L9L$>]K<9DG*O0V.0F#.ZSC#F7LZ_ Z^!UP!5X?><1DWD=V>+
MZW9+:4<1>LB>CP W,#< "<P-3#3,C01P8&Z[I92L\$":Q&YLE#<47X+U#0X'
M-('#=QX=F<.1XPT<;K>4GD2$'B'!@&C(&[-'_E<6^\G [U=VS5&!!:P.L%K,
MZB_WP>J[@Y?,ZLCP!E:W6TI-5E8VRHG,)Z(;^S( @X/! 4P+&1SY878(&YG!
MD>,-#&ZWE':R7A03#.#0&:@;B+2<N@]!W;L#BDS=2.T&ZK9;2IN1< ;7?A*1
MY1W%XM@?9'U?TA]ME8RC,/$1ZP92!U:!U &7!:DCF1M(W6XIK=0L=[^I?E;9
M')]>:?-7!TF1NS7C'#)C&:>(B0/7 \(6<_US</WNH"AS/7*_@>OMEM*+CB/.
MG6[;:W6%TT]%,R(H08TT<#B@:3&'OP"'[PXZ$H<?(O,;.-QN*:U'83\/;/\K
M\FE,.46,.6H>B(:/\^;@=$ 5.!UH67(Z,L"!T^V64K?9]=JN<$[:KGM&?X"]
MP=X I87L_1+LO3NXR.R-/&]@;[NE5#C]KV%T$ZC!I4D9PQ8YF>F<QE6DD?@@
M_>"9%_*A-4=G:5<#<>R',NS[9+)[89+ZJ=YVQVXZ>!]PMICW409UAQ"5>1]9
MXL#[=DNI0V0_* F_K9)4IEH! .-L_D("X^S46F;&04XS,([=4CIO:+;5I>2S
MU)?""2>BDXW'4<S6Y?\<UQ.0T.:OK8.7KU>1T)^I[ 6J^%S_,#?VXKGO5.8I
M?^MK;M8X2GS]NE@%DHO'O;_Q!^E5,625;YD9?[<__8KL)5&0I<N_4I&AON(#
M VN:>?_ZUE@L':?JSZMX*MJ7ZEDO5O+K,SFDCKR3P8V<)+/='?GAL^K8S@_+
M=]Y9?9*,+^EA^9!S+]<T<IWZJ7MTT7 [2P;PT=O3OU*#+%#B8&__X(E\NHQZ
MEOVL$XI)/Q3.8!"K)*&&#:,X#X)-EBZ8&6 [>/&B@$>?<#E,WSW3'ZUKAF9&
MI+=T1.K1:.2GS!FFI)0S'@>$YX0>XES%O#Q)Q.E2PD[*]$J)#D$1WU>:.&5]
M27%$5HZ5 M'_88%PO_E)JE.$JI36M>Y]/58#/[6R@X,?[F!Y,)L>T1H.2<[C
MVX*^YJZ]W#O8_]%^+?OIA4D6R[!_6T W:C73D+Q=@6^=K)?X U_&ODIJ>13@
M)VI]%O/?YS).0YKG*W]L%GN+%G0LW']G?CH17GBM$H,$%@K"VQ48MNQG(Y*A
M[K2_ ,37WJ7#_9_H$E?W#?CT928#<1Y'8R*NB95]^W',/5):A11.O\_G2),\
M?K6?Q3[/8/FYE=W]&02>3J&= GIX7^![2EU-KT1=QHIS;EO7U]?$H??5UX:O
MPD24^L//*TX;Q4LT@DNEQ:.&]E(UX/KCNS@PSY</3,FX]SDNLU;BH1V#\.:^
MUE>7M+A$]DT1W!N?8,4A]37P:4266VK6&,[NWZ?>!Z]KB]WL?KOR>TRY]S4[
MQU$\TN$L2>)?AN46&/V9C<8FKZ-5'?]PWQTG>YH,:#8T!#L5?+*L[+&*BU[7
M[[O77MB/M>.95)JNHL^TZFVJ8VDSA/]U+F.5[X):-1I'#SX:S<@Z$7#ON].V
MS_+Q?7=8BWAQ3MZJKI[<=U=-+\M.G\=J+"<6SO'I?7>\K:ZCX)K5,@N7L'??
MO=6VMAIHE\E$'"FF<+WI9*>8_W7O_:>Y5F%_8C%S?[SW/M^0=//[+,:SQGUV
M6IM7%WN=/=&5WY:H:[8X*(H!.+OO6?^>5K)XH_@NF\A++2WL/<],[4]N/7-/
M_,%__W:W4 4+-ZS?/_X$+(JE^>V?SIG;/'*/A-,\$FVWTW6Z]$>][1YYW>IQ
MRSN+^8SOZ?7Z/ S=*S\1=^J<H!OU#!#E^V$:Y:ZGOS(B@\.W-7&X?_"F)N0H
MXBBB,_INYTNG)KQF?8\^)?4@D#?LT.U'\3@/3A%/V&_UQ^]O#@\YS,N,W>,/
MPNHD&:.Q#"?K:QS'Q='X'+Q_6BM'59RV&D=>\Z0F&GN-/3.^C2CS$V(F*0)_
MY'/L5E"D\* AUYT03ZP>:F>D!GXR2<1I%+"CUH(QU\ZH-+I4>N-3>P]98G.A
MJ DE^U<T]E8/ZX<HCJ,;%=LRG/3.P+BE QI!ZP&@&+[$@O%[:L;K)).Q) ".
M$_%DH(9T]T"0?"H_S&_(R\PON,H3\,%I?A2M8T:3ME=W:J*YYS"$$ T,B,K]
M)(VU&B6<2X+[6E7E-PXZ?@CIV"]>OZ\++TDR%>_],/%9P.CG;;?AG7E-I_U%
M:,ICDNO\\?O+-^\WD,<_G[IMU^D8 2B%UOQY.168L;;5&<Y4&IFK02XM<Y>T
MJ,CPJW;/CZA1?5D1%3DK*M*(2E**2C 5E4"'1/%C^CHBBO0(EIF:N)+TS1F-
M(KV2J>CGP74F?FKJ(*R)@61>,VJ'DUUF22H.WVC%XZ5XPHWBK2^Z(XK%*!J0
M<4:_#^-H)%(::3Y J_\=QS[=H-]&4!Z0*4 *"^^0;0 :E=M^\X-C SJ9I-XT
MY9N^?,8F!DB8I4"\GURQO&CQTC<LG0:^;22_JE*(9;$;:\)3C%CVI=F.S&5P
MZ=-H066]?Q%9%G?R!J]OOINHE(-.22,QX/[C$+S^06^V/HLN#_QQJ^W6" *X
M@XE/TF[,@WQC>Y3I\*5^=*U"68RD+ 8IR0> O\M#K@8+)['X]O3+#"1#4D:B
MF^3G0+_*87.A!&\>8$P/[F:G\OF*0 EOC0 V%VFQ]^JY'@ZV_^G_1^ZQU_2Z
M7JO9T0:G4Z^W+II=LF=$UVV?W=[K7C$/LV\Z?'4KIF-]$\&!MH\S!PL/_\R.
MS"MSC&8%LQSEJB*[^M:HZWXG </&09R3B"S1Z@V!$GM:IMC.(&7PA[$_Y7$7
MR94, J,8:>13DO-S5M&^I^@+OX)7_R*UR1].9@;H^:M'6"8KE(>'4K?NTH35
MQ^3^S5Z5:B#*VL:(S&<6AT0+AIPVK"9NKHQ_(KV*H^R2'1*LTA('I-/8)]:)
MZ7/%D=[,J]I73G)9N86,!;KP1#ZE&T?R7U',KJ.<@C]%6D'II%'_*S\JTB]D
MQHU)@OE2=).'BK,F3Y1+NCFK/Z&Y\YRNL;_/#_M!IL\9:HK.XOZ53/1.L:0F
MCO/^R)C-%7X/O4&?&.1C!_1GXM/H2NKI9*RH,SK4=Z)5,QZ/F#[+M$.FVK"R
M.61:\$NU#4!:5H]FG.=(?5-QWT_T$9:>MG_$510,]'C2%Z/AT^D(T_5JF_7;
ME F'+P=EP4#0M6P<A?K9^>MF^\QW%+VF95Z;=CW)]:!D&M?,EE+MKN_6CWK2
MHSE-"$,2\]:9.;FY\NE)K'CI[$$D6X1 /-99+TFI03[]/3$?&EF8/DFW(7],
MI"T\*0B'_$1/H[8#Z;->1N+(L9QE,\M/LI F8O9!/PWR#X)A/V  V6HR5C!,
MYY(JU6L+3,8*HI7K:M8$X'-U[+HFX1CY*2-6M3]:EV?)U&*5!YDDO$SY.^5Y
M#KU"^)//M+))F%LWK.F4AU\FC%3J&[T^O%3E^I/&(T+BJ?\T!D:H#)JR*[BV
MO&%3Q!A+7Y-_7Y(-&6D$*=]$@E^>I3&K-1%/HAS*J>G_0U:/<6+4Y=CGZ+ <
M?X=5+[1XDAN') )L@=+JGJYF'2$LZN7[Z@88GS[-U^NX/$]0KLX;!B<>V&D7
M)AH<I0:R&>\)OR<;C4IKK5C'"Z:*OC100Q6SKX<G-9\L?BIW8ICQH2,-SM/!
MH]NX-WQ=/SF_J?@JJ5-S]G'4)Y2,5=C/X76BF8 &@<,TC$O+,! ?40PGI?R4
MDA.K,<V#TM^9%4OJ=]^,B_YB&:":F B^:<AZ;=K/V2_7A"OC4+2R5+1ZI(KE
M3@!^I)GTBDE;N!'X745W-?:.^$@+O]+ MI]HX=2\IO)@A>+^\B89JYHAXPEU
M,!GS@%4&SG"-&:5T2E2Q(H,YXW-@-&013XN6X2&IGT8.HJ&O!=:\/O"_JJ?%
MJ.=0+L0QWYG%XR@Q:L= <3/]L!A>>4E]II&87_9ZV9BU/[O@*QQ>R-O,NIL=
M)&[+PD$W>G9/B?5%&.#H^)V88L!+@C?A>+:T322_^:-L5)EE#7XTR\\BFN5R
M*9/ %\*>*W(,Z?R!P53?B/D@ZF?%VN?)9<&,;@G6SVYPP-CZ 45E8'R;S'-Y
M9&%ER=IC?VD+B96.*HC'OMY&T-TIFU]GP#R3H<RSK#A3@"_/*M)MIYR&I7+1
M$)56V@-V>R;Y_>K;6(6)M@ TS0T6*"5"A02;_6GZT&*[=>I.I>OJ,J+6UL2L
M.394C/;$6+$^PD]?'OA)+XN3O,V\@T-K+E&!IA.]^=UG>BOX>D F6#\UVE+^
M^XS%%R6JL-0&6DDK692W)G.@G.4C8M-,?Z0!@'F(/ZB17G!#XY'[S>DRKW"-
MB^543,E^U@JDC[FC9J])]OLQ/=]\TV@THQ'K#WK\>D9QO)1^F*1+5,KR-%&)
M,CGO$$'VE1I,I8(_/"(U@;[85H&OAOILHPA)8NF>JBTEC4H\,#?34.N+TP?6
M1*SS]03:JAJ6XZ]ON]U3CKJ1[&>B4>\'TA\E"YZI-V_L! 9NY37I!H-U8D!-
MV#DX+,;K'9?5N&V\ I5U8U0O,H)8#3<:FOF= /%&CF>^JQ&M9/&<EJ?/ BL_
M!BO?C@FQAXOG A08U]@HZ<NQ[+-AO212H8+(.2EJH3HJ=,%:@>XD<'T"6?YK
MP6,@?^N1/V[PP>OW29Z)QAYQ9$E:V6!I$D8Q-YLPFC%[8&)?1Y](D[!"FRGE
M?@^I W9.S'P.K?624)1K/[DG)1]F7K?305TV.V123A;$"841+](95YO,XS_R
M #NL_T=?__^3D6I+MX22C A[%CZ[J58T5'O?>$&/2$HY8YJQ?Y8)I/5R]:M[
M$KG$.0/>X5*<U::T0O2HKG-BRQFEY=XW3L4D\\D0K1AT3PJ+:U8KJ(E_D;6I
MBW%4O>EDW&JSJ\;V]#ACJ*=G\8Z>>?QE1,,0Y@? ?9WD(]> B1,RC@AC'(M[
M?EH<FYASD&L/*^=K#2;,%SU%*O9P?IL@*O4=UI"JF;^>LELUD#?Y-H?95-20
MVE/L+,CW+?C;)]6F.AF9]+&^=\!;J:G?YUOY*R2-5=-?>^*-Y5GULFGE/[SV
MXZAX9%EV]*FQS_U$C EKC9%?*]S\9>[:N_>1/<.Q(IKEG9_"HN?;38Z4W /R
M_><4E_*-D\G=6V#]HMX&LEA9%<<>NM N1!9^UUG<U.FV/=UU\7'Q39"H1Y$H
MX]ZS1GAJM[PBLK*K83R(M?D@#PVFQB4;3&I5#VTP*>.&HE"9T'FML/!&G2K1
M,]\XUOA'H)S_&1@]QGQF;&IVH)I( [YA>F8J;TC94@CO(PAON;M:2=MKC2 7
MO%GF$V9/81# P'IL(7G0(R0_)Q@,,7.'(2 +CR +CW($]\=$XBKWW.2QT+=W
M\'UFFD'63Z.8@V5B>1G+\55^[@-2\PA2LR@'O VB,U6V*\$@N<$V3=5T+/O:
MY%R@6)'R/;VO./UJ=H)-I)H.$2O[+)[T91RS:'(D2FZLDM#24VGD_!&I[^-
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MQK2-&NK-HQ<-5D_Q:\HA"X4,2*Y"G:KHE@ZZ,2[VYS:<+ N7<05_3% O\[.
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MRD6#C35LOIL'P@#?\_"><<AM;<&]-M2/IT),1N0A,4"_V1QZ4 S0_6;UH3!
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MDFTO^$8\C78<3R?^.#A*WIPG071M,$>;Z'=CB'Z(VEOB"4C*Z,Q+WI/5Y<@
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MN)G7XP$:XTE"]^QNW1%LZ T]]":!Z1*A-!7A8BK8.+[(?<LWE)8&T ^#@W9
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MF"&/,Z7= \R064,(G?*AD'/N[ZA;2^9H<0(0(EFJ=TDA\.Z98I\L'#BF5I&
ME%N(N:4ME+5)I.&0.<0AHR7FTIO#192;-CD3:ZUP7B4._E6#8?0B!)_Z;$)E
M!H+(]#HOBOR6D!^,SCQ?PH B1<KX=3X[]_I_!^DZ@'2EB/7UJ_H/$E7V#M>%
M2:G@5)^KN8<[8\UW@D_"(EV%63Y8^RYSYBU(V%QG$=Q)98JCDA1<C"A))S7)
MQ+^ 9S5-")98UW&9(F3+@B9GD,:#2>-[==N??H 0_+PT9<,M92"AX#<:.)Z]
M--[+K*P+ZC#YJ E1Q@8:?WJ&W/1,8;8$=V^!:/OD:A;Z)BF9XG;[[>Q]7KRR
M<7#^SINDY+X=V!*5^('VVR^?C@/"6KVEFGOP'KD=S:OQ;I/52-#.A.<=T>WN
M-SP[/7WVS8\R60DZ()+Y''8X^163G_]'4:;AOC%,SKYQ#,/6/L#6E@YL+N[K
MS?:V+1NMMG(J:KLB\(9!.@XG'7T$+NA"5Z1^PZV]3B _C5XD+WO: ?ZF^"<;
M Q2OZPUF0A/6<1=Y6B^GB1I$\0"B^/%U?V2/G28AD6>FF;RP<>]V'.IZ#3;!
MLA-C<+OD_/5:?%[\M5I\AEV_SZXO<LX_OKT#B:Z+/D7R%;/N&DP!X9 V9(9<
MG=LP89174&<:4M%O:?=Y;-;52&1PX]8VT'_NNDS!.L)-@LAFHG$0Y!33MW2=
MW-<O?/*KB#K^[-<1W3,,B]/1*H5R94\(P&4:A+&]A![=GA9*REU@T95#^:8C
M?0MP  ,S&N(R<ERFW=-ZC55DN+)V ;YV8KT[Y:HYB>T_/:X)'(R9 Z@U^+DW
MFDSHF(EJID$P$V3@CJ,APW\<6T4V(I@%RD^, YUQ%##!:K_/((/4*!J!P-+/
MINO(@,,(N\"-Y@8&HNJP0+\I[Q>DJ$G@M57!#:@EJRG; B!M*"#&W(,2Y77!
MG?Z88<0,Y\T0J3Z@*&L, \5Z"CH)<[(]DNS2T8V3?..9+4JV1O'B:CG4@W!(
M!G%MP:_"SOIC^.J">1Y!G#$B(309,;-)NRD@!/)$3;'R&O$6._3N+^?G5\3-
MA<W^"M%Q5G!8E2G!$%.>%[87/';L"IQI2.YD=J/Q*ER0,N<)ZG,N-9AR:B<.
MEGFF&Q#>^&+>,3^VR$M^!;/!MY#I,QC;%,R?YED,8X"7MI"@,"7X#VYCOU;&
M D.978WE!@5CV+I:;-$:6H;J2Y1#UW;X)!Z$47O4[/DC?5$B(=Q2I=H-HTJJ
M%(N L+>=L)?<4-G#PNG)'3:H&9GCQ+NRS%P;80B.%C2JQ4&=@&07&%Y&C] 5
M'MDAL.](PQ($*#<DDA;$V$H3/-G;3$=;-.%4"B3& F_=FB*$F[+L7AW=69Z@
MD.TXY68JIZOAOE.5?8:KQ'A! 0=11@$O^6\&PXO(*-!XKT1H&AJ^*0MZ<ZA-
M;'GJ%= S70C)&(L,B 4C1MDU(R[7XB9!P%5_,2H$;G>$JJ:'>J^)='."J_Y6
M%5GP.ZB-W_TMB9#(^ ;G?JMS2Y81 [F!KV!A\!@1%IEP7(M!&/R)M67)+*%[
M&;6RWJ94&!_HGIW,16LT>0@>B%4&^&^5(( ASB]!Y_AG-ASNFH%Z!!2IN2ZB
M9)=)A9;IFZ2$0:>,_7PA_('751Y]MN5$S2W$*\2?6:8$T0ORO.WB:S$5Z341
MA9D1!F5EJ4$#1:(Y'0U*X@[*,!P6O(>)I-!+EJ6N2JL%&G=8V9<W@4>_),.\
M9YM#4>Y(@#^>&FEA\5R2O<080?8Q,(I^F@0>;OI1H7<(>>?U>.>Z\UJASF"U
M3ZP<##9^E"VT8^/X6FR?G3;>:ZL19TF\B?$E;T1;" P34;@&4LJ2"X%\*^G/
M1=L;W%!0J\)M 5:^_35-_JR3F'U9OAUA_/53@%=I?50C%M5Z46LFW*PS:D=#
M1#2PO>+2J?<.TYNPQ7%]2T&C95QZ02YSZ.;HE?&JD8!TW0DC#B!IVK2:$SU*
MZ+>^^;(=2H6:>RJC4##O0T8P<^:L15-;3G(XKK&BLY2C&]'WB$:NR&$ON;/<
MD/H(OEG;#MLPR^DH]W:N&1599W"M:U #_0NV!W8$_L&3ZITE[0#2EOFNA-*B
MY&(5VHB]Y;1@RE*"_3ZJA)O^@7[.TNC(V$AJFM\(U&*'8?1YY_9WXFBU-CL*
M_9SJ02#W$L@_>B.0ZP;-"BC</XAXXT:(-YH1Q.;?;'U@5>H4;0QXU96\+4=,
MF,?%N3@10TV2*>,%T,6@H9P*'$64;951;8RHL(B*FYAVVT^_Q _(8!<S.66%
M%K_08%<-I2B'C#.B&7)IW;F^55\K:BCAH+89(P=6R+JFXCAF7Z?F-K!^]^VV
M'^3KX>4+(R?]D251:LCH3E$U] 5<,ZX$05..6VP4E7A-5QOM53;0M0(IRR79
M H9V!O>.3+AVUFX8OG(/Y+(74_8J;0(8H3 \#E@7!58[V\%7W.TEMU)X=]H"
M#C1L^_/WZ4/FME(L&D^,P6[BBK 9(^NW>RVD5&1:<"NIJJM%3MQ+>*E,36.B
M\YDF@HQQT(R<FQ[OT %2>TC/LI>CI(CJ)6_VTFN,-9!4IB5(,@X8!82=#W.0
MKOENX@)Z3'K]W#RVY_7($9]!41Y 45*YFR ]G9L-U!_525$I.\;.JKMF),QL
M/Z;=OA>*W@4;2(MQS@V^ZT W2!\A[I69G-!+<BC&Q)(.=#SXIWF\#BGA@.$5
MC=P:*>=/;,)*$WLB6*28>Z' -_P8U6@A($+>/"FY+C ,_@ 5A3H3])*ZHXSE
M4&%H*PQ?_K4J#(^DO3S1QGW6M&=7U&?(4 S>^<R,AX83$<XY;P>/FFFWLEX5
MZDEFFG-@]R2&\$#ZN]_6&#@$H^3?F3B6C4\O9(MAJV/_L:GV$>U=ZEK.DBZM
M_1_ZLFC/HX877!T2I[= J26P#S&L'+$M&8G)E&D,UA+O]PWI7-?C*F43A44(
M+5 Q5H6QKMR-0F0$)^5(O)QXL?*G!.Z5*OC_."FXP\Q^D9G5W*\PY\@ :A4U
M#5\8U3;$%NQG6P]!,"B&Q)>ZG<:R#YAZ!IGB.@_:OZ3 ?EHD12P,7%=JG1=[
M014;J_3YR1D28@\SAS.'K8GS0BW+'W(*?P3[VB2@>F-2AQMU=%RW3B:TS;+M
M2 VV$N>6VD_J0J75FV*S<(]\F42V1736_#91A+?J[%CS>K72-L_(-,IYP5EL
M*F'RTRG!"!_9:V%8%0D5CM';Y7T(=HZYNW\M<$#.&^+#,I7,O_F-O:+F4>@M
M55,RS(GKWX+3W5ZMA622.?(3WU @E<#$B.20,7T\B!3_&G$(A8KI/CD2YO?6
MHZE Q*:F0\/>G;!7:4O.6B M4NH#WQ1!I\<P=[A7 ;+7N&SNW+R0$W.A3=S_
M]?C]EF!W$TK[;5Y@!7<0<1U)&&CFNI??FW[SS,;G;#C/U5QR.@=K/@0B.M4W
MF@IJA1,//B)8W5F:W[IJ@(:T(VH.:Q[-I5Q=W\'E4>M]7YFXN&[&S2+*76LE
MPLYW$@2LAUT_O]^4:E 12(#O;!ZJY@H#"D&:EXWR2%M\2MFRG%5@DE%J;,PO
M/VV497"X@DO06DJ:Y7I?E2N!DV:RNE64L=_D)*6IR6@7VQH$P?L*460LK1*7
MQH.Q<69*$B\ ! N:D?& _C6@?WW=O)@N*F-.6"O.6%(,Z.7U#( .BO.B%)<0
M=9!!-&'M*>A\>U0FGP0$KLQ$&$;\'<]X-Y28,LP9J.-!ATO*@E2Y<*%*<H)P
M-^V]";)0,T!A0Q<[#6LJ\VW M*DD-PF#-;5.4I:=Z$9GK"\ZA\)3O51WR;)>
MNCI?M.VD<ZY10-"A'9OHAH)*U+ R37D!F*H(<3)32;602?;7N)][H5?^ ['3
M@CLZY7)"+/C Y<@Y3RXNY^!5'E J8K]=H0\BLA%_Z'\1I4UWGIZ<3H9\YU]B
MY\!1W8?=LA7\C*A;S<&%"\I[B+1NTR9QT5/!UF6$OIH8)9&4V/3*8S FQA(/
MCE0[]+%&!X4%MV92:'Q@08X'\OQLUI],-;E_U(-IGM5HE'D\++,OCDPMS5V1
M[2KU\]AV/5Y+V7L#[(%X="@6MF9&< X.F^3U]:U:>1=P+\BUU<G>%2/?BF(B
MT'E"D3P)WO5] <OC*W":]GY.$LS-Y*AS,_80O$1U@:XC/6< :T/+>$IZS  )
M2E69[9%B"ERKJE!4YSD(ZN#N/TYW?P%K?W/<TE]R:K,\T%AE+BXV:,:W=X('
MX/5RHK,=V+,W&'G5? Q.5R*A$-CF$KWMYYSWY= ;<I"'LWG[4]779?%ZYX+6
M'#V28(XSV>4(Z><LGR,,2:J#_SVJ!8*M">J&BQ_%[">C\8HM=(>G12<OQ^LE
M6H84(BFL2-'B$>_G=/=%@PT*[.'7FI'SD1'J@S!%]<=[I^9-?;="=JP;\I0+
M%2>Y8A(:VQU$Z;%;A!,O+33/PKX690?ODLC[?FB^[:K10&?6U'7A8Y>L=%7D
MJ:Z7G'DTO\38YTU@<0CD(\A?<]7\17*Z5!(RU665<S&;_$R@)5+#:1BZX*LP
MC'6T@)D6!M-ILEKH;(U_@C?'@A!\"K_.,D\)C( X>>1%ESJF8NS69 BDT,;[
MPUFQT$N\@I]MIX!&AVD$J<'#II"<Z@4D9R)1$$D+4L.6%+.V%!S!OV0W29&;
M.JOWZK;W^_H[U9?]JE5:+8(+#/,@)\"N@_JH)YNI43("8WB?; =2,"M4S2TV
M:EJ7#!0=MCI]S%7G697\GR3Z/%719^HCP&:GT;.S%E_IY.G9J7HYA0-SS*DJ
M^&KQF:Y^<JW3V4=JRF:)Z;S\I^=9)I?B19=97'-C5/<5_#P%[SIZ;AYYD=PD
M:? .-@"2\*EDR22KHZ>3YK77P=.79S\-]*H=]*H=K9B-^=RV>KSXRJS$T'QA
MFR]>#<T7!Y!="D!0_3FJYFTB^N1E0U-\R#--*#U7.@/=OMYY[4LEU_HDFJLB
M7];I?..@I"R_H?4P(>96,Z91N^AC_'IY=7[.<>T/=.HCEA+&]_BW)!9W1(^]
M>B/;AV54-=PO](87@K^2,$A:G$<UYS)@IK'L@<)L)=?\<V$TG&-+./Q [2Y#
MTR9K^[BM:964^(X(NT;5#,9,0$ Y\)JDJDMN&"U 8 @4#^PK+JF*O6(/-(/P
MO(T_:[WBK@36,02.@X!Q9M0<D2\T@> (8IXQCC*-WY7>,CYB2EZG14)U7&#C
MZ"48G6LM#7"(I>.@S6SEHJFEQ.P,IV\66!1WN\@]V!QMXEST#:]99\'& 2Z<
M>?^2 .RX[:U4,XW_KHKD1D6N?')M.CYJ7'"$/T(40@L,X=9:V3(2#I#BF_G/
M)%#%9#FMI;*&JS[ E.N]=?8C>%TZGC/M9H^<+0?^FC #::16*L+:(,J-KBB7
MQ?A[F/JZR+$[+&)\$*ES9T I;I^ON':TY-+1]D4,'.AGR5!ZNWA*L,()1'B1
M3!.'&=C/935QJO^^O#QRR-WC!2*M$)S/L)-+>L.40]6?CC< [4QNTZ[5L )?
M$RLTC1D9GW )ERE7+;IO7*NM5."$'BYP"PEEDI^>CI&W6'KAR(8+]UIJMBFV
M;^)AC;]XC>]585Q(+I4'78O(/&_;5"9!;#BHC&&]'GZ]N.9F7^6)FQQ#_1$!
MF^X^-!D&M[&$(TR)8@VO7[L?$:RJ*3WVAN%]R7%NV''197'KLJ%*_Y&F[8]?
MI;\!<FN276RYNB(TV50BO>C[D,E&Z/IXZA@)QIZ4SFTT#IO=-*8&GS!^8LJ8
MJ<#9RW">IFN+0>@5XGL 00P;-#)D!989@WV>3-^J=&S;7;:\V+!U'N?6F=4%
MFD;#U/11J\Q,A*)57B;GEL\18FMQM^Y/6YF+=^P$"C-5#EU(@6';O/)43(,%
M8<OU79;!MN^.@V5=5AP4<G4 JE% L [>" $X#ORWO$*:AAU(A\ZC("W6^?Z]
MC^1\KSP;QD+[@\Z"2R:I/\?Y?)47E6FU0E?, /W)1XYQ^\66</*#5[\^RNS3
MSDCY7TK^J:\ 5!$)6ZIZ@5:T$S&EGX=D \=E?E0LZ;^F^%9]$%RIT&CB8#MC
M08KKVPT]B-]1E<VF'PR+)R5S_G&=#^DJV:B6/L>6ZLS:=HF?Q,(_\VR94D.)
MC[M*:5:)MWF=QO07K^]WBF^"22$3**#^HN:EH$DIT8E%/T6"AD0:K"37*<:;
M4!):+!M,P4D2+R+( (S;\P"V/SQ"+'LP@4S1&=@X8!7!1V\Y:KJ%9>@FR=.&
M:6?FWAF6&RO 4VKBL6A =4YI[W?;CY#V^O"I#_FNG<=2Q;1I8'";A*]Q1!3#
M,([*L=QH$)D#B$R>P=[&;$CO):>?$V@,FK.3TZ>C:#!H?O#]<OGNXW4?=@J[
MPL2"9A%H/;SXTJ+3>WCR9E>!SKT\OPX^VKJD8/+B] 41KI^=GIYM-<O,'PJ=
MZANLJ^H WBJ]"$QM<BL^_P_F59/^ATY^!%%=6I/X7\1#\]_,0],;\35Y>1-@
M9 ,9Z6W^9Y$CY<3O1+?FU:QT#1W+H.<%EL\_D;>8T?]^/M0[Q1)8Y, JA0M;
MUC.BH"$T'T=BMX8<F<#!EBI0/V:L;#CW UC[-9O5F,U)<N12+M$%B9BI01-[
MD./7Z]R>KG1N_Y:I(T_Q?KU4IY,MS%U'%Q!4@3T<V$Z:KVD_IQ*!.=GQ1CG&
M",*<H?W(A>4]EY5YB@R?(-AO7U]^>G-.6X+V9<<64CX],A;NI&FP37-:EALU
MGQ=Z3BJKZWGM>]*S=^FUA I9#6\>[,V5+B*"G)^<_H-RJ5_X6@]\OAY=#G8<
MO#W>59Y<N<7OX3OL=4YOD^7O>AS^\V_/7_W,M:_#N?@UY^+0]V/[?G[Z2_?]
M]%A6!]MML-T>PG9KI"F^P7+;RVJ;$:F0,=N>;[?:N@;=_81$X-NWO+X#Q!C.
MQL%G//ZT/EZ]\YNN@H]8+5[OWG'?I'""$?<J&BA[!(&@FQ%"==X:!'8S-FYG
MV3WQ1;;JBW'8O,]WUF<[[_W5BNPP,_-#A)SW*/>XS"*>7<SZ$UIZCRH^FHYD
M!_4LPR<N\2\&6JO*B?%C1OPK?S\[/0U/Y;^>I@3A;>JCHOP(7TQ#^SC@_ 0%
MA+I@1$7!WLI3PDM]IR)!JU\*1QRC7X-?R 4U>5_3L%%*%2^(/I(<-0D;J&E^
MHQ\1"MG9R2E6XAU[VC;KK8?MO6-[;^QOH6+'-+"CWT#SQ#L./B%GA.QQ-E&B
MNBB&+?Z7V>+#'M^W!2P]]A8G?JR@SM)D21W(RJ&IRP8ON0O0D U_$"::]XA(
MK.9PK.-;P>%NBS&QFK6$#TL&Y/? )%1FK8)=1D'9L L>H?P?5_RYI6F;0N;Y
M-1KY$4[N<6>7? N_A)Q*O@D H$4&P"S')T'P3NCVU$TNJ$SHC^3UM JE$OO^
M+3'LAV^C',!Y%:&7!6":OVU[Y!%.\I%GF3J^VV *#1(V%][UQ9D8&UD;;>RM
M/L-A&#.Q.QIY:!O16#S]GJON(/AAY^J'B,_UO22TK5>9OP2.M-X4A08JF)I!
M,4A%64G1<@GV;5JI3",<\\:K(.Z,S8.5"JS:3^L58STZ^A;Z?/OI E_>P.:@
M;US__NXC/R'T6<+E=DCA6[H$FQ  ^#ULFZ,E<(YR@S1)*&)_B.-O<F0=/&B4
M(VB4BWP)#BM^TAN5$AKR;M6UMP1 I[T1=WEJ(75!>ES11%W^N6N;DU+ZADW>
M-0Q"V))A8WTJ_CL ZPSH,=_J/U?D>W% R"+GS6JFR"7/;->6:$+#N+Y."4#%
MYLAK\E ;#FI\U.]U17U+^+CSW4'LK]E7PW%PA./ 3'Z?#@,GYV&'VN^(/NQ4
MN.'7)F)8AHVUN-5"W$ Q_[+AN?*(W-M>JN)[X20,^^((^X*7JS>[HN&L,%1@
MV6;OS8*."A/O9<P-B;7FRS=1NRHK*<R^9#:B!J6F$&D.HGL,T86%[(_@@E"I
M^(:B]T:5=DH?"UXM6,V#E= [D=JJ&WHD:\$?,CCE%)?P?E6)PL)#"1X195=O
M*53?WA&N=7!Q7(=#W^FHIMPV:'1768[G1X0T) ["":?4$J24_9W8GN5^!EUV
M+%WV 0G\,);3%V2=O?P<Y\Q;F&ALX6S#-WF((%_HB]@B\.'X[9/(_I;W0TC-
M*8LD7@D:^X@&4C4IE3WAX^05<F!YS,$[C#^-P4?PS<'_O<<9W^)G"R_!(S[Q
MW_3S./K+-2.?G?ZUFI$'O;R77H[U%.SA3)?](8DVR3./O@SCB<2\DD1UJ@HO
MDHIT$'%-"IK;>3S,U5F>II35AZ\N.-0#&AM[MGQ<^L2; _Q[FC"$MW34M1V#
M7\[/KP@CXDO,AA76TF;S)ZF>L3#V6&"/6IK3G*FSIR>O<!YP3=_5U#?L2RPE
M'G_893AF)</&,DQH'8C3&1F//GEYM_]6:=U-,_=CK\\QD3>W;Y-?:E6 H8A$
MIVT'S,_&7#:4'JO+"HN7\-L<@.\M_FFORBU%[IE?Q)!Y83T$3/0/*_IQGT1_
M8F5_FU"7#3C0GLMU>?3:6$/%U<]9.C+B<7/;HTF:P:9?)"LT'?\@Z+X;ANYK
MD ZIUM\,%6Y2E3I%ZC1XU96\+1NAW(-EC%'A0\G61.[*P"D^R=HFU:XN-'9>
M8W!CKC/B!I?1;HRTP/+Z%#>-1"&\;00WT'<K.$7*=,W!"D051-)NI)FV%0)N
M&$S!9D<R1-<.X\4M,SZU/ZD[W1]7CA 5:$AAX.V&MX9"7?Z4+%<YDEVR!'4%
MCE=J3>%<$R[#R%MFX*?M(>S*(^43CQG4Y&'EPS?"*V\1C9H0U.@DTH!ODQ(;
M5\JH2*:/P2@Z[MD1!K_3*M.Z#EO_8%L?[/T^[/D-,H7^.Q,F?SJ9G)P^&[H'
M_@(;!M,F]/&P8[YYQ[P<MLN/OEW*/ 4W(>I3.767@?BA3JM$+U=IOL9 3*H$
MV2O*,T:Q8)>+G944T2<PNL\O5VVA+#&2_NSLV7/\_>W'R^N!5>R 4M>C0KR5
M+BJ59((@KCRY0FX;NTL&Z3B$=%0Z36%OUBH-KHH<EZ8_ZHD2D%4!?BJL^&>D
MG#0_FT(2?!_X'!YVDU -L?M:D*DE.L11OEH7^ 3_Y];U*X6>JOVA\Z^!N<D,
M.8L7X,O"S_ MG6&@$5U?]LH3?TI7,J5R\2#2AQ'I0B)\P1L][9'B:T0#5YCW
MJQX7],Q+K(Q=#([=7V$+$2:"A K[4@=+VZC!*B(F:Q/F(=Q 4Y?F\2;40Y,;
MC\Q9BF<:9*-&&;!)@MD^;PZ">ND#NO96<1VB35P:B'<9Z&O$I?B(]Z.OYT5P
MC54U^,KMH;^NRX0TQ1OO'3ZH(EJ$P;_J3(=@5*\JO9Q2+#8&71>Y7[YU_,&(
M/(/FX,I@JM%J$_ A^IY#Y^@ V,**8=!N&)&6+&)2>ORQ/P:J\Z/9S"3UO=G&
M#5R'KOV[XET*1_E2ZGYS(2!&<2:1;5Z&?FB<E%/,IA$"%C@6-V!]<:Z:?Z^2
MK):.R/;5N&VTM,M[#\I!^$>3<4!P<X6&7YZ.@R7<:5%R:I"[[4=-B"Y''!ZH
M&Y6DDGH<AUR3GS+7]^ZJ:(2IH)']EE=@9P[8$ ,VQ-?MNA^YPE+WJ7Z&RV>H
M.:=I:E# [#:OT]A+A>J,TK2*C!13Q8#94M4\^VT[#R548U9GJ#<R^(![JS6I
MK<95?AE"XP\SN!N7XV;LL48JU<@WS%HM=%41!*(E=0S-]^$AR0O8H:R0F&9C
M)#]VZ>*L/_+W'+RSG0(XU3#5I5FR3B-3M:0A&$EY  FI8QJBDX_E-<CJ)3PD
MHGX:4( 83<[Y',5K+"!;X[:"7TP2-.N4L?&FD'6.^*MN_N/7%<[[(Y>FKA!$
M98L>(;T&XKG.OX/K,C0JN4:ER="H-#B$70YAL@S>6;*X:TL6UQOOD#9\G:DZ
MIMK-R*?BZV2Y$QUA6&K1F4/_:8/%BIJ9DA).C.#/6A7HNK%-19&5X.DD#,Y.
MSR:A]#7A*395*?4LE0NM*P[U-Q\,7\V7F@KIP&FU28F%*O0B3PULVN3ESP&B
MJ3%2*1I7BV"6YK=#5N @0G\#QTZO $DV>_,8N#Y."HP<$(*W_*PBD)LR,17-
MB7T9V^YL;F":\^!SWD<>%=>J!@DG7-Q"<E6-^\Z"MRR=YI 6MB^_'R/D<&:0
M4I3&0/=@:$6M$FRU;K&_A:Z)ANJJR[)>KLSC,!D"_X8!1PEWC\UUAO!EG&@C
M6R*AB?.'B=$8GY-N9VVY=Q^>R\:="*\*%4H!KS%G( 0_86/-85D5N/V<7QDU
M3KN-8N/^8WK[441\(>?NE87@P ^>1CF,&)^*R2VF^Q'TNJ5?N>LDW3F.WK<4
M)2:I\QV_A_#PIO=3Q:A1/*B':0GZBJA'+.E8CO/?8B"[,5UK8FF;YP]Z[2!Z
M#4S1K,)&A3=):4S4WB@Y$LDT)^D/P1]<(K<-1V-C$).BCF2#ATRP0OR16(=K
MVS>DUEU]QLW,"85IFD1!30#?K#)MFGVS5EWN.G11'%0J/U[W1P)11?T[(S.2
M#-V2#SCD8A)>TN":ZT<&T3B :%Q?]48TNLL?W^L*O0(D "\TN!]\R%KT3!(=
MX?*ZQAY@,+6NL$4;!*@,)C_]],H\@Q05. TVSW.9@9Q4-4<TFG=ZK3)2<._5
M+3SJZ:N?[3U#A+(YH3@<G:\I\A6#\5*47(G)S6D4^UCC68]Y*.9*\CG"J'\-
MC99(#UG70X@Y3#8LDVF-ZI%CO;_(MS\-SEU9G ,#V[S6F,QBKLL4A YVD;WS
M#(]_^I7B3U2G#^.1O?+^GW][]O+GBT FTM0T&/]^M'&NC]DG<%A26^["\3ZN
M/>U\@6%[//SV>%PPH8\9,^SM43N\?UR0T!<GDZ=#'>0/KJ6N/N3%O$]XV69$
MP04%R]!J#(/?3H9.FD-(0YTA'6!?2LHWVAU]H-=^SJ K(Y\\&W3G7V:WF#+R
M8=<,NV;8-3O7^CW&)ZO^ 9 WR9=B*<IID(:9S@5Z 7&_.UH"&J_&US3Y\YJE
M/\;OA_^R)W+S/4#;!UD]A*S>]B*L!:=,K^<I[<D\R1Z&QZ9,RY2N&>(W\2/1
M(1Z'<#GLYYF.$>LLY&H7VHII'DG9#7CUU&FK%2:ZPZ"H4_QG7B?HYF?TD9[7
MJ:F& 6>?RG:X)3>6EED5@_I(RJJ@$CS*S==Q0K4]7$S,)39%H.IJD1<)/\LE
M]SGO#L.';U<V9>C?U8N1$[G0.O@EOX'7%?UQ+O==!]$"-(..731"([Q))#PQ
M^SY$HI\PJUY3Q\9;8DE0*(4>\,BXECG$='M9>7W%H7GQ__ \TMVY<[0,[--,
MG(J#N^&.MVPRR;>AG#UN9'IU5.,@O8,R/8 RE4#U.9?4]$A?M/,%)#WN8'>T
M"A1*-U1RDY<_ES[[*,HK@XXG*]XPU("PMA%ZRV7>%1S$J\_=?G)/O](%5J^J
M^7#B'U!(^\@[GW$5>2GE8A%GK$!N$<P&*T>*?(E=#(4B(?,@#-M9+J[H0D<1
M=>)4ZPQNDRQ-6Z'7&@CJ,^,NV!SI#KDNU707.B&UTS7(Z.%D5!;SK1&*WHCJ
MEQ0=F)2]-6% SAIBSC";JZ00I\Q:(5+I; KWS'>E"%"^-LCCX>21,]"]D4)*
M':!4G'/OENDWCM0*''$L42])^E@F63I+3TFB -5\\DLFWG*\>M=Y^?7.BT\"
M[&W&_6#1],7XU/.<R$9LPH-K68?6'MO:<_;7:NTYDFZ1XNE6'4E;@^-7WMZ!
MA\<6<5O>FU3,M#VH)LP*=][;V'.TT#%X]L'DY'1R9+CXD^"2;2]]H\T9AAVH
MRYQ!X#.":FA7_/AT\41=H#$&02HHR:00B>[*U4H-0.O2K*V<,,U[&WUJJ^P%
M%@6NH0>9BULC2C(K.>90=I[-IAF0TWWP"<W[2/L(PS+B"E+]'T80DF)PA@YX
ML/]ND=+[%.5#%^3>8+V:S^&@I=B>-(<P5 D#(J%$@[>4&5\)R< \VIM--=?/
M=5JE]5$7IC736*L+,_GOS/,ISVGVRT;7DK?AK?]8CCO;@I:KNC*FTSX+N=7=
M<(U$G861OJ9C6>HNY>JG'%BLY9/3%\<]QF@)<28WH+'.'3%Y,B/8A6T;.%";
MRX,A"W(&V;I <QZO*(-IS:I UA</"M#SLI0D&94UR?%*=!F=?VE[6O&#CV@,
M/#V9/#-_O;R^"N\7%W,P3NU9ZJD2H[H,03&/LL1C="DXL9WR/)QR!SCE+CX%
MGS#IVI=,]&-&>3\Y?7I4O**AAN,@6X:2('W8*QSIH82-:&MN.BY;'JFR#H[-
MWU!BG?5Q"0*@J%,:XP+L.F%G-]_7[Y46D"$$0]AZT\[2;__H0Y^,S)&D<#$E
MR1:7.):2OR'X5KX')-Y/Z3"V3*Y8\Q<].$L:U+ =#K4=N!NW/YL"I>&\F98_
MGY/A16)MLII=0F-KDIH.^2!+!Y.ECW#DKQ+4%7V1J@<> MWQOQ!@(XGV<3F/
M.2/>H3/LHM[N(C2=?Y_-DEZ5FB@;<.U6S1W1U-S$,YRDY?1:!!U!/SG@%3%3
M' 6A$GQ,@_QB2(>E?J4UBO^+Q5DPEYD"(R.T!)UL FT^U=Q<GHI>-Q4A4#\V
MOB?^F^4HMAO05=OF@'$+N4)!GK@DC$4R<F@JSN'C-)&809O7%,,):)U5282_
M2ZE?,"5*BXX+Z%=[QV%S'F)S-J,HO=F>G.05P(/4CE(*;22IY<)(A)*VX/)2
M%L[=2;)!M@XO6WY#?Y_DS.??:5:X6@@_6QF#6@W^$M-?"<!VXRW]?NU-#0Q_
M12BA3MB!02B/()1O,83-:]^7H*/S&7VH[A(3T<'HY1@_+8-5D>0VZ7M?YPL"
M6%"0GTY8PDGNPOX.[P/7'L!<CB&B[P:.X&^,A9]A+'Q@DOK+[9QKQ,1:]LNL
M-1E'_2=2]HD"Q^ RCQSA4__^XC2$0>%_CN6^4\V?!,&G+NPD\^*HY[$1PG;O
MH-+'H'ALN%7S<-NM!X$]@,#>Z (Q*B]-Y71_:),>L;I_>3*9P#X:U/T/OGL2
MW2M'<HW%H=4<]G,8K%(=X[^+]0HC=I'4P7%.D6MN8DUUX#[6<QCH+*J7%"#3
MV)>)%C_WO^;%VN+38JYQ'$H/*0-:VV+3D#V#I')?!]<A8E_ @D][ER#,6 -O
M6AQ8R<*2D]MQ X:^_9QDQ'TF7[X%7Z7,4:FU,;$MZS(V]*K40]ZND@I^+32R
MWI('[JJ2\$+4BOP;4^G"@V^5]V[>A%$*F>Y&1;$^(:X!"10P?QA42NI6>E";
MB&N4A@8W/P"IR_)E$EF(2UYER6[;OH'!*SK(9E\2J.Z%I>_^!(M>JJA?X20B
M"L537-AVSYM8^BRS'FCZ(^7E/2H878.]S"H6URWI4R :K&^<_JGPP*/%FQ0Q
M&<:>2F!L?"0<R+ H<<4P0EC''VNF$<"?-ZD#XJ1D3>PP\3T8?JX2H4[CH@ C
MFROO,^)89$O\QN^Y&^B$7,_1TZUS\4/V' W'P#['0-XG@,0M?> (_6$*#["=
MQO&L<K:JGU-[CG@)H)LN+X^JW%MXMWYK.[/U*@?#A";B%H FS-2T"*4',^TP
M^[.'..1M(*)V_P-*W&\Y@PS!CT(C) F1"[@48?!!ONR;\5_>:1-[DTJ^%A"[
M^;130D5!;(!3RT4=GU.]ADU.1H2&A( G!9J1Z*'@;^0F$5O.!7)^>8/W+<S'
M!H!\=F0XPA;,O.>D>LCRN<.?1YPES;7,[?Z81@FTOUV,Q(ZP@T;";<QSJN]\
M7_H:O7&XZZ\88FB6,C?^3NO_065*''O[S<%A/90F9"[UWJA!$#SQ/"33H#PD
MI)'$8["WV3\Z[3?&AH^-F>Z-T=,DMJ>BNM?H('W$Q#-]%#+E6.NZUI?PNM:M
MV".+Y5+0;K7M#-OX9@-I[/'XTF<GIV='#E6'AMO6-- ]8OZ!=T<](YHUFC1C
MCBE'K?"\=?0\706703MLRK.>D:.!YDN19TD4K.!$Y[\4_L<5!L2624D;K%R7
ME:;GVW7=9P2PQ^EKJP)+,(EB>[E*M2%5P!.-;X!V.3)OEPG&,[BXMV"#W7@[
MPRESH%,&^Q(2W5]KFQ2S]8%1CN@3L;+S05 .("@?5%GUC0)G)SPZU;\ARITE
M997YO;Y5*TP#5$A9)K<:).@0$H1,WHCO&J,5IX.WE!7K@R#YN9>E&::2848+
M3&T2;R\%A3:^(-D]@U/BLVI/I?B1,K<:W7Y)*1*";IIPE@&Y=T=,=4OLQ&2K
MRFEJ\Q/!R#&)-Q*YG(S-":3',HO[>MWT:"2%P?+!X]KG&@^1L51G[%K>+O)4
M&U/=OFRR7*FD,'7+^ @)%#!+V5+'B;9/[[1-&LTO/KJ'[\-RLD60AFP*9N.5
MN@8,MCJ&,="NV7C9W,'>['PR^QG;5KA>288HU7.5$D#Q#?P;TT_3A/N4C#04
M!I+9O(::*_3U-RA?9YMC<53-7(*E.-<T:*D#:BES0O1&/W5#<1JF<W9>9<RT
MUVQ<!_6:%6F)W>VOI)S6L:HH-!O-]#0TU$^K*<MD1-FI,2,,_1 8)['QRX(D
M#J]:8%:;<]Z$ZMZZ,4&AP?-\+28=>8[C'!-TT2(,LCSS!@PZ%?])4PN./E-)
MBN4G5/:1P=()]CHG>"L#(8 ;_":)F9"<Z1L;:$DPZKQ.8P&D4=.4_#9]MV+<
M=+C[0H$N4L&6DW#8W@?9WCWD*OE.]"-TPNY#./+#H_'M$@&1SP_J+EG6,#NF
MAO8C?A-6@6;!BZ<?-22T0_,+_\)C"U;.CQRL)-/5+3(7 _D=S1SO(E7M.$!W
M='ICO5:1(TS:4M%-P*S'<_$"3U#,P%1XHV6>\64$?8?U1TNTF3E(1C4DP3QA
ME@![,SX6S'I;=&PY=SKTQ:,3A5%R5&GP@,?K@LI?70U62XD^YCD^[B0SO*=%
MC0TM9$#-2.]@/$9:QR4;6MCR:M+F69F#=T49T):63@@P%&MPJ^#TY/EI(.A*
MBK?&4G3[KEL@1]<C+9\\>G>";6Q>YB4"6474[)R42+?T9PU6,Q56Q_0U9XX;
M!7NK3%DC*U;1LIZG011.C&G\>-;E!8).'WE=\KX6AX$7>-2)&6%9G;9<*F65
MY[%KUH_Y2)ZUP6I5&A$G&)7X1XM=^D0H, 2ICHITK6(SONL>)[A) 6X_?]@\
MP=)E; !$.!;83@C0"^9%0HXFU6VTWV5K.'S'.XD!/&8<EWX*%A4AQ?JH+6]A
M3^<&A?JX\V+."9'$]J:Z[YAO5IS!H>\D.#0T'GMMJ\=SBO3$,#8VVJ9E?(]Z
M>H0SG1QSIL<;YG$W$/6LQJCC@"1]J#@A*)1:(@3]Z:G>B]@8P_WMT]]\!95B
MY$(4ECW4#_+?:/BY*A\9V?CDN':WY 71'T5X'-&5+9=(S##Q@T*IBZN+8/1L
MW/INV?IR("B('0\BA=R\.ARHIUP;V+.M<_%#MH$=29L;G)&9L$5PNL_HH+ =
M+6A4!NZ[!X9PPA!.Z$4XH?<6V#ZJ<9\<F8[!*DWBEOUQS*EO]V'I8*%56BTB
M56B"Q\#2\XB"+_-"+0,-OT_3I%QPV?$GPG?XW\O_-;KE.B<5<6T0*LZC"E31
M6?#OD^N3BY/@GW^;O'CY<S!Y^M.+AWYMNN/^L-E@G97ZSZ/N@K%M&6*,$5TR
M!X(VW)A<-V$XYE-UB[3Q=<KL\?,Z-14H,)1:I=2OP63S\SI!-9ZA]5KXZ;H2
M0_;2AX\ZG(P?66M#GT#-*%C+!\^<Z9AZU^P 1X9%OF'>[B465"U?ZEM\+[C[
MS'3,-<= ]2ZI'#KNN3@)JQ1S_7B*+6ECI;[ @M5-T3L8391GF9P"9*'[#Z ;
MF;>BN90*/#N=^,UEG<[5'G?CQ:&J-QBR1^W7[.W#/^ZQ;KS2C11IZ-BHN=;'
M6UD>M[>T\J0YN"!%QBUI=;5 ,!JL[OF"UW*KC-@R>65P6J01A8,9(([];V3[
MKHJ\T.TR^V.JCRV*'!LBZZ*APTT4$:QM#MK'28E2&F_1[O]]>7GY1?H=U/OS
M0;T?2KWCIO34P$,J]/LD83^5;GR;7NI(/$7NU9+PRP^L)'^$>"/( U<LV'9[
MYMGL7]@1<<@YRMBN2FL#!D38WL<(^I3X@;]BB[O!K8LB C*=JE01R[%)Y7$=
M;EQS;;%&(%)L@P_>%3DU1B#F=H[1V2"N"]/IN*(@;7"+51T6/ 4'4"5B@ 5O
M]$S5J0#Z,P-'!YPJTC(O8&4HFK HM,9;4X'#:'+Z]!]CHTXV1V/Z%':S;W<0
M;C,; 6YUG[(6IINVJ\SW].'FNY/E[/'A.X!('CEMUM=$,,W,\4OM^CPYQQ:<
M;]!$OWM*X]R2(ON<S![KM_/X/-I!]W"/*WE7GWDW'98DX)$*,0?["('MP$2$
MIPX6Q $LB#R/UX8,JC=60] 8EB!7(D/FM2YN$FS&N<RB$^=H& I-XUX,DG,(
MR6'4X3X(#:S\HYBK_NRP5E\:[J1FC%QUT\Z&#:K=F29CFU"-%WD:6RCJ$H&F
MI8BQ*NJ2=3]_I._ EZX,GH?7TTK5E)3[*\A0G2-. WX% :EWM5*,J,.:GJ.U
MC?M,=:9GB6T\[L0=V?9E V9E>J$3IJDWZQACNX7M=80_,NH*0I4PBDV$6,Y5
M4LY41!C:.T8_Z*K#[3^[;GW@4_40W/-; A*6G10[!'$F^W);) 7A8<CA?D[T
M=;0 %QRLN.<G9Z>C^/C5B%M(P#<%PBP*(R)G+>2]]@(U<=[;JV20HK'P(*&J
M/*0+%]!X:@PCU6<&L<V39N ^TD@^;N2@,(ZA,(+K>D4'4_]@1K?T>?H2"L?2
M'^:/5N[^^;?GKW[^$F%:(8%/-G^2ZAF+3H_%ZZC$6\V9.GMZ,GF%$Z&D'M=:
M0,*-I JX<^ST@5$4-JZNM>/ @&O(?6[870V&#%\5&=;?ACA09\8/N_#'C,FT
M%O[YR8NG.!')S/1=WQ,A@>5"?(I6( 3302LZ3A"#C[,YB&+S9%HG*<9[BQMM
M 6_*I-*N>:BI!B)N+KZO,UG"-,QJXA*KD93.8>39B.8J3Y,(+63B=9%:.LP@
MI0H;-2EB-&MW8="!ARFN#!-P+3O9]R^V#D]"W)WC"P/N"E%<ZOS=[\\X'^@_
MZ94F<<<)GFE"0(39%C22.$CY3K@X2(3)-8C-E313S=\JT;"SI8KPE (<$[(W
M/)1,Q#Q,!.TGUE@*Z5B+%?)+% D! 8M4Z+M($XT$N7**8G0&@L0E)?E5:3'9
M&9QB.VR\U30QB:=K\]0W&NZ=^C@(7++R'F_&:=5K><<_\H0J.?TL/*<W\Y6_
M/Y:P 2-$K':W&.J3;7WR\Q^Y/GF?\^9(Q\MY66)%@*5M)@QW)1Q36"R@V2&X
M\E7"M2@!"B2<G9Y-:">%1@L3FT/ERI%WG! AG \:O(*S,'@:!L_"X,5(C?'_
MI_#_+^GGE_#S:$(_1/#_K\+@IS"8P+<G\/7)"_CO)8?S)Z]0WWPB!7!NJ&!<
M@?6/;27\T3\KX?S]IW,;0=L\?NU1*YE?\B&WG5&@M$'MLV[?<=2W/8=-FX'@
MO6IKBG;>Q8*A6 L6^X$*6Q+3,D*008!2ZP2#Q\BL!O0NQ:ZB O%I#)^<F1#F
MI<N[[-DPF&&>BX*88!,7)I$%%@?!B_$3+&-;*8>B1YB%(<;2'-%;)YY/89L!
MPT/RVV)_?!G=E6N6-+\=F!6YU/4P<G^A]S,@?^P]^[D_>]:X=!IK(7#)1[8N
MPD*,S'!91L_'#3)SCT.]8V]0I(C*.#9CS>NQ0-6!AQ/8\K7->Q#RX[L4H0I^
M5?]!X^S*)R3$E+XE9=_WRC 8G;N'<F)@N:PS9F<T4.Z==TSSB,O*F!,8=M**
MV[C%"K6')S_XTFZ[*UL;_7K<ME>=AVN3A ;[3T6?L_P6B3 -["CV#B4K)G&4
M+R$? 8$LX3&.X#$[D@L3,^_DBB-.(NF[KYCYL[$%&]PYD>2BT/V[;_8=9I4'
M=#&&QZ\$@K5#X2&LK,.C:GWKJS!C ]DP.-09#<W=\(NTIM/"5*_8;$[EEWZO
M;GE$F5KN/+\,+*3-(Y=^E(794TD/DU^>YB5.^EH3]>=4@_J>;<D;_=CJ..V/
M.O[B0$L#5AC9O:Z(7O$R&)$P['L;]LZEO19$ODX=F++<T;OYY1A.]INDR&T)
M;EF"O#$E)W(_VM0 V$#+?6TX7U2SU@/H'4 19"HIM(ML&!);_ZMQ D)&1QE[
M&.0]<SRG0]5)>KAS0&S0R 0R"@P\^8?=!LO^;(/3D\GWB3<BE=T*OLZ8/P1<
M'6 =:*DM%K 79*9$O=&PU@?88JK#@&&CE'O$(.D8-#NTV]#V0'/WVRU#\NP
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M1'J+4FN]?_B4V?!FJ)AE?F9)'#457;'%5'BX[\WLR,1WEDC=:\-T' 7!>Z*
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M*UX.&.)Q>G1R"F;HOHO.QIV\DYT,4\9GS)@!?TP9\''S[&+S8'D*+K=N3C^
M;3.LLWB/^_0__H\&WU]<G 6^Y0J0-=D'*/OP;\RY'__T6E-YOC&8?$P^?OBW
M]X;COMO)OFN3!0U@VUF0\_@Z31;2RI?:R?$@PP!#(NF< .A\C6&*U==@$3(&
M+,CWJ5*LT:C-ARJ57Q99QEGT5AE)/@^):2Q;>UH+):H9PIJ[$\7-<I;D\=HF
M9*K8&ZT2Y"G#*A/!PIO!6%_=Y_$,DJF0)1\<S.'7SZMZE#=O]AL;,(4(A6+&
M*C5$U=,]TBHPJ(JQ2%//Y-.3WKD8BS2_G,#.Q:50H2(-Q0-]D%P5U%=-D-;<
MG$G <YM*SYQRG'OO FM$*??LM'2/79D7S)+Z%J-?_??:5')W% 1GV/JR +6*
M=Q-="X_5A3XZ!"8TXIO:2T7.3M:MK0IL[%G!C4'%XGG2V(UF*787L3'RC]P?
M?I<GH'@KU-B@Z%8%-[-3(/CK=(6O17$WW4-2L1WE&B^OX>JMV:#/?*^PY9 C
M(A2#!\T2^,'"\QB,[+<ZJ!) SS"U^&N\J'C>-[+;% 8F 7%JV^<]"'FM'_)@
M$)VR6)4IW406@WUL)1N"=OL\2L/1UMR)K5F7:<R5,.MA%143ES4JG!0%&0M*
MU.Z=HZ1@SV*2,JYQ89(L_G?HJ52$[8JY-N2^Q637393!RT[5M]R1!I'2'JX3
M3[M--"];E$DA:/I;_!ZU(3=,*IH:97Y.>%73#W0NG6M"JS<HF)5I3C%_2EE@
MZ6\*,QR5JAHS1+4>7V.>P-)B+KLWO%23]$S(0&;!;GFJZDRIPK0N9#;"@%F#
MBQEV:&-CG:C/*(NR$(/1W#.XC4ID.<$2IY40XZD)*E&X"-PN[:O5!&SSPJUJ
MUH>^\ZC&=J'&5-I: \2'H\>B8*8&1338H+S82L0MWF0@)DG15&TLNMIR5;1,
M@O?K5<+.I^P(RA?"%01GO_SC]3L%8!?@@OZE;D+XEHLW5#4W&0_RB&[2?_C>
MJ\4@N.^V@>,&W^4&1RJ:M!Z4I1)* 948Y.YF"NFXL'@2X$*T;);1QZ2SY\4:
M9B4V;L1[QY+0QM)FD@,Q(6=<@2_^T*M1&8MDP^]<7$H5,E[%:E0"SE".O\@4
MRD504P7\A&B6;'L%02@H+<1L9D-C3/ZO6%'\*1%7D01)%U#GJ->+P68(X^MD
MWH W>H("L6=B<4/K%D?<+%*TG$^?Z)X;[NRK7\K)>T8MTI:*,0C^;*0/I;U7
MN9;26CUP_^,"7RTB^6)R%+1R2P5^<GQGB:ZS)V[?YJ 4PKYY6;ECJ YTT9\T
MF;+A5)N3.1[%OM:AGIYU#,[6'%P"RS2JP,#<7-/*R)D&?/::7Q*6@IDL4,2P
ML2D)G MAP#C;=\^?:U;$T0[9I1VB@+>#LT(,]9,+<G9;:_E.+,,**$ZN?6JU
M314=&VV=3AU@I^?0I1^W#E47[#R*\@Y%61''#TF4^R6W3\&*\A1![-&\HY#M
M6\B"WZ*Z(6S*4&!X'*7Y5Y.M Z2K.#T^?3%6.HR5#@]L)"'IO;D8:.CL14[_
MO;"O+8JS,4QZ$:_.X94QM1@S%;9]NU&+[5*+#:?!O>^@Q+A25009T>\R3Y#O
M&!2JW(2\"9LK5%7*5)2U]_S0-1*Y$6RZR=.A%+@J7TDHKY5\6F&IV=W/I=P+
M-;_8RJ:$*T>3<C#[!.9_"+ODH,M4]AY0'??,+O?,[\60[.$($43+M*H0I0-6
MC"&"=C,4B/&);HI2-3IU3\H@(>Q&[(L@=!6VOQQ2/5>06.WTB@"+ZA3LI;6*
MTA+L:+"$"!>?KM-96@>_C)O[<6_NR__^SZ<__/1V.+OZ$L-Y43D/:&#!VZ(P
MD3M3"W*9E#>$9?_UUW,L!JD4V(7@+_)2P<]9,:/"D?B(LV@$,&IBQ&)RM3-F
M./K%[-M#:)]^6PCM445LHR*BC*&XOV+7U%D4?PS>E_ D1B@/1G/XR\BZ\#B-
MBUNS@T?8O"N!.#(8,5O;T,1L'9KFL<(>?HNJ0R<^G6?01^8A$B:I$DRG@<[!
MF5LD/!0$*2?X,^K  M_"?Q=-AB8")C=F$D3!3C()H04)Q7>;\\4&RR?0P7FH
MT/'JBU*P^QGUNZ61Z6=J"*+^A*'Q-;6XR>>4JL'.3HNB;)DP&KLEU46!76@D
M!I*^ZRPAMZ;(YO;[PVC'XWT7>S>G73JI]NJF==FA*QF89O.G,@T,ON0@;[$!
M^'_(4PS+@%F _0-^QFY$C&V8I%C40-'&/UZ?G4]#^_+?)>1RR=V)UL%YT8#E
MD/%%%PT*)VQ:N!I!SK^D5?!;]'<"LZ)MC?=<\+<.)H->X%]^>S^ A9U:@.8D
M2VZH2%%6N%(5&&-M[B[134A,%-U$:1;-.'@_E&36 0>\1GK ;V,+79P/8:.8
M<O9+J\<>&'BZPR7E,2KF=1?KUAR0X/@:E@5R>CDU)X:Q &@,RF;1B+X>16PG
M&L4!S@U)WL )P"+,B!MUN/@^$![Z(YF3)&)Q'F7-5"<!TV)S3I]'NDKD#JA@
MR+7*<VG-Z41PV6C3K:(KP:=*^":T".XZ7[V,\H\X GALF<81A6_]):,=.CSR
M>-M<>%)\+.Q[SK>M9X^[:/>[:( ,6EWHSLDH&3N1C 8=RO.HN@;7#AO$D8 ,
MLC/QNG^8FA#AKEB6#F^W;X4:<)2XW4G<+\D<>X\/4\Y256O)!!0Q52W'ZY"H
M06#%L>2'3,N0:8Y43_7+VVC%W;VI8SNB9>I:M]<:YH(H]J _]TL?=/\=S!(T
M[MO=[EL+J#6@/9MEG:H$_.QL/J?,(F5".^,?Q69W8C.\[KPQ$M.1$9P)DM?O
M\%A>DZ\#.W]F=)%<Y#,O*F'Z>0,W6V+\G=.%]%E</(D4@U35S.2/:+4J\"S:
M2./C*78[G-K"'X^.GX]QPF]'!V!?"\/DS)T0!Z,4#,<;;2D+UDQ6B&EX+:QG
MB>Z:>J"PM;U:?./6V]'6XXCX63P@)ZL5K3^+J0SPY,>G3Y&20>6KT82+5-"J
M4A%#Z5I_U61B[2&\M<FNN 6(9C <Q6MWXB6D@8<#=V)X$@.;A-H8H^EF_&2'
M)<@)AH+IO:2RH17,@DA":W!2U;2/2D+@45WG5I%*R@6(G$9(E#1)-FBDV[1*
M-$B(HA!7&/5'B*>"<N@@1HHORAQZ5:BXVBKDK(N3] ;Y%/ /G,"*.^W4V(:*
ML5#J:GP"<4(W45;9I';F=XH$CIH@4[8:W"Z%?+*!I_#2]D%JO>^X9W>V9]=#
MC+TQA8[)FY4J;Z:%.NK/G)UG184;D--DFG;%+FOH=:%:/&HZ_@3[?Y3)'<CD
M'Z_?#4L*=;@(80)XI0+58_D+D1=4+B1/'/37";P4]?6#H=PD.K&* _U_1?F1
M"#LC"UP?&7$LRNE1/PWZ*&U?4MI #>"4#43]C9U0],/%:,,"Z+;A]BJ"QP67
MZ7*5)425&0;'1R?'_Q5,3HZ#652EX I@N*R:,G]<^_>TKW'M^4:OLR*JU7[>
M<"M%*]>^G6;LA*>ET[[?$RP<3I,V?2?H!.246\*$7&LP[;PIA7";'IH^Z+;U
M-1R1?&/-H:)N/-;PF!J>IV,-SW@T^(X&CWH8P!FAW-F%.(US)"")@D76Q'7#
M(RW%HU*>7R@N9PR*0J"02$B(AJ[+8Y+\+[AU2D4:)N++N,2,+-D[]6T1?#BZ
M/+)+"ZP(CGT_0DLR];<PJ.C*(&*0L C+B1Y<J<%@EH 8$]B9>/.BFFS\D<)G
MI/!Y,(4/"G1I,?BLFEF65M=@L&L9/3D!"?OAI^/C(#I:'J'H=9OU,@L0W"S?
M:$6( T&_]V\C(81<I"6<V5ONIR!=+I,YADNH+4EJ2G)Y:Z2RI['6?JC"L,J:
MO29_S;(9PW]4+(>I6!9-B?(_3LV =6ZOAM1L:!EJ-QAO'OR3E$7(2K-T+I$V
M[?B]IT>@0]X[ADWV9AL/AB)*Y?!=+AHV)&=)1!0WXBTCV1H+&WC5W-6+FTXN
MTIR[\("(R6KTO;<\=A2]'8A>D=U0U[-ST_5L2!)7J?'97=G2_)"A(?\:H2'?
MPIX:0O2;@IT',%?Q8'BU-X$:J&,>Q8<X&.3XL2&?AMK'Q6LPU$YZ*4JE\9Q*
M@QH.%!>5 )87&%Y1S7R?K-7JHC84]'!]EG)!/755,S@); D-_T5OU[G"?0+'
M[WD(24485QQ<%64)]3EU1AE55<*M&%IC1'_?6)E6>Q:: ^JM"48FMLI$4AB!
M,*@7G]&#U!@[4U P]<P\F=6*RF4MG4$"%0(GN5XB%S!2SF *P;[#O$AXB$PC
M$V 9)OY ?SY+LC1!TE6AF\$!TU0VI3P7&6O,),(/UH7B\N>'Z,2">@MY1PEP
MT-CA%_9-U+OPN&'8\ZEO7I/\*KKB[+JBWV&&5PL@P^^CJ)-G1</=<NB7=_P0
MK?T.7,9T)E!R>5LTV9Q:L5''>^J1VN3(2%+DL'[PHDMT)>)HA<DOR:HDG1>B
MI9:IL5;5G9G0EMVB56S A:ZQS4_OS*,Z^XL2=@&WMVU*;ORF9D'U']$[R+]5
M;)Y@NW/M<M4('*(EZ+K37$9I;.E8PAL^EM>,TS)NEMS5M0J23]+8SF;=1;B0
M;,;.(V0=K'F?82=:U$V\K]3&P!XL-8::87EE8Y@M-A[Z.SC(-(G(J[12.;NA
MG&J*\0C[^VC^+TV88PU8M]UI@Z^M7CQ]?4 O'2":?*@U40/>7QB0[VAM3;P2
M>]=6\FQ/ U7KMA8JD Y&*XJ,C\.2$][)6F_17M-/F[I=Q+>9#]J$V*\ZJZ57
MN2BW&+:DD%E@>R1KF.-NV^5NNP )'73]TU^PCK?4L>X7U-3G4<GFRR]%M4IC
M$$ B$'U;8"?V9L$7_9)$&?P KY7O?\,NNG4=.=^W;T,?O"_3X)RW@74M?3]*
MYDXE\R9A<^-5LHA ?PQ&0DD%MD=W0)5M/^R?]7VH60IGBA;[;2Q9#+4NWYFD
M_79?'#7R+C4RE@?/P'%"6W!8VM@>F>I/OKE[;DI4&61"+X+OGH\-+O<A4(9-
M8UCB9+%\<(R+(T6$LHET@]\$5C[%  W&0YA71341TIU^K?; YYJ,1=/_877A
M1(5!;>3/54HBS.V3AF]1G!P?G9SL<PFGX[[=Y;X=8CDE90MP\YXAESJ''[B,
MTAM:"N7<N$D8<M4?J: 0(0=";.9Y%]NF^-UG:QA->865CQA$*;)T'JFJ35T>
MR4D$IG,2!J>$RQA5I2*VP/ >N]01+9Y:49CD1H]>*GU0G51.P=@KZ?M=J9Q"
M%;PMB^!U42XCBA=EJ6D^C5#8JF;Z*+AWA!5M<93%4M4L+8#-[YFRKYOWZ=R&
M7U&>S^';]A4<#5)/8_A#9#WK)58:C'M]!WN]F7%&H-9M\@9S3A\P__3)R=')
MB]%A>O1[1TZ)(>P6(H111?N""H)1KPI5T(5&:P[?7Z>K,/@;B[@"/%(HQYJE
M2^K&8++-L<DN\/FC4Q$)1I(I'<WYT2A81G\S>;6<1=5U5#)&\L^"],IE7<0?
M*<]9\\F%J<-9DB>+-.:\"?5*(18!VO&&MDH_!GYM> ?($L?P\=QT@@G=5C!8
MA58T5]=4W8'9OH*2H'AH(I2]Y*0_O%>!45_5(498 (+@0TZ)>_-(K7U"2O*4
MR2*A [VB]BZ8X<2S4"'VM&CHY2%[O_TU#$)=P)E4NBW?RLT3V3]I98#&DCI3
M4O=L+*D;]71'3ZM2]Z$4TAVP93-VUOA&]LP*+ <T"?[G]2!Z;!SPE@%GX/39
MN&$>^8:QB;>'L&'<8)GB(^;R)ARKS2,6"K4#?H' #.X1 N^6WC!'D7OQHBAO
ML?$KW<S]RC"1JWOI#XI5Z^?F*Q58KZ@0/&72;?D7RMTGOALY(^HN,T2:DOV>
M4T"=0VOTE_\G^$_U:/5CYV]]$^=3OIG[E@X[>_?%VASM[3GJS/XB*U3'16LF
M,V0W:WTH//"^)8S+HJJ>Z"OZ5EI?H(==K8K:7@(7_"4L:P[MG%P!"SBS@66Y
M]@!Q!JX*U-,6%HV^E[4@&"["MV$J"^\OIR;86I0,X,W%2;-9\A )3O7+S(#$
M@+R_+4SZ,JJH\Z:A[2(,[LS=%^[K\;M\A*4WG63(;4H(Z[M(RV4DDR<^<)G8
MSS716<*V@ABEZL[,E&=&+ R 4I'3'JQ5+2Y!7X(3\IPCISC).#[DE=ZL57 &
MQB[XU>SVJY[*Z]9/7XN0ZB35;_QLJS.0(PB=H4WT>G2GN"ZN>.ET.U8U?95T
MO<,&[<,NN6C/QP"4^M3A)E73;T/!6X#\1AHDK3NK.]H$.[()!MFNX(X&S+3K
M];A580+6/R<EJ2HC5]:FU^EQ]RR31F6Z1*(R&Q^/)S4P')+4"2@;'[-CRH:.
M)L^^GUJ!+T^*?13I'8GT>PM0_B<60@U&L"E=J^1:F216_->QTO$(HN;;=?01
MQ8U-$::I)3$36(;<)TNN*%0M?8^I9"=/:L;.ZU.1HZL,>.<&XZU'HD5N&)28
MD(4(:6O!C]"'GI\BW@FCYDD>Q%E!->--S>:)M1Y4F#:IIH$%-\$L-[Q6.:?D
M+S&WX&X+57*V^VMC)#E#U;@5/4X=!A^P'QYG$79'WSL4UM0LM=9'A3:B\N.3
MNGB"_TUJLY(+W:N^+;V5?1?F$6A65!MH1'Z9SM4=K=;/T1S9!*3M, CR_S9%
M;<C,B?B%^SRBY1875SF\Z1R>%F5DLWOE<\*V,#)&LY62F!8%(D7>_@4CJ&<G
MBEM14G"W3OAK,%H;2X_4H%@P6@0:AX.Y/STZ'D-]W\Q68OTUG'W4::*;<I%X
M'*VBF,C+M7JGRD-WFYG0CR&'KO05&2ORL;O%?B1M( Q'!YR&0=6\9QMPW#.[
MWC/#;?#5LG.T579@QLZ>L0 J *]Y* Z8\.K?^RY#Y&@R>8@T8]AA8H7VPAWM
M'ULY'IYMJJ!)L,"[+/(T#E995/,WI?TQ!0J7:47,!M6ZJA-ZKE[/;0: X0J\
M;%4*12V"%[.DEAXNV.U/W%GLB@$.<D7E/'^ ,QHGNBT+W"(#HPF_X<TXVCB[
MU=>7F.M:ID-(M.@:,55&Z/"3(S*4Y0:#>=^=ZJI"$S;#R]XE-T5&]5VOP?HF
M@AEFV.F^,J8Q$9]+"4*\!],R!9&T#R9NIIY[CC+Z]65TG</DP[$-'A_V)#,Y
MG>'(*EGE19[4!!@VR1L;%\YI&\*$!%7Q)(X000U:5]X.2= 63V911G'BZCKA
MF&$=?0I*T*8YW8^ZLI&GR#ET*_:]$/@V1ELQ653 -JD498VFS+).B\LH8Y(/
MFM99%'^T2\ZJ:;OZ*D;.-PH262E/INDO&"*P6B51J<A46V_B\J?-FIIMAY!C
MIM818 ,:7B6S&I&C2(6V"'Z-;BL=V5=,<<P]A?5,UQ%&0F$U_S%1W=2IZG+'
M,,$P/$;QL7JY)*(JR3]PIS]X6YS8,4"Z@SW^'F8R&<39L]''[B4)?HMY@!IM
M'JLP\DZ&X&^O0N!Y[UR,%0+?[M[_-"!F+ *D*=I1A"-R.]0:!QG"^7O#C*9+
MV'R8!9PW3 XY3^:- OGAN7)=9'C(.DUB\8AM5O;7Z#O1,2TM61=)4IE$(9YH
M5_ !/<RD!$W'$#"*SQHXP[#\JPU.,DV E!E+9R>:$P0ER:.,^22-XR5=1<;S
M;@<RC]UA!IX+1-"0,(&BY90NFZR.\J1H*FYN0UD+7748+9/@_7I%%J7F'$7#
M$:\PS7 DU2'L,?J7[3YVRVB>M+NR\D,I$5(=5ISN9!*/D>]O84>?:P;@P6SI
M4*@D:"=96RBDW*2+,UQ&'Q$UHG>W"KDHLM-QT]TGIIOF=[!C"94SXH6H)AM\
M48R>TQ%.3$@%L6<E<YMPN4K(U:]!+:[( 4BL?F.\M)HH.T?56@PV-2A@]. $
M%VN_F0R+02J.J$I">7:M?6U5E+OSKWXF)]]9A8%O"LQ@B 7^;)9\@;V)+(YS
M:_V$+QM/XQ4A@MDN"R4E(.8:_4D_%<E Z!?&[*G!&0C-HBR6+%BXC?&_+A21
M8,BM/DI"0JYEUM"1ZQ/XW&(Y5T3,G@-:@CJP(;&.YPR[NM-L,)$-9@]>25^^
M[YX]/QZ9X79\4JD ]I#.*<-L+W#-?M7I2)RR0U$471FT%*I-9C]*V8ZE+/@-
MV?[Q'Z\&0@+ [LZ_FFP=/#T.@]/CTQ=C/\C#I!,>1--#TT]'-3QI]5C6ZLJ_
M)TS.'2_,X6TQ"!4GI+OL.XVZ:T>Z:V#PTM;Y2#5CB1BM\ T&%"O'=QL/O'T(
MS8@4?02N^[A==K1=?B^&9 U&")- -%Q1KO$,3W08V@Z"P09:1#?2/,AQVQ,T
MT<!/D<"V4<7J-FU'/SQDP.1OXP[]!G8H)FT&LT/!0_OA)Z>&MYTWZO(CNZDG
MML.)G65%-?1YLW3AA>;ZR[C$<E_J<5W?%L&'H\LC*_F*H2VTWS&):AOHE5NH
MBSP[6**K^#1)!WB''5$Q,#'OW$19PA%"W^6CHSHZJ@]V5+7\BY]J.&ZTV)Z<
MT$8[/@ZBH^61Z19K=Y)E7Y=Z-9@=8["0_ETD,>%%6H(L;[F=@G1)E+$$+9<A
M<CR<MX&+41SFPJ^R9J\ %X[$XVJ<47) XT7[M4N;@4"3;MDD]5UM^Q(3_K36
M9/A8O8@?JGEMU0CJ$Y-E2WCA:Z58V=I"$&JT'A7CJ!@?K!B-^/62=Y L)BG3
MHK6YUH8YM<.@WQANFS4U/WM./Y,TI94-+F9@NZ% GR56-_-_DK((+9'5T>,Y
M)G+G]#WI[E53(GBPTD\8.<CVX4(-)C"H(AVFE(G=(CMR3$<^4A>6B:!,+400
MM<!)HK(R)@$&IOED9Q:<P2).AJ(,%_V%!%IB[BP>&'?IE]^E[Y)5%HFO/I1,
M]0&'\D>Z^F]L_UB.VQ"VCHE'"#GTDZPHB&V01DL^)9U;D=2UPWE&91;GOUT$
MDPX=3V2JW]%WAGFH%E%<8[9 7%AO?3SYTB;,XE8[8MW%NZ2I$:Y4\>QA(1,]
MW6($(&>WE'8]ACBN*IHR3H15B)0#_L2BDP/=(;# >8* 1&(!WL0FT $-CN6/
MN]A!UVDY%_K7M]&Z& [LH%MQU!FKXJUZ2QS82?>"48+V($'8S_&JC)8')4DR
MYCLE2ETX2M8N) N</(07!6>$O1V.0'UWLD5'\6^OQOI%[UR,-=;?["8N4.&>
M<VN9BT\@U4TY'!-=U:A9H,9.,4"3-QA;LJI/0BN(I5XI#/ZP,/]GNEC E :H
M8@&RE-7#P$#O_YTW$-:]QPBWW(-$=R5@D$)M15LWB[>YT @ZB6?W1;4 ^FX^
MBN(>1=%2)0/BM7 KJOK5G9L9 #%N\10S9=1__^>S[W\ZM_NKC)*V TE;KX:D
MX+KX#TXF$>NUHN.BJM4.,*3L0/-&^?GZ\O/A?!#M1(U"^I"GA'8^U_%-^">V
MKJ@(V,4M8 06?5E+ZPH<S?\KRH\CW&>$^SP8[H/-M"1-)<2)IN&0^UU>Y$^Z
M5Q,4D9IE,E5AQ?!%"RF7,OCM'%M)PD<@VJUVB??9 %'P-]R^FJ<R",H*$!3$
MNS7"87?W.TP]Y"54L)(TS@IUP3>2IZDH,8,05OBTT[#*"%IX#X%4PCB>H3N0
MW7\'K],\RDE(WDA?O4&1T:+6>?GNW2N0:ABU]%>;*+80RGHJJ!GVK-+,)V_?
MG07OFBR9%<5'NCY"U@X?D\B4*J6:[,K.)\(>PK_^#4^;P_5ORP;E*"77Z$I!
MAC5?W50%^5?,QFHU<'WS^NV[#]BX^X7:.*_/SX)?P._X,B,SRW=>Y$C;9[/H
M,26+M- ",Q8G$+:Y=&5.S7JS(Y3F-XD"5*?ELF(":?6K2'7<,N$BWXV*LG.?
M<2?O9">_2RBJ[TCF<#8RRJ[J*G0!/GC$?;--6V!"%<0V, $S^9%Z$T6S5RK>
M?28>4$S1I7EY,6+Z=-LHC3N01E929,H-(FR$TC;L&3NZ/!K"1.%FM<\97D*K
M%=BX?7:Q?<HD7<Z:$L/HP\E4'S!Z\Q31F_%TDHX SF]@[X#U )XK9EBCZGH(
M.\<DT<0XF4N,PZE##6W'@=K#8$<703\:KLS!;[83W&Q[KDO  W_8LP0JZ71R
M-81.TAZ&S,;>13'L(II0W$[!A:[IU[$@2H,@I(U(V(U_R+6R+OWK=R?'AB$S
M"$:-N!/3<HOB],'H28[Y.(1S*#NKNO,%XL\YQD%NY$*QM*K7>Y//04[*-0FO
M<09_HR;F%1+9%O !JU[\J8HX@]5;Q!^#BT_Q=91?)2I,_CJ94^@;'.VDO#'N
MK/Z9T! 4JX1CIC,UUED24[66[(HU7AD%&>RZ#-G.4OS(Q*X6\IP,>P3)6[7,
M<;[0OL 3-G<H=D?;8T<[32O#@>TH,RXN?$Q1C*[ DO_'"9PJF4)R M4/0?N
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M<"DG;Z:@2^SX3CNX(S\D=+B.Q^*AQY5I" &C>)2/;M@Y\(5>Y@T_T820'_I
MFU1_X?=U[M)W</B"*.,\M"'A$=+KQF4B?B]^/>:J=:[ZI'<NQESUEYOF=\E-
MD9%A^CJ*&?AO(XZ&K?*D.?PDW;-W5"*4$N>0:D%AVCBVGFRA("A2E9.*="RB
M0S"(NLLPN9A.3J?[/KGU*=2N,-:'4ENO9T4E,1<"^-[IBV'+-SM(H]4X0B,D
M<FA!Z^.F@IV/N1PQS"Z;_.>HG%NFF'P1<VT6/4!3TFJAX,BJ C_=D>30+R_C
M44P6OO$8NJ;636U:)(NH^8Y'PSDM#]6#D,(IZ]S.!$;-/J"FN5-3:9WDA^<J
M>';&RS&\=4\MLAZ %@DY)3+O)%_OE%\J=<" >]BUAS_MVAY>?Q5SF.(!?9IP
MRT3.UB;TNL^$?H-/Q!!YE!%1RT$;,H_0DCE,A0U:Z)<AV#+#U]O/<,KV2=^S
M%XNO7^N,)N#GFH"]<_NX;$)0,:_VNFV&FOGH5\9[-@D/1!D/(0A\?\.Y7Z-^
MFY9T_WQ\8=.:WNN?Z1;76^=.)CA/BPF$CUQ)3\\98$:UE](?%O&C:9*;ZJV&
ML3[:GE>L!1-U00?UQ;U)_- B RJ:=CA9]:!L?G(A>).E<!8[F$BYNFH%JTC0
MG1=&$%%<,UNY?D*WG:,7@87H<P&GP8]4DR!]._/FW8*?C4O$LVLS5-&L,@2A
M7<M@E2$:@+#=+GE3\8/WQSVB:3!-N(3O#+W-6^GA+K.VTI@O=>V_FAPK^E_!
MK$]-CMF:#0\)3I>N[J ,A'W7: 23M%9>(&GJ&KE):#>C^,X90>?KK6K1#2AH
M^"RJ/B:UZ ;E5*J&##V2$+7DP)*!T,/=,$^61%Z)^W;,G^G\V>F8/]O!-+<K
M*UJZFK8!#/QZ$PAL6]T>2$^M9LEZ7?<JMR[!1J]8AZ1LC^E1@%J:GW-3I$R8
M@JJ\:' [">+;X0IA!@1AO5MH&+O]JD0CH%GPI'2$Z<N42^V<IQA8L@XBY#^E
M[B7( 8Y:A*RW1;#(&CP!V:=3O2%U>8IP.U@%*G-FAFG_S*E%N7CYYOVKLRF!
MN/$X4PPQ/@-C>TA>V#=?V,-/58(97@C#>]?WZG0[YT7@%9"Q=],9[ 6T;Y8A
M,#Q6VH12K#HR"[*4T<<$^68O-$GM 1R>"C2T;P\1@;)]5I#8N_>*85LAV#L
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M4NILBD>EFH977T?]7P3S.'<-@[)._V&+4T+SE=BCHXH:5=0C4E$HEG_11PB
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MGTJ<]'W7QS2'*#MD/E,C2!>?1])_\L/QD%9FF"3]=/*L=>D>5T0I*Z"S)(S
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M"J?'HI<N>OTX%KV^PC)S.C02:D;\MQ)]L4,R!*TUW;6AY&?'F)2EB#^)-9T
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M=.K==9'S2F'D(*,^8!?14.@-LF"D.@GD<>IRBB8@$$KLDXYGEZ-(H<S-30-
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M7DDLP,3;K@0Z7A%-/W<CMP% F@XC&K"V!?!'SQMALJ3;]L+TAS/2%KG HRW
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M,):&R[F,<G/D,X+K(1E1#%/)2S0ER)*Q:FZ,K3$/#K=@NCCW%L.4@W7>],K
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M>MPK+0KLN#  NMA9=*:P;R3R;$A&[7 ILLS3B"LJMG-2R>+IB.\BTVDE<K:
MBC_>PI,?6S]Y#U.6\>J*!YGAS:DF8#IH*35H7LQ,.N(R 7(6VG4"OV,@ /2
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M]S1WJ1A2E.SY(74S<6S$+4:[OZE[W30W]H^YR7IJM0Y[DM$9&0]?M6GQN1V
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MS8284&P A2@L Q24!@KF]LFULD9#.Z&#B1JL+.*><+Y=&$9_-NN^(U?A><$
M<O!"3EZ=)OJ>X?<\'(GJ>V#./,V+NPAK@BP^'0S]/M9'R,O8QX[L.1F/D:PM
M7OT6>&J@VV-+<T+GW;E ^F+6%6M3?11H:[#X$WS=X\FO]BF;?GIU%P_!!U$.
MK-IVA'_(\/FA@YZP[[H/S<JD*=GE/F"FO?1KJ.!G4148W:K$FN>I=U2(PU7
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MR94F@':E*Q& 'Z000QH&FZ+0Z7C-XZ)VT2,550.1#]#]8#)U6:IYUM55423
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M7-#M(^\)5A7)+-:  ZX=92J,C$X?K >%0^I/W!IUVQ)Y-9S=@4[7E88X1E8
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M"JKS.P[FY=_^-T("#0BS,TH1>*[9_4* 2++*W8KKL&W_\UYM?U$.?H%>]+E
MCK#^B*TN"$37D$/C@X)O('@%IO3#=ISV&8J]'-(X'N\ X0O]SX#+R/=L:V_*
M92E1JZZS-;I4Q0IKXC<%D#MFT$9%V"#^;_FZ3F9XUX0V,B>D"P1M.JJ+@I>
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M0,VS!J L%EY!.--2ZI^OD2N)52+&P"8!Z"TDJ^++T*/NV.0]G]Q^3, =FF.
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MBIF_G 6@ST+#H>3 28GWEW-)K_8E$<!.G=89-\B;)0D@0HO,8MT%*L7UVTC
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MX,D]5@:5 87*:3,. %Y;8KX^<IC33!^T7Y5]NID8&1FI#2;X[1+T?GCSXZ7
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MX*W("9*5_\RPXO?_< ?1\BU(P,)_JPE.NR[$9.E+E+6=(EI@PQ7Y8<)0K;8
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M&YQ!*?3L+XM1=FO9137<<T1E2YGL0"3<:P+(Y9,U2\NJECIJ#C !T"&KV]N
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M0-Q_3BE(8Y32-/[TN][PE"Z#T=EWAB7/D<?[#_?!+0=B+:7#L99>G;QZCHG
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MF"]WD==VVVL^Y/I1><&,_?%W7ITP3GRG.[,8*GYEQP5KAT/F>'K^-//X**Q
MOGP<YKX\>'*@-G)6G(<C#<U?6?C0,@I<@76[\=,AQ5('2$33-LP\^^A *6F>
M2"FLL3I&)I[37UMOPDJ'M.>'5S7>VO)I;I.[L.&C15I'POCPLX)B/BUS6I<Z
MG<HGP6^>T\)!P::<WG!=K=0(^4$^4].U!NG3WZQ+0UNF*9[<G(L,_V0.;NE
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MK:FE#0HP;KM6"W M+$".!)KT[>V[0SJ@PR;/T>"T9>'"4L?)/$_K93=YTC+
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MSNTNKQ;Z3^N6>)/P2YQ] AW"^9T]/A+3J:T<-8J*W\PYYQINT&;O?.WHB[Q
MY]MY1]#I,SIB$VBRR>T?X<I=8U#$ 8$+)P:X_>C^R+=/?8]3?]NA$$(LI<X
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M"UDRTB^T'4<9$2+ @ULJSG"H$R1$F,J]JT3O=D2U*%3+\^\&U;)C;0H%#Z>
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M?HY!A)$T>WB%6:>FR*V;A!4R8@!D4E@^^>,L7MZ5*>M5VD_':0D$+ N6GLK
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M5W-0/$Y<\:5!S^]? UW+>2Q/GSV-)H\?/WD*X[3_?7&_Z_+#B:N.T%C>;E+
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M%A;+!YRO7IH;B/$ZT2A*E[9K/5OSA<>ZO$VWCK"3!M39EQ7!KU(440#42D@
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M3E_LD:$^6Z_AF!7'XB7)*APM]8-::L7@YLT,M_[3_)>2PT51"PA5YTA:#4F
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M0U8-[PX_? 4_4>'R36HR5Y<QC0@"-S?NV3DV@$I[Q-K,Z;9J5 0I+WU/;"?
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M3FFKTXK-6"BY&&RXAO/[T/O.E-U.%KM.1+X'-A*\1,]D'^GQYHKH2/E*#^8
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M$']Y0"P[R.V#!!S=Q$G(\)ZBWW2A)WB[I'(6Y9Q^9'0MX*2Y7<%NRW0^2$B
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MZT;0MB0+'0?.(O3D=^-)EB8)-(BGSK/ 3%D?J'-\&<T(P0DRS0R;8_Y4_L'
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M'DD7?6*)^56S-_CJM7N]UA_=L^;I)4OI=0>D\+R-;P!B^I7W$^R23\V!UQZ
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M\6\0H[RT>8DTM3[5%L0C>)%$EB!,5<L8^M5"=8U5\X 08"F85YV? T,^DH7
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MJ!/9S0BJE[?B6OR=FG<AH_;N< &UITQAW>$^(S0X 4#HC%5ZS2MX3*/<3S5
MD22>S1>4]T.J]L  3_+FKV4\JG-H"]/[G1<](?1$)@J-,67P((*6*50:22 2
M)3P=@1GIAX* Y(XL9%+2P;F<@ R$&,<T1V8C<UXVLBSZB0>#7L*(;"2E&Y9Q
M\C&^">.@0Y[H2Y2)805I&QIH5&3X%T16R^94&3Q%<ZN-H9(IUM_#5@UY"%&Y
M8(L=KH+A"S3OR;8)9GZ(>QZ-?W=&+*=A%L"OL9!I\$0U]XAP%&@<VW:""5\B
MYMW";RY5NY\PTF%PE8TW> GG/=Q%Q^0HY_]0C30*_ 5ITZZ2C:I+NS?Q_^++
MG8D!;_0&5##!WZ)@P4/#V8:_WP?#- 1/!8Q"!=CG(8UQ^L+A4J%^Q;OBN%R)
MZ:0S 6#^+?@UB1.9NY[",8HZ*4[4ZLYOE0L[!/D(M%$DT439'#S9_'0<ATR>
M[J5$'BRNTHBL^#U5AQ GE$S-1*V0S!FF). >>2J *?S8.HLG!GFF$RONJ&&@
MSEK$OR8JUH6"MX4*]8EQ5#?EA!8&Y6.2FR5K)2QUB#A D.!3<"$I)2/YIA+7
M B[/>!9/VRY^"NLN&7LY=J?^Z$^\"WLGV@LR/GC^]ED(N[J_.=1UJDVR:SHR
M6A!Q5O/7"S@9=66: <'35=)>*0V:<JZ.T6 >78IBW[A0H\+-ENRH%L;+7=>Q
M^*&9'F9D2X+2I;AX@7C NBXE;>K?P744)TXY(_B JC@E7Z?DF E40LB*MF3B
M,.HT+'JA;00FVAM-M;E( O0A \5'+]TP-.8GTTA'\KBWPLP-3LD<_1+&\(R4
MAR[1/+995(.=C*RO2/7 I4F\O+G-':SJH"087H#G':;(DU#RKO#+<<S"R[K3
M9\2+D5>=DL#S6+<(V:'D[(<M2LY>]YO>57/0:W<'7A/.PTX,IV=034^[7$1^
MPBS2NQW.(E5*5=L-$4(J(OVW!1FS]\X>*&2.:'*1*]A &.4TB*Q"EW\/+8!P
MD0;3"4.@P%+-1R1H$+J$%ZX))](?:3T,*NMAI^UDQN25(RFK$/8&Z/-X[78;
MK[A:#@^\RP/OZ/#=JS=OO3TQQLG[G?KW7G>TB(?P[..W#>_X\/!H?]_;JSS:
MV'K=:B0G0I(T&U$1#S'@T. 0TX- O"@)%$8<CN8C&V44=PU+1^!6SZNLA_T3
M2>:Q)$48]">;8#Q.)!"1N8=G"@%R3R; @8\!J&RWVQ4(,Q<=C^XAC_\A]^02
MH(&U>N+RYS>$Z]!(U\%&-FS&S9Y5F&Y5\8(3IFNH@@>3H!6_66P;GB+&@6:F
M;-43[#F40:6F=RCY4[/YE,.0G'&,*.#K %,E\6'Z'LI.Q/H0[R%>)MYHF8+>
MY0@-B)_8A(OPU0Q<<@0BTBWPOLERJN&%A%/G$E>W792M.]3TGU*!&]5F=.\C
M6)C;< [ND+K'[IA^QX=;9/J=Q;"/N+W);R WO%S]X(XZ95VJ&%8U5?;S1>8D
M*S$;1.3M^?LVUL3^T_82C3[#$@7*K^"B_5LO6BJ+9@*/I@D3.]Z4!W8KP<%*
MB6A+HE*=S>*Q3HIR0L$IX5)8\J*"<Q-?GBT72W^JZEG!I8?C:X3Z56A$Y)\-
M?:[D7E# \H4CIF<O_#_AW=/R.Y@4U*KY42.V5:5[R]F.B-CPB2)&LR9+)O,V
MU>&^,$F"NWA$#?&X,DA7^]!ENC((C5@X4W3A# :!L+LGH9C2F#\<Q:^0/@++
M65:ME3[I^535>/BB"@Y5A9TECU#4-ORV79OA1L)>19)=9%!;A1OAPHH!8ZU
M9(NK"M=(TV]&<L(8%L54$2;-@!?DYZ-<4JW%4QG)>1),X+'1B%EMQD3!PZ$W
M?Q;SB'=%P$>E MYFARJ;^J9*?RU%/.T8X=2]W&V^@*(*!I6>ME;$ZM4I(3PD
M$1@O*0".J ^61:>ZQ/[].B!:REI1YH(6G^Y![ >-XMT!KV5:TY>\#Z5$97"-
M[+!V1$#&I0(R*#D!]"0:-B<Z$%-3U;@-C7%_E#5:0KMM0<^)XDJW?,Y,.4F=
M59E=@#</M8*G.\E6ELHD+'T-3*[*3]. M'-BE5_)EC7Y>/9@DF?EG$9A F<
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M?":7)1*AD&+I[QQ0_]9I54PW59E.1$]RS!9AR957 )I:JP+S)XG:CXQ*0.I
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M-!MZLIY?I$C*Z5CD,B1J^RMQ0:'VFKR@4$.?H2?KN:$ZABPMIFI><(O,656
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M1(*PB'.Y1GN=8(K5?S/&K.T2"[76^,MO_%](.E'X$@J(<Y%2(\JZ<-/K[0@
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MIK /024.F/9$48U]4E2DITJL3UU]YI/Z**KQ%$T^*>T)OJ83!H4]!IMPK*.
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M6,-QIQEF=1G-Z2,IN4=VUY; H5T+!_](Z<X$@KI(]\1\+@6WJVA=IGM8!\8
MX$J[@3DD.=Y@8LJV<YW66S@Z2NM('<KG0]V>VC8(:@\-E:6-N)QMHJG5'YU1
M]A>-H"-VLQ6E^T;PML\X^ ;FO.%W9?.6+-J&8C?$QJU=[$TPG+IS\DI3O"ZK
MXP=RA_'J)]+1N=@U_?R99!8SYI:N/'W6AIG7HA=ZU4Y/P"O8A2$WP-L3HZ7\
MC)IS]V =&#5666S9!:QH< >8[[(4;G](RZW5"UJ8^!(BH<]M4@%_P$N#W<2L
MPL*7JB,?@?N.>E?SM"%_"UW-+(V=(EGB?!V+<.S0V@L"%7*?L:/;2#5S%J-
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M/N:%[?LV7I>Q&I[]PG_^9>%M)T(E!E"3GNB\M6TS:8[V$&R+Z[;;]>_)\(7
M%/B<*J<E&O1<NTCZ ?Y:1[48CM( 5M*.%(I-PBX:-V]"G1$[Z@$),9$Y=36]
MD+TU'A+Z<G@M 9A1IP:;XMU,W>5,KML5;$W.#-(GT9PM3D2V9==4<2^9PG[U
M/*ONIYID8I3A-#]1L/!-J@0$/^%K3,>,*=E:]\9]2>YZ"']X_AG!.74)#G:H
M<],(:1FJ0\:B]Z)26,&BCUK3)0\*8@R.+[754=UI0C@PV':B_ZI!K)R@PX)
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MB05ZWHD"7YXW:2323WDU+\<+/ ' OWV0*?Y[DHL*NWSXI1_D A\T &YL''G
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MR-BIR:NBY".I;@&I'1A'EOEC\N <>#H0E4\*$6>=L@%'B"<R)M>* )T('K0
M@PM$"<]!<-$:#]#Q%KLZ#A" 5>-4=,=+(5FR@?0AIHL:>-UVV0,\6,=3#"_J
MX]Y(L3E661O,8&FLU4IG.'+#\B,'?DQ-5$8)N?H'=1;\:\"&W(1/O3IW$JN"
M!I;IC7/(2'EO02/,L%84UT#O< T\KNT([;!VU2_5.X9LTHY!]$<_;5-]W_L\
M^P2L?R]#=<!*DK[N3W7 QH^3;8T/;+:1^(GX +HT= ;!\2K4K*"2H9&1;#XR
MBH+/V FR51U?G$CV]$P\TA;/D5F,Q71IJG>A!HU\ 0S 2!2,(T5U4GC.W4MC
MDM>18VKU&['=FH(],17)I.UU:K-=.WS#"9K)V,'<GW/C=(O.C4M0ZO=;G;2_
M<^5F1^U&657:'+?Q'!% 52AP9&V6 2=Q14/-_" JG)7 G <;.9_2[#&1\3V9
M3^8BK'$%7B7DI];]T%>D4:0J!9NJM,E]BJ*M=/!L*_-7> ,=C,.\]D!'5KC_
M7G"O?6*R"TO9,2<RV%D,K\LDOR0A^*52[47YFS\.:A_*WZ*;\Y^'-Q\NKGZ.
M[GXYC\X^_GH]O/IG3_)3+N;C9NO@>K*A6U8(][%=(75FRK,BJI';XM/5;7<2
M-J<.1IO.2X_UU^UBM9=6H25.%1H\<I:ECU(D):$9_2H*.&6F%3@;5.?5:@);
M+M9;_9I=97R-LI#L4=>XS3DFCV9JG4[9;V^)GN"N6\ R6_1&A6:4X6N,F7&*
MY#A^0E%%7*-^QL(Y;JF?#+ZR]Q08@'HT7TD;%BJPY@Z>SR^S:"'Z$"9!W14S
MHFZ(^KV?B]+38@?<]"ZLQ1H$B$>$P#_F2KJD;0SAT9VY]/V2%'TD&C1JNP:Z
M!*59ZB>*3@Q.1ZGVJ11BFZKZ;JM1H6(E<N"!/FA!JFQ%84$] :)*77#4H4/!
M7HP)C^OTY#F7]=0A4VVEN_'6/G'F-A7I?+UZ4_[!4M'/1KBU'VTE'B(K?O/B
MW%9KN2W.;;<H;K(X=[5=U5VVZ[S[^K+=+M/@FY7MZACD4V6LS;W_XNK>3KH^
MM[JW3?RGBGO%D\6V7[&V]^F'->CO7V7OH%7:FW24]EYZ6MK;$T7O(=3E5B:W
M3L#XVNAF;KK^M6R'*C9<_XK)B%  ZUL!K,LE?TD![ JV= M@NVR?%96PF&%Z
M!CN%*I"52NI-J +Y.MI^*U76%Y5;=\GG$^76JBFHH>"ZJ^"ZL:^FX%H]M"JN
MFQY0J+C^#ZFX/A-S1%B+;LML_&E; \?;ZDELD%&>X48LA>(Y;V7#ZNV@^X C
M & -HN)Q2L*MM#N?H=(6*N6$Y<(X[Q,P-RO,L]7!L0&8<T7%<!Q.S=&@]AI,
M55)=Z]Y1)%^_A XDH+:J"^R*.G_:?(ZV'0V6WT1G#0N1D,+'=S.^CF,6P\_D
M?48(8\O!+;>TVQ8Q@%TMHRFP"0:DP.Q%:R[:04KMFIOJ?:!HA?."2[F/YE%:
MBX=Y=X=@C?US;VJ["F=R-M+)4U4_(5_! G0 <P^"2_]6@ K\9[YYDQ\LZ\!-
MY.?Q%&FC@UAPBG4MT]GQ^N9C??.N/HE&QT Q(-3W<:[HE_;#.;+1O&2/BC_B
MMRO<7YDWK'\#SC,] _\P3#:!TS(O<+[HI"KP7&PW*>@Y&^8H=N4.%DTD'U#[
M0;/I8"RJ0F>9QQG:'@[M- XDI\?0=['+)IL(49&?N9NZ-8OWT\37X(B78V4<
M--@#.!*T_%(GRD25C(\]5G-K,Y@HWYI^AU4B@MS)P?,Z8.[&T5DL^I3=VZ:.
MB)]4"OI/D04!9C?ITBTU(WH2Z?4MI?=,6^C51E]\K3F$Z+?@'B+*2GOT5EUT
M@S71>'V5BBKFK(E(R#0HIE*VLW2Z>.:#'-/Y&AT?#J*C@Z,C&@'*^M:#.:"7
MV#%0VG=^KQ=TBPOR822HC3KS>#;=C6C0=1"\;5:;;' ^RS2&,VB!/94E#EV@
MPB;VB6G>"T83:OK!U2.5M@FY%-[LIN2A+FUH?GH AA4<Y=2H,;&:T[ZUGB:N
M"[VPGR3!<[[0S)5GU?V4WI(-= \X9)WZWR1G[+,,;:UGZ+$V9-[K(GQD?)F)
M4'FR&*P<6<>WJ 7 #C[IEBU*(M'J4*:,/(.3I+*X*3+DSZA4VY"=[_B('L\<
MY\GGZX;J=23.?QX.KP<&9;*LL;$Q_@6^(_[3^5U5Z#&M^KM$A^70>H4;5REY
M23,)-FU,F(I%-3,>RUS/0A\X*6[\-R;1QE)7YE)E1XS>\H"?Z[P'Z(VBX.9J
M,M-M@PY?BITSNJB%7P"XZKXN9S7)'U'8'-X+E=5 AV99JS[ /T;9@QQ8VHE1
M(;77/,FR,LU*ZJ/6K%:8&N8_^19&J2O[_!13DTAEQ*PD^I /5^A0,7Y"P5 \
M(O8D)D1C-._H05_7PPBU $LSYE?'FTP9E DF-8<P4[2:XD9UU!Z[NLCQK%+^
M)R6434A?9]4HM0H674P./E+?!..-G[W+E@55D[#,<[FZ Y-JB\:7YV5RS@;5
M@:X'UX\SA5@3H0-'30O#RN&$ O6[!F"UL0V@%JI<:S!ZKQQV%4NW,#? $F/>
M;+"DH>8X2<*HDP$XY_CL;EO4!R.C87=2"XX/)D9-<*Y1 '6@8IX&QA"[I.CN
M[W-YC_DH<\3HGDC=INL66YQ_QE[B%FW_9$>Q4<2NR(A<T=FT@G.8:W>&NW6#
MPID-5I%&?;^K@U@.NDAC,U9<2$<O9:EI;2@3S<J[+^%EZAMQ^9D&,EOLX4'K
ML";D$9/ZPUVX@.6.8.^X\0,/Q\_CI(I-8-J5N=8A@5^;Q*%NOJZC>DWL%9N,
M;%S<P&"^%(]T;,)AZ3ZS-ENUTECGD_'IOO. O(F0)-TWV@[[U]L:J_[8 ?X-
M-6XU?;%BY6)38.ZIX(^PZ(CRX8+*HD&<E*X-<A 3T!H$R;-UI*9J%/T2<Z.I
MX '8<UFR^T'#8] \E#K73UEY$)BZ_!73WTY;N'+>BV?01P]@7*0EZB\TPN]3
MKAE.&R6TYI)2?)*IJ130A=I+T?$URWSB3F;T(>R$3"8ZD4\1#7X5O-LCUCWM
M5?/VK4)QTTK)>1N*F[Z."EK!KD8$>2Y5AHG'V," F9:'&L>23[VV3..ICMXF
M\#+XT_##PBW#T3<PS:!]RAYM$R[*L(X#G $=0*6"&_(@DVR^S8FDZ)8<*K0?
MEET7DW0W_)J-M;&/;+FZ)7A; YD;Y,8G<CILZIO^E\\8NRQXDO-:?ZIXBK:-
MSNVZA;P1*^AV=)YTU+L:\H&'OCH@14A?ND;I#(3M'@[S>!#-"2F(:I&*:O2'
M'#L'$U7'.V>+C2F;4TISVS75M..%!.A)Z:>>T,[#P"*8F#2Y"0UQ)IQ!\30Z
MU])I#G1V GLEV-A4CM2BW]-!BO5BW">"^^=!<C70(&*Z<[53-]TUF9>K&%=4
MI5' JNN*NJA+ET@U2Q_K\C-=D;94BNB &;SP_K9:? 3G3,'UZZ/2^4&?F"WV
MB=E8NQAL%(HTU'C&G-?*9[;\+;, *\+MCM91U+I:?VV[0T_(*'TB(U-QK!,V
M8.[-9'Y/XY%8U-S22=3J6:)B8:/Q ]U?5O\*DSE85 J'1]DZ4R@=H!OD,$B0
MC3^9?@^-7LCL $M,3?N(/5&TF&..@=S8DM%V^L07$W_XXM7^ 6T$!_0:'8NZ
M78+A)W5DSVIA^[,D0Y1QW>[H@M#TB6#W_A#,Z./5!).?"?N3NPL:P/ %"],$
M,4&_DHE'T!AUURL=#[:_H..-X+;@5I1]8HZI?\P12VO]=;)%L/ [Z*C\H>.K
M_=/CAI";XAT$^P/_'$UWD8C<:2]LX'.WTRH$#3@!BPTT\P".5BSHQ401MI_,
MYDFVD'C+QB!;9X:$>3B]S==6&#688R.'W&A82O!N5$OB>Q#P\,#3(&"?!/4/
M_P1U+A3XX&@+L0<NX@<,F,;13F,6"\)8+4S1MI;@>E".J1;5OQF8NQ@?*I=J
M-D)I,W>0=1G-GQ/*74:OFF&M9D'6'-KM%%=P8PGP82()MW]YPIJ^J%'S4IN$
MC3H>]B<Z,?M=M1/.IIKE/_G#\L;&0+-2$H\CK\BR3#1?)'8" /H.6?+ !4::
MO>B4^3PF3V\2_<_7KP;P[ER-@ R1<ADL=RKTA'B)/\0S^DK#XS#Q'H5ZT+33
M8T)(F 2X]"A:Z%L\B*22G:0;O$QD^R24,W_H>K!_2'0U,$?2R00,#*ZQ045:
MHGK=$X#WUV61C22MJ6Y\(;7_C((.M3>U,=F;XAMO9#?U1W;M@4IN%D?8E_MF
MR&^J42 ID%-FB+X 9F(V)XFOD_RV,'^TX*I\M#)S.4DXCZLEMZMKJ%<G;^8?
ME=%FSQ4;3A3G%C,08$0>*LJ\&ILT"AA!E4A*L*8R4*--+P+KG<>9!715*7AZ
MJ-AWE\LI:YR#.A[O MDU>]"PLGWP='W_&D@#YD$)[*K-@SZ=]W/_N*DC"LQ0
M'3KH\YX=R^@Z$9R-15H9;Q,=34;.0F5"IWZOI/]?_M&K+?V)&"&D)7Q$GGYS
MXIX>V8=%V'T2H]P?LICL5XW@9\#0DT3']$!%8JV!*NA UF33QW.ABW=1B!CX
M>94X:AU*8-0TFD6'@5!]DR"".J;#]^0UO.("8[/&)89U/F K+ YDT9"S/&U9
MSR:!N^GY+U1>(5,&$B+-K&N+ZZA33N.9[W&@#OSK0:851X_P)1J( K;YKWX1
M[D*.S%PY.J9&DBR0LC4WBM]H 'Z P6+"L<.T%0-\M7I 3%&_9./E](V%>>I(
M H<SAI9%*6Q-JNJ-@!3^",C)_DG3K6R8(A,R5"IL'B6&I%2"X2"V/2CG,# X
MS0\L)B;GT+8_..R0IA4URC?GC3J!AT,;>7!QHA0.!\*':QD%ZZC2 4=%K\HP
ME@MX)\Q_B3S!WY0J9YX'J^@^%[.BOJO3W4)64/VGLU 75]C<HK%'M355+]NY
MZ"O$;OO$^J4_K&]"9;$$IM'G@A.]?T+;<\N%1C%8MICAK9.%>SM[HAB;S'*A
MV\]J#;8L MT=9SD!NQ'60NX4S]50HSVKBZO\88^&!8YZ4'OO#7ZX$Y\CJ2V)
M@?,3H^0<-Y_/N8%QYMNW7 H(#$QW'B5NN#8/'W<CRRI/!\N)F+$^+1W\<3=J
MC]>2Q6G0S8M"_XA:\F-IBDGM5"K^M2# /P1JG. ]I.Y;EFXC$S4D%]JSI;AC
M;E0_S=W0ZI-/^B:B[]I7TTU/[@ L8SSK1O,VIH$&]-7'4[U?QC5R)1(=8O'9
MX CW1((>_),@KD\J[;S#+G#1_B FO_9E_Y_1LW:G2I;":QLRVM8^-=\+1S;)
M%^N[QRALR%UX@E !!Q82L#&4,S&@PA/"F;(])7.J!J491F8<Z6/:,8K*1B.7
MF\U,/C*6&I 5+\^R3YUIR<,#= ZVN(_05TY8;OFCP;NE5A)T'./LRJ)1WU7/
M\W*'=5$9";8S(]KOQ("<=?))772RPZ5C6&C.A\5(MG^SRQ&5]=Q$(QOJ_ C\
M?'VGXP0,)N;U!/$4-8-32UL#P*C5[C9P&R\G]<R86!6,Z8 NWDM189XHKENW
MD" 2WT D' ;N'@GD#M]8^FT.3)MAP,Z=&&U1/.MQS12UMPT22\"!&C6+6WIU
M$Z[&T&G.*^ZB_Q9456X'_=>=>$V2J<*.+7_,\D\U_ H?J 8ALFNB(9"W*/.%
MTREME<4C*B?JF\9_L-ZAZ@\"]Y/_JFCV^"H42(LUB0H6:PKQ SM-:F$ +Q';
M$:OX)8U:+UCW3F7"8)7PP7[@IJ]C:J$]9<X:/B[ITM5,MG8\* H_UG83=A?=
M#N<^(K /14<K> B=SGQFZ:GGK1Y\"U/4,41HQ> Z)[6(MQNTTL5V^!$B%U+#
M.0)7POL5!;.CN98EYMF/1534-5/C+3"Q,4/*[)[Q$MG01 ')8@LJ2J>\CF 4
MNIJ*"]/U_%2-?%287K5!I"A^,'"&XG*PD&=TLE-%8U/W#0)V^[^A+FJU%WW8
M[[JHS08HWFQ1@.)&@LSKX,1B2T,3/0DL^@=F<D=H^>X)&4L<@3/B CCOS90W
M_@*C>X.7>\F1@4X]L(D]LXBYC:'FM8_0Y$<=UV@/SNI$B&9DYT7S#ML0V/29
MC9\RN-U UK)MK7_4I.D.S[SW03C,>Y*0>"$5QJ, =9T[H8SF#MJ]5J6>=E)L
M<>C*8_8?<+MO@TVTI]7I$':@LE&X5[A!7M/.2\*!W]MA>KJO1#;=T(&!%T.Z
M,P^T!E_S;?6<=XL_S3ZL5IV<^VV.9]=Y9#O3&S%&:FA;3*]KO%SKA&J,HDOQ
MR)Y=*YZK1VVX 7 ]<YZC("L\/,?O- #:[A9>?AL7M/6RM>MN767C0M?=/DU&
M>+Z[SI61.6^_SMD[-&*.6GIN[=UO<6#2:^GNP$]$8=-6!]4="ULNY\!T&:I7
M# :$L)UPC_'"B%%+76-MI^*25"/*^H<-AOJ:*?R _+=RI(B6=$<88SNLH"Z6
M'"$2-@W93FFTJUMTT653.TK:S.7FAD#=:40E-LV!GG.QT+^<S10A$CL5:HWJ
M3JTR1GGV29>QB7O292N&0G2]H$%&?I $BPQ:*8:O+<1X?7][^\XVELZU5W-\
M.IDD5K4MW8PJFD<T]$%1495!,]>+[U[[5W7_-QLW>NN+6#RGL$5\QMY6.)%\
M*VAY7@1T_YOL]9OG'3F;/.^VU0O8H' \!0L3\)3_FB$?U$530YT80YTL,UT/
MSA6].Z7XQ$.+""V5K.MF&6VQ6Q^&.*0ZF^=T2U1KVG>B]D[T(NH:5SVYB$83
MV?Y@KJ+A!V,&%_\WA8^F(IDL#1PWPP<0[::91J;*WRC6*;?LD0:KFR%D<$\R
M/:<TJ"QME=[N+@^.'YK\G/OR]-YKZL]69K;M/*8O&H6(/W1*DO&-T$'<7_(%
M\=>4"*>)A;A#VJ9XBD*M371)4Z</E^_>81P9 !_Z'BGYJ$N?B7MT]PDU^$K$
M@M,3'<F.0TA XQ /&+(3G7?LW>EH*]"\@&__$_6C_;YW1)\<'KQ]6Z^@:6%Q
MQ[JS)G8AJ&J%:;B&,N35.U(2O(EOZDU4*?$0<V0K8D&E;%JSF,FD9F+OBHJ[
M6'&W'Y?ED6A381(WB^L8(#8Z\@QC?NQ.<SR9^P.+;\B_E$4)PJF**4N-QCE
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MCM7907K[ 6/2UH-R6WF:0;V\2T8$66*L_L!G>M?\_&P]ZRU +J62$;XE$AT
M"@:5H:$\M1$$?)]TCD]P@6EU9,8-ZIC+ZPE\NGUL];"^5)=?-JXOIOA6SI G
M7((NL=7K_9)2W99F  M_IW7RO% QV$-IMQ&+:N=;ZZ:X91WNKOL+W%8]<7[5
M2' ^P^KQ2W9XTJ#>7=1NX+ H#+(E:N9TB5'5'">\%QJ,$GZ;RD=3Z??$RW>R
M5ET/(;%"6N1-M$C)_5NM\&'VR$53VGUZSLE,[[,-&'8;=)] ?5@8=08XP<W&
MII#S]$'EF>$HLFPR1(5R/]44'3A#CEN=C=[O_>DF]YX[([!=Q<A&J\#[%[*Q
MQKBQ;"1M[48?;1!JZ^N.D]ILJ&6#_/IRQ+*&LG "+ZC(S^PAN*4!EZWMJ-BH
MREMCK6I\KIZX,_X%LKIB+B;'UXGW]>4!EP[CX=EQ%@K&]H0)O/-IOR(76&(O
M&?@M(V:)&73W#1&_:<<SS.BE)!CE&^E@5Z_GBE#;=_@FU/;]YX#V=!4^V""!
M$\WH%.CE(,*@$<5%\95%:890Z)D4SBP*4-CU> D+W;@B E&'CBF$Q(CT6("(
MP5$WH5[?$KNZE@X0VT.V%$REZI<\FF<4XQ!)]R\FU)].0 8: V:<%>B[CA,I
MTFIN_F1TRD+:KS4D#T[Z&[O7S2G(2Y4 ?U3Y8J#Q/&#)L9@1%DPJRBKG\S&K
M\C&\!'_#,U"!]?-4+J()%DFNT)2].@P]Q( IOPVL]S.1NKNPM8V'7\ R2V?Z
M0YWM6&(2B[C:$S[Q#R&@2]UB:0A7B4UX7D["5@O^YA?Q;]!Y655$M]4(LVB@
M-(M,%S/=\YRTP@*A=&2'MD%9G9W?G%T.F\@FRPJL+^TS'G9[WDV79XQ0$I6:
MJ.G0VYHQ+IN-2=AX:I;H]%0]T/!Y&UR/]@''9@RZGO+\#6D ,0<Y=Y&+S4?P
M?%74\$K?5H@V&[Y\[8L4/2-\:;$KXNC.R2N&<.5?JQHVR#)/=X8OP6 -X VS
M\2<<%XX?S^1LQ'!=\"IPFBZ!B#W/MN2A?\!K*J[H$-?XN_QT>P4\QKR'_4S-
M$)0($WN\0>; MMS-A=H8A,,<.T_O:ULFHD;*,MWI-+5PIDH#$><"=]F<=[U*
M3@<WZZMYYN;2S&1KFE3%<\?2<K-$PY;*"';<S*%]#I4&-8UJ1*8ET#=,7N<2
MFV8:$W1DD*ZO+%T86K2-1NY6,VFY0H3 U>="U34FHN2J>E7WAVMTS/Z<HF^V
MZ!0];Q8[7HH1$.97-GRV]2CU7JK?^%O[2V5G7!FT$O5.T"<_R5%>8770ZT%T
M='!T;'N^E(&V(TQZQ $@P.T_LE%$H)^#*)'I?4FC* HSS &+8G$V)PW^:,.2
M8J0&6WT*D8 M+K$LS,U8[5(,M"CLF!Y\0XUJQ).@#884JIXJQ\  =TEBOYDI
MR24T U[$*$NKHFZ@WIFHSQKL@Y"B);6;Y MXKJ+ZTH&=&L1^-@&SMQ?A8@72
M0N R>A#[\&.0FHQ&$M7PW:0YL]SV'IGA.APNZ.H C";P@G"^8BAY.R3!W^K,
MNC5W0%M-_;EZZ[>HT<MC93-H81$;I.T',=:5]84:?^*B=Q0%#7T\(7*XDB"L
MCJ*4"LA+GH$&HTI0:V&#>NDH%%V>ZKH58N/M"'8X.HHL0J5?*@+;([&Q]OKC
M-#/=X8RUU>BA!G*2[D2"H%,"^C*N*)+3JC#^_]E[T^:VK6QM]*^@SKGW%%D%
MJRP[SO"FZE31LISH;5GVE>3.R4>0!"7$),#&(%G]Z^\:]X"!HAPE 'E8U=61
M21#8V,,:G_4LA\C+M$Q8QEAIRJ4+IJB>")6IUX#"8>UEM/E@F+-D36&$N5%:
M996G3-:,R&G643OLHP]XNX2@R\?_]9_'W[_\N85 P'%XT0;(D#M;<C8P]J7$
MTJ=@CH+#1TE,GS,:'="DI/XV8#> &<):&M'47V*ONN,&OK_CSB"23UT$5;J(
M$K0+IN2RF-H?L^/:QX"I!Z0MK;<[::V1!_W';S^23H*;N\+R6.0)(?_SA;8^
MC/)I4FI-DO\5VC85(\=KO^GN2)**M?'W/=/I5[)]>Z^4NHO8])[,*\)V4X<Z
MNAZ^L=9M1+G ;>(\ED_#Q)UCLR%YFJI4^4-A^O@?&>R,-/DW;4_<+(F$IN^R
MY9UA.K##H8>83F6/;Z(\_N9,:+/>PN#T?>21^.O/!D#SFP@67D.;6OD=3:L;
ME7=:X#!';%N!'JR_^8$<X[;+QMO7[KFE>Y@N)EN$V@K<)CF7WAD! 4)+^OW@
M'')<SZH=^I%7/]C2@P;+=]P1$#^(3PP2MA8-BEY3T22;T32+6- B8&2-,1_S
M__K/[W[XF7T,LIFNHZ]QO58DD0H]\G*L.^AU-2$N/V;X("K_]%\5/A#>P_A1
M3>ZIKIX$E@2+RB9#X_D9ERFT!)Y&'!_P9]U1J9_V#G_64WS)\^E-_RHV$0LU
M8$U@?(6;GNW*W-#)-@]/Q)S4U!%H%3T0)Z;<6KE(#&J3V3K9'_(/U(;>*#I0
MV,KE"T<2$C +/TIO(N;U]LB8I'RV?%C'3@\E+WKK5MLI0]$C[]9A2>^&,SW@
MWD;XA;^V=EEKC<M"T^^[*Y,",E^H!9$^'(2[(7PGSEOJ&VE*%-E.R:JR#2U3
M-]D:[>S<'>?GVNMV0FOQOFL<U#F]'+VGP05;B*\:I"5KU47OA<:+@C.]9D)\
MT@IQ/TW;(>I34I]9K<PEZB)^T281#8X";YND%9EV=H[&&P.PMQY'EAVX5JK[
M0UW;]K]*@2VOUU6EK\:H$TFI6:0:B]6"6#)=:/NE7>()HP+%;4MG4O=>=(.N
M[;H&PZR*4D--ZW>2?A>C'ZD[@9(<QC+&:>AJ,FPN<E@.]B=/]=,.Y:DFLQGK
MP4O"4=.IQ)4SGW_B&/FNYZQV'(<WO+*J">>I*=:G>R6W>ZC>T"D9LP..>B@6
M^#RX'%&P(#YKE\! )&&&\'EF<0<91'<T%3-(@H"9@E1X+\F%5T?1"53X? QQ
M2DP,-#XAXMO0)O+"@4:CX.=@.JFJ[)ZTD*D!( 7@O+SA==2>EQ0^$[M2J!],
MI ,N!2L YK>P!J#4"X!W1N]]DV5S8<W+[I)"B@74..:QDB+C;GU=0\KC!6%+
M).0@J&VD:P/5)%$"4.P-ZE U<EF%;!U $K".C,O,"<@A\#G1DH_2+WG%N42?
M QT?IM_.'MR6M7MRG =8((?GV1QD38Q28$+L.PSVID4S:^T>ZRP%\^*O/-M'
MP54B+1>"M]&2CN'5;0R^#CM%=4N/,3)HE-5?;8N1"(=+A "IU!B326'D M-N
M>*--Z!'.B/?'KGGU<BB;=@N[YFV>?2%*U%TU7*[=&AVW";F^& ,1"]0&X!PL
M<(?DA1C67+#@L-E[T17ND)O&-=1B-XL0Q5P\N/<T$J9@"J78[F5&V=$_2/U-
M.968@O2_C9:+)A)4277PZ-C&>?MS;(YWZ=B UC6V_ZX>G:%'N_K<$=N U/#;
M-%I)-&>9S9RH)8)/88\XV0&0/*"&A>^<NDBIIF\/ON#/C3H.Z4=YI2&$>4Q)
M 1)=T2(V_YYF7R5P4NA8'2@$#[C$5_%=DM#]1Y!6C'?67 Z_H[P5(U[@E;E,
M\=]LKL]SK-NG,"R%:#&@P@;/C-H<TU=EMD>LQJ]>[9"X^I3=<VW!1"KU=E5D
MV;C][B#@^MPI3^#9U6()+$!-U;L4JE*OSW1W$+2K=F1L\S^,?I5<D&Q*4SYJ
M'(<V&LF]$1P]4IT]67 X#'.[#<K?DX#(\.*;.YI)??5ZN+!D9CH;35IQB8^0
MH3>@48;O=",#;0T452.69 J)T=MQJ\)H8Y9I'93++'/ RG3N#!L_.F!E_MP9
M\SB0M^4@:F<<(MZ.ME-!.923<>!RQ5BV^@W02?D%>4FF,Q797":,W\HQTYU*
M<)(5AEO>>R/$^3DG?XM^9+57/N05_KJ6TSNK1P=;067TJ%\]F'*FPP%@4_ZB
M'0<*^J2@',>RA< 0D=>=2M/A+U<8L^G!W5+1V-H[A!TBES7_L#F>;W.(3=/:
M88#@Q,_88*"1&I#GG]2K+BR*BK/ CS4Z;&'=]%ZD*W,O:&I&)[0W9Z";8TX]
M,,7UF]HUR!N]4UU(J&VG]0DF99CY;(,N-N473V95:V-+@QOD\5WV)>8.\ABE
MQ&;O!3XE;'8Z\!L;<*\# Q+@Z9&7/&VQS=L:R;2OV>,-&_Z\L>*,.3"XA+M,
M"QMU.J*E3DA!GWLM3%%LR=RTW]DQ@=XWG .+U6N=A$6R9$/%RM,\QEYZA4 \
M3=]9_*?MC4@_ +DSWU80TS@(:TH8X$XHRY[8-L.C(]U=TV:P98O6M*%,$P.C
MVLN/Y$N,!+!DQ>"L%+AIPMRI'=*DCQ8XN6>2?UF,FUCM;:,24K_63A;=;4JI
MJO+Z?CG=TV \U[=)/@\^4;GFI^@!;;>1 ,C_GC7\H74-&\/RVK[UN;L$3S_N
M%(C60MHHQUNA1$@H$56%7RZ"3T'=S25A<.:XI'/N/GH!'TN%F]9MA096R&23
M<Y2X\HW79QPV%)>)B//:U?0H;VZ6=FO,]+[A5*:K;_,X64T1"<45  ;GGYL_
MJ0\1;%C8ROP*^*Y,M8&&(66O-%IE'?W'+:2VX3^E6)79#-5LLD;;DQ89)X5D
M!\,D/8.F?8X*MFSL2V&<XR:/5C0EG[#Q'\R7?J9<7$Q(AMQF\B^M86H>=U;S
M7RG=C):*U"VMR5 I'_766J?5/:NA10 QFY>81&NZTMVP[G3,9;^B-X=F2[7&
MOVC*<*MS6/81@)VQ.1]?HQP/>(.4+-,1U9?$K5KPMYRN1,OB^+W4;0T.\<W.
MT *:&R.;MX>UJ:,Y/*! *HR(? :IJW!<JUJ[Q*<?8F.-/AXN<Y!C:+<0K<X2
M3OV,<1;"=%X8?%:+CO':CS<CX\B_.\="Y]\>JZ-.XT1RK/8^Z?;T?X(+4P:[
MPK#5H3!E?COXR\0\PDVUKSC\HIK*L9&MT29S'H(%"#=RFQ9Y5*%ADHI<8*XC
M$85(ES2/%V2_V_[EBQC^@OE^3_<X84MD,BM91%88DL>J&2%SXB?QO;&R?VP9
M%OP4]!-FK"2RJ&>9LX@]1:K*Q@>!+(=-SEZ9R$53WRUSDPOSA^-:-29Y7YR2
M 9*[7[0?N([39/>#W2-N(?E6'>,WG#>2I9NR!0S^-U%"ZP 821LR+['(W'D\
MC8C!@=2N/L[4*#9KU/0X:DDQG;H;JQ#HD,.MG(W+3>WQZO?R8]:JP0E*5547
M[NF'R[][%7P^NCHZ.0HPA/+#S\'QZU<OHQ<_3$>+\=C:G&Z90S!+[A*P4,%\
M*5%%POO"8QZ(!K\HC%!1U^WX^-6/$Q7W5QEA[JZTF_ $N4EA,]&EW)]YGG"T
ME4VS._H7G<@ &1&X%'J-P8H4]BM;;_@\KJG&\@W<&PFQGT6S4F-R/G"8HKR8
ME#'GO1&QV32'CK=#?7Z5UI\LUD<WWNP6A(44R08>=WS,'!O1(P]G(09G "L;
M:(?4AM_&I\&Z@Q0#*=M%B4=F&O_[WTNQFC%]23RU6 %1P3KE#\I9GW#Q;NC
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M=PFL.KY1-4]*!PPJ1J8X?:$R9N=4QK3</-RM?(X(?3[PDR*>&*PAFLNZBGD
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M@,H!'/(-P?H?AB+3MPC6?P!)A'WYTCBK#L'YO0W.OW-HZ1TL2$'<@$()R/2
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MJ2JXF201W^<S;3)IG)!X@2M4<.?+' M@4KK>M)P2C&J=_]_M2BG1 XSUE?P
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MRIBRXS>$*3L&PSTN[Y&>8(+UMV"&A\%9.CNBV_V:P;+_EN5HV)^?GP0C?.X
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M2$J5?.BV+2>4F96B+694'FI*T$J>5[WRF:C<:&/&$F&.Q""@3"K$Q,_C L1
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MA7@-[2K63;0]T%]?2 &*[#')S;GMWN,7\=>$=Z1M$((]7TO)LM8WCN!(T6=
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M"QVSXI2W\&AP6GS/W'"0V5X!+L.*(E-&1-H#+XU=;S@?(%^-G=>*30+ 3S.
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M>--?INBB(@**4)*'"<?24U<8->A[.T30.!2PD"-.73EK"/T[I2?,#W+MV?(
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M";_-H2%N( 1#5X]6R2YC>G8AQ?P5RKB9=)B,V]:-MV0AG0]!3X"X'@)#*HH
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MNSXMD4H/BXT'K;):0-9 ,J,#0[H>E>5B%,6WHK5UY1HBYYTCG1^X&-!K451
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MFXIJ3&/"Z1?&4@,7!&00[]*BJ3*0YDCL=QSN$_D]95K<+\.LDSL*^1&Z@US
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MSXX0Z1M!9>CGD(\[8E.<*:0F$3H:3@].D5OH_/KB9@C634E1!@ VCBPT?F!
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M ZS&\"N[1LB=XHNL>HS7QR>'IZ]/GLGUF'3NC&G%EYZH8SC/7K\RW^:O^PO
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MTV+_;C^@_O9X$"0-!7>D -GJ!K:/,VYP,<@N %?]/IHCSCO3BP+^@3]*&=9
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M/'OV8A \>_/F\/35FY=;^$##NL[Q45;Q<EQ%31:\/0I^;2I]"^T#[3% JS%
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M^<)4:0<<8 ^ 35"DD<3[*]>#@OWUIGM_S?4636=$H,M7L00Q<HNB/ !V,&0
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MNV(V.[LSJRGJUFUCL^T?<D93T7_B$TQ/)MH4^-^^.*K.@^+#]<%K!;H++/V
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MC.LK+HB1$39Y/M-3*$>[U]"S7>#\S2)]G9H]A?76H!X(2HZZR.< OQR3]+@
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M5"0+_3_3>I;]]/\!4$L! A0#%     @ T$"D5KLZ[8RO[ $ Z[P4 !$
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M &%M960M,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( -! I%9=A;^SU <
M '(?   8              "  <';! !A;65D+3(P,C,S,3 S>&5X>#,Q,2YH
M=&U02P$"% ,4    " #00*16(WX!<=<'  "#'P  &               @ '+
MXP0 86UE9"TR,#(S,S$P,WAE>'@S,3(N:'1M4$L! A0#%     @ T$"D5N]-
M3*S3!   (A   !@              ( !V.L$ &%M960M,C R,S,Q,#-X97AX
M,S(Q+FAT;5!+ 0(4 Q0    ( -! I%:9MEISXP0  (40   8
M  "  >'P! !A;65D+3(P,C,S,3 S>&5X>#,R,BYH=&U02P$"% ,4    " #0
M0*16DH?($:0H  !4Y0  '@              @ 'Z]00 97AH:6)I=#$P,5]S
M97!A<F%T:6]N86=R964N:'1M4$L! A0#%     @ T$"D5H[;Y9_:& , 0W8A
M !X              ( !VAX% &5X:&EB:70Q,#)T:&ER9&%M96YD;65N='1O
M+FAT;5!+ 0(4 Q0    ( -! I%;:G+]HI%0! (A:#  >              "
M ? W" !E>&AI8FET,C%?97%U:71Y<'5R8VAA<V5A9RYH=&U02P4&      X
,#@#( P  T(P)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
